{"meta":{"query_hash":"c6c8d2e0904f","filters":{"venue":"Clinical Lymphoma Myeloma & Leukemia"},"cohort_total":503,"direct_labels_cover":1,"predictions_cover":503,"exported":503,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/c6c8d2e0904f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Lymphoma+Myeloma+%26+Leukemia"},"results":[{"id":"W1117787078","doi":"10.1016/j.clml.2015.07.650","title":"Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; Centre Hospitalier de l’Université de Montréal; University of Alberta; McGill University; Princess Margaret Cancer Centre; Thunder Bay Regional Health Sciences Centre; McMaster University; Hôpital Maisonneuve-Rosemont; St. Paul's Hospital; Memorial University of Newfoundland; University of British Columbia; Lakehead University; University of Toronto; Western University; University of Windsor; Jewish General Hospital","funders":"World Health Organization","keywords":"Medicine; Polycythemia vera; Phlebotomy; Ruxolitinib; Internal medicine; Oncology; Myelofibrosis; Thrombosis; Disease; Pegylated interferon; Intensive care medicine; Immunology; Bone marrow; Ribavirin","score_opus":0.06055785830586164,"score_gpt":0.34054404136767774,"score_spread":0.2799861830618161,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1117787078","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97965735,0.0037484514,0.00017031399,0.0063125966,0.0010401515,0.0031467052,0.00016988156,0.000095730844,0.00565884],"genre_scores_gemma":[0.99276435,0.00018168696,0.0030632026,0.0015654843,0.00066679687,0.0007158438,0.000059480986,0.000076809105,0.0009063215],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965697,0.00030713264,0.001056057,0.0007881214,0.00057827635,0.0007007135],"domain_scores_gemma":[0.99569947,0.0011406209,0.00037694475,0.0008698417,0.00095460186,0.0009585391],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00091727055,0.0004736224,0.0010017593,0.0001714534,0.0005344886,0.00008130149,0.00037259143,0.00043977282,0.000089581445],"category_scores_gemma":[0.0017670542,0.0003205716,0.0007340471,0.00047020547,0.00071567594,0.00017540186,0.000107417196,0.00033334157,0.00005324854],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029350368,0.002114249,0.65846354,0.0001687192,0.0030262507,0.00012445303,0.009012142,0.000080208396,0.00060667266,0.10743625,0.02047291,0.1955596],"study_design_scores_gemma":[0.007949897,0.0017146133,0.96799135,0.00024109376,0.00054321653,0.00014468796,0.00225245,0.0015325387,0.0018833915,0.002747175,0.012605428,0.00039415996],"about_ca_topic_score_codex":0.006793501,"about_ca_topic_score_gemma":0.025254153,"teacher_disagreement_score":0.30952784,"about_ca_system_score_codex":0.0033950554,"about_ca_system_score_gemma":0.0067464937,"threshold_uncertainty_score":0.99992466},"labels":[],"label_agreement":null},{"id":"W1751193725","doi":"10.1016/j.clml.2015.06.004","title":"Central Nervous System Complications and Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Neurological Complications and Syndromes","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Canadian Nuclear Safety Commission","keywords":"Medicine; Hazard ratio; Hematopoietic stem cell transplantation; Retrospective cohort study; Cumulative incidence; Incidence (geometry); Internal medicine; Transplantation; Confidence interval; Surgery","score_opus":0.04753207381242587,"score_gpt":0.3070498538989017,"score_spread":0.25951778008647586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1751193725","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248266,0.0004937928,0.00096137304,0.0014658049,0.00022844544,0.0005845494,0.000036972167,0.00024254085,0.0035038826],"genre_scores_gemma":[0.9964704,0.00007937831,0.00093514554,0.001811035,0.000083628656,0.00013720988,0.000054334334,0.000035289864,0.00039359496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9975039,0.0002038853,0.0009442967,0.0006228564,0.00031173535,0.0004133311],"domain_scores_gemma":[0.9978616,0.00041649325,0.00017974192,0.00064829306,0.0001511777,0.0007426549],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00033104714,0.00027789292,0.000670674,0.0000776666,0.00011408655,0.000050709346,0.00018949091,0.00025336962,0.000014247217],"category_scores_gemma":[0.00003914865,0.00021463241,0.00023973965,0.00017937098,0.0002501891,0.000083177714,0.00006728448,0.00018172004,0.00017697876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006152419,0.0005230092,0.85404646,0.00051755155,0.000120788456,0.00074206543,0.0004309903,0.000023722909,0.00023981313,0.0033333611,0.0008891259,0.13851787],"study_design_scores_gemma":[0.0022407307,0.0003334971,0.9925379,0.00005779762,0.00022460343,0.0012767522,0.00014742046,0.00044540258,0.00006556606,0.00019305301,0.002255687,0.00022155991],"about_ca_topic_score_codex":0.000021972875,"about_ca_topic_score_gemma":0.0000050395543,"teacher_disagreement_score":0.13849148,"about_ca_system_score_codex":0.00026413065,"about_ca_system_score_gemma":0.00030574677,"threshold_uncertainty_score":0.8752456},"labels":[],"label_agreement":null},{"id":"W1944400929","doi":"10.1016/j.clml.2015.05.007","title":"Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Vancouver General Hospital","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Lenalidomide; Internal medicine; Multiple myeloma; Clinical endpoint; Randomized controlled trial; Refractory (planetary science); Bortezomib; Oncology; Surgery","score_opus":0.047607298519740625,"score_gpt":0.3588236787743686,"score_spread":0.311216380254628,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1944400929","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989181,0.0008966381,0.000009594175,0.00086576585,0.0001161709,0.008707957,0.000037025435,0.00005580798,0.0001300762],"genre_scores_gemma":[0.99701166,0.00006755871,0.0012607947,0.0006710794,0.000108122564,0.0005222472,0.00012716146,0.00006421873,0.00016714107],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9895399,0.0040149568,0.003479714,0.0010283337,0.0010524392,0.0008846557],"domain_scores_gemma":[0.9881696,0.008319411,0.0010760291,0.0007902216,0.00028558794,0.0013591254],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.010520088,0.0005564298,0.0034285893,0.0004281162,0.000120316465,0.000056437686,0.00028319887,0.00044219915,0.000025384561],"category_scores_gemma":[0.024408827,0.0003537197,0.00028147866,0.00078666094,0.00084987836,0.00020216638,0.00021573683,0.00064125634,0.00002696503],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.77268606,0.0028741662,0.07947816,0.000106896965,0.00034270537,0.00014745502,0.001396176,0.000004500574,0.00014124451,0.000009485929,0.00010495865,0.14270818],"study_design_scores_gemma":[0.5539096,0.00408814,0.43993494,0.0002201678,0.000057859444,0.000011398356,0.00017259689,0.0013050105,0.000020420732,0.000041965563,0.000036118985,0.0002017803],"about_ca_topic_score_codex":0.0020391408,"about_ca_topic_score_gemma":0.00028098514,"teacher_disagreement_score":0.3604568,"about_ca_system_score_codex":0.0006768205,"about_ca_system_score_gemma":0.0021845624,"threshold_uncertainty_score":0.99989146},"labels":[],"label_agreement":null},{"id":"W1963599260","doi":"10.1016/j.clml.2013.05.012","title":"A Critical Review of Trials of First-Line BCR-ABL Inhibitor Treatment in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","year":2013,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute","keywords":"Nilotinib; Dasatinib; Imatinib; Medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Tyrosine kinase; Internal medicine; Clinical trial; Oncology; Pharmacology; Cancer","score_opus":0.08339020883833671,"score_gpt":0.40468084065048987,"score_spread":0.32129063181215317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1963599260","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.03453264,0.9481316,0.000010328543,0.000116572286,0.00067897077,0.015329782,0.0007914922,0.000109341956,0.000299253],"genre_scores_gemma":[0.0039011587,0.9870268,0.00079458876,0.0002013891,0.0014093161,0.0033433922,0.0025995504,0.0004454562,0.00027831012],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.97481763,0.0029476918,0.0155993095,0.0028516355,0.0018072586,0.0019764432],"domain_scores_gemma":[0.9737307,0.015116298,0.0055747894,0.003555898,0.00084847776,0.0011738343],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004199227,0.0027319135,0.023061924,0.0012469382,0.00009528667,0.000047116104,0.0010980085,0.0024080405,0.0013682025],"category_scores_gemma":[0.01612781,0.0019103616,0.0041233012,0.002418895,0.0014208136,0.00040906185,0.0004469083,0.0014309981,0.0003049506],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0012766888,0.0037968385,0.0014530773,0.13511117,0.0013322195,0.00069233036,0.00003675393,0.000007868361,0.0000015779951,0.0000281229,0.0012297214,0.85503364],"study_design_scores_gemma":[0.10736105,0.019088862,0.010906312,0.4723766,0.008458938,0.000099800214,0.000007992053,0.0001613787,0.000041013078,0.000023107728,0.3799087,0.0015662299],"about_ca_topic_score_codex":0.0017538834,"about_ca_topic_score_gemma":0.00073305285,"teacher_disagreement_score":0.8534674,"about_ca_system_score_codex":0.096985005,"about_ca_system_score_gemma":0.05879513,"threshold_uncertainty_score":0.9995447},"labels":[],"label_agreement":null},{"id":"W1965354201","doi":"10.1016/j.clml.2012.08.008","title":"Rapidity and Quality of Response to Steroid-Based Induction Therapy, Without the Addition of Novel Agents, Does Not Affect Post Transplant Outcomes in Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Regimen; Multiple myeloma; Induction therapy; Salvage therapy; Oncology; Internal medicine; Induction chemotherapy; Maintenance therapy; Transplantation; Surgery; Urology; Overall survival; Chemotherapy","score_opus":0.140409532724376,"score_gpt":0.40292710964915174,"score_spread":0.26251757692477573,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1965354201","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99568987,0.000099075245,0.00021066009,0.0012498982,0.0002587764,0.0016791801,0.00074783975,0.000042486477,0.000022233557],"genre_scores_gemma":[0.9975601,0.000055393964,0.0011479933,0.0007225004,0.00012202995,0.00014151046,0.00015111403,0.000041192376,0.00005818555],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99527735,0.0014679495,0.0013882304,0.0005172543,0.00077675586,0.0005724787],"domain_scores_gemma":[0.9928454,0.0052254265,0.00043565087,0.00078810606,0.00022616463,0.00047926477],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041188314,0.00036631216,0.0011152719,0.00027942334,0.00012254223,0.00001813693,0.00023213364,0.00032328203,0.00006189685],"category_scores_gemma":[0.0033661607,0.00021278721,0.00037768204,0.00032559634,0.0005072543,0.00018223262,0.00006625379,0.00028204083,0.0000106746875],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041078206,0.0018746423,0.7832063,0.00014021953,0.00020018741,0.0000108259,0.00038334855,0.000007794415,0.07819837,0.000013128601,0.000020692538,0.09486631],"study_design_scores_gemma":[0.020755883,0.0014296402,0.9206009,0.0002389982,0.000065599175,0.000010155735,0.00013480133,0.0005516663,0.055850506,0.0000036048748,0.00015550744,0.00020273113],"about_ca_topic_score_codex":0.0009846354,"about_ca_topic_score_gemma":0.00034022503,"teacher_disagreement_score":0.13739464,"about_ca_system_score_codex":0.0003972452,"about_ca_system_score_gemma":0.0005957337,"threshold_uncertainty_score":0.8677211},"labels":[],"label_agreement":null},{"id":"W1973979329","doi":"10.1016/j.clml.2014.07.015","title":"A Canadian Evidence-Based Guideline for the First-Line Treatment of Follicular Lymphoma: Joint Consensus of the Lymphoma Canada Scientific Advisory Board","year":2014,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; Queen Elizabeth II Health Sciences Centre; University of Calgary; McGill University; University of Toronto; Dalhousie University; BC Cancer Agency; Princess Margaret Cancer Centre; Jewish General Hospital","funders":"","keywords":"Guideline; Follicular lymphoma; Medicine; Lymphoma; Family medicine; Disease; Executive summary; Intensive care medicine; Front line; Internal medicine; Political science; Pathology","score_opus":0.10358129079999641,"score_gpt":0.35496664619442087,"score_spread":0.25138535539442447,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1973979329","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011836782,0.9691123,0.000026691203,0.005704411,0.003496351,0.0080108335,0.0015797314,0.000060202983,0.00017273746],"genre_scores_gemma":[0.069137335,0.92088896,0.0008033979,0.003055017,0.0014342839,0.002409284,0.0007155454,0.00034578246,0.001210415],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9876653,0.0007736765,0.0065903952,0.0019613942,0.0015579454,0.0014512831],"domain_scores_gemma":[0.97992575,0.00920817,0.003600045,0.004700962,0.0013323659,0.0012327161],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0025499763,0.001670018,0.0070007998,0.0004314508,0.00089316524,0.00010993867,0.0014125576,0.0011399,0.00009908345],"category_scores_gemma":[0.0038575497,0.000893511,0.0058535584,0.0012790287,0.0016811283,0.000055406912,0.00023446744,0.0001518062,0.000034809415],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00031322511,0.0009844113,0.0010356781,0.004966446,0.0022016922,0.0002253741,0.000023902167,0.000044702512,7.7398266e-7,0.000119254175,0.040146075,0.9499385],"study_design_scores_gemma":[0.01169449,0.0015594611,0.021816071,0.018090706,0.010802427,0.00022841581,0.000027057902,0.0010666118,0.00016575532,0.00002866712,0.9337709,0.0007494161],"about_ca_topic_score_codex":0.7477101,"about_ca_topic_score_gemma":0.7807855,"teacher_disagreement_score":0.94918907,"about_ca_system_score_codex":0.020723531,"about_ca_system_score_gemma":0.107809246,"threshold_uncertainty_score":0.99960464},"labels":[],"label_agreement":null},{"id":"W1974414813","doi":"10.1016/j.clml.2011.05.021","title":"509 The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects with Treatment Refractory or Relapsed Acute Myeloid Leukemia","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Histone Deacetylase Inhibitors Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Tolerability; Refractory (planetary science); Myeloid leukemia; Internal medicine; Safety profile; Oncology; Phases of clinical research; Adverse effect; Clinical trial","score_opus":0.04674116976032461,"score_gpt":0.36483350137479786,"score_spread":0.31809233161447326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1974414813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948527,0.00018646369,0.000017860277,0.00015369158,0.00017154703,0.0042100027,0.00006084422,0.00002928717,0.00031757238],"genre_scores_gemma":[0.9983512,0.00015531664,0.0001278909,0.00016485722,0.00018940367,0.0002922392,0.000046042507,0.0000731155,0.0005999071],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934918,0.0020776808,0.001599396,0.0013907113,0.0007163411,0.0007240679],"domain_scores_gemma":[0.9961278,0.00080587185,0.00025461422,0.0021204196,0.00029789924,0.00039338987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034072106,0.00058125216,0.0010151267,0.000110947796,0.00045726064,0.00004426684,0.0008795179,0.00028219054,0.00003907793],"category_scores_gemma":[0.0011420681,0.00031048758,0.00023745032,0.00055118656,0.000896013,0.000020773594,0.0006864543,0.00040917296,0.00001735242],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16303197,0.02742825,0.042601623,0.000051870044,0.0022068184,0.0010256623,0.028072843,0.000075784155,0.06527129,0.000013794115,0.0006747156,0.6695454],"study_design_scores_gemma":[0.04257213,0.13773347,0.7832963,0.00007589565,0.0004322283,0.00008760881,0.0041859644,0.00009805367,0.02619949,0.000009849367,0.0046555265,0.0006535179],"about_ca_topic_score_codex":0.0016443104,"about_ca_topic_score_gemma":0.0052675963,"teacher_disagreement_score":0.74069464,"about_ca_system_score_codex":0.0010122628,"about_ca_system_score_gemma":0.0027858538,"threshold_uncertainty_score":0.99993473},"labels":[],"label_agreement":null},{"id":"W1975530543","doi":"10.1016/j.clml.2012.05.005","title":"A Phase I Study of the Metal Ionophore Clioquinol in Patients With Advanced Hematologic Malignancies","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":43,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Clioquinol; Pharmacology; Medicine; Pharmacodynamics; Refractory (planetary science); Drug; Pharmacokinetics; Internal medicine; Biology","score_opus":0.021139978226570166,"score_gpt":0.29706952187877533,"score_spread":0.2759295436522052,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975530543","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9981414,0.00036465283,0.0000064904416,0.00001706985,0.00026045006,0.00085566245,0.00002266251,0.000013116086,0.0003184906],"genre_scores_gemma":[0.9993279,0.000018789151,0.00017597695,0.00017905726,0.000107664106,0.00009530558,0.000029410334,0.000026060183,0.000039848303],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792135,0.0003269297,0.00069301104,0.00039941297,0.00024693785,0.00041237913],"domain_scores_gemma":[0.99869144,0.00006633155,0.00032772182,0.0006840094,0.000100802485,0.00012969923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004741006,0.00023758813,0.00043241697,0.00003961594,0.000076052704,0.000009159462,0.0004016399,0.00022240296,0.0000124050075],"category_scores_gemma":[0.00022347682,0.0001507897,0.00016390729,0.00023388414,0.00023424655,0.0000128653455,0.00027638325,0.00012509649,0.000010752941],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018267115,0.0058015417,0.905062,0.00003926716,0.00012294827,0.000006763155,0.00024137995,0.00001089392,0.008945245,0.00009464629,0.00009165402,0.0777569],"study_design_scores_gemma":[0.011674053,0.0041704434,0.9420831,0.000051047067,0.000045981174,0.000008425087,0.00028591484,0.00000626093,0.04047711,0.000028852939,0.0009322351,0.00023657874],"about_ca_topic_score_codex":0.000011897931,"about_ca_topic_score_gemma":0.000014696282,"teacher_disagreement_score":0.07752032,"about_ca_system_score_codex":0.00005990579,"about_ca_system_score_gemma":0.00019618131,"threshold_uncertainty_score":0.6149025},"labels":[],"label_agreement":null},{"id":"W1975539073","doi":"10.3816/clml.2011.n.005","title":"Efficacy and Safety of Pegylated Liposomal Doxorubicin in Combination With Bortezomib for Multiple Myeloma: Effects of Adverse Prognostic Factors on Outcome","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Bortezomib; Medicine; Multiple myeloma; Internal medicine; Regimen; Adverse effect; Oncology; Refractory (planetary science); Thalidomide; Population","score_opus":0.04915552958730707,"score_gpt":0.33045641490591665,"score_spread":0.2813008853186096,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1975539073","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953876,0.00008502495,0.00007800522,0.000037664733,0.00013617947,0.0038763096,0.000049333034,0.00006303476,0.00028681936],"genre_scores_gemma":[0.9977863,0.000045084125,0.0016489277,0.000044064254,0.000038939,0.00012911718,0.00015639701,0.00006557361,0.000085590815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964906,0.00024059249,0.0014917365,0.00068921305,0.0005074461,0.0005804193],"domain_scores_gemma":[0.993456,0.004737094,0.0005166253,0.00055714155,0.00028785702,0.0004452753],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00052536675,0.0004296209,0.0013387995,0.00034284414,0.000077769444,0.0000053088943,0.00019066349,0.00036932103,0.00001772773],"category_scores_gemma":[0.0044407067,0.00031123203,0.00026430155,0.0004038128,0.0005146549,0.00012774054,0.00009064866,0.0002591221,0.000009137316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026427016,0.0028340386,0.8940939,0.0007077264,0.00040195658,0.00022627023,0.00036681723,0.0000032467565,0.001006268,0.0001944686,0.000010377996,0.07372792],"study_design_scores_gemma":[0.061384857,0.010511782,0.9115741,0.0008135078,0.0002874024,0.000019571868,0.0000794613,0.0009114323,0.01409836,0.000048890193,0.000025121275,0.00024548458],"about_ca_topic_score_codex":0.00030912232,"about_ca_topic_score_gemma":0.00008016731,"teacher_disagreement_score":0.07348243,"about_ca_system_score_codex":0.00037727586,"about_ca_system_score_gemma":0.00047034683,"threshold_uncertainty_score":0.99993396},"labels":[],"label_agreement":null},{"id":"W1979590202","doi":"10.3816/clml.2010.n.079","title":"Bendamustine Produces Durable Responses With an Acceptable Safety Profile in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":57,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Bendamustine; Medicine; Rituximab; Internal medicine; Refractory (planetary science); Gastroenterology; Salvage therapy; Chronic lymphocytic leukemia; Follicular lymphoma; Chemotherapy; Surgery; Lymphoma; Oncology; Leukemia","score_opus":0.013917964573779846,"score_gpt":0.29288665793761726,"score_spread":0.2789686933638374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1979590202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99356645,0.000100060744,0.0000074689083,0.00043728878,0.00053062337,0.0025257433,0.00016371901,0.00022599325,0.0024426593],"genre_scores_gemma":[0.99065757,0.00007938107,0.005597504,0.0007757843,0.0005670502,0.00047453973,0.0006570337,0.00017511683,0.0010159976],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99359375,0.00033939874,0.0017482452,0.0019002054,0.0011561903,0.001262199],"domain_scores_gemma":[0.9949422,0.0008058863,0.0006736338,0.0019773599,0.00060304574,0.0009979137],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012213682,0.00092021574,0.0017613651,0.0003756055,0.00034775023,0.00015002741,0.00054016494,0.000645887,0.00067249173],"category_scores_gemma":[0.00077946717,0.00062459125,0.00025941365,0.0008487663,0.0007144764,0.0008023783,0.00021564828,0.0005259713,0.00027798416],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020723693,0.0086154435,0.60080284,0.00008106384,0.00020065268,0.00043298345,0.00015283927,0.000004046958,0.00014289291,0.000037878974,0.0005621338,0.36824355],"study_design_scores_gemma":[0.0540026,0.009004774,0.9225539,0.0004899871,0.00030414795,0.00012166408,0.0001238899,0.00013704642,0.0029401353,0.000017134427,0.009533,0.00077171077],"about_ca_topic_score_codex":0.0008485492,"about_ca_topic_score_gemma":0.0009527349,"teacher_disagreement_score":0.36747184,"about_ca_system_score_codex":0.0015253568,"about_ca_system_score_gemma":0.003941066,"threshold_uncertainty_score":0.99962056},"labels":[],"label_agreement":null},{"id":"W1982192898","doi":"10.1016/j.clml.2011.06.015","title":"Ribosomal Protein Metallopanstimulin-1 Impairs Multiple Myeloma CAG Cells Growth and Inhibits Fibroblast Growth Factor Receptor 3","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"RNA Research and Splicing","field":"Biochemistry, Genetics and Molecular Biology","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; National Institutes of Health; McGill University","keywords":"Fibroblast growth factor receptor; MAPK/ERK pathway; Fibroblast growth factor receptor 3; Fibroblast growth factor; Cancer research; Fibroblast growth factor receptor 1; Multiple myeloma; Biology; Fibroblast growth factor receptor 4; Cell growth; Receptor; Signal transduction; Molecular biology; Cell biology; Immunology; Biochemistry","score_opus":0.027430513190586658,"score_gpt":0.27022768661623703,"score_spread":0.24279717342565038,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1982192898","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9967938,0.00028535564,0.0003492479,0.000080527185,0.00022966224,0.0008466453,0.00014762983,0.00009441651,0.0011726829],"genre_scores_gemma":[0.9919202,0.00022530998,0.005249618,0.00027608557,0.00060302654,0.00010104919,0.0001233892,0.00011203423,0.0013893051],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99559283,0.00042203473,0.0011236555,0.0013396797,0.00044293032,0.0010788593],"domain_scores_gemma":[0.99754226,0.00017719349,0.00031375716,0.00071081484,0.00028962284,0.00096637406],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005740385,0.00060473144,0.00071079197,0.000121994766,0.00028671118,0.00009624266,0.0006579449,0.00075732137,0.00011698718],"category_scores_gemma":[0.0016117594,0.0005403741,0.00044790359,0.00024959215,0.00070731144,0.000044747412,0.0006621266,0.00037554651,0.00017987001],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010127008,0.00020392763,0.015288309,0.00011879968,0.00019846506,0.00005747449,0.000108295935,7.7471674e-7,0.9553293,0.00009195804,0.00083246274,0.026757527],"study_design_scores_gemma":[0.0029611015,0.0016048413,0.23040086,0.00010587676,0.000028806311,0.000038252485,0.000078437086,0.00020657612,0.7628894,0.00009178698,0.00094023667,0.0006538331],"about_ca_topic_score_codex":0.00033165995,"about_ca_topic_score_gemma":0.000072653645,"teacher_disagreement_score":0.21511255,"about_ca_system_score_codex":0.00012447327,"about_ca_system_score_gemma":0.00071836053,"threshold_uncertainty_score":0.9997048},"labels":[],"label_agreement":null},{"id":"W1986307017","doi":"10.1016/j.clml.2012.01.003","title":"Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by Flow Cytometry Is Associated With NPM1 and FLT3 Mutation Status in Cytogenetically Normal Acute Myeloid Leukemia","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Vancouver General Hospital","funders":"BC Cancer Agency; University of British Columbia","keywords":"NPM1; CD34; Flow cytometry; CD19; Myeloid leukemia; CD33; CD14; Mutation; Gene mutation; Leukemia; Medicine; Molecular biology; Cancer research; Myeloid; Internal medicine; Immunology; Oncology; Biology; Gene; Karyotype; Genetics; Stem cell","score_opus":0.01838067840154703,"score_gpt":0.3085404674738134,"score_spread":0.29015978907226636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1986307017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99463314,0.0014289754,0.0012574921,0.00025864274,0.00021402334,0.0010555054,0.00021396509,0.00014007995,0.0007981806],"genre_scores_gemma":[0.99338317,0.0011882667,0.003115644,0.0009118202,0.00034124227,0.00008853806,0.00027379487,0.00015550385,0.00054203713],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327314,0.0006919291,0.0019323314,0.0011554629,0.0012370462,0.0017100779],"domain_scores_gemma":[0.99489284,0.0017665899,0.00061913434,0.0007922432,0.0005189405,0.001410235],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002720669,0.000710912,0.001630464,0.00063614594,0.00020861268,0.00008414044,0.00029251812,0.0011771268,0.00009945372],"category_scores_gemma":[0.0022867064,0.00063056854,0.0002452547,0.001540319,0.0012466796,0.0006040601,0.0003705687,0.0010486383,0.00005262685],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041873194,0.0004948634,0.48132786,0.00022699147,0.0009509725,0.0003868892,0.00080377224,0.000012815237,0.037296057,0.000029970146,0.0012747394,0.47300777],"study_design_scores_gemma":[0.014715067,0.00226844,0.9540532,0.00029248756,0.0005512031,0.0006875112,0.0002648179,0.009295472,0.016019981,0.00006734533,0.0011315707,0.0006528642],"about_ca_topic_score_codex":0.00040117148,"about_ca_topic_score_gemma":0.00011548703,"teacher_disagreement_score":0.4727254,"about_ca_system_score_codex":0.0039237705,"about_ca_system_score_gemma":0.0021903955,"threshold_uncertainty_score":0.9999},"labels":[],"label_agreement":null},{"id":"W1993258964","doi":"10.1016/j.clml.2011.09.025","title":"1.24 Telomere Shortening in CLL Correlates with Cell Cycle-Dependent Dysregulation of Shelterin Proteins","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Telomere; Shelterin; Chronic lymphocytic leukemia; Telomere-binding protein; Molecular biology; Biology; Metaphase; Telomerase; Cancer research; Genetics; DNA; Chromosome; Leukemia; Gene; DNA-binding protein; Transcription factor","score_opus":0.020306824279727808,"score_gpt":0.2529292012094969,"score_spread":0.23262237692976911,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1993258964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938905,0.00015713177,0.0012788854,0.000009315384,0.00024220913,0.0005107913,0.000010626512,0.00004571077,0.0038548193],"genre_scores_gemma":[0.9899573,0.000043676526,0.009148875,0.000076661665,0.00012195204,0.00006345405,0.000045135166,0.00006772792,0.00047523715],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9975315,0.00017216703,0.0009235687,0.0007144532,0.0002607707,0.00039756275],"domain_scores_gemma":[0.9986292,0.000045280907,0.00036016546,0.0006924104,0.0001102393,0.0001627049],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005594638,0.00029602414,0.00044365955,0.00008715797,0.000044744887,0.000014825731,0.00037712298,0.00048943504,0.000056876186],"category_scores_gemma":[0.00009843116,0.00026482574,0.00017825012,0.00016829562,0.0002079876,0.00001585099,0.0002343312,0.0001668909,0.000032546333],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026253725,0.0008334069,0.16752878,0.00014605456,0.00017542754,0.00020058326,0.0003512362,0.0003009776,0.60687095,0.00053102575,0.00013160359,0.22030461],"study_design_scores_gemma":[0.0024788766,0.0016586159,0.4577645,0.00011734009,0.000049817194,0.000055491713,0.00014177857,0.0011789784,0.5353986,0.00050329714,0.0002239736,0.0004286945],"about_ca_topic_score_codex":0.00009846542,"about_ca_topic_score_gemma":0.000113585964,"teacher_disagreement_score":0.29023576,"about_ca_system_score_codex":0.00011674242,"about_ca_system_score_gemma":0.00037442378,"threshold_uncertainty_score":0.9999804},"labels":[],"label_agreement":null},{"id":"W2002092032","doi":"10.1016/j.clml.2015.03.002","title":"A Canadian Perspective on the First-Line Treatment of Chronic Lymphocytic Leukemia","year":2015,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Vancouver General Hospital; Hôpital du Sacré-Cœur de Montréal; Ottawa Hospital; Dalhousie University; Foothills Medical Centre","funders":"Lundbeck Canada","keywords":"Medicine; Fludarabine; Bendamustine; Chlorambucil; Obinutuzumab; Rituximab; Ofatumumab; Chronic lymphocytic leukemia; Ibrutinib; Chemoimmunotherapy; Alemtuzumab; Internal medicine; Oncology; Cyclophosphamide; Leukemia; Chemotherapy; Lymphoma; Transplantation","score_opus":0.12119501693494986,"score_gpt":0.42049155741971544,"score_spread":0.2992965404847656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2002092032","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0022065719,0.9704333,0.0000032578603,0.00061042205,0.0011918918,0.005839307,0.00039570619,0.00021328864,0.019106276],"genre_scores_gemma":[0.005052629,0.9826212,0.000051055755,0.0007020383,0.003773431,0.00095873565,0.00037310988,0.00047895996,0.00598886],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9880324,0.0010302671,0.0040096133,0.0025317979,0.0020315258,0.0023644175],"domain_scores_gemma":[0.984382,0.0054435423,0.0014816885,0.004765491,0.001218909,0.002708382],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0023649503,0.00208815,0.008071879,0.0010295529,0.00043828934,0.00012407317,0.0018628027,0.0025672296,0.0006239396],"category_scores_gemma":[0.0030750523,0.0012914009,0.0040319515,0.0019868063,0.0017851784,0.00011546272,0.00039457373,0.0010912673,0.003494156],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005318446,0.00029501712,0.0000062665445,0.00398664,0.002385674,0.0023407503,0.000231578,0.00004443808,8.7375575e-8,0.0019419161,0.012938129,0.97529763],"study_design_scores_gemma":[0.019972095,0.006791871,0.00014459284,0.013644815,0.003812043,0.0019288321,0.00013240222,0.0033578076,0.0000075300954,0.00036878942,0.9487739,0.0010652774],"about_ca_topic_score_codex":0.223345,"about_ca_topic_score_gemma":0.044428088,"teacher_disagreement_score":0.9742324,"about_ca_system_score_codex":0.8437404,"about_ca_system_score_gemma":0.63599193,"threshold_uncertainty_score":0.999186},"labels":[],"label_agreement":null},{"id":"W2005981818","doi":"10.1016/j.clml.2013.12.015","title":"Activity of 129 Single-Agent Drugs in 228 Phase I and II Clinical Trials in Multiple Myeloma","year":2014,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Deutsche Forschungsgemeinschaft; National Cancer Institute; Celgene; Amgen; American Society of Hematology","keywords":"Thalidomide; Medicine; Lenalidomide; Multiple myeloma; Pomalidomide; Oncology; Teniposide; Clinical trial; Bortezomib; Internal medicine; Cyclophosphamide; Melphalan; Pharmacology; Prednisone; Chemotherapy; Etoposide","score_opus":0.2745757903204223,"score_gpt":0.5036168554340602,"score_spread":0.22904106511363792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2005981818","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.47867358,0.51436013,0.000020765468,0.00011657814,0.0007524979,0.0051172916,0.00026410093,0.000090604175,0.000604446],"genre_scores_gemma":[0.18390968,0.8127165,0.00074858015,0.00012240246,0.0009966774,0.0004326899,0.00042776825,0.00020234718,0.00044337078],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.97230595,0.011081353,0.011241582,0.0025674817,0.001259735,0.0015439035],"domain_scores_gemma":[0.9591464,0.03301345,0.003679907,0.0021626642,0.0002575263,0.001740042],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.024131928,0.0014987449,0.017440228,0.0011765532,0.00017012462,0.00007135824,0.0007688385,0.0027778838,0.00015949912],"category_scores_gemma":[0.048297472,0.0011547691,0.0038620932,0.0011533069,0.00145018,0.00021626939,0.0010043508,0.0020440621,0.00016167513],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003939034,0.0067653526,0.012090787,0.008164853,0.00096011907,0.0008614726,0.000067095854,2.0241659e-7,0.00001455147,0.000021928328,0.00043664547,0.96667796],"study_design_scores_gemma":[0.08686087,0.007707328,0.26812726,0.03152999,0.0025943092,0.00026689313,0.00004221057,0.0010772959,0.000065077846,0.00009316303,0.6001364,0.0014992161],"about_ca_topic_score_codex":0.0004595842,"about_ca_topic_score_gemma":0.00021447577,"teacher_disagreement_score":0.9651787,"about_ca_system_score_codex":0.0023290534,"about_ca_system_score_gemma":0.0044923355,"threshold_uncertainty_score":0.9997762},"labels":[],"label_agreement":null},{"id":"W2010658726","doi":"10.1016/j.clml.2013.03.004","title":"Does Functional Imaging Distinguish Nodular Lymphocyte-Predominant Hodgkin Lymphoma From T-Cell/Histiocyte-Rich Large B-Cell Lymphoma?","year":2013,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Medicine; Lymphoma; Hodgkin lymphoma; Histiocyte; Radiology; Pathology","score_opus":0.014538373546597984,"score_gpt":0.2669038417416777,"score_spread":0.2523654681950797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2010658726","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97198504,0.004138135,0.0005689201,0.0012691682,0.0047340323,0.0020893728,0.00047685456,0.00084013265,0.013898321],"genre_scores_gemma":[0.977414,0.0008595835,0.004083256,0.0052666334,0.0038163615,0.00092344015,0.0015536307,0.00036926992,0.0057138125],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9879473,0.0006382502,0.0036231163,0.0033747423,0.0018882934,0.002528315],"domain_scores_gemma":[0.9900052,0.0026461831,0.0013356301,0.0029387167,0.0010225812,0.0020516925],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.001225688,0.0018325115,0.0028225959,0.00042165292,0.0010051429,0.00055507984,0.0010326861,0.0010664259,0.003438047],"category_scores_gemma":[0.0013702044,0.0013014248,0.0018343304,0.00088576024,0.00087667396,0.0006650074,0.00092735805,0.0003077617,0.007858887],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014758265,0.01078206,0.296185,0.00021601008,0.0007031279,0.002608725,0.0002307088,0.000010343076,0.0016089804,0.00032380325,0.05044381,0.6354116],"study_design_scores_gemma":[0.05983892,0.0005426516,0.83446413,0.00044862562,0.0011731158,0.0002853096,0.00040621415,0.0049965493,0.0091159865,0.00078617176,0.0863646,0.0015777175],"about_ca_topic_score_codex":0.0040677227,"about_ca_topic_score_gemma":0.00008139633,"teacher_disagreement_score":0.6338339,"about_ca_system_score_codex":0.008206922,"about_ca_system_score_gemma":0.0043862374,"threshold_uncertainty_score":0.999442},"labels":[],"label_agreement":null},{"id":"W2016111806","doi":"10.1016/j.clml.2014.12.008","title":"Effects of Ruxolitinib Treatment on Metabolic and Nutritional Parameters in Patients With Myelofibrosis From COMFORT-I","year":2014,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"University of Texas MD Anderson Cancer Center; National Cancer Institute; National Institutes of Health; Incyte; Gilead Sciences; Sanofi; Genentech; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Placebo; Internal medicine; Clinical endpoint; Gastroenterology; Post-hoc analysis; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.013702949473495459,"score_gpt":0.2692774016353615,"score_spread":0.25557445216186603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016111806","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975336,0.0002663501,0.000011695616,0.00016737131,0.000115662246,0.0013548122,0.00010428085,0.00003524352,0.00041094527],"genre_scores_gemma":[0.9952232,0.00033359777,0.002756009,0.00078566733,0.00012848726,0.0004182326,0.00027743063,0.000042218166,0.000035136884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973273,0.000282521,0.00086095906,0.000714589,0.00044095,0.00037365535],"domain_scores_gemma":[0.99553084,0.003301759,0.00027327344,0.0004152026,0.0001041945,0.0003747437],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00018367665,0.00042131395,0.0013325313,0.00015106998,0.00006643289,0.000022054994,0.0000859772,0.00023268926,0.000025987061],"category_scores_gemma":[0.00033570876,0.00028852248,0.0002356991,0.00018138713,0.0003074607,0.00007278625,0.00004114707,0.00012213188,0.000027558879],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027537649,0.0027822503,0.72364306,0.000056480134,0.00035891827,0.000029309758,0.00005770749,0.0000044696176,0.000023572771,0.0010304205,0.00005518412,0.26920483],"study_design_scores_gemma":[0.03198386,0.0076860148,0.9483048,0.0006278123,0.0004349133,0.000003482387,0.000010210589,0.00010335513,0.008983926,0.0003624578,0.0012552772,0.00024391487],"about_ca_topic_score_codex":0.00027319626,"about_ca_topic_score_gemma":0.000029766516,"teacher_disagreement_score":0.26896092,"about_ca_system_score_codex":0.00038993626,"about_ca_system_score_gemma":0.00021630214,"threshold_uncertainty_score":0.99995667},"labels":[],"label_agreement":null},{"id":"W2016375132","doi":"10.3816/clml.2010.n.039","title":"Leukemia Cell–Selective Uptake of Cytarabine and Daunorubicin in the Bone Marrow Compartment Mediated by CPX-351 Liposome Injection","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Nanoparticle-Based Drug Delivery","field":"Materials Science","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Celator Pharmaceuticals (Canada)","funders":"","keywords":"Daunorubicin; Cytarabine; Bone marrow; Leukemia; Pharmacology; Medicine; Liposome; Pharmacodynamics; Flow cytometry; Drug delivery; Chemistry; Pharmacokinetics; Immunology; Biochemistry","score_opus":0.013588768470774368,"score_gpt":0.2639485287841484,"score_spread":0.250359760313374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2016375132","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969033,0.00039016534,0.0000232509,0.00039572894,0.0008969956,0.00071463,0.00010152151,0.00010835417,0.00046603495],"genre_scores_gemma":[0.99808556,0.0000841722,0.00054868765,0.0007432077,0.00024165167,0.00008765767,0.00006166909,0.00004568498,0.000101703874],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99511623,0.0007074189,0.0018431236,0.0009116714,0.00070058217,0.00072094303],"domain_scores_gemma":[0.9959721,0.0020446659,0.0006286293,0.0008647875,0.00019814007,0.00029168412],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033219568,0.00042491217,0.00088131824,0.00015904079,0.00018885048,0.00010002682,0.0006412335,0.00042777718,0.00015944647],"category_scores_gemma":[0.00088620384,0.00033227928,0.00017232435,0.00070504635,0.00089214026,0.00034541724,0.00020930092,0.0005625804,0.00023655033],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00075215707,0.00052191503,0.009570386,0.000043157783,0.000020233509,0.00005598944,0.00044926495,0.00007350412,0.96284723,0.00016697444,0.0056879115,0.019811248],"study_design_scores_gemma":[0.00616299,0.0011479354,0.50047344,0.00006446442,0.000099772835,0.00009405975,0.00029527268,0.0030981808,0.48459062,0.0005033024,0.0029415404,0.00052843674],"about_ca_topic_score_codex":0.00080882356,"about_ca_topic_score_gemma":0.0004576912,"teacher_disagreement_score":0.49090302,"about_ca_system_score_codex":0.00067157147,"about_ca_system_score_gemma":0.0009484736,"threshold_uncertainty_score":0.9999129},"labels":[],"label_agreement":null},{"id":"W2019329008","doi":"10.1016/j.clml.2014.04.004","title":"Clinical Features of Patients With Philadelphia-Negative Myeloproliferative Neoplasms Complicated by Portal Hypertension","year":2014,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institute on Aging","keywords":"Medicine; Portal hypertension; Internal medicine; Ascites; Thrombosis; Myeloproliferative neoplasm; Gastroenterology; Polycythemia vera; Incidence (geometry); Population; Cardiology; Myelofibrosis; Cirrhosis; Bone marrow","score_opus":0.019999368163987532,"score_gpt":0.2955877178174157,"score_spread":0.2755883496534282,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2019329008","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177074,0.00019740949,0.00015066596,0.0016680397,0.00042113912,0.0020475034,0.00024062111,0.00017409462,0.003329765],"genre_scores_gemma":[0.99101305,0.00024034125,0.00313757,0.0035423236,0.00046113555,0.00023085564,0.00094959815,0.000121014506,0.000304112],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933451,0.00072642433,0.0025578267,0.0015598873,0.001060284,0.0007505154],"domain_scores_gemma":[0.9920613,0.0033289937,0.0011714589,0.0011193673,0.0013686839,0.00095016],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008961439,0.0008435164,0.0026104546,0.0001554035,0.00026290995,0.00004821812,0.00034907274,0.0007489055,0.0001835121],"category_scores_gemma":[0.0020283,0.0005736245,0.00068475347,0.00051672815,0.001292849,0.00020312333,0.00018875096,0.0006621445,0.00014331783],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0055975863,0.004341708,0.78625774,0.00008042051,0.0012838478,0.00012527908,0.00011016155,0.000006230684,0.00008197266,0.001170996,0.02995432,0.17098972],"study_design_scores_gemma":[0.019668167,0.007177253,0.9628609,0.00036952042,0.0006276118,0.00010285736,0.000053570886,0.00043230818,0.0020933615,0.00026019212,0.005762438,0.0005918413],"about_ca_topic_score_codex":0.000078596735,"about_ca_topic_score_gemma":0.000038339575,"teacher_disagreement_score":0.17660312,"about_ca_system_score_codex":0.00030733028,"about_ca_system_score_gemma":0.000804312,"threshold_uncertainty_score":0.9996715},"labels":[],"label_agreement":null},{"id":"W2020431842","doi":"10.1016/j.clml.2012.08.003","title":"An Open-Label Single-Arm Pilot Phase II Study (PX-171-003-A0) of Low-Dose, Single-Agent Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":120,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; Beatrice Hunter Cancer Research Institute; Saint John Regional Hospital; Princess Margaret Cancer Centre; University of Toronto","funders":"Onyx Pharmaceuticals","keywords":"Carfilzomib; Medicine; Multiple myeloma; Bortezomib; Lenalidomide; Internal medicine; Thalidomide; Refractory (planetary science); Adverse effect; Regimen; Clinical endpoint; Phases of clinical research; Proteasome inhibitor; Anemia; Oncology; Surgery; Clinical trial; Gastroenterology","score_opus":0.09475273562003522,"score_gpt":0.37707119894691077,"score_spread":0.28231846332687555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2020431842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99335605,0.00037239183,0.000011028413,0.0000618213,0.00040004178,0.0047282954,0.00013964006,0.0001247785,0.00080596865],"genre_scores_gemma":[0.99610424,0.000047265577,0.002124692,0.00028938305,0.00029175097,0.00024037246,0.00042816464,0.00019072344,0.00028343595],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9923425,0.00096178096,0.0022840765,0.001487654,0.0013779476,0.0015460507],"domain_scores_gemma":[0.9938057,0.0010987835,0.00078535767,0.0018401345,0.0004899743,0.0019800416],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016863159,0.00087142695,0.002014186,0.00044397032,0.00035572913,0.00011397199,0.00078085356,0.0004214865,0.00012271339],"category_scores_gemma":[0.0018240912,0.0006932717,0.00013913629,0.0007916698,0.000742705,0.0010707155,0.0008524708,0.0006386352,0.000055026943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028384982,0.16652094,0.5206991,0.00010691405,0.00043276165,0.00027721253,0.00061074796,0.0000010294708,0.0029651138,0.00000919063,0.00014939676,0.27984262],"study_design_scores_gemma":[0.1478761,0.11864545,0.7302318,0.0003707744,0.00024010388,0.000023659506,0.00032657286,0.00025264718,0.0010856476,0.000010594547,0.00041333697,0.00052330364],"about_ca_topic_score_codex":0.00073872297,"about_ca_topic_score_gemma":0.0003684796,"teacher_disagreement_score":0.27931932,"about_ca_system_score_codex":0.0017454431,"about_ca_system_score_gemma":0.0009343886,"threshold_uncertainty_score":0.99955183},"labels":[],"label_agreement":null},{"id":"W2023428359","doi":"10.1016/j.clml.2014.12.015","title":"Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; BC Cancer Agency; University of British Columbia","funders":"Roche","keywords":"Medicine; Internal medicine; Rituximab; Oncology; Plerixafor; Transplantation; Hematopoietic stem cell transplantation; Lymphoma; Autologous stem-cell transplantation; Vincristine; Chemoimmunotherapy; Etoposide; Progression-free survival; Cyclophosphamide; Gastroenterology; Chemotherapy","score_opus":0.02383174685501354,"score_gpt":0.28165116699961157,"score_spread":0.257819420144598,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2023428359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955068,0.00039329694,0.00019457663,0.00011007812,0.000089323745,0.002006561,0.00023993409,0.0001183908,0.0013410171],"genre_scores_gemma":[0.9971073,0.00013720033,0.001062056,0.00026713195,0.000045599896,0.0002259189,0.00064490427,0.00013484673,0.0003750211],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99539393,0.00019479734,0.0013385549,0.0011388408,0.0012570707,0.0006768161],"domain_scores_gemma":[0.99657595,0.00037112398,0.000768945,0.00078896765,0.00057222706,0.0009227698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036767422,0.0008260036,0.0018474236,0.00015511317,0.00013138901,0.000066696404,0.00021985099,0.00030585006,0.000026082347],"category_scores_gemma":[0.00001909741,0.00048476248,0.00016410746,0.0004921015,0.00063420343,0.00026379726,0.000051669034,0.00016311987,0.000033769855],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014668599,0.0039858,0.94939256,0.00046395394,0.00076422456,0.00060830096,0.00053757906,0.000006128263,0.000027770397,0.000022796308,0.00088072056,0.02864156],"study_design_scores_gemma":[0.12537977,0.013520992,0.8533948,0.0009687151,0.002163129,0.00018434576,0.00034740943,0.00007120559,0.002758391,0.0000033249785,0.0005888753,0.0006190458],"about_ca_topic_score_codex":0.00033983993,"about_ca_topic_score_gemma":0.00008387698,"teacher_disagreement_score":0.11071117,"about_ca_system_score_codex":0.00093958474,"about_ca_system_score_gemma":0.0009423646,"threshold_uncertainty_score":0.9997604},"labels":[],"label_agreement":null},{"id":"W2039514741","doi":"10.1016/j.clml.2013.10.003","title":"Aberrant Expression of CD13 Identifies a Subgroup of Standard-Risk Adult Acute Lymphoblastic Leukemia With Inferior Survival","year":2013,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Vancouver General Hospital","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Oncology; Subgroup analysis; Internal medicine; Leukemia; Meta-analysis","score_opus":0.01675742087627859,"score_gpt":0.30062479821141896,"score_spread":0.2838673773351404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2039514741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915115,0.00022893201,0.0028075362,0.00018097684,0.000633773,0.0018378324,0.0002661665,0.00022907696,0.0023041945],"genre_scores_gemma":[0.99116564,0.00078578154,0.0053047584,0.00022814343,0.000456758,0.00022973274,0.000115647286,0.00022536125,0.0014881735],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98984396,0.00073122856,0.0036582078,0.001517287,0.0028102736,0.001439009],"domain_scores_gemma":[0.9882841,0.003615886,0.0018188662,0.0022937234,0.0027913225,0.0011960614],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016289897,0.0009747018,0.003142032,0.000518336,0.00024267792,0.000106149906,0.0010628068,0.000995645,0.0007645319],"category_scores_gemma":[0.0040242644,0.00071362994,0.00089875085,0.0011820688,0.002540542,0.00063779193,0.00071912754,0.0007650588,0.0003676532],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.040063795,0.0018112228,0.4850033,0.0031215819,0.0045312117,0.0017381494,0.0020307759,0.00021370512,0.20659822,0.0010490601,0.025616162,0.22822283],"study_design_scores_gemma":[0.026093923,0.004493102,0.8992186,0.0022757878,0.0012355633,0.00037713072,0.0006903573,0.0037271092,0.06006759,0.0005652576,0.0004083033,0.000847284],"about_ca_topic_score_codex":0.0022818048,"about_ca_topic_score_gemma":0.00011273878,"teacher_disagreement_score":0.4142153,"about_ca_system_score_codex":0.0038881607,"about_ca_system_score_gemma":0.009586489,"threshold_uncertainty_score":0.99993575},"labels":[],"label_agreement":null},{"id":"W2047725399","doi":"10.1016/j.clml.2013.03.020","title":"Subcutaneous Omacetaxine Mepesuccinate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With 2 or More Tyrosine Kinase Inhibitors Including Imatinib","year":2013,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":65,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Teva Pharmaceutical Industries","keywords":"Medicine; Nilotinib; Dasatinib; Internal medicine; Adverse effect; Gastroenterology; Imatinib; Neutropenia; Clinical endpoint; Confidence interval; Myeloid leukemia; Surgery; Randomized controlled trial; Toxicity","score_opus":0.01974581216089715,"score_gpt":0.3045457770249775,"score_spread":0.2847999648640803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2047725399","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9893976,0.0014803438,0.00003387846,0.00046774585,0.0002949927,0.0067973738,0.00008972389,0.00068229047,0.00075609435],"genre_scores_gemma":[0.99143934,0.00041443846,0.0019073243,0.00063279056,0.0009223809,0.0009328321,0.0010714559,0.00049267797,0.0021867636],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9888446,0.00048253877,0.0034750917,0.0027300837,0.0017536053,0.0027141222],"domain_scores_gemma":[0.99252146,0.0010025991,0.0014251706,0.0025307827,0.0008419021,0.0016780538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0008092487,0.0019676345,0.0033412552,0.00069447135,0.00043344373,0.00021958309,0.00084594765,0.0010862974,0.0013866517],"category_scores_gemma":[0.0007875328,0.0013277001,0.0005391811,0.0021663788,0.0011584716,0.00092559436,0.00049288064,0.0013289681,0.00071928994],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022043569,0.0033712557,0.2982164,0.0010961015,0.0013178819,0.008062768,0.00040731527,0.00031876567,0.0011649553,0.0000240643,0.00264423,0.66133267],"study_design_scores_gemma":[0.13558146,0.027636489,0.81476265,0.0040251478,0.0010791839,0.0012674889,0.000098828285,0.0073201642,0.0040319846,0.000018479406,0.0022501242,0.0019279671],"about_ca_topic_score_codex":0.0023701934,"about_ca_topic_score_gemma":0.0010440876,"teacher_disagreement_score":0.65940475,"about_ca_system_score_codex":0.039960723,"about_ca_system_score_gemma":0.0121199675,"threshold_uncertainty_score":0.9995262},"labels":[],"label_agreement":null},{"id":"W2055073381","doi":"10.1016/j.clml.2013.09.010","title":"A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation","year":2013,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Hematopoietic cell; Tyrosine kinase; Medicine; Lymphocyte; Hematopoietic stem cell transplantation; Haematopoiesis; Immunology; Transplantation; Term (time); Oncology; Cancer research; Internal medicine; Stem cell; Biology; Receptor; Genetics","score_opus":0.017275716060362396,"score_gpt":0.29798285927303064,"score_spread":0.28070714321266826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055073381","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99733895,0.0007462543,0.000014096542,0.000070065296,0.00014545985,0.0014807178,0.000041063515,0.00004064398,0.00012275612],"genre_scores_gemma":[0.9981558,0.00022534146,0.00092519127,0.00016310427,0.000035434277,0.00013913935,0.00018535127,0.00006382479,0.000106839274],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99622655,0.0001629662,0.0019794535,0.00064043066,0.00054205564,0.00044855542],"domain_scores_gemma":[0.9975137,0.0005646015,0.0006560546,0.0006739756,0.00023409358,0.00035756154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00022716387,0.00045457997,0.0015231601,0.00026258442,0.000046785306,0.000017008271,0.0001670823,0.0004014021,0.00014034266],"category_scores_gemma":[0.00012480315,0.00034560036,0.00024253535,0.00036968724,0.00048803768,0.00019255334,0.00009704426,0.00020375902,0.000037368303],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022858963,0.0015870002,0.9384838,0.0006131288,0.00014166374,0.00009360316,0.0005067305,0.000011077121,0.0006200752,0.000003929269,0.00003826253,0.055614833],"study_design_scores_gemma":[0.032060187,0.0015396507,0.9583008,0.00088439457,0.00045313375,0.000021082313,0.0000505909,0.000076799646,0.006296476,0.000011959236,0.0000075241696,0.0002973855],"about_ca_topic_score_codex":0.00042856776,"about_ca_topic_score_gemma":0.00014324133,"teacher_disagreement_score":0.05531745,"about_ca_system_score_codex":0.0010994789,"about_ca_system_score_gemma":0.00089114986,"threshold_uncertainty_score":0.9998996},"labels":[],"label_agreement":null},{"id":"W2055127103","doi":"10.3816/clml.2010.n.015","title":"Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia","year":2010,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; Rituximab; Waldenstrom macroglobulinemia; Macroglobulinemia; Internal medicine; Oncology; Proteasome inhibitor; Multiple myeloma; Lymphoma","score_opus":0.0433455937624061,"score_gpt":0.3944574783435849,"score_spread":0.3511118845811788,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2055127103","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17480767,0.81148,0.000007086577,0.000077998906,0.0011240266,0.0073668794,0.00017265399,0.00033870648,0.0046250164],"genre_scores_gemma":[0.0025256043,0.9875618,0.0012842335,0.00026552228,0.0015009174,0.0007568251,0.0019470291,0.00044152208,0.0037165454],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9896373,0.00060851144,0.0038000795,0.0025222148,0.0016663736,0.0017655115],"domain_scores_gemma":[0.9924098,0.0015894417,0.0011858551,0.0029244674,0.00045954558,0.0014308669],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010670513,0.0017442614,0.0065237093,0.00069153536,0.00015877033,0.00014267028,0.0008946485,0.0033184476,0.0003806083],"category_scores_gemma":[0.0012634334,0.0011940042,0.0018537403,0.001276864,0.00093451247,0.00019134983,0.00041336607,0.0018911766,0.0027363894],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0015979111,0.0012905209,0.0015827066,0.0034018152,0.00058736873,0.0026274978,0.000028964278,0.000001009717,1.3775004e-7,0.000089198664,0.00038946824,0.9884034],"study_design_scores_gemma":[0.051660527,0.0039919345,0.03192471,0.013923551,0.0022482607,0.0012827344,0.0000096381345,0.00017010374,0.0000026063597,0.000039269096,0.8935719,0.0011747251],"about_ca_topic_score_codex":0.0008594824,"about_ca_topic_score_gemma":0.0001959356,"teacher_disagreement_score":0.9872287,"about_ca_system_score_codex":0.081717394,"about_ca_system_score_gemma":0.07426788,"threshold_uncertainty_score":0.9995303},"labels":[],"label_agreement":null},{"id":"W2066703629","doi":"10.1016/j.clml.2012.08.004","title":"Relocalization of KIT D816V to Cell Surface After Dasatinib Treatment: Potential Clinical Implications","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Institute of Cancer Research; Institut National Du Cancer; Ligue Contre le Cancer; Conseil Régional, Île-de-France; Institut National de la Santé et de la Recherche Médicale; Centre National de la Recherche Scientifique; Association pour la Recherche sur le Cancer","keywords":"Medicine; Dasatinib; Cell; Cancer research; Internal medicine; Tyrosine kinase; Receptor","score_opus":0.027405054881650785,"score_gpt":0.312405694227233,"score_spread":0.28500063934558223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2066703629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99034697,0.0015084384,0.0009469275,0.00041729902,0.0019087787,0.00050698675,0.00017033867,0.00009474976,0.0040995236],"genre_scores_gemma":[0.9892602,0.00034849264,0.001144397,0.0005904656,0.00038852778,0.000031786072,0.00028723208,0.00004998487,0.007898939],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962302,0.0005699397,0.0018354312,0.0006242583,0.000075988966,0.000664199],"domain_scores_gemma":[0.9974978,0.0006761132,0.0004681686,0.00091982476,0.00018407733,0.00025403546],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0008409871,0.0003394922,0.0008274971,0.00008026723,0.0001668718,0.000017063314,0.00035329306,0.0007729418,0.0012677656],"category_scores_gemma":[0.00024618758,0.00029698943,0.0005044697,0.0002721948,0.0004901424,0.00013092428,0.00019168456,0.00019810158,0.002270853],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0027664765,0.004676482,0.48889107,0.00009495865,0.00055891986,0.000018798102,0.00071406947,0.00011785688,0.055654775,0.0030880363,0.024731137,0.4186874],"study_design_scores_gemma":[0.0027992378,0.00074586214,0.8060485,0.000023075696,0.00019051156,0.000024981859,0.00003380999,0.000018883753,0.005408027,0.00005719139,0.18435538,0.0002945324],"about_ca_topic_score_codex":0.00014574268,"about_ca_topic_score_gemma":0.0000229499,"teacher_disagreement_score":0.4183929,"about_ca_system_score_codex":0.00025915226,"about_ca_system_score_gemma":0.00037739475,"threshold_uncertainty_score":0.9999482},"labels":[],"label_agreement":null},{"id":"W2069385780","doi":"10.1016/j.clml.2011.03.033","title":"Addition of AEG35156 XIAP Antisense Oligonucleotide in Reinduction Chemotherapy Does Not Improve Remission Rates in Patients With Primary Refractory Acute Myeloid Leukemia in a Randomized Phase II Study","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":53,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Charles-Le Moyne; Université de Montréal; Hôpital Maisonneuve-Rosemont; Aegera Therapeutics (Canada); University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Idarubicin; Cytarabine; Medicine; Chemotherapy; Myeloid leukemia; Internal medicine; Refractory (planetary science); XIAP; Induction chemotherapy; Gastroenterology; Oncology; Randomized controlled trial; Acute leukemia; Leukemia; Pharmacology; Surgery; Apoptosis; Caspase; Biology","score_opus":0.012524397527758146,"score_gpt":0.2751546296371883,"score_spread":0.26263023210943015,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2069385780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99770135,0.00006443392,0.000069857175,0.000017652004,0.00031845993,0.001630322,0.00003292386,0.000019570496,0.00014542128],"genre_scores_gemma":[0.9974875,0.0005770286,0.00091669225,0.00012997093,0.00013834116,0.000086394255,0.0003710806,0.00005709069,0.00023593004],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9962753,0.0005849039,0.0016029705,0.0008673305,0.00029983599,0.00036963093],"domain_scores_gemma":[0.9983048,0.000112747766,0.00071058393,0.00059100037,0.00015652757,0.00012432678],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001485811,0.00037633948,0.0010410954,0.00024862617,0.00006713418,0.0000138476835,0.00021587865,0.0005292735,0.000037187558],"category_scores_gemma":[0.000254641,0.0002745359,0.00022382959,0.00028233707,0.00023516233,0.0000472288,0.0001320551,0.00024185136,0.000002245052],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18042418,0.003015892,0.0121952025,0.000050140537,0.00015726981,0.000047523798,0.0005733942,0.000018782677,0.4795633,0.000013954839,0.000038241007,0.32390213],"study_design_scores_gemma":[0.20357674,0.0042317966,0.5747704,0.00018254755,0.00007401742,0.0000041130493,0.00012058607,0.00031754334,0.21606211,0.00014490746,0.00010629415,0.00040896382],"about_ca_topic_score_codex":0.00036581638,"about_ca_topic_score_gemma":0.00011954302,"teacher_disagreement_score":0.56257516,"about_ca_system_score_codex":0.00055719906,"about_ca_system_score_gemma":0.00056298857,"threshold_uncertainty_score":0.9999707},"labels":[],"label_agreement":null},{"id":"W2072682306","doi":"10.1016/j.clml.2014.09.014","title":"Modified EBMT Pretransplant Risk Score Can Identify Favorable-risk Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for AML, Not Identified by the HCT-CI Score","year":2014,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Hematopoietic cell; Medicine; Internal medicine; Framingham Risk Score; Transplantation; Oncology; Hematopoietic stem cell transplantation; Haematopoiesis; Stem cell; Biology; Disease","score_opus":0.029110504772991874,"score_gpt":0.29127703168845037,"score_spread":0.2621665269154585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2072682306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9561708,0.00021452771,0.036673233,0.00026039046,0.0012288803,0.0030662667,0.0012979847,0.0002701047,0.00081781595],"genre_scores_gemma":[0.9923834,0.001835734,0.00093861966,0.000977638,0.00038507406,0.00033780656,0.0023142279,0.00020971957,0.0006177887],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992261,0.0010465408,0.0027075736,0.0015798452,0.0012577177,0.0011473051],"domain_scores_gemma":[0.99145955,0.004868311,0.0012335677,0.0013494211,0.00041598582,0.0006731442],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027167283,0.00084660354,0.0013720329,0.00020543125,0.000811041,0.00020723055,0.000753793,0.00087035535,0.000055324286],"category_scores_gemma":[0.00077577267,0.0006792096,0.00091033685,0.00046009436,0.0004851585,0.0002347645,0.00004846573,0.0007095769,0.00017178114],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007453243,0.0014018446,0.8391803,0.007625546,0.0010811996,0.00013145561,0.0039471206,0.0009322931,0.008106941,0.0005977869,0.005097452,0.12444482],"study_design_scores_gemma":[0.02129284,0.0011588394,0.93447363,0.0013580906,0.0033900123,0.00015442129,0.00020542298,0.0038716246,0.031522565,0.0012173601,0.00039062012,0.00096457254],"about_ca_topic_score_codex":0.00046051573,"about_ca_topic_score_gemma":0.000424341,"teacher_disagreement_score":0.123480245,"about_ca_system_score_codex":0.00061259477,"about_ca_system_score_gemma":0.0008867984,"threshold_uncertainty_score":0.9995659},"labels":[],"label_agreement":null},{"id":"W2083459234","doi":"10.3816/clml.2010.n.059","title":"Phase II Study of Obatoclax Mesylate (GX15-070), a Small-Molecule BCL-2 Family Antagonist, for Patients With Myelofibrosis","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Internal medicine; Anemia; Adverse effect; Gastroenterology; Cyclophosphamide; Rash; Surgery; Chemotherapy; Bone marrow","score_opus":0.028101131469983387,"score_gpt":0.3297646416348803,"score_spread":0.3016635101648969,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2083459234","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99241924,0.00007870701,0.000058320238,0.00019733587,0.0005873116,0.005435687,0.00022814503,0.00013471214,0.00086052675],"genre_scores_gemma":[0.9936135,0.00005646936,0.0031218433,0.000642597,0.0003548597,0.0013868243,0.0002952471,0.0001359933,0.00039265727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99517065,0.00017887558,0.001871563,0.0012903865,0.00072576996,0.00076272595],"domain_scores_gemma":[0.99540025,0.0009875308,0.000751933,0.0012699941,0.00088249677,0.0007077731],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00059471175,0.0007238982,0.0017972117,0.00018642811,0.00043765255,0.000059689097,0.0003728965,0.00045736742,0.00008201716],"category_scores_gemma":[0.0006563284,0.00052578683,0.0005417772,0.0004388641,0.00043807953,0.0001387624,0.00022283994,0.00039364293,0.000046604793],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014770713,0.04927507,0.503628,0.00019994278,0.0017783296,0.00019349884,0.000640886,0.0000023679959,0.00362709,0.00036181856,0.0020113103,0.42351097],"study_design_scores_gemma":[0.08139604,0.06599637,0.8374758,0.00020952467,0.0011337956,0.000023322807,0.00021223434,0.00022837789,0.0071691605,0.000053360294,0.005530482,0.0005715378],"about_ca_topic_score_codex":0.00015202191,"about_ca_topic_score_gemma":0.0001599115,"teacher_disagreement_score":0.42293945,"about_ca_system_score_codex":0.00035717397,"about_ca_system_score_gemma":0.0012294645,"threshold_uncertainty_score":0.9997194},"labels":[],"label_agreement":null},{"id":"W2100711325","doi":"10.3816/clml.2010.n.025","title":"Excessive Neurotoxicity With ABVD When Combined With Protease Inhibitor–Based Antiretroviral Therapy in the Treatment of AIDS-Related Hodgkin Lymphoma","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; St. Michael's Hospital; Sunnybrook Health Science Centre; University of Toronto; Health Sciences Centre","funders":"","keywords":"ABVD; Neurotoxicity; Medicine; Protease inhibitor (pharmacology); Lymphoma; Antiretroviral therapy; Hodgkin lymphoma; Human immunodeficiency virus (HIV); Virology; Oncology; Pharmacology; Internal medicine; Chemotherapy; Viral load; Toxicity; Vincristine","score_opus":0.01809085295704455,"score_gpt":0.28839843860109304,"score_spread":0.2703075856440485,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2100711325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947561,0.00015865178,0.000016202956,0.0007677361,0.00023278991,0.003004619,0.000029995223,0.00011324408,0.0009206817],"genre_scores_gemma":[0.99698627,0.000112742906,0.0004313564,0.0015446882,0.00017270958,0.00040271875,0.00007510474,0.00008724072,0.00018715234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99611294,0.00048523652,0.0011583366,0.00082787557,0.0007647165,0.0006508937],"domain_scores_gemma":[0.9971262,0.0005740204,0.0007312729,0.0010341766,0.0002399963,0.00029432392],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006344548,0.0005881742,0.0012400915,0.00018545997,0.00016294883,0.000070049595,0.00038803587,0.0005359032,0.000063101455],"category_scores_gemma":[0.00023716874,0.00032789828,0.00039502012,0.00076492404,0.0009471478,0.00020878333,0.000024537207,0.0003888857,0.000013628109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027849112,0.0054305005,0.5402335,0.000057099256,0.0003640377,0.0008731083,0.0009857588,0.00002008773,0.0029323879,0.0001638669,0.00027788876,0.42081264],"study_design_scores_gemma":[0.07380049,0.048698414,0.8687255,0.0001911672,0.00020784266,0.00005000232,0.000282357,0.00054167793,0.006057197,0.00022475366,0.00080296444,0.00041763383],"about_ca_topic_score_codex":0.0009063897,"about_ca_topic_score_gemma":0.00033937435,"teacher_disagreement_score":0.42039502,"about_ca_system_score_codex":0.000571349,"about_ca_system_score_gemma":0.0025674491,"threshold_uncertainty_score":0.9999173},"labels":[],"label_agreement":null},{"id":"W2105740844","doi":"10.3816/clml.2010.n.078","title":"Outcome of Patients With IgD and IgM Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation: A Retrospective CIBMTR Study","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University Health Network","funders":"National Cancer Institute; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; V Foundation for Cancer Research; American Cancer Society","keywords":"Medicine; Immunoglobulin D; Multiple myeloma; Hematopoietic stem cell transplantation; Transplantation; Internal medicine; Oncology; Myeloma protein; Bone marrow; Antibody; Immunology; B cell","score_opus":0.024492553527734683,"score_gpt":0.3122991664099886,"score_spread":0.28780661288225395,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2105740844","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961996,0.000068688874,0.00007823035,0.000079664795,0.00027393052,0.0021121902,0.00010568345,0.00014220239,0.0009398167],"genre_scores_gemma":[0.9976037,0.00004263452,0.00149988,0.00009447894,0.000115201816,0.000103849685,0.00008662748,0.00008605608,0.0003675322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955561,0.0002652956,0.0014534168,0.0010578599,0.0009745625,0.00069275894],"domain_scores_gemma":[0.99591076,0.0015534182,0.00046686557,0.0009274089,0.00042789325,0.00071365334],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062348833,0.0005234632,0.0013700825,0.00021678851,0.00024327588,0.000052413267,0.00027467162,0.00038043168,0.0000817516],"category_scores_gemma":[0.00039626495,0.0003932163,0.0002625194,0.00040414697,0.0006099739,0.00019893126,0.00013078263,0.00060681277,0.000055801145],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003541727,0.002182,0.94210374,0.00036488136,0.00038263752,0.0007155399,0.0007367787,0.0000012158628,0.00014920402,0.000059672762,0.000029010085,0.04973357],"study_design_scores_gemma":[0.03006519,0.004604958,0.96273404,0.00012920935,0.00043393625,0.00012464827,0.00050111907,0.00021504522,0.00073728146,0.00005571346,0.000040055464,0.0003588271],"about_ca_topic_score_codex":0.00015459028,"about_ca_topic_score_gemma":0.00058148644,"teacher_disagreement_score":0.049374744,"about_ca_system_score_codex":0.00036552906,"about_ca_system_score_gemma":0.0006994943,"threshold_uncertainty_score":0.999852},"labels":[],"label_agreement":null},{"id":"W2106082064","doi":"10.1016/j.clml.2015.07.649","title":"Novel Therapies for Chronic Lymphocytic Leukemia: A Canadian Perspective","year":2015,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Toronto; Jewish General Hospital; McGill University; BC Cancer Agency; Princess Margaret Cancer Centre; Foothills Medical Centre","funders":"","keywords":"Ibrutinib; Obinutuzumab; Venetoclax; Idelalisib; Chemoimmunotherapy; Chronic lymphocytic leukemia; Fludarabine; Medicine; Rituximab; Ofatumumab; Oncology; Internal medicine; Cyclophosphamide; Bendamustine; Leukemia; Immunology; Lymphoma; Chemotherapy","score_opus":0.14684593771245646,"score_gpt":0.4434761803015968,"score_spread":0.29663024258914034,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2106082064","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00024439945,0.9776943,0.00015347959,0.00019906167,0.0021361161,0.008154573,0.0009178466,0.00052055327,0.009979726],"genre_scores_gemma":[0.00040555105,0.97667426,0.0018691503,0.00095177384,0.0074001746,0.0022291567,0.0011382716,0.0009266132,0.008405024],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98571014,0.0006470031,0.004313651,0.0036948607,0.0019152868,0.0037190586],"domain_scores_gemma":[0.9835171,0.004227197,0.0013779786,0.0038538792,0.002348047,0.004675793],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004245972,0.0024661827,0.009347534,0.0014642767,0.0005851364,0.00033106515,0.0022999789,0.004594964,0.00032404411],"category_scores_gemma":[0.0057552676,0.0020527155,0.004907114,0.0019111994,0.0019400091,0.0003115473,0.0006593718,0.0018372423,0.0022559757],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0004799847,0.00010108079,0.00000175286,0.013042806,0.0025962836,0.0012448218,0.00023376198,0.000010826796,9.1583087e-7,0.0020290418,0.027838487,0.95242023],"study_design_scores_gemma":[0.032859806,0.0017558321,0.00011825891,0.012617427,0.00491882,0.006576729,0.00023078462,0.0031242145,0.000002230555,0.00059734186,0.9353019,0.0018966249],"about_ca_topic_score_codex":0.13294496,"about_ca_topic_score_gemma":0.024393959,"teacher_disagreement_score":0.9505236,"about_ca_system_score_codex":0.79308957,"about_ca_system_score_gemma":0.7726949,"threshold_uncertainty_score":0.9988075},"labels":[],"label_agreement":null},{"id":"W2130965960","doi":"10.1016/j.clml.2011.06.012","title":"A Prospective Phase II Study of RICE Re-Induction, Then High-Dose Fludarabine and Busulfan, Followed by Autologous or Allogeneic Blood Stem Cell Transplantation for Indolent B-Cell Lymphoma. ClinicalTrials.gov ID: NCT00144092","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; Alberta Health Services; University of Saskatchewan; University of Calgary","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Fludarabine; Mantle cell lymphoma; Busulfan; Surgery; Transplantation; Internal medicine; Etoposide; Rituximab; Carboplatin; Induction chemotherapy; Ifosfamide; Autologous stem-cell transplantation; Oncology; Chemotherapy; Lymphoma; Hematopoietic stem cell transplantation; Cyclophosphamide; Cisplatin","score_opus":0.050369952640332456,"score_gpt":0.32793063732195543,"score_spread":0.277560684681623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2130965960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901344,0.0011845345,0.000060530798,0.00014540546,0.0008682421,0.0065197265,0.0004400717,0.00021858282,0.00042851054],"genre_scores_gemma":[0.99375933,0.0015132315,0.0014552226,0.00036821864,0.00042532617,0.0013288505,0.00028328685,0.00014038499,0.0007261313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9924341,0.000670005,0.003458447,0.001885828,0.0007191828,0.0008324452],"domain_scores_gemma":[0.9940164,0.0020270536,0.0015400337,0.0011853565,0.00050582597,0.0007252931],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017118629,0.00089207664,0.0025216064,0.00023958212,0.00044019168,0.00004313012,0.00041936635,0.00081542565,0.00006611664],"category_scores_gemma":[0.00034957912,0.00066490436,0.0006088059,0.00052625773,0.00042740235,0.0002365178,0.00016850256,0.00021285319,0.000025312966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11802463,0.18643416,0.090158544,0.0014322328,0.0046591274,0.0019052797,0.012276485,0.000003639469,0.012693951,0.00012674244,0.0052999756,0.56698525],"study_design_scores_gemma":[0.22725429,0.059027974,0.65275306,0.0001969297,0.006182963,0.00023009258,0.0015276815,0.000044241428,0.05132367,0.00012720612,0.0006161436,0.00071573077],"about_ca_topic_score_codex":0.0008181789,"about_ca_topic_score_gemma":0.00008239281,"teacher_disagreement_score":0.5662695,"about_ca_system_score_codex":0.0007079562,"about_ca_system_score_gemma":0.0014938116,"threshold_uncertainty_score":0.9995802},"labels":[],"label_agreement":null},{"id":"W2147495729","doi":"10.1016/j.clml.2013.07.003","title":"Multiple Myeloma International Staging System: “Staging” or Simply “Aging” System?","year":2013,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"Cedars-Sinai Medical Center","keywords":"Staging system; Medicine; Multiple myeloma; Comorbidity; Malignancy; Hematologic malignancy; Oncology; Internal medicine; TNM staging system; Cancer","score_opus":0.11293239350661946,"score_gpt":0.41674017536947283,"score_spread":0.3038077818628534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2147495729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0032842935,0.958493,0.00041002876,0.00030404134,0.0069704056,0.009920573,0.0011302294,0.0024821407,0.017005285],"genre_scores_gemma":[0.01388642,0.9598894,0.0038275297,0.0003224063,0.0053499257,0.0020897978,0.0028098559,0.00075902,0.01106564],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9847305,0.0014681359,0.005729498,0.0031366167,0.0025117404,0.002423528],"domain_scores_gemma":[0.98644626,0.0046790694,0.002259044,0.0030956406,0.0009752906,0.0025447165],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022269385,0.0023009721,0.007802446,0.0011952015,0.0005625534,0.0006266092,0.0021307538,0.0019137838,0.0006398328],"category_scores_gemma":[0.0032697197,0.0016236724,0.003316008,0.0011433717,0.0006817219,0.0005253527,0.0013408721,0.0017680761,0.007845593],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00051934534,0.00039763606,0.0032668598,0.03965222,0.003791211,0.006696686,0.000038963597,0.0000010186158,0.0000015726844,0.0003047788,0.0066428822,0.93868685],"study_design_scores_gemma":[0.00934718,0.0006109958,0.013669761,0.054660883,0.002881493,0.0029454522,0.0003597435,0.0030074401,0.000008061402,0.000004366823,0.9109928,0.0015118354],"about_ca_topic_score_codex":0.0008291219,"about_ca_topic_score_gemma":0.000028625118,"teacher_disagreement_score":0.937175,"about_ca_system_score_codex":0.012362321,"about_ca_system_score_gemma":0.0077726953,"threshold_uncertainty_score":0.99938196},"labels":[],"label_agreement":null},{"id":"W2151220011","doi":"10.1016/j.clml.2012.09.007","title":"Normal Karyotype CALLA-Positive Adult Pre-B ALL: Dismal Outcome With Chemotherapy for Patients With Loss/Gain of ABL1 and/or BCR FISH Signals","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Vancouver General Hospital","funders":"Abbott Laboratories","keywords":"Karyotype; Myeloid leukemia; Oncology; Chemotherapy; Internal medicine; Abnormality; breakpoint cluster region; Chromosomal translocation; Biology; Medicine; Chromosome; Genetics","score_opus":0.02284942118008485,"score_gpt":0.3313068805484545,"score_spread":0.3084574593683696,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2151220011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939114,0.00005838067,0.001761187,0.00080752914,0.00016634726,0.0023528766,0.0002846992,0.000099490455,0.0005581119],"genre_scores_gemma":[0.98664695,0.000074226686,0.0067679523,0.0041678543,0.0006193305,0.00019315878,0.00028528328,0.00017866096,0.0010665667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949857,0.00021211157,0.0015217406,0.0008600027,0.0010993973,0.0013210254],"domain_scores_gemma":[0.99356943,0.0029150152,0.0006028806,0.00079279504,0.0010167921,0.0011030975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000930514,0.0006364839,0.0015349344,0.00015998064,0.00014590347,0.00004117651,0.00039512847,0.000571165,0.00012848245],"category_scores_gemma":[0.0013261124,0.00040283566,0.00029161805,0.00038863558,0.0011329396,0.00040829577,0.00019403924,0.00037615694,0.00002564466],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.056321044,0.0015816236,0.86890084,0.0004441567,0.0010363755,0.00010275853,0.00063554,0.000008274607,0.000096605254,0.00019137883,0.0020996989,0.068581685],"study_design_scores_gemma":[0.036252722,0.009396976,0.9496419,0.00041808715,0.00047644216,0.00015458638,0.000087574714,0.0010260333,0.00092786545,0.000027125854,0.0010372672,0.0005534562],"about_ca_topic_score_codex":0.00017781026,"about_ca_topic_score_gemma":0.000044532368,"teacher_disagreement_score":0.080741,"about_ca_system_score_codex":0.0012573169,"about_ca_system_score_gemma":0.0019247198,"threshold_uncertainty_score":0.99984235},"labels":[],"label_agreement":null},{"id":"W2154735909","doi":"10.1016/j.clml.2015.06.007","title":"PTHrP-Induced Refractory Malignant Hypercalcemia in a Patient With Chronic Lymphocytic Leukemia Responding to Denosumab","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Bone health and treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Chronic lymphocytic leukemia; Bone marrow; Pathology; CD38; Medicine; Cytogenetics; Biopsy; Leukemia; Karyotype; Mass cytometry; Flow cytometry; Oncology; Internal medicine; Biology; Immunology; Phenotype; Chromosome; Stem cell; Gene","score_opus":0.05665848836649529,"score_gpt":0.3473685471968315,"score_spread":0.29071005883033624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2154735909","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99098194,0.0008483998,0.000017375398,0.00041005024,0.00075634243,0.0017159542,0.000014785304,0.00026316743,0.004991987],"genre_scores_gemma":[0.99292475,0.00010311611,0.0015264404,0.0033049688,0.00037345456,0.00029568817,0.000060968756,0.00016191979,0.0012486653],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934239,0.00044149256,0.0020408682,0.0014795322,0.0010783545,0.001535877],"domain_scores_gemma":[0.9944965,0.00066649326,0.00042163918,0.0014438293,0.0003263751,0.0026451293],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011634763,0.00071902835,0.0015889885,0.0008614251,0.00016567975,0.000059148577,0.000352449,0.000749215,0.00005696184],"category_scores_gemma":[0.0013815704,0.0005659925,0.00028699473,0.001733286,0.00020763876,0.00025513864,0.0002461048,0.0005675461,0.0012706354],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.023219133,0.00060782,0.058442913,0.0002468388,0.0003087503,0.016012233,0.0011996536,0.00017798056,0.0013324757,0.00029557795,0.0036324519,0.89452416],"study_design_scores_gemma":[0.04333823,0.020505577,0.8827649,0.0026370054,0.0004007549,0.0032947958,0.0004444531,0.0020406717,0.0026961758,0.00020378332,0.04036106,0.001312582],"about_ca_topic_score_codex":0.0023208263,"about_ca_topic_score_gemma":0.0006776228,"teacher_disagreement_score":0.8932116,"about_ca_system_score_codex":0.067563236,"about_ca_system_score_gemma":0.04115594,"threshold_uncertainty_score":0.99967915},"labels":[],"label_agreement":null},{"id":"W2155971057","doi":"10.1016/j.clml.2015.09.001","title":"Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"American Society of Hematology","keywords":"Medicine; Myelofibrosis; Myeloproliferative neoplasm; Natural history; Blood transfusion; Neoplasm; Internal medicine; Pathology; Bone marrow","score_opus":0.02921214319194814,"score_gpt":0.2926505366442652,"score_spread":0.26343839345231707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2155971057","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9865511,0.0012484096,0.000005892949,0.00064719544,0.0010168626,0.0019131915,0.000043370328,0.00009075966,0.008483195],"genre_scores_gemma":[0.99646443,0.0004421052,0.00022771802,0.0006165247,0.00019252374,0.00029155854,0.00007414959,0.00007142694,0.0016195681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941506,0.0015042505,0.0017111446,0.0008764794,0.0012035891,0.0005539563],"domain_scores_gemma":[0.9916556,0.0053585833,0.0008799896,0.0009278592,0.0006767077,0.0005012644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023671119,0.0006437016,0.0018311586,0.00016833581,0.0001101588,0.000015715781,0.00040497616,0.000552394,0.00011226535],"category_scores_gemma":[0.0033805338,0.00039844724,0.000841762,0.00042929006,0.00067292014,0.0001257998,0.00011534976,0.0005551678,0.000068079076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035000667,0.009258863,0.55874306,0.0009908549,0.0038528563,0.0008639663,0.004315326,0.00008341922,0.049111396,0.0016401855,0.033899646,0.30223975],"study_design_scores_gemma":[0.022719638,0.018862698,0.6308115,0.0009222931,0.0015273796,0.00007635431,0.00013242027,0.00064367265,0.32176855,0.00009993972,0.0019304401,0.00050509325],"about_ca_topic_score_codex":0.00020292026,"about_ca_topic_score_gemma":0.00005533569,"teacher_disagreement_score":0.30173466,"about_ca_system_score_codex":0.0020096423,"about_ca_system_score_gemma":0.0026258454,"threshold_uncertainty_score":0.99984676},"labels":[],"label_agreement":null},{"id":"W2156482194","doi":"10.1016/j.clml.2012.09.003","title":"Desensitization to Lenalidomide in a Patient With Relapsed Multiple Myeloma","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Drug-Induced Adverse Reactions","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Desensitization (medicine); Thalidomide; Regimen; Internal medicine; Gastroenterology; Oncology; Pharmacology; Surgery","score_opus":0.032796412335361166,"score_gpt":0.3141479145424928,"score_spread":0.2813515022071316,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2156482194","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9860472,0.00005307015,0.00040744714,0.0007621845,0.00065680366,0.001044075,0.000010981422,0.00021110836,0.010807141],"genre_scores_gemma":[0.99062324,0.000020709456,0.0057452107,0.0023119294,0.0006053234,0.00010426931,0.000070633774,0.000097997676,0.0004206648],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965635,0.00025121405,0.0011503758,0.0006334313,0.00054643827,0.0008550304],"domain_scores_gemma":[0.99675673,0.0009646489,0.00026186183,0.000789374,0.00021951618,0.0010078627],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007050007,0.00037295904,0.0007784252,0.00032944485,0.000115629984,0.000028068824,0.00013476847,0.00037690985,0.000021484728],"category_scores_gemma":[0.0022567816,0.0003152958,0.00022930307,0.0008386144,0.00015812257,0.0003468195,0.00011873727,0.00038445272,0.000908699],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000997686,0.0008967336,0.1603027,0.000044924378,0.0001333613,0.00067806407,0.0007521464,0.00015314204,0.004959322,0.00030097316,0.00065872044,0.83012223],"study_design_scores_gemma":[0.0063124564,0.00028771267,0.9526169,0.00036773802,0.00012263251,0.0008338853,0.00046673242,0.00060460897,0.0030695407,0.000023247405,0.034902975,0.00039161785],"about_ca_topic_score_codex":0.000219526,"about_ca_topic_score_gemma":0.0001638528,"teacher_disagreement_score":0.82973063,"about_ca_system_score_codex":0.0019742502,"about_ca_system_score_gemma":0.000852007,"threshold_uncertainty_score":0.9999299},"labels":[],"label_agreement":null},{"id":"W2163290737","doi":"10.1016/j.clml.2011.09.201","title":"5.47 Tyrosine Kinase Inhibitor, Gefitinib, is Cytotoxic Against Zeta-Chain-Associated Protein Kinase 70-Positive but not Zeta-Chain-Associated Protein Kinase 70-Negative CLL Cells","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Gefitinib; Tyrosine kinase; Syk; Cancer research; Cytotoxic T cell; LYN; Kinase; Proto-oncogene tyrosine-protein kinase Src; Tyrosine-kinase inhibitor; Protein kinase B; Chemistry; Medicine; Epidermal growth factor receptor; Signal transduction; Cancer; Internal medicine; Biochemistry","score_opus":0.04686491458162083,"score_gpt":0.30493677093078114,"score_spread":0.2580718563491603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2163290737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97701955,0.0005109901,0.00007182805,0.0012883459,0.0010202704,0.01092963,0.0017945865,0.0012428346,0.006121959],"genre_scores_gemma":[0.9726081,0.00021120675,0.0012552169,0.00617624,0.001600054,0.0017873541,0.0008952704,0.0007678385,0.014698719],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9772285,0.0032673834,0.005989545,0.0046249097,0.0041115396,0.004778101],"domain_scores_gemma":[0.9832856,0.0032738904,0.0029882218,0.0037183366,0.003081107,0.003652841],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.006099004,0.0028463856,0.0050078337,0.0010125968,0.0011682047,0.00035966758,0.0020507195,0.0037062787,0.0011160265],"category_scores_gemma":[0.015183007,0.0026863688,0.0026893665,0.0029931066,0.0034581635,0.00094187073,0.0017520968,0.0033128697,0.002857312],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03125769,0.017989043,0.0015233641,0.0017486863,0.007040614,0.04251597,0.0066760583,0.00003799089,0.774202,0.0016534664,0.018399164,0.09695595],"study_design_scores_gemma":[0.08532242,0.006642161,0.037015524,0.004810118,0.0011694726,0.000220327,0.0008314542,0.010104632,0.8480484,0.0008362355,0.00152952,0.0034697799],"about_ca_topic_score_codex":0.0048986096,"about_ca_topic_score_gemma":0.00040219398,"teacher_disagreement_score":0.09348617,"about_ca_system_score_codex":0.05445056,"about_ca_system_score_gemma":0.027186658,"threshold_uncertainty_score":0.9997971},"labels":[],"label_agreement":null},{"id":"W2167992370","doi":"10.1016/j.clml.2012.08.009","title":"Lenalidomide Plus Melphalan Without Prednisone for Previously Untreated Older Patients With Multiple Myeloma: A Phase II Trial","year":2012,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Saint John Regional Hospital; University of Toronto; Western University; University of Calgary; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Dalhousie University; London Health Sciences Centre; McMaster University; University of Alberta; Queen Elizabeth II Health Sciences Centre","funders":"Canadian Cancer Society Research Institute; Celgene","keywords":"Lenalidomide; Multiple myeloma; Melphalan; Medicine; Prednisone; Internal medicine; Oncology","score_opus":0.04623544334153758,"score_gpt":0.368569340505802,"score_spread":0.3223338971642644,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2167992370","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98666286,0.00051723333,0.0005579976,0.00021900628,0.0006861437,0.009995479,0.00033561717,0.00039011586,0.00063555175],"genre_scores_gemma":[0.9866011,0.000066837376,0.0048844963,0.00045530204,0.001821365,0.0016807466,0.0018025952,0.00024470314,0.0024428295],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99264693,0.00046018398,0.0019718325,0.0013504158,0.0012722705,0.0022983758],"domain_scores_gemma":[0.99309826,0.0016649503,0.0006975612,0.0014286388,0.0007388845,0.002371718],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013317355,0.0009725064,0.0021698796,0.0002783275,0.00062833505,0.00009468028,0.00045780552,0.0006880931,0.00023426874],"category_scores_gemma":[0.0031883286,0.0006936915,0.0008349049,0.0005158659,0.00058193336,0.0006683639,0.0002910154,0.0004366822,0.0002303909],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32695064,0.011010037,0.34343088,0.00022063374,0.0016768402,0.000110063214,0.00044824107,0.000002396631,0.00008983268,0.000041475887,0.002661641,0.31335732],"study_design_scores_gemma":[0.46759415,0.01417012,0.5084291,0.00030991642,0.0008612108,0.000054798125,0.000046371795,0.0011352999,0.00061233324,0.00001674786,0.006213978,0.0005559969],"about_ca_topic_score_codex":0.00020192735,"about_ca_topic_score_gemma":0.000060371134,"teacher_disagreement_score":0.31280133,"about_ca_system_score_codex":0.0019123274,"about_ca_system_score_gemma":0.002036557,"threshold_uncertainty_score":0.9995514},"labels":[],"label_agreement":null},{"id":"W2183796916","doi":"10.1016/j.clml.2015.11.008","title":"Alemtuzumab and CHOP Chemotherapy for the Treatment of Aggressive Histology Peripheral T Cell Lymphomas: A Multi-Center Phase I Study","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Clinical Oncology Group; Princess Margaret Cancer Centre; University Health Network; McMaster University; Juravinski Hospital; Sunnybrook Health Science Centre","funders":"Canadian Cancer Society Research Institute; Cancer Research Institute","keywords":"Alemtuzumab; Medicine; CD52; CHOP; Gastroenterology; Internal medicine; Cyclophosphamide; Vincristine; Chemotherapy; Urology; Transplantation","score_opus":0.07798139945745185,"score_gpt":0.39170102953465846,"score_spread":0.3137196300772066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2183796916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880264,0.0068064746,0.00009349411,0.0007667038,0.0006454521,0.0032350754,0.000083475206,0.000070022754,0.00027292583],"genre_scores_gemma":[0.993475,0.0020046346,0.0013017491,0.0008026819,0.00044383254,0.000910725,0.00005711303,0.00007555849,0.000928714],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99686325,0.0001822568,0.0012021422,0.0008648795,0.0003444678,0.0005430286],"domain_scores_gemma":[0.9964006,0.000955657,0.0008563928,0.00092462753,0.0003116504,0.0005510604],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00040247958,0.0005412553,0.0013915774,0.00008900753,0.00017118987,0.000036014742,0.00022866578,0.0002935264,0.00004831324],"category_scores_gemma":[0.00026336475,0.00032905964,0.000587522,0.0001529689,0.00056675886,0.000076481985,0.00006413312,0.00006607286,0.000020691934],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008185268,0.040543284,0.21885283,0.000047417267,0.001213691,0.00044191294,0.003427923,0.0000025939912,0.000050350398,0.000030752413,0.0022879615,0.72491604],"study_design_scores_gemma":[0.2909936,0.030325724,0.61967075,0.000075454045,0.0011448029,0.00032441472,0.0015869942,0.0025835265,0.0010182764,0.00003112826,0.051877365,0.0003679754],"about_ca_topic_score_codex":0.0002945671,"about_ca_topic_score_gemma":0.000055601467,"teacher_disagreement_score":0.72454804,"about_ca_system_score_codex":0.0024837973,"about_ca_system_score_gemma":0.0012663233,"threshold_uncertainty_score":0.99991614},"labels":[],"label_agreement":null},{"id":"W2198348523","doi":"10.1016/j.clml.2015.07.180","title":"Noninvasive diagnosis of actionable mutations by deep sequencing of circulating cell free DNA (cfDNA) in multiple myeloma (MM)","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"KRAS; Neuroblastoma RAS viral oncogene homolog; Deep sequencing; DNA sequencing; Cell-free fetal DNA; Mutation; Genome; Medicine; Biology; Computational biology; Gene; Cancer research; Genetics; Prenatal diagnosis","score_opus":0.07559077949666501,"score_gpt":0.33915242373242827,"score_spread":0.2635616442357632,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2198348523","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993927,0.0006151787,0.00030030124,0.0002016695,0.00021042068,0.0009816737,0.00016952539,0.00007019344,0.0035240229],"genre_scores_gemma":[0.9922936,0.00013649651,0.006389703,0.00012576496,0.00015804132,0.00022261775,0.00030806818,0.00007565658,0.00029003725],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99519867,0.00037608363,0.001874598,0.0007733523,0.001008986,0.0007683324],"domain_scores_gemma":[0.99361753,0.003152336,0.0007135624,0.001010885,0.000677542,0.0008281115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010416781,0.00040126118,0.0012275609,0.00035203437,0.000119251745,0.000024991372,0.000433355,0.00044772538,0.00011568729],"category_scores_gemma":[0.008037499,0.00038326636,0.00044525554,0.0008314146,0.0005272706,0.00030151752,0.00026726245,0.00036906282,0.00007903188],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000959371,0.0011953161,0.8370013,0.00034405987,0.0003081351,0.00079995475,0.0007414617,0.0002567586,0.0073601273,0.000054333148,0.0015916033,0.14938754],"study_design_scores_gemma":[0.023861539,0.0014588068,0.8492759,0.0005502028,0.0002201935,0.00014792,0.0018884978,0.012839698,0.10808152,0.0007339477,0.0005004733,0.00044130188],"about_ca_topic_score_codex":0.00220088,"about_ca_topic_score_gemma":0.0003935616,"teacher_disagreement_score":0.14894624,"about_ca_system_score_codex":0.002248976,"about_ca_system_score_gemma":0.0028442661,"threshold_uncertainty_score":0.9998619},"labels":[],"label_agreement":null},{"id":"W2224508227","doi":"10.1016/j.clml.2015.04.042","title":"Decitabine Improves Outcomes in Older Patients with AML and Higher Blast Counts","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Medicine; Cytarabine; Azacitidine; Myeloid leukemia; Myelodysplastic syndromes; Hypomethylating agent; Internal medicine; Oncology; Chemotherapy; Bone marrow","score_opus":0.028737950033295146,"score_gpt":0.3252584698696322,"score_spread":0.29652051983633704,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2224508227","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987686,0.00016221269,0.0000101475625,0.00069753814,0.00034503953,0.0005709853,0.00001536939,0.00008151739,0.010431209],"genre_scores_gemma":[0.9903935,0.000043178257,0.0010179924,0.0015580809,0.00025658662,0.000037576163,0.00004454216,0.00007154258,0.006577009],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973964,0.00010998752,0.0007020461,0.0006029229,0.0006458573,0.0005428031],"domain_scores_gemma":[0.99788284,0.00045161956,0.00013544374,0.00056166126,0.0003142184,0.0006542066],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005825566,0.0003043025,0.000762455,0.0001612876,0.000042234282,0.00004251146,0.0002094189,0.00033171164,0.00014342407],"category_scores_gemma":[0.000808373,0.00021180556,0.00009619008,0.0003188334,0.00044515578,0.00017081923,0.000202973,0.00036878916,0.00046915878],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00080605934,0.00029484014,0.7542674,0.000032438675,0.000087861816,0.00014612637,0.000060292372,2.6610473e-7,0.00001704834,0.00008442258,0.008979291,0.23522398],"study_design_scores_gemma":[0.015822202,0.00072856847,0.96912247,0.00010957017,0.0000538356,0.000024395635,0.000038012895,0.00013347427,0.000022928609,0.00010708511,0.013589577,0.000247903],"about_ca_topic_score_codex":0.0000894357,"about_ca_topic_score_gemma":0.000019234783,"teacher_disagreement_score":0.23497608,"about_ca_system_score_codex":0.0011427987,"about_ca_system_score_gemma":0.001302196,"threshold_uncertainty_score":0.863718},"labels":[],"label_agreement":null},{"id":"W2237949876","doi":"10.1016/j.clml.2015.07.216","title":"IMiDs induced Ikaros-dependent downregulation of MYC in myeloma is mediated through the repression of the 3’ IGH enhancer activity and the NURD complex repositioning","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Psychological repression; Enhancer; Downregulation and upregulation; Cancer research; Mechanism (biology); Cell biology; Chemistry; Transcription factor; Biology; Genetics; Gene expression; Gene; Physics","score_opus":0.09292985716171397,"score_gpt":0.3854794540345133,"score_spread":0.2925495968727993,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2237949876","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925939,0.00031411272,0.000047084806,0.00316022,0.00017794708,0.0013236006,0.000026948905,0.000030164745,0.0023260403],"genre_scores_gemma":[0.99871016,0.00012849594,0.00028052778,0.00037957248,0.00015306166,0.00008949885,0.00003056819,0.000029614584,0.00019848521],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954359,0.0012315372,0.0012653935,0.00058098783,0.0010859455,0.00040022685],"domain_scores_gemma":[0.9952296,0.0021444322,0.00079185906,0.0012583479,0.00036841922,0.00020735619],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0019964809,0.00028957025,0.000879335,0.000069127236,0.00022383919,0.00003452375,0.00039531433,0.00033079396,0.000052082487],"category_scores_gemma":[0.0029125896,0.00013880811,0.00030276316,0.00053029717,0.0012470623,0.00020172191,0.0004306711,0.00043613245,0.000010899073],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.030404245,0.0017666081,0.23721808,0.0002941022,0.0012699789,0.00016170226,0.0142471865,0.000092953764,0.14939938,0.0015158938,0.0016953152,0.56193453],"study_design_scores_gemma":[0.01403509,0.00033413252,0.94004816,0.00035829024,0.00013075088,0.00006891496,0.0003938988,0.0044714264,0.03899946,0.00094516744,0.00008586419,0.00012883323],"about_ca_topic_score_codex":0.0024765886,"about_ca_topic_score_gemma":0.00014518588,"teacher_disagreement_score":0.7028301,"about_ca_system_score_codex":0.0005422486,"about_ca_system_score_gemma":0.00087799464,"threshold_uncertainty_score":0.566043},"labels":[],"label_agreement":null},{"id":"W2254870088","doi":"10.1016/j.clml.2016.01.001","title":"Differences in Quality of Life Between Bendamustine-Rituximab and R-CHOP/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University; University of Ottawa","funders":"","keywords":"Medicine; Rituximab; Mantle cell lymphoma; Bendamustine; Vincristine; Internal medicine; Prednisone; CHOP; Quality of life (healthcare); Nausea; Cyclophosphamide; Oncology; Lymphoma; Surgery; Chemotherapy","score_opus":0.031877460195867464,"score_gpt":0.3067462599513314,"score_spread":0.27486879975546397,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2254870088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964727,0.00046697303,0.000018777837,0.00030195626,0.00016408638,0.0018567237,0.00019504862,0.000088871035,0.00043484615],"genre_scores_gemma":[0.9973872,0.0007403308,0.0007733208,0.00031820463,0.00014101063,0.00021850028,0.00009926503,0.0000970298,0.00022519636],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992795,0.00054071355,0.0031169958,0.0015411534,0.0009223843,0.0010837851],"domain_scores_gemma":[0.9938653,0.002794481,0.001085253,0.001099768,0.0003000396,0.0008551568],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093040586,0.0008776346,0.003027214,0.00041957982,0.00009803984,0.000043450156,0.00041886282,0.0006329865,0.000094855575],"category_scores_gemma":[0.0011327787,0.0005182326,0.0003172301,0.00078035763,0.00068432844,0.0003207506,0.00031402515,0.00013140967,0.00006066167],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006827441,0.00370928,0.60455614,0.00021595559,0.00015490329,0.00010701019,0.0001486363,3.3893147e-7,0.000036749003,0.000018439907,0.000051373918,0.38417372],"study_design_scores_gemma":[0.13320395,0.003827262,0.85900664,0.0018172495,0.00021919035,0.000008180172,0.00011060446,0.000027530205,0.0009965509,0.000034079258,0.00014446619,0.0006043165],"about_ca_topic_score_codex":0.0011615185,"about_ca_topic_score_gemma":0.00053404237,"teacher_disagreement_score":0.3835694,"about_ca_system_score_codex":0.0018751938,"about_ca_system_score_gemma":0.002086119,"threshold_uncertainty_score":0.99972695},"labels":[],"label_agreement":null},{"id":"W2258102812","doi":"10.1016/j.clml.2015.07.549","title":"Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the upfront therapy of transplant ineligible patients with multiple myeloma","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary; University of Alberta","funders":"","keywords":"Bortezomib; Multiple myeloma; Melphalan; Regimen; Dexamethasone; Prednisone; Medicine; Cyclophosphamide; Oncology; Internal medicine; Surgery; Chemotherapy","score_opus":0.05295383253533732,"score_gpt":0.33134190167031297,"score_spread":0.27838806913497566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2258102812","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920827,0.0030116509,0.00086211466,0.0004153399,0.00023761063,0.0027656194,0.000215952,0.00008345968,0.00032551386],"genre_scores_gemma":[0.9918007,0.0016727025,0.004981049,0.0004808565,0.00020305722,0.00031495705,0.00021650874,0.00009087497,0.00023928135],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99637103,0.00018187534,0.0010984952,0.0007644327,0.0008355621,0.00074861886],"domain_scores_gemma":[0.99453324,0.0026544249,0.0003328871,0.0008847123,0.00070859434,0.0008861147],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010438228,0.00047805108,0.0010924742,0.00012120549,0.00018628623,0.000044047647,0.00033866445,0.00030588606,0.000024998884],"category_scores_gemma":[0.001191913,0.0002729544,0.00031090179,0.0003408372,0.0007320664,0.00016428364,0.000087614,0.0002493568,0.000018962144],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014669908,0.0005915762,0.5839267,0.000048791295,0.00055797125,0.00004440454,0.00016584435,0.0000068194117,0.000056017678,0.000037835453,0.0007157092,0.39917842],"study_design_scores_gemma":[0.049110048,0.0037616906,0.93369037,0.00016139362,0.0001985544,0.000036655216,0.0001001508,0.0021256118,0.0013586448,0.00012675599,0.009036862,0.00029326067],"about_ca_topic_score_codex":0.000549917,"about_ca_topic_score_gemma":0.00009958935,"teacher_disagreement_score":0.39888516,"about_ca_system_score_codex":0.0003379829,"about_ca_system_score_gemma":0.0012446983,"threshold_uncertainty_score":0.9999723},"labels":[],"label_agreement":null},{"id":"W2283642020","doi":"10.1016/j.clml.2016.02.002","title":"Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":36,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Université de Montréal; University of Toronto; Princess Margaret Cancer Centre","funders":"National Cancer Institute; University of Texas MD Anderson Cancer Center; Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Medicine; Imatinib; Adverse effect; Chronic myeloid leukaemia; Oncology; Internal medicine; Myeloid leukemia","score_opus":0.03791484173415468,"score_gpt":0.3841168110887788,"score_spread":0.34620196935462416,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2283642020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929412,0.00005938748,0.000006425091,0.00048608784,0.0002934816,0.005724811,0.000037107853,0.0000919072,0.00035958417],"genre_scores_gemma":[0.9983939,0.000016602575,0.0001141198,0.0002729784,0.00021296676,0.00035243575,0.000030250587,0.00013008929,0.00047664344],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99259603,0.0011883251,0.0023549744,0.0012102947,0.0016062804,0.0010440892],"domain_scores_gemma":[0.992478,0.0034291823,0.00096100685,0.0023202824,0.00035713086,0.00045437654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00283037,0.0007499234,0.0013698862,0.00023250397,0.00021719896,0.000012177582,0.0008608428,0.00031992575,0.0002800785],"category_scores_gemma":[0.0029385255,0.00031506555,0.000606739,0.0011982648,0.0003558049,0.00015920593,0.00035379888,0.00055221707,0.0005088351],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056915926,0.003419686,0.7887046,0.00003367527,0.0009642623,0.000051368097,0.0008407273,0.00044581303,0.0002531641,0.000013300281,0.00021620146,0.1993656],"study_design_scores_gemma":[0.05129638,0.022448663,0.9231609,0.0012603031,0.00036931096,0.000020209945,0.0001680058,0.00068315753,0.00014945073,0.00006723768,0.000017789154,0.00035860986],"about_ca_topic_score_codex":0.00071976404,"about_ca_topic_score_gemma":0.00012422018,"teacher_disagreement_score":0.19900699,"about_ca_system_score_codex":0.010030925,"about_ca_system_score_gemma":0.004682755,"threshold_uncertainty_score":0.99993014},"labels":[],"label_agreement":null},{"id":"W2286499359","doi":"10.1016/j.clml.2015.07.339","title":"Continuous Lenalidomide and Low-Dose Dexamethasone for the Treatment of Patients with Newly Diagnosed Multiple Myeloma and Renal Impairment in the First Trial","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Thalidomide; Melphalan; Internal medicine; Prednisone; Dialysis; Oncology; Surgery; Gastroenterology","score_opus":0.04745924129519422,"score_gpt":0.3306398906729909,"score_spread":0.28318064937779663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2286499359","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913945,0.0010330433,0.00005043073,0.0008767657,0.00015237466,0.0063121547,0.00010823618,0.000027145468,0.000045338424],"genre_scores_gemma":[0.99628234,0.00055448094,0.0012389778,0.00032174517,0.0003274574,0.0010330459,0.00010689474,0.000046520014,0.000088519686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996657,0.00034230846,0.0010400079,0.00066103466,0.0006753698,0.00062423816],"domain_scores_gemma":[0.9909191,0.0072397445,0.00034469622,0.00072674354,0.00026930493,0.0005004149],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0012467975,0.0004279589,0.0010549582,0.000111511894,0.00019056561,0.00006956601,0.0002340685,0.00021648195,0.000007891533],"category_scores_gemma":[0.0018635874,0.00020729717,0.00025782312,0.00024983144,0.0007322493,0.0001077568,0.000081143924,0.00015296669,0.0000057666975],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.17820291,0.003284022,0.46379602,0.00005439188,0.00045456947,0.00019572611,0.0009451981,0.000008519453,0.000006068558,0.00001562197,0.00048135893,0.3525556],"study_design_scores_gemma":[0.29012692,0.015756061,0.68850654,0.0001111629,0.00026248104,0.000020959398,0.00031729726,0.0011218808,0.000098758,0.000038425456,0.003484048,0.00015549826],"about_ca_topic_score_codex":0.00075650006,"about_ca_topic_score_gemma":0.00077947543,"teacher_disagreement_score":0.3524001,"about_ca_system_score_codex":0.00058671535,"about_ca_system_score_gemma":0.00073253043,"threshold_uncertainty_score":0.8453333},"labels":[],"label_agreement":null},{"id":"W2292288256","doi":"10.1016/j.clml.2015.07.432","title":"A Retrospective Analysis at the Princess Margaret Cancer Centre of the Initial Therapy of AL Amyloidosis: CyBorD versus Other Regimens","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Medicine; AL amyloidosis; Retrospective cohort study; Oncology; Internal medicine; First line therapy; Surgery; Multiple myeloma; Immunology","score_opus":0.04940912910403168,"score_gpt":0.36199422660039793,"score_spread":0.31258509749636626,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2292288256","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938058,0.0019233308,0.000012070703,0.0016755735,0.00062357454,0.000457903,0.0002447445,0.000017988634,0.0012390033],"genre_scores_gemma":[0.99603117,0.0014120929,0.000080232814,0.0013318241,0.00029049956,0.000091584894,0.000048144186,0.000050278402,0.0006641784],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9969178,0.00055240904,0.00087817176,0.00071641774,0.00052684685,0.00040839994],"domain_scores_gemma":[0.99696773,0.0002574633,0.00084354274,0.0013857195,0.00036397096,0.00018158519],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00059179054,0.0003670484,0.00074373966,0.00005609005,0.00012710268,0.000019952717,0.00082959095,0.0003645614,0.00013186337],"category_scores_gemma":[0.0005635773,0.0002198446,0.00094225234,0.0005883524,0.00095221197,0.000010363056,0.00049769745,0.00014268876,0.0000118657035],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002791588,0.00032281797,0.9591256,0.000006926398,0.004774061,0.000005286648,0.00027667382,0.00011264452,0.00202496,0.00012928051,0.009022255,0.021407954],"study_design_scores_gemma":[0.0060997563,0.00049513363,0.90621686,0.000030196119,0.00068117067,0.0000024525507,0.00024209188,0.000040012,0.060064506,0.000045546927,0.025812875,0.0002694033],"about_ca_topic_score_codex":0.00077736954,"about_ca_topic_score_gemma":0.0018537154,"teacher_disagreement_score":0.058039546,"about_ca_system_score_codex":0.00060594024,"about_ca_system_score_gemma":0.0008625408,"threshold_uncertainty_score":0.8965003},"labels":[],"label_agreement":null},{"id":"W2299207322","doi":"10.1016/j.clml.2015.07.324","title":"Continuous Treatment With Lenalidomide and Low-Dose Dexamethasone for Patients With Transplant-Ineligible Newly Diagnosed Multiple Myeloma in the First Trial: Impact of Age","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Alberta Cancer Foundation; Royal Victoria Hospital","funders":"","keywords":"Medicine; Lenalidomide; Dexamethasone; Multiple myeloma; Hazard ratio; Thalidomide; Prednisone; Internal medicine; Melphalan; Oncology; Randomized controlled trial; Gastroenterology; Surgery; Confidence interval","score_opus":0.05105834596086928,"score_gpt":0.34641336190987404,"score_spread":0.29535501594900476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2299207322","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928601,0.00030848477,0.000067701476,0.0002010514,0.00007817468,0.006002999,0.00026378199,0.00005464077,0.0001631044],"genre_scores_gemma":[0.99611944,0.00024249872,0.001853575,0.00015697404,0.00018700669,0.00084645307,0.00041431817,0.000087583314,0.0000921287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.996042,0.00033818383,0.0011758986,0.0008191197,0.0007561921,0.000868616],"domain_scores_gemma":[0.99341315,0.0042464905,0.00039918028,0.00083371904,0.00034436453,0.0007631134],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009594138,0.00061326567,0.0016447076,0.00021688094,0.00012426317,0.00007057993,0.00029263375,0.00028716607,0.000010202449],"category_scores_gemma":[0.0011108429,0.00031255904,0.00043806902,0.00044149623,0.00055849424,0.00017815016,0.00004269275,0.00020199256,0.000010472717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25488105,0.003276519,0.6235626,0.00009044432,0.00068988185,0.0009801271,0.00071947154,0.000021810498,0.00001503206,0.0000059448435,0.00024643636,0.1155107],"study_design_scores_gemma":[0.3227519,0.026645869,0.6485217,0.000313764,0.0003130963,0.000052960324,0.00013724738,0.00048372868,0.00011725497,0.000023935803,0.00039829014,0.00024018886],"about_ca_topic_score_codex":0.0027127047,"about_ca_topic_score_gemma":0.0017342907,"teacher_disagreement_score":0.11527052,"about_ca_system_score_codex":0.0010046862,"about_ca_system_score_gemma":0.0016531224,"threshold_uncertainty_score":0.99993265},"labels":[],"label_agreement":null},{"id":"W2301842411","doi":"10.1016/j.clml.2015.07.298","title":"A single centre retrospective analysis of diagnostic fluorescence in situ hybridisation reveals distinct groups of cytogenetic abnormalities, which affect early survival of new myeloma diagnosis","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Thomas Hospital","funders":"","keywords":"Fluorescence in situ hybridization; Multiple myeloma; Multivariate analysis; Fish <Actinopterygii>; Internal medicine; Oncology; Biology; Multivariate statistics; Affect (linguistics); Medicine; Pathology; Genetics; Gene; Chromosome; Psychology","score_opus":0.061943823010377916,"score_gpt":0.3387572941521385,"score_spread":0.2768134711417606,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2301842411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99685585,0.0006086532,0.00007029864,0.00012213986,0.00019027016,0.001068315,0.00025679605,0.000041650335,0.00078604213],"genre_scores_gemma":[0.99817985,0.0002512317,0.00078118674,0.000018690156,0.00018182836,0.000053914882,0.00034204344,0.000053528776,0.00013773248],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9935688,0.00095281145,0.0023836496,0.0008902309,0.0014575648,0.00074696494],"domain_scores_gemma":[0.9901641,0.0058037266,0.0010275323,0.0010896049,0.0009999737,0.00091505604],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017892357,0.00046984895,0.0024617622,0.0006845347,0.00004628362,0.000024173954,0.00042075847,0.00034662374,0.00008823686],"category_scores_gemma":[0.023926541,0.00042406312,0.0007257078,0.0029219422,0.00053547707,0.00020115901,0.0002467601,0.00026798467,0.000020693476],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018749194,0.0014206916,0.9324846,0.00021760035,0.0015223023,0.00022277827,0.00075597496,0.00003259233,0.0014123775,0.00014274029,0.00020010692,0.05971328],"study_design_scores_gemma":[0.008032766,0.002420636,0.9753942,0.0006805049,0.0016433285,0.000010440309,0.00024935632,0.0005146965,0.010378025,0.0003624111,0.0000147749215,0.00029886016],"about_ca_topic_score_codex":0.0038445655,"about_ca_topic_score_gemma":0.0035298422,"teacher_disagreement_score":0.059414424,"about_ca_system_score_codex":0.0016271624,"about_ca_system_score_gemma":0.0016934394,"threshold_uncertainty_score":0.9998211},"labels":[],"label_agreement":null},{"id":"W2308400377","doi":"10.1016/j.clml.2015.07.338","title":"Long Term Cryopreserved Autologous Blood Stem Cells For Salvage Autologous Stem Cell Transplantation (ASCT) in Relapsed Multiple Myeloma (MM) Patients","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Cryopreservation; Medicine; Stem cell; Autologous stem-cell transplantation; Multiple myeloma; Transplantation; Autologous blood; Surgery; Oncology; Internal medicine; Biology","score_opus":0.05442501528796141,"score_gpt":0.3211895658432269,"score_spread":0.2667645505552655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2308400377","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922035,0.0005391329,0.00023842673,0.0001372025,0.0009989209,0.00426794,0.0003642895,0.00040776198,0.00084282615],"genre_scores_gemma":[0.9935064,0.00018684058,0.002092103,0.00030299436,0.00031949993,0.00060711615,0.0008273565,0.00019467538,0.001963018],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918679,0.00086638867,0.002572871,0.0017430395,0.001198831,0.0017509661],"domain_scores_gemma":[0.99311185,0.0025916565,0.0006710215,0.0013529521,0.00062042754,0.0016521211],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015088832,0.000887239,0.0018659108,0.00047196442,0.00024435436,0.000111855355,0.00074209605,0.0011530778,0.000043109103],"category_scores_gemma":[0.00050300406,0.00079175015,0.00078025984,0.000605506,0.0004140716,0.00032606858,0.00021215939,0.00065892213,0.00033824373],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009156208,0.0026743915,0.63795567,0.0006576736,0.0003496432,0.0027439527,0.0005044737,0.00004095718,0.0011517453,0.000011915704,0.00093380985,0.3438196],"study_design_scores_gemma":[0.069032885,0.0038880769,0.9028697,0.00036067315,0.0005138414,0.00012619914,0.00014855791,0.003396038,0.018624503,0.000046123412,0.00031524734,0.00067815493],"about_ca_topic_score_codex":0.00027197797,"about_ca_topic_score_gemma":0.0003178038,"teacher_disagreement_score":0.3431414,"about_ca_system_score_codex":0.0014065125,"about_ca_system_score_gemma":0.0020419967,"threshold_uncertainty_score":0.99945337},"labels":[],"label_agreement":null},{"id":"W2315067778","doi":"10.1016/j.clml.2015.07.162","title":"Moderate/Severe Grade of Chronic Graft Versus Host Disease and Younger Age (Less Than 45 Years Old) Are Risk Factors for Avascular Necrosis in Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Bone and Joint Diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Avascular necrosis; Medicine; Transplantation; Disease; Hematopoietic cell; Complication; Surgery; Graft-versus-host disease; Haematopoiesis; Hematopoietic stem cell transplantation; Necrosis; Internal medicine; Stem cell; Biology; Femoral head","score_opus":0.03586748771741347,"score_gpt":0.2859563984696677,"score_spread":0.2500889107522542,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2315067778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974093,0.0009039696,0.000072132745,0.000056968747,0.00029554308,0.0008713779,0.00032044327,0.000048201007,0.000022094502],"genre_scores_gemma":[0.9974485,0.0015086994,0.00017434717,0.00013069762,0.000101585014,0.00006258702,0.00045445544,0.000064183936,0.000054915614],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99748313,0.00019215587,0.0008657827,0.00061863894,0.00041910715,0.00042118444],"domain_scores_gemma":[0.9976984,0.0006480286,0.00035465046,0.0004302164,0.00017497761,0.0006937221],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025741814,0.00032992277,0.00078567804,0.00012605266,0.00007140385,0.0000338601,0.00013135091,0.00027748948,0.00000637336],"category_scores_gemma":[0.0005997875,0.00030408826,0.0004201911,0.00018277639,0.00022089099,0.00019922777,0.00004912191,0.00016272011,0.0000075156345],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006158971,0.0010368807,0.984318,0.0013052654,0.0002552256,0.00025166868,0.0009114551,0.0001609699,0.0001156923,0.000031538537,0.00027406344,0.005180265],"study_design_scores_gemma":[0.025514336,0.00084774866,0.9697831,0.0005814943,0.0010535339,0.0000037431328,0.0004681171,0.00057506276,0.0005416153,0.0002633122,0.000029293271,0.00033863573],"about_ca_topic_score_codex":0.00038702498,"about_ca_topic_score_gemma":0.00039165135,"teacher_disagreement_score":0.019355366,"about_ca_system_score_codex":0.00048278482,"about_ca_system_score_gemma":0.0008752072,"threshold_uncertainty_score":0.9999411},"labels":[],"label_agreement":null},{"id":"W2332763467","doi":"10.1016/j.clml.2015.07.588","title":"A Phase 1/2 Trial of the Insulin Growth Factor 1 Receptor (IGF-1R) inhibitor, Linsitinib in Combination with Bortezomib (BTZ) and Dexamethasone (Dex) for the Treatment of Relapsed/Refractory Multiple Myeloma (MM)","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Jewish General Hospital; Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Dexamethasone; Pharmacology; Multiple myeloma; Insulin-like growth factor; Medicine; Refractory (planetary science); Clinical trial; Proteasome inhibitor; Receptor; Internal medicine; Oncology; Growth factor; Biology","score_opus":0.07643165159987207,"score_gpt":0.3600412260199811,"score_spread":0.28360957442010903,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2332763467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919453,0.0010743858,0.00008442123,0.0006942205,0.00053671934,0.0052210526,0.0002862568,0.000046004774,0.000111619214],"genre_scores_gemma":[0.99605405,0.0008619186,0.0015397439,0.00010812462,0.00043314326,0.0005405859,0.00013777701,0.000077762525,0.00024687048],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9954707,0.000621714,0.001683251,0.000751069,0.00088387704,0.00058939966],"domain_scores_gemma":[0.9914727,0.0055370866,0.000819765,0.00095296965,0.00068083976,0.00053661386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011599094,0.0005008015,0.001368693,0.00020613025,0.00015533193,0.000034174886,0.00031730256,0.00045343876,0.000019284838],"category_scores_gemma":[0.0053260797,0.00027380462,0.00046799707,0.0005763058,0.0009429808,0.0001826729,0.0001105838,0.00030320443,0.00000920889],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.23104772,0.014001933,0.086187124,0.0001427342,0.0007575459,0.00005833979,0.0012535348,0.000002795509,0.0015386639,0.00009253433,0.0003841631,0.6645329],"study_design_scores_gemma":[0.46963832,0.037271984,0.47236928,0.00030697792,0.00032945754,0.000027568009,0.00039726085,0.0020983864,0.012901843,0.00011636593,0.004264821,0.00027773567],"about_ca_topic_score_codex":0.0005708738,"about_ca_topic_score_gemma":0.00024177265,"teacher_disagreement_score":0.6642552,"about_ca_system_score_codex":0.0012017577,"about_ca_system_score_gemma":0.002392843,"threshold_uncertainty_score":0.9999714},"labels":[],"label_agreement":null},{"id":"W2333953137","doi":"10.1016/j.clml.2011.09.190","title":"5.36 Effect of Valproic Acid on Fludarabine Activity in Chronic Lymphocytic Leukemia","year":2011,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; Apoptosis; Medicine; XIAP; Pharmacology; Histone deacetylase inhibitor; Cancer research; Histone deacetylase; Programmed cell death; Leukemia; Immunology; Histone; Caspase; Internal medicine; Chemotherapy; Biology; Biochemistry","score_opus":0.0516179069728787,"score_gpt":0.3532618317112995,"score_spread":0.3016439247384208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2333953137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9798751,0.0008092747,0.000046466495,0.000049491966,0.00073900877,0.0020673948,0.000024382958,0.00030695926,0.016081944],"genre_scores_gemma":[0.99639004,0.00046601155,0.00033216167,0.00033485668,0.00079634826,0.0002493322,0.00004119052,0.0002200535,0.0011699757],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9906898,0.0012143049,0.002539355,0.0019658164,0.001681061,0.0019096584],"domain_scores_gemma":[0.9922715,0.0027894876,0.000731467,0.0028455886,0.00028176632,0.0010801823],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0039444836,0.0010739352,0.003033851,0.0007740475,0.00014544946,0.000036336663,0.0011261625,0.0013109924,0.00066645077],"category_scores_gemma":[0.0034570808,0.00089282525,0.0012079419,0.0015967389,0.0014881066,0.00032857113,0.00059087697,0.0011592369,0.0013664786],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.049343124,0.00080150575,0.015119677,0.0029658102,0.00092370313,0.004988559,0.00048962346,0.00025184028,0.029959695,0.0006175437,0.0022725214,0.8922664],"study_design_scores_gemma":[0.086901136,0.013731507,0.60272163,0.001760158,0.00041144982,0.00067434274,0.000025498488,0.031100793,0.26046938,0.00027566432,0.00095816,0.0009703025],"about_ca_topic_score_codex":0.0032880523,"about_ca_topic_score_gemma":0.00016265867,"teacher_disagreement_score":0.8912961,"about_ca_system_score_codex":0.2510769,"about_ca_system_score_gemma":0.08556637,"threshold_uncertainty_score":0.9999855},"labels":[],"label_agreement":null},{"id":"W2345460629","doi":"10.1016/j.clml.2015.07.606","title":"A single centre retrospective analysis of the addition of clarithromycin (biaxin) to lenalidomide and dexamethasone (len-dex) during time of progressive disease in patients with multiple myeloma (MM)","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Dexamethasone; Clarithromycin; Medicine; Multiple myeloma; Internal medicine; Oncology; Progressive disease; Disease; Pharmacology","score_opus":0.021835613811933528,"score_gpt":0.2889869361719164,"score_spread":0.26715132235998285,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2345460629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976265,0.00013829024,0.00001290416,0.00015493753,0.000036868052,0.0014796602,0.0004613473,0.000021378206,0.000068156645],"genre_scores_gemma":[0.9983353,0.000006657962,0.0012007328,0.000046952293,0.000042529762,0.000045155837,0.00019613391,0.000038566475,0.0000879778],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961936,0.00044325454,0.0011813578,0.0006825316,0.0010321728,0.0004671163],"domain_scores_gemma":[0.99627274,0.0006349823,0.00070558337,0.0008069198,0.0008380555,0.0007417226],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00049796415,0.00032305447,0.0013927101,0.00043333924,0.000058232974,0.0000144542555,0.00023064179,0.00019700722,0.00006396873],"category_scores_gemma":[0.0035172354,0.00022100637,0.00035670862,0.0014878071,0.0006349419,0.00015309709,0.0002194277,0.00020901131,0.000006551745],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014377873,0.0018460002,0.9633373,0.000121594916,0.0014329941,0.000074640375,0.00038780167,0.00007747589,0.00079620635,0.000010102776,0.000036957706,0.017501075],"study_design_scores_gemma":[0.02008457,0.0012834717,0.96966714,0.0007651976,0.001086495,0.00000259072,0.00013108856,0.0013538062,0.0053932015,0.0000338212,0.0000072958715,0.00019130921],"about_ca_topic_score_codex":0.00030172113,"about_ca_topic_score_gemma":0.00017800402,"teacher_disagreement_score":0.017309764,"about_ca_system_score_codex":0.0009514286,"about_ca_system_score_gemma":0.0007176652,"threshold_uncertainty_score":0.9012378},"labels":[],"label_agreement":null},{"id":"W2346817266","doi":"10.1016/j.clml.2016.04.012","title":"Cyclophosphamide and Bortezomib With Prednisone or Dexamethasone for the Treatment of Relapsed and Refractory Multiple Myeloma","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Bortezomib; Prednisone; Cyclophosphamide; Tolerability; Dexamethasone; Regimen; Internal medicine; Multiple myeloma; Refractory (planetary science); Gastroenterology; Peripheral neuropathy; Surgery; Chemotherapy; Adverse effect; Endocrinology","score_opus":0.05131108994435344,"score_gpt":0.344220347304109,"score_spread":0.29290925735975554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346817266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991696,0.0036831857,0.00053735595,0.00108185,0.0001312314,0.002477367,0.00016184794,0.00008449485,0.00014667158],"genre_scores_gemma":[0.9783629,0.010917704,0.0066441223,0.00016058427,0.00026867603,0.00048791367,0.000029728199,0.0000880637,0.003040313],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968117,0.0001752847,0.00097040425,0.00089788495,0.00045908985,0.00068565225],"domain_scores_gemma":[0.9881351,0.009606814,0.00036675882,0.00095780427,0.00025637203,0.0006771786],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005668084,0.0004813686,0.0011377936,0.000104979714,0.00024773608,0.000033294535,0.00017595211,0.0003249666,0.000058546833],"category_scores_gemma":[0.0019515383,0.00020573621,0.00025695332,0.00021309212,0.001280379,0.00015272835,0.000083899664,0.000106236,0.0000142123245],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0251583,0.0007741332,0.22627507,0.00008849658,0.00091406953,0.00019444955,0.00013416974,2.557025e-7,0.0014721957,0.000044605786,0.0002513593,0.74469286],"study_design_scores_gemma":[0.048772722,0.013538251,0.9077841,0.00032781146,0.0005388907,0.00022139137,0.00011782215,0.00041755495,0.0045658736,0.00007588389,0.023372184,0.0002675153],"about_ca_topic_score_codex":0.00022505486,"about_ca_topic_score_gemma":0.00019983691,"teacher_disagreement_score":0.74442536,"about_ca_system_score_codex":0.00060392206,"about_ca_system_score_gemma":0.00094068114,"threshold_uncertainty_score":0.838968},"labels":[],"label_agreement":null},{"id":"W2346818737","doi":"10.1016/j.clml.2016.03.005","title":"Bortezomib-Containing Regimens for the Treatment of Newly Diagnosed and Relapsed Amyloid Light Chain Amyloidosis: A Single-Center Experience","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation","funders":"","keywords":"Bortezomib; Amyloidosis; AL amyloidosis; Immunoglobulin light chain; Medicine; Amyloid (mycology); Oncology; Single Center; Center (category theory); Internal medicine; Multiple myeloma; Pathology; Immunology; Chemistry","score_opus":0.029460334528527244,"score_gpt":0.302709273698907,"score_spread":0.27324893917037973,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2346818737","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992048,0.0032469695,0.000571691,0.0020951626,0.00048222896,0.0012486975,0.000119345066,0.000051787534,0.0001360801],"genre_scores_gemma":[0.98919415,0.0062639695,0.0008700488,0.0009003931,0.00053005613,0.001236245,0.000045299206,0.00008818831,0.00087166793],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9966635,0.00019438715,0.0011352389,0.0010964131,0.00023676951,0.00067366386],"domain_scores_gemma":[0.99614745,0.0016612426,0.00058012595,0.0011524312,0.00015518547,0.0003035409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00037753323,0.0005468362,0.0007917437,0.00006719175,0.00024284149,0.000050248163,0.0004514953,0.00045201005,0.000021050158],"category_scores_gemma":[0.00090877473,0.0003238487,0.00062423665,0.00013073167,0.000629954,0.000022889055,0.00016237149,0.000053394095,0.000013540829],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022904547,0.0015790932,0.27079767,0.000026424856,0.0009570075,0.000036043748,0.0008592905,0.0000029452299,0.0841382,0.00017633438,0.0028838357,0.6362527],"study_design_scores_gemma":[0.03061424,0.009654138,0.58631307,0.0002787765,0.00046013788,0.00006411802,0.000832737,0.000048384038,0.2067401,0.00009631547,0.16397978,0.00091818476],"about_ca_topic_score_codex":0.000073970295,"about_ca_topic_score_gemma":0.00011083236,"teacher_disagreement_score":0.63533455,"about_ca_system_score_codex":0.0004164878,"about_ca_system_score_gemma":0.00029605036,"threshold_uncertainty_score":0.9999214},"labels":[],"label_agreement":null},{"id":"W2410851753","doi":"10.1016/j.clml.2016.06.001","title":"Revised International Staging System Applied to Real World Multiple Myeloma Patients","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services","funders":"","keywords":"Medicine; Multiple myeloma; Staging system; Real world data; Oncology; Internal medicine; Cancer; Data science","score_opus":0.03628137295759545,"score_gpt":0.3403525894437358,"score_spread":0.3040712164861404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2410851753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96067953,0.000020463878,0.00039052533,0.0013102327,0.0011110668,0.0018042672,0.00016320733,0.00047570193,0.034045007],"genre_scores_gemma":[0.9878152,0.000075975695,0.0030276862,0.00078835845,0.0011448163,0.00030385022,0.00021106306,0.00012242504,0.0065106493],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994282,0.00023049577,0.00170185,0.0013384873,0.0013440562,0.001103133],"domain_scores_gemma":[0.9948667,0.0014189014,0.000369253,0.001209356,0.0005360969,0.0015996451],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008793737,0.00055780396,0.0011103958,0.00049819844,0.00021939867,0.00009494838,0.00065004255,0.00028053095,0.0003008681],"category_scores_gemma":[0.001784572,0.00038483113,0.0004837389,0.00057631,0.00024882282,0.00020642737,0.0004951716,0.00023999123,0.0030767838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029969388,0.00032448093,0.4819785,0.00007421347,0.0003085327,0.00023212149,0.000038811835,7.944719e-7,0.0007602341,0.00053687836,0.003635567,0.50911295],"study_design_scores_gemma":[0.020173699,0.0004509847,0.9521636,0.0008419245,0.00009500627,0.000015717347,0.000040990137,0.00029484858,0.001081672,0.000034083507,0.0243847,0.00042278558],"about_ca_topic_score_codex":0.00021849314,"about_ca_topic_score_gemma":0.000078569006,"teacher_disagreement_score":0.5086901,"about_ca_system_score_codex":0.0040265336,"about_ca_system_score_gemma":0.0008069777,"threshold_uncertainty_score":0.99986035},"labels":[],"label_agreement":null},{"id":"W2411574854","doi":"10.1016/j.clml.2016.06.006","title":"Vaccination in Multiple Myeloma: Review of Current Literature","year":2016,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Aurora Research Institute","keywords":"Multiple myeloma; Vaccination; Medicine; Current (fluid); Virology; Immunology; Engineering","score_opus":0.10768974702617448,"score_gpt":0.445554923738294,"score_spread":0.33786517671211946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2411574854","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00017909546,0.9927259,0.000015204852,0.00012868369,0.00083260913,0.004185835,0.0004354016,0.00009920171,0.0013980819],"genre_scores_gemma":[0.0002967658,0.99498385,0.0003081882,0.00016903834,0.0009226016,0.0006175331,0.0017829086,0.00017062167,0.0007485064],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.990211,0.0013529232,0.004632241,0.0015840231,0.001179419,0.0010403695],"domain_scores_gemma":[0.99182385,0.003085645,0.0016598263,0.0019056837,0.00068162597,0.00084335264],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021170166,0.0011454722,0.0066469987,0.00079038145,0.00008210422,0.000041190557,0.00075521035,0.0012607438,0.0004667462],"category_scores_gemma":[0.007963673,0.0007361319,0.0027483758,0.0015911933,0.00023523283,0.00022957775,0.00041436398,0.0011425392,0.00089468947],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00018784207,0.00059191167,0.000968661,0.1802324,0.00034484643,0.0005345293,0.000009703972,6.654602e-9,3.5243312e-7,0.00007322771,0.0034542936,0.8136022],"study_design_scores_gemma":[0.0040041204,0.0002875171,0.04280297,0.3778717,0.00058022933,0.00018294448,0.0000010025583,0.000008067513,0.0000024759465,0.000041196126,0.5738353,0.00038247398],"about_ca_topic_score_codex":0.000014924722,"about_ca_topic_score_gemma":0.000010641098,"teacher_disagreement_score":0.8132197,"about_ca_system_score_codex":0.00280384,"about_ca_system_score_gemma":0.0047076703,"threshold_uncertainty_score":0.99988323},"labels":[],"label_agreement":null},{"id":"W2511176690","doi":"10.1016/j.clml.2016.08.010","title":"Myelomatous Involvement of the Central Nervous System","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":60,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"","keywords":"Medicine; Central nervous system; Multiple myeloma; Cerebrospinal fluid; Odds ratio; Magnetic resonance imaging; Confidence interval; Complication; Bone marrow; Cohort; Plasma cell; Internal medicine; Pathology; Gastroenterology; Radiology","score_opus":0.03741777232020433,"score_gpt":0.3179641029791642,"score_spread":0.2805463306589599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2511176690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991946,0.00027823204,0.00011661385,0.0011596477,0.0008679981,0.0010821625,0.00006840673,0.00016856336,0.00431241],"genre_scores_gemma":[0.9961688,0.00012684957,0.00044988355,0.00036374468,0.0004952056,0.00007543495,0.000013667386,0.000060747374,0.002245678],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99554574,0.00038437618,0.0014256653,0.00067922636,0.0010058301,0.00095913],"domain_scores_gemma":[0.9962572,0.00076609035,0.0004251443,0.0014963606,0.0002766707,0.0007785474],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00066328177,0.00037305232,0.0009148842,0.00009906109,0.00017362986,0.000023300601,0.0005713236,0.0003218019,0.0001413026],"category_scores_gemma":[0.00094784907,0.0001823769,0.00080657634,0.00036201187,0.00070316193,0.0001060001,0.0003806348,0.0001692231,0.00035473783],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009177642,0.00036603314,0.34125507,0.00023461832,0.0004308712,0.00032781065,0.000048664355,7.663259e-7,0.0026965362,0.0014699347,0.0021054957,0.6501464],"study_design_scores_gemma":[0.0085610915,0.00055767194,0.9750032,0.0009207586,0.00016967644,0.00021654714,0.000090477464,0.00018433352,0.008331556,0.000107383064,0.0056515853,0.00020571971],"about_ca_topic_score_codex":0.00027951927,"about_ca_topic_score_gemma":0.000036463876,"teacher_disagreement_score":0.6499407,"about_ca_system_score_codex":0.0018512979,"about_ca_system_score_gemma":0.0016580118,"threshold_uncertainty_score":0.7437114},"labels":[],"label_agreement":null},{"id":"W2523106824","doi":"10.1016/j.clml.2016.07.094","title":"Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Imatinib; Medicine; Tyrosine-kinase inhibitor; Myeloid leukemia; Internal medicine; Tyrosine kinase; Oncology; Dasatinib","score_opus":0.025605541508677207,"score_gpt":0.3167900096385131,"score_spread":0.2911844681298359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523106824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248827,0.002563623,0.00008615478,0.00053057796,0.0006327183,0.0027831683,0.0001604976,0.0003071885,0.00044783365],"genre_scores_gemma":[0.9889298,0.0014474187,0.0013932007,0.00032076632,0.0011442361,0.00035424388,0.00039494433,0.00031442876,0.0057009235],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99067616,0.00049991097,0.003154294,0.0026396234,0.0010601075,0.00196989],"domain_scores_gemma":[0.99309564,0.0018851743,0.0008232331,0.002749956,0.0001916558,0.0012543363],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0009646756,0.001526887,0.0029557387,0.0006616233,0.00022360381,0.00007568934,0.0007745632,0.0011462129,0.0008328905],"category_scores_gemma":[0.001542125,0.00094873935,0.0005881155,0.0009952149,0.0007125224,0.0007176846,0.00051437685,0.00060269446,0.00017261984],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013435947,0.0014845254,0.30643076,0.00021623928,0.00047130574,0.0025798047,0.00013294825,0.000024899571,0.0027168347,0.000026204088,0.00048753794,0.671993],"study_design_scores_gemma":[0.24162652,0.015691455,0.7225223,0.0027443094,0.0004715077,0.00021457917,0.000031327723,0.0010032012,0.0024262958,0.0000791479,0.012105183,0.0010841367],"about_ca_topic_score_codex":0.0011062962,"about_ca_topic_score_gemma":0.0049329815,"teacher_disagreement_score":0.67090887,"about_ca_system_score_codex":0.063873895,"about_ca_system_score_gemma":0.017683677,"threshold_uncertainty_score":0.999748},"labels":[],"label_agreement":null},{"id":"W2523708385","doi":"10.1016/j.clml.2016.08.006","title":"An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices","year":2016,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":40,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Comprehensive Cancer Network; Takeda Oncology; Takeda Pharmaceutical Company","keywords":"Medicine; Internal medicine; Retrospective cohort study; Myeloid leukemia; Medical record; Cancer; Cohort; Pediatrics","score_opus":0.04286069260701756,"score_gpt":0.3989409932947389,"score_spread":0.35608030068772134,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2523708385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972338,0.00007832865,0.00010038414,0.0005526722,0.000097520555,0.0013318118,0.0003180973,0.000049149152,0.00023823525],"genre_scores_gemma":[0.9967564,0.0016775763,0.00047230572,0.00026248884,0.00010131098,0.0002152346,0.0004089994,0.00006131307,0.000044373603],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9901793,0.004094892,0.0020735464,0.0010052248,0.0018663784,0.0007806454],"domain_scores_gemma":[0.98701847,0.00756415,0.0019764283,0.0015768101,0.0012083714,0.00065576704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0050434307,0.0005284937,0.0027521495,0.00071327767,0.00012062182,0.000023266206,0.0005924135,0.00092469476,0.00033651132],"category_scores_gemma":[0.0071526254,0.0003325926,0.00041401864,0.0011225538,0.00090840046,0.0004327463,0.00021575799,0.00086770917,0.0000080835025],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0031053626,0.0014479172,0.63091195,0.000015298869,0.0040912325,0.00009675226,0.00051923207,0.000006001022,0.0002013807,0.000013718812,0.000016801607,0.35957435],"study_design_scores_gemma":[0.034934577,0.021481378,0.9314091,0.00022888677,0.006441696,0.000020518839,0.00045836618,0.0040614866,0.00040134252,0.00018168252,0.000073444004,0.00030747076],"about_ca_topic_score_codex":0.04315553,"about_ca_topic_score_gemma":0.061753035,"teacher_disagreement_score":0.35926688,"about_ca_system_score_codex":0.018979678,"about_ca_system_score_gemma":0.014137339,"threshold_uncertainty_score":0.9999126},"labels":[],"label_agreement":null},{"id":"W2588432408","doi":"10.1016/j.clml.2017.02.009","title":"Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Karyotype; Oncology; Univariate analysis; Internal medicine; White blood cell; Myeloid leukemia; Leukemia; Medicine; Lymphoblastic Leukemia; Biology; Chromosome; Multivariate analysis; Genetics; Gene","score_opus":0.027078453148965998,"score_gpt":0.33114300448424244,"score_spread":0.30406455133527643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2588432408","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97897357,0.00059765694,0.000045511155,0.00030345775,0.0005479547,0.0018426708,0.00012663807,0.00018183763,0.017380698],"genre_scores_gemma":[0.99406457,0.0006033885,0.0009703206,0.00040666055,0.0006845486,0.0001795685,0.00016314018,0.00018860215,0.0027391952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921254,0.00065871724,0.0025856595,0.001633198,0.0013175039,0.001679557],"domain_scores_gemma":[0.9897559,0.005033317,0.0011336644,0.0025484662,0.00039268212,0.0011359251],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0020231383,0.0010421892,0.002925331,0.00051545235,0.0005387699,0.00023458048,0.0014318976,0.0010779257,0.00023250918],"category_scores_gemma":[0.0042279204,0.0008901897,0.0006275195,0.00045068856,0.0031321046,0.000640438,0.0014003719,0.00082037796,0.00030814076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011000482,0.0006872449,0.87748057,0.0021713253,0.0009125551,0.0055799987,0.0002596557,0.00003530068,0.0073206457,0.0005050601,0.007166023,0.08688117],"study_design_scores_gemma":[0.027913997,0.0044612135,0.9502577,0.00095073937,0.00076651573,0.0010442688,0.00004202635,0.009668233,0.0029796716,0.00027010153,0.00087394106,0.0007715794],"about_ca_topic_score_codex":0.00093411026,"about_ca_topic_score_gemma":0.00007396994,"teacher_disagreement_score":0.086109586,"about_ca_system_score_codex":0.0034867907,"about_ca_system_score_gemma":0.005176611,"threshold_uncertainty_score":0.9995808},"labels":[],"label_agreement":null},{"id":"W2605893447","doi":"10.1016/j.clml.2017.03.075","title":"Evaluating the Role of Tregs in the Progression of Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; Child and Family Research Institute","funders":"","keywords":"Multiple myeloma; Immunology; Treg cell; Compartment (ship); Medicine; Biology; T cell; Immune system","score_opus":0.11263952864315159,"score_gpt":0.4621159181353165,"score_spread":0.3494763894921649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2605893447","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885852,0.0008392469,0.0000041955786,0.0007853794,0.0001351038,0.0013778008,0.000021335103,0.000023686109,0.008228061],"genre_scores_gemma":[0.9978337,0.00012969055,0.0012664491,0.0001059042,0.00026199518,0.00015186916,0.000027246237,0.000034744153,0.00018838583],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99565613,0.00072673237,0.0013529068,0.0005233021,0.0011766155,0.0005642969],"domain_scores_gemma":[0.99353,0.002833917,0.0009185015,0.0022222595,0.00028563218,0.00020969145],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0035119767,0.0002875053,0.0008258382,0.00010205877,0.00041269723,0.00005873766,0.0011704321,0.00027043995,0.000056890334],"category_scores_gemma":[0.008876164,0.00014713722,0.00047388228,0.00021116454,0.0011844344,0.00015393914,0.00037259018,0.0003830834,0.000045986544],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014856056,0.00042872105,0.39204484,0.00005144321,0.000093672854,0.0000671301,0.00028537764,0.000002065193,0.002554466,0.00017768411,0.00005238955,0.6027566],"study_design_scores_gemma":[0.008335732,0.001866937,0.9704231,0.00048231156,0.00011427441,0.000056381738,0.0005518084,0.009313161,0.0072801583,0.0005450241,0.0009007597,0.0001303277],"about_ca_topic_score_codex":0.00057807314,"about_ca_topic_score_gemma":0.00012037374,"teacher_disagreement_score":0.60262626,"about_ca_system_score_codex":0.00017384351,"about_ca_system_score_gemma":0.0009730248,"threshold_uncertainty_score":0.9994725},"labels":[],"label_agreement":null},{"id":"W2606367272","doi":"10.1016/j.clml.2017.03.256","title":"Updated Results from ASPIRE and ENDEAVOR, Randomized, Open-Label, Multicenter Phase 3 Studies of Carfilzomib in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Carfilzomib; Multiple myeloma; Medicine; Open label; Refractory (planetary science); Oncology; Phase (matter); Randomized controlled trial; Internal medicine; Lenalidomide; Materials science; Physics","score_opus":0.08929741469129712,"score_gpt":0.40360225369489794,"score_spread":0.31430483900360084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2606367272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99177897,0.00088890025,0.0000049054042,0.00036103604,0.00036346252,0.00394772,0.0006697082,0.00006829241,0.0019170282],"genre_scores_gemma":[0.99348044,0.0010432784,0.0028381918,0.0002892677,0.00018945256,0.00024868778,0.00090431725,0.0001064833,0.00089985365],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99276364,0.0009217124,0.0027125275,0.0016420584,0.00095556426,0.0010045078],"domain_scores_gemma":[0.99035543,0.0039679846,0.0016391781,0.0023058583,0.0008687785,0.0008627647],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021725479,0.000769822,0.0033062203,0.00027192337,0.00051271846,0.00020343975,0.0009936831,0.00052858266,0.00005109107],"category_scores_gemma":[0.015874261,0.0005429069,0.00027372033,0.00020990093,0.0024047315,0.00081796065,0.001349376,0.00060506514,0.00007310892],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4514314,0.004354679,0.21640596,0.00009228731,0.0017399666,0.0009602445,0.00038799006,6.617088e-7,0.00013215223,0.000019413117,0.0007025992,0.32377267],"study_design_scores_gemma":[0.48304832,0.0027510494,0.51068556,0.00064491376,0.00031434878,0.0000062942995,0.00016172514,0.0008708859,0.0004556533,0.00004635279,0.0007095591,0.00030532482],"about_ca_topic_score_codex":0.0036590125,"about_ca_topic_score_gemma":0.00073564926,"teacher_disagreement_score":0.32346734,"about_ca_system_score_codex":0.00083662407,"about_ca_system_score_gemma":0.00088953244,"threshold_uncertainty_score":0.9997023},"labels":[],"label_agreement":null},{"id":"W2607390287","doi":"10.1016/j.clml.2017.03.011","title":"Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS)","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Lenalidomide; Medicine; Melphalan; Multiple myeloma; Oncology; Internal medicine; Maintenance therapy; Autologous stem-cell transplantation; Placebo; Surgery; Chemotherapy; Pathology","score_opus":0.052263338673336115,"score_gpt":0.3196888583339865,"score_spread":0.2674255196606504,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607390287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99635816,0.00056553906,0.00008632453,0.00030170789,0.00022182986,0.0015179007,0.0003923041,0.000080174,0.00047606966],"genre_scores_gemma":[0.99677116,0.00027919168,0.0014490043,0.00020557512,0.00007294287,0.00018798382,0.00029353658,0.00010091021,0.00063968386],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99297976,0.00073438993,0.0020918355,0.0016039193,0.001329359,0.0012607228],"domain_scores_gemma":[0.99291635,0.0026594528,0.0010811123,0.0020756486,0.00030243772,0.0009650119],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015835935,0.0008430796,0.0045491825,0.00053200015,0.0003633188,0.00014256926,0.00076982676,0.0005090925,0.00008919983],"category_scores_gemma":[0.0008038077,0.00059454265,0.0020863244,0.00046121416,0.00067193544,0.000438951,0.00027718526,0.0004954504,0.00003262977],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011885724,0.0016406241,0.861202,0.0001749612,0.04422234,0.00417117,0.00031373894,0.000070565875,0.00012992702,0.000060435235,0.00006483204,0.07606371],"study_design_scores_gemma":[0.0534978,0.0014337385,0.90434635,0.00014503293,0.036517728,0.000017270082,0.000070615824,0.0027443334,0.00057354127,0.000030078272,0.0001075986,0.0005158971],"about_ca_topic_score_codex":0.005070613,"about_ca_topic_score_gemma":0.0031223497,"teacher_disagreement_score":0.075547814,"about_ca_system_score_codex":0.00067599915,"about_ca_system_score_gemma":0.0007750429,"threshold_uncertainty_score":0.9996506},"labels":[],"label_agreement":null},{"id":"W2607449242","doi":"10.1016/j.clml.2017.03.122","title":"Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Center Experience","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Oncology; Refractory (planetary science); CD38; Internal medicine; Monoclonal; Monoclonal antibody; Antibody; Immunology; Lenalidomide; Stem cell","score_opus":0.10248146687702306,"score_gpt":0.3935936168366012,"score_spread":0.2911121499595781,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2607449242","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918199,0.0011472797,0.00021470212,0.00068578264,0.0010115491,0.0021802175,0.00017830801,0.0000871006,0.0026751282],"genre_scores_gemma":[0.99283004,0.00095511193,0.0016710318,0.00016997308,0.00077481376,0.0005974224,0.000103488164,0.0000810049,0.0028170943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99625784,0.0001421365,0.0011961864,0.00090605405,0.000623364,0.0008744031],"domain_scores_gemma":[0.9930969,0.002553558,0.0006878431,0.0026975984,0.00036114804,0.0006029912],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041294008,0.0004920877,0.001086348,0.000094648276,0.0010564497,0.00013218776,0.00077121524,0.00036662823,0.000104327504],"category_scores_gemma":[0.0028614837,0.000306493,0.0009889369,0.00010240314,0.0014189592,0.000264528,0.0001829765,0.00017388834,0.000120738565],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005754257,0.0038429247,0.21910608,0.00006419149,0.0006265289,0.00023857519,0.0005081776,0.0000010283663,0.0016245899,0.00007561166,0.001093418,0.76706463],"study_design_scores_gemma":[0.027859367,0.005578129,0.8472975,0.0001554573,0.00021484541,0.00009014673,0.00018875058,0.0014975087,0.006687982,0.00005816721,0.110107884,0.0002642807],"about_ca_topic_score_codex":0.00033779515,"about_ca_topic_score_gemma":0.00015263511,"teacher_disagreement_score":0.76680034,"about_ca_system_score_codex":0.0011734524,"about_ca_system_score_gemma":0.000693961,"threshold_uncertainty_score":0.9999387},"labels":[],"label_agreement":null},{"id":"W2613195890","doi":"10.1016/j.clml.2017.04.001","title":"Chronic Lymphocytic Leukemia Patients With Deletion 11q Have a Short Time to Requirement of First-Line Therapy, But Long Overall Survival: Results of a Population-Based Cohort in British Columbia, Canada","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Royal Columbian Hospital; Vancouver General Hospital; University of British Columbia; BC Cancer Agency","funders":"","keywords":"Chronic lymphocytic leukemia; Cohort; Medicine; Oncology; Population; Leukemia; Internal medicine; Demography; Gerontology; Environmental health; Sociology","score_opus":0.02586023800880946,"score_gpt":0.30130201839262377,"score_spread":0.2754417803838143,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2613195890","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99521506,0.00016022265,0.000037759954,0.00015580161,0.000267234,0.00312106,0.00034329426,0.000061003706,0.0006385689],"genre_scores_gemma":[0.9961975,0.00012359966,0.0002745449,0.00027833236,0.00032940882,0.00016865818,0.0009341407,0.0001428264,0.0015509378],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914662,0.00031465435,0.0031554739,0.0014448223,0.0024883444,0.0011304873],"domain_scores_gemma":[0.99310946,0.0012199173,0.0011252555,0.0026202954,0.0011548022,0.0007702645],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020714789,0.0005068064,0.0020610588,0.00019154057,0.0003132287,0.00017435908,0.0009914534,0.0005275162,0.00023266331],"category_scores_gemma":[0.0032592607,0.0006118262,0.00035992806,0.00036753854,0.0005728284,0.00025157168,0.00035388872,0.0003493354,0.000021787477],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004714225,0.0002905592,0.8813792,0.00037478216,0.00032472893,0.0005532895,0.00002264832,0.0022268877,0.00003723578,9.903973e-7,0.0013774622,0.10869801],"study_design_scores_gemma":[0.06317255,0.002238992,0.89719915,0.0021367122,0.00013736356,0.000033895834,0.000009424328,0.03352509,0.00023586035,0.0000104869505,0.0007649496,0.0005355426],"about_ca_topic_score_codex":0.9599525,"about_ca_topic_score_gemma":0.95694184,"teacher_disagreement_score":0.10816247,"about_ca_system_score_codex":0.16885738,"about_ca_system_score_gemma":0.090552576,"threshold_uncertainty_score":0.9996333},"labels":[],"label_agreement":null},{"id":"W2627091086","doi":"10.1016/j.clml.2017.06.001","title":"Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Bosutinib; Renal function; Medicine; Imatinib; Internal medicine; Oncology; Gastroenterology; Dasatinib","score_opus":0.018810396390509344,"score_gpt":0.2963083973831734,"score_spread":0.27749800099266403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2627091086","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935518,0.00015574535,0.000014028297,0.00030218036,0.00055660796,0.0021122107,0.000049482405,0.00010004692,0.0031579032],"genre_scores_gemma":[0.99767494,0.00013317344,0.00025146757,0.00039141282,0.0005052081,0.00017023775,0.0002255418,0.00011642677,0.00053157826],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99538773,0.00024962806,0.0014113928,0.001274115,0.0008680825,0.00080903945],"domain_scores_gemma":[0.9951534,0.0010561575,0.0011151625,0.0018911541,0.00025896466,0.0005251154],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036306411,0.00076521403,0.0016943212,0.00026316085,0.00031631486,0.00005885326,0.00042216005,0.00061607227,0.000082687395],"category_scores_gemma":[0.0008042673,0.00056852493,0.0005073663,0.0002324369,0.0007473077,0.00028947653,0.00016116964,0.00039687692,0.00020654777],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023677295,0.004874914,0.552016,0.00023153576,0.001373822,0.0010001682,0.0001825742,0.000032291577,0.00044578942,0.00019593246,0.0006289273,0.41534072],"study_design_scores_gemma":[0.06624033,0.016611164,0.9056219,0.001484183,0.00074673793,0.000024737526,0.000012268571,0.00012069756,0.007810016,0.000071213915,0.00081443385,0.0004423524],"about_ca_topic_score_codex":0.00042188592,"about_ca_topic_score_gemma":0.000067671805,"teacher_disagreement_score":0.41489837,"about_ca_system_score_codex":0.009056215,"about_ca_system_score_gemma":0.0024825528,"threshold_uncertainty_score":0.99967664},"labels":[],"label_agreement":null},{"id":"W26452364","doi":"10.1016/j.clml.2015.07.347","title":"Outcome of t(4;14) in Multiple Myeloma – Princess Margaret Cancer Centre Experience Over the Last 10 Years","year":2015,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Thalidomide; Melphalan; Multiple myeloma; Internal medicine; Bortezomib; Autologous stem-cell transplantation; Dexamethasone; Chemotherapy; Induction chemotherapy; Cancer; Surgery; Oncology","score_opus":0.09018790762246759,"score_gpt":0.392261338032704,"score_spread":0.30207343041023643,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W26452364","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956904,0.0006065536,0.000007620655,0.0004836686,0.0005278051,0.00093868107,0.00006763993,0.00007414179,0.0016034909],"genre_scores_gemma":[0.99631476,0.00017672872,0.00043032895,0.0004985575,0.00032847884,0.00014329326,0.000048882095,0.000063755404,0.0019951873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99530786,0.00037498615,0.0014934147,0.0007988909,0.0011386626,0.00088620355],"domain_scores_gemma":[0.99631786,0.0010429744,0.0003571807,0.0011127846,0.00033389297,0.00083528704],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00097418576,0.00039915575,0.0010240962,0.00016942239,0.00008473174,0.000044066528,0.0006516082,0.0003566588,0.00056903047],"category_scores_gemma":[0.00310716,0.00027869883,0.00037051074,0.0006574047,0.0008314299,0.00020204567,0.0004260365,0.0004070998,0.00027790572],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014074642,0.00039437893,0.8103629,0.000051000676,0.00011713725,0.0004908284,0.00063004385,0.0000144696405,0.00006489425,0.00005036924,0.0021530709,0.18426348],"study_design_scores_gemma":[0.012060359,0.00030274803,0.9639221,0.00020949249,0.000054993645,0.00003231791,0.0005081198,0.0013226658,0.0004862129,0.00005065874,0.020787084,0.0002632576],"about_ca_topic_score_codex":0.001973011,"about_ca_topic_score_gemma":0.0016884296,"teacher_disagreement_score":0.18400022,"about_ca_system_score_codex":0.0012630561,"about_ca_system_score_gemma":0.0014245698,"threshold_uncertainty_score":0.9999665},"labels":[],"label_agreement":null},{"id":"W2678327441","doi":"10.1016/j.clml.2017.06.015","title":"Bath Psoralen-ultraviolet A and Narrowband Ultraviolet B Phototherapy as Initial Therapy for Early-stage Mycosis Fungoides: A Retrospective Cohort of 267 Cases at the University of Toronto","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Mycosis fungoides; Psoralen; Dermatology; Retrospective cohort study; PUVA therapy; Medicine; Ultraviolet b; Cohort; Ultraviolet a; Methoxsalen; Stage (stratigraphy); Surgery; Psoriasis; Lymphoma; Internal medicine; Chemistry","score_opus":0.041429639393741065,"score_gpt":0.36966811648169806,"score_spread":0.328238477087957,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2678327441","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924032,0.0019244615,0.000026216276,0.000340694,0.000120757366,0.0024493576,0.00064759614,0.000036340403,0.0020513828],"genre_scores_gemma":[0.9876262,0.00904968,0.00016807644,0.00032942687,0.0001701207,0.00004302069,0.000053870026,0.00006651091,0.002493087],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968883,0.00030458975,0.00078639964,0.00084647094,0.00064685143,0.00052743807],"domain_scores_gemma":[0.9952878,0.0015875808,0.0007081902,0.0013763023,0.00070798444,0.00033216376],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0010523015,0.0004003107,0.0012808479,0.00005232655,0.0007784915,0.00005869285,0.0006007876,0.00041056395,0.000802557],"category_scores_gemma":[0.0017163674,0.00031437632,0.0005677856,0.000082558094,0.0027195811,0.00020490418,0.0001747808,0.00021282723,0.000011279747],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.024328433,0.0005549619,0.8763338,0.00012841041,0.0008961554,0.00026505912,0.002051666,6.9295646e-7,0.010212075,0.00015823256,0.001344553,0.08372602],"study_design_scores_gemma":[0.01239417,0.0046958965,0.96693206,0.00020940829,0.00017031387,0.00034207618,0.0011682601,0.00012314522,0.01037769,0.00015056763,0.0031295994,0.00030683822],"about_ca_topic_score_codex":0.017331522,"about_ca_topic_score_gemma":0.0027955486,"teacher_disagreement_score":0.09059829,"about_ca_system_score_codex":0.0010798038,"about_ca_system_score_gemma":0.0011981018,"threshold_uncertainty_score":0.99999446},"labels":[],"label_agreement":null},{"id":"W2725714565","doi":"10.1016/j.clml.2017.06.020","title":"Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":48,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Oncology; Cohort; Multiple myeloma; Hazard ratio; Confidence interval","score_opus":0.032282119663963285,"score_gpt":0.33413161693560944,"score_spread":0.30184949727164617,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2725714565","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9973874,0.000045320896,0.00002455738,0.00006272155,0.000057784673,0.0020112684,0.00005358387,0.00002662397,0.000330742],"genre_scores_gemma":[0.9986813,0.000039129336,0.0007035795,0.00002148874,0.000037868536,0.00009854116,0.00031851177,0.000043322972,0.000056253815],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99699026,0.00020326069,0.0009047291,0.0006263479,0.0008890431,0.00038635187],"domain_scores_gemma":[0.99684215,0.0004676277,0.0007462562,0.00080711074,0.00074447994,0.00039238943],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006429516,0.00028774753,0.0008286852,0.00020080802,0.0001487931,0.000048373462,0.00027339396,0.00024550117,0.000022992583],"category_scores_gemma":[0.0016256752,0.00020944964,0.00007829307,0.00015965392,0.0004529613,0.00047641387,0.0001400894,0.00019852705,0.000006963074],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004909698,0.001783069,0.9132151,0.00018920352,0.00019865067,0.00009765225,0.000093235016,0.0000048127736,0.00015920121,0.000079223726,0.0000045665165,0.079265565],"study_design_scores_gemma":[0.02575205,0.0047585955,0.96307164,0.0004698756,0.00016983054,0.000013780224,0.000038592192,0.001831251,0.0036281322,0.000056396213,0.000009048383,0.00020079095],"about_ca_topic_score_codex":0.000239804,"about_ca_topic_score_gemma":0.000213137,"teacher_disagreement_score":0.07906477,"about_ca_system_score_codex":0.00029358396,"about_ca_system_score_gemma":0.00060873566,"threshold_uncertainty_score":0.85411084},"labels":[],"label_agreement":null},{"id":"W2727129020","doi":"10.1016/j.clml.2017.06.031","title":"Distribution and Impact of Comorbidities on Survival and Leukemic Transformation in Myeloproliferative Neoplasm-Associated Myelofibrosis: A Retrospective Cohort Study","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Public Health Ontario; University of Toronto","funders":"","keywords":"Myelofibrosis; Myeloproliferative neoplasm; Medicine; Retrospective cohort study; Cohort; Internal medicine; Overall survival; Oncology; Neoplasm; Myeloproliferative Disorders; Transformation (genetics); Survival analysis; Pathology; Bone marrow; Biology","score_opus":0.03255570675065547,"score_gpt":0.35152802420942897,"score_spread":0.3189723174587735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2727129020","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99489206,0.00008706846,0.000008960568,0.00024028472,0.00019227459,0.0026509808,0.00036166536,0.000053179803,0.001513551],"genre_scores_gemma":[0.9983978,0.00068974786,0.000027029504,0.000046491765,0.00010695928,0.00035952908,0.0002671417,0.000037995018,0.00006727328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963749,0.00044570665,0.0013057941,0.0008135924,0.0006011313,0.0004588969],"domain_scores_gemma":[0.9971795,0.0007730028,0.000731638,0.0006446099,0.0003528072,0.00031844297],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014312845,0.0005208906,0.0017517922,0.00015080144,0.00045337336,0.00014215757,0.00016233578,0.0003746424,0.000023332774],"category_scores_gemma":[0.0017144795,0.00041105732,0.00029163426,0.0001789496,0.0006604129,0.00038910576,0.00010614077,0.00037687962,0.00000909751],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001927791,0.0013057407,0.96584994,0.000041810123,0.0007790658,0.00007753097,0.0009775931,0.0000063749576,0.00005976673,0.0006584887,0.000083919265,0.028231962],"study_design_scores_gemma":[0.014118373,0.0064729103,0.97598255,0.0004465225,0.0003449383,0.000034446013,0.0007089262,0.00082676555,0.0004142856,0.0003079858,0.000010598878,0.00033167706],"about_ca_topic_score_codex":0.0015880502,"about_ca_topic_score_gemma":0.0007881738,"teacher_disagreement_score":0.027900284,"about_ca_system_score_codex":0.0025622768,"about_ca_system_score_gemma":0.0007510603,"threshold_uncertainty_score":0.9998341},"labels":[],"label_agreement":null},{"id":"W2735666722","doi":"10.1016/j.clml.2017.07.006","title":"Cardiovascular Events After Exposure to Nilotinib in Chronic Myeloid Leukemia: Long-term Follow-up","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Nilotinib; Myeloid leukemia; Medicine; Chronic myeloid leukaemia; Term (time); Internal medicine; Oncology; Imatinib","score_opus":0.033579433887023086,"score_gpt":0.32650502168535495,"score_spread":0.2929255877983319,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2735666722","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98568875,0.0046410584,0.000087699635,0.00057172496,0.0030869795,0.0027669896,0.00006306816,0.00031390198,0.0027798363],"genre_scores_gemma":[0.9861891,0.0010690262,0.0006655857,0.001246492,0.0028284886,0.0008041496,0.00015090097,0.00031996757,0.006726291],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9899355,0.0004908736,0.0028020802,0.0028169453,0.0017561818,0.002198406],"domain_scores_gemma":[0.9898584,0.00048761396,0.00071866176,0.006831367,0.00034618116,0.0017578148],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002206696,0.0013425593,0.0032180608,0.00045382045,0.0005603188,0.00023125995,0.00180664,0.0014936705,0.00056732295],"category_scores_gemma":[0.0023993275,0.0012647257,0.0026796262,0.0004880237,0.0006174929,0.0006335622,0.0013435931,0.0011638138,0.0032619545],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0024898376,0.0002794803,0.5237573,0.00030296456,0.001453439,0.0050446126,0.00017648558,0.00006101605,0.00024698203,0.000020340824,0.0010830782,0.46508446],"study_design_scores_gemma":[0.03658669,0.0017977927,0.9467103,0.0016856536,0.0009788942,0.00049746956,0.00002512841,0.0001143333,0.0007796427,0.00007949765,0.009614227,0.0011303723],"about_ca_topic_score_codex":0.0009221312,"about_ca_topic_score_gemma":0.0010561257,"teacher_disagreement_score":0.4639541,"about_ca_system_score_codex":0.02891776,"about_ca_system_score_gemma":0.00993309,"threshold_uncertainty_score":0.9999325},"labels":[],"label_agreement":null},{"id":"W2745909886","doi":"10.1016/j.clml.2017.08.100","title":"High-dose Thiotepa, Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplantation as Upfront Consolidation for Systemic Non-Hodgkin Lymphoma With Synchronous Central Nervous System Involvement","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Memorial University of Newfoundland","funders":"Sigma Theta Tau International; Otsuka Pharmaceutical; Roche; Merck; Pfizer","keywords":"ThioTEPA; Busulfan; Medicine; Cyclophosphamide; Transplantation; Lymphoma; Central nervous system; Consolidation (business); Autologous stem-cell transplantation; Hematopoietic stem cell transplantation; Chemotherapy; Internal medicine","score_opus":0.016503654627004604,"score_gpt":0.28074507179223007,"score_spread":0.2642414171652255,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2745909886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99104905,0.0012440792,0.0010914233,0.0004861535,0.001109397,0.004000069,0.00016219796,0.00030565937,0.0005519866],"genre_scores_gemma":[0.9938407,0.0013270961,0.0020912641,0.0004594116,0.0005519091,0.00074730936,0.00043727548,0.0001547872,0.0003902571],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99462515,0.00020453111,0.0018623022,0.0015377988,0.0006712051,0.0010990213],"domain_scores_gemma":[0.99498624,0.00078014896,0.0013852273,0.0015893823,0.00038454123,0.00087447395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007614749,0.000869221,0.0018310137,0.00015830497,0.0009980586,0.00036919143,0.00046264005,0.00070822035,0.000014753385],"category_scores_gemma":[0.00008173124,0.00070410996,0.00045018303,0.00012312371,0.00053897337,0.0003570498,0.00011362164,0.00016075955,0.0001045078],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0064956103,0.0009709828,0.05546876,0.0025366752,0.0008423417,0.0035578294,0.0007035468,0.00010594872,0.00047782017,0.0011221782,0.00070364925,0.92701465],"study_design_scores_gemma":[0.025849966,0.003606745,0.9535113,0.0020699808,0.0018117484,0.0035720475,0.0007255072,0.0021805635,0.0053991037,0.000040855783,0.00050063076,0.0007315664],"about_ca_topic_score_codex":0.0023108034,"about_ca_topic_score_gemma":0.0001898584,"teacher_disagreement_score":0.9262831,"about_ca_system_score_codex":0.0034936361,"about_ca_system_score_gemma":0.0021626067,"threshold_uncertainty_score":0.999541},"labels":[],"label_agreement":null},{"id":"W2752250321","doi":"10.1016/j.clml.2017.07.115","title":"ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Myeloid leukemia; Medicine; Internal medicine; Oncology; Blast Crisis; Imatinib","score_opus":0.021696032878341164,"score_gpt":0.3103709124858914,"score_spread":0.2886748796075502,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2752250321","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99204934,0.002349534,0.000008413965,0.00060619885,0.00049727893,0.0030777622,0.00015873158,0.0001913729,0.0010613431],"genre_scores_gemma":[0.9896654,0.0031708318,0.00051899947,0.00019367327,0.00080380344,0.0008116011,0.00092581846,0.00024710002,0.0036628065],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99192035,0.00041181577,0.0023944904,0.0025580437,0.000973175,0.0017421093],"domain_scores_gemma":[0.9926654,0.00056626555,0.0012315097,0.004241789,0.00020960778,0.0010854399],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.000689731,0.001509609,0.0024307305,0.000492811,0.000642764,0.00022187261,0.00081622595,0.0011180143,0.00046508465],"category_scores_gemma":[0.0005926778,0.001168563,0.0004555621,0.00041133715,0.0010458735,0.0008988887,0.0006290765,0.00049307465,0.00025075037],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010158884,0.0015153701,0.59835577,0.00016246302,0.00032073093,0.0013167211,0.00018534737,0.000067087145,0.0004717913,0.000023893674,0.00026342622,0.38715854],"study_design_scores_gemma":[0.15426391,0.010108728,0.81921566,0.001198379,0.00054278085,0.00013511296,0.000022845272,0.0014537548,0.00258025,0.00007487669,0.00949054,0.00091316464],"about_ca_topic_score_codex":0.0048931786,"about_ca_topic_score_gemma":0.0088002,"teacher_disagreement_score":0.38624537,"about_ca_system_score_codex":0.10944497,"about_ca_system_score_gemma":0.010569037,"threshold_uncertainty_score":0.9997653},"labels":[],"label_agreement":null},{"id":"W2753212558","doi":"10.1016/j.clml.2017.07.213","title":"Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 In Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)—An Interim Analysis","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Université de Montréal; Centre Intégré Universitaire de Santé et de Services Sociaux du Centre-Sud-de-l'Île-de-Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Interim; Diffuse large B-cell lymphoma; Oncology; Interim analysis; Internal medicine; Clinical trial; Chimeric antigen receptor; Refractory (planetary science); Phases of clinical research; Medicine; Follicular lymphoma; Lymphoma; Biology; Cancer; Immunotherapy","score_opus":0.039864800314428975,"score_gpt":0.37971674502119257,"score_spread":0.3398519447067636,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2753212558","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947119,0.00007797535,0.000023287515,0.00018203133,0.0008238042,0.002266343,0.0002927193,0.00008878961,0.0015331517],"genre_scores_gemma":[0.9963458,0.00026777378,0.00017968376,0.0006295253,0.00049769494,0.00010459749,0.00023576015,0.00011200215,0.0016271343],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9924976,0.0011159466,0.0022475661,0.0013688605,0.0016744577,0.0010955661],"domain_scores_gemma":[0.99213445,0.00071802293,0.0014765732,0.004201594,0.00074065663,0.0007286792],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016775236,0.00070569577,0.002103385,0.00031735795,0.00040354938,0.00015915374,0.0018188426,0.00077674934,0.0007784231],"category_scores_gemma":[0.0023512393,0.00043119278,0.0012702176,0.0012311949,0.0011547522,0.00042599236,0.0004911724,0.000519423,0.00003523867],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.34601772,0.040766343,0.32044542,0.00004670031,0.0012019842,0.00022411032,0.00026929213,0.0000012564503,0.00084607885,0.000022073724,0.0002698182,0.2898892],"study_design_scores_gemma":[0.39208654,0.008221565,0.5962593,0.00010993209,0.00038448308,0.00000753916,0.000086714004,0.0006543852,0.00056522945,0.00001677976,0.001280243,0.00032730584],"about_ca_topic_score_codex":0.0010807123,"about_ca_topic_score_gemma":0.0013920875,"teacher_disagreement_score":0.2895619,"about_ca_system_score_codex":0.0018568857,"about_ca_system_score_gemma":0.0026585662,"threshold_uncertainty_score":0.999814},"labels":[],"label_agreement":null},{"id":"W2762528795","doi":"10.1016/j.clml.2017.10.003","title":"Are We Choosing Wisely in Lymphoma? Excessive Use of Surveillance CT Imaging in Patients With Diffuse Large B-cell Lymphoma (DLBCL) in Long-term Remission","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Radiation Dose and Imaging","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Occupational Cancer Research Centre; Health Sciences Centre; Cancer Care Ontario; Institute for Clinical Evaluative Sciences; Sunnybrook Health Science Centre","funders":"Association Canadienne des Radiologistes; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Cancer Care Ontario","keywords":"Medicine; Diffuse large B-cell lymphoma; International Prognostic Index; Lymphoma; Cumulative incidence; Prednisone; Rituximab; Incidence (geometry); Cohort; Population; CHOP; Vincristine; Radiology; Internal medicine; Cyclophosphamide; Nuclear medicine; Surgery; Chemotherapy; Environmental health","score_opus":0.03024046470386714,"score_gpt":0.31702844076089287,"score_spread":0.2867879760570257,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2762528795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9972624,0.00059588015,0.00003169329,0.00051781227,0.00035740432,0.00078453467,0.00003717796,0.00006178483,0.0003512897],"genre_scores_gemma":[0.99806136,0.00049336354,0.00021357776,0.0006544346,0.00017084634,0.000029585719,0.00008853435,0.00011217396,0.00017612411],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946144,0.00040223106,0.0020913617,0.0011702898,0.00073835545,0.0009833248],"domain_scores_gemma":[0.9949324,0.00071231497,0.0020435404,0.0016210127,0.00024883644,0.00044186244],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010722427,0.00058022665,0.0015359751,0.00057428697,0.00020683657,0.000196582,0.00063567935,0.0002506679,0.000021246513],"category_scores_gemma":[0.0023872287,0.0005144594,0.00025668216,0.00051670213,0.00041327576,0.0012479568,0.0003355907,0.0002990303,0.000022874425],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0013175602,0.003334768,0.7354041,0.00016254692,0.000020631363,0.0011886472,0.00015125993,0.000008468996,0.000063998705,0.0000032195305,0.00013838933,0.25820646],"study_design_scores_gemma":[0.07472042,0.00013378433,0.91787064,0.003454195,0.000036016856,0.00003405913,0.00007668109,0.0022628342,0.00047471924,0.000021779832,0.00039354272,0.00052133144],"about_ca_topic_score_codex":0.0005136276,"about_ca_topic_score_gemma":0.00042339662,"teacher_disagreement_score":0.25768512,"about_ca_system_score_codex":0.001826721,"about_ca_system_score_gemma":0.0010218536,"threshold_uncertainty_score":0.9997307},"labels":[],"label_agreement":null},{"id":"W2766219238","doi":"10.1016/j.clml.2017.10.009","title":"Early Relapse for Multiple Myeloma Patients Undergoing Single Autologous Stem Cell Therapy: A Single-center Experience","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Multiple myeloma; Single Center; Medicine; Center (category theory); Stem cell; Oncology; Surgery; Internal medicine; Biology","score_opus":0.08481384470598866,"score_gpt":0.3450338676793674,"score_spread":0.26022002297337876,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2766219238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916597,0.0002713577,0.00021553457,0.0002947788,0.0011710224,0.002656208,0.00011927041,0.00027954066,0.00333257],"genre_scores_gemma":[0.992163,0.00013354735,0.0028810555,0.00057146227,0.0005278548,0.00046184167,0.00015130544,0.00017539607,0.002934534],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99426293,0.0002722367,0.001518902,0.0015387508,0.00089395995,0.0015132157],"domain_scores_gemma":[0.9930424,0.0020766815,0.00090010633,0.0022960696,0.000553319,0.001131434],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005350071,0.0007173362,0.0012591853,0.0001787358,0.0012220142,0.0004261536,0.0009946551,0.0006663686,0.00006574846],"category_scores_gemma":[0.0022444346,0.00060302985,0.0008645259,0.0001519041,0.0008657004,0.00059468765,0.00047768053,0.00037372104,0.00033867484],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0040156986,0.002574793,0.52786326,0.0000884238,0.00020000602,0.0002635589,0.0003693966,5.780772e-7,0.001352748,0.000016417653,0.0005736474,0.46268147],"study_design_scores_gemma":[0.041951608,0.006243236,0.934216,0.00033199866,0.00008136023,0.00005404568,0.00012914234,0.00066537614,0.007123051,0.0000800634,0.008553384,0.00057072507],"about_ca_topic_score_codex":0.00013906103,"about_ca_topic_score_gemma":0.00007455252,"teacher_disagreement_score":0.46211076,"about_ca_system_score_codex":0.0015304494,"about_ca_system_score_gemma":0.0009005152,"threshold_uncertainty_score":0.99964213},"labels":[],"label_agreement":null},{"id":"W2776794568","doi":"10.1016/j.clml.2017.12.004","title":"The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study","year":2017,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Lenalidomide; Medicine; Placebo; Myelodysplastic syndromes; Discontinuation; Quality of life (healthcare); Internal medicine; International Prognostic Scoring System; Anemia; Randomized controlled trial; Physical therapy; Multiple myeloma; Bone marrow","score_opus":0.0369554667939113,"score_gpt":0.35811880182063327,"score_spread":0.32116333502672195,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2776794568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9925628,0.0001868457,0.0000062518775,0.0018046391,0.000609976,0.0039314963,0.0003281513,0.000049594742,0.0005202555],"genre_scores_gemma":[0.99880475,0.00019277005,0.000055494824,0.00024368845,0.0002180398,0.000101322876,0.00009968445,0.00010323433,0.0001810397],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98687357,0.0042551435,0.004488927,0.0013068455,0.0020543113,0.0010212306],"domain_scores_gemma":[0.96106535,0.029075785,0.004038172,0.004749554,0.0004166135,0.00065450015],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.013486379,0.0006824341,0.0029241457,0.00015757275,0.000841033,0.00009523518,0.0019893749,0.0005143677,0.00002372706],"category_scores_gemma":[0.046097144,0.00034906596,0.0005439296,0.0004983283,0.002065858,0.00017752332,0.00066116673,0.0015896771,0.00011052249],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08599262,0.0010303056,0.8323872,0.000105493644,0.0009698396,0.0000921808,0.00043829868,0.000058128662,0.00000851657,0.000014342513,0.0021519572,0.07675112],"study_design_scores_gemma":[0.0713485,0.0173127,0.9087258,0.0010499511,0.00023501972,0.0000039927513,0.00024331834,0.00057167344,0.00005200125,0.00005153929,0.00010849703,0.0002970228],"about_ca_topic_score_codex":0.016783878,"about_ca_topic_score_gemma":0.0014175237,"teacher_disagreement_score":0.076454096,"about_ca_system_score_codex":0.0016460166,"about_ca_system_score_gemma":0.0034650248,"threshold_uncertainty_score":0.9998961},"labels":[],"label_agreement":null},{"id":"W2781661609","doi":"10.1016/j.clml.2017.12.011","title":"A Comparison of the Efficacy of Immunomodulatory-containing Regimens in Relapsed/Refractory Multiple Myeloma: A Network Meta-analysis","year":2018,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"Janssen Pharmaceuticals","keywords":"Lenalidomide; Medicine; Internal medicine; Daratumumab; Oncology; Carfilzomib; Ixazomib; Multiple myeloma; Hazard ratio; Subgroup analysis; Pomalidomide; Progression-free survival; Meta-analysis; Chemotherapy; Confidence interval","score_opus":0.21187975904621487,"score_gpt":0.4481643213528339,"score_spread":0.23628456230661904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781661609","genre_codex":"review","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.05890362,0.93647206,0.0000124298995,0.00003255232,0.000449188,0.00321905,0.00015677532,0.000067328816,0.00068697316],"genre_scores_gemma":[0.5309739,0.46540278,0.0011503327,0.00007995577,0.0006401705,0.00039666818,0.00038803666,0.00023359992,0.00073453947],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98500913,0.0031702248,0.0071326117,0.0017922058,0.0015534698,0.0013423265],"domain_scores_gemma":[0.98007303,0.00991035,0.0046454314,0.0041942084,0.0005544438,0.0006225192],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow","metaepi_broad"],"category_scores_codex":[0.0037828442,0.0013372982,0.017135955,0.000829409,0.00022077764,0.000037447164,0.0015635439,0.0016591668,0.00027132803],"category_scores_gemma":[0.0055657215,0.0008297683,0.0146666635,0.0036663073,0.0015054899,0.00009579037,0.0007500837,0.0015317602,0.00012272097],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019097049,0.0024243286,0.07138459,0.0040718056,0.22348475,0.00020709667,0.00020521166,0.00005595941,0.0000022424983,0.00005174109,0.00091643113,0.69528615],"study_design_scores_gemma":[0.009414127,0.0017836819,0.534814,0.004709184,0.29513195,0.000050617236,0.000051594932,0.000664461,0.000015650712,0.000023988214,0.152576,0.0007647518],"about_ca_topic_score_codex":0.0005199301,"about_ca_topic_score_gemma":0.00030548885,"teacher_disagreement_score":0.69452137,"about_ca_system_score_codex":0.0018066774,"about_ca_system_score_gemma":0.0044670543,"threshold_uncertainty_score":0.99993783},"labels":[],"label_agreement":null},{"id":"W2781805276","doi":"10.1016/j.clml.2017.12.009","title":"Single-center Experience in Treating Patients With t(4;14) Multiple Myeloma With and Without Planned Frontline Autologous Stem Cell Transplantation","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Southlake Regional Health Center; Princess Margaret Cancer Centre","funders":"Celgene; Amgen","keywords":"Medicine; Bortezomib; Multiple myeloma; Hazard ratio; Autologous stem-cell transplantation; Single Center; Internal medicine; Stem cell; Transplantation; Oncology; Progression-free survival; Surgery; Confidence interval; Chemotherapy","score_opus":0.036924814555313594,"score_gpt":0.31338370039348784,"score_spread":0.27645888583817424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2781805276","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99631876,0.00007611218,0.00027331893,0.00007064135,0.00011662204,0.0013802899,0.000078388235,0.00014513276,0.0015407255],"genre_scores_gemma":[0.99307144,0.000040946023,0.0055572838,0.00024357469,0.00017981489,0.00014769431,0.0002774161,0.0000865395,0.00039530126],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961526,0.00024941593,0.0009619694,0.0010891696,0.0006807266,0.0008661612],"domain_scores_gemma":[0.9976825,0.0005162998,0.00031148677,0.00055639475,0.0003059084,0.0006273756],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00027546956,0.0005241613,0.0009223659,0.00021589866,0.00022501551,0.00007264278,0.00019560443,0.0003103734,0.000045952227],"category_scores_gemma":[0.00013615012,0.0003622275,0.00009924765,0.00035194049,0.00080013985,0.00031040618,0.000069385016,0.00027827444,0.00005602031],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01754865,0.0010166565,0.74021167,0.00009391898,0.000094911746,0.00038974997,0.0010005744,0.0000016145111,0.00018242288,0.0000019358724,0.000027256789,0.23943062],"study_design_scores_gemma":[0.04308218,0.008082752,0.9429398,0.0005841875,0.000101245445,0.00020396957,0.000293912,0.001619939,0.0023476314,0.0000031903216,0.00034637598,0.00039477125],"about_ca_topic_score_codex":0.00018283384,"about_ca_topic_score_gemma":0.0007470174,"teacher_disagreement_score":0.23903584,"about_ca_system_score_codex":0.00059980707,"about_ca_system_score_gemma":0.00039851185,"threshold_uncertainty_score":0.999883},"labels":[],"label_agreement":null},{"id":"W2793628030","doi":"10.1016/j.clml.2018.03.008","title":"Leukocytoclastic Vasculitis and Desensitization to High-dose Methotrexate in Primary Central Nervous System Lymphoma","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; BC Cancer Agency","funders":"","keywords":"Primary central nervous system lymphoma; Methotrexate; Medicine; Central nervous system; Vasculitis; Regimen; Desensitization (medicine); Adverse effect; Lymphoma; Internal medicine; Oncology; Disease","score_opus":0.022570352002123463,"score_gpt":0.2987677718504183,"score_spread":0.2761974198482948,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793628030","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939578,0.00038575067,0.00042915737,0.0005714371,0.0009796645,0.0013312383,0.000038494298,0.00028721077,0.0020192508],"genre_scores_gemma":[0.99069136,0.0002023083,0.005131751,0.002100095,0.0012119917,0.0001550021,0.00013325141,0.00011347908,0.00026074948],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9950037,0.0004452105,0.0015807726,0.0013261746,0.0005917819,0.0010523855],"domain_scores_gemma":[0.996402,0.0009847389,0.00027887573,0.0009136195,0.0002904196,0.0011303377],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00081477663,0.0005948024,0.0014822615,0.00034742933,0.0002124823,0.000112964764,0.0002120552,0.0004814591,0.00004855379],"category_scores_gemma":[0.00072810095,0.0005293845,0.00034267092,0.0007836838,0.0004415201,0.00018833537,0.0002884612,0.00012825824,0.00047903103],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014992941,0.0004696465,0.06469396,0.00021031205,0.00024209617,0.0019941414,0.00023807382,0.000018038385,0.00036099696,0.0010220981,0.001005668,0.92824566],"study_design_scores_gemma":[0.011578563,0.0014631798,0.9784369,0.00086259656,0.00040159145,0.0010956097,0.000120759374,0.0015486471,0.0010981512,0.00009013968,0.0028043457,0.00049951614],"about_ca_topic_score_codex":0.0012398534,"about_ca_topic_score_gemma":0.00023331649,"teacher_disagreement_score":0.9277462,"about_ca_system_score_codex":0.005433241,"about_ca_system_score_gemma":0.0014365361,"threshold_uncertainty_score":0.99971575},"labels":[],"label_agreement":null},{"id":"W2806039308","doi":"10.1016/j.clml.2018.05.022","title":"An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University","funders":"National Cancer Institute; Gilead Sciences","keywords":"Medicine; Internal medicine; Gastroenterology; Peripheral edema; Anemia; Hypoalbuminemia; Adverse effect; Leukopenia; Hyponatremia; Surgery; Chemotherapy","score_opus":0.0460260974443202,"score_gpt":0.3835334315622945,"score_spread":0.33750733411797434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2806039308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.989796,0.00039604126,0.000019717761,0.0004913866,0.001173494,0.003456311,0.00032856976,0.00017165947,0.0041668415],"genre_scores_gemma":[0.9925147,0.00032048003,0.0015340458,0.0017517235,0.0021319631,0.00047995913,0.00042272118,0.00016353691,0.0006808666],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9919349,0.00075241475,0.003071926,0.0019141089,0.0009556192,0.0013710139],"domain_scores_gemma":[0.9942731,0.00091623777,0.0010109663,0.0019892415,0.0006342186,0.001176198],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001994489,0.00092480885,0.0025257657,0.00039834928,0.00039505746,0.00014058445,0.0010504251,0.000885767,0.00023261346],"category_scores_gemma":[0.0011875252,0.0008002249,0.00043624273,0.0012414533,0.000813035,0.0005389787,0.00090951927,0.0002769998,0.00027082386],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15616682,0.3573297,0.02387852,0.0001312151,0.00047601966,0.0013692838,0.0009844749,2.1091955e-7,0.0060519567,0.00085252646,0.011520497,0.44123876],"study_design_scores_gemma":[0.6866194,0.061695166,0.19733725,0.00043526865,0.00050418766,0.00007621074,0.00011125552,0.00053796015,0.031488094,0.00017091485,0.0203151,0.00070919236],"about_ca_topic_score_codex":0.0010557091,"about_ca_topic_score_gemma":0.00033580046,"teacher_disagreement_score":0.53045255,"about_ca_system_score_codex":0.0022619676,"about_ca_system_score_gemma":0.0036637078,"threshold_uncertainty_score":0.99944484},"labels":[],"label_agreement":null},{"id":"W2808748371","doi":"10.1016/j.clml.2018.06.018","title":"Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":89,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"Janssen Pharmaceuticals; Takeda Oncology","keywords":"Medicine; Multinational corporation; Multiple myeloma; Clinical Practice; Oncology; Internal medicine; Family medicine; Law","score_opus":0.08839271982467811,"score_gpt":0.45732599415284003,"score_spread":0.3689332743281619,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2808748371","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97627884,0.00010170055,0.000025301584,0.0006319591,0.0006068428,0.0038447587,0.00018961508,0.00014149408,0.018179478],"genre_scores_gemma":[0.9844839,0.0001841922,0.008227562,0.00018021297,0.0012455058,0.00043314035,0.00027029405,0.000086529304,0.0048886663],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99001735,0.0014685049,0.0043957476,0.0017314721,0.0014779902,0.0009089193],"domain_scores_gemma":[0.9883669,0.0066602896,0.0011648476,0.001438746,0.0015678508,0.00080133614],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004158187,0.00062122906,0.0017790234,0.0006177092,0.00021777929,0.000056924728,0.00043606354,0.00040630493,0.00024014796],"category_scores_gemma":[0.015625596,0.0005047767,0.000977092,0.0011376885,0.0011985505,0.00037273573,0.00033935157,0.0004878622,0.0005293978],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023029536,0.018309807,0.69665796,0.000035250057,0.0010507025,0.0011292121,0.00031700093,0.0000018784324,0.000038199927,0.0001719986,0.0009519074,0.25830653],"study_design_scores_gemma":[0.071335636,0.016033057,0.90163565,0.00029423216,0.00030395767,0.00008362451,0.00045030846,0.0021593864,0.00041183762,0.00011674509,0.0068269665,0.00034861523],"about_ca_topic_score_codex":0.0035320153,"about_ca_topic_score_gemma":0.006376223,"teacher_disagreement_score":0.25795794,"about_ca_system_score_codex":0.0026776097,"about_ca_system_score_gemma":0.0027780656,"threshold_uncertainty_score":0.99974036},"labels":[],"label_agreement":null},{"id":"W2810788428","doi":"10.1016/j.clml.2018.06.016","title":"Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"Pharmacyclics","keywords":"Ibrutinib; Medicine; Mantle cell lymphoma; Chronic lymphocytic leukemia; Internal medicine; Adverse effect; Discontinuation; Oncology; Lymphoma; Leukemia","score_opus":0.039115926688504936,"score_gpt":0.33680849784259154,"score_spread":0.2976925711540866,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2810788428","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98547906,0.0027926306,0.00022438049,0.000054410204,0.0008113183,0.0065226643,0.00017211822,0.00024078436,0.0037026647],"genre_scores_gemma":[0.99084973,0.0022879469,0.0017864447,0.0005230613,0.00067166274,0.000516372,0.00026522327,0.00031360536,0.0027859737],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9791838,0.0025992785,0.009627544,0.0027855635,0.0031735294,0.002630299],"domain_scores_gemma":[0.9722911,0.015418807,0.004036098,0.0037263494,0.0033379942,0.0011896656],"candidate_categories":["metaresearch","metaepi_narrow","metaepi_broad","sts","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.008103445,0.0019121872,0.015897727,0.002798805,0.00034828845,0.00008732928,0.0017601867,0.0014218291,0.0006390303],"category_scores_gemma":[0.010057704,0.0013062428,0.003864979,0.006479516,0.0071250647,0.00039729485,0.0010539885,0.00036805775,0.00021911475],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8570135,0.0017347351,0.017135238,0.0020677228,0.024791168,0.0010002344,0.0010248589,0.0014455831,0.00016263782,0.00029312805,0.00049079995,0.09284034],"study_design_scores_gemma":[0.69871557,0.0042025894,0.18935941,0.0015417008,0.011045064,0.00011337395,0.00029500184,0.091263756,0.0019558717,0.00008426267,0.00035336468,0.0010700446],"about_ca_topic_score_codex":0.00345181,"about_ca_topic_score_gemma":0.0014277376,"teacher_disagreement_score":0.17222418,"about_ca_system_score_codex":0.19781068,"about_ca_system_score_gemma":0.14270997,"threshold_uncertainty_score":0.99987453},"labels":[],"label_agreement":null},{"id":"W2883998043","doi":"10.1016/j.clml.2018.07.290","title":"Outcomes of Intermediate Risk Karyotype Acute Myeloid Leukemia in First Remission Undergoing Autologous Stem Cell Transplantation Compared With Allogeneic Stem Cell Transplantation and Chemotherapy Consolidation: A Retrospective, Propensity-score Adjusted Analysis","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Stem cell; Myeloid leukemia; Transplantation; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Propensity score matching; Autologous stem-cell transplantation; Chemotherapy; Surgery; Biology; Genetics","score_opus":0.03240517190489464,"score_gpt":0.2981481263687543,"score_spread":0.26574295446385965,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2883998043","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951969,0.00015571862,0.001829036,0.00019133711,0.00015185702,0.0015450321,0.00014614912,0.00016551575,0.00061849947],"genre_scores_gemma":[0.9922436,0.0048276777,0.0014636889,0.00028732835,0.0001300674,0.000058137455,0.00041248425,0.00010440522,0.00047261943],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941976,0.00070097786,0.002042443,0.0014231763,0.0008687344,0.000767036],"domain_scores_gemma":[0.9955357,0.0013037372,0.001145124,0.00090489973,0.00061790535,0.0004926594],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012760508,0.0006896111,0.002228599,0.0007900366,0.00029138415,0.00006852375,0.00042920138,0.00070486387,0.0000649583],"category_scores_gemma":[0.00006272789,0.000553917,0.00038887523,0.0018131909,0.0010447713,0.0003435074,0.00008631115,0.00073527347,0.000026592737],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012889124,0.00021008648,0.9450003,0.00071902986,0.0013178289,0.00061200926,0.0022776197,0.00017476625,0.0026300887,0.000010020739,0.00009736994,0.034061793],"study_design_scores_gemma":[0.017827127,0.0021490906,0.95067126,0.0005002308,0.0029391143,0.00020528593,0.00045397013,0.007373435,0.01728515,0.000019485813,0.00003269412,0.0005431414],"about_ca_topic_score_codex":0.0005162451,"about_ca_topic_score_gemma":0.001855882,"teacher_disagreement_score":0.033518653,"about_ca_system_score_codex":0.002892205,"about_ca_system_score_gemma":0.0027206508,"threshold_uncertainty_score":0.99969125},"labels":[],"label_agreement":null},{"id":"W2888974667","doi":"10.1016/j.clml.2018.07.090","title":"Treatment-Free Remission (TFR) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) and Stable Deep Molecular Response (DMR) Discontinuing Dasatinib (DASFREE)","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Dasatinib; Discontinuation; Myeloid leukemia; Medicine; Tyrosine-kinase inhibitor; Tyrosine kinase; Internal medicine; Imatinib; Oncology; Cancer research; Receptor; Cancer","score_opus":0.015153637621143239,"score_gpt":0.3076260359295255,"score_spread":0.29247239830838223,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888974667","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920392,0.0022271913,0.0003105087,0.0004389958,0.0004458857,0.0028290567,0.00011424789,0.0003584562,0.0012364369],"genre_scores_gemma":[0.99188775,0.0004393129,0.0031763136,0.00039063554,0.0010345089,0.00024075099,0.00045141848,0.00033530506,0.0020439979],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9904348,0.0009216921,0.0025989332,0.0026739435,0.0012722524,0.0020983554],"domain_scores_gemma":[0.9922892,0.001315886,0.0009275242,0.003576182,0.00043335865,0.0014578721],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013580965,0.0014797451,0.0023651393,0.0005313274,0.0004535748,0.0001789756,0.000836734,0.0010396324,0.00042603203],"category_scores_gemma":[0.0021918458,0.001181625,0.00049348146,0.0010620244,0.0015900731,0.00063655083,0.00073810655,0.00073808775,0.00023547979],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037414685,0.0019627393,0.19635108,0.00025213143,0.0008437108,0.0021620716,0.00068081764,0.000043074087,0.007523962,0.00008813546,0.00081885303,0.7518587],"study_design_scores_gemma":[0.13303211,0.022707168,0.81514716,0.0015345896,0.0007265562,0.00024099513,0.000108922395,0.004284085,0.007265294,0.00011853309,0.013567574,0.0012670063],"about_ca_topic_score_codex":0.00084949285,"about_ca_topic_score_gemma":0.000826541,"teacher_disagreement_score":0.75059175,"about_ca_system_score_codex":0.03545437,"about_ca_system_score_gemma":0.0102156475,"threshold_uncertainty_score":0.9997952},"labels":[],"label_agreement":null},{"id":"W2889097815","doi":"10.1016/j.clml.2018.07.155","title":"Extended 5-Year Follow-Up of the Phase 3 ELOQUENT-2 Study of Elotuzumab Plus Lenalidomide/Dexamethasone (ELd) Versus Ld in Relapsed/Refractory Multiple Myeloma (RRMM)","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine; Milestone; Progression-free survival; Cancer research; Overall survival","score_opus":0.07937008621541364,"score_gpt":0.3886256237391009,"score_spread":0.3092555375236873,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889097815","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99180394,0.00041814923,0.000014303262,0.00011697966,0.0016682573,0.0028635436,0.000088562825,0.00010067977,0.0029255848],"genre_scores_gemma":[0.9970708,0.00011237628,0.00061800133,0.00011815617,0.00049590896,0.00019008544,0.00004823418,0.00013075022,0.0012157126],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9914549,0.0013395939,0.0028963452,0.0013636616,0.0017512104,0.001194271],"domain_scores_gemma":[0.9914396,0.0034405256,0.0010634849,0.0025989807,0.00071132876,0.0007460797],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020631396,0.00071862334,0.0021271799,0.00045590432,0.00024150964,0.000033249504,0.0010439077,0.0006398049,0.00046260012],"category_scores_gemma":[0.0072219134,0.0005294547,0.0009146687,0.0013497731,0.001525659,0.00018721572,0.0006497025,0.00079698773,0.00020294153],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.16276519,0.016439432,0.25331298,0.00026653626,0.0026812064,0.0009586857,0.0031606057,0.000007903982,0.0063195964,0.00018959334,0.0016006371,0.55229765],"study_design_scores_gemma":[0.2220444,0.01357011,0.75194895,0.00040685578,0.0004141516,0.000033590502,0.0023263923,0.0008015936,0.0069677946,0.000065028304,0.0010359467,0.00038517284],"about_ca_topic_score_codex":0.0020419394,"about_ca_topic_score_gemma":0.0012708042,"teacher_disagreement_score":0.5519125,"about_ca_system_score_codex":0.0019625998,"about_ca_system_score_gemma":0.0030824456,"threshold_uncertainty_score":0.9997157},"labels":[],"label_agreement":null},{"id":"W2889099819","doi":"10.1016/j.clml.2018.07.092","title":"ENESTop 144-Week Update: Long-Term Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After Stopping Second-Line Nilotinib","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Myeloid leukemia; Medicine; Internal medicine; Chronic myeloid leukaemia; Oncology; Imatinib","score_opus":0.026631027669511552,"score_gpt":0.3220819260204965,"score_spread":0.295450898350985,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889099819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99197453,0.0020441895,0.00006937143,0.00027033355,0.0009315413,0.0033143482,0.00017138208,0.00038124592,0.000843083],"genre_scores_gemma":[0.98946565,0.00072386034,0.00085166685,0.00091734156,0.002507861,0.00054818194,0.0012667936,0.00039746126,0.0033211703],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9886367,0.0006119718,0.003710677,0.0031198703,0.0013243544,0.0025964617],"domain_scores_gemma":[0.9924955,0.0007153914,0.0010672197,0.0038858273,0.00044408237,0.0013919756],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0010771935,0.0018211871,0.0029562227,0.00089041743,0.00029170536,0.00013252934,0.0011488895,0.0014014274,0.00270427],"category_scores_gemma":[0.00066558825,0.0015068125,0.00069599407,0.0015770597,0.0013084355,0.00079568586,0.0006987599,0.001115431,0.0010120724],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.015877964,0.003092332,0.47803256,0.00041168946,0.0005024495,0.0028086095,0.00028636455,0.00003695488,0.0008082152,0.000019872034,0.00066427496,0.4974587],"study_design_scores_gemma":[0.13163997,0.017754527,0.83416456,0.0025611727,0.00045510486,0.00019396155,0.000019982936,0.0010966555,0.0033081982,0.00004293628,0.0074799093,0.001282997],"about_ca_topic_score_codex":0.0006559013,"about_ca_topic_score_gemma":0.005624861,"teacher_disagreement_score":0.4961757,"about_ca_system_score_codex":0.08730309,"about_ca_system_score_gemma":0.019375678,"threshold_uncertainty_score":0.999895},"labels":[],"label_agreement":null},{"id":"W2889132102","doi":"10.1016/j.clml.2018.08.015","title":"The Adverse Consequences of Initial Watchful Waiting for Patients With Follicular Lymphoma","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Watchful waiting; Follicular lymphoma; Medicine; Adverse effect; Follicular phase; Lymphoma; Internal medicine; Cancer; Prostate cancer","score_opus":0.02672849279340848,"score_gpt":0.3369291938266099,"score_spread":0.3102007010332014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889132102","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99470353,0.00018695768,0.000038028546,0.0006757528,0.00061054603,0.0013646721,0.000077069475,0.0000847756,0.002258692],"genre_scores_gemma":[0.9960184,0.00009334756,0.001661763,0.00084912387,0.00079921813,0.00023359872,0.00009997648,0.000058349782,0.00018622464],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9965075,0.00016008917,0.0013498709,0.0006895304,0.0006163929,0.00067656283],"domain_scores_gemma":[0.9949674,0.002291243,0.00063038117,0.00080431404,0.00093502784,0.00037163848],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007000122,0.0004068089,0.00088273844,0.00006710654,0.00050899567,0.000041519674,0.00033027006,0.0002929554,0.00004365929],"category_scores_gemma":[0.0012636066,0.00023520706,0.0005546187,0.0002768233,0.002186757,0.00013761237,0.000119607954,0.00006770123,0.00008391127],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041508195,0.0010245743,0.37045312,0.00006509737,0.0007564409,0.000094679956,0.00012942319,6.8170624e-7,0.000044979457,0.0020678155,0.0018563223,0.61935604],"study_design_scores_gemma":[0.021259326,0.005079646,0.94194067,0.00035367385,0.00059188897,0.000056427332,0.00019194468,0.00020819438,0.005953852,0.00049070804,0.023562063,0.0003116033],"about_ca_topic_score_codex":0.00014612978,"about_ca_topic_score_gemma":0.000042164036,"teacher_disagreement_score":0.6190444,"about_ca_system_score_codex":0.0005438521,"about_ca_system_score_gemma":0.0017239607,"threshold_uncertainty_score":0.95914656},"labels":[],"label_agreement":null},{"id":"W2889471460","doi":"10.1016/j.clml.2018.07.297","title":"Management of Polycythemia Vera: A Survey of Canadian Physician Practice Patterns","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Princess Margaret Cancer Centre; St. Michael's Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"","keywords":"Polycythemia vera; Family medicine; Medicine; Internal medicine","score_opus":0.05114154268951311,"score_gpt":0.35426591931080276,"score_spread":0.30312437662128966,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2889471460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96789,0.0001814697,0.00002920193,0.00083995593,0.00040864598,0.00076897064,0.00021077532,0.000029553625,0.029641392],"genre_scores_gemma":[0.9948271,0.0006216097,0.0017420917,0.0018423923,0.00031659656,0.00007348488,0.00013994216,0.00004855808,0.00038824673],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9968466,0.0003266968,0.0012220914,0.000602636,0.00049488636,0.00050709094],"domain_scores_gemma":[0.99626267,0.0010086416,0.0005397992,0.0008659946,0.000758304,0.0005645669],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010257779,0.00032566523,0.0009745559,0.0002817813,0.00010284025,0.000016480035,0.00024720537,0.00023955682,0.00019335814],"category_scores_gemma":[0.00056837517,0.0002781317,0.0002847449,0.00076626445,0.00040858318,0.00011574772,0.00010945714,0.0001534332,0.00019202336],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015050571,0.001081456,0.48002288,0.00019355539,0.0015960017,0.0005304341,0.00019439026,7.183464e-7,0.00007240471,0.0017571759,0.0041227858,0.5089232],"study_design_scores_gemma":[0.0038056567,0.0015757222,0.97203195,0.0005201991,0.000453275,0.000037930196,0.00014863595,0.000063267915,0.0051517356,0.000039799343,0.015955407,0.00021641096],"about_ca_topic_score_codex":0.09451647,"about_ca_topic_score_gemma":0.026428878,"teacher_disagreement_score":0.50870675,"about_ca_system_score_codex":0.00068764604,"about_ca_system_score_gemma":0.0014092312,"threshold_uncertainty_score":0.9999671},"labels":[],"label_agreement":null},{"id":"W2900750202","doi":"10.1016/j.clml.2018.11.002","title":"Are We Choosing Wisely With Autologous Hematopoietic Cell Transplantation Screening? The Utility of Pulmonary Function Testing Prior to Autologous Hematopoietic Cell Transplantation","year":2018,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; University of Ottawa","funders":"University of Ottawa","keywords":"Medicine; Hematopoietic cell; Transplantation; Hematopoietic stem cell transplantation; Haematopoiesis; Pulmonary function testing; Oncology; Intensive care medicine; Internal medicine; Stem cell; Genetics","score_opus":0.04679049909338519,"score_gpt":0.3015993118845955,"score_spread":0.2548088127912103,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2900750202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9255982,0.00029021886,0.06576244,0.0008884014,0.000479759,0.00203849,0.000072559844,0.00042422768,0.0044456893],"genre_scores_gemma":[0.98502386,0.00016021854,0.01303533,0.0008396901,0.00037087986,0.00012352498,0.00012460742,0.00013882326,0.00018307468],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9936141,0.00061928935,0.0023780526,0.001360294,0.0011021248,0.0009261334],"domain_scores_gemma":[0.9939354,0.0023418886,0.0013041523,0.0010974458,0.00076209166,0.0005590274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001558232,0.0007500114,0.0014131657,0.00028973893,0.00055620965,0.00007200797,0.0004777933,0.00067559065,0.00014601246],"category_scores_gemma":[0.0002604702,0.00057568756,0.00039403484,0.0012334927,0.00092223106,0.00027314105,0.00004374907,0.0005580244,0.00016084939],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023980027,0.0020950316,0.42217314,0.015439228,0.0004755372,0.0031877963,0.010996941,0.00029110876,0.030968776,0.00012075546,0.0008795594,0.4893921],"study_design_scores_gemma":[0.0044149375,0.0015955913,0.9428547,0.0026013667,0.001730512,0.0035975012,0.0010303162,0.0042236177,0.036927633,0.00018080694,0.00022036675,0.0006226352],"about_ca_topic_score_codex":0.000117173804,"about_ca_topic_score_gemma":0.0000519133,"teacher_disagreement_score":0.52068156,"about_ca_system_score_codex":0.0002584896,"about_ca_system_score_gemma":0.0008642289,"threshold_uncertainty_score":0.99966943},"labels":[],"label_agreement":null},{"id":"W2903833951","doi":"10.1016/j.clml.2018.12.007","title":"Addition of Cyclophosphamide “On Demand” to Lenalidomide and Corticosteroids in Patients With Relapsed/Refractory Multiple Myeloma—A Retrospective Review of a Single-center Experience","year":2018,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene","keywords":"Medicine; Lenalidomide; Multiple myeloma; Cyclophosphamide; Single Center; Refractory (planetary science); Center (category theory); Oncology; Internal medicine; Chemotherapy","score_opus":0.04712718828424388,"score_gpt":0.3537560554148936,"score_spread":0.3066288671306497,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2903833951","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.39077225,0.6028127,0.000010237589,0.000022404745,0.00023240954,0.0051563927,0.0005429457,0.000041591993,0.0004090297],"genre_scores_gemma":[0.08478495,0.91242576,0.0007096333,0.00039772884,0.0001659811,0.0005566028,0.0007150438,0.00014096055,0.0001033696],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9924787,0.00071614597,0.0033365618,0.0014903194,0.0012265431,0.0007516864],"domain_scores_gemma":[0.99378306,0.001634995,0.0017114977,0.0013620255,0.00072498346,0.00078343676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008457327,0.0008950966,0.0048786975,0.00047267915,0.00007423044,0.000021850807,0.0003996072,0.00063775404,0.000119867625],"category_scores_gemma":[0.0051571648,0.0006394503,0.00071961066,0.0008236395,0.00081605196,0.0001838099,0.00030939942,0.0005343412,0.00007597432],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004929451,0.0022713935,0.13920869,0.02705587,0.00050016283,0.00017922514,0.000083551044,5.3035585e-8,0.0000032033772,0.0000061732007,0.0007085012,0.82505375],"study_design_scores_gemma":[0.012672409,0.008727738,0.6865076,0.23069626,0.0005715643,0.000048209604,0.000011586669,0.000003289548,0.000035631245,0.000006051125,0.060231887,0.00048778087],"about_ca_topic_score_codex":0.000052879237,"about_ca_topic_score_gemma":0.000028508572,"teacher_disagreement_score":0.82456595,"about_ca_system_score_codex":0.0022121465,"about_ca_system_score_gemma":0.0010805733,"threshold_uncertainty_score":0.99960566},"labels":[],"label_agreement":null},{"id":"W2943115873","doi":"10.1016/j.clml.2019.04.014","title":"Geriatric Assessment and Frailty Scores Predict Mortality in Myeloma: Systematic Review and Meta-analysis","year":2019,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"American Society of Clinical Oncology; Janssen Biotech; National Cancer Institute; Foundation for the National Institutes of Health","keywords":"Medicine; Meta-analysis; Hazard ratio; Multiple myeloma; Internal medicine; Confidence interval; Incidence (geometry); Adverse effect","score_opus":0.2212138162500832,"score_gpt":0.4785600637822102,"score_spread":0.257346247532127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2943115873","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0013156306,0.98620224,0.000013149015,0.00010562399,0.00010739705,0.011048258,0.00051508646,0.0000989937,0.0005936344],"genre_scores_gemma":[0.0019325543,0.99267703,0.00051093433,0.00045769056,0.00012943,0.0020810943,0.000824141,0.00013696856,0.0012501709],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98626,0.003165282,0.0056457366,0.0024448845,0.0014266785,0.0010573976],"domain_scores_gemma":[0.9898181,0.0038445217,0.0019925232,0.0028812762,0.0002658318,0.0011977652],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004980954,0.0015336974,0.026523307,0.0009815211,0.00013909469,0.00017069494,0.0006129316,0.0011592598,0.00036869777],"category_scores_gemma":[0.0023074818,0.0009633676,0.0057938397,0.002171116,0.00048642428,0.00021380489,0.0007182838,0.0010840467,0.00017005161],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000029358636,0.00030686776,0.0061208797,0.6952391,0.18185186,0.000688773,0.0000060162483,1.14966404e-7,2.3201189e-8,0.000037838465,0.00019865934,0.11552047],"study_design_scores_gemma":[0.0018230887,0.00034667423,0.21812116,0.03442813,0.73911273,0.00023608313,0.0000050591825,0.00009136782,5.1721653e-8,0.00002142674,0.0051992554,0.00061497896],"about_ca_topic_score_codex":0.00029218697,"about_ca_topic_score_gemma":0.00009065809,"teacher_disagreement_score":0.660811,"about_ca_system_score_codex":0.001699419,"about_ca_system_score_gemma":0.0034362827,"threshold_uncertainty_score":0.99974114},"labels":[],"label_agreement":null},{"id":"W2947892248","doi":"10.1016/j.clml.2019.05.018","title":"POEMS Syndrome: Indian Experience From a Tertiary-Care Institute","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Tertiary care; Poetry; POEMS syndrome; Medicine; Family medicine; Art; Literature; Internal medicine","score_opus":0.02104932027585453,"score_gpt":0.30606750315567555,"score_spread":0.285018182879821,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2947892248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99063146,0.0007776238,0.000019430552,0.0003902319,0.0024658293,0.0005743535,0.000033541022,0.0002339981,0.0048735226],"genre_scores_gemma":[0.990145,0.00017496114,0.00046009466,0.0075070406,0.00032979905,0.00004474202,0.00013177475,0.00006410882,0.0011424437],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99695605,0.0001041218,0.00092544657,0.00096966035,0.00046213067,0.0005825921],"domain_scores_gemma":[0.9978214,0.00019028131,0.00019506918,0.001100197,0.000102693535,0.0005903802],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00013471693,0.0003834228,0.00079216226,0.00008612037,0.00012499206,0.000059834918,0.00042712546,0.00042886744,0.0008343872],"category_scores_gemma":[0.0003736882,0.000331496,0.0004389179,0.00028958867,0.00055165915,0.0003356272,0.00023438419,0.00035651596,0.0016221831],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005640539,0.00022108476,0.64098173,0.00011184363,0.00010264849,0.0031067387,0.002096034,0.000009246651,0.001224,0.000072832874,0.0023378804,0.3491719],"study_design_scores_gemma":[0.004640102,0.0005465086,0.943141,0.00025886876,0.00005322838,0.00025981106,0.0016828363,0.00014646443,0.0001917557,0.00009821428,0.04858716,0.00039409383],"about_ca_topic_score_codex":0.0006482559,"about_ca_topic_score_gemma":0.00010194861,"teacher_disagreement_score":0.34877783,"about_ca_system_score_codex":0.00039200878,"about_ca_system_score_gemma":0.000786394,"threshold_uncertainty_score":0.9999137},"labels":[],"label_agreement":null},{"id":"W2961471425","doi":"10.1016/j.clml.2019.07.004","title":"Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"Cilag; Janssen Pharmaceuticals; TG Therapeutics; H. Lundbeck A/S; BeiGene; Pharmacyclics; Genentech; Sunesis; Astellas Pharma; Exelixis; Sun Pharma; Regeneron Pharmaceuticals; F. Hoffmann-La Roche; AbbVie; Janssen Biotech; Teva Pharmaceutical Industries; Gilead Sciences; Janssen Research and Development; MorphoSys; Pfizer; Biogen; Celgene; AstraZeneca; Amgen; Alexion Pharmaceuticals; Roche; GlaxoSmithKline","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Oncology; Internal medicine; Leukemia","score_opus":0.04643419086277679,"score_gpt":0.37937275578762464,"score_spread":0.33293856492484786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2961471425","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99304736,0.002336966,0.000017119346,0.000078854915,0.0007630268,0.0023857667,0.00001601721,0.00019556604,0.0011593186],"genre_scores_gemma":[0.9958797,0.0011384056,0.00048860087,0.0006656056,0.0003162377,0.000096974356,0.000105800296,0.00021209918,0.0010965575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912712,0.00051032705,0.0029193736,0.0016786855,0.0019889814,0.0016314253],"domain_scores_gemma":[0.99237144,0.002880226,0.0009648674,0.002286646,0.0008951994,0.00060161995],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017857661,0.00096732413,0.003235992,0.0005680854,0.00013958749,0.00009309498,0.00090414047,0.0007715977,0.00026711673],"category_scores_gemma":[0.0012898109,0.00070670625,0.00069352175,0.0012354704,0.0013263744,0.0005980425,0.00054968905,0.00068761484,0.00042083857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0026789447,0.00034896217,0.83507097,0.0006702816,0.0010717666,0.00026620372,0.00019729759,0.00019228544,0.00009738119,0.000059669117,0.000175762,0.1591705],"study_design_scores_gemma":[0.1030234,0.003181414,0.88796705,0.0016128818,0.00018358999,0.00006548141,0.00012543045,0.002280816,0.00066572154,0.000046257337,0.00016660427,0.0006813471],"about_ca_topic_score_codex":0.0005086615,"about_ca_topic_score_gemma":0.00009201391,"teacher_disagreement_score":0.15848915,"about_ca_system_score_codex":0.14910379,"about_ca_system_score_gemma":0.073858365,"threshold_uncertainty_score":0.9995384},"labels":[],"label_agreement":null},{"id":"W2970030949","doi":"10.1016/j.clml.2019.07.205","title":"Five-Year Follow-Up After Ibrutinib Therapy for First-Line Treatment of Chronic Lymphocytic Leukemia","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Chlorambucil; Medicine; Oncology; Bruton's tyrosine kinase; Internal medicine; Leukemia; Chemotherapy; Receptor; Tyrosine kinase","score_opus":0.038030738120085956,"score_gpt":0.34495970751860233,"score_spread":0.3069289693985164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970030949","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9856286,0.004104902,0.00012180077,0.0002553252,0.0018795517,0.0048021986,0.00015061484,0.00028027926,0.0027767445],"genre_scores_gemma":[0.9720488,0.0049680048,0.00084610394,0.0006412754,0.0020789322,0.00086289,0.00026983634,0.0002922799,0.017991873],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920229,0.00025603367,0.0027247975,0.0019418001,0.0012499122,0.00180461],"domain_scores_gemma":[0.99160725,0.0032262062,0.0006947147,0.0028203775,0.00068457815,0.00096686406],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0011383464,0.0010472597,0.0027981566,0.00037221197,0.00017978018,0.000076015924,0.00077441,0.0011517208,0.0013585052],"category_scores_gemma":[0.00082078384,0.0008428876,0.0021861414,0.0007552465,0.00084493606,0.00025066713,0.00026518782,0.0002883924,0.0016708574],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.062520176,0.0014193713,0.020825632,0.0018915193,0.0028226518,0.00066573307,0.0008746008,0.000583066,0.0013745916,0.0007548031,0.0073699104,0.89889795],"study_design_scores_gemma":[0.44781148,0.034577623,0.23501654,0.0014233381,0.0009100189,0.0005830894,0.00019794655,0.08896216,0.014443281,0.00077893725,0.17347771,0.0018178646],"about_ca_topic_score_codex":0.0010884677,"about_ca_topic_score_gemma":0.00019020821,"teacher_disagreement_score":0.89708006,"about_ca_system_score_codex":0.16057779,"about_ca_system_score_gemma":0.080264136,"threshold_uncertainty_score":0.9995544},"labels":[],"label_agreement":null},{"id":"W2970066205","doi":"10.1016/j.clml.2019.07.245","title":"Assessing the Clinical Significance of Major (MMR) and Deep (DMR) Molecular Responses for Overall (OS), Progression-Free (PFS) and Event-Free (EFS) Survival in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKIs)","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Precision Nanosystems (Canada)","funders":"","keywords":"Myeloid leukemia; Overall survival; Medicine; Internal medicine; Oncology; Clinical significance; Event (particle physics); Progression-free survival","score_opus":0.017227433463172674,"score_gpt":0.32058193472298846,"score_spread":0.3033545012598158,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970066205","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99164623,0.0020308783,0.00010059018,0.00050550024,0.00030915625,0.005010569,0.0001188143,0.00011927835,0.00015899638],"genre_scores_gemma":[0.9941899,0.00029988878,0.0038360397,0.00033566199,0.00032546764,0.00033286514,0.0001958488,0.00021788703,0.00026643643],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99197114,0.0010038238,0.002664964,0.001944127,0.001267468,0.0011484995],"domain_scores_gemma":[0.9907229,0.004098806,0.0013470871,0.0026400187,0.00052904635,0.00066216255],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024722824,0.0010025244,0.0022714543,0.00027220754,0.00023497222,0.00015625065,0.00078307354,0.000788174,0.000041928837],"category_scores_gemma":[0.0027355917,0.00064613833,0.00039421045,0.000688185,0.001623056,0.0005302957,0.0006384275,0.0007796876,0.000010751746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016815213,0.0008793186,0.841584,0.0005367975,0.0005898317,0.00025259666,0.000081668666,0.000038688882,0.0010107447,0.00013758994,0.0002295565,0.13784397],"study_design_scores_gemma":[0.075351365,0.00802167,0.9086467,0.002135605,0.00070488313,0.00006209401,0.00010337503,0.001579766,0.0019819883,0.00016716174,0.00053788157,0.0007074765],"about_ca_topic_score_codex":0.00032879054,"about_ca_topic_score_gemma":0.000266798,"teacher_disagreement_score":0.13713649,"about_ca_system_score_codex":0.0035890783,"about_ca_system_score_gemma":0.005446781,"threshold_uncertainty_score":0.999599},"labels":[],"label_agreement":null},{"id":"W2970263617","doi":"10.1016/j.clml.2019.07.158","title":"Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; McMaster University","funders":"","keywords":"Cytokine release syndrome; Lymphoma; Medicine; Refractory (planetary science); Cytokine; Diffuse large B-cell lymphoma; Immunology; Immunotherapy; Oncology; Biology; Immune system; Chimeric antigen receptor","score_opus":0.03538236938760417,"score_gpt":0.3367846881046666,"score_spread":0.30140231871706247,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970263617","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959078,0.00036756383,0.000005938994,0.00006779928,0.00029601136,0.0013415017,0.00008617172,0.00009352002,0.0018337],"genre_scores_gemma":[0.9942544,0.0005570942,0.00008494193,0.00055392494,0.00007122507,0.000037407248,0.00020750418,0.00010655884,0.0041269567],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939996,0.0009817261,0.0018670065,0.0012691908,0.0009650014,0.0009174886],"domain_scores_gemma":[0.99525636,0.0020393673,0.0005798278,0.0011293225,0.0002994391,0.0006956573],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009904589,0.0005644462,0.0017707029,0.0004551908,0.00008077365,0.000017192775,0.0004020031,0.00082024763,0.0009603084],"category_scores_gemma":[0.0012842363,0.00047475318,0.0005061055,0.0009037516,0.00042558427,0.00021660536,0.00044066642,0.00063856196,0.0003878839],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0068077887,0.008816128,0.91359246,0.00014813445,0.00021171187,0.00091113744,0.00010370775,0.0000038368185,0.0068332125,0.00001508463,0.00016267446,0.06239412],"study_design_scores_gemma":[0.058554113,0.0051947474,0.930927,0.00021449017,0.0001827129,0.000112585214,0.000037486374,0.0020125932,0.001032507,0.00007178361,0.0012743808,0.00038562954],"about_ca_topic_score_codex":0.00024174342,"about_ca_topic_score_gemma":0.000018110475,"teacher_disagreement_score":0.06200849,"about_ca_system_score_codex":0.00072831823,"about_ca_system_score_gemma":0.0006317992,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W2970269237","doi":"10.1016/j.clml.2019.07.140","title":"Assessment of Symptom Burden in Patients with Hematologic Malignancies using Edmonton Symptom Assessment System (ESAS) at the Time of Admission to the Institute for Oncology and Radiology of Serbia (IORS) as a Treatment Tailoring Concept","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cancer survivorship and care","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Quality of life (healthcare); Documentation; Rating scale; Cancer; Scale (ratio); Performance status; Physical therapy; Intensive care medicine; Internal medicine; Nursing; Psychology","score_opus":0.021512995420963927,"score_gpt":0.3385073112614096,"score_spread":0.3169943158404457,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970269237","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99610484,0.00028469137,0.000095353724,0.0002778424,0.0003927996,0.0023398704,0.00006311755,0.000017414688,0.00042409363],"genre_scores_gemma":[0.99868906,0.000032736432,0.0006972365,0.00013144348,0.00008207671,0.0001293827,0.000052930194,0.000025211863,0.00015994972],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9973215,0.00034293605,0.001164766,0.0004991615,0.0003546449,0.00031702372],"domain_scores_gemma":[0.99716014,0.0010601035,0.00071907503,0.0006314997,0.00027149016,0.00015772096],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00079337496,0.00028047984,0.001425675,0.00009174676,0.0000770247,0.000008001309,0.00022607105,0.00027126985,0.000026378299],"category_scores_gemma":[0.0001122365,0.0001514727,0.00020919829,0.00022335252,0.0003632368,0.00006421661,0.00019825007,0.00011137267,0.0000025149943],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003478505,0.00039381976,0.9570784,0.0007391035,0.0005068219,0.000027915532,0.0020463376,0.001244917,0.003394476,0.0013442412,0.000054415566,0.029691039],"study_design_scores_gemma":[0.008927099,0.0079115,0.9750255,0.0012945896,0.00037408844,0.000068527086,0.001463352,0.0021552807,0.0014413929,0.000013111087,0.0011470771,0.00017847789],"about_ca_topic_score_codex":0.0013375432,"about_ca_topic_score_gemma":0.00030426533,"teacher_disagreement_score":0.02951256,"about_ca_system_score_codex":0.0025879017,"about_ca_system_score_gemma":0.0018381331,"threshold_uncertainty_score":0.67672724},"labels":[],"label_agreement":null},{"id":"W2970731184","doi":"10.1016/j.clml.2019.08.004","title":"Comparison of Time to Next Treatment, Health Care Resource Utilization, and Costs in Patients with Chronic Lymphocytic Leukemia Initiated on Front-line Ibrutinib or Chemoimmunotherapy","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"National Cancer Institute; Janssen Scientific Affairs; Sunesis; AbbVie; BeiGene; TG Therapeutics","keywords":"Medicine; Chemoimmunotherapy; Ibrutinib; Hazard ratio; Internal medicine; Ofatumumab; Rituximab; Chronic lymphocytic leukemia; Oncology; Leukemia; Confidence interval; Lymphoma","score_opus":0.07058158062732924,"score_gpt":0.3954478741314718,"score_spread":0.3248662935041426,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2970731184","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190754,0.0018215689,0.000011991824,0.00015590023,0.00011346862,0.0036540919,0.000073931915,0.00014646658,0.0021150508],"genre_scores_gemma":[0.99456954,0.0003974174,0.00034210636,0.0016124438,0.00017125574,0.00009324419,0.0007535816,0.00017637317,0.0018840628],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99373513,0.00046577654,0.0022346147,0.00138179,0.0010551247,0.0011275514],"domain_scores_gemma":[0.9951937,0.001379602,0.00068318925,0.0015448126,0.00042298442,0.00077567034],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006541807,0.0007342208,0.0024218906,0.000476293,0.00013665522,0.0000644777,0.00043044786,0.0005420293,0.0007242138],"category_scores_gemma":[0.00052632287,0.0005478735,0.00021643197,0.0009810992,0.00043762085,0.00017625511,0.00019157179,0.0003407548,0.00068958016],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04848307,0.0009900515,0.14793925,0.000616468,0.0004888662,0.000097794175,0.001956099,0.0012597666,0.00010280906,0.000022965925,0.0026347316,0.7954081],"study_design_scores_gemma":[0.16497667,0.035992295,0.74690926,0.0029046193,0.00012313481,0.000046719942,0.0004455346,0.026380915,0.0014716974,0.0000025285335,0.01998554,0.00076109654],"about_ca_topic_score_codex":0.002064215,"about_ca_topic_score_gemma":0.0003976923,"teacher_disagreement_score":0.79464704,"about_ca_system_score_codex":0.19315444,"about_ca_system_score_gemma":0.07092841,"threshold_uncertainty_score":0.99969727},"labels":[],"label_agreement":null},{"id":"W2971213137","doi":"10.1016/j.clml.2019.07.116","title":"Clinical Benefit of Glasdegib Plus Low-Dose Cytarabine in Patients with De Novo and Secondary Acute Myeloid Leukemia: Long-Term Analysis of a Phase 2 Randomized Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hamilton Health Sciences; Juravinski Hospital","funders":"","keywords":"Cytarabine; Medicine; Myeloid leukemia; Internal medicine; Oncology; Randomized controlled trial; Chemotherapy; Leukemia","score_opus":0.012573456916716548,"score_gpt":0.3092272931367638,"score_spread":0.2966538362200472,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2971213137","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997183,0.0004969766,0.00016663069,0.00001939836,0.0003183686,0.0014484338,0.00021026151,0.000018330078,0.00013858237],"genre_scores_gemma":[0.99761134,0.00059097225,0.000597993,0.0002293474,0.00021158978,0.000063657244,0.0004847633,0.00005698014,0.0001533458],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9943559,0.0006543628,0.0029074142,0.001114394,0.00040934348,0.00055858487],"domain_scores_gemma":[0.9960755,0.0011206404,0.0011584566,0.0009747748,0.00037512445,0.00029547449],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026211168,0.0005008211,0.0032029985,0.00029483176,0.0000525614,0.000022092083,0.00047581774,0.00076627074,0.000044064232],"category_scores_gemma":[0.0011556005,0.0004107179,0.001052743,0.0005969831,0.0010880451,0.000020004807,0.00039702636,0.00034328733,0.0000063030693],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.59488076,0.00095284224,0.34392384,0.00011604151,0.0057785823,0.00004695979,0.00010256706,0.00014962516,0.0029288747,0.000016930155,0.000026112577,0.051076863],"study_design_scores_gemma":[0.47900215,0.0026723605,0.51438427,0.00009507715,0.0014729808,0.0000036414508,0.000013129918,0.00045548746,0.0015634601,0.000012853583,0.000026058593,0.00029852556],"about_ca_topic_score_codex":0.00006475971,"about_ca_topic_score_gemma":0.00011917529,"teacher_disagreement_score":0.17046046,"about_ca_system_score_codex":0.00028717215,"about_ca_system_score_gemma":0.00180055,"threshold_uncertainty_score":0.9998345},"labels":[],"label_agreement":null},{"id":"W2979878708","doi":"10.1016/j.clml.2019.09.619","title":"Outpatient Autologous Stem Cell Transplants for Multiple Myeloma: Analysis of Safety and Outcomes in a Tertiary Care Center","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Tertiary care; Center (category theory); Multiple myeloma; Medicine; Stem cell; Surgery; Internal medicine; Chemistry; Biology","score_opus":0.02158837584531826,"score_gpt":0.32015317837497,"score_spread":0.29856480252965173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2979878708","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99555445,0.00052313716,0.000077291275,0.00011627217,0.00021732961,0.0021163335,0.0009080573,0.000055518878,0.0004316212],"genre_scores_gemma":[0.9973126,0.00020986734,0.00088598445,0.00023409877,0.000033301272,0.00009837407,0.00063562655,0.000050084644,0.0005400362],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9959882,0.0002443569,0.0016259105,0.0009236071,0.0004885838,0.00072937994],"domain_scores_gemma":[0.9963541,0.0018855046,0.00031758507,0.0007678523,0.00020331412,0.0004716423],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046390865,0.00042223936,0.001887581,0.00053397426,0.00007129385,0.000019339901,0.00023994918,0.00044335373,0.000053104388],"category_scores_gemma":[0.00017690052,0.00032876365,0.00084860297,0.00043481422,0.00020554122,0.00010811335,0.00012145807,0.00023412569,0.000037158272],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038590904,0.00066312077,0.77045834,0.000462458,0.0011945618,0.00012872861,0.0006031606,0.000022319406,0.00015886486,0.000008362976,0.000017349896,0.22242364],"study_design_scores_gemma":[0.02520077,0.0010886886,0.9632401,0.00016901975,0.00092446024,0.000013330668,0.0004136642,0.0074973875,0.00071984174,0.000004716717,0.00045168298,0.00027632885],"about_ca_topic_score_codex":0.000248233,"about_ca_topic_score_gemma":0.00036668187,"teacher_disagreement_score":0.22214732,"about_ca_system_score_codex":0.000666944,"about_ca_system_score_gemma":0.00044340183,"threshold_uncertainty_score":0.99991643},"labels":[],"label_agreement":null},{"id":"W2980239934","doi":"10.1016/j.clml.2019.09.618","title":"Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Juravinski Cancer Centre; McMaster University","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institutes of Health; Agency for Healthcare Research and Quality; National Cancer Institute; Institute of Translational Health Sciences, University of Washington; Centers for Medicare and Medicaid Services","keywords":"Lenalidomide; Multiple myeloma; Medicine; Internal medicine; Oncology","score_opus":0.02879022313772613,"score_gpt":0.33143374279881693,"score_spread":0.3026435196610908,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980239934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916449,0.00023912807,0.000070647344,0.0005398647,0.00036484905,0.0037840914,0.00004264046,0.00020339967,0.0031104507],"genre_scores_gemma":[0.9898478,0.00011471606,0.0045447466,0.0017667718,0.0003485125,0.00048177553,0.00013972413,0.00013179211,0.0026241827],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939483,0.00033132467,0.0014986766,0.0016631221,0.0011028451,0.001455742],"domain_scores_gemma":[0.9941085,0.0021727239,0.0002717511,0.0015460264,0.00032193243,0.0015790977],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007859058,0.0006786096,0.0015217582,0.00039345789,0.00010608092,0.0000859844,0.0005679096,0.00048577305,0.0007585086],"category_scores_gemma":[0.0019630522,0.0005194365,0.00041214377,0.0009286493,0.00026529885,0.0002861764,0.0002988646,0.00056796503,0.0048244526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013775465,0.0007718876,0.57634556,0.00013944707,0.0001498513,0.002241523,0.00026249955,0.000024099652,0.00021062902,0.00002846012,0.0009623511,0.40508822],"study_design_scores_gemma":[0.058599163,0.003922181,0.92918867,0.0017248166,0.000062944295,0.00015220344,0.0003261939,0.0018079954,0.0011909867,0.000022202066,0.0024322968,0.0005703762],"about_ca_topic_score_codex":0.0016449969,"about_ca_topic_score_gemma":0.0012328377,"teacher_disagreement_score":0.40451783,"about_ca_system_score_codex":0.0012661696,"about_ca_system_score_gemma":0.0017056098,"threshold_uncertainty_score":0.9997257},"labels":[],"label_agreement":null},{"id":"W2980405531","doi":"10.1016/j.clml.2019.09.531","title":"Clinical and prognostic impact of circulating plasma cells on peripheral blood smears in multiple myeloma at presentation and during follow-up","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"","keywords":"Multiple myeloma; Plasma cell leukemia; Medicine; Peripheral blood; Proportional hazards model; Internal medicine; Multivariate analysis; Oncology; Single Center; Presentation (obstetrics); Gastroenterology; Surgery","score_opus":0.03751029044061064,"score_gpt":0.3497344506432094,"score_spread":0.31222416020259874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980405531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99725145,0.00017568035,0.0000013835113,0.000041432777,0.0002727683,0.0017553926,0.000041028354,0.00006088302,0.0003999802],"genre_scores_gemma":[0.9981571,0.00023445416,0.00061986136,0.000042657543,0.00018569597,0.000052945477,0.00006533905,0.00007561087,0.00056637963],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99533695,0.00048259037,0.0016859494,0.0010943122,0.0006309525,0.00076922076],"domain_scores_gemma":[0.99524534,0.0028462387,0.00040596147,0.00062376633,0.00014149609,0.00073722535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00087150984,0.0004522343,0.0012749973,0.00023697113,0.00013369031,0.000050405277,0.0001623961,0.00047620767,0.00011531768],"category_scores_gemma":[0.002264267,0.000375361,0.00049960957,0.00029872963,0.00050346146,0.000194673,0.000297812,0.00044752922,0.00007205437],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005720416,0.00058841653,0.8874856,0.00027503466,0.00045906845,0.0005189368,0.00018933263,0.000044662345,0.009585758,0.000007734844,0.0000213271,0.0951037],"study_design_scores_gemma":[0.0398427,0.0029678047,0.9396128,0.0005480596,0.00015660019,0.0002184604,0.00007757231,0.01396533,0.002278979,0.000023227674,0.000011185393,0.00029727808],"about_ca_topic_score_codex":0.00038470223,"about_ca_topic_score_gemma":0.000111475696,"teacher_disagreement_score":0.094806425,"about_ca_system_score_codex":0.0005783952,"about_ca_system_score_gemma":0.0005610157,"threshold_uncertainty_score":0.9998698},"labels":[],"label_agreement":null},{"id":"W2980562306","doi":"10.1016/j.clml.2019.09.375","title":"Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) Delivers a Reduction and Delay in Worsening of Pain Symptoms for Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplant","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Daratumumab; Multiple myeloma; Dexamethasone; Internal medicine; Oncology; Quality of life (healthcare); Physical therapy","score_opus":0.02003324017375479,"score_gpt":0.29692993721462285,"score_spread":0.27689669704086806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980562306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942038,0.0003859444,0.0010261608,0.00011138388,0.0001354752,0.0038818927,0.00015974855,0.000046506477,0.00004906603],"genre_scores_gemma":[0.9854824,0.0002644049,0.013150867,0.000099205514,0.00009778893,0.0003681792,0.0003558147,0.000072637864,0.00010871043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9967262,0.00024961814,0.0010536134,0.00089068915,0.00039945668,0.0006804202],"domain_scores_gemma":[0.9945527,0.0039291675,0.00032269311,0.00041303568,0.0003241587,0.00045830006],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012542031,0.00040296454,0.0011099457,0.00030755295,0.00012152118,0.000029369456,0.00013297451,0.00033823898,0.0000104349465],"category_scores_gemma":[0.0014038775,0.00032112672,0.00021467125,0.00032429126,0.00033480694,0.00023356754,0.00005629543,0.00019993914,0.0000038652092],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023476955,0.00044518485,0.68213314,0.00042151051,0.00030430563,0.00004367179,0.00023564616,0.000025958905,0.000451622,0.000033379896,0.000083975974,0.29234463],"study_design_scores_gemma":[0.07811169,0.0047377506,0.90045524,0.0009112095,0.00021865664,0.000044902037,0.00017933533,0.013634079,0.00081144506,0.000061958715,0.0004981012,0.0003356034],"about_ca_topic_score_codex":0.00038405013,"about_ca_topic_score_gemma":0.00018840736,"teacher_disagreement_score":0.29200903,"about_ca_system_score_codex":0.00036216,"about_ca_system_score_gemma":0.00043123402,"threshold_uncertainty_score":0.99992406},"labels":[],"label_agreement":null},{"id":"W2980592905","doi":"10.1016/j.clml.2019.09.162","title":"Mass cytometry reveals increase in marrow resident monocytes associated with response to daratumumab and pomalidomide","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Daratumumab; Pomalidomide; Mass cytometry; Bone marrow; Immune system; Immunology; CD38; Monocyte; Medicine; Cancer research; Multiple myeloma; Biology; Antibody; Monoclonal antibody; CD34; Stem cell; Lenalidomide; Cell biology","score_opus":0.026794748634111715,"score_gpt":0.336731276792525,"score_spread":0.3099365281584133,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980592905","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454457,0.0003708812,0.00001437866,0.0010440005,0.000114161965,0.0018012791,0.000072958675,0.00012489872,0.0019128581],"genre_scores_gemma":[0.9912859,0.00009515314,0.0015121859,0.0010479279,0.00010679548,0.00012920938,0.00009454493,0.00009273032,0.0056355256],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9944405,0.0012482497,0.0012099401,0.0011754603,0.0009069624,0.0010188748],"domain_scores_gemma":[0.9928554,0.004183031,0.0002670804,0.0010596872,0.00024985085,0.0013849254],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032674007,0.0004927428,0.0013604172,0.0006355403,0.00010391491,0.00010503874,0.00030175468,0.00045437188,0.00018947978],"category_scores_gemma":[0.009460946,0.00039095053,0.00020522987,0.0011010895,0.00025799213,0.00021257634,0.00027047965,0.00045793277,0.0005675927],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057627782,0.00034402742,0.89951515,0.0000747227,0.0003580966,0.004051788,0.000113634094,0.0000045258275,0.007754483,0.00004043603,0.0009826644,0.029132692],"study_design_scores_gemma":[0.024584472,0.0030208759,0.96843356,0.0008902304,0.00009874709,0.00015770552,0.0001385663,0.00036473988,0.0010605186,0.00016589812,0.0006761167,0.0004085895],"about_ca_topic_score_codex":0.00046124356,"about_ca_topic_score_gemma":0.00015411607,"teacher_disagreement_score":0.06891839,"about_ca_system_score_codex":0.0022890186,"about_ca_system_score_gemma":0.0013509117,"threshold_uncertainty_score":0.99985427},"labels":[],"label_agreement":null},{"id":"W2980751160","doi":"10.1016/j.clml.2019.09.116","title":"The three-dimensional (3D) spatial distribution of lamin A/C in the nuclei of Myeloma Cells","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Lamin; Nuclear lamina; Multiple myeloma; Malignancy; Biology; Hematologic malignancy; Cancer; Cancer research; Cancer cell; Cell nucleus; Nuclear protein; Cell biology; Pathology; Gene; Nucleus; Medicine; Immunology; Internal medicine; Genetics","score_opus":0.008940248270644217,"score_gpt":0.2500209677268493,"score_spread":0.24108071945620507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980751160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9977488,0.00016927431,0.00012630913,0.00016702239,0.0006951641,0.0002618984,0.00004323854,0.0000059211575,0.0007823975],"genre_scores_gemma":[0.99900615,0.000049496455,0.00009318978,0.00024427037,0.00030756308,0.0000058574115,0.00014017566,0.000017704202,0.00013558488],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99824846,0.00020689056,0.0006947445,0.0003410126,0.00027137817,0.00023753809],"domain_scores_gemma":[0.99861693,0.00027066196,0.0003033721,0.00065405475,0.00011021157,0.000044790828],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00077976583,0.00016232552,0.0002725003,0.00001780061,0.0000751028,0.0000146949205,0.0004051932,0.00031261006,0.000032619337],"category_scores_gemma":[0.00018805446,0.000100832025,0.00022780237,0.00013322645,0.00032432735,0.000005962025,0.00014874095,0.00014404551,0.00003815151],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002271358,0.00022855484,0.047514994,0.00005544123,0.0001529743,0.00001020568,0.00006258884,0.00015803726,0.20679936,0.0023675046,0.009315445,0.73106354],"study_design_scores_gemma":[0.0011624658,0.0006087979,0.94373965,0.000023841696,0.000026807676,0.000012527025,0.000038020215,0.00075180735,0.016926825,0.00032867864,0.036246236,0.0001343221],"about_ca_topic_score_codex":0.0001324984,"about_ca_topic_score_gemma":0.0001953926,"teacher_disagreement_score":0.8962247,"about_ca_system_score_codex":0.000047100824,"about_ca_system_score_gemma":0.0002226401,"threshold_uncertainty_score":0.41118106},"labels":[],"label_agreement":null},{"id":"W2980792813","doi":"10.1016/j.clml.2019.09.275","title":"Elotuzumab, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Efficacy After Additional Follow-Up of the ELOQUENT-3 Study","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Pomalidomide; Lenalidomide; Dexamethasone; Internal medicine; Medicine; Ixazomib; Multiple myeloma; Oncology; Hazard ratio; Refractory (planetary science); Progression-free survival; Bortezomib; Overall survival; Carfilzomib; Biology; Confidence interval","score_opus":0.03648884867608198,"score_gpt":0.3331541773261949,"score_spread":0.2966653286501129,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980792813","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915183,0.00056603923,0.000016608117,0.00020613598,0.00085208914,0.00490361,0.0008989419,0.000091168935,0.000947076],"genre_scores_gemma":[0.9914336,0.00005686596,0.0013370487,0.0003978729,0.0003743689,0.0008222996,0.00032347586,0.00011750594,0.005136961],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947504,0.00056225894,0.0015598527,0.0012078076,0.0010464387,0.0008732825],"domain_scores_gemma":[0.99006945,0.0068212887,0.00051964354,0.001483611,0.00044165127,0.00066437566],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011352953,0.0005689502,0.0013602594,0.00019426667,0.00022577157,0.000052970252,0.00045927954,0.000462371,0.001590028],"category_scores_gemma":[0.0046915207,0.00039778367,0.00091345434,0.00041191862,0.0006164126,0.00019559039,0.00044153575,0.0004596397,0.0002681051],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.022341073,0.0033902442,0.70776045,0.00021106108,0.0014749672,0.00017994303,0.00030678598,0.0000019653219,0.00056669395,0.000112814065,0.0047535417,0.25890046],"study_design_scores_gemma":[0.062826835,0.0033937106,0.91988593,0.00032264888,0.0003957458,0.00008063506,0.00028899987,0.0003232831,0.00039126383,0.00009527112,0.011639183,0.00035648388],"about_ca_topic_score_codex":0.00015149925,"about_ca_topic_score_gemma":0.00008223379,"teacher_disagreement_score":0.25854397,"about_ca_system_score_codex":0.00073462294,"about_ca_system_score_gemma":0.0014232752,"threshold_uncertainty_score":0.9998474},"labels":[],"label_agreement":null},{"id":"W2980805176","doi":"10.1016/j.clml.2019.09.410","title":"Greater Treatment Satisfaction in Patients Receiving Subcutaneous (SC) Versus Intravenous (IV) Daratumumab (DARA) for Relapsed or Refractory Multiple Myeloma (RRMM): COLUMBA","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary","funders":"","keywords":"Daratumumab; Medicine; Refractory (planetary science); Internal medicine; Adverse effect; Multiple myeloma; Oncology; Lenalidomide","score_opus":0.04796568004329691,"score_gpt":0.3345886507110818,"score_spread":0.28662297066778486,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980805176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99053466,0.00012158461,0.000017413515,0.00012933397,0.002196783,0.0050835954,0.00016454351,0.00023959068,0.0015125112],"genre_scores_gemma":[0.99239314,0.0002679707,0.001622708,0.00017997745,0.00047457384,0.0005156359,0.0007232534,0.00019838146,0.0036243366],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99342644,0.00045294687,0.0019211897,0.0017195839,0.0009339118,0.0015459249],"domain_scores_gemma":[0.9937488,0.0029767212,0.00053827267,0.001436523,0.00041018068,0.0008895293],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006152468,0.000842172,0.0017783161,0.0004094703,0.0003166497,0.00011974998,0.00032980138,0.00090519805,0.00041209316],"category_scores_gemma":[0.002260564,0.0006848664,0.00067842857,0.00052770873,0.00027465192,0.0003392051,0.00015491227,0.0005148726,0.000881044],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06314322,0.0010701902,0.44092497,0.00009895201,0.0004589849,0.00072184217,0.00017279011,0.000007889321,0.00018571295,0.0000061686046,0.00035985588,0.49284944],"study_design_scores_gemma":[0.0883533,0.025986917,0.8765307,0.00033495892,0.00024334507,0.00011889739,0.000103304366,0.0018729952,0.0004509281,0.000021329364,0.0053731306,0.0006101618],"about_ca_topic_score_codex":0.0012147255,"about_ca_topic_score_gemma":0.0025104843,"teacher_disagreement_score":0.49223927,"about_ca_system_score_codex":0.00779667,"about_ca_system_score_gemma":0.001940459,"threshold_uncertainty_score":0.9998969},"labels":[],"label_agreement":null},{"id":"W2980929842","doi":"10.1016/j.clml.2019.09.414","title":"The Impact of Lenalidomide Maintenance on Second Line Chemotherapy in Transplant Eligible Patients with Multiple Myeloma in the Canadian Setting","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; University of Saskatchewan; Université de Montréal; Leukemia & Lymphoma Society of Canada; McGill University Health Centre; University Health Network; Ottawa Hospital; Princess Margaret Cancer Centre; University of Alberta; Canadian Council on International Law; Dalhousie University; University of British Columbia","funders":"","keywords":"Lenalidomide; Multiple myeloma; Oncology; Medicine; Maintenance therapy; Internal medicine; Chemotherapy","score_opus":0.017786836732838505,"score_gpt":0.31902921537140455,"score_spread":0.30124237863856607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2980929842","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445015,0.00009505039,0.0000015382158,0.00082000816,0.00008306039,0.0019144252,0.00013304078,0.000017648294,0.0024850806],"genre_scores_gemma":[0.99829316,0.000114316426,0.000114285416,0.0007981003,0.00008939892,0.000080440754,0.00012989675,0.000055038963,0.00032536473],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961805,0.00039538954,0.0010794984,0.0005987818,0.00067376456,0.0010720893],"domain_scores_gemma":[0.99577117,0.0024215768,0.00026969842,0.00092542445,0.00018418679,0.00042794395],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0015991227,0.00039739304,0.00079388253,0.00024427864,0.00016421577,0.000058468046,0.000513981,0.00026515656,0.000109503664],"category_scores_gemma":[0.00057547115,0.00019389727,0.0003470503,0.0005652522,0.00030624462,0.00010637205,0.000029005854,0.00058467616,0.00009704526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008094569,0.00044810033,0.89006585,0.0000433192,0.00018392895,0.00024538094,0.0003461295,0.00007720017,0.00006905611,0.00003714475,0.0003693296,0.10001998],"study_design_scores_gemma":[0.026690457,0.002364651,0.9665916,0.0005206976,0.000018622692,0.00003042274,0.00009881421,0.0022797205,0.00035249162,0.00005999246,0.00078316574,0.0002093658],"about_ca_topic_score_codex":0.04286089,"about_ca_topic_score_gemma":0.15264869,"teacher_disagreement_score":0.10978779,"about_ca_system_score_codex":0.0018811856,"about_ca_system_score_gemma":0.002541651,"threshold_uncertainty_score":0.9635128},"labels":[],"label_agreement":null},{"id":"W2981119159","doi":"10.1016/j.clml.2019.09.572","title":"The Princess Margaret Cancer Centre Experience: Transitioning to GCSF Alone for Stem Cell Mobilization in Myeloma Patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Plerixafor; Medicine; Regimen; Multiple myeloma; Apheresis; Mobilization; Cyclophosphamide; Surgery; Febrile neutropenia; Internal medicine; Oncology; Neutropenia; Chemotherapy; CXCR4","score_opus":0.028423449931071165,"score_gpt":0.3459116521429805,"score_spread":0.3174882022119093,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981119159","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99360865,0.00025579607,0.0001488029,0.00077621144,0.00062622054,0.0037715458,0.000080599144,0.00007379695,0.0006583496],"genre_scores_gemma":[0.9949656,0.00022758805,0.0004815314,0.0006245459,0.00020149814,0.0007381008,0.00019183564,0.00007045458,0.0024988204],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99612355,0.00022826834,0.0011141072,0.0009031288,0.00070685474,0.0009240899],"domain_scores_gemma":[0.9971128,0.0009849898,0.00021544538,0.0007033242,0.0004001011,0.00058330595],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005831842,0.00035498178,0.00069306866,0.00013152962,0.00027187355,0.00009414823,0.0003711506,0.00028422152,0.0001312333],"category_scores_gemma":[0.00024654964,0.0002601351,0.00027900195,0.0005130484,0.00015783113,0.00020154579,0.00011953115,0.00021293499,0.00019764362],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024414705,0.00040119406,0.5931508,0.00012691245,0.000059744227,0.000028314289,0.0007914571,0.00007264982,0.00026137792,0.000049836854,0.00047055172,0.4021457],"study_design_scores_gemma":[0.013068458,0.0007525388,0.96893114,0.00034310375,0.000044839995,0.000003786943,0.0007402047,0.0034264487,0.002937468,0.00003405747,0.0094291195,0.00028881442],"about_ca_topic_score_codex":0.00023477363,"about_ca_topic_score_gemma":0.0003248509,"teacher_disagreement_score":0.4018569,"about_ca_system_score_codex":0.0014331432,"about_ca_system_score_gemma":0.00090530945,"threshold_uncertainty_score":0.9999851},"labels":[],"label_agreement":null},{"id":"W2981157362","doi":"10.1016/j.clml.2019.09.022","title":"Elotuzumab plus lenalidomide/dexamethasone for relapsed/refractory multiple myeloma: Final overall survival results from the phase 3 ELOQUENT-2 trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Lenalidomide; Dexamethasone; Hazard ratio; Internal medicine; Medicine; Interim analysis; Multiple myeloma; Oncology; Refractory (planetary science); Progression-free survival; Neutropenia; Confidence interval; Randomized controlled trial; Overall survival; Chemotherapy; Biology","score_opus":0.10961399750232273,"score_gpt":0.3883472726813034,"score_spread":0.2787332751789807,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981157362","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9821738,0.0008441638,0.00024595635,0.0015347224,0.003391663,0.006610257,0.0018096892,0.00030687134,0.0030828821],"genre_scores_gemma":[0.97981936,0.00031150857,0.0026432986,0.0011765952,0.0036628754,0.0005917269,0.0027896625,0.00021381599,0.00879114],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9899926,0.001227619,0.0030394201,0.0022479277,0.001715682,0.0017767372],"domain_scores_gemma":[0.9730167,0.021407487,0.0009946942,0.002803771,0.00053371664,0.001243645],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003560306,0.000992566,0.0023080504,0.00018783966,0.00049755175,0.00021042931,0.0010701893,0.0009912169,0.0006081221],"category_scores_gemma":[0.012653143,0.0007010843,0.0017377988,0.00043527008,0.00067281624,0.0003690907,0.00043101824,0.001066466,0.0016862422],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6086452,0.0027745606,0.007678479,0.00007524882,0.0016771543,0.0005515832,0.00030551336,0.000015502452,0.000980796,0.0002902406,0.013367408,0.3636383],"study_design_scores_gemma":[0.58214617,0.0076301508,0.32585979,0.000287553,0.00047713373,0.000045883724,0.00020984924,0.0042288,0.00054095476,0.0003198458,0.077590354,0.0006635129],"about_ca_topic_score_codex":0.002119316,"about_ca_topic_score_gemma":0.00018377716,"teacher_disagreement_score":0.36297482,"about_ca_system_score_codex":0.0027514107,"about_ca_system_score_gemma":0.0044295993,"threshold_uncertainty_score":0.999544},"labels":[],"label_agreement":null},{"id":"W2981166293","doi":"10.1016/j.clml.2019.09.033","title":"Copy number gain of the MCL1 gene locus (1q21) and acquisition of BCL2 mutation mediate resistance to venetoclax in multiple myeloma (MM) patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Locus (genetics); MCL1; Gene; Genetics; Cancer research; Biology; Medicine; Leukemia; Downregulation and upregulation","score_opus":0.020977209466760783,"score_gpt":0.31538119349890215,"score_spread":0.29440398403214135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981166293","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99664533,0.00016695997,0.00002373173,0.00021894151,0.00028608998,0.0017375264,0.00012507763,0.00002506797,0.00077128067],"genre_scores_gemma":[0.9975062,0.00009088982,0.0012657907,0.0003123579,0.00009792685,0.000074970914,0.00013417614,0.00004742483,0.00047027113],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962648,0.00038844522,0.0013373025,0.0006597276,0.0008332931,0.00051641004],"domain_scores_gemma":[0.99691963,0.0010562282,0.00044613195,0.0008092159,0.00038687585,0.00038188923],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007379032,0.000300979,0.0008623414,0.000150821,0.00006864235,0.000015826086,0.00027518603,0.0003074908,0.00010523014],"category_scores_gemma":[0.0014908729,0.00023008083,0.00023523567,0.0005761902,0.00032315898,0.0001321008,0.00022234273,0.00020982025,0.00016275873],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003815843,0.00033955235,0.9238518,0.00022587586,0.000111953945,0.000058703998,0.00023467855,0.000041717336,0.0033579352,0.000053947053,0.00030028966,0.06760771],"study_design_scores_gemma":[0.013251253,0.0005830183,0.95649225,0.00051347614,0.000057861074,0.00001168723,0.000051665895,0.00070175616,0.027625678,0.00021920927,0.00030246025,0.00018969708],"about_ca_topic_score_codex":0.00028016092,"about_ca_topic_score_gemma":0.00021479174,"teacher_disagreement_score":0.06741801,"about_ca_system_score_codex":0.0010530138,"about_ca_system_score_gemma":0.0007665232,"threshold_uncertainty_score":0.9382424},"labels":[],"label_agreement":null},{"id":"W2981169884","doi":"10.1016/j.clml.2019.09.063","title":"Profound MRD negativity rates after frontline tandem autologous-allogeneic stem cell transplantation followed by bortezomib maintenance in high-risk or young myeloma patients","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; McGill University Health Centre; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Oncology; Internal medicine; Stem cell; Transplantation; Minimal residual disease; Bone marrow; Surgery","score_opus":0.015983547934228324,"score_gpt":0.297058285405214,"score_spread":0.28107473747098566,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981169884","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941813,0.00040815596,0.00015938972,0.00018456107,0.0007960825,0.0031287996,0.00046837213,0.00017864064,0.0004947248],"genre_scores_gemma":[0.9900932,0.0009634155,0.0011701979,0.00040733608,0.00018319766,0.00042745384,0.0008648354,0.00013263023,0.0057577714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9932356,0.000857101,0.0019433837,0.0015817974,0.0009834835,0.001398628],"domain_scores_gemma":[0.996237,0.0010513983,0.0006344448,0.0010024172,0.00032611907,0.0007486543],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010625633,0.000778052,0.0016802058,0.0002433319,0.0001648617,0.00009308205,0.00041937132,0.00076262973,0.00032864214],"category_scores_gemma":[0.00040314262,0.0005824942,0.00047918345,0.00058477855,0.00029041158,0.0004159605,0.0001372689,0.00067919696,0.00074205105],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01340175,0.0012373223,0.8489008,0.00023299536,0.0002461699,0.0012149228,0.00016191347,0.0000059007116,0.00040694297,0.000007051646,0.0012476933,0.13293654],"study_design_scores_gemma":[0.03701372,0.0024584366,0.9553373,0.0003632898,0.0002727409,0.00005492651,0.00007735807,0.0011673514,0.0019120002,0.000072406634,0.0006739738,0.0005965088],"about_ca_topic_score_codex":0.0009272378,"about_ca_topic_score_gemma":0.001169786,"teacher_disagreement_score":0.13234003,"about_ca_system_score_codex":0.0018758138,"about_ca_system_score_gemma":0.0013056841,"threshold_uncertainty_score":0.99966264},"labels":[],"label_agreement":null},{"id":"W2981240392","doi":"10.1016/j.clml.2019.09.064","title":"Maintenance therapy with either Lenalidomide or Bortezomib equally improves PFS and OS in High Risk Myeloma initially treated with Autotransplant.","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada","funders":"","keywords":"Lenalidomide; Bortezomib; Medicine; Multiple myeloma; Maintenance therapy; Internal medicine; Regimen; Autologous stem-cell transplantation; Oncology; Transplantation; Progression-free survival; Surgery; Overall survival; Chemotherapy","score_opus":0.025264289345250025,"score_gpt":0.3063023602096018,"score_spread":0.28103807086435173,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2981240392","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99388766,0.00036692328,0.00006693393,0.00036411057,0.00008120291,0.0025244202,0.00013596578,0.00021372318,0.002359084],"genre_scores_gemma":[0.9906816,0.0022444401,0.0023482854,0.0008537878,0.00020709286,0.00022247287,0.00013372852,0.00017695145,0.003131627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99457437,0.00052036875,0.001277354,0.0014847077,0.00085325,0.0012899584],"domain_scores_gemma":[0.9959831,0.0014555515,0.00045945108,0.00096833275,0.00029231585,0.0008412496],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009610671,0.0008177996,0.001696295,0.00028982048,0.00015049858,0.000118128526,0.00036483083,0.0005178015,0.0003416151],"category_scores_gemma":[0.00031667104,0.00046185078,0.00021791163,0.00062528317,0.0007328188,0.00033625725,0.00008726521,0.00067819346,0.00020130316],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07165425,0.0006583828,0.5407372,0.00012798261,0.00095882005,0.00574498,0.0001602276,0.00000869296,0.0011254232,0.00008164714,0.000097413125,0.378645],"study_design_scores_gemma":[0.070470944,0.010478149,0.9131411,0.0008707041,0.00020357111,0.0008989651,0.000120974844,0.0009438762,0.0013369763,0.00007447384,0.00084589724,0.0006144057],"about_ca_topic_score_codex":0.0021750305,"about_ca_topic_score_gemma":0.0009123741,"teacher_disagreement_score":0.3780306,"about_ca_system_score_codex":0.0006271943,"about_ca_system_score_gemma":0.0020668835,"threshold_uncertainty_score":0.99978334},"labels":[],"label_agreement":null},{"id":"W2982939401","doi":"10.1016/j.clml.2019.11.005","title":"Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"AL amyloidosis; Medicine; Cyclophosphamide; Bortezomib; Internal medicine; Regimen; Dexamethasone; Gastroenterology; Surgery; Chemotherapy; Multiple myeloma; Immunology; Immunoglobulin light chain; Antibody","score_opus":0.02417701691864129,"score_gpt":0.3491676142661456,"score_spread":0.32499059734750435,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2982939401","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99452984,0.0024485523,0.00005210396,0.0005301416,0.00050982623,0.0014805272,0.0003511274,0.000025809908,0.000072063296],"genre_scores_gemma":[0.9924074,0.005381806,0.0005974649,0.00054479734,0.00012387092,0.00029181535,0.00008359202,0.000086319524,0.00048296488],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99656683,0.00045085087,0.001215905,0.0009026398,0.0003178952,0.00054588565],"domain_scores_gemma":[0.9909603,0.006584767,0.00065268006,0.0013701399,0.00017956499,0.0002525285],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009317605,0.00059204217,0.0013229328,0.000088793946,0.0001037413,0.000028570183,0.00044387748,0.0004443068,0.00003840373],"category_scores_gemma":[0.0016118726,0.0003774227,0.0013295215,0.00017919161,0.00047597865,0.000012883252,0.00012846054,0.00008412896,0.000018448403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009908433,0.0010806513,0.8196078,0.000021169057,0.0017326592,0.000009983111,0.00007743237,0.00010983536,0.008037803,0.00004898761,0.00085548847,0.15850975],"study_design_scores_gemma":[0.0131742,0.010649242,0.9491003,0.0000427202,0.0003223035,0.0000053486256,0.000109823166,0.00009891934,0.020509625,0.000033003074,0.0056020855,0.0003523893],"about_ca_topic_score_codex":0.0004723442,"about_ca_topic_score_gemma":0.000057933114,"teacher_disagreement_score":0.15815735,"about_ca_system_score_codex":0.0003718415,"about_ca_system_score_gemma":0.0007241079,"threshold_uncertainty_score":0.9998678},"labels":[],"label_agreement":null},{"id":"W2990885519","doi":"10.1016/j.clml.2019.11.017","title":"Response Kinetics and Clinical Benefits of Nonintensive AML Therapies in the Absence of Morphologic Response","year":2019,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Agios Pharmaceuticals; AbbVie; Bayer; Celgene; GlaxoSmithKline; Pfizer","keywords":"Medicine; Oncology; Internal medicine; Chemotherapy; Intensive care medicine; Venetoclax; Leukemia","score_opus":0.12426377567878884,"score_gpt":0.42504620386672626,"score_spread":0.30078242818793743,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2990885519","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.41915587,0.57758504,0.0000035340433,0.0006017397,0.00030971222,0.0020254964,0.00014329633,0.000029571012,0.00014574217],"genre_scores_gemma":[0.030007936,0.9666519,0.0009018829,0.0011284476,0.00031535444,0.00008962868,0.00006909732,0.00015331627,0.0006824117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.980318,0.0099319555,0.0059661325,0.0016099685,0.0012335482,0.0009404047],"domain_scores_gemma":[0.937646,0.055731226,0.0023254298,0.002974376,0.00093002943,0.00039299438],"candidate_categories":["metaresearch","metaepi_narrow","sts","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.018378159,0.0009807673,0.007055577,0.0007044299,0.00006680662,0.00003933757,0.0017080932,0.002384821,0.000064708816],"category_scores_gemma":[0.03319356,0.0006121449,0.0019490492,0.0013847917,0.00370242,0.00009105859,0.00088727963,0.002231576,0.00016221721],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021441165,0.0005614001,0.0028112624,0.0039998363,0.0006181119,0.00083401287,0.0002728872,0.0000012370184,0.000040858093,0.00011923734,0.0019965307,0.96730345],"study_design_scores_gemma":[0.005672206,0.0071326797,0.6533562,0.015124047,0.0011761847,0.0015791181,0.00038586912,0.000055014734,0.000015672773,0.000057660054,0.3148245,0.00062087696],"about_ca_topic_score_codex":0.00007653468,"about_ca_topic_score_gemma":0.000010497159,"teacher_disagreement_score":0.9666826,"about_ca_system_score_codex":0.0010899334,"about_ca_system_score_gemma":0.007182381,"threshold_uncertainty_score":0.999633},"labels":[],"label_agreement":null},{"id":"W3003488950","doi":"10.1016/j.clml.2020.01.017","title":"Consensus Guidelines on the Diagnosis of Multiple Myeloma and Related Disorders: Recommendations of the Myeloma Canada Research Network Consensus Guideline Consortium","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; University of British Columbia; Western University; University of Manitoba; London Health Sciences Centre; Vancouver General Hospital; CancerCare Manitoba; Memorial University of Newfoundland","funders":"Memorial University of Newfoundland; Queen's University; Centre Hospitalier Universitaire de Québec; Saskatchewan Cancer Agency","keywords":"Guideline; Multiple myeloma; Consensus conference; Medicine; Family medicine; Intensive care medicine; Pathology; Immunology; Internal medicine","score_opus":0.1785388692396007,"score_gpt":0.438239768301308,"score_spread":0.25970089906170735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3003488950","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.018159907,0.92392343,0.0000020485284,0.043788146,0.0015957725,0.007910425,0.0019846503,0.000109464556,0.0025261252],"genre_scores_gemma":[0.022454554,0.97203326,0.0011190169,0.0010801738,0.00076260685,0.00069171545,0.00049779966,0.00024359999,0.0011172711],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9830373,0.004598389,0.0070669935,0.0016642502,0.0020904455,0.0015426175],"domain_scores_gemma":[0.9570074,0.0346838,0.002501529,0.0027510629,0.0020522529,0.0010039454],"candidate_categories":["metaresearch","metaepi_narrow","sts"],"consensus_categories":[],"category_scores_codex":[0.0052657924,0.0011689625,0.004742422,0.00028212013,0.0008467939,0.000059347112,0.0013428732,0.0010963099,0.00023734936],"category_scores_gemma":[0.046520475,0.00067987613,0.0016038809,0.0023466921,0.0032638174,0.00003407964,0.0013393726,0.002099451,0.00006129133],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004970184,0.00025157974,0.004095435,0.0015853109,0.0018719741,0.00026792297,0.000024995798,0.000009700896,8.4852394e-7,0.00046105322,0.2370571,0.75387704],"study_design_scores_gemma":[0.00425441,0.00082274457,0.02390226,0.013053407,0.0014601613,0.00031822175,0.00021457755,0.00091376604,0.000020772155,0.00031869975,0.9541667,0.0005542872],"about_ca_topic_score_codex":0.039625976,"about_ca_topic_score_gemma":0.039846133,"teacher_disagreement_score":0.7533228,"about_ca_system_score_codex":0.001497515,"about_ca_system_score_gemma":0.017470155,"threshold_uncertainty_score":0.99956524},"labels":[],"label_agreement":null},{"id":"W3007747266","doi":"10.1016/j.clml.2020.02.012","title":"Day 14 Bone Marrow Evaluation During Acute Myeloid Leukemia Induction in a Real-world Canadian Cohort","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hematological disorders and diagnostics","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Western University; University of British Columbia","funders":"","keywords":"Medicine; Bone marrow; Internal medicine; Gastroenterology; Myeloid leukemia; Myeloid; Biopsy; Acute leukemia; Leukemia; Cohort; Multivariate analysis; Complete remission; Retrospective cohort study; Surgery; Chemotherapy","score_opus":0.051316397173553636,"score_gpt":0.33768366791870097,"score_spread":0.28636727074514734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3007747266","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97598827,0.0002702905,0.000019431998,0.005434197,0.0005342767,0.0014460795,0.00003220057,0.00019044844,0.016084822],"genre_scores_gemma":[0.99171233,0.0008252375,0.00044279237,0.005290362,0.0007086171,0.00016853605,0.0003219358,0.00007292253,0.0004572665],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99496496,0.00044633858,0.0017434396,0.0011152625,0.0008218872,0.000908113],"domain_scores_gemma":[0.9964528,0.00064023735,0.00030769184,0.0006251684,0.00031509396,0.001658973],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016610073,0.0004505521,0.001248943,0.0003357487,0.00019348788,0.00006557054,0.00026594088,0.000725508,0.00064562116],"category_scores_gemma":[0.0062764087,0.0004244503,0.0003457472,0.001229818,0.00027585262,0.00021565684,0.00012878989,0.00071643834,0.0005411158],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011580132,0.00022239918,0.8030558,0.0001804121,0.00031843784,0.0028596676,0.00033801427,0.00013353756,0.0010270783,0.0007366704,0.0150968265,0.1748731],"study_design_scores_gemma":[0.0057335664,0.0003776568,0.98135126,0.00022096376,0.0004719225,0.00010655539,0.000093680115,0.005566249,0.00041564927,0.00038103038,0.004824203,0.00045724973],"about_ca_topic_score_codex":0.01907629,"about_ca_topic_score_gemma":0.03704014,"teacher_disagreement_score":0.17829543,"about_ca_system_score_codex":0.0040448913,"about_ca_system_score_gemma":0.005370529,"threshold_uncertainty_score":0.9998207},"labels":[],"label_agreement":null},{"id":"W3016522843","doi":"10.1016/j.clml.2020.04.002","title":"KRD-PACE Mobilization for Multiple Myeloma Patients With Significant Residual Disease Before Autologous Stem-Cell Transplantation","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Genzyme; Bristol-Myers Squibb Canada; Seattle Genetics; Celgene; Sanofi; AbbVie; Bristol-Myers Squibb; GlycoMimetics","keywords":"Medicine; Multiple myeloma; Autologous stem-cell transplantation; Mobilization; Minimal residual disease; Transplantation; Stem cell; Oncology; Internal medicine; Genetics; Bone marrow","score_opus":0.033885022541965536,"score_gpt":0.30530949325010304,"score_spread":0.2714244707081375,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3016522843","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907221,0.00012330101,0.0026310317,0.0011763405,0.00016372015,0.003869053,0.00081215735,0.00032418038,0.00017809309],"genre_scores_gemma":[0.9916467,0.00008193341,0.0028440256,0.00093969307,0.00042692674,0.0004465424,0.003029024,0.00013934202,0.00044578707],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.995463,0.00028448223,0.0011726747,0.00127907,0.00092959945,0.0008711611],"domain_scores_gemma":[0.9956615,0.0009918977,0.00037854924,0.00064688415,0.00053721585,0.00178395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032951185,0.00055902684,0.0009183955,0.00012658194,0.00030270562,0.000075682634,0.00030657896,0.00034517178,0.000057965695],"category_scores_gemma":[0.0006945987,0.00043228795,0.00038267166,0.00042330407,0.00035616648,0.00026738597,0.00006993072,0.00026730425,0.00014894921],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025906868,0.001116363,0.67110664,0.00083800894,0.00027510163,0.0005988041,0.0004098829,0.00009441993,0.00020807436,0.000052518106,0.0011059041,0.29828742],"study_design_scores_gemma":[0.027832925,0.00502535,0.9539093,0.00017766528,0.00056834216,0.000010661103,0.0001092015,0.009480725,0.0011630519,0.000041894928,0.0012627697,0.0004181396],"about_ca_topic_score_codex":0.00004166257,"about_ca_topic_score_gemma":0.000035124463,"teacher_disagreement_score":0.2978693,"about_ca_system_score_codex":0.000566278,"about_ca_system_score_gemma":0.0015708571,"threshold_uncertainty_score":0.9998129},"labels":[],"label_agreement":null},{"id":"W3017829147","doi":"10.1016/j.clml.2020.04.010","title":"No Differences in Outcomes Between JAK2 V617F–Positive Patients with Variant Allele Fraction &lt; 2% Versus 2-10%: A 6-Year Province-wide Retrospective Analysis","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; St. Paul's Hospital; Canada's Michael Smith Genome Sciences Centre","funders":"Novartis","keywords":"Medicine; Internal medicine; Incidence (geometry); Gastroenterology; JAK2 V617F; Thrombosis; Retrospective cohort study; Hematology; Myelofibrosis; Bone marrow","score_opus":0.03235531661503044,"score_gpt":0.2941142322710267,"score_spread":0.26175891565599624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3017829147","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289995,0.00002961943,0.00016017327,0.0012686711,0.00014205917,0.0014541878,0.00017940869,0.00010899654,0.0037569162],"genre_scores_gemma":[0.9963001,0.000063539905,0.0012467505,0.0008814747,0.00035390994,0.00022404839,0.00057036825,0.00005292842,0.0003068747],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99564433,0.00035690967,0.0012258055,0.0013136838,0.0008843282,0.0005749386],"domain_scores_gemma":[0.99569803,0.0020937403,0.00054274965,0.00052008807,0.000510068,0.0006353325],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00031334328,0.00057877286,0.0021231514,0.0002192368,0.00016484126,0.00008163733,0.00022818928,0.00038235035,0.0005064248],"category_scores_gemma":[0.0020608916,0.0004095287,0.0005586891,0.0009650246,0.0002509277,0.00025202948,0.00013821779,0.00043034062,0.00041935104],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005406822,0.0008990506,0.9740467,0.000025770332,0.0040316186,0.0002963068,0.00015492665,0.0000048910383,0.0000014942932,0.00013108048,0.00056994037,0.0144314],"study_design_scores_gemma":[0.01781027,0.005991708,0.97206515,0.000094319614,0.0022948426,0.0000010946725,0.000070873226,0.00034892347,0.000057287958,0.000031547195,0.0008072304,0.00042672968],"about_ca_topic_score_codex":0.000285891,"about_ca_topic_score_gemma":0.0003093516,"teacher_disagreement_score":0.014004671,"about_ca_system_score_codex":0.001905226,"about_ca_system_score_gemma":0.0008738706,"threshold_uncertainty_score":0.99983567},"labels":[],"label_agreement":null},{"id":"W3021072568","doi":"10.1016/j.clml.2020.05.001","title":"Outcomes of Patients with Transformed Mycosis Fungoides: Analysis from a Prospective Multicenter US Cohort Study","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Cancer Institute; Pharmacyclics; Valeant Pharmaceuticals International; Eisai; Celgene; Spectrum Pharmaceuticals; Kyowa Hakko Kirin; Eli Lilly and Company","keywords":"Medicine; Mycosis fungoides; Dermatology; Prospective cohort study; Cohort; Multicenter study; Internal medicine; Lymphoma; Randomized controlled trial","score_opus":0.022588910623416163,"score_gpt":0.3259025153036758,"score_spread":0.30331360468025964,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3021072568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99390167,0.000054208977,0.00022016004,0.00035211165,0.000059202728,0.0044100806,0.00030262425,0.00011387156,0.00058607233],"genre_scores_gemma":[0.99743664,0.000032669166,0.00051426556,0.0011942462,0.00008895364,0.00024449974,0.00029981855,0.00008053413,0.00010837804],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945233,0.00038503957,0.0016722104,0.0013061706,0.001528496,0.0005848208],"domain_scores_gemma":[0.99595463,0.001142169,0.0003847344,0.0008440482,0.0009432989,0.0007310935],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004174001,0.0005204236,0.0024364968,0.00024790445,0.00011999396,0.000044980796,0.00039658288,0.0002563435,0.0005833782],"category_scores_gemma":[0.0017154847,0.00037510105,0.0008590006,0.001549449,0.0004768418,0.0001476398,0.00013929536,0.0003396812,0.000093130126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010920031,0.0034629914,0.95255345,0.000051520732,0.013054296,0.00016379538,0.0017950571,0.000017318825,0.000038287788,0.0000028872994,0.000080819846,0.01785954],"study_design_scores_gemma":[0.021005291,0.0038574813,0.96746355,0.00003707197,0.0045764884,0.0000020487466,0.00082452537,0.0015766114,0.00021281632,0.000009072727,0.00007125143,0.00036376494],"about_ca_topic_score_codex":0.0009224996,"about_ca_topic_score_gemma":0.0005272302,"teacher_disagreement_score":0.017495776,"about_ca_system_score_codex":0.00080721924,"about_ca_system_score_gemma":0.0008792885,"threshold_uncertainty_score":0.9998701},"labels":[],"label_agreement":null},{"id":"W3023957398","doi":"10.1016/j.clml.2020.04.014","title":"Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":14,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Kingston Health Sciences Centre; Hôtel-Dieu de Québec; University of Ottawa; Ottawa Hospital; Princess Margaret Cancer Centre; University of Toronto; Université Laval; University of Alberta; Queen's University","funders":"Johnson and Johnson; Alexion Pharmaceuticals; Bristol-Myers Squibb Canada; Gilead Sciences; Sanofi; Amgen Canada; Queen's University; Amgen","keywords":"Medicine; Thrombotic microangiopathy; Carfilzomib; Bortezomib; Multiple myeloma; Proteasome inhibitor; Internal medicine; Dexamethasone; Cyclophosphamide; Melphalan; Oncology; Gastroenterology; Pharmacology; Chemotherapy; Disease","score_opus":0.055817742547673084,"score_gpt":0.3291006389050129,"score_spread":0.2732828963573398,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3023957398","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.103558384,0.8889107,2.3791729e-7,0.00012989569,0.00054521137,0.0059278277,0.00089185656,0.000027568674,0.00000828141],"genre_scores_gemma":[0.05651377,0.9419395,0.000025368277,0.00012553914,0.00013303894,0.0008228427,0.00030405706,0.00006058355,0.00007532263],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99235946,0.0035376062,0.002614772,0.000898551,0.00015344676,0.000436176],"domain_scores_gemma":[0.99397624,0.0026532977,0.0017817818,0.0013299785,0.00018094103,0.00007775637],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006300558,0.00084985263,0.003958185,0.00010274078,0.00015234404,0.000045062236,0.0007005802,0.0004845879,0.000025231466],"category_scores_gemma":[0.000821553,0.00040914846,0.0012082037,0.0007168261,0.00082978146,0.00012604265,0.00027767298,0.00042872867,0.000020753028],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002405215,0.00093552563,0.0017579676,0.068152584,0.0010759269,0.0012059874,0.0010523644,4.0811255e-8,0.000042035164,0.000088482964,0.0012866504,0.9241619],"study_design_scores_gemma":[0.0040387963,0.0018447208,0.009243663,0.2113498,0.0031681408,0.009408748,0.0002684078,4.85987e-7,0.00012333521,0.0000069166,0.7599085,0.0006384895],"about_ca_topic_score_codex":0.00010939698,"about_ca_topic_score_gemma":0.00019124975,"teacher_disagreement_score":0.9235234,"about_ca_system_score_codex":0.00047547513,"about_ca_system_score_gemma":0.0014984425,"threshold_uncertainty_score":0.999836},"labels":[],"label_agreement":null},{"id":"W3024907887","doi":"10.1016/j.clml.2020.05.006","title":"A Noninterventional, Observational, European Post-Authorization Safety Study of Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Bristol-Myers Squibb Canada; Janssen Biotech; Roche Italia; Celgene; Bristol-Myers Squibb; Takeda Pharmaceutical Company; Takeda Canada; Novartis; Amgen","keywords":"Medicine; Lenalidomide; Refractory (planetary science); Authorization; Observational study; Internal medicine; Multiple myeloma; Oncology; Expanded access","score_opus":0.06524772035819815,"score_gpt":0.3229437420080261,"score_spread":0.25769602164982797,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3024907887","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99546075,0.000057597033,0.00035697586,0.00043208562,0.00006913557,0.002339341,0.00026916573,0.00019061781,0.000824317],"genre_scores_gemma":[0.99486774,0.000023527477,0.0013500679,0.00055218564,0.00024100872,0.00007482386,0.002406707,0.00014708603,0.0003368777],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994165,0.000903835,0.0018020967,0.0011367357,0.0014237611,0.0005685862],"domain_scores_gemma":[0.99513555,0.0009261195,0.00080788764,0.00074114924,0.0015010164,0.0008883098],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060716795,0.0005641314,0.0011406022,0.0001821255,0.0002515638,0.000053204618,0.00037497052,0.00019304644,0.00024749115],"category_scores_gemma":[0.0019345916,0.00040060916,0.00034893973,0.0008127399,0.00035315735,0.00036976102,0.00019856631,0.00039459096,0.00016820857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.036725976,0.005282697,0.8879331,0.00013389812,0.001308962,0.0005297745,0.0003167239,0.000058715013,0.00016889344,0.000038223377,0.00032525393,0.0671778],"study_design_scores_gemma":[0.053601235,0.01945893,0.9231611,0.0003342611,0.000433067,0.000015496362,0.00029439386,0.0010217669,0.00013554019,0.0000029393907,0.0011725489,0.0003687101],"about_ca_topic_score_codex":0.00019180914,"about_ca_topic_score_gemma":0.00008657801,"teacher_disagreement_score":0.06680909,"about_ca_system_score_codex":0.00058155804,"about_ca_system_score_gemma":0.00088620174,"threshold_uncertainty_score":0.99984455},"labels":[],"label_agreement":null},{"id":"W3029322331","doi":"10.1016/j.clml.2020.05.018","title":"Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; MedImmune; Takeda Canada; Sunesis; Daiichi-Sankyo; CTI Biopharma; National Institutes of Health; Arog Pharmaceuticals; Genentech; Acceleron; Astex Pharmaceuticals; Boehringer Ingelheim; AbbVie; Otsuka America; Memorial Sloan-Kettering Cancer Center; LAM Therapeutics; Novartis; Celgene; Jazz Pharmaceuticals; Takeda Pharmaceuticals U.S.A.; Pfizer; Astellas Pharma US; Astellas Pharma; Constellation Energy Group","keywords":"Medicine; Myelofibrosis; Meta-analysis; Oncology; Internal medicine; Intensive care medicine; Bone marrow","score_opus":0.1528373252975107,"score_gpt":0.41745414368467365,"score_spread":0.26461681838716294,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3029322331","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000033877768,0.9885717,0.00000638578,0.0009810562,0.00008735663,0.009713247,0.0001458818,0.000109485685,0.00035098652],"genre_scores_gemma":[0.00021664245,0.98601574,0.0002998216,0.0051062647,0.00014635306,0.0071610287,0.00033728132,0.00015504893,0.00056179817],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.9886173,0.0023227376,0.005708905,0.0020564457,0.0006636289,0.0006310015],"domain_scores_gemma":[0.9926642,0.00280677,0.0018192661,0.0017297785,0.0001981947,0.00078178087],"candidate_categories":["metaepi_narrow","metaepi_broad"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0018220602,0.001593774,0.03261614,0.00052456406,0.00008991427,0.00011711923,0.0005172396,0.00093675987,0.0005832099],"category_scores_gemma":[0.00129709,0.0009381074,0.0094566075,0.0019739785,0.0002557343,0.000115925235,0.000287047,0.0007583075,0.00046514388],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000054641718,0.00030084848,0.00006909079,0.457806,0.22042626,0.00044805033,0.000027046946,5.1688126e-8,1.6240861e-8,0.00006923117,0.0005215024,0.32027724],"study_design_scores_gemma":[0.0011536946,0.0011134422,0.0010971961,0.07867712,0.77789986,0.00020362576,0.000008437184,0.000008431479,5.4591567e-7,0.0000141281935,0.13917881,0.0006447324],"about_ca_topic_score_codex":0.000046901638,"about_ca_topic_score_gemma":0.000030561492,"teacher_disagreement_score":0.55747354,"about_ca_system_score_codex":0.0012048822,"about_ca_system_score_gemma":0.0014126404,"threshold_uncertainty_score":0.999681},"labels":[],"label_agreement":null},{"id":"W3033703217","doi":"10.1016/j.clml.2020.05.027","title":"Timing of Autologous Stem Cell Transplantation for Multiple Myeloma in the Era of Current Therapies","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Bristol-Myers Squibb Canada; Array BioPharma; Celgene; Novartis; Merck","keywords":"Medicine; Multiple myeloma; Melphalan; Autologous stem-cell transplantation; Internal medicine; Transplantation; Surgery; Cohort; Progression-free survival; Stem cell; Oncology; Overall survival","score_opus":0.09837376150056121,"score_gpt":0.37212455258916083,"score_spread":0.2737507910885996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3033703217","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99428076,0.0015175253,0.0012047857,0.0008977056,0.00013548306,0.0015140317,0.00013873329,0.000040706313,0.00027027796],"genre_scores_gemma":[0.9963655,0.00069742725,0.0021472187,0.00030863084,0.00016661962,0.00013474478,0.00012620955,0.000034428216,0.000019220623],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.997014,0.00033452673,0.0012660975,0.0004691657,0.0004917498,0.00042445827],"domain_scores_gemma":[0.99610466,0.0027318269,0.00036215506,0.00039855746,0.00017786383,0.00022495838],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006888716,0.0002619319,0.0008387918,0.00008103821,0.00007144524,0.000013932468,0.00034374476,0.0001977428,0.000026713715],"category_scores_gemma":[0.0003732793,0.00017930924,0.00044623864,0.00033531667,0.00028385883,0.00008782493,0.000040717718,0.00030436378,0.000017335806],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043573473,0.0005686689,0.09715726,0.0010452383,0.00011262652,0.00010115612,0.0029358454,0.00001222008,0.0026456453,0.000086263746,0.00022951279,0.8907482],"study_design_scores_gemma":[0.011987832,0.0017101815,0.9625877,0.00028703464,0.00016515667,0.00002583008,0.00058621715,0.009475849,0.011875825,0.00007506347,0.0010616316,0.00016169419],"about_ca_topic_score_codex":0.00006111817,"about_ca_topic_score_gemma":0.000023919181,"teacher_disagreement_score":0.8905865,"about_ca_system_score_codex":0.00014585374,"about_ca_system_score_gemma":0.00065021124,"threshold_uncertainty_score":0.7312018},"labels":[],"label_agreement":null},{"id":"W3038047590","doi":"10.1016/j.clml.2020.06.015","title":"Perspectives in the Rapidly Evolving Treatment Landscape of Multiple Myeloma: Expert Review of New Data Presentations from ASH 2019","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Bristol-Myers Squibb Canada; bluebird bio; Takeda Pharmaceutical Company; AbbVie; Celgene; AstraZeneca; GlaxoSmithKline; Amgen","keywords":"Medicine; Multiple myeloma; Intensive care medicine; Internal medicine","score_opus":0.18091232221144657,"score_gpt":0.4590091025912288,"score_spread":0.27809678037978225,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038047590","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00034525734,0.9913602,0.000022244412,0.000846463,0.00021983587,0.0043087527,0.0016897041,0.000052361287,0.0011551842],"genre_scores_gemma":[0.00073793094,0.9886833,0.0027489925,0.00018588142,0.0011726316,0.00027131982,0.005682453,0.0001174064,0.00040011518],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9914078,0.0016322035,0.0034206612,0.001697085,0.0011789904,0.0006632319],"domain_scores_gemma":[0.9867106,0.0072527453,0.0014322009,0.0036745162,0.0002897264,0.0006401869],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010570866,0.00093167427,0.005696189,0.00028226193,0.000094469186,0.000046221354,0.0018777933,0.0005759854,0.00057581736],"category_scores_gemma":[0.007094577,0.0005702732,0.0017234237,0.0011148094,0.00040859092,0.00024130059,0.0006972867,0.0005850657,0.0001991314],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00028041858,0.0010453613,0.0025799535,0.01061078,0.0016265105,0.0004345623,0.00063266535,9.658099e-8,0.0000015632451,0.000015176102,0.041549068,0.94122386],"study_design_scores_gemma":[0.0083283,0.0010478469,0.10785197,0.064261556,0.0029432212,0.00009938464,0.0006856682,0.00021779927,0.000005010654,0.000021672871,0.81405145,0.0004861002],"about_ca_topic_score_codex":0.002515697,"about_ca_topic_score_gemma":0.00016189567,"teacher_disagreement_score":0.9407377,"about_ca_system_score_codex":0.0008603817,"about_ca_system_score_gemma":0.007528213,"threshold_uncertainty_score":0.99967486},"labels":[],"label_agreement":null},{"id":"W3038822856","doi":"10.1016/j.clml.2020.06.024","title":"Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Takeda Canada; Takeda Oncology; Amgen; Takeda Pharmaceuticals U.S.A.; British Microcirculation Society; Celgene","keywords":"Medicine; Bortezomib; Ixazomib; Internal medicine; Regimen; Multiple myeloma; Proteasome inhibitor; Clinical endpoint; Oncology; Surgery; Randomized controlled trial; Carfilzomib","score_opus":0.07255064007328885,"score_gpt":0.3545877338522112,"score_spread":0.2820370937789224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3038822856","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919617,0.00022218128,0.0003127967,0.0030686362,0.0001304777,0.0035802661,0.0003847747,0.00010981626,0.00022930569],"genre_scores_gemma":[0.9957329,0.000083314626,0.0008885265,0.0016436027,0.0002796225,0.0002855518,0.0009686571,0.00007372435,0.00004408705],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942393,0.0005580034,0.0021277596,0.0014001693,0.0008446649,0.00083013595],"domain_scores_gemma":[0.9966769,0.0008137942,0.00029547274,0.00077354664,0.00020187555,0.0012384168],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00076858327,0.000501397,0.001496266,0.00024957905,0.00006715645,0.00003743769,0.00024701096,0.0005734831,0.00021277908],"category_scores_gemma":[0.0023173452,0.00047723632,0.0004434192,0.0009513091,0.0003241846,0.00029555833,0.00016469495,0.00055494654,0.00024672877],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0112924315,0.0016376112,0.780507,0.00024857515,0.000114121765,0.001482891,0.00053994276,0.000016987033,0.023456799,0.0000070701444,0.00052564236,0.18017092],"study_design_scores_gemma":[0.025641613,0.001459438,0.951283,0.0005903174,0.00006360823,0.000021670374,0.00008396863,0.0027376474,0.017563513,0.00009072309,0.00009663466,0.00036789684],"about_ca_topic_score_codex":0.0010269122,"about_ca_topic_score_gemma":0.0006718417,"teacher_disagreement_score":0.17980303,"about_ca_system_score_codex":0.0016250168,"about_ca_system_score_gemma":0.0009491781,"threshold_uncertainty_score":0.99976796},"labels":[],"label_agreement":null},{"id":"W3039517308","doi":"10.1016/j.clml.2020.07.001","title":"Gemtuzumab Ozogamicin Combined With Intensive Chemotherapy in Patients With Acute Myeloid Leukemia Relapsing After Allogenic Stem Cell Transplantation","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; Sanofi Pasteur; Celgene; Sanofi; Takeda Canada; MaaT Pharma; Therakos; Novartis; British Microcirculation Society; Amgen; Pfizer; Astellas Pharma; Roche","keywords":"Gemtuzumab ozogamicin; Medicine; Calicheamicin; Hepatic veno-occlusive disease; Myeloid leukemia; Internal medicine; Salvage therapy; Hematopoietic stem cell transplantation; CD33; Toxicity; Chemotherapy; Cytarabine; Gastroenterology; Transplantation; Oncology; Surgery; Stem cell; CD34","score_opus":0.016301026541720144,"score_gpt":0.2704746716757513,"score_spread":0.2541736451340311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3039517308","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99363077,0.00015562259,0.00044506107,0.0020516263,0.0001655291,0.00238546,0.00007540098,0.00028072376,0.0008097972],"genre_scores_gemma":[0.9835221,0.00062093337,0.0027229057,0.011456493,0.0002770704,0.0001472092,0.00042316673,0.00029199367,0.00053813396],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99341893,0.00043149167,0.0017896168,0.001777008,0.0012830278,0.0012999005],"domain_scores_gemma":[0.9958837,0.00062763726,0.00053326355,0.0010232722,0.000886815,0.0010452864],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005677407,0.0009357231,0.0018300922,0.00032958988,0.00014995117,0.00009697343,0.0006085513,0.00077403075,0.00015435579],"category_scores_gemma":[0.00011586595,0.0007231187,0.0003898227,0.001313015,0.0007136618,0.00045524986,0.0001541539,0.0014056975,0.00029573904],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29274493,0.00068810093,0.45249295,0.0006747587,0.0013704766,0.0077478886,0.0033535345,0.00010235285,0.002091614,0.000037421367,0.0020924686,0.2366035],"study_design_scores_gemma":[0.060500346,0.011263836,0.9202604,0.0006645617,0.00061706925,0.00017781452,0.000432156,0.0016010451,0.0027305495,0.000018431881,0.00084817474,0.00088558946],"about_ca_topic_score_codex":0.000113981674,"about_ca_topic_score_gemma":0.000054055337,"teacher_disagreement_score":0.46776748,"about_ca_system_score_codex":0.004936336,"about_ca_system_score_gemma":0.004169823,"threshold_uncertainty_score":0.999522},"labels":[],"label_agreement":null},{"id":"W3080672747","doi":"10.1016/j.clml.2020.08.008","title":"Daratumumab With Cetrelimab, an Anti–PD-1 Monoclonal Antibody, in Relapsed/Refractory Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Research and Development; Takeda Canada; Genentech; Celgene; Sanofi; Bristol-Myers Squibb; Janssen Biotech; Roche; GlaxoSmithKline; Amgen","keywords":"Daratumumab; Medicine; Internal medicine; Adverse effect; Oncology; Discontinuation; Multiple myeloma; Lenalidomide","score_opus":0.054986441452762595,"score_gpt":0.3589540105480418,"score_spread":0.3039675690952792,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3080672747","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991883,0.000599151,0.00010293404,0.0015847798,0.00026080615,0.0013725798,0.00011381415,0.0004056378,0.0036773018],"genre_scores_gemma":[0.9908602,0.00034538037,0.0043028807,0.002166722,0.00094374415,0.00009725374,0.0007726888,0.00020046999,0.00031064873],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926688,0.00059141906,0.001815619,0.0020127997,0.0013530706,0.001558292],"domain_scores_gemma":[0.9942867,0.0010720498,0.00041432475,0.0013783504,0.00034014994,0.0025083842],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007528075,0.00087848026,0.0018619286,0.00033614202,0.00029615712,0.00012634773,0.0007092714,0.0007391777,0.00032572838],"category_scores_gemma":[0.0018622756,0.0007065025,0.00050037773,0.0011624908,0.00079973135,0.0005137013,0.00033725778,0.0011940877,0.000936229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011979852,0.0018990895,0.7124725,0.0001625893,0.00038104405,0.008696097,0.00028092484,0.00003931042,0.0032708626,0.00008020391,0.00093333883,0.2598042],"study_design_scores_gemma":[0.03292043,0.0063266573,0.93619573,0.00032270412,0.00014381547,0.0003398636,0.00019652947,0.013478308,0.001206579,0.000035629935,0.008113907,0.0007198197],"about_ca_topic_score_codex":0.00044539198,"about_ca_topic_score_gemma":0.00021513563,"teacher_disagreement_score":0.25908437,"about_ca_system_score_codex":0.0010716332,"about_ca_system_score_gemma":0.0024198005,"threshold_uncertainty_score":0.99984163},"labels":[],"label_agreement":null},{"id":"W3081207055","doi":"10.1016/s2152-2650(20)30443-2","title":"How the COG is Approaching the High-Risk Patient with ALL: Incorporation of Immunotherapy into Frontline Treatment","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto","funders":"","keywords":"Blinatumomab; Medicine; Cog; Tolerability; Oncology; Chemotherapy; Immunotherapy; Internal medicine; Clinical trial; Refractory (planetary science); Calicheamicin; Intensive care medicine; Lymphoblastic Leukemia; Leukemia; Adverse effect; Cancer; Myeloid leukemia","score_opus":0.04984465424495905,"score_gpt":0.3120130129867003,"score_spread":0.26216835874174127,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3081207055","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9715738,0.0010168044,0.00086994586,0.02414306,0.000115883406,0.0018451889,0.000022431954,0.00007418823,0.00033863928],"genre_scores_gemma":[0.990299,0.0012253331,0.0019560233,0.0049233027,0.00057490484,0.00018778854,0.00007820357,0.00008249995,0.0006729743],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9967055,0.0006514505,0.0008782895,0.00059711427,0.0008017912,0.00036590596],"domain_scores_gemma":[0.9967909,0.0010386392,0.00059843645,0.0010656734,0.00024197971,0.00026438502],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00070531026,0.00036208436,0.00077871786,0.000046302695,0.00022513368,0.00010649171,0.00041035892,0.00021665829,0.00025817082],"category_scores_gemma":[0.00029744243,0.00016929988,0.0003759632,0.0003772955,0.00063451624,0.00012074432,0.000120391305,0.0004252103,0.00004332057],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004558993,0.00036491765,0.014058528,0.000029629491,0.0010780051,0.000039621496,0.004214064,0.00003657826,0.0052243858,0.00013182554,0.0015741504,0.9686893],"study_design_scores_gemma":[0.03075338,0.029342012,0.7024807,0.00024036781,0.0011267128,0.0001463727,0.0041392073,0.024703786,0.034452524,0.0013497833,0.17041476,0.00085042685],"about_ca_topic_score_codex":0.0015837922,"about_ca_topic_score_gemma":0.000063942454,"teacher_disagreement_score":0.9678389,"about_ca_system_score_codex":0.0006541921,"about_ca_system_score_gemma":0.0008051614,"threshold_uncertainty_score":0.69038486},"labels":[],"label_agreement":null},{"id":"W3087419444","doi":"10.1016/j.clml.2020.09.003","title":"Quality of Life Effect of the Anti-CCR4 Monoclonal Antibody Mogamulizumab Versus Vorinostat in Patients With Cutaneous T-cell Lymphoma","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; National Cancer Institute; Eisai Incorporated; National Institutes of Health; Galderma; Kyowa Hakko Kirin; Kyowa Kirin Pharmaceutical Development; Manitoba Beekeepers' Association; Portola Pharmaceuticals; Celgene; Takeda Pharmaceuticals U.S.A.; Novartis; Helsinn Therapeutics; Merck","keywords":"Medicine; Vorinostat; Monoclonal antibody; Monoclonal; Lymphoma; Oncology; Cancer research; Antibody; Internal medicine; Immunology","score_opus":0.03388055340965346,"score_gpt":0.34752306725639187,"score_spread":0.3136425138467384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087419444","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99560505,0.00020790873,0.000018003586,0.00039160834,0.0002997811,0.0019009009,0.0001656152,0.0000612088,0.0013499425],"genre_scores_gemma":[0.99883986,0.00007996198,0.00019050957,0.00043869216,0.0001464547,0.000026091999,0.00011677613,0.00009657175,0.000065089975],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926627,0.0013546522,0.002326576,0.0010595563,0.0018078185,0.0007886856],"domain_scores_gemma":[0.9931756,0.0034201744,0.00091647403,0.0011785222,0.00061144354,0.00069775566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008626885,0.000603791,0.0023090043,0.00015341169,0.000113370166,0.000026105186,0.0007976024,0.0004552272,0.000094574694],"category_scores_gemma":[0.006134448,0.00041057664,0.0007086876,0.0011598724,0.0011755528,0.000116597184,0.0004826604,0.00041552007,0.00005067623],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.05788359,0.0013375414,0.88114303,0.0007257125,0.00030665466,0.00018445835,0.00024128305,0.00008271177,0.0009511473,0.000033227272,0.0002044442,0.05690618],"study_design_scores_gemma":[0.056147207,0.008246353,0.9287552,0.00019610797,0.00013744712,0.000037212096,0.00008609874,0.0013881936,0.004431875,0.0000093036415,0.00018952989,0.00037542256],"about_ca_topic_score_codex":0.000403707,"about_ca_topic_score_gemma":0.00004067586,"teacher_disagreement_score":0.056530755,"about_ca_system_score_codex":0.0006804621,"about_ca_system_score_gemma":0.003234449,"threshold_uncertainty_score":0.9998346},"labels":[],"label_agreement":null},{"id":"W3087469327","doi":"10.1016/j.clml.2020.08.022","title":"Can Next-Generation PI3K Inhibitors Unlock the Full Potential of the Class in Patients With B-Cell Lymphoma?","year":2020,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Biotech; AstraZeneca France; Servier; Incyte; AbbVie; Genentech; Bayer; Celgene; Bristol-Myers Squibb Canada; Gilead Sciences; Novartis; Roche","keywords":"Medicine; Idelalisib; Follicular lymphoma; Adverse effect; Oncology; PI3K/AKT/mTOR pathway; Clinical trial; Lymphoma; Targeted therapy; Internal medicine; Population; Cancer; Chronic lymphocytic leukemia; Ibrutinib; Leukemia","score_opus":0.05178835764682573,"score_gpt":0.31977349260169624,"score_spread":0.26798513495487053,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3087469327","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.25816852,0.73016167,0.00000821441,0.000809061,0.0022042484,0.0072366083,0.00017261958,0.00012907859,0.0011099591],"genre_scores_gemma":[0.27982995,0.7144387,0.00011342343,0.00083615445,0.0028337906,0.00032226765,0.000515591,0.00039107984,0.0007190621],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888944,0.0017562476,0.0040417453,0.001719255,0.0023950508,0.0011933281],"domain_scores_gemma":[0.9928737,0.0013454085,0.0019315862,0.0026695163,0.00051243097,0.00066734006],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0014616216,0.0012228998,0.004205764,0.0002964355,0.00027757636,0.00014017387,0.0018601776,0.001556033,0.000062409395],"category_scores_gemma":[0.0013917988,0.0006513341,0.0019605195,0.0021446736,0.0014560918,0.00015679636,0.0011066247,0.0012917627,0.00016680532],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0007604297,0.000781047,0.0003785248,0.0045787967,0.0004300606,0.0002683122,0.00010039025,0.000017039896,0.000006820223,0.0000444883,0.0030074692,0.98962665],"study_design_scores_gemma":[0.08569009,0.0036717204,0.026885638,0.022800596,0.005256061,0.0006121698,0.00015867526,0.0047339555,0.00011639878,0.000056150213,0.84796137,0.0020571637],"about_ca_topic_score_codex":0.0006641995,"about_ca_topic_score_gemma":0.00024471036,"teacher_disagreement_score":0.98756945,"about_ca_system_score_codex":0.03157977,"about_ca_system_score_gemma":0.06496993,"threshold_uncertainty_score":0.9997402},"labels":[],"label_agreement":null},{"id":"W3090860704","doi":"10.1016/j.clml.2020.09.010","title":"Burden of Treatment Among Older Adults With Newly Diagnosed Multiple Myeloma","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Cancer Centre","funders":"National Cancer Institute; National Center for Advancing Translational Sciences; Agency for Healthcare Research and Quality; National Institutes of Health","keywords":"Medicine; Multiple myeloma; Interquartile range; Disease burden; Internal medicine; Comorbidity; Epidemiology; Odds ratio; Malignancy; Logistic regression; Disease; Emergency medicine; Intensive care medicine","score_opus":0.034343741437501914,"score_gpt":0.31534074407744117,"score_spread":0.28099700263993926,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3090860704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99382865,0.0004091176,0.000117825395,0.0010593378,0.00013141065,0.0023188377,0.00010930474,0.00026419692,0.0017613077],"genre_scores_gemma":[0.9937316,0.00038671042,0.003161415,0.00053928053,0.0008759547,0.00027488024,0.0002872557,0.00013866957,0.0006042227],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99499696,0.00028122147,0.0015062925,0.0013322928,0.00088069856,0.0010025308],"domain_scores_gemma":[0.99456304,0.001510606,0.00048403995,0.0010861272,0.00039665063,0.0019595225],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00025574502,0.00071733416,0.0017202948,0.0001525458,0.00015799252,0.000047608322,0.0004115615,0.00046180075,0.00039071962],"category_scores_gemma":[0.0015036699,0.0005052478,0.00071932835,0.00063405506,0.0007830652,0.00021544128,0.00018576128,0.00031478496,0.0004008488],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010444074,0.0007826307,0.45479977,0.00022095801,0.00096005114,0.0025210576,0.0011700345,0.000043773132,0.00022172318,0.000016348953,0.0008653544,0.5279542],"study_design_scores_gemma":[0.05382907,0.008332623,0.9197009,0.00065881154,0.00038840933,0.00007606154,0.0006070384,0.010072336,0.0031600294,0.0000072246744,0.0027173122,0.00045014016],"about_ca_topic_score_codex":0.0018570635,"about_ca_topic_score_gemma":0.00017497977,"teacher_disagreement_score":0.5275041,"about_ca_system_score_codex":0.0010568169,"about_ca_system_score_gemma":0.0018215505,"threshold_uncertainty_score":0.9997399},"labels":[],"label_agreement":null},{"id":"W3094761049","doi":"10.1016/j.clml.2020.10.014","title":"Invasive Mold Infections in FLT3-Mutated Acute Myeloid Leukemia","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myeloid leukemia; Mold; Medicine; Myeloid; Leukemia; Internal medicine; Biology; Genetics","score_opus":0.04650270858194126,"score_gpt":0.3454282493436217,"score_spread":0.29892554076168043,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094761049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97620046,0.0003798983,0.00022997642,0.008471503,0.0005838647,0.0017665459,0.00008923922,0.00077607395,0.011502465],"genre_scores_gemma":[0.97981036,0.001393662,0.0017486507,0.013009993,0.0016228989,0.00024632763,0.0003651942,0.0002564484,0.0015464553],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9914511,0.00070938957,0.0028193132,0.002061709,0.0011793223,0.0017791922],"domain_scores_gemma":[0.9928259,0.0023419994,0.0005053708,0.001466226,0.00056893163,0.0022915588],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013188568,0.0009387399,0.002183186,0.0005785201,0.00029461234,0.00014994689,0.0009912292,0.0013274178,0.0008109334],"category_scores_gemma":[0.0068886606,0.0008988711,0.0009621695,0.0031351366,0.0010049597,0.0005512368,0.00088367495,0.002281673,0.004098477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.008568377,0.0013440576,0.33165336,0.00075018354,0.0030772046,0.020314185,0.0020489278,0.00047938048,0.034839254,0.0015456077,0.10334541,0.49203405],"study_design_scores_gemma":[0.022173371,0.0031308203,0.92138314,0.00044890222,0.0006653538,0.0014000172,0.0003574447,0.010435591,0.008090051,0.00055853685,0.030032651,0.0013241143],"about_ca_topic_score_codex":0.00066283107,"about_ca_topic_score_gemma":0.00018278968,"teacher_disagreement_score":0.5897298,"about_ca_system_score_codex":0.0074836,"about_ca_system_score_gemma":0.01300175,"threshold_uncertainty_score":0.99996907},"labels":[],"label_agreement":null},{"id":"W3100902974","doi":"10.1016/j.clml.2020.11.004","title":"BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; BC Cancer Agency","funders":"Genentech; Celgene; MorphoSys; H. Lundbeck A/S; Juno Therapeutics; Incyte; F. Hoffmann-La Roche; Alexion Pharmaceuticals; Janssen Pharmaceuticals; Gilead Sciences; AstraZeneca; Bristol-Myers Squibb; TG Therapeutics; Amgen","keywords":"Diffuse large B-cell lymphoma; International Prognostic Index; Hazard ratio; Medicine; Internal medicine; Lymphoma; Immunohistochemistry; Confidence interval; Oncology; Population; Proportional hazards model; Venetoclax; Multivariate analysis; Pathology; Leukemia","score_opus":0.02652340087100352,"score_gpt":0.28697465696309593,"score_spread":0.2604512560920924,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3100902974","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938284,0.0007480606,0.000070263035,0.0024931403,0.00027544316,0.0016024166,0.00006532804,0.00027679797,0.0006401586],"genre_scores_gemma":[0.9929968,0.0004262371,0.001030354,0.004017608,0.00042525193,0.00046167284,0.000394146,0.00011313722,0.00013478324],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949297,0.0002348715,0.0017838727,0.001353611,0.0008620505,0.0008359279],"domain_scores_gemma":[0.99717975,0.00055598246,0.000561469,0.00065323303,0.00018339326,0.0008662049],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00032567896,0.0006553618,0.0013054493,0.00017822973,0.00024950437,0.000112621135,0.000271364,0.00047908464,0.00010993471],"category_scores_gemma":[0.0005345724,0.0004857499,0.0004822587,0.0006897031,0.00015278991,0.000318128,0.00029339816,0.00018679239,0.00029489736],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0036967166,0.013965488,0.76708466,0.00033549313,0.00015836912,0.0018023732,0.00084863394,0.000030713796,0.00025804868,0.000042735723,0.0037845438,0.20799226],"study_design_scores_gemma":[0.050626677,0.0028204692,0.9254639,0.00082709733,0.0003001468,0.0000672026,0.00023150445,0.0024449567,0.008721525,0.000052730105,0.007893755,0.00055001676],"about_ca_topic_score_codex":0.00033005618,"about_ca_topic_score_gemma":0.0002046564,"teacher_disagreement_score":0.20744224,"about_ca_system_score_codex":0.0012979046,"about_ca_system_score_gemma":0.0005262872,"threshold_uncertainty_score":0.99975944},"labels":[],"label_agreement":null},{"id":"W3110959026","doi":"10.1016/j.clml.2020.12.006","title":"Outcomes for Patients With Acute Promyelocytic Leukemia in South Africa","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Retinoids in leukemia and cellular processes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Acute promyelocytic leukemia; Confidence interval; Cohort; Pediatrics; Leukemia; Internal medicine; Retinoic acid","score_opus":0.019617453935553093,"score_gpt":0.274792995369838,"score_spread":0.2551755414342849,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3110959026","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9957889,0.00020986963,0.001507223,0.00018327626,0.0002117851,0.00096761604,0.00008395405,0.000067398985,0.0009800202],"genre_scores_gemma":[0.9936856,0.00004876349,0.0032332907,0.0013643339,0.00042714653,0.00022676276,0.00034380602,0.000106306405,0.0005639622],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965613,0.00013132815,0.0010174931,0.0012016242,0.00035827907,0.0007300074],"domain_scores_gemma":[0.9981896,0.00017097656,0.0003512196,0.00062939996,0.00024579998,0.0004129685],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000328066,0.00050609006,0.0007508513,0.000057054112,0.00012560863,0.0000677455,0.0007185226,0.0005638098,0.00001765814],"category_scores_gemma":[0.0010116464,0.00040616238,0.00035849406,0.00031249836,0.00032048955,0.000019684161,0.00026217732,0.0002322521,0.0000544683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007827008,0.0004496514,0.8682034,0.000480705,0.0010928335,0.00018138139,0.0014955321,0.00028413962,0.004759167,0.0003013429,0.0063765044,0.10854833],"study_design_scores_gemma":[0.019173048,0.004611555,0.9132481,0.000102810984,0.00030691567,0.000011334292,0.00021075834,0.0011161375,0.009839544,0.0002985338,0.04957469,0.0015065648],"about_ca_topic_score_codex":0.0000048275797,"about_ca_topic_score_gemma":0.000004592167,"teacher_disagreement_score":0.10704176,"about_ca_system_score_codex":0.00044399197,"about_ca_system_score_gemma":0.0022544228,"threshold_uncertainty_score":0.999839},"labels":[],"label_agreement":null},{"id":"W3111002581","doi":"10.1016/j.clml.2020.12.011","title":"Does Up-front Autologous Stem-Cell Transplantation at First Relapse Improve Outcome in Transplant-Eligible Follicular Lymphoma Patients Whose Disease Relapses Within 24 Months?","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Medicine; Transplantation; Chemoimmunotherapy; Internal medicine; Rituximab; Follicular lymphoma; Hematopoietic stem cell transplantation; Surgery; Oncology; Autologous stem-cell transplantation; Lymphoma; Melphalan","score_opus":0.019056866536807496,"score_gpt":0.2795864168338753,"score_spread":0.2605295502970678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111002581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9897157,0.0022293734,0.000019680045,0.0011700055,0.0036873848,0.0016401444,0.00061907136,0.00027797453,0.0006406965],"genre_scores_gemma":[0.9859116,0.003382658,0.00047679924,0.0014649418,0.0002503924,0.0004940073,0.0012924043,0.00015333747,0.0065738326],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99219954,0.00047389,0.0031056758,0.0020350479,0.0010592138,0.0011266199],"domain_scores_gemma":[0.99509317,0.0011110752,0.000677935,0.0015139985,0.00030227503,0.0013015611],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060198177,0.0009898068,0.0019182233,0.00024212534,0.00037877582,0.00011610321,0.00039508563,0.0008324691,0.00014785877],"category_scores_gemma":[0.0002448452,0.00069782813,0.0011707486,0.0004449694,0.00032041842,0.00037612204,0.00016486435,0.00028835167,0.0005019401],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054626036,0.0040715975,0.9051649,0.0008546723,0.0003475019,0.012517668,0.0011146562,0.00006759397,0.00012822644,0.0001025443,0.0012129721,0.068955086],"study_design_scores_gemma":[0.035250265,0.00085053995,0.9489072,0.0009193726,0.0014792014,0.00014956844,0.00015743129,0.00061511406,0.0070871194,0.00014106461,0.0035654458,0.00087769923],"about_ca_topic_score_codex":0.0005953214,"about_ca_topic_score_gemma":0.0012142387,"teacher_disagreement_score":0.068077385,"about_ca_system_score_codex":0.003764666,"about_ca_system_score_gemma":0.0018692603,"threshold_uncertainty_score":0.9995473},"labels":[],"label_agreement":null},{"id":"W3111063908","doi":"10.1016/s2152-2650(20)30952-6","title":"MM-296: A Real-World Study of Panobinostat, Weekly Bortezomib, and Dexamethasone in a Very Heavily Pre-Treated Population of Multiple Myeloma Patients","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Medicine; Panobinostat; Bortezomib; Dexamethasone; Context (archaeology); Internal medicine; Multiple myeloma; Population; Retrospective cohort study; Toxicity; Surgery","score_opus":0.04744791081935797,"score_gpt":0.3499770439149999,"score_spread":0.30252913309564194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111063908","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962573,0.00013266392,0.000004953332,0.00015556242,0.00009197504,0.0028480785,0.00012290156,0.00009418157,0.0002923588],"genre_scores_gemma":[0.99835193,0.00015791623,0.0005825663,0.00014169673,0.000110116904,0.0001094753,0.00035185897,0.000081147504,0.00011326749],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9941433,0.0006951278,0.0024466312,0.0010802269,0.00095778797,0.0006769327],"domain_scores_gemma":[0.9957246,0.0015957085,0.0007123086,0.00075546035,0.00037783646,0.0008340817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062006037,0.0005092712,0.0018745591,0.00042432017,0.00008540254,0.00002507417,0.00026630875,0.00031526134,0.000039621347],"category_scores_gemma":[0.0027802994,0.00044773833,0.0002924854,0.0012360706,0.0002990912,0.00023703687,0.0003035279,0.0003656135,0.00001722045],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010325013,0.0035387047,0.8204697,0.000245524,0.00039135065,0.00025233155,0.0008148097,0.0000086994005,0.00056651747,0.000007953648,0.0001182867,0.16326115],"study_design_scores_gemma":[0.03768548,0.007246821,0.950153,0.00032774702,0.0002546171,0.000006534741,0.00032607594,0.0027619414,0.0008559973,0.000022903305,0.000057191657,0.000301702],"about_ca_topic_score_codex":0.011356962,"about_ca_topic_score_gemma":0.0023885083,"teacher_disagreement_score":0.16295944,"about_ca_system_score_codex":0.000622122,"about_ca_system_score_gemma":0.0005216243,"threshold_uncertainty_score":0.99979746},"labels":[],"label_agreement":null},{"id":"W3111089436","doi":"10.1016/s2152-2650(20)30971-x","title":"MDS-171: Effects of Luspatercept on Serum Ferritin in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) with Ring Sideroblasts (RS) in the Phase 3 MEDALIST Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hemoglobinopathies and Related Disorders","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Placebo; Medicine; Internal medicine; Myelodysplastic syndromes; Gastroenterology; Serum ferritin; Anemia; Ferritin; Iron deficiency; Surgery; Bone marrow; Pathology","score_opus":0.014892358631090593,"score_gpt":0.27778940024515764,"score_spread":0.262897041614067,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111089436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582267,0.00009235366,0.000031540007,0.00082924665,0.00035605623,0.002219366,0.00003189044,0.00008017736,0.0005367258],"genre_scores_gemma":[0.99798906,0.000105107225,0.00009964818,0.0013683023,0.00018321429,0.000079948346,0.000051793562,0.0000899677,0.000032959524],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99535,0.0006722776,0.001437965,0.00089827727,0.0009117342,0.000729732],"domain_scores_gemma":[0.9964005,0.0018823193,0.0005283321,0.0006460227,0.00011175981,0.00043110063],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068395905,0.0005695718,0.0014305088,0.00019548797,0.00011192946,0.00004441824,0.00040701675,0.0005075599,0.000053494503],"category_scores_gemma":[0.0019806474,0.0003430906,0.00026257697,0.00087954046,0.00050352764,0.00013614402,0.00010900624,0.00095023913,0.000062152816],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.32338637,0.008860583,0.41767755,0.0018694449,0.00073242496,0.00582151,0.0034788242,0.0011209896,0.00008677762,0.00012528866,0.000821817,0.2360184],"study_design_scores_gemma":[0.21295151,0.023380203,0.75846535,0.002236745,0.00031280197,0.000032645858,0.00037097398,0.001496677,0.00011039737,0.000021031374,0.00021307451,0.00040861417],"about_ca_topic_score_codex":0.0001945147,"about_ca_topic_score_gemma":0.00012847845,"teacher_disagreement_score":0.34078777,"about_ca_system_score_codex":0.00036831896,"about_ca_system_score_gemma":0.0006887932,"threshold_uncertainty_score":0.9999021},"labels":[],"label_agreement":null},{"id":"W3111170629","doi":"10.1016/s2152-2650(20)30716-3","title":"AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Blood disorders and treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Neutropenia; Context (archaeology); Transplantation; Febrile neutropenia; Rituximab; Salvage therapy; Venetoclax; Refractory (planetary science); Bendamustine; Surgery; Gastroenterology; Leukemia; Lymphoma; Chemotherapy; Chronic lymphocytic leukemia","score_opus":0.013651388097824346,"score_gpt":0.27991105462354066,"score_spread":0.2662596665257163,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111170629","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99545085,0.00028363417,0.00014287383,0.00039127498,0.000094931915,0.0027498114,0.0008165362,0.00002958735,0.000040469473],"genre_scores_gemma":[0.9953144,0.0003399004,0.0008660388,0.00043964552,0.00012278809,0.0002835771,0.0025528525,0.000057262103,0.000023497561],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99695206,0.0004689734,0.0010358468,0.0009259139,0.00030521615,0.00031200572],"domain_scores_gemma":[0.9980259,0.0006710203,0.00053889543,0.00037067934,0.00018265373,0.00021085347],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00030488116,0.00040425276,0.000891597,0.00004847232,0.00014258851,0.000038311813,0.00019396543,0.0002752389,0.000014056278],"category_scores_gemma":[0.0006069079,0.00024586628,0.00015086749,0.00024393172,0.00041157138,0.000031914748,0.00006538769,0.00017850133,0.0000036641325],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9732258,0.0019709626,0.008443025,0.00003673078,0.00065777614,0.00007880332,0.00078660314,0.00006560257,0.002309736,0.0000071808404,0.00025157424,0.012166237],"study_design_scores_gemma":[0.5783883,0.008751501,0.39157873,0.00015445694,0.00033829696,0.0000035898117,0.00013827742,0.000086461536,0.020206103,0.000018701328,0.000066914334,0.0002686812],"about_ca_topic_score_codex":0.00021380799,"about_ca_topic_score_gemma":0.00010499777,"teacher_disagreement_score":0.39483747,"about_ca_system_score_codex":0.000094863666,"about_ca_system_score_gemma":0.0004042537,"threshold_uncertainty_score":0.99999934},"labels":[],"label_agreement":null},{"id":"W3111184799","doi":"10.1016/s2152-2650(20)30965-4","title":"MDS-107: MDS Patients' Needs from Online Discussion Forums: An Artificial Intelligence and Natural Language Processing Analysis of 20,000 Posts in US, UK, Canada, and China","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Conversation; Context (archaeology); Psychology; Medicine","score_opus":0.024099092959422794,"score_gpt":0.32406632793393175,"score_spread":0.29996723497450895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111184799","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958795,0.0009308343,0.0000664608,0.002025275,0.00010805541,0.0004531249,0.0004562829,0.000042973403,0.000037534723],"genre_scores_gemma":[0.99546385,0.000116071766,0.0010513973,0.0015763086,0.00033663906,0.00000909153,0.0013423539,0.000049091952,0.000055171316],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99593776,0.00027745962,0.0015493645,0.0008818542,0.000747955,0.0006056164],"domain_scores_gemma":[0.9976742,0.00044731182,0.00036394695,0.0004968328,0.00019541038,0.00082226435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00048026975,0.00039710477,0.001321479,0.00040152945,0.000115952236,0.00006237974,0.00035979893,0.00034994018,0.00008216373],"category_scores_gemma":[0.0015421878,0.0002835524,0.00017732641,0.0018486587,0.00045248782,0.00024627804,0.00039731432,0.000693564,0.000002172483],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014241955,0.00019257647,0.41577375,0.00007570437,0.00020983524,0.00015994262,0.0018334973,0.000023542105,0.00097279035,0.0000092789405,0.00011034832,0.5792145],"study_design_scores_gemma":[0.0014133829,0.00056074595,0.88251114,0.00017586953,0.00046605148,0.000006731378,0.0019521244,0.11198142,0.00048720208,0.00003820354,0.00011201822,0.00029511534],"about_ca_topic_score_codex":0.16769396,"about_ca_topic_score_gemma":0.23004188,"teacher_disagreement_score":0.5789194,"about_ca_system_score_codex":0.0009216232,"about_ca_system_score_gemma":0.0021019978,"threshold_uncertainty_score":0.9999617},"labels":[],"label_agreement":null},{"id":"W3111348559","doi":"10.1016/s2152-2650(20)30949-6","title":"MM-250: Impact of Prolonged Dose Delays on Response with Belantamab Mafodotin (Belamaf; GSK2857916) Treatment in the DREAMM-2 Study: 13-Month Follow-Up","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Glaucoma and retinal disorders","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Adverse effect; Context (archaeology); Surgery; Internal medicine","score_opus":0.03952901289389708,"score_gpt":0.3395630148326094,"score_spread":0.3000340019387123,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111348559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9920692,0.0002031579,0.0000046632645,0.0032195025,0.00012771202,0.0030962764,0.00004757649,0.000103000864,0.0011289333],"genre_scores_gemma":[0.9976792,0.00007388904,0.00009045289,0.001314527,0.00021002635,0.00019205813,0.000058741465,0.000091370806,0.000289732],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99436814,0.0015809335,0.0014588716,0.0009999687,0.0008460776,0.0007460231],"domain_scores_gemma":[0.9957848,0.0019776202,0.00046182546,0.0011001707,0.00014467095,0.0005308974],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015376812,0.0006705016,0.0015198464,0.00018033068,0.00015177262,0.00004149421,0.00053400535,0.00037776664,0.000082874794],"category_scores_gemma":[0.0012579914,0.00035861277,0.0008165237,0.0008723716,0.00044942036,0.00008713289,0.000101319616,0.0005317859,0.00012039277],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18499953,0.0038865774,0.7257601,0.00005206392,0.0008669397,0.0031865328,0.0048804665,0.00002620388,0.00041846916,0.000025724881,0.001210175,0.074687235],"study_design_scores_gemma":[0.034498975,0.05646736,0.90425,0.0002007437,0.00050251855,0.00017691063,0.002447725,0.00039731452,0.00012130848,0.000024339739,0.0005629263,0.0003498323],"about_ca_topic_score_codex":0.0010545972,"about_ca_topic_score_gemma":0.0005785346,"teacher_disagreement_score":0.17848995,"about_ca_system_score_codex":0.0009307363,"about_ca_system_score_gemma":0.0020714228,"threshold_uncertainty_score":0.9998866},"labels":[],"label_agreement":null},{"id":"W3111494345","doi":"10.1016/s2152-2650(20)30973-3","title":"MDS-179: Clinical Benefit of Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) and High Transfusion Burden (HTB) in the Phase 3 MEDALIST Study","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Anemia; Placebo; Myelodysplastic syndromes; Internal medicine; Population; Clinical trial; Refractory (planetary science); Surgery; Gastroenterology; Bone marrow","score_opus":0.03284904733416601,"score_gpt":0.3388579974242956,"score_spread":0.30600895009012963,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111494345","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941104,0.000119186916,0.00004743054,0.0018753211,0.0002636203,0.0031986842,0.000119028926,0.0000789488,0.00018735361],"genre_scores_gemma":[0.9973539,0.000564742,0.00029788376,0.00089312636,0.00046321115,0.00011101223,0.00012728675,0.00011796151,0.00007083648],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9911109,0.0015403794,0.003089149,0.0016691085,0.0016377671,0.0009526595],"domain_scores_gemma":[0.9934063,0.0035694237,0.0006088639,0.0012257291,0.00034868272,0.0008410104],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033836507,0.00070596446,0.002340884,0.0003257161,0.00015761028,0.00007371127,0.0009578133,0.00066997716,0.00019901588],"category_scores_gemma":[0.0032119763,0.0004732068,0.00035498178,0.0013740121,0.0011524799,0.00025962025,0.00040735057,0.0017040153,0.00007199109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017118502,0.0033452606,0.75454575,0.00017220792,0.00026907556,0.001309884,0.002000442,0.000039419996,0.000029231125,0.000026008209,0.0003629364,0.22078127],"study_design_scores_gemma":[0.06547463,0.019236125,0.90947026,0.00037226945,0.0004523013,0.000041816053,0.0011832806,0.0028099294,0.000014937165,0.000051458548,0.0004416067,0.00045137195],"about_ca_topic_score_codex":0.0018790138,"about_ca_topic_score_gemma":0.000543713,"teacher_disagreement_score":0.2203299,"about_ca_system_score_codex":0.0007058227,"about_ca_system_score_gemma":0.0012975899,"threshold_uncertainty_score":0.99977195},"labels":[],"label_agreement":null},{"id":"W3111817003","doi":"10.1016/s2152-2650(20)30955-1","title":"MM-347: Ixazomib Plus Lenalidomide-Dexamethasone (IRd) vs. Placebo-Rd for Newly Diagnosed Multiple Myeloma (NDMM) Patients Not Eligible for Autologous Stem Cell Transplant: The Double-Blind, Placebo-Controlled, Phase 3 TOURMALINE-MM2 Trial","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Calgary; University of Alberta","funders":"","keywords":"Lenalidomide; Ixazomib; Placebo; Multiple myeloma; Medicine; Dexamethasone; Internal medicine; Double blind; Oncology; Pathology","score_opus":0.09393117564019866,"score_gpt":0.36876817165603426,"score_spread":0.2748369960158356,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3111817003","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9531873,0.00062049786,0.0033534835,0.0049651517,0.0018588165,0.03313319,0.0018669137,0.0005575851,0.00045705916],"genre_scores_gemma":[0.9765123,0.00034959344,0.0025234872,0.0034544163,0.0033518625,0.009879622,0.002036805,0.00037580085,0.001516116],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98765105,0.00107512,0.004389993,0.0026176572,0.0016106064,0.0026555536],"domain_scores_gemma":[0.97368574,0.020288724,0.0014463225,0.0016739042,0.0009353401,0.001969958],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0030816558,0.0016171968,0.0043701474,0.00033943003,0.0010398879,0.00034074386,0.0014914182,0.0013529841,0.00015066654],"category_scores_gemma":[0.0041129473,0.0011588467,0.0031441688,0.0006802246,0.0007125143,0.00041528762,0.00030336017,0.0010389435,0.0004184794],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.82236993,0.0028258518,0.0017235896,0.00052493275,0.0017955144,0.00041949566,0.00081688137,0.00015599246,0.0005776597,0.00005050803,0.009596532,0.15914309],"study_design_scores_gemma":[0.90772957,0.016002951,0.0059801834,0.00023747858,0.0022094857,0.000046263518,0.00029694175,0.03554045,0.011392415,0.00003274189,0.019404134,0.0011274018],"about_ca_topic_score_codex":0.00031782678,"about_ca_topic_score_gemma":0.00012951059,"teacher_disagreement_score":0.15801568,"about_ca_system_score_codex":0.0014833511,"about_ca_system_score_gemma":0.0038096213,"threshold_uncertainty_score":0.9999435},"labels":[],"label_agreement":null},{"id":"W3112032975","doi":"10.1016/s2152-2650(20)30789-8","title":"CLL-091: Acalabrutinib Versus Idelalisib Plus Rituximab (IdR) or Bendamustine Plus Rituximab (BR) in Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): ASCEND Final Results","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; University of New Brunswick","funders":"","keywords":"Bendamustine; Ofatumumab; Rituximab; Chronic lymphocytic leukemia; Idelalisib; Medicine; Refractory (planetary science); Ibrutinib; CD20; Alemtuzumab; Leukemia; Immunology; Antibody; Biology","score_opus":0.13107819012937313,"score_gpt":0.38457676341337677,"score_spread":0.2534985732840036,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112032975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9684045,0.0045899292,0.00018463879,0.0031912134,0.0033331588,0.0038697599,0.0005498732,0.001442852,0.014434131],"genre_scores_gemma":[0.9768872,0.0025834243,0.0021063744,0.00435629,0.0066667325,0.00035227466,0.0010007623,0.0006380013,0.005408936],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9773025,0.0013307236,0.00767596,0.005135856,0.0039420314,0.0046129385],"domain_scores_gemma":[0.9808542,0.008357853,0.0017657907,0.004037227,0.0009047397,0.0040801885],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"category_scores_codex":[0.0040925485,0.002407176,0.0056093135,0.000880559,0.0006470389,0.00035841693,0.002965875,0.003226593,0.0017212011],"category_scores_gemma":[0.022511825,0.0021882565,0.0018243871,0.0037870596,0.002685905,0.0008475568,0.0022144106,0.0041110613,0.0064844927],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.39989832,0.002495521,0.00043173204,0.00408964,0.0023028187,0.048788764,0.0024636667,0.0063286135,0.001293164,0.0010750542,0.1645832,0.36624947],"study_design_scores_gemma":[0.585737,0.00988218,0.021294279,0.0020782782,0.0009991613,0.0018392948,0.00057910173,0.2646387,0.0009983531,0.00012266255,0.109184705,0.0026463289],"about_ca_topic_score_codex":0.004955827,"about_ca_topic_score_gemma":0.0010273037,"teacher_disagreement_score":0.36360314,"about_ca_system_score_codex":0.34955493,"about_ca_system_score_gemma":0.2604436,"threshold_uncertainty_score":0.99919134},"labels":[],"label_agreement":null},{"id":"W3112737547","doi":"10.1016/j.clml.2020.12.004","title":"Autologous Stem Cell Transplant for Treatment of Multiple Myeloma in a Patient with Concomitant Porphyria Cutanea Tarda","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Porphyrin Metabolism and Disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université de Montréal","funders":"","keywords":"Porphyria cutanea tarda; Porphyria; Heme; Medicine; Concomitant; Multiple myeloma; Internal medicine; Gastroenterology; Dermatology; Chemistry; Biochemistry; Enzyme","score_opus":0.020823381336315526,"score_gpt":0.25911122337952525,"score_spread":0.2382878420432097,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112737547","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564856,0.001546607,0.0007786553,0.00017824626,0.00017777018,0.0009106264,0.00038441332,0.000030022406,0.0003450958],"genre_scores_gemma":[0.9965027,0.00050534384,0.0016806448,0.000640773,0.00016466615,0.00014373996,0.00026356758,0.00005309964,0.000045487424],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9973218,0.00016443196,0.0010350455,0.0008060235,0.00018902739,0.00048366303],"domain_scores_gemma":[0.9985777,0.00020765762,0.00034993308,0.00046056716,0.00008779705,0.00031632435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00014864375,0.00039426427,0.00085867057,0.00004295158,0.00005678597,0.000014659849,0.0002840164,0.00035542418,0.0000097970205],"category_scores_gemma":[0.00006268586,0.0003127883,0.00038868084,0.00015340083,0.00024303919,0.0000080075815,0.000050678496,0.000057190555,0.000009705241],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021528037,0.0018559673,0.08704171,0.00029938403,0.0004738969,0.0007317315,0.0022725551,0.0006857195,0.13030927,0.00013967259,0.0012123866,0.7534497],"study_design_scores_gemma":[0.046746008,0.026734635,0.45587504,0.00012739903,0.0004816773,0.00021985869,0.0014374736,0.0046493653,0.3192427,0.000103762126,0.1425656,0.0018165195],"about_ca_topic_score_codex":0.00007727074,"about_ca_topic_score_gemma":0.00009670209,"teacher_disagreement_score":0.75163317,"about_ca_system_score_codex":0.00008684215,"about_ca_system_score_gemma":0.00068032014,"threshold_uncertainty_score":0.9999324},"labels":[],"label_agreement":null},{"id":"W3112812421","doi":"10.1016/s2152-2650(20)30993-9","title":"MPN-149: Long-Term Safety of Momelotinib in JAK Inhibitor-Naïve and Previously JAK Inhibitor-Treated Intermediate-/High-Risk Myelofibrosis Patients","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada)","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Anemia; Randomized controlled trial; Gastroenterology; Bone marrow","score_opus":0.019220719240198473,"score_gpt":0.28417587199586775,"score_spread":0.2649551527556693,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3112812421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948512,0.0007107514,0.000013048478,0.0005278272,0.00047779825,0.00256143,0.00029075026,0.00016161906,0.00040563053],"genre_scores_gemma":[0.9936397,0.0030815417,0.00043417083,0.0010356649,0.0007131885,0.00028399113,0.00058088877,0.00013814634,0.00009269438],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99269056,0.0006335998,0.0032461039,0.001664973,0.00083719083,0.0009275532],"domain_scores_gemma":[0.9948644,0.0015516195,0.0010704857,0.000800055,0.0004527652,0.0012606558],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006859612,0.00092086685,0.00252373,0.00027240257,0.0001647373,0.00006804871,0.00033873343,0.0007881306,0.00017621244],"category_scores_gemma":[0.0023550985,0.00076948036,0.00057410327,0.0008083523,0.000714165,0.00030048602,0.0005213377,0.0006588536,0.00017862028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0035736049,0.0013234039,0.7614133,0.0003395645,0.00038656374,0.0002494269,0.0005395269,0.00000441466,0.00016113429,0.00004352194,0.00075138616,0.23121415],"study_design_scores_gemma":[0.023681128,0.005484374,0.9608016,0.0013577425,0.0005525182,0.000021771251,0.00007046588,0.00017060337,0.00681832,0.000048250415,0.00037838347,0.0006148615],"about_ca_topic_score_codex":0.00031043278,"about_ca_topic_score_gemma":0.00015162438,"teacher_disagreement_score":0.2305993,"about_ca_system_score_codex":0.0009963242,"about_ca_system_score_gemma":0.0007626622,"threshold_uncertainty_score":0.9994756},"labels":[],"label_agreement":null},{"id":"W3113268117","doi":"10.1016/s2152-2650(20)30930-7","title":"MM-128: Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies","year":2020,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Carfilzomib; Daratumumab; Medicine; Dexamethasone; Oncology; Subgroup analysis; Multiple myeloma; Internal medicine; Lenalidomide; Meta-analysis","score_opus":0.07079603572095108,"score_gpt":0.3867732350962609,"score_spread":0.31597719937530977,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3113268117","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917008,0.0050376737,0.000012202438,0.00030025744,0.00012715964,0.00237785,0.00034314502,0.000044738696,0.00005617103],"genre_scores_gemma":[0.99473625,0.0031091014,0.0015289378,0.00015556756,0.00009422522,0.000119639575,0.00006129984,0.00008731965,0.000107669366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99384755,0.0011601466,0.0021920297,0.0012260139,0.00094035093,0.00063388323],"domain_scores_gemma":[0.9913845,0.005514107,0.0009886249,0.0010293778,0.00041480034,0.0006685909],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013131638,0.0006676476,0.0028711946,0.00031662086,0.00017590214,0.00004058824,0.0004210588,0.00045941916,0.00009786973],"category_scores_gemma":[0.004414188,0.00043493792,0.00046455313,0.0017834621,0.0014869538,0.00017849595,0.00037191712,0.00052337133,0.000001954177],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048776224,0.0021488518,0.6060725,0.00019708836,0.0036490185,0.000115824354,0.00283143,0.0000019845236,0.008194574,0.00000518054,0.00006842999,0.32793888],"study_design_scores_gemma":[0.102328114,0.005665871,0.87901956,0.00016532891,0.001602452,0.000019269162,0.0020517947,0.0032719055,0.0051683183,0.0000075982566,0.0003441095,0.00035566016],"about_ca_topic_score_codex":0.002628876,"about_ca_topic_score_gemma":0.0016281161,"teacher_disagreement_score":0.32758325,"about_ca_system_score_codex":0.00027414103,"about_ca_system_score_gemma":0.00096940546,"threshold_uncertainty_score":0.9998102},"labels":[],"label_agreement":null},{"id":"W3119618866","doi":"10.1016/j.clml.2021.01.009","title":"Symptomatic BK Virus Disease in Patients With Heavily Pretreated Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"BK virus; Polyomavirus Infections; Subclinical infection; Virus; Nephropathy; Viremia; Virology; Hemorrhagic cystitis; Immunosuppression; JC virus; Immunology; Disease; Merkel cell polyomavirus; Medicine; Urothelium; Biology; Pathology; Internal medicine; Urinary system","score_opus":0.01416383392981419,"score_gpt":0.2782861005232468,"score_spread":0.26412226659343263,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3119618866","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954753,0.001465411,0.0000115452885,0.0002672688,0.00037393125,0.0008201086,0.0001566874,0.00028046436,0.0011492992],"genre_scores_gemma":[0.99603945,0.00018602508,0.0003551376,0.0014882301,0.00021009498,0.00007592697,0.0005921884,0.000114280716,0.00093869044],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955499,0.0003354366,0.0014306165,0.0010865229,0.0007614195,0.00083611545],"domain_scores_gemma":[0.99599624,0.0006792254,0.00030732475,0.0011854222,0.00033125957,0.0015005186],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00024470227,0.00054705364,0.0011217594,0.00018884326,0.00015455225,0.000067127694,0.00024602743,0.00045627702,0.00029152934],"category_scores_gemma":[0.0018335306,0.000421876,0.00046475205,0.00088730326,0.00040416076,0.00021738262,0.00017832464,0.00039907388,0.00042606893],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00441871,0.00255688,0.89803314,0.00016761273,0.0003066873,0.0026661768,0.000047102396,0.000031982134,0.000089025394,0.000039411025,0.0007598792,0.0908834],"study_design_scores_gemma":[0.019254113,0.00064023014,0.97428817,0.0011811655,0.00057052914,0.000027820437,0.000026377144,0.0018648572,0.000426382,0.00008482973,0.0011027203,0.00053283625],"about_ca_topic_score_codex":0.00015538784,"about_ca_topic_score_gemma":0.000065330554,"teacher_disagreement_score":0.09035056,"about_ca_system_score_codex":0.0008413446,"about_ca_system_score_gemma":0.00272437,"threshold_uncertainty_score":0.99982333},"labels":[],"label_agreement":null},{"id":"W3120636941","doi":"10.1016/j.clml.2021.01.007","title":"To Treat or Not? Remission Induction of Acquired von Willebrand Syndrome Secondary to Chronic Lymphocytic Leukemia: A Case Report","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen's University; Ottawa Hospital; University of Ottawa","funders":"Takeda Pharmaceutical Company; CSL Behring; Bayer","keywords":"Medicine; Chronic lymphocytic leukemia; Von Willebrand factor; Immunology; Leukemia; Platelet","score_opus":0.04758273240337041,"score_gpt":0.3628521424247844,"score_spread":0.315269410021414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3120636941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917371,0.000722757,0.00020554784,0.00087441434,0.0012817828,0.0018993238,0.000075358184,0.00033394675,0.0028697224],"genre_scores_gemma":[0.9725263,0.00027903853,0.0024823481,0.0021362593,0.0012675741,0.00021251816,0.00021668889,0.00024619786,0.020633057],"study_design_codex":"case_report","study_design_gemma":"case_report","domain_scores_codex":[0.9893032,0.00060242525,0.003859621,0.0026434963,0.0019457289,0.00164558],"domain_scores_gemma":[0.990211,0.0017627032,0.00070621015,0.0034728232,0.001152676,0.0026945488],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025387246,0.0009415842,0.002754761,0.00064186833,0.00035885003,0.00012609549,0.00066181296,0.0014157903,0.0015497546],"category_scores_gemma":[0.008754322,0.00080497185,0.0009457048,0.002654923,0.0005848969,0.00039463016,0.0011499893,0.00050296163,0.00068987167],"study_design_candidate":"case_report","study_design_consensus":"case_report","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.010935567,0.00026383862,0.00030189095,0.0015249591,0.00044730766,0.5932915,0.0004178287,0.00038433724,0.027756251,0.000033606026,0.015495878,0.34914702],"study_design_scores_gemma":[0.049234558,0.0047519053,0.043438513,0.002698859,0.00077172637,0.77561986,0.00048608924,0.0042544547,0.0956092,0.00005886275,0.021831937,0.0012440291],"about_ca_topic_score_codex":0.0017579506,"about_ca_topic_score_gemma":0.0002788567,"teacher_disagreement_score":0.34790298,"about_ca_system_score_codex":0.18254972,"about_ca_system_score_gemma":0.19953318,"threshold_uncertainty_score":0.99988055},"labels":[],"label_agreement":null},{"id":"W3128661142","doi":"10.1016/j.clml.2021.01.022","title":"Comparison of the Prognostic Ability of the HCT-CI, the Modified EBMT, and the EBMT-ADT Pre-transplant Risk Scores for Acute Leukemia","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Comorbidity; Acute leukemia; Myeloid leukemia; Transplantation; Leukemia; Hematopoietic stem cell transplantation; Oncology","score_opus":0.03322757108119568,"score_gpt":0.3514059282764778,"score_spread":0.31817835719528215,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3128661142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912256,0.00085525087,0.0014335952,0.0018109846,0.0006246591,0.0030254007,0.00030913818,0.00004138299,0.00067396514],"genre_scores_gemma":[0.99796975,0.00041757146,0.00045198816,0.00051082403,0.0001833526,0.00018697747,0.000043797903,0.000045116616,0.00019061865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945555,0.0013332174,0.0022080892,0.00066449767,0.0007873036,0.0004514237],"domain_scores_gemma":[0.9869967,0.009746151,0.0009711142,0.0017340943,0.00039756816,0.00015435448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0026446872,0.00038123401,0.0012859565,0.000028984221,0.00042100425,0.000040345833,0.00077402464,0.00038952185,0.000025489826],"category_scores_gemma":[0.0021918654,0.00016498358,0.00092020695,0.00045419778,0.002578272,0.000057939156,0.0001820459,0.0005554953,0.000004546703],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0067913854,0.00054481643,0.9272692,0.0014882529,0.001525484,0.000020387484,0.0056025847,0.0003283892,0.0059351563,0.004352126,0.0012332215,0.044908985],"study_design_scores_gemma":[0.008378967,0.00022844956,0.94851154,0.0007428203,0.003104627,0.00015301107,0.00034087567,0.011349792,0.024787439,0.0019112345,0.00030834335,0.00018291657],"about_ca_topic_score_codex":0.00023456,"about_ca_topic_score_gemma":0.0001358494,"teacher_disagreement_score":0.04472607,"about_ca_system_score_codex":0.000273809,"about_ca_system_score_gemma":0.002013312,"threshold_uncertainty_score":0.949975},"labels":[],"label_agreement":null},{"id":"W3134398991","doi":"10.1016/j.clml.2021.02.012","title":"Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Terry Fox Research Institute; Vancouver General Hospital; University of British Columbia","funders":"","keywords":"Medicine; Autologous stem-cell transplantation; Multiple myeloma; Internal medicine; Population; Oncology; Transplantation; Salvage therapy; Surgery; Chemotherapy","score_opus":0.04923739033260672,"score_gpt":0.33478305367199535,"score_spread":0.28554566333938863,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3134398991","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99553007,0.00041879556,0.0003929518,0.00008437891,0.0008642893,0.00067257695,0.0005661472,0.00038373575,0.0010870822],"genre_scores_gemma":[0.981855,0.00029741132,0.011966382,0.00027327458,0.00048783195,0.00007295181,0.004619138,0.00011672749,0.0003113154],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99359024,0.0011098156,0.001787346,0.001520937,0.0011369985,0.00085466437],"domain_scores_gemma":[0.995142,0.0017203694,0.0005312848,0.0013159529,0.00024568307,0.0010447446],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010404496,0.00055287156,0.0013280004,0.00013562824,0.00045361675,0.0001419298,0.00030807417,0.0006884914,0.00021720506],"category_scores_gemma":[0.0007881343,0.00053860404,0.00070697593,0.0004913692,0.00017345908,0.00042424453,0.000061734354,0.00064269226,0.00042823577],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012049486,0.00073984737,0.7849559,0.000095388634,0.0007269215,0.002911178,0.0003924288,0.00007131685,0.0018894607,0.00010670275,0.00003277641,0.2068731],"study_design_scores_gemma":[0.013493322,0.000620172,0.9643766,0.0002626242,0.0010561616,0.00007654921,0.00037022712,0.002241593,0.016477086,0.00046241487,0.000059533,0.0005036884],"about_ca_topic_score_codex":0.0054458296,"about_ca_topic_score_gemma":0.0015048217,"teacher_disagreement_score":0.20636941,"about_ca_system_score_codex":0.0008134932,"about_ca_system_score_gemma":0.0012994399,"threshold_uncertainty_score":0.99970657},"labels":[],"label_agreement":null},{"id":"W3158356424","doi":"10.1016/j.clml.2021.04.013","title":"Sex Differences in Multiple Myeloma Biology but not Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":52,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"Institute of Cancer Research; Cancer Research UK; Myeloma UK; National Cancer Research Institute; Celgene; University of Leeds; National Institute for Health and Care Research; Melanoma Research Alliance; Amgen; University of Birmingham; Cancer Research Institute","keywords":"Multiple myeloma; Dyscrasia; Lenalidomide; Incidence (geometry); Internal medicine; Disease; Cancer; Medicine; Oncology; Clinical trial; Plasma cell dyscrasia; Immunology; Plasma cell","score_opus":0.11725789145464567,"score_gpt":0.3878514811505375,"score_spread":0.27059358969589187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3158356424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908182,0.00021374175,0.000014616779,0.0020462638,0.0019260253,0.002455954,0.0009064908,0.0001351403,0.0014835864],"genre_scores_gemma":[0.99023926,0.0005807599,0.0010614484,0.0032595994,0.0013445016,0.00033344372,0.0021457153,0.00009556273,0.00093973445],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9841821,0.0044760327,0.005523608,0.002622364,0.001428898,0.001766968],"domain_scores_gemma":[0.9709875,0.024241727,0.00085266633,0.0025292425,0.0004163885,0.0009725033],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.003977279,0.0009728278,0.0032794364,0.00037764042,0.00027657003,0.0001625264,0.0012647784,0.0015410297,0.00020257973],"category_scores_gemma":[0.034803845,0.0006582863,0.0013629089,0.0010528322,0.0011530627,0.00024383377,0.0006948339,0.0016805287,0.00063492445],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.039547086,0.0034269406,0.68225485,0.000020300906,0.00038140945,0.001970397,0.00026226742,5.416754e-7,0.00003650388,0.00004297067,0.00070996,0.27134678],"study_design_scores_gemma":[0.19529606,0.0022118594,0.7980563,0.0001946929,0.00013080965,0.000024192137,0.0004087301,0.00064317085,0.00019986129,0.00036762093,0.0019487615,0.0005179556],"about_ca_topic_score_codex":0.0038379286,"about_ca_topic_score_gemma":0.0032197724,"teacher_disagreement_score":0.2708288,"about_ca_system_score_codex":0.0010150113,"about_ca_system_score_gemma":0.0027107238,"threshold_uncertainty_score":0.9997552},"labels":[],"label_agreement":null},{"id":"W3161580798","doi":"10.1016/j.clml.2021.05.002","title":"Trajectory of Symptoms in Patients Undergoing Autologous Stem Cell Transplant for Multiple Myeloma: A Population-Based Cohort Study of Patient-Reported Outcomes","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Hamilton Health Sciences; Institute of Aging; Juravinski Cancer Centre","funders":"Takeda Canada; Ontario Ministry of Health and Long-Term Care; Institute for Clinical Evaluative Sciences; Janssen Pharmaceuticals; Celgene; Sanofi; Roche; Amgen","keywords":"Medicine; Multiple myeloma; Population; Cohort; Internal medicine; Odds ratio; Environmental health","score_opus":0.02771372705732486,"score_gpt":0.3153239903634349,"score_spread":0.28761026330611006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3161580798","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995666,0.00010242363,0.000051320007,0.00002528141,0.0003119635,0.0035279521,0.00015092635,0.00007152239,0.00009256115],"genre_scores_gemma":[0.9980767,0.000013461268,0.0006780428,0.000079330086,0.000029301005,0.00029502512,0.0006642961,0.00007447059,0.000089396235],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940194,0.0005020176,0.0028776636,0.00096516486,0.0009852763,0.0006505078],"domain_scores_gemma":[0.99364895,0.0035966786,0.0008594131,0.0009414033,0.0005677082,0.00038585],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00056616246,0.00045092162,0.0018897477,0.0003242834,0.00010073034,0.000014834325,0.0002076196,0.00037279777,0.000029854564],"category_scores_gemma":[0.0010235385,0.00039187775,0.00063317356,0.0005073211,0.00013352171,0.00009680994,0.000067999186,0.00022844312,0.000004999182],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034720344,0.008238063,0.9094995,0.0004394235,0.000812233,0.00039327255,0.000310362,0.00016764272,0.00010414178,0.000004375472,0.000014249285,0.076544695],"study_design_scores_gemma":[0.04951668,0.004227237,0.9406328,0.0002973447,0.00048619378,0.000009037233,0.00032272414,0.0022736015,0.0019263262,0.000011085425,0.000009218462,0.00028775018],"about_ca_topic_score_codex":0.0006946363,"about_ca_topic_score_gemma":0.00080774806,"teacher_disagreement_score":0.076256946,"about_ca_system_score_codex":0.0008972327,"about_ca_system_score_gemma":0.0019665454,"threshold_uncertainty_score":0.9998533},"labels":[],"label_agreement":null},{"id":"W3179993901","doi":"10.1016/j.clml.2021.06.011","title":"A Prospective Economic Analysis of Early Outcome Data From the Alliance A041202/ CCTG CLC.2 Randomized Phase III Trial Of Bendamustine-Rituximab Compared With Ibrutinib-Based Regimens in Untreated Older Patients With Chronic Lymphocytic Leukemia","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Ottawa; University of Toronto; Western University; Santé Montérégie; Juravinski Cancer Centre; Victoria Hospital; Princess Margaret Cancer Centre; Foothills Medical Centre; Moncton Hospital; Centre intégré de santé et de services sociaux de la Montérégie-Centre; McMaster University; Queen's University; Ottawa Hospital; Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Janssen Pharmaceuticals; National Cancer Institute; Pharmacyclics; National Institutes of Health","keywords":"Bendamustine; Ibrutinib; Rituximab; Alliance; Internal medicine; Medicine; Oncology; Randomized controlled trial; Political science; Lymphoma; Chronic lymphocytic leukemia; Leukemia","score_opus":0.04909731416074531,"score_gpt":0.36561030297382136,"score_spread":0.31651298881307605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3179993901","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99219143,0.0006189424,0.00022658963,0.00015450116,0.00024770695,0.0049541644,0.0012445312,0.00010185487,0.00026024782],"genre_scores_gemma":[0.9937446,0.0001306406,0.0010463294,0.00023071287,0.00030959016,0.00029422037,0.003864828,0.00014026245,0.00023882264],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9886357,0.0015103105,0.004675731,0.0024103292,0.0016085004,0.0011594231],"domain_scores_gemma":[0.9825187,0.00889886,0.0022484262,0.0048416196,0.000956638,0.0005357676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002760147,0.0009418886,0.006491446,0.00041351884,0.00015711506,0.00009547914,0.0015671002,0.00058713794,0.00050500827],"category_scores_gemma":[0.002573721,0.00062645564,0.0010366322,0.002741441,0.0025905522,0.0003280574,0.0006359233,0.0006953617,0.00005018683],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8608739,0.002234136,0.116005,0.00021996931,0.010222685,0.00063499395,0.00037598255,0.0045775888,0.000034947847,0.00005650966,0.00032563094,0.0044387016],"study_design_scores_gemma":[0.5643899,0.0014563801,0.26153696,0.0006211227,0.0052759494,0.000010812692,0.000074953816,0.16585077,0.0003306885,0.00001142027,0.000043521883,0.00039753082],"about_ca_topic_score_codex":0.017140511,"about_ca_topic_score_gemma":0.005125457,"teacher_disagreement_score":0.29648393,"about_ca_system_score_codex":0.062406003,"about_ca_system_score_gemma":0.1035593,"threshold_uncertainty_score":0.99961865},"labels":[],"label_agreement":null},{"id":"W3184807749","doi":"10.1016/j.clml.2021.07.020","title":"Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Janssen Pharmaceuticals; Sierra Oncology; Pfizer","keywords":"Medicine; Refractory (planetary science); Diffuse large B-cell lymphoma; Oncology; Internal medicine; Lymphoma; Oligonucleotide; Cancer research; DNA; Genetics","score_opus":0.0171050615275064,"score_gpt":0.2825302489685589,"score_spread":0.2654251874410525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184807749","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.996105,0.00097552023,0.000004465376,0.00022705086,0.00020722757,0.00084182434,0.00006807868,0.00007966816,0.001491171],"genre_scores_gemma":[0.99417543,0.0027650811,0.00066436426,0.0013638063,0.00012459676,0.000039806946,0.00019403514,0.00009613396,0.0005767646],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99568415,0.0003540058,0.001627948,0.0010508756,0.00060765835,0.00067538087],"domain_scores_gemma":[0.9958782,0.0016636556,0.00049508805,0.0011202985,0.00030698153,0.00053574686],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004914922,0.0005342276,0.0015216004,0.00015752079,0.000117400574,0.000036842484,0.00019663907,0.00044173532,0.00013715884],"category_scores_gemma":[0.0007220778,0.00036671595,0.00034157795,0.00058068667,0.00033205064,0.00016246206,0.00019076138,0.00017073951,0.000048459693],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016690213,0.025436299,0.56029147,0.00008541471,0.00030280644,0.0010392136,0.00022625277,5.192502e-7,0.000076318975,0.000097478005,0.0002965166,0.3954575],"study_design_scores_gemma":[0.18710391,0.003451536,0.79769546,0.00042243814,0.00018060977,0.000043494558,0.00007391891,0.00003259498,0.0014715317,0.00001453027,0.009175969,0.00033401235],"about_ca_topic_score_codex":0.000095492884,"about_ca_topic_score_gemma":0.00007958848,"teacher_disagreement_score":0.39512348,"about_ca_system_score_codex":0.0010166897,"about_ca_system_score_gemma":0.0019596093,"threshold_uncertainty_score":0.99987847},"labels":[],"label_agreement":null},{"id":"W3184984409","doi":"10.1016/j.clml.2021.07.003","title":"Light Chain Amyloidosis (AL) Associated With B Cell Lymphoma a Single Center Experience","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"AL amyloidosis; Medicine; Lymphoma; Rituximab; Amyloidosis; Internal medicine; Single Center; Lymphoplasmacytic Lymphoma; Waldenstrom macroglobulinemia; Incidence (geometry); Progression-free survival; Diffuse large B-cell lymphoma; Immunoglobulin light chain; Gastroenterology; Macroglobulinemia; Oncology; Chemotherapy; Immunology; Antibody; Multiple myeloma","score_opus":0.01905818708996288,"score_gpt":0.2809848681788172,"score_spread":0.2619266810888543,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3184984409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921099,0.0012975042,0.00011745168,0.0011751759,0.00056957087,0.00034962996,0.000080227415,0.00013220975,0.004168317],"genre_scores_gemma":[0.98731315,0.0007418438,0.0008616278,0.0066915955,0.0003601587,0.00022319087,0.0004784401,0.00014775785,0.0031822172],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951184,0.0004984297,0.0011283312,0.0017054421,0.0005309899,0.0010184535],"domain_scores_gemma":[0.9967732,0.0003434559,0.0005386567,0.0014287676,0.00036028033,0.00055562984],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00036397463,0.0007105164,0.0008863694,0.0000762037,0.0002785351,0.00014852565,0.0006514512,0.0007222961,0.00013332439],"category_scores_gemma":[0.0010629429,0.0006313516,0.0006424253,0.00048600766,0.00035138873,0.000028944589,0.0005298467,0.00014917053,0.00017031336],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009354174,0.00796814,0.60453475,0.00005322712,0.0012759054,0.0013958405,0.0005208817,0.000017699558,0.20110278,0.0000819026,0.030103285,0.15201016],"study_design_scores_gemma":[0.010086449,0.0011841214,0.47541928,0.00016682016,0.00017436237,0.00015285486,0.00037309408,0.000044905442,0.40646002,0.000022937533,0.10486421,0.0010509313],"about_ca_topic_score_codex":0.000038972958,"about_ca_topic_score_gemma":0.00014871836,"teacher_disagreement_score":0.20535725,"about_ca_system_score_codex":0.0007681154,"about_ca_system_score_gemma":0.0010083225,"threshold_uncertainty_score":0.99961376},"labels":[],"label_agreement":null},{"id":"W3186039091","doi":"10.1016/j.clml.2021.07.017","title":"Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Karyopharm Therapeutics","keywords":"Medicine; Lymphoma; Diffuse large B-cell lymphoma; Nuclear export signal; Cancer research; Pharmacology; Internal medicine; Cell nucleus; Psychiatry","score_opus":0.010531489982220076,"score_gpt":0.27944115505508965,"score_spread":0.26890966507286956,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186039091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9984343,0.0004247482,0.000016586237,0.000031176445,0.00038779585,0.00021700468,0.000036720947,0.000004998948,0.00044667153],"genre_scores_gemma":[0.99949163,0.00009057589,0.000113211434,0.00011541635,0.000100433055,0.0000032922376,0.0000137685165,0.000026183614,0.00004549606],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9978667,0.00064538326,0.000736692,0.00037711236,0.00018133469,0.00019277567],"domain_scores_gemma":[0.9986266,0.00020545913,0.0004027793,0.00052226125,0.00019067737,0.000052237137],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005082141,0.00017374281,0.0005078466,0.000022925822,0.00007195595,0.0000067776973,0.00023751888,0.00034066185,0.0000073824262],"category_scores_gemma":[0.00049394835,0.00011759639,0.0002653602,0.00026834875,0.0003309339,0.0000069540256,0.00037537786,0.00012027378,9.159733e-7],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0025468534,0.0014717466,0.561293,0.00019799458,0.00012955647,0.0000042633023,0.0002261827,0.000016071092,0.39569262,0.00035356876,0.00060893915,0.037459232],"study_design_scores_gemma":[0.0042765383,0.00020434415,0.71199787,0.00006056845,0.000042197542,0.000007350106,0.0001326433,0.00010841465,0.28066486,0.00007812967,0.002333779,0.000093292],"about_ca_topic_score_codex":0.000040778174,"about_ca_topic_score_gemma":0.00009394837,"teacher_disagreement_score":0.15070492,"about_ca_system_score_codex":0.00006769362,"about_ca_system_score_gemma":0.00038742862,"threshold_uncertainty_score":0.47954416},"labels":[],"label_agreement":null},{"id":"W3186645017","doi":"10.1016/j.clml.2021.07.016","title":"A Phase 2 Study of PNT2258 for Treatment of Relapsed or Refractory B-Cell Malignancies","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; Merck; Pfizer","keywords":"Medicine; Chills; Tolerability; Adverse effect; Nausea; Internal medicine; Mantle cell lymphoma; Gastroenterology; Vomiting; Refractory (planetary science); Diarrhea; Phases of clinical research; Follicular lymphoma; Surgery; Lymphoma; Oncology; Clinical trial","score_opus":0.042828390636790385,"score_gpt":0.34967223232318806,"score_spread":0.30684384168639767,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3186645017","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9975152,0.0007142744,0.00024097253,0.000017782799,0.0003544389,0.0006835236,0.000095392315,0.000021100164,0.00035732146],"genre_scores_gemma":[0.9922917,0.0003211097,0.00297708,0.00008444252,0.0002189692,0.00013115689,0.00013229459,0.000050164934,0.0037930924],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9974726,0.00022894732,0.0011084998,0.0006890176,0.00020433894,0.00029660016],"domain_scores_gemma":[0.9977713,0.00028438753,0.0004647296,0.0009991251,0.00033152083,0.00014888983],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003386701,0.0002673786,0.00073048694,0.000040093666,0.000054228774,0.000009798304,0.00024621512,0.00034478758,0.00003800685],"category_scores_gemma":[0.0005979561,0.00022093552,0.000471731,0.00014216285,0.00013586371,0.0000053584217,0.00013079881,0.000032380754,0.000005955169],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004265804,0.015308364,0.00093862717,0.00010309784,0.0003800745,0.00012622906,0.00023520252,0.000005821039,0.781792,0.000049684622,0.0008960985,0.19589902],"study_design_scores_gemma":[0.030806055,0.04134824,0.0073631676,0.000037804086,0.0002541117,0.000026184161,0.00091444066,0.00008386818,0.8943066,0.00008049027,0.024487536,0.00029149052],"about_ca_topic_score_codex":0.000021663982,"about_ca_topic_score_gemma":0.00004317916,"teacher_disagreement_score":0.19560754,"about_ca_system_score_codex":0.00013494417,"about_ca_system_score_gemma":0.0013024913,"threshold_uncertainty_score":0.9009489},"labels":[],"label_agreement":null},{"id":"W3188942243","doi":"10.1016/j.clml.2021.07.028","title":"Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium","year":2021,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; London Health Sciences Centre; Vancouver General Hospital; CancerCare Manitoba; Memorial University of Newfoundland; University of Manitoba; Centre hospitalier universitaire de Québec; Université de Montréal; Western University; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Guideline; Multiple myeloma; Medicine; Family medicine; Intensive care medicine; Disease; Internal medicine; Pathology","score_opus":0.17558033125824968,"score_gpt":0.460361134728241,"score_spread":0.2847808034699913,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3188942243","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.01604137,0.9408071,0.000021622858,0.0059402655,0.0010728678,0.013634699,0.004011052,0.00005281182,0.01841821],"genre_scores_gemma":[0.21930152,0.7688244,0.002625461,0.00026710643,0.0004512679,0.0011552143,0.005787055,0.00023633144,0.001351617],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9834907,0.0049788323,0.005423488,0.0015548127,0.002559693,0.001992445],"domain_scores_gemma":[0.98078716,0.00773704,0.002039811,0.002892099,0.0053688926,0.0011750265],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["sts"],"category_scores_codex":[0.008365914,0.0008370556,0.003343023,0.0007012377,0.0014951988,0.0000884948,0.0014476548,0.0008449783,0.00023364242],"category_scores_gemma":[0.0028971361,0.0005765242,0.00094838836,0.0035004823,0.004619808,0.0000869416,0.0012248013,0.0019308917,0.000021041118],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00025093823,0.0002543645,0.0023236973,0.0066519217,0.0022682329,0.00051278534,0.00016651998,0.0000036860185,0.0000019025065,0.005651086,0.030010385,0.9519045],"study_design_scores_gemma":[0.003272462,0.0008607512,0.300193,0.013731155,0.0017247434,0.00062643446,0.003610684,0.00016454149,0.000017329852,0.0002823294,0.67497474,0.0005418013],"about_ca_topic_score_codex":0.519768,"about_ca_topic_score_gemma":0.77155876,"teacher_disagreement_score":0.95136267,"about_ca_system_score_codex":0.0060640243,"about_ca_system_score_gemma":0.03588663,"threshold_uncertainty_score":0.99980474},"labels":[],"label_agreement":null},{"id":"W3196332160","doi":"10.1016/s2152-2650(21)01891-7","title":"ABCL-346: Overall Survival with Tafasitamab + Lenalidomide (LEN) vs Routinely Administered Therapies for ASCT-Ineligible Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Outcomes from the Observational RE-MIND2 Study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"","keywords":"Lenalidomide; Medicine; Diffuse large B-cell lymphoma; Observational study; Oncology; Internal medicine; Refractory (planetary science); Lymphoma; Overall survival; Multiple myeloma","score_opus":0.10291016399823841,"score_gpt":0.3575752979245393,"score_spread":0.25466513392630086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196332160","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98614514,0.0013282596,0.000093172035,0.0066299434,0.0012222072,0.0026535534,0.00081510824,0.00028006287,0.0008325482],"genre_scores_gemma":[0.9766195,0.00047567236,0.0025096168,0.008867098,0.0012042907,0.00090446585,0.0013894361,0.00023711174,0.0077928356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9914531,0.0009609366,0.0026799708,0.0020783488,0.0015524635,0.0012751551],"domain_scores_gemma":[0.9836966,0.011145767,0.0010677318,0.0025275967,0.0008518246,0.00071049714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015981776,0.0012091827,0.0026804989,0.000112410125,0.0007213001,0.00034994908,0.00080454024,0.0006576836,0.00042241698],"category_scores_gemma":[0.0022235683,0.0007126604,0.0012832037,0.00052940694,0.0003140628,0.00040328887,0.00043004312,0.00034301865,0.0001789409],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020117607,0.034459926,0.8951899,0.00010036563,0.0036894646,0.0023597628,0.0012467824,0.0000032380062,0.000102176135,0.00044408542,0.012340207,0.029946527],"study_design_scores_gemma":[0.1660421,0.0035273896,0.787006,0.0002662967,0.0015153822,0.0000674935,0.0020665466,0.00017657207,0.00048713837,0.0001907913,0.037909087,0.00074515713],"about_ca_topic_score_codex":0.00071296096,"about_ca_topic_score_gemma":0.0011180345,"teacher_disagreement_score":0.1459245,"about_ca_system_score_codex":0.002575568,"about_ca_system_score_gemma":0.006450671,"threshold_uncertainty_score":0.99953246},"labels":[],"label_agreement":null},{"id":"W3196898846","doi":"10.1016/s2152-2650(21)01833-4","title":"MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Context (archaeology); Myelofibrosis; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Clinical trial; Bone marrow; Biology","score_opus":0.045024014868734766,"score_gpt":0.37888645680329724,"score_spread":0.3338624419345625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3196898846","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99630904,0.0002303022,0.00001207648,0.0001908779,0.0003787324,0.002110026,0.00022209722,0.0000458397,0.00050102436],"genre_scores_gemma":[0.9980049,0.00020928751,0.00034672697,0.00016292787,0.00025592215,0.0001211168,0.00054231065,0.000093646326,0.00026317575],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9897597,0.0015181215,0.004711632,0.0016465505,0.0015269208,0.00083708845],"domain_scores_gemma":[0.9902384,0.0048022396,0.0012575361,0.0023059289,0.00091046025,0.00048540224],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017487939,0.0006625046,0.0030208328,0.00060305774,0.00009148282,0.000054887925,0.0007249101,0.0006415008,0.00028936783],"category_scores_gemma":[0.00317224,0.00048339381,0.001207221,0.0034426798,0.00096495735,0.00021922552,0.0006000019,0.00063730875,0.00003259557],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009443871,0.037453946,0.8127077,0.00011389533,0.0020193567,0.0006050025,0.0011871353,0.00004675404,0.00019112721,0.00008839879,0.00006380063,0.13607897],"study_design_scores_gemma":[0.15332508,0.008799978,0.82862574,0.0007285261,0.0016502185,0.000017484217,0.0012806931,0.0027978567,0.0022296342,0.000076347926,0.000116014206,0.00035243973],"about_ca_topic_score_codex":0.0058831475,"about_ca_topic_score_gemma":0.005608736,"teacher_disagreement_score":0.1438812,"about_ca_system_score_codex":0.013327414,"about_ca_system_score_gemma":0.009127766,"threshold_uncertainty_score":0.99976176},"labels":[],"label_agreement":null},{"id":"W3197000240","doi":"10.1016/s2152-2650(21)01747-x","title":"CLL-045: Long-Term Follow-up, Up to 7 Years, in the RESONATE-2 Study of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Chlorambucil; Medicine; Chronic lymphocytic leukemia; Internal medicine; IGHV@; Gastroenterology; Oncology; Leukemia; Chemotherapy","score_opus":0.09057944067365786,"score_gpt":0.39874494230696444,"score_spread":0.3081655016333066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197000240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896298,0.0020728374,0.000079742706,0.000506245,0.0013713532,0.005543621,0.00009782987,0.00015668072,0.00054187735],"genre_scores_gemma":[0.98929876,0.0010022529,0.0003194749,0.00093097036,0.0014525539,0.0011653785,0.000290526,0.00021944211,0.005320628],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98988664,0.00087601907,0.003332229,0.0022129214,0.0018022163,0.0018899861],"domain_scores_gemma":[0.9893731,0.0050415616,0.00055784563,0.0034627283,0.00067635125,0.00088844664],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002712407,0.00095819845,0.0025766068,0.00044824235,0.00029028615,0.00014397572,0.0013792813,0.00082028314,0.00025934994],"category_scores_gemma":[0.0034681545,0.00075227045,0.0012155884,0.0019533297,0.0005239159,0.00018405322,0.0007163508,0.0005321949,0.0002965835],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.022415401,0.0041047214,0.05439557,0.0015805657,0.0024519835,0.012546368,0.008733732,0.001403113,0.00069175224,0.00035636465,0.010182743,0.88113767],"study_design_scores_gemma":[0.24855497,0.017223269,0.68714166,0.0013824278,0.0012462919,0.0012588357,0.001869308,0.01338297,0.0033450846,0.00018309992,0.023201898,0.0012101566],"about_ca_topic_score_codex":0.0026935635,"about_ca_topic_score_gemma":0.008195008,"teacher_disagreement_score":0.8799275,"about_ca_system_score_codex":0.14923938,"about_ca_system_score_gemma":0.07466608,"threshold_uncertainty_score":0.9994928},"labels":[],"label_agreement":null},{"id":"W3197174889","doi":"10.1016/s2152-2650(21)01654-2","title":"ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Biology; Myeloid leukemia; Myeloid; Cancer research; Leukemia; Genetics","score_opus":0.04683102647443164,"score_gpt":0.3638453538167832,"score_spread":0.3170143273423515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3197174889","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98849934,0.00082264194,0.0004700805,0.00086078845,0.0006087564,0.00068303,0.000035837027,0.00017066576,0.007848884],"genre_scores_gemma":[0.98670906,0.0006200044,0.0054816375,0.0022662333,0.0009095852,0.00006210725,0.0004164375,0.00015273095,0.003382217],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9922009,0.0006586377,0.0031109394,0.0014315287,0.001393577,0.0012044146],"domain_scores_gemma":[0.99416333,0.0017540312,0.0006003544,0.0018227295,0.0008211644,0.0008383714],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018514809,0.00060044095,0.0019012855,0.00040963572,0.00009610351,0.000056753426,0.00058520463,0.0011718944,0.0005632637],"category_scores_gemma":[0.0048092077,0.0005851689,0.000869503,0.00148885,0.0007468021,0.00025600608,0.00055436825,0.00081266486,0.0006131038],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004863083,0.0018271054,0.0848682,0.00092929945,0.0011719987,0.010328523,0.00056512415,0.00047726143,0.05964311,0.0013818605,0.01381871,0.8201257],"study_design_scores_gemma":[0.016806861,0.00065538986,0.9273016,0.0005793335,0.0003235111,0.0010048512,0.0001669012,0.015641714,0.028299773,0.0005058809,0.008134293,0.0005798949],"about_ca_topic_score_codex":0.00077286485,"about_ca_topic_score_gemma":0.00015310937,"teacher_disagreement_score":0.8424334,"about_ca_system_score_codex":0.007799281,"about_ca_system_score_gemma":0.015338475,"threshold_uncertainty_score":0.99965996},"labels":[],"label_agreement":null},{"id":"W3198886567","doi":"10.1016/s2152-2650(21)01226-x","title":"Optimal Timing of Blinatumomab for the Treatment of B-Lymphoblastic Leukemia","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hospital for Sick Children; University of Toronto; SickKids Foundation","funders":"","keywords":"Blinatumomab; Medicine; CD19; Oncology; Clinical trial; Lymphoblastic lymphoma; Lymphoma; B cell; Internal medicine; Lymphoblastic Leukemia; Antibody; Leukemia; Immunology; T cell; Immune system","score_opus":0.05895125059316061,"score_gpt":0.36710443935373127,"score_spread":0.3081531887605707,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3198886567","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98598635,0.003399084,0.0053848736,0.0006904627,0.0008490591,0.001425461,0.00014352573,0.00009652667,0.0020246278],"genre_scores_gemma":[0.9803124,0.0019692152,0.012571365,0.00035171068,0.0009966913,0.00022045712,0.00012476473,0.0001392552,0.0033141603],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99435526,0.00026265281,0.0023763364,0.0010285376,0.0010125716,0.0009646464],"domain_scores_gemma":[0.9855322,0.010174091,0.0007046354,0.0017639685,0.0013066924,0.0005183964],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009734809,0.0005666321,0.0018763253,0.00019926735,0.00022226214,0.000038237777,0.00058416347,0.00061121857,0.00027287795],"category_scores_gemma":[0.0037453284,0.00039638,0.0014843185,0.00086747966,0.0012681388,0.000114518894,0.00024038766,0.00022779207,0.00006816641],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.009276558,0.0029358969,0.006598873,0.0010296676,0.0029718785,0.0011503851,0.0007870009,0.0011243435,0.014903685,0.0021338903,0.010944867,0.946143],"study_design_scores_gemma":[0.06462723,0.013760251,0.52898365,0.0011999327,0.003968721,0.0019889611,0.0013017826,0.18838665,0.13127373,0.0006290386,0.06274421,0.0011358632],"about_ca_topic_score_codex":0.00013849222,"about_ca_topic_score_gemma":0.000016999955,"teacher_disagreement_score":0.9450071,"about_ca_system_score_codex":0.005254374,"about_ca_system_score_gemma":0.014685403,"threshold_uncertainty_score":0.9998488},"labels":[],"label_agreement":null},{"id":"W3205641125","doi":"10.1016/j.clml.2021.10.004","title":"Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Outcome (game theory); Lymphoma; Retrospective cohort study; T-cell lymphoma; Internal medicine; Oncology","score_opus":0.03910560402765996,"score_gpt":0.3267734776531193,"score_spread":0.28766787362545937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3205641125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970083,0.00089975196,0.00010784024,0.00017760943,0.00043011756,0.0003998726,0.000146855,0.00005651337,0.000773122],"genre_scores_gemma":[0.9933988,0.0012641437,0.0036907329,0.00085139944,0.00019415877,0.00009700706,0.00016890574,0.000036686033,0.0002982099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961351,0.00015597584,0.0017044455,0.0009848188,0.00051004096,0.00050958694],"domain_scores_gemma":[0.9976562,0.00048592142,0.0004206367,0.0006678181,0.00031880513,0.00045058312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002302344,0.00044716388,0.0014721821,0.000130535,0.00012251343,0.000037592992,0.00017750074,0.000299919,0.000098268116],"category_scores_gemma":[0.0010408729,0.00037944605,0.00040412458,0.0006030543,0.00088888145,0.00016014757,0.00020823177,0.00015787185,0.00006127317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003578374,0.002659412,0.85358113,0.000112399954,0.00008946154,0.002455216,0.0004565626,0.0000015898596,0.00032299667,0.00022542078,0.000038229384,0.13969976],"study_design_scores_gemma":[0.014822402,0.00043613295,0.9794963,0.00016892554,0.00015289595,0.00034224326,0.0002441885,0.00060221495,0.0017222419,0.000019678635,0.0016528406,0.00033993585],"about_ca_topic_score_codex":0.00025697923,"about_ca_topic_score_gemma":0.00016580377,"teacher_disagreement_score":0.13935982,"about_ca_system_score_codex":0.0014982892,"about_ca_system_score_gemma":0.0015490622,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W3211920496","doi":"10.1016/s2152-2650(21)02092-9","title":"OAB-018: A BCL2L1 armoured BCMA-targeting CAR T cells to overcome exhaustion and enhance persistence in multiple myeloma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Chimeric antigen receptor; CD28; TIGIT; T cell; CAR T-cell therapy; CD19; Cancer research; Biology; Immunology; Cell biology; Antigen; Medicine; Immune system","score_opus":0.05083502320690806,"score_gpt":0.34308830516624084,"score_spread":0.29225328195933276,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3211920496","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944144,0.0012286849,0.00013655523,0.0012494337,0.00058830215,0.0008455741,0.000022317743,0.00012827381,0.001386487],"genre_scores_gemma":[0.9852969,0.0007455145,0.004339693,0.0018136441,0.00076712883,0.00008128577,0.00006231568,0.00009983021,0.006793677],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9946033,0.000507167,0.001434727,0.0015247856,0.0008585193,0.0010715397],"domain_scores_gemma":[0.99543494,0.0019674571,0.00021159621,0.0009907403,0.00042991256,0.0009653315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017740616,0.00047344575,0.0011853194,0.00025518765,0.00019493747,0.00011235586,0.00034288075,0.0005688348,0.0008214122],"category_scores_gemma":[0.004097317,0.00048568405,0.00041820618,0.0010409789,0.00037839773,0.0001940308,0.00045971342,0.00073036185,0.00033926687],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018873105,0.00036983666,0.07355593,0.0002308901,0.00011588274,0.0017544301,0.0010357106,0.000040564217,0.5942529,0.00002055249,0.0015925091,0.32514346],"study_design_scores_gemma":[0.005743489,0.0006334628,0.8556371,0.00055968534,0.00007881848,0.00022345426,0.0009896934,0.0028379168,0.1161997,0.0000658971,0.01646373,0.0005670804],"about_ca_topic_score_codex":0.00020803191,"about_ca_topic_score_gemma":0.00017282135,"teacher_disagreement_score":0.7820811,"about_ca_system_score_codex":0.0016258276,"about_ca_system_score_gemma":0.0014070022,"threshold_uncertainty_score":0.9997595},"labels":[],"label_agreement":null},{"id":"W3212141161","doi":"10.1016/s2152-2650(21)02314-4","title":"P-187: Expert elicitation of long-term survival (LTS) for patients (pts) with relapsed/refractory multiple myeloma (RRMM) treated with idecabtagene vicleucel (ide-cel, bb2121) in the KarMMa phase 2 trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pomalidomide; Multiple myeloma; Clinical trial; Expert opinion; Facilitator; Oncology; Internal medicine; Lenalidomide; Intensive care medicine","score_opus":0.05124793519729414,"score_gpt":0.3540276618320754,"score_spread":0.30277972663478125,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212141161","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953939,0.0007480561,0.0008075893,0.0002907218,0.0007862149,0.0014307455,0.00016678387,0.000060475704,0.00031555298],"genre_scores_gemma":[0.9951451,0.00022767825,0.0020524461,0.00091151457,0.00022871101,0.00021292426,0.0006405467,0.00007007072,0.0005110258],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99429846,0.0018472486,0.0017950505,0.0010592676,0.00025449024,0.00074549654],"domain_scores_gemma":[0.9920419,0.0055667297,0.0007181651,0.00092303165,0.0006244392,0.00012575809],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016176855,0.00055074546,0.0012992778,0.00014195291,0.00023746568,0.00005008709,0.0005774593,0.0009243491,0.00018227255],"category_scores_gemma":[0.0021425495,0.00034557478,0.00045670292,0.0006488907,0.0008824509,0.00019071154,0.00011848279,0.00046753645,0.000030649466],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15532564,0.008381658,0.09439742,0.00010452284,0.001006243,0.0002457266,0.00052187964,0.0000034468865,0.026104962,0.0001485319,0.0013303552,0.71242964],"study_design_scores_gemma":[0.20983517,0.0113304565,0.72708297,0.0002585416,0.00041920162,0.000045187084,0.00036589144,0.00008033521,0.044224318,0.00006201656,0.005614214,0.0006817032],"about_ca_topic_score_codex":0.00009703247,"about_ca_topic_score_gemma":0.00029445358,"teacher_disagreement_score":0.7117479,"about_ca_system_score_codex":0.0003044949,"about_ca_system_score_gemma":0.0007755385,"threshold_uncertainty_score":0.9998996},"labels":[],"label_agreement":null},{"id":"W3212319088","doi":"10.1016/s2152-2650(21)02339-9","title":"P-212: DREAMM-5 platform trial: Belantamab mafodotin (belamaf; GSK2857916) in combination with five different novel agents in patients with relapsed/refractory multiple myeloma (RRMM)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Interim analysis; Cohort; Oncology; Refractory (planetary science); Dosing; Internal medicine; Multiple myeloma; Biomarker; Adverse effect; Combination therapy; Lenalidomide; Interim; Clinical trial","score_opus":0.04562237161427093,"score_gpt":0.3188402669338923,"score_spread":0.2732178953196214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212319088","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440205,0.00013022784,0.000052774307,0.0002629986,0.00042754723,0.0033222297,0.00017324493,0.00014105605,0.0010878551],"genre_scores_gemma":[0.99396026,0.00014694428,0.0011416026,0.00043178455,0.00019320312,0.0003787154,0.0020679631,0.00017849015,0.0015010209],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924358,0.0004309376,0.0021355627,0.0017381905,0.0017959165,0.0014635584],"domain_scores_gemma":[0.99468166,0.0018206943,0.0006451351,0.0013444063,0.0005634544,0.00094465783],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007574814,0.0009202043,0.00193895,0.00057165214,0.0002061197,0.00011273336,0.00044153884,0.0007593475,0.00020609696],"category_scores_gemma":[0.0018427613,0.00068833015,0.0003765152,0.0011144066,0.00042757698,0.00048410127,0.0003445284,0.0011000752,0.00013977368],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.09544959,0.010754054,0.74471766,0.00011322995,0.00044858328,0.002089906,0.0002085987,0.000014600059,0.00006048957,0.00006550713,0.00024938677,0.1458284],"study_design_scores_gemma":[0.2966602,0.005279678,0.69447106,0.0008109246,0.00013402429,0.000053509913,0.00015268975,0.0009901015,0.0003752371,0.000042413263,0.00050976145,0.0005203692],"about_ca_topic_score_codex":0.00063504744,"about_ca_topic_score_gemma":0.0022010047,"teacher_disagreement_score":0.20121063,"about_ca_system_score_codex":0.003571287,"about_ca_system_score_gemma":0.0020986896,"threshold_uncertainty_score":0.9995568},"labels":[],"label_agreement":null},{"id":"W3212884449","doi":"10.1016/s2152-2650(21)02100-5","title":"OAB-026: MagnetisMM-1 study of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA) targeted CD3-engaging bispecific molecule, for patients (pts) with relapsed or refractory multiple myeloma (MM)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Institute of Cancer Research; McGill University Health Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Medicine; Cytokine release syndrome; Common Terminology Criteria for Adverse Events; Adverse effect; Internal medicine; Minimal residual disease; Pharmacokinetics; Multiple myeloma; Oncology; Gastroenterology; Pharmacodynamics; Neutropenia; Pharmacology; Toxicity; Chimeric antigen receptor; Bone marrow; Immunotherapy; Cancer","score_opus":0.038156058875315195,"score_gpt":0.32254077801467923,"score_spread":0.28438471913936403,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3212884449","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9926033,0.00070150103,0.00029928135,0.00016671128,0.0005156944,0.0043972824,0.0002848147,0.00021434457,0.0008170665],"genre_scores_gemma":[0.9864747,0.00040341192,0.008127131,0.00027320994,0.00034043688,0.00044300986,0.0016961792,0.00022976416,0.002012168],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9919453,0.00094376685,0.0023505352,0.0018847362,0.00161782,0.0012578082],"domain_scores_gemma":[0.99215776,0.0024732684,0.00091573177,0.0018225968,0.0016979078,0.00093271176],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008962682,0.0008569445,0.0018421533,0.00041771238,0.00050623924,0.00012861758,0.0005224665,0.00059156993,0.00033563268],"category_scores_gemma":[0.0035852902,0.0006675845,0.0005682467,0.0011768718,0.00036706924,0.00041003054,0.0003017973,0.00070228876,0.0001249913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.057110205,0.023690885,0.41267657,0.0009506349,0.0019715792,0.0043813465,0.0011944808,0.000027018672,0.012115473,0.000024398996,0.005078759,0.48077863],"study_design_scores_gemma":[0.07675521,0.013611869,0.8891897,0.000412468,0.00047194815,0.00007645214,0.0015566392,0.0026974801,0.01063495,0.00002078339,0.0038834566,0.0006890178],"about_ca_topic_score_codex":0.00024127967,"about_ca_topic_score_gemma":0.00030677303,"teacher_disagreement_score":0.4800896,"about_ca_system_score_codex":0.0010862611,"about_ca_system_score_gemma":0.0024538094,"threshold_uncertainty_score":0.9995775},"labels":[],"label_agreement":null},{"id":"W3213285350","doi":"10.1016/j.clml.2021.11.004","title":"Comparison of Outcomes After Second Allogeneic Hematopoietic Cell Transplantation Versus Donor Lymphocyte Infusion in Allogeneic Hematopoietic Cell Transplant Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hematopoietic Stem Cell Transplantation","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Donor lymphocyte infusion; Internal medicine; Univariate analysis; Hematopoietic cell; Transplantation; Gastroenterology; Hematopoietic stem cell transplantation; Graft-versus-host disease; Multivariate analysis; Haematopoiesis; Surgery; Stem cell","score_opus":0.028962404733564553,"score_gpt":0.32076222720420783,"score_spread":0.2917998224706433,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213285350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932292,0.0013084563,0.0003163669,0.00011414944,0.0011653553,0.0011274895,0.00020451084,0.00011196756,0.0024224764],"genre_scores_gemma":[0.99503225,0.0010840124,0.0016697665,0.0005002455,0.00009461204,0.00014286273,0.0009497853,0.00013851296,0.0003879416],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992152,0.00059540593,0.0038065498,0.0013628032,0.0011276996,0.0009555723],"domain_scores_gemma":[0.99545276,0.0017340236,0.00074007345,0.0010949635,0.00037287382,0.0006052933],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00073404197,0.0008328923,0.0023894303,0.00036905607,0.000110210625,0.000045535573,0.00040373194,0.00097581866,0.0008446138],"category_scores_gemma":[0.0001124634,0.0007996651,0.00089843647,0.0007264403,0.00032101228,0.00021504801,0.00007658502,0.0004581505,0.00025482837],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005816784,0.00255649,0.9614522,0.004288956,0.00017869845,0.0012880517,0.0037175375,0.000070663606,0.010373134,0.000032040967,0.00008063562,0.010144809],"study_design_scores_gemma":[0.026868185,0.0006895261,0.83684844,0.0008635311,0.00080359075,0.00014406329,0.00039435647,0.00013400956,0.1322701,0.00004391054,0.00027340383,0.0006668604],"about_ca_topic_score_codex":0.000064891734,"about_ca_topic_score_gemma":0.00033198946,"teacher_disagreement_score":0.12460373,"about_ca_system_score_codex":0.0008752474,"about_ca_system_score_gemma":0.001614497,"threshold_uncertainty_score":0.99944544},"labels":[],"label_agreement":null},{"id":"W3213290240","doi":"10.1016/s2152-2650(21)02148-0","title":"P-014: Disruption of chromosome territories in Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba","funders":"","keywords":"Lamin; Fluorescence in situ hybridization; Biology; Chromosome; Immunofluorescence; Western blot; Nuclear lamina; Genome instability; Molecular biology; In situ hybridization; Genetics; Gene; Nuclear protein; Gene expression; DNA; Antibody; DNA damage","score_opus":0.0182380406075895,"score_gpt":0.2848266532310725,"score_spread":0.266588612623483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213290240","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99711555,0.00047104296,0.00010932689,0.00009729699,0.001093516,0.00010518264,0.000032100797,0.00002000759,0.0009559803],"genre_scores_gemma":[0.9967557,0.00023732062,0.0009231378,0.0002615466,0.0010612534,0.000010751141,0.00031008985,0.000032992757,0.00040719903],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9981364,0.00016319721,0.00071231846,0.0005420976,0.00017436652,0.00027159232],"domain_scores_gemma":[0.99893594,0.000085743704,0.0001810414,0.0005525684,0.00013587323,0.00010886255],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024377518,0.00019501406,0.0003647493,0.000043419037,0.000058533948,0.000022011676,0.00018241434,0.00044931256,0.000060487804],"category_scores_gemma":[0.0006551216,0.00019314777,0.00023993007,0.00019078288,0.00021791492,0.000011941927,0.00017733146,0.00012542201,0.000026653597],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000537745,0.00017974032,0.1688852,0.00006077984,0.00008966878,0.00008835683,0.0000700474,0.000025263947,0.39673263,0.00036225896,0.0013879429,0.43158036],"study_design_scores_gemma":[0.0015415999,0.0002823927,0.86917126,0.00003769596,0.000020488154,0.00005981172,0.00007840091,0.00012105984,0.0839159,0.0002464328,0.04431086,0.00021408008],"about_ca_topic_score_codex":0.000072459174,"about_ca_topic_score_gemma":0.0003143285,"teacher_disagreement_score":0.7002861,"about_ca_system_score_codex":0.00009860578,"about_ca_system_score_gemma":0.00036067035,"threshold_uncertainty_score":0.7876337},"labels":[],"label_agreement":null},{"id":"W3213542315","doi":"10.1016/s2152-2650(21)02075-9","title":"OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Medicine; Lenalidomide; Internal medicine; Multiple myeloma; Daratumumab; Dexamethasone; Clinical endpoint; Hazard ratio; Interim analysis; Surgery; Gastroenterology; Oncology; Confidence interval; Randomized controlled trial","score_opus":0.04464540784505627,"score_gpt":0.3670065401425495,"score_spread":0.32236113229749325,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213542315","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9928766,0.0014368818,0.00010366181,0.00081305124,0.00035493987,0.0030619996,0.00046056838,0.00019324533,0.0006990819],"genre_scores_gemma":[0.99259645,0.001376936,0.0019386987,0.00014193344,0.0003646988,0.0006170393,0.0018004538,0.00014091963,0.0010228686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.992019,0.0013466579,0.0019063607,0.001932169,0.0014962621,0.0012995775],"domain_scores_gemma":[0.9933295,0.0031187837,0.00039542373,0.001530306,0.00037644623,0.0012495117],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013014423,0.00095265836,0.0021029292,0.00026059663,0.0003594107,0.00022036719,0.0003603329,0.00048144892,0.00017675293],"category_scores_gemma":[0.0015982949,0.00070865103,0.00032601636,0.0007325123,0.00043040342,0.0004128635,0.00020628843,0.00051770784,0.000064929234],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02744276,0.017492661,0.64784217,0.00012942035,0.0011217681,0.017065298,0.00048038116,0.000006859257,0.0021410908,0.000037530186,0.0008187165,0.28542134],"study_design_scores_gemma":[0.21696638,0.007873899,0.76640797,0.00037412698,0.00044913747,0.00028971996,0.0006348404,0.0015230165,0.003213789,0.00004794003,0.0015893637,0.0006298261],"about_ca_topic_score_codex":0.0019517548,"about_ca_topic_score_gemma":0.0049751224,"teacher_disagreement_score":0.2847915,"about_ca_system_score_codex":0.0014484419,"about_ca_system_score_gemma":0.0019242539,"threshold_uncertainty_score":0.99953645},"labels":[],"label_agreement":null},{"id":"W3213899689","doi":"10.1016/s2152-2650(21)02101-7","title":"OAB-027: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy, for the treatment of patients with relapsed and refractory multiple myeloma (RRMM): updated results from KarMMa","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lenalidomide; Pomalidomide; Fludarabine; Internal medicine; Bortezomib; Carfilzomib; Rituximab; Daratumumab; Regimen; Multiple myeloma; Refractory (planetary science); Clinical endpoint; Oncology; Cyclophosphamide; Gastroenterology; Surgery; Clinical trial; Chemotherapy; Lymphoma","score_opus":0.03591386775633376,"score_gpt":0.310774505472544,"score_spread":0.2748606377162102,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3213899689","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908775,0.0032405322,0.00003400752,0.00061422604,0.0004479277,0.0028764934,0.0010790719,0.00022152449,0.00060868246],"genre_scores_gemma":[0.9827449,0.0050521935,0.0022925076,0.0006732825,0.0005748494,0.00026900452,0.002379075,0.00021847348,0.0057957405],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9937177,0.00068668264,0.0020287773,0.0016431137,0.0010233179,0.0009004529],"domain_scores_gemma":[0.98888385,0.0062949415,0.0007393107,0.0021724412,0.0012417085,0.00066772127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008581199,0.0007418296,0.0016604593,0.00016004319,0.00032694652,0.00008827494,0.0004368392,0.0006578644,0.0004542765],"category_scores_gemma":[0.0012122812,0.0004920127,0.0006494287,0.00073070877,0.00076190056,0.00014968123,0.00015393179,0.00038959464,0.000040998388],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.074666865,0.004920714,0.07622638,0.00006924595,0.0020620592,0.00035075203,0.0012070349,0.000011081304,0.0772812,0.0000047654416,0.004443677,0.7587562],"study_design_scores_gemma":[0.07930446,0.006063672,0.7344058,0.0001340962,0.00043389824,0.00001487657,0.00023787346,0.0013025197,0.062352937,0.00003681131,0.115247406,0.0004656463],"about_ca_topic_score_codex":0.00084503146,"about_ca_topic_score_gemma":0.00027638656,"teacher_disagreement_score":0.7582906,"about_ca_system_score_codex":0.001127131,"about_ca_system_score_gemma":0.0022031183,"threshold_uncertainty_score":0.9997532},"labels":[],"label_agreement":null},{"id":"W3214080616","doi":"10.1016/s2152-2650(21)01925-x","title":"TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Brentuximab vedotin; Internal medicine; Prednisone; Vincristine; CHOP; Clinical endpoint; Progression-free survival; Anaplastic large-cell lymphoma; Cyclophosphamide; Phases of clinical research; Gastroenterology; Oncology; Surgery; Lymphoma; Randomized controlled trial; Chemotherapy; CD30","score_opus":0.04101108403857088,"score_gpt":0.34309924268759184,"score_spread":0.30208815864902094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214080616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911904,0.0012189688,0.0000024285664,0.00022617847,0.0004150498,0.005732842,0.0002807736,0.00002762032,0.0009057466],"genre_scores_gemma":[0.99731266,0.0009136526,0.0003263685,0.00004941944,0.00018276382,0.0006177683,0.00034180091,0.000066312015,0.00018922749],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99362093,0.00097488676,0.002947915,0.0010710708,0.000882162,0.0005030623],"domain_scores_gemma":[0.99317914,0.0031787679,0.0014734747,0.0011742418,0.0006777153,0.0003166419],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010702693,0.00064986886,0.0034794742,0.00018951317,0.000096147334,0.000032195774,0.000237148,0.0003379114,0.00003975782],"category_scores_gemma":[0.00063636503,0.00039920802,0.0007470099,0.0005975474,0.0007283023,0.00011764178,0.00016189551,0.00012192814,0.0000053165654],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.78091884,0.059635326,0.06459223,0.000067240915,0.0018208437,0.00028325856,0.0016931721,0.0000099386425,0.000019875519,0.000029891471,0.00004925335,0.090880126],"study_design_scores_gemma":[0.6130716,0.019981973,0.36134672,0.00020773766,0.0016308663,0.000008479778,0.00091454055,0.00009729744,0.0024028043,0.0000054502752,0.00012522956,0.00020727277],"about_ca_topic_score_codex":0.0015222261,"about_ca_topic_score_gemma":0.0003837023,"teacher_disagreement_score":0.29675448,"about_ca_system_score_codex":0.001258916,"about_ca_system_score_gemma":0.0017341753,"threshold_uncertainty_score":0.999846},"labels":[],"label_agreement":null},{"id":"W3214339588","doi":"10.1016/s2152-2650(21)02153-4","title":"P-019: Real-world treatment patterns, clinical outcomes, and healthcare resource utilization of individuals with light chain (AL) amyloidosis in Alberta, Canada: a population-based study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Population; Amyloidosis; Comorbidity; Health care; AL amyloidosis; Intensive care medicine; Internal medicine; Immunoglobulin light chain","score_opus":0.02880243841736477,"score_gpt":0.3346546945162651,"score_spread":0.3058522560989003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3214339588","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9951563,0.00036576387,0.000009036718,0.0030901118,0.00015179884,0.00096039067,0.00016928636,0.00002047832,0.00007686591],"genre_scores_gemma":[0.99421084,0.00061040325,0.00030431946,0.002857992,0.00010597568,0.000216721,0.0011430959,0.0000774038,0.00047323803],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9945113,0.0011955928,0.0019922275,0.0013191353,0.00046742355,0.00051430013],"domain_scores_gemma":[0.99635124,0.0012562169,0.0007291192,0.0011036935,0.00016816838,0.00039155586],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00066482805,0.0005393192,0.0013016381,0.00013598558,0.00012687055,0.000037157788,0.00026211017,0.00036099937,0.000020757898],"category_scores_gemma":[0.0007066915,0.00044758106,0.0002823732,0.00042222935,0.00009776281,0.000012446924,0.00017841117,0.00015709638,0.0000020978696],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0002947807,0.0012835885,0.9514294,0.00003757191,0.00046483253,0.000102328304,0.000069195215,0.00004155481,0.000008164262,0.000028772854,0.00036907487,0.04587073],"study_design_scores_gemma":[0.0077324477,0.0014011317,0.9839245,0.00012579458,0.00021022078,0.0000054390475,0.00032439787,0.000051851308,0.0008690523,0.000005811394,0.0049343114,0.00041505895],"about_ca_topic_score_codex":0.49290588,"about_ca_topic_score_gemma":0.94059706,"teacher_disagreement_score":0.44769117,"about_ca_system_score_codex":0.00080401055,"about_ca_system_score_gemma":0.0031573367,"threshold_uncertainty_score":0.9997976},"labels":[],"label_agreement":null},{"id":"W4200053736","doi":"10.1016/s2152-2650(21)01829-2","title":"MPN-303: Longitudinal and Individual Symptom Analyses from the SIMPLIFY-1 Study Demonstrate Clinically Comparable Symptomatic Benefit of Momelotinib to Ruxolitinib in JAK Inhibitor-Naive Myelofibrosis Patients","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital; University of Toronto; University of British Columbia; University Health Network","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Internal medicine; Longitudinal study; Oncology; Pathology; Bone marrow","score_opus":0.08829957035055626,"score_gpt":0.3818298745004986,"score_spread":0.29353030414994236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200053736","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99499923,0.0004909872,0.0000129266455,0.0009201717,0.00034939367,0.002289132,0.0004803121,0.00006885146,0.0003889786],"genre_scores_gemma":[0.9951671,0.00021664,0.0017141977,0.0016299579,0.00034656908,0.00038303508,0.0004085782,0.00007321564,0.000060725175],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9917378,0.00087237364,0.0037826519,0.0016252227,0.0011542917,0.00082766835],"domain_scores_gemma":[0.9888859,0.0075018173,0.0008450448,0.0012104592,0.00075269246,0.0008041124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013426103,0.00075460214,0.0025867734,0.00021139746,0.0002652718,0.00017461347,0.00046125925,0.00042634475,0.0001531511],"category_scores_gemma":[0.0025834555,0.00055655546,0.0005476512,0.0010704106,0.00048871123,0.00019496761,0.0006778902,0.00050205673,0.00009719358],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001040876,0.004759716,0.92462534,0.00006123743,0.0013853606,0.00023712186,0.0009174338,0.000033799843,0.000094236246,0.0001041246,0.0005229962,0.06621776],"study_design_scores_gemma":[0.01343458,0.0037946347,0.9762831,0.0008608659,0.0012883398,0.000028066266,0.0014332248,0.00020145059,0.0017092195,0.00033160998,0.00014475537,0.0004901939],"about_ca_topic_score_codex":0.0009810259,"about_ca_topic_score_gemma":0.00070467696,"teacher_disagreement_score":0.06572756,"about_ca_system_score_codex":0.00047067582,"about_ca_system_score_gemma":0.0012201287,"threshold_uncertainty_score":0.99968857},"labels":[],"label_agreement":null},{"id":"W4200201152","doi":"10.1016/s2152-2650(21)01530-5","title":"Poster: ABCL-274: Outcomes in Patients with Lymphoproliferative Diseases and COVID-19: Results of a Subgroup Analysis of the CHRONOS19 Registry","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Liver Disease Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Coronavirus disease 2019 (COVID-19); 2019-20 coronavirus outbreak; Subgroup analysis; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Virology; Internal medicine; Disease; Outbreak","score_opus":0.016989429145578435,"score_gpt":0.30768861852860774,"score_spread":0.2906991893830293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200201152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9961255,0.00055492105,0.0000025284028,0.0012749286,0.00006837344,0.00053304934,0.0012013086,0.000016998672,0.00022235469],"genre_scores_gemma":[0.99772865,0.00014489928,0.000057008554,0.0014595627,0.000030228946,0.000043135413,0.00040652716,0.000019287456,0.00011068178],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99706733,0.00031888514,0.0011857533,0.00066234416,0.0005148041,0.0002508552],"domain_scores_gemma":[0.9963731,0.0012726432,0.0005804093,0.0009906142,0.00029336757,0.00048986403],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00022058241,0.0002768696,0.001319297,0.00014674969,0.0000643053,0.000019281346,0.00016453127,0.00015531434,0.00003561807],"category_scores_gemma":[0.0019422177,0.00016488381,0.00054975296,0.000860583,0.00055085786,0.00008080281,0.00018444708,0.00008498946,0.000001790284],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003311405,0.0024169413,0.9819741,0.00014710057,0.0028702696,0.00017052195,0.0003065927,0.000021723761,0.0000024233673,0.000058506695,0.00018063419,0.008539776],"study_design_scores_gemma":[0.020114547,0.00058679795,0.97426987,0.00021960706,0.004117145,0.000004317583,0.00016637066,0.00009134005,0.00013999826,0.00003273608,0.00009572491,0.00016153074],"about_ca_topic_score_codex":0.00045289227,"about_ca_topic_score_gemma":0.00024639873,"teacher_disagreement_score":0.016803142,"about_ca_system_score_codex":0.0007238378,"about_ca_system_score_gemma":0.002477821,"threshold_uncertainty_score":0.6723767},"labels":[],"label_agreement":null},{"id":"W4200328156","doi":"10.1016/s2152-2650(21)01578-0","title":"Poster: MM-379: MagnetisMM-1: A Study of Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA)-Targeted, CD3-Engaging Bispecific Antibody, for Patients with Relapsed or Refractory Multiple Myeloma (MM)","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; McGill University Health Centre; Alberta Cancer Foundation; University of Calgary","funders":"","keywords":"Bispecific antibody; Refractory (planetary science); Medicine; CD3; Antigen; Antibody; Multiple myeloma; Daratumumab; Immunology; Monoclonal antibody; Materials science; CD8","score_opus":0.03499639870044778,"score_gpt":0.33360450492688143,"score_spread":0.29860810622643363,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200328156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919504,0.00083989097,0.00015654767,0.00021042673,0.0006395339,0.004891253,0.0004752986,0.00021650369,0.0006201817],"genre_scores_gemma":[0.9884838,0.00043327684,0.005332775,0.00027545978,0.00041301586,0.00029899622,0.0029178625,0.00023424749,0.0016105875],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915864,0.00093542127,0.0025163195,0.0019635695,0.0016538847,0.0013443945],"domain_scores_gemma":[0.9916145,0.0027599768,0.0009870277,0.0019634224,0.0017245766,0.000950498],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009856998,0.00091569865,0.0020185048,0.00046649456,0.0005479834,0.00015559173,0.00055586756,0.0006195679,0.00033596868],"category_scores_gemma":[0.002938611,0.0007013663,0.00062272936,0.0011111726,0.0003942661,0.00052770623,0.00036074006,0.0007281981,0.00013073892],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.041396003,0.0134903,0.67762434,0.00067623437,0.0012432922,0.002493041,0.00083944073,0.000006527218,0.0070761847,0.000009520892,0.0014646677,0.2536804],"study_design_scores_gemma":[0.07421188,0.013305246,0.90045583,0.0005434686,0.0004948585,0.00010171238,0.0012757146,0.0010584794,0.0038875262,0.00001750187,0.003949184,0.0006985776],"about_ca_topic_score_codex":0.00027842613,"about_ca_topic_score_gemma":0.00031398295,"teacher_disagreement_score":0.25298184,"about_ca_system_score_codex":0.0009476902,"about_ca_system_score_gemma":0.0024911223,"threshold_uncertainty_score":0.9995437},"labels":[],"label_agreement":null},{"id":"W4200378581","doi":"10.1016/j.clml.2021.12.016","title":"Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pharmacyclics; MorphoSys; Genentech; AstraZeneca; Celgene; Gilead Sciences; Astellas Pharma; F. Hoffmann-La Roche; Amgen","keywords":"Medicine; Internal medicine; Oncology; Refractory (planetary science); Chemoimmunotherapy; Diffuse large B-cell lymphoma; Adverse effect; Population; Nausea; Lymphoma; Gastroenterology; Rituximab","score_opus":0.01333812479618569,"score_gpt":0.29545439313857635,"score_spread":0.2821162683423907,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200378581","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9969879,0.00064516376,5.5892644e-7,0.00029553316,0.000085829,0.0017557772,0.00018496325,0.000013080476,0.00003121304],"genre_scores_gemma":[0.9991072,0.00031180526,0.000027163684,0.00032893452,0.000030627445,0.00006222348,0.00006252583,0.000035418754,0.000034145727],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960728,0.0010312482,0.0012187519,0.0006717788,0.0006905136,0.00031485423],"domain_scores_gemma":[0.9939431,0.0036384247,0.0005951858,0.0011787526,0.00035052368,0.00029400553],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009796771,0.00040206697,0.0015557237,0.00014820579,0.000102128106,0.000019051526,0.00022455849,0.00014829838,0.000019003302],"category_scores_gemma":[0.0012327303,0.00019088246,0.00041097938,0.0010416149,0.00035491146,0.000058830894,0.00022952832,0.000113355505,0.0000010724107],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029082589,0.025021968,0.79385537,0.00009639066,0.0014583827,0.000075813536,0.00030124997,0.000002755256,0.000027980695,0.000032593765,0.000013750223,0.15003115],"study_design_scores_gemma":[0.11113294,0.007407922,0.8775574,0.00024943822,0.0025118582,0.0000022202257,0.000115583076,0.00011680732,0.0006441463,0.0000030831814,0.00010000991,0.00015862416],"about_ca_topic_score_codex":0.00016875053,"about_ca_topic_score_gemma":0.00009480126,"teacher_disagreement_score":0.14987253,"about_ca_system_score_codex":0.00028306743,"about_ca_system_score_gemma":0.00082075445,"threshold_uncertainty_score":0.77839607},"labels":[],"label_agreement":null},{"id":"W4200532097","doi":"10.1016/s2152-2650(21)01625-6","title":"Poster: CT-423: Neuropsychiatric Disorders in Hospitalized Patients Undergoing Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Chimeric antigen receptor; Medicine; Multiple myeloma; Oncology; Cancer research; Immunotherapy; Internal medicine; Cancer","score_opus":0.016431627211519938,"score_gpt":0.2961186559334963,"score_spread":0.27968702872197637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200532097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98835856,0.0027579356,0.00006741676,0.0014421401,0.0025656035,0.0025079763,0.00008452936,0.0002007767,0.0020150936],"genre_scores_gemma":[0.9846628,0.010028065,0.0009066502,0.0024610541,0.0005035509,0.00027220338,0.00034860868,0.0001753984,0.0006416745],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9950986,0.00037363818,0.0016685358,0.0013707901,0.0005251824,0.00096326676],"domain_scores_gemma":[0.9960932,0.0018956081,0.0005272827,0.000707334,0.0004062033,0.00037035072],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0004163599,0.000627123,0.0012521973,0.00026167874,0.0002757646,0.00005983882,0.0002846209,0.00026562033,0.00011385493],"category_scores_gemma":[0.0021289529,0.00060457614,0.0008067408,0.0011526492,0.0003016929,0.00020102774,0.00022459686,0.0003895541,0.00015531047],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0021970926,0.001471854,0.69040805,0.00011823735,0.00023137323,0.000037985872,0.000124298,0.0000036702409,0.00022199938,0.0000047256917,0.0026769103,0.30250382],"study_design_scores_gemma":[0.042761974,0.002793495,0.93724024,0.00028606656,0.00012132245,0.000012668688,0.0001512901,0.00018228634,0.0006988585,0.00011883512,0.015014801,0.0006181345],"about_ca_topic_score_codex":0.00007412454,"about_ca_topic_score_gemma":0.00016549812,"teacher_disagreement_score":0.3018857,"about_ca_system_score_codex":0.00085141824,"about_ca_system_score_gemma":0.0015076986,"threshold_uncertainty_score":0.9996406},"labels":[],"label_agreement":null},{"id":"W4200579559","doi":"10.1016/s2152-2650(21)01540-8","title":"Poster: IBCL-373: Updated Experience from Mosunetuzumab in Multiple Relapsed Follicular Lymphoma: Promising Efficacy from a Phase I Trial","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; Jewish General Hospital","funders":"","keywords":"Follicular lymphoma; Follicular phase; Medicine; Oncology; Internal medicine; Lymphoma; Medical physics","score_opus":0.052081749084664515,"score_gpt":0.3529540528641047,"score_spread":0.3008723037794402,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4200579559","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916086,0.0024976623,0.000028023007,0.00072495895,0.0017519572,0.0020799267,0.00033679308,0.00033466867,0.0006373926],"genre_scores_gemma":[0.9900986,0.00034023236,0.0023288638,0.0018100558,0.0013007164,0.00041291866,0.0032989637,0.00014974983,0.0002599001],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99146456,0.00079523394,0.0030778134,0.0024853197,0.0010272503,0.0011498175],"domain_scores_gemma":[0.99298406,0.0028563035,0.0006601936,0.0021794601,0.00029605537,0.001023915],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00054629997,0.00094104785,0.0024489625,0.00019327614,0.00028201417,0.00023597301,0.00053378363,0.0010246718,0.00076248],"category_scores_gemma":[0.0031362593,0.0008497637,0.0011676613,0.00096151937,0.00042749828,0.0003668361,0.00044212438,0.00033196877,0.00050434953],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08327125,0.022204762,0.13186967,0.000034283545,0.0013378437,0.023058234,0.0018928288,0.00001155755,0.0068025608,0.000053343898,0.0023924946,0.72707117],"study_design_scores_gemma":[0.3882185,0.0012215738,0.57824457,0.00054405245,0.00050579675,0.00011861883,0.00027435485,0.0017037297,0.01861993,0.00013754987,0.009738466,0.0006728931],"about_ca_topic_score_codex":0.0030666683,"about_ca_topic_score_gemma":0.00023035839,"teacher_disagreement_score":0.7263983,"about_ca_system_score_codex":0.0034059535,"about_ca_system_score_gemma":0.0035517723,"threshold_uncertainty_score":0.9993953},"labels":[],"label_agreement":null},{"id":"W4206027642","doi":"10.1016/j.clml.2022.01.004","title":"Granulomatous Myositis as a Manifestation of Chronic Graft-Versus-Host Disease: A Case Series and Review of the Literature","year":2022,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Inflammatory Myopathies and Dermatomyositis","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Royal Columbian Hospital; Vancouver General Hospital","funders":"","keywords":"Myositis; Medicine; Host (biology); Dermatology; Graft-versus-host disease; Disease; Series (stratigraphy); Pathology; Biology","score_opus":0.02876218896861643,"score_gpt":0.3446816956025472,"score_spread":0.31591950663393076,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4206027642","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0062754233,0.98904425,7.156254e-7,0.00020576055,0.0009823109,0.0022207038,0.0006937921,0.000065269385,0.00051176065],"genre_scores_gemma":[0.0007239571,0.997007,0.000052707266,0.0005488842,0.00043307987,0.00028304366,0.000512652,0.00011660941,0.0003220722],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9940807,0.001090059,0.002873296,0.0007890417,0.00074532116,0.0004215689],"domain_scores_gemma":[0.9947714,0.0011612237,0.0018946335,0.0014926678,0.00026097012,0.00041909207],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000922302,0.000718588,0.0035572127,0.00016666838,0.00028154542,0.00004245811,0.0003996225,0.0005162816,0.0003098652],"category_scores_gemma":[0.0013557195,0.00050592376,0.0019279656,0.00088877074,0.0007400501,0.00018104659,0.0005190977,0.00072354265,0.000019340945],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00037019415,0.00008165157,0.000034744262,0.26247233,0.00032390453,0.016623234,0.000073441544,3.544605e-8,2.7514514e-7,0.0007054723,0.0017244851,0.7175902],"study_design_scores_gemma":[0.0016374134,0.00068268424,0.002149504,0.18767495,0.004125288,0.0669134,0.000036496553,0.0000048352576,0.000001541798,0.0000504119,0.7363302,0.0003932627],"about_ca_topic_score_codex":0.00003980159,"about_ca_topic_score_gemma":0.00001204323,"teacher_disagreement_score":0.7346057,"about_ca_system_score_codex":0.0009279123,"about_ca_system_score_gemma":0.0048713544,"threshold_uncertainty_score":0.9997392},"labels":[],"label_agreement":null},{"id":"W4214599468","doi":"10.1016/j.clml.2019.09.215","title":"TAZ functions as a tumour suppressor in multiple myeloma by downregulating MYC","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Hippo pathway signaling and YAP/TAZ","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Atlantic Cancer Research Institute; University of New Brunswick","funders":"","keywords":"Cancer research; Hippo signaling pathway; Oncogene; Transcription factor; Biology; YAP1; Downregulation and upregulation; Bortezomib; Carcinogenesis; Gene knockdown; Apoptosis; Cancer; Signal transduction; Multiple myeloma; Cell cycle; Cell biology; Gene; Immunology; Genetics","score_opus":0.015978107794341466,"score_gpt":0.2758703009154403,"score_spread":0.25989219312109885,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214599468","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935637,0.0005527648,0.00016336587,0.00017008182,0.00074355426,0.00046031587,0.000112241316,0.00009063991,0.0041433256],"genre_scores_gemma":[0.9910046,0.00004413083,0.000489722,0.0007899844,0.00064816244,0.00007420009,0.0005700109,0.00009139291,0.006287795],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.99611706,0.00036330076,0.0011737385,0.0012131705,0.0003378754,0.00079488434],"domain_scores_gemma":[0.9978749,0.00037723753,0.000305811,0.000939461,0.00013736988,0.00036519562],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008905394,0.00045269052,0.0006302783,0.00009898325,0.00017889227,0.00007985852,0.00054353557,0.00077836076,0.00023471836],"category_scores_gemma":[0.0011716296,0.000447746,0.00044003804,0.00028875828,0.00022813147,0.000019602603,0.00029972274,0.00033859684,0.0012157541],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00045921898,0.0002137068,0.036534715,0.000032996642,0.00008294302,0.000037007143,0.000062310566,0.00021531865,0.90931666,0.0000447362,0.0032780594,0.049722325],"study_design_scores_gemma":[0.009631579,0.0017243745,0.5703325,0.0002396187,0.00008023769,0.00015891728,0.00040870384,0.004238756,0.2782126,0.0002581662,0.13316624,0.0015482642],"about_ca_topic_score_codex":0.00022243513,"about_ca_topic_score_gemma":0.0000813838,"teacher_disagreement_score":0.63110405,"about_ca_system_score_codex":0.00018558119,"about_ca_system_score_gemma":0.00068072317,"threshold_uncertainty_score":0.9997974},"labels":[],"label_agreement":null},{"id":"W4214747639","doi":"10.1016/s2152-2650(21)01485-3","title":"Poster: HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Stage (stratigraphy); Medicine; Oncology; Internal medicine; Hodgkin lymphoma; Chemotherapy; Lymphoma; Biology","score_opus":0.015252845093914086,"score_gpt":0.287328684901338,"score_spread":0.2720758398074239,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214747639","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99339724,0.00022284227,0.00002845521,0.00120534,0.00030122045,0.0039115637,0.00019854248,0.00013660161,0.00059819064],"genre_scores_gemma":[0.9949804,0.00013433001,0.0010786195,0.0014523475,0.00022829091,0.0003774005,0.0003323958,0.00017129237,0.0012449541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434793,0.00045285936,0.0016689015,0.0014635245,0.0010897608,0.0009770183],"domain_scores_gemma":[0.9948513,0.00092033716,0.0008543338,0.0019165324,0.0009370106,0.0005204732],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000589546,0.00080538925,0.0018943714,0.00010110515,0.00028735117,0.000099555175,0.0005107098,0.00041161058,0.00014091367],"category_scores_gemma":[0.00034135647,0.0004701972,0.0006841268,0.00076654996,0.00057855493,0.00016025537,0.00028796095,0.00019871925,0.000043156906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011478547,0.014808476,0.81875044,0.00013501852,0.0018231827,0.00030278804,0.00032999806,0.0000034432067,0.00002661447,0.00014840931,0.0012763169,0.15091679],"study_design_scores_gemma":[0.108194724,0.008080298,0.87392986,0.00049543945,0.0012592048,0.000067923815,0.00029769397,0.00007345575,0.0026862503,0.000025560497,0.004397771,0.0004918068],"about_ca_topic_score_codex":0.00015792316,"about_ca_topic_score_gemma":0.00020008718,"teacher_disagreement_score":0.15042497,"about_ca_system_score_codex":0.0014442188,"about_ca_system_score_gemma":0.0032869913,"threshold_uncertainty_score":0.999775},"labels":[],"label_agreement":null},{"id":"W4214752487","doi":"10.1016/s2152-2650(21)01456-7","title":"Poster: MPN-356: Transfusion Independence is Associated with Improved Overall Survival in Myelofibrosis Patients Receiving Momelotinib","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Sierra Wireless (Canada); Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Medicine; Independence (probability theory); Internal medicine; Oncology; Statistics","score_opus":0.022652808920628105,"score_gpt":0.28902741310178715,"score_spread":0.26637460418115905,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4214752487","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99284935,0.00025772507,0.000023149392,0.0006330121,0.0008184409,0.0011230153,0.000110319175,0.00025212578,0.003932867],"genre_scores_gemma":[0.99346876,0.0005434907,0.0006181322,0.0019905844,0.00025565806,0.00008655013,0.0006189613,0.0001864216,0.0022314398],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99234164,0.00068531645,0.0022109528,0.0019680965,0.0014741167,0.0013198814],"domain_scores_gemma":[0.9948905,0.001533962,0.00062665896,0.001379909,0.00080623094,0.0007627214],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011800734,0.0008527955,0.0019527043,0.00024173866,0.00021187522,0.000115077106,0.00044559556,0.0011937645,0.00052846014],"category_scores_gemma":[0.0024793716,0.0007631235,0.00060100644,0.0011596623,0.00030643572,0.0004375177,0.00032073059,0.0009922256,0.00015557668],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002359454,0.0016675817,0.79531217,0.00011327798,0.00052876107,0.0011617193,0.0005387781,0.0000047227268,0.0019470784,0.000013523762,0.00041235995,0.19594057],"study_design_scores_gemma":[0.03718366,0.0016776555,0.95273185,0.0014909431,0.00034575307,0.00011622945,0.000098639626,0.000660267,0.0043320428,0.000068210524,0.0005371064,0.00075761875],"about_ca_topic_score_codex":0.00079597614,"about_ca_topic_score_gemma":0.0012608048,"teacher_disagreement_score":0.19518295,"about_ca_system_score_codex":0.0071831625,"about_ca_system_score_gemma":0.0053526885,"threshold_uncertainty_score":0.999482},"labels":[],"label_agreement":null},{"id":"W4221035698","doi":"10.1016/j.clml.2022.03.002","title":"Survival and Outcomes of Newly Diagnosed Multiple Myeloma Patients Stratified by Transplant Status 2007-2018: Retrospective Analysis from the Canadian Myeloma Research Group Database","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Ottawa Regional Cancer Foundation; University of Calgary; Vancouver General Hospital; Princess Margaret Cancer Centre; Saint John Regional Hospital; BC Cancer Agency; McGill University; Juravinski Cancer Centre","funders":"Janssen Pharmaceuticals","keywords":"Medicine; Multiple myeloma; Bortezomib; Lenalidomide; Cohort; Internal medicine; Retrospective cohort study; Oncology; Autologous stem-cell transplantation; Database","score_opus":0.05144154557177737,"score_gpt":0.3483073221873166,"score_spread":0.2968657766155392,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4221035698","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9774237,0.00066248403,0.0000266266,0.0007907833,0.00047895228,0.0019727156,0.017673489,0.00006961026,0.00090161496],"genre_scores_gemma":[0.98825234,0.00041277095,0.00044595497,0.0004117786,0.00020014503,0.0003454787,0.009458439,0.00009623941,0.0003768634],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98921174,0.002430528,0.0017870971,0.0016844259,0.00302934,0.0018568751],"domain_scores_gemma":[0.9882721,0.006673693,0.0004405797,0.0018910896,0.0005947568,0.0021278276],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003175808,0.0006465176,0.0018574195,0.00062927743,0.0016074721,0.00015575546,0.0008816173,0.00036343624,0.0009781143],"category_scores_gemma":[0.0035760615,0.00049329933,0.00070089026,0.0019627414,0.0012933916,0.00025349358,0.00053264975,0.001354561,0.0000525679],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0029080831,0.0010705232,0.932501,0.000028214534,0.003534869,0.0006549067,0.00050708686,0.000005050842,0.00016117342,0.00012950425,0.0067261276,0.05177347],"study_design_scores_gemma":[0.016433338,0.0015481564,0.9745608,0.00004612862,0.0009547348,0.000006758093,0.0009250251,0.0012864171,0.00012308142,0.000111679845,0.0035699385,0.00043396148],"about_ca_topic_score_codex":0.39644977,"about_ca_topic_score_gemma":0.37879753,"teacher_disagreement_score":0.051339507,"about_ca_system_score_codex":0.0036164222,"about_ca_system_score_gemma":0.003051506,"threshold_uncertainty_score":0.99993515},"labels":[],"label_agreement":null},{"id":"W4223929697","doi":"10.1016/j.clml.2022.04.010","title":"Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Internal medicine; Vincristine; Oncology; Rituximab; Prednisone; Lymphoma; Cyclophosphamide; B symptoms; Diffuse large B-cell lymphoma; Gastroenterology; Chemotherapy","score_opus":0.03097032527377933,"score_gpt":0.33002867521397455,"score_spread":0.2990583499401952,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4223929697","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98707086,0.0014094417,0.000050501865,0.005476139,0.001288558,0.0024632127,0.0017436645,0.00016707036,0.00033056678],"genre_scores_gemma":[0.9814336,0.00012872073,0.003472951,0.008600062,0.0012158527,0.0019464408,0.0011040393,0.0001335727,0.0019648117],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9943883,0.00034647537,0.0021784236,0.0015171125,0.0007177988,0.00085191615],"domain_scores_gemma":[0.99486405,0.0025309029,0.0004436306,0.0013237182,0.00023687929,0.00060081336],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015826981,0.00056891434,0.0015503886,0.00024482282,0.00025606412,0.000065797496,0.00044339857,0.0002068039,0.00052978174],"category_scores_gemma":[0.0027121103,0.0005160976,0.00071198045,0.00079534197,0.00011355961,0.00011907755,0.0003496586,0.00029967361,0.00025560413],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016826697,0.0059759365,0.23330729,0.000051516592,0.00072202826,0.0010885238,0.0007913133,0.00005508233,0.00083678024,0.00013550752,0.035462305,0.704747],"study_design_scores_gemma":[0.028187655,0.0015858179,0.77514714,0.00011236301,0.00025975655,0.000090576155,0.00013593842,0.0014992286,0.0015008864,0.00013552676,0.190906,0.0004391021],"about_ca_topic_score_codex":0.0017629523,"about_ca_topic_score_gemma":0.000042070715,"teacher_disagreement_score":0.7043079,"about_ca_system_score_codex":0.002019446,"about_ca_system_score_gemma":0.0016707475,"threshold_uncertainty_score":0.99972904},"labels":[],"label_agreement":null},{"id":"W4225130992","doi":"10.1016/j.clml.2022.04.011","title":"Predicting the Risks of Aggressive-Intent Chemotherapy Toxicity in Older Patients With Lymphoma: A Prospective Observational Pilot Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Frailty in Older Adults","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"Princess Margaret Cancer Foundation","keywords":"Medicine; Internal medicine; Geriatric oncology; Prospective cohort study; Cancer","score_opus":0.0758603787867388,"score_gpt":0.3493106045989104,"score_spread":0.2734502258121716,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225130992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454,0.00009204444,0.000018746303,0.00074084406,0.0003911123,0.0036370195,0.00007847273,0.00009435456,0.0004074364],"genre_scores_gemma":[0.9969942,0.000012651757,0.00025271726,0.0014404551,0.0002208707,0.0006695253,0.000070595765,0.000077529316,0.00026148322],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.994977,0.00056996994,0.0015660506,0.00089015614,0.0014776341,0.00051919685],"domain_scores_gemma":[0.99569196,0.0012853072,0.0013877747,0.0009109991,0.00052897865,0.00019499312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013079055,0.00039860833,0.00093199976,0.0001386925,0.00031720148,0.000025003761,0.00056442496,0.00009969026,0.00020066135],"category_scores_gemma":[0.0019419665,0.0002797225,0.0001967381,0.00086356903,0.00046846445,0.00014327327,0.0004194098,0.0005026457,0.000009109337],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0061117555,0.0098902695,0.92210764,0.000038147176,0.00033485744,0.00011318891,0.0017672913,0.000101976075,0.000022489356,0.000037405523,0.00043171606,0.059043277],"study_design_scores_gemma":[0.03395646,0.012233546,0.9502605,0.0002459015,0.00013526856,0.00004694301,0.0014506221,0.0010864963,0.000104643914,0.00011680757,0.00009095741,0.00027185],"about_ca_topic_score_codex":0.0007735903,"about_ca_topic_score_gemma":0.00019079575,"teacher_disagreement_score":0.058771428,"about_ca_system_score_codex":0.0021916637,"about_ca_system_score_gemma":0.0013649877,"threshold_uncertainty_score":0.9999655},"labels":[],"label_agreement":null},{"id":"W4225273169","doi":"10.1016/j.clml.2022.03.014","title":"Patient characteristics, treatment patterns, and outcomes among black and white patients with multiple myeloma initiating daratumumab: A real-world chart review study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Weill Cornell Medical College; Janssen Scientific Affairs","keywords":"Medicine; Daratumumab; Multiple myeloma; Chart; Oncology; Internal medicine; Bortezomib; Statistics","score_opus":0.03021988995951118,"score_gpt":0.32775632858393355,"score_spread":0.29753643862442236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225273169","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99321294,0.0003394789,0.0000020111122,0.00028746814,0.00017694785,0.0048163054,0.0004972688,0.0001417689,0.0005257872],"genre_scores_gemma":[0.99392605,0.0023236144,0.00018563202,0.0009677736,0.00012083463,0.00094961515,0.00087442296,0.00012286077,0.00052921],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99400896,0.00081641186,0.0017192661,0.001411611,0.0011592817,0.000884453],"domain_scores_gemma":[0.9961061,0.00088268466,0.00072401296,0.0010371488,0.00026850184,0.0009815868],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006669191,0.0007719619,0.001928165,0.00026083682,0.0007072816,0.00010251201,0.00020089511,0.00011161777,0.00022677999],"category_scores_gemma":[0.00063190906,0.0005645856,0.00026477006,0.00040797488,0.0004076069,0.0002206457,0.0006583599,0.000450773,0.00003086911],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011607883,0.0022054915,0.7238695,0.00036725454,0.0006452617,0.00082975696,0.0004727371,3.2866186e-7,6.279111e-7,0.0000020466646,0.00018463626,0.27026156],"study_design_scores_gemma":[0.01983767,0.0088358335,0.96719897,0.00082858204,0.00060691696,0.000034366236,0.00054096116,0.0003604376,0.0000044110025,0.0000028985653,0.0012275117,0.00052143284],"about_ca_topic_score_codex":0.0012521818,"about_ca_topic_score_gemma":0.0008287088,"teacher_disagreement_score":0.26974013,"about_ca_system_score_codex":0.0014059605,"about_ca_system_score_gemma":0.0004475953,"threshold_uncertainty_score":0.9996806},"labels":[],"label_agreement":null},{"id":"W4225299329","doi":"10.1016/j.clml.2022.04.023","title":"Patient Preferences for Benefits, Risks, and Administration Route of Hypomethylating Agents in Myelodysplastic Syndromes","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Myelodysplastic syndromes; International Prognostic Scoring System; Duration (music); Family medicine; Demography; Internal medicine","score_opus":0.12889227360627842,"score_gpt":0.38700451483447024,"score_spread":0.2581122412281918,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225299329","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964734,0.00072338665,0.000047183115,0.00028401846,0.00029544014,0.001334292,0.00022869755,0.000051080126,0.0005625317],"genre_scores_gemma":[0.9948604,0.00026322124,0.003716023,0.0002409776,0.0001162861,0.0003932204,0.00020890715,0.00005179088,0.00014914628],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99586153,0.00038506993,0.0016534255,0.0007797004,0.0007449117,0.00057535816],"domain_scores_gemma":[0.99588174,0.0026042324,0.0005252234,0.00047306743,0.00018394303,0.00033179024],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015351927,0.00030070098,0.0009303559,0.00033468998,0.00022735374,0.000032578635,0.00027311002,0.0002284152,0.000121354446],"category_scores_gemma":[0.0027062604,0.00028766788,0.00022584388,0.0005974436,0.0002816905,0.00014369338,0.0004643319,0.00047106575,0.00000744285],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024119692,0.0004127898,0.28939274,0.00029968095,0.00015788888,0.00013167963,0.00031562563,0.00016701233,0.00026018036,0.0005184391,0.00052176806,0.70541024],"study_design_scores_gemma":[0.00543732,0.004683322,0.97955143,0.00018491953,0.000117503114,0.0001985239,0.0006939173,0.0061088786,0.00047396103,0.00077460275,0.0015055877,0.00027002403],"about_ca_topic_score_codex":0.00022224849,"about_ca_topic_score_gemma":0.000041570773,"teacher_disagreement_score":0.70514023,"about_ca_system_score_codex":0.0013290482,"about_ca_system_score_gemma":0.0022345912,"threshold_uncertainty_score":0.99995756},"labels":[],"label_agreement":null},{"id":"W4225424677","doi":"10.1016/j.clml.2021.10.018","title":"Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"National Center for Advancing Translational Sciences; National Cancer Institute","keywords":"Medicine; Outcome (game theory); Lymphoma; Retrospective cohort study; T-cell lymphoma; Internal medicine; Oncology; General surgery; Family medicine","score_opus":0.03910560402765996,"score_gpt":0.3267734776531193,"score_spread":0.28766787362545937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225424677","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970083,0.00089975196,0.00010784024,0.00017760943,0.00043011756,0.0003998726,0.000146855,0.00005651337,0.000773122],"genre_scores_gemma":[0.9933988,0.0012641437,0.0036907329,0.00085139944,0.00019415877,0.00009700706,0.00016890574,0.000036686033,0.0002982099],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9961351,0.00015597584,0.0017044455,0.0009848188,0.00051004096,0.00050958694],"domain_scores_gemma":[0.9976562,0.00048592142,0.0004206367,0.0006678181,0.00031880513,0.00045058312],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002302344,0.00044716388,0.0014721821,0.000130535,0.00012251343,0.000037592992,0.00017750074,0.000299919,0.000098268116],"category_scores_gemma":[0.0010408729,0.00037944605,0.00040412458,0.0006030543,0.00088888145,0.00016014757,0.00020823177,0.00015787185,0.00006127317],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0003578374,0.002659412,0.85358113,0.000112399954,0.00008946154,0.002455216,0.0004565626,0.0000015898596,0.00032299667,0.00022542078,0.000038229384,0.13969976],"study_design_scores_gemma":[0.014822402,0.00043613295,0.9794963,0.00016892554,0.00015289595,0.00034224326,0.0002441885,0.00060221495,0.0017222419,0.000019678635,0.0016528406,0.00033993585],"about_ca_topic_score_codex":0.00025697923,"about_ca_topic_score_gemma":0.00016580377,"teacher_disagreement_score":0.13935982,"about_ca_system_score_codex":0.0014982892,"about_ca_system_score_gemma":0.0015490622,"threshold_uncertainty_score":0.9998658},"labels":[],"label_agreement":null},{"id":"W4226022053","doi":"10.1016/j.clml.2021.12.003","title":"An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy","year":2021,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Emergent BioSolutions (Canada)","funders":"","keywords":"Chimeric antigen receptor; Multiple myeloma; Medicine; Malignancy; Plasma cell; Antigen; Cancer research; Antibody; Clinical trial; Cancer; Immunology; Oncology; Immunotherapy; Internal medicine","score_opus":0.17085119738957352,"score_gpt":0.4525105370994986,"score_spread":0.28165933970992507,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4226022053","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0132687185,0.9796699,0.0000068765435,0.000038536597,0.00080131274,0.0023270014,0.00016529555,0.00015396539,0.0035683396],"genre_scores_gemma":[0.00045650726,0.99002767,0.00043579144,0.00041203015,0.0015113098,0.00012742546,0.0031017216,0.00033972264,0.0035878038],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98999304,0.002312588,0.0037182337,0.0016571332,0.001413701,0.0009052983],"domain_scores_gemma":[0.9916521,0.0023464023,0.0014716544,0.0028852983,0.00073528604,0.0009092683],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0023817548,0.0010729416,0.006511242,0.00040162855,0.0001141614,0.00009892142,0.001033604,0.0022416296,0.004283728],"category_scores_gemma":[0.00046682,0.0008584643,0.00295525,0.0014365856,0.00047872338,0.00017069957,0.00023690308,0.0012341468,0.0005044041],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00032155516,0.0008090205,0.00012222705,0.011139112,0.00046288702,0.00045335642,0.00006405373,3.0230615e-7,0.0011431505,0.000020006768,0.002119622,0.98334473],"study_design_scores_gemma":[0.0037292335,0.001281242,0.0056699193,0.007984215,0.00076715124,0.0001561983,0.000036247297,0.000053275402,0.0008729284,0.0000145504,0.97868925,0.0007457683],"about_ca_topic_score_codex":0.00012472365,"about_ca_topic_score_gemma":0.000008006579,"teacher_disagreement_score":0.98259896,"about_ca_system_score_codex":0.0013104868,"about_ca_system_score_gemma":0.00952791,"threshold_uncertainty_score":0.9993866},"labels":[],"label_agreement":null},{"id":"W4231637248","doi":"10.1016/j.clml.2019.07.097","title":"Efficacy and Safety of Single-Agent Quizartinib, a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) With FLT3-Internal Tandem Duplication (FLT3-ITD) – Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled QuANTUM-R Trial","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital","funders":"","keywords":"Myeloid leukemia; Refractory (planetary science); Medicine; Tandem exon duplication; Fms-Like Tyrosine Kinase 3; Oncology; Internal medicine; Pharmacology; Cancer research; Gene duplication; Mutation; Chemistry; Gene; Biology","score_opus":0.016329411479683698,"score_gpt":0.3141284784032331,"score_spread":0.2977990669235494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4231637248","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812443,0.0005531831,0.00012898036,0.00065598014,0.00045350342,0.016015198,0.00007097684,0.00010852527,0.00076932565],"genre_scores_gemma":[0.9969093,0.0007340228,0.00027622242,0.0005459342,0.0003317424,0.0006848529,0.00022635379,0.00011704364,0.00017449868],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9867841,0.0035285817,0.0048819087,0.0018248903,0.0017504187,0.0012301097],"domain_scores_gemma":[0.987978,0.0073214187,0.0020054865,0.0012324057,0.0007787295,0.0006839644],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0071315663,0.0010475201,0.0053928792,0.00054762786,0.00019255438,0.00014141078,0.00066840084,0.0009563432,0.000064985055],"category_scores_gemma":[0.0061519872,0.0006830603,0.000779445,0.0013357644,0.0013383995,0.00039667106,0.00036055315,0.0013729882,0.00006255504],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.91921467,0.0035801847,0.031647872,0.000105868,0.0014557767,0.00026632653,0.00081798644,0.000033385677,0.0014916067,0.00016830389,0.00027201828,0.040946014],"study_design_scores_gemma":[0.7423394,0.00866122,0.23990525,0.0006470094,0.0008387561,0.00012361785,0.0002451484,0.0060465373,0.000323622,0.000116154224,0.00022270097,0.00053063064],"about_ca_topic_score_codex":0.00048043352,"about_ca_topic_score_gemma":0.00008052895,"teacher_disagreement_score":0.20825738,"about_ca_system_score_codex":0.006158844,"about_ca_system_score_gemma":0.0036908872,"threshold_uncertainty_score":0.9995621},"labels":[],"label_agreement":null},{"id":"W4236520012","doi":"10.1016/j.clml.2019.07.113","title":"Delayed Hematologic Recovery in AML Patients After Induction Chemotherapy is Associated with Inferior Relapse-Free Survival and Persistence of Preleukemic Mutations","year":2019,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Chemotherapy; Medicine; Induction chemotherapy; Persistence (discontinuity); Myeloid leukemia; Myeloid; Oncology; Internal medicine; Immunology","score_opus":0.023949305998262213,"score_gpt":0.2915467072011887,"score_spread":0.26759740120292647,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4236520012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99677074,0.00015639905,0.000014170504,0.00054041325,0.00022527059,0.0012301336,0.00006753115,0.000076725424,0.0009186126],"genre_scores_gemma":[0.9970331,0.00029649783,0.00080053677,0.00071023585,0.000059011956,0.00009163056,0.00012394054,0.0000762965,0.00080875726],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99610376,0.00035486982,0.0013163773,0.0008821432,0.0007456013,0.0005972343],"domain_scores_gemma":[0.9966814,0.0010485064,0.00052857836,0.00094181957,0.00050421496,0.00029548677],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009823705,0.0003885937,0.0011947366,0.0003168914,0.000063920146,0.000032042797,0.00033649104,0.0007291696,0.00019578497],"category_scores_gemma":[0.0021565983,0.000324623,0.00023907698,0.000846695,0.0005991954,0.00034086523,0.00020950314,0.0006274462,0.00006476956],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006514965,0.00048176,0.95456934,0.00013674177,0.00036950133,0.00009539707,0.00046978198,0.000008935233,0.00048823535,0.000022240212,0.00066506903,0.03617804],"study_design_scores_gemma":[0.017431214,0.0026061703,0.9769944,0.0005331729,0.00012329896,0.000057943318,0.00026536372,0.00075166166,0.000532438,0.00023229618,0.00013452873,0.0003375161],"about_ca_topic_score_codex":0.0002057565,"about_ca_topic_score_gemma":0.000097791686,"teacher_disagreement_score":0.035840526,"about_ca_system_score_codex":0.0025107083,"about_ca_system_score_gemma":0.0019136394,"threshold_uncertainty_score":0.9999206},"labels":[],"label_agreement":null},{"id":"W4239038218","doi":"10.1016/s2152-2650(11)70011-8","title":"Abstracts From: The 14th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myelomas March 17-21, 2010; Whistler, British Columbia","year":2010,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Internal medicine; Oncology; Gerontology","score_opus":0.026824651494692812,"score_gpt":0.3099915816923784,"score_spread":0.2831669301976856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4239038218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9662103,0.0003560344,0.000006421057,0.007541514,0.0066573764,0.0015141587,0.0010388222,0.00038293493,0.016292453],"genre_scores_gemma":[0.9476807,0.0010375906,0.0011143206,0.0076178852,0.0033212001,0.00024091735,0.0004791874,0.00021709278,0.03829108],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9912751,0.00050916034,0.0023369133,0.0022793869,0.0020256238,0.0015738494],"domain_scores_gemma":[0.988551,0.0063610976,0.00077248004,0.0021822765,0.0008364289,0.0012966935],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity","insufficient_payload"],"category_scores_codex":[0.0025301373,0.00081341446,0.00167897,0.00018772313,0.0007775282,0.0009319539,0.0018527756,0.0016339538,0.0024065138],"category_scores_gemma":[0.0059835496,0.00073848455,0.00064290146,0.0005376828,0.002670533,0.00038508023,0.0009031196,0.002566909,0.0011007853],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019502337,0.00069115794,0.0683148,0.00005697242,0.0005038185,0.0038557302,0.00012828756,0.0000036419676,0.00094411697,0.00043612032,0.6382613,0.28485382],"study_design_scores_gemma":[0.0097710835,0.00095614465,0.8055563,0.00055500824,0.0001480676,0.001959767,0.00026818324,0.00034941727,0.0004887357,0.0013587106,0.17785916,0.0007294027],"about_ca_topic_score_codex":0.014940902,"about_ca_topic_score_gemma":0.0112543795,"teacher_disagreement_score":0.7372415,"about_ca_system_score_codex":0.0023007756,"about_ca_system_score_gemma":0.0037237487,"threshold_uncertainty_score":0.9997342},"labels":[],"label_agreement":null},{"id":"W4281392664","doi":"10.1016/j.clml.2022.05.006","title":"Tumor Infiltrating Lymphocytes Predict Survival in Solid Organ Transplant Recipients With Monomorphic Post-transplant Lymphoproliferative Disorders","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre; Princess Margaret Cancer Centre; University of Alberta; Leukemia & Lymphoma Society of Canada","funders":"Canadian Institutes of Health Research; Alberta Innovates - Health Solutions; Leukemia and Lymphoma Society of Canada","keywords":"Medicine; Internal medicine; Stage (stratigraphy); Lymphoproliferative disorders; Proportional hazards model; Univariate analysis; Gastroenterology; Multivariate analysis; Oncology; Progression-free survival; Pathology; Overall survival; Lymphoma; Biology","score_opus":0.015057356882213066,"score_gpt":0.2758049557330485,"score_spread":0.2607475988508354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4281392664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99342406,0.00044793476,0.00007210243,0.0010902114,0.0007915629,0.0012587587,0.0005106724,0.00025640093,0.002148299],"genre_scores_gemma":[0.9946547,0.0004676259,0.00017245316,0.0029938188,0.0002352096,0.00040041577,0.00068224536,0.0001526206,0.00024091541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99384475,0.0006805814,0.0018111565,0.0012970242,0.0011601711,0.0012062989],"domain_scores_gemma":[0.9973327,0.00067585363,0.0005584946,0.0006666735,0.0001782937,0.00058797473],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001301875,0.00071445236,0.0015320497,0.00031898875,0.0006010002,0.000069295136,0.0005228489,0.00029208366,0.00038451742],"category_scores_gemma":[0.00030280344,0.0006373297,0.00044416302,0.001072939,0.00046965395,0.00026193686,0.00012737779,0.0007546827,0.000035883313],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012034303,0.0010463976,0.9314286,0.00008749908,0.00047366275,0.0012103375,0.0023279148,0.0010324444,0.00044991844,0.00011136114,0.00029640878,0.049501132],"study_design_scores_gemma":[0.027979897,0.004267979,0.95872223,0.00041120418,0.00033358188,0.00044567857,0.0023239546,0.0034160272,0.0003037251,0.00015157698,0.00080383,0.00084033166],"about_ca_topic_score_codex":0.001689985,"about_ca_topic_score_gemma":0.0016373178,"teacher_disagreement_score":0.0486608,"about_ca_system_score_codex":0.003440669,"about_ca_system_score_gemma":0.0051470324,"threshold_uncertainty_score":0.9996078},"labels":[],"label_agreement":null},{"id":"W4285498294","doi":"10.1016/j.clml.2022.07.004","title":"Real-World Persistence and Time to Next Treatment With Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Scientific Affairs; AbbVie; Merck","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Discontinuation; Stroke (engine); Atrial fibrillation; Lower risk; Oncology; Leukemia; Confidence interval","score_opus":0.04458121361638287,"score_gpt":0.3073229471894323,"score_spread":0.2627417335730494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4285498294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9912924,0.00025562622,0.000021538917,0.00008619404,0.00038637803,0.0066762976,0.0005687549,0.00021567856,0.0004971411],"genre_scores_gemma":[0.98745346,0.00036532318,0.0020579943,0.00027303598,0.0009386883,0.0005918779,0.0009810244,0.00033068715,0.0070078885],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98993045,0.0007760506,0.0023972401,0.002736833,0.0020214834,0.002137922],"domain_scores_gemma":[0.99146765,0.0037915818,0.0010913278,0.0017114525,0.00055506977,0.0013828919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014257571,0.0012653812,0.0024201036,0.00092311145,0.0012515916,0.00018878545,0.0006899139,0.0004492556,0.00057727686],"category_scores_gemma":[0.0010073144,0.00097932,0.00064069347,0.0018070288,0.0006767893,0.0003988524,0.0012729616,0.00030824184,0.00025961542],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.14542517,0.0004090483,0.33566877,0.000424521,0.0013567118,0.00049896614,0.0007015932,0.014447973,0.000044351993,0.000029371093,0.0005555145,0.50043803],"study_design_scores_gemma":[0.24480735,0.031907264,0.63446623,0.0005400965,0.0010775609,0.00018241566,0.00011710409,0.07685842,0.00016428255,0.000020565183,0.008529316,0.0013293786],"about_ca_topic_score_codex":0.0066211536,"about_ca_topic_score_gemma":0.0021217084,"teacher_disagreement_score":0.49910864,"about_ca_system_score_codex":0.5160893,"about_ca_system_score_gemma":0.078195915,"threshold_uncertainty_score":0.99999386},"labels":[],"label_agreement":null},{"id":"W4289526484","doi":"10.1016/j.clml.2022.07.016","title":"Characteristics and Outcomes of Alberta Lymphoma Patients with a History of Immunosuppressive therapy for Autoimmune Conditions","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Viral-associated cancers and disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Children's Hospital; Alberta Health Services","funders":"","keywords":"Lymphoma; Medicine; Immunology; Internal medicine","score_opus":0.015476243220913174,"score_gpt":0.2812959906559092,"score_spread":0.26581974743499603,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4289526484","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99604845,0.0010209866,0.0000075260214,0.00022432834,0.0004571802,0.00080071803,0.00038121906,0.000025775089,0.0010338151],"genre_scores_gemma":[0.9959712,0.00023750184,0.00012201382,0.0009998982,0.000030084695,0.00020945714,0.0005131166,0.00004408801,0.0018726541],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99792045,0.00011303982,0.0009841976,0.00035775645,0.0003496545,0.0002748903],"domain_scores_gemma":[0.99749213,0.0008016244,0.00087518344,0.00044111809,0.00027282254,0.000117091775],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00024108969,0.00023461989,0.0010252881,0.00009852578,0.00012614131,0.000005175871,0.00018036923,0.00014615264,0.00020906051],"category_scores_gemma":[0.00042658043,0.00019618304,0.00031116302,0.00012870671,0.00050238566,0.000072234725,0.000102156046,0.0001092447,0.0000014715589],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0062961737,0.0017161322,0.82466114,0.000120873745,0.0010171254,0.000009517132,0.0008758638,0.0000031821091,0.0003040068,0.00047686102,0.00750136,0.15701778],"study_design_scores_gemma":[0.024522156,0.0028910208,0.9527169,0.000051801842,0.00026015413,0.000005405645,0.00017333418,0.0001213134,0.000034920584,0.00011611582,0.018903991,0.00020289925],"about_ca_topic_score_codex":0.00043576863,"about_ca_topic_score_gemma":0.000009781569,"teacher_disagreement_score":0.15681489,"about_ca_system_score_codex":0.0011974743,"about_ca_system_score_gemma":0.0017890066,"threshold_uncertainty_score":0.8000112},"labels":[],"label_agreement":null},{"id":"W4292533762","doi":"10.1016/j.clml.2022.08.008","title":"An Epidemiological Model to Estimate the Prevalence of Diffuse Large B-Cell Lymphoma in the United States","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Broadcom (Canada); Vancouver Coastal Health","funders":"","keywords":"Epidemiology; Medicine; Diffuse large B-cell lymphoma; Incidence (geometry); Disease; Population; Lymphoma; Relative survival; Mortality rate; Internal medicine; Environmental health; Cancer registry","score_opus":0.05327180857641299,"score_gpt":0.3865145714777316,"score_spread":0.3332427629013186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4292533762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936113,0.00045745738,0.00014352924,0.0035316052,0.00015642305,0.0012894992,0.00026719627,0.0000908065,0.00045220717],"genre_scores_gemma":[0.98365784,0.00042457067,0.0010094312,0.013548755,0.00010471187,0.00069331034,0.00022762577,0.00004567033,0.00028810493],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99405265,0.0017823883,0.0016464893,0.00090776506,0.0007917457,0.0008189355],"domain_scores_gemma":[0.9935093,0.0038607386,0.00041394343,0.0016852269,0.00013036637,0.00040043073],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0041605295,0.00044627796,0.001003647,0.00017624894,0.0004163476,0.00003740051,0.0012008672,0.0002023981,0.00011151307],"category_scores_gemma":[0.0011104296,0.00024345328,0.00046450004,0.00094608846,0.00035926286,0.00009046406,0.0005360382,0.0002916287,0.000050506882],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0043220865,0.047561556,0.7695375,0.0004440476,0.00027311427,0.0013624273,0.0044554793,0.02363556,0.00019675225,0.008413502,0.013434821,0.12636314],"study_design_scores_gemma":[0.012923836,0.0021129618,0.83960253,0.0000661913,0.0002458512,0.00011669813,0.00053190085,0.13743247,0.00011738169,0.0010613162,0.0055343723,0.00025449603],"about_ca_topic_score_codex":0.0003831503,"about_ca_topic_score_gemma":0.000029978379,"teacher_disagreement_score":0.12610865,"about_ca_system_score_codex":0.0010397602,"about_ca_system_score_gemma":0.00078529044,"threshold_uncertainty_score":0.99277365},"labels":[],"label_agreement":null},{"id":"W4293107714","doi":"10.1016/s2152-2650(22)00591-2","title":"P-261: Treatment attrition rates in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Multiple myeloma; Attrition; Internal medicine; Medicine; Oncology; Myeloma protein; Dentistry","score_opus":0.13385913341498837,"score_gpt":0.41054080873491755,"score_spread":0.27668167531992915,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4293107714","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9876787,0.0014604424,0.000016440143,0.002574705,0.00039779072,0.0028392277,0.0006060021,0.00019951804,0.0042271623],"genre_scores_gemma":[0.98917514,0.0004868077,0.00093260803,0.00069255853,0.0005583586,0.0020911752,0.002772897,0.0001592767,0.00313116],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98714805,0.0029884244,0.0022639153,0.0023291947,0.00231869,0.002951715],"domain_scores_gemma":[0.9913259,0.0029734091,0.0003244885,0.002046466,0.00050760014,0.0028221428],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004341008,0.00085420616,0.0021722221,0.0037301423,0.0017039619,0.00019454092,0.00086951075,0.00058905367,0.0023051412],"category_scores_gemma":[0.0022497925,0.0008001614,0.0014497496,0.00662555,0.0008165044,0.00030272215,0.000591691,0.0013291256,0.0007661972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035124084,0.0021460825,0.627881,0.000056647765,0.0020638409,0.007860613,0.0003366396,0.00009381325,0.00039461252,0.00026104317,0.0025720343,0.3528213],"study_design_scores_gemma":[0.017415253,0.003975259,0.92616695,0.00008263263,0.00059747626,0.00023759365,0.00088843366,0.010728055,0.00032636017,0.0002970555,0.038645755,0.0006391598],"about_ca_topic_score_codex":0.18323658,"about_ca_topic_score_gemma":0.2706521,"teacher_disagreement_score":0.35218212,"about_ca_system_score_codex":0.01987467,"about_ca_system_score_gemma":0.0060187606,"threshold_uncertainty_score":0.9996162},"labels":[],"label_agreement":null},{"id":"W4296468281","doi":"10.1016/s2152-2650(22)01287-3","title":"AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Interleukin-3 receptor; Medicine; Internal medicine; Adverse effect; Chronic myelomonocytic leukemia; Bone marrow; Myeloid; Myeloid leukemia; Gastroenterology; Oncology; Myelodysplastic syndromes","score_opus":0.021524954406898934,"score_gpt":0.2972253262426553,"score_spread":0.27570037183575635,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468281","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99620396,0.0003434891,0.00004369999,0.00032680298,0.00016151542,0.0014492592,0.00045792622,0.00030058622,0.00071277097],"genre_scores_gemma":[0.99435276,0.00016953814,0.0013757751,0.000955036,0.000046662437,0.00023213972,0.0021948447,0.00009526551,0.00057795167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924709,0.0013391605,0.002406036,0.0012519899,0.0015170762,0.0010148358],"domain_scores_gemma":[0.9952037,0.0013819447,0.00077207416,0.0013842093,0.0008088155,0.00044925348],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0019723065,0.0006029489,0.0026898945,0.0014402854,0.00025625832,0.000029456509,0.0008152639,0.00041151882,0.001923554],"category_scores_gemma":[0.0015052451,0.00045571307,0.0007891254,0.0083176885,0.0007906095,0.00014595142,0.0005230433,0.0010520318,0.00002988299],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015961515,0.0017439389,0.90437406,0.000055133776,0.0029271108,0.00045695578,0.00031783042,0.00032587993,0.00043961775,0.00013300295,0.0018632042,0.07140175],"study_design_scores_gemma":[0.015750887,0.0030219085,0.96843195,0.00008707228,0.0006721458,0.000028132457,0.00041236688,0.006348733,0.00042572123,0.000045088014,0.004303008,0.0004729714],"about_ca_topic_score_codex":0.0009357673,"about_ca_topic_score_gemma":0.00016293894,"teacher_disagreement_score":0.070928775,"about_ca_system_score_codex":0.003744808,"about_ca_system_score_gemma":0.0033048824,"threshold_uncertainty_score":0.9997895},"labels":[],"label_agreement":null},{"id":"W4296468325","doi":"10.1016/s2152-2650(22)01359-3","title":"CML-047 Post Hoc Analysis of Responses to Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) by Baseline BCR::ABL1 Level and Baseline Mutation Status in the OPTIC Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ponatinib; Internal medicine; Cohort; Population; Myeloid leukemia; Imatinib; Dasatinib","score_opus":0.02755615042185004,"score_gpt":0.3304778041480667,"score_spread":0.30292165372621666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468325","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99065304,0.0014548175,0.000112936534,0.00079704274,0.00028251857,0.0039171795,0.002624106,0.00007914286,0.00007920782],"genre_scores_gemma":[0.99071425,0.00024140619,0.001104601,0.0014529221,0.0002959686,0.00070361426,0.0049782246,0.00013574409,0.00037328052],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9887602,0.0026764881,0.003416785,0.0018159829,0.0019889972,0.0013415775],"domain_scores_gemma":[0.9908353,0.005308927,0.0010667496,0.0016918044,0.0004409079,0.0006562932],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0054624714,0.0008843149,0.002352984,0.0015215927,0.0003138096,0.00007290732,0.00071272044,0.00039528028,0.00060553296],"category_scores_gemma":[0.004146055,0.00070778845,0.0005292984,0.004302427,0.0005074793,0.00029141147,0.00046356797,0.0009794813,0.000026674059],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.35284412,0.0064949095,0.08512642,0.00028976824,0.002594844,0.0014145167,0.001760196,0.005298384,0.0007912503,0.00008039931,0.0025492331,0.540756],"study_design_scores_gemma":[0.22924545,0.024751673,0.7229617,0.00021827573,0.0019391511,0.0000575195,0.0005079742,0.015784957,0.00013229228,0.000012587662,0.003695096,0.0006933132],"about_ca_topic_score_codex":0.0025398077,"about_ca_topic_score_gemma":0.002024011,"teacher_disagreement_score":0.63783526,"about_ca_system_score_codex":0.021523278,"about_ca_system_score_gemma":0.012040549,"threshold_uncertainty_score":0.99953735},"labels":[],"label_agreement":null},{"id":"W4296468436","doi":"10.1016/s2152-2650(22)01379-9","title":"CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Bosutinib; Medicine; Discontinuation; Adverse effect; Internal medicine; Imatinib; Oncology; Gastroenterology; Myeloid leukemia; Nilotinib","score_opus":0.017877768513283668,"score_gpt":0.30418020024713993,"score_spread":0.2863024317338563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468436","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9885666,0.0019533301,0.00000604397,0.00026936253,0.0006979915,0.0068431688,0.0013164325,0.00020532364,0.0001417902],"genre_scores_gemma":[0.99448144,0.00041874815,0.00029349746,0.00047958546,0.0006641229,0.0008381442,0.0023003211,0.00030055983,0.00022355355],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98526984,0.0013506499,0.0059237853,0.0034194824,0.0021329806,0.0019032825],"domain_scores_gemma":[0.9920948,0.0018118167,0.00189553,0.0028205458,0.00029001862,0.0010872813],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0022978657,0.0015667516,0.003655596,0.0009663722,0.0004168505,0.000089910725,0.00091033336,0.00067763746,0.0005866649],"category_scores_gemma":[0.00098932,0.0014381054,0.00047469084,0.0021850828,0.0009519666,0.0005283379,0.0014412923,0.0019059727,0.00007290538],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.31053472,0.031100482,0.121261485,0.00032741722,0.0012690374,0.005105431,0.0032187765,0.00087453786,0.0005995738,0.0000115802795,0.0013101147,0.5243869],"study_design_scores_gemma":[0.37426057,0.028251387,0.5882556,0.000859006,0.0006469178,0.000040363328,0.00031334005,0.0018785113,0.00047063568,0.000010987644,0.004112571,0.0009001227],"about_ca_topic_score_codex":0.004058436,"about_ca_topic_score_gemma":0.002156829,"teacher_disagreement_score":0.52348673,"about_ca_system_score_codex":0.039953392,"about_ca_system_score_gemma":0.013567683,"threshold_uncertainty_score":0.99970806},"labels":[],"label_agreement":null},{"id":"W4296468442","doi":"10.1016/s2152-2650(22)01463-x","title":"MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Placebo; Gastroenterology; Anemia; Internal medicine; Danazol; Clinical endpoint; Hematocrit; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.023011113189529718,"score_gpt":0.31756661395067076,"score_spread":0.29455550076114106,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99055123,0.000381048,0.0000021576143,0.00011777054,0.00026275482,0.00819472,0.00007910399,0.000109327855,0.00030189264],"genre_scores_gemma":[0.994979,0.0002215731,0.00019370856,0.00016632878,0.000094630384,0.0038420355,0.00027076135,0.00010152387,0.00013039788],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99294823,0.0013798997,0.0025954763,0.0012564842,0.0011193833,0.00070050906],"domain_scores_gemma":[0.99458903,0.0028340502,0.0009519384,0.0008437582,0.00024989073,0.00053131365],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012928903,0.0007263953,0.0031019903,0.0004335463,0.00027483696,0.00004821827,0.00026584812,0.0001984845,0.0001645696],"category_scores_gemma":[0.0008877609,0.00055235834,0.00037874092,0.0009266505,0.00043881574,0.00016420319,0.00034922382,0.00038955896,0.000013127708],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25058454,0.021826468,0.6492174,0.00024854537,0.0017854591,0.00052368024,0.0020648318,0.00003789882,0.00010270177,0.000050996925,0.0003093778,0.07324809],"study_design_scores_gemma":[0.52414936,0.021792945,0.44938183,0.00031688454,0.0012796863,0.00003968623,0.0010969203,0.00096111937,0.00044949437,0.000013855269,0.00012061788,0.000397583],"about_ca_topic_score_codex":0.00041461037,"about_ca_topic_score_gemma":0.000099440156,"teacher_disagreement_score":0.27356485,"about_ca_system_score_codex":0.0015519907,"about_ca_system_score_gemma":0.0007377359,"threshold_uncertainty_score":0.9996928},"labels":[],"label_agreement":null},{"id":"W4296468443","doi":"10.1016/s2152-2650(22)01478-1","title":"HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Refractory (planetary science); Phases of clinical research; Gastroenterology; Population; Adverse effect; Dosing; Surgery; Toxicity; Lymphoma; Hodgkin lymphoma","score_opus":0.059413759715631224,"score_gpt":0.3922615825630272,"score_spread":0.33284782284739595,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468443","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306,0.00013354368,0.000006230787,0.00013505934,0.00033827728,0.005676548,0.0001843911,0.0001618092,0.0003041613],"genre_scores_gemma":[0.99648494,0.00007306426,0.00062130496,0.00057255453,0.00017126433,0.0003727597,0.0007230969,0.00022274767,0.00075826386],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98917186,0.0020574701,0.0031586778,0.0022293746,0.0020962309,0.0012864039],"domain_scores_gemma":[0.99268734,0.002328963,0.00092171464,0.0023706274,0.0005167998,0.001174574],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024842843,0.0008248876,0.0023625463,0.00052987016,0.00048194607,0.00012467963,0.0016123918,0.00045035742,0.0005561015],"category_scores_gemma":[0.001987859,0.0006575381,0.00011887413,0.0016854937,0.0009777881,0.00057175325,0.0026088324,0.0009864336,0.000030875126],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.29361096,0.093677856,0.092354104,0.00019546271,0.0006393406,0.0038979568,0.0011168907,0.000033550492,0.00031195584,0.000038672846,0.0014185618,0.5127047],"study_design_scores_gemma":[0.39250448,0.04673936,0.5463693,0.0001590852,0.00025412065,0.00010908282,0.0007761311,0.008809892,0.000048951973,0.000005364809,0.0037062806,0.0005179294],"about_ca_topic_score_codex":0.001307104,"about_ca_topic_score_gemma":0.0004896017,"teacher_disagreement_score":0.51218677,"about_ca_system_score_codex":0.022994414,"about_ca_system_score_gemma":0.015652515,"threshold_uncertainty_score":0.9995876},"labels":[],"label_agreement":null},{"id":"W4296468472","doi":"10.1016/s2152-2650(22)01343-x","title":"CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Discontinuation; Atrial fibrillation; Oncology; Leukemia","score_opus":0.05117018586394753,"score_gpt":0.3203578797929642,"score_spread":0.26918769392901665,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468472","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850406,0.00025053075,0.000010841081,0.00006298892,0.00035225786,0.013211823,0.00056136283,0.00022427634,0.0002852995],"genre_scores_gemma":[0.98806167,0.00031318748,0.0009957881,0.0001542918,0.0008343119,0.001425101,0.0008166551,0.00034051947,0.0070585064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98879397,0.001128498,0.0026290263,0.003159,0.0021084498,0.002181083],"domain_scores_gemma":[0.9911978,0.003725949,0.0011474557,0.0019895367,0.00052196276,0.0014172728],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00137537,0.0015278121,0.0028983352,0.0009898464,0.0013963752,0.00021406104,0.00065087725,0.0003923611,0.00043777667],"category_scores_gemma":[0.00069609756,0.0011211383,0.00069801987,0.0018654795,0.0005524077,0.00036933538,0.0011177494,0.0002547142,0.00021419492],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12846932,0.0012440662,0.46590537,0.0001857963,0.0019563285,0.00064245693,0.0015633352,0.009328415,0.000015820186,0.0000073564847,0.000166149,0.3905156],"study_design_scores_gemma":[0.2840961,0.08137058,0.586966,0.000300634,0.0016625837,0.00012942454,0.00035833046,0.0398962,0.00008326026,0.000008103273,0.0039915666,0.0011372471],"about_ca_topic_score_codex":0.012725408,"about_ca_topic_score_gemma":0.00595432,"teacher_disagreement_score":0.51065207,"about_ca_system_score_codex":0.5894055,"about_ca_system_score_gemma":0.07875341,"threshold_uncertainty_score":0.9999037},"labels":[],"label_agreement":null},{"id":"W4296468477","doi":"10.1016/s2152-2650(22)01464-1","title":"MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Gastroenterology; Internal medicine; Danazol; Placebo; Myelofibrosis; Ruxolitinib; Anemia; Hematocrit; Clinical endpoint; Randomized controlled trial; Surgery; Bone marrow; Pathology","score_opus":0.033995052927979164,"score_gpt":0.337825457765041,"score_spread":0.30383040483706186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468477","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98776096,0.000289443,0.0000033274055,0.00017873528,0.00044360047,0.010423585,0.00011271564,0.00012881748,0.0006587854],"genre_scores_gemma":[0.9927237,0.00019202242,0.00022024123,0.00029677086,0.00014943362,0.005640023,0.0004157492,0.00013427743,0.0002277947],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9908878,0.001923673,0.0031897337,0.0015720549,0.0015213226,0.0009053777],"domain_scores_gemma":[0.99377203,0.0028414521,0.0011959014,0.0012175072,0.00038034804,0.0005927671],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017126206,0.000864241,0.004085836,0.00045828428,0.00034065545,0.00005612451,0.00045789249,0.0002414141,0.0004730005],"category_scores_gemma":[0.0010811945,0.00065515976,0.0007237552,0.001338916,0.0004622957,0.00021319324,0.0005031758,0.000550899,0.000039198832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.44045648,0.041603252,0.43480453,0.00014117533,0.0027591002,0.0008323912,0.0021517833,0.00006392181,0.00013964418,0.000095765645,0.00071847026,0.076233506],"study_design_scores_gemma":[0.56181175,0.030000687,0.40303254,0.00023737962,0.0013777128,0.000025212452,0.0011388467,0.0003609758,0.0009206008,0.0000114187005,0.00061183685,0.00047105178],"about_ca_topic_score_codex":0.00079309667,"about_ca_topic_score_gemma":0.00025303575,"teacher_disagreement_score":0.121355265,"about_ca_system_score_codex":0.002738378,"about_ca_system_score_gemma":0.0015922254,"threshold_uncertainty_score":0.99959},"labels":[],"label_agreement":null},{"id":"W4296468504","doi":"10.1016/s2152-2650(22)01293-9","title":"AML-432 Overall Survival (OS) by Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant- Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Medical Research Council","keywords":"Medicine; Internal medicine; NPM1; Oncology; Myeloid leukemia; Cohort; Refractory (planetary science); Gastroenterology; Biology; Genetics","score_opus":0.045896842606901425,"score_gpt":0.3575394815419613,"score_spread":0.3116426389350599,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9829161,0.00031463176,0.000024226347,0.0007142512,0.0005842277,0.012349457,0.0014265197,0.00020618523,0.0014644088],"genre_scores_gemma":[0.97594285,0.0006249902,0.00045144113,0.0021360358,0.00042778006,0.002940588,0.0054799714,0.00039498013,0.011601358],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98184603,0.005384357,0.004113492,0.0027860838,0.0037016626,0.0021683453],"domain_scores_gemma":[0.9886632,0.005614372,0.0016375545,0.0024022618,0.0007309917,0.00095161796],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0061938763,0.0014963545,0.0043469756,0.00068536,0.000862645,0.00038429716,0.0026805168,0.0008777351,0.0036105288],"category_scores_gemma":[0.0021968866,0.0009042054,0.0006029895,0.0023183564,0.0016134612,0.00078855234,0.0013760584,0.0033457368,0.00012505395],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.9482018,0.006099422,0.00744182,0.00014464163,0.0017888144,0.010436148,0.0011934657,0.00009284402,0.00041439687,0.0001310059,0.010472439,0.013583229],"study_design_scores_gemma":[0.9211389,0.019504186,0.025348406,0.00037515382,0.0009860443,0.00026250008,0.0015950187,0.0012740907,0.0002794658,0.000034238783,0.027882325,0.0013196594],"about_ca_topic_score_codex":0.002564262,"about_ca_topic_score_gemma":0.0012195944,"teacher_disagreement_score":0.027062861,"about_ca_system_score_codex":0.012964643,"about_ca_system_score_gemma":0.014456339,"threshold_uncertainty_score":0.99977857},"labels":[],"label_agreement":null},{"id":"W4296468589","doi":"10.1016/s2152-2650(22)01538-5","title":"ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Neutropenia; Lenalidomide; Internal medicine; Adverse effect; Lymphoma; Follicular lymphoma; Gastroenterology; Refractory (planetary science); Cereblon; Bendamustine; Oncology; Chemotherapy; Rituximab; Multiple myeloma","score_opus":0.04331036471946438,"score_gpt":0.33594556762685157,"score_spread":0.2926352029073872,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296468589","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942159,0.000106777174,0.00009492465,0.00011001922,0.0007771554,0.0033581932,0.0010208337,0.000054255306,0.00026191646],"genre_scores_gemma":[0.9952639,0.00005971559,0.0008608287,0.0007543581,0.00029042736,0.00046446527,0.0017412684,0.00018354309,0.000381542],"study_design_codex":"nonrandomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9904258,0.001438495,0.0035244706,0.002679984,0.0009189437,0.0010122784],"domain_scores_gemma":[0.9943779,0.00051179575,0.0018332332,0.0023037565,0.00034223645,0.0006310555],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024266208,0.0009413286,0.0017023447,0.00029768015,0.0003817855,0.00014189881,0.0019313603,0.0007643181,0.000064633714],"category_scores_gemma":[0.0013168772,0.0009225934,0.00038887328,0.0006948642,0.00043908658,0.000108577,0.002386809,0.0007712175,0.000030644755],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.068913125,0.5486732,0.20383294,0.00010718793,0.00118027,0.0005399468,0.00051768735,0.00014601117,0.021738434,0.000015807118,0.0061434135,0.14819194],"study_design_scores_gemma":[0.44313702,0.014257828,0.5168328,0.00017205277,0.00017206348,0.000004707745,0.00017399271,0.003279973,0.012569361,0.000013851918,0.008109091,0.0012772355],"about_ca_topic_score_codex":0.0035005878,"about_ca_topic_score_gemma":0.0020620157,"teacher_disagreement_score":0.5344154,"about_ca_system_score_codex":0.0010707151,"about_ca_system_score_gemma":0.0012731322,"threshold_uncertainty_score":0.9993225},"labels":[],"label_agreement":null},{"id":"W4296528992","doi":"10.1016/s2152-2650(22)01358-1","title":"CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Adverse effect; Internal medicine; Myeloid leukemia; Dosing; Oncology; Dasatinib; Imatinib","score_opus":0.03763956775805979,"score_gpt":0.3360157777617022,"score_spread":0.29837621000364245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296528992","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916668,0.0027298264,0.00007583554,0.000877489,0.0004571451,0.0030592917,0.00071877637,0.0001102393,0.00030460145],"genre_scores_gemma":[0.9948243,0.0004265463,0.00086662004,0.00036218172,0.00047732287,0.00046619624,0.0021208543,0.00014205073,0.00031393507],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9918762,0.0014560083,0.0030317863,0.0014288293,0.001355666,0.0008515221],"domain_scores_gemma":[0.9915258,0.004275165,0.001651255,0.0018739321,0.00024586113,0.0004279395],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030600836,0.0007246173,0.002208508,0.00023757982,0.00037463047,0.000058960173,0.0007189575,0.00041330027,0.00048038876],"category_scores_gemma":[0.001927977,0.000532756,0.00045984695,0.00091245194,0.00079866836,0.00023845729,0.00058759877,0.0009523417,0.000036546913],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013356484,0.002362439,0.18503489,0.00022872844,0.0012335024,0.0002686835,0.00075220334,0.0012134367,0.00035636002,0.0010433478,0.0015258479,0.79262406],"study_design_scores_gemma":[0.076605715,0.004969195,0.88539016,0.00034103935,0.00075502397,0.000051873343,0.00027970097,0.028764013,0.00014143607,0.00025449914,0.0019225288,0.00052480365],"about_ca_topic_score_codex":0.0016860326,"about_ca_topic_score_gemma":0.0004532585,"teacher_disagreement_score":0.7920993,"about_ca_system_score_codex":0.028479364,"about_ca_system_score_gemma":0.009866438,"threshold_uncertainty_score":0.9997124},"labels":[],"label_agreement":null},{"id":"W4296529229","doi":"10.1016/s2152-2650(22)01498-7","title":"ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Health Sciences Centre; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Rituximab; Vincristine; Internal medicine; Prednisone; Gastroenterology; CHOP; Hazard ratio; Cyclophosphamide; Clinical endpoint; International Prognostic Index; Surgery; Confidence interval; Lymphoma; Chemotherapy; Randomized controlled trial","score_opus":0.016170071289462105,"score_gpt":0.2827769139615351,"score_spread":0.26660684267207296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529229","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9749622,0.012672566,0.000009114409,0.0007665054,0.00096467586,0.0075729713,0.002274357,0.00041337986,0.00036422597],"genre_scores_gemma":[0.99050105,0.0031024325,0.00045435858,0.0017648926,0.00043279596,0.0008822467,0.0020825306,0.00033496643,0.00044471308],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98645204,0.0015394575,0.003935031,0.003666619,0.0022024813,0.0022043486],"domain_scores_gemma":[0.98921406,0.0043167956,0.0016750781,0.0029559163,0.0004700821,0.001368045],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002021089,0.0019838463,0.0037114827,0.00040219547,0.0016319164,0.00036007958,0.0010748373,0.0006847157,0.00015025501],"category_scores_gemma":[0.0010208912,0.0014652812,0.00055136683,0.0016530928,0.0008587014,0.0005149066,0.001511246,0.0010214762,0.000061527615],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18650578,0.11556724,0.54302853,0.00007467736,0.0018942411,0.0022036552,0.0042942856,0.000014008124,0.000073761665,0.000054913042,0.0023389808,0.14394994],"study_design_scores_gemma":[0.44162685,0.01262207,0.5381161,0.0002052253,0.0008978588,0.000051583673,0.0011740777,0.00054655096,0.00014919264,0.000039919545,0.0037014051,0.00086916244],"about_ca_topic_score_codex":0.017601097,"about_ca_topic_score_gemma":0.0015176507,"teacher_disagreement_score":0.25512108,"about_ca_system_score_codex":0.0054783206,"about_ca_system_score_gemma":0.0024628998,"threshold_uncertainty_score":0.9996678},"labels":[],"label_agreement":null},{"id":"W4296529430","doi":"10.1016/s2152-2650(22)00990-9","title":"Poster: HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"Brentuximab vedotin; Oncology; Stage (stratigraphy); Internal medicine; Medicine; Classical Hodgkin lymphoma; Chemotherapy; Hodgkin lymphoma; Lymphoma; Biology","score_opus":0.019777399116568974,"score_gpt":0.29484443637337776,"score_spread":0.2750670372568088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529430","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99615157,0.00015246945,0.000022720444,0.00068800297,0.00041047725,0.0013935906,0.00054209126,0.00017222064,0.00046683702],"genre_scores_gemma":[0.9933378,0.00010411874,0.0003647953,0.0014545899,0.00017335404,0.00020766379,0.0036873876,0.00014268019,0.00052757945],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99251723,0.0006233197,0.002536746,0.001726308,0.0015650505,0.0010313682],"domain_scores_gemma":[0.9954794,0.00070652255,0.0010499791,0.0017186768,0.00034038007,0.0007050127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011056485,0.0008625796,0.0029792702,0.0007526937,0.00028188832,0.00007316115,0.00068306853,0.00045055762,0.00070363755],"category_scores_gemma":[0.00014725213,0.0007151365,0.0009760449,0.0020718025,0.0004593824,0.00028486433,0.00047654574,0.00036689322,0.00002319787],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018363563,0.012780829,0.798163,0.000054592594,0.0034860068,0.00044986804,0.00036851698,0.0003484632,0.00006494004,0.00013583885,0.00047307066,0.16531132],"study_design_scores_gemma":[0.08047811,0.006880336,0.89970875,0.00006433445,0.001793371,0.000013620909,0.00013313956,0.006880114,0.00030974727,0.000026857253,0.003046782,0.0006648607],"about_ca_topic_score_codex":0.0017736065,"about_ca_topic_score_gemma":0.00076872966,"teacher_disagreement_score":0.16464646,"about_ca_system_score_codex":0.004843094,"about_ca_system_score_gemma":0.002053859,"threshold_uncertainty_score":0.99952996},"labels":[],"label_agreement":null},{"id":"W4296529438","doi":"10.1016/s2152-2650(22)00691-7","title":"Oral Abstract: AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Azacitidine; Myeloid leukemia; Medicine; Placebo; IDH1; Oncology; Internal medicine; Mutation; Biology; Pathology; Genetics","score_opus":0.04273344456218377,"score_gpt":0.36451510903937834,"score_spread":0.3217816644771946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529438","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98628247,0.00010706783,0.0000792401,0.00025324826,0.000534623,0.011241168,0.00040836647,0.00030695027,0.0007868813],"genre_scores_gemma":[0.99281794,0.00008119747,0.0014294538,0.00043194322,0.00036642604,0.0023246466,0.0021271056,0.00026337348,0.0001579354],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9865906,0.0016690723,0.0039260755,0.0024347987,0.0036391288,0.0017402816],"domain_scores_gemma":[0.9905349,0.0029496595,0.001781037,0.0021902157,0.001173541,0.0013706401],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.004198793,0.0013373176,0.004109207,0.00084993965,0.00054686656,0.00016475571,0.0013173205,0.00057519873,0.0006114834],"category_scores_gemma":[0.0011779116,0.0010949624,0.00058884406,0.0031509504,0.0013746389,0.0010198589,0.0007241013,0.0018546891,0.00006772933],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.87013733,0.00890349,0.050582204,0.00012066521,0.0021207558,0.0055431826,0.0009120207,0.0014058636,0.00007639218,0.00009307993,0.0006699589,0.059435043],"study_design_scores_gemma":[0.7280246,0.028641012,0.23512703,0.00018038771,0.0015720109,0.00016974869,0.0028694598,0.0021038402,0.00019888973,0.0000409851,0.00016304679,0.00090900843],"about_ca_topic_score_codex":0.0044756904,"about_ca_topic_score_gemma":0.0016914451,"teacher_disagreement_score":0.18454483,"about_ca_system_score_codex":0.010339156,"about_ca_system_score_gemma":0.007480352,"threshold_uncertainty_score":0.9999378},"labels":[],"label_agreement":null},{"id":"W4296529454","doi":"10.1016/s2152-2650(22)00699-1","title":"Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Health Sciences Centre; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Prednisone; Vincristine; Medicine; Doxorubicin; Rituximab; Cyclophosphamide; CHOP; Internal medicine; Oncology; Chemotherapy; Gastroenterology; Lymphoma","score_opus":0.01905922969332775,"score_gpt":0.29031897160643977,"score_spread":0.27125974191311203,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9781217,0.009975769,0.0000053244835,0.0006254126,0.00095135334,0.0071019833,0.0024059706,0.00039644804,0.00041601935],"genre_scores_gemma":[0.99153507,0.0024626483,0.0004344323,0.0015476139,0.00039204233,0.0007497293,0.0022145412,0.00032513292,0.0003388161],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9870138,0.0010943394,0.003994293,0.0035229255,0.0021837284,0.0021909014],"domain_scores_gemma":[0.98971707,0.0039720177,0.0017377953,0.0027508985,0.00046170093,0.0013605354],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.002097206,0.0019644804,0.0036711928,0.00038448154,0.0015512223,0.00037819616,0.001037897,0.0007028861,0.00019040258],"category_scores_gemma":[0.00095652335,0.001454708,0.0005454646,0.001469667,0.0009335237,0.00056490226,0.0013095255,0.0010841477,0.000066110595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.18350068,0.12060816,0.5066136,0.000078394136,0.0017997171,0.0025622302,0.0037927143,0.000015582486,0.00008158962,0.00004521926,0.0023096278,0.17859249],"study_design_scores_gemma":[0.43099856,0.010626554,0.55128145,0.00019413176,0.0008279946,0.000048164206,0.0010723658,0.00038852,0.0001436025,0.000035385234,0.0035279717,0.0008552725],"about_ca_topic_score_codex":0.018114846,"about_ca_topic_score_gemma":0.0016500098,"teacher_disagreement_score":0.24749789,"about_ca_system_score_codex":0.004440675,"about_ca_system_score_gemma":0.0023038115,"threshold_uncertainty_score":0.99974865},"labels":[],"label_agreement":null},{"id":"W4296529456","doi":"10.1016/s2152-2650(22)01102-8","title":"Poster: MM-233 Evaluation of the Comparative Effectiveness of In-Class Transition (iCT) to ALL-Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) After Bortezomib (V)-Based Induction Therapy vs Patients Who Continued to Receive Parenteral V-Based Therapy in Newly Diagnosed Multiple Myeloma (NDMM)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVRAZ (Canada)","funders":"","keywords":"Lenalidomide; Dexamethasone; Ixazomib; Induction therapy; Bortezomib; Medicine; Oncology; Internal medicine; Multiple myeloma; Chemotherapy","score_opus":0.07614721502983941,"score_gpt":0.37314232684239695,"score_spread":0.29699511181255756,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529456","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894147,0.00014467219,0.000058718044,0.0006961605,0.0004785555,0.008792196,0.00033537784,0.00003755406,0.000042089574],"genre_scores_gemma":[0.9942513,0.000025289615,0.00025386707,0.0016595504,0.00007476382,0.0031495367,0.00049917103,0.000078203906,0.00000829217],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98714834,0.0070960843,0.0019316243,0.0011029362,0.0019787154,0.0007423084],"domain_scores_gemma":[0.99402857,0.0029986075,0.00061731297,0.00095093175,0.0009879691,0.0004165813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004390095,0.0005923063,0.0018024016,0.00068174425,0.00013830149,0.000035033914,0.00047783335,0.00029263212,0.000150277],"category_scores_gemma":[0.0013762722,0.00047635057,0.00063399336,0.0014669717,0.000258119,0.00019922016,0.0001318288,0.0005596173,0.000012851742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13604142,0.0039009273,0.7018035,0.00009329829,0.00034665837,0.000053506858,0.0021345532,0.0036363967,0.005935052,0.0000019489746,0.00010065358,0.14595208],"study_design_scores_gemma":[0.08913777,0.0067544435,0.8608533,0.00070714415,0.00010847389,0.000003236691,0.00023365031,0.010025857,0.031676438,0.000032465556,0.00011582386,0.00035140166],"about_ca_topic_score_codex":0.0014302955,"about_ca_topic_score_gemma":0.0006844632,"teacher_disagreement_score":0.1590498,"about_ca_system_score_codex":0.00306751,"about_ca_system_score_gemma":0.0017593172,"threshold_uncertainty_score":0.9997688},"labels":[],"label_agreement":null},{"id":"W4296529771","doi":"10.1016/s2152-2650(22)01353-2","title":"CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada)","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Incidence (geometry); Adverse effect; Retrospective cohort study; Oncology; Leukemia","score_opus":0.036764102197981624,"score_gpt":0.3554531914982372,"score_spread":0.3186890893002555,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99062365,0.00021792606,0.000015972828,0.00072129734,0.0011942353,0.0010030265,0.00006446341,0.00020466199,0.005954747],"genre_scores_gemma":[0.9876622,0.00013070377,0.0006910345,0.003969526,0.000683245,0.00013675078,0.00023997344,0.00015102731,0.006335517],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99241966,0.00088017026,0.00235359,0.0013746645,0.0019096833,0.0010622122],"domain_scores_gemma":[0.9946279,0.0011857426,0.0006056782,0.0022505536,0.00029810297,0.0010320134],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002505,0.0005139958,0.0015133802,0.00030865884,0.0003853239,0.000029274423,0.0009356217,0.00040586674,0.004413886],"category_scores_gemma":[0.001242453,0.00040929008,0.00089281367,0.0006902744,0.0009073131,0.00021365724,0.0013172984,0.00076000235,0.001033334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.027422227,0.008794311,0.0598681,0.0016206366,0.001744406,0.039601676,0.0025370603,0.00054868095,0.023726152,0.0029343555,0.07145732,0.75974506],"study_design_scores_gemma":[0.062325057,0.006179317,0.81435394,0.0004147444,0.0006240494,0.0058463374,0.002533762,0.011569161,0.005627646,0.0019546016,0.08738061,0.0011908007],"about_ca_topic_score_codex":0.0014134487,"about_ca_topic_score_gemma":0.000030731433,"teacher_disagreement_score":0.7585543,"about_ca_system_score_codex":0.01625678,"about_ca_system_score_gemma":0.016233597,"threshold_uncertainty_score":0.9998359},"labels":[],"label_agreement":null},{"id":"W4296529960","doi":"10.1016/s2152-2650(22)01087-4","title":"Poster: TCL-323 Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) With Intention for Curative Therapy Incorporating High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Refractory (planetary science); Oncology; Chemotherapy; Internal medicine; Lymphoma; Stem cell; Peripheral T-cell lymphoma; Hematopoietic stem cell transplantation; Transplantation; T cell; Immunology; Biology; Immune system","score_opus":0.028208172304721193,"score_gpt":0.28940357171932724,"score_spread":0.26119539941460607,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529960","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99432164,0.0021249277,0.00008524845,0.0007023161,0.0002731458,0.0019149997,0.00014506925,0.00009766514,0.0003349791],"genre_scores_gemma":[0.99511045,0.00093517004,0.001183093,0.0012779875,0.00010337059,0.00049434014,0.00017829509,0.00012105123,0.00059623853],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9959543,0.0003436237,0.0016180761,0.0010271043,0.0005610941,0.0004958127],"domain_scores_gemma":[0.99690396,0.00095579657,0.00095482793,0.0006064703,0.00020239086,0.00037653124],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074736227,0.00061242364,0.0014735002,0.00015320694,0.0003836023,0.00005970346,0.00021039521,0.00027402284,0.00005844087],"category_scores_gemma":[0.000023747167,0.00046860543,0.00038736273,0.00026670343,0.00046988946,0.00020591229,0.000107875494,0.00020921062,0.000003647154],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021849252,0.0058064624,0.45661795,0.00078889617,0.00076811947,0.0005380149,0.0045520253,0.000008746628,0.0069444026,0.0004927873,0.00030422508,0.5013291],"study_design_scores_gemma":[0.089107886,0.016041026,0.8733849,0.00034708402,0.00050157367,0.0005676094,0.0022894635,0.0005801561,0.013711632,0.00027851822,0.0024211952,0.0007689685],"about_ca_topic_score_codex":0.00020986218,"about_ca_topic_score_gemma":0.0000197216,"teacher_disagreement_score":0.50056016,"about_ca_system_score_codex":0.0010395481,"about_ca_system_score_gemma":0.0007005716,"threshold_uncertainty_score":0.99977654},"labels":[],"label_agreement":null},{"id":"W4296529971","doi":"10.1016/s2152-2650(22)01483-5","title":"HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC","funders":"","keywords":"ABVD; Dacarbazine; Brentuximab vedotin; Medicine; Internal medicine; Vinblastine; Hazard ratio; Oncology; Bleomycin; Progression-free survival; Chemotherapy; Chemotherapy regimen; Confidence interval; Lymphoma; Surgery; Vincristine; Hodgkin lymphoma; Cyclophosphamide","score_opus":0.02059907530529329,"score_gpt":0.29731698021762476,"score_spread":0.27671790491233145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296529971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964046,0.00014809768,0.00004150884,0.00058124564,0.0004007041,0.0013333167,0.00046741875,0.00017560598,0.0004475288],"genre_scores_gemma":[0.9936369,0.00011488995,0.0005611134,0.001203802,0.0001825644,0.00023151228,0.0033619897,0.0001392555,0.0005679448],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925706,0.0006031456,0.0024936295,0.0017182912,0.0015889948,0.0010253744],"domain_scores_gemma":[0.99550474,0.00073078164,0.0010326754,0.0016991141,0.00032866225,0.00070404273],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001165254,0.0008451743,0.0029847156,0.0007395976,0.0002893802,0.000066734676,0.0006719561,0.00044765882,0.0007834861],"category_scores_gemma":[0.00016748263,0.0007012927,0.00096902845,0.0022382857,0.0004816441,0.00026865356,0.00043618778,0.00037197443,0.000022748813],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016789172,0.013910213,0.77585804,0.000054042564,0.0036631122,0.00042740026,0.0003351102,0.0006940702,0.000058468908,0.00023114459,0.0006210423,0.1873582],"study_design_scores_gemma":[0.08009349,0.00586605,0.89476895,0.000057906505,0.001774982,0.000009964797,0.0001508894,0.012278521,0.00026065882,0.000035611203,0.0040525757,0.00065042294],"about_ca_topic_score_codex":0.0018441093,"about_ca_topic_score_gemma":0.0007835152,"teacher_disagreement_score":0.18670776,"about_ca_system_score_codex":0.0050355354,"about_ca_system_score_gemma":0.0022017225,"threshold_uncertainty_score":0.99954385},"labels":[],"label_agreement":null},{"id":"W4296530176","doi":"10.1016/s2152-2650(22)01456-2","title":"MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis – JAK Inhibitor-Naïe or With Suboptimal Response to Ruxolitinib – Preliminary Data From the MANIFEST Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Anemia; Phases of clinical research; Fibrosis; Extramedullary hematopoiesis; Surgery; Bone marrow; Clinical trial; Haematopoiesis; Stem cell","score_opus":0.050845993663231476,"score_gpt":0.3320740202494757,"score_spread":0.28122802658624424,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296530176","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98708814,0.000073686824,0.000006587828,0.0016392539,0.00026212406,0.007661905,0.0027161215,0.00024561505,0.00030657285],"genre_scores_gemma":[0.9896997,0.000010049644,0.0021902039,0.0013390447,0.0005465692,0.0013678046,0.003433396,0.0002984722,0.0011147371],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872471,0.0027319398,0.0020314034,0.0028713457,0.00326745,0.0018507474],"domain_scores_gemma":[0.9874219,0.005441955,0.00063042546,0.0044843983,0.0005084155,0.0015129221],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028172699,0.0011628337,0.0018822122,0.00042143578,0.0009630996,0.00024324899,0.0020188878,0.0002644894,0.00056112383],"category_scores_gemma":[0.0018633275,0.0006869888,0.0002037592,0.0018358737,0.00077827036,0.0005341234,0.0028239738,0.0013199046,0.00022499815],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38051194,0.006233795,0.58944845,0.00004169438,0.0006506159,0.0047319434,0.00069571426,0.00002454472,0.000021879665,0.000006356866,0.0032474333,0.014385619],"study_design_scores_gemma":[0.06947618,0.07887579,0.84329087,0.0005303151,0.0005193849,0.00018485762,0.0033045157,0.00030682652,0.000057266727,0.0000075991825,0.002640174,0.00080625725],"about_ca_topic_score_codex":0.0018602333,"about_ca_topic_score_gemma":0.001197379,"teacher_disagreement_score":0.31103575,"about_ca_system_score_codex":0.0020491632,"about_ca_system_score_gemma":0.0043673147,"threshold_uncertainty_score":0.99955815},"labels":[],"label_agreement":null},{"id":"W4296530244","doi":"10.1016/s2152-2650(22)00769-8","title":"Poster: AML-131 ERG: From a Fortuitous Discovery to Potential Treatment for AML","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Click Chemistry and Applications","field":"Chemistry","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Erg; Medicine; Oncology; Ophthalmology; Retinal","score_opus":0.032545852797152705,"score_gpt":0.3174039294071079,"score_spread":0.28485807660995516,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296530244","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902198,0.00015659354,0.0004437474,0.0012709078,0.0004800962,0.00048375272,0.0036132683,0.00023824761,0.0030936182],"genre_scores_gemma":[0.9800674,0.000044251065,0.0006297556,0.0011727622,0.0021311152,0.0019940676,0.0020768389,0.00009581779,0.01178802],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99645054,0.000051418167,0.0011821492,0.0012550654,0.00039492713,0.0006658843],"domain_scores_gemma":[0.9967755,0.0010134211,0.0003312704,0.001323822,0.00006880582,0.00048718462],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00020110699,0.00045883935,0.0006970381,0.000039383463,0.00068338047,0.0001470345,0.00083645806,0.00027685592,0.0012198718],"category_scores_gemma":[0.00021505996,0.00046696953,0.00088057714,0.00020748113,0.00013634433,0.00013072729,0.00058594084,0.00023099077,0.00012416027],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031331806,0.002154026,0.00406324,0.000078407415,0.00069344795,0.00021911846,0.00033145005,0.000329924,0.17337532,0.00044204504,0.029173417,0.78600645],"study_design_scores_gemma":[0.012268815,0.0010111881,0.044076435,0.000092794326,0.0006855785,0.00016309186,0.00076256145,0.0013094827,0.2084011,0.004696216,0.7248157,0.0017170442],"about_ca_topic_score_codex":0.00033263874,"about_ca_topic_score_gemma":0.00003725206,"teacher_disagreement_score":0.78428936,"about_ca_system_score_codex":0.0018633648,"about_ca_system_score_gemma":0.0007481187,"threshold_uncertainty_score":0.9997782},"labels":[],"label_agreement":null},{"id":"W4296531520","doi":"10.1016/s2152-2650(22)01225-3","title":"AML-131 ERG: From a Fortuitous Discovery to Potential Treatment for AML","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network; University of Toronto","funders":"","keywords":"Erg; Biology; Myeloid; Cancer research; ETS transcription factor family; Haematopoiesis; Myeloid leukemia; Molecular biology; Transcription factor; Stem cell; Cell biology; Genetics; Gene; Biochemistry","score_opus":0.046372543334708104,"score_gpt":0.3594096536005253,"score_spread":0.3130371102658172,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296531520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9848182,0.00043269157,0.0024622006,0.0044252365,0.0018915102,0.0032245487,0.0013398497,0.00030600064,0.001099757],"genre_scores_gemma":[0.96518064,0.00018905949,0.005726892,0.0059511675,0.003739057,0.0022293783,0.0013749292,0.00023909156,0.015369814],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9934431,0.00041029722,0.001705835,0.0018021226,0.0012065406,0.0014321517],"domain_scores_gemma":[0.99469244,0.0017502119,0.0003257736,0.0017597103,0.0002247008,0.0012471878],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010173687,0.0006726283,0.0015906966,0.0003197548,0.0007171318,0.00015685837,0.0008637974,0.00039073205,0.00072491047],"category_scores_gemma":[0.0011156736,0.0005976407,0.0014085021,0.0006507438,0.00030459004,0.00024520236,0.0010405924,0.00055616646,0.00042783204],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016210524,0.0015254946,0.0072312444,0.000057452133,0.0012202527,0.002257851,0.00036921704,0.00031876125,0.004630184,0.00041829038,0.087637566,0.87812316],"study_design_scores_gemma":[0.03419509,0.013689064,0.47637108,0.00012537214,0.0010388794,0.0005390627,0.00086253637,0.008478884,0.002632144,0.001984701,0.45884103,0.0012421564],"about_ca_topic_score_codex":0.0014351557,"about_ca_topic_score_gemma":0.00009048861,"teacher_disagreement_score":0.876881,"about_ca_system_score_codex":0.010228192,"about_ca_system_score_gemma":0.0054560816,"threshold_uncertainty_score":0.9996475},"labels":[],"label_agreement":null},{"id":"W4296531529","doi":"10.1016/s2152-2650(22)01009-6","title":"Poster: ABCL-412 Clinical Activity of CC-99282, a Novel, Oral, Small Molecule Cereblon E3 Ligase Modulator (CELMoD) Agent, in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma (R/R NHL) –Results From CC-99282-NHL-001 (NCT03930953) a First-in-Human, Phase 1, Open-Label, Multicenter Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Protein Degradation and Inhibitors","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Cereblon; Ubiquitin ligase; Refractory (planetary science); Medicine; Lymphoma; Cancer research; Oncology; Internal medicine; Chemistry; Materials science; Ubiquitin; Biochemistry","score_opus":0.04134696371287629,"score_gpt":0.33305286343685647,"score_spread":0.2917058997239802,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296531529","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939817,0.00010873242,0.00005716349,0.00011565371,0.00079078344,0.0034605688,0.0011426916,0.00005341477,0.00028925322],"genre_scores_gemma":[0.99535626,0.00005441571,0.0006045493,0.00089907594,0.0002777888,0.00041841262,0.0018869573,0.00018546621,0.00031704325],"study_design_codex":"nonrandomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99040544,0.0014616251,0.003549346,0.0026664566,0.0009063023,0.0010108581],"domain_scores_gemma":[0.99437535,0.0004949741,0.0018413597,0.0023092208,0.00035139237,0.00062768854],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023011537,0.00095024373,0.001697821,0.00030335074,0.00037294277,0.00014986497,0.0019205058,0.0007598543,0.000059538947],"category_scores_gemma":[0.0011840056,0.0009293746,0.00039181949,0.0006537181,0.00046333185,0.00011436301,0.002501858,0.0007548973,0.000030535757],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07720656,0.5214218,0.23038022,0.0001105722,0.0011788993,0.00057923724,0.0005841167,0.00008654125,0.023579136,0.000011352119,0.004957301,0.13990426],"study_design_scores_gemma":[0.41153285,0.015054801,0.55057997,0.00017112518,0.00016296294,0.0000056724894,0.00014466673,0.0018970717,0.012946564,0.000009615448,0.0063027325,0.0011919467],"about_ca_topic_score_codex":0.0028180159,"about_ca_topic_score_gemma":0.0016927491,"teacher_disagreement_score":0.50636697,"about_ca_system_score_codex":0.0008982987,"about_ca_system_score_gemma":0.0011430768,"threshold_uncertainty_score":0.9993157},"labels":[],"label_agreement":null},{"id":"W4296531778","doi":"10.1016/s2152-2650(22)00998-3","title":"Poster: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Classical Hodgkin lymphoma; Refractory (planetary science); Open label; Medicine; Phases of clinical research; Oncology; Internal medicine; Multicenter study; Hodgkin lymphoma; Lymphoma; Dermatology; Clinical trial; Materials science; Randomized controlled trial","score_opus":0.05618524231538953,"score_gpt":0.38786569538728344,"score_spread":0.3316804530718939,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296531778","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99278593,0.00013801776,0.000003524661,0.00016213053,0.00034903554,0.0058638253,0.00021598987,0.00015974099,0.0003218028],"genre_scores_gemma":[0.9965883,0.000066743334,0.00040518053,0.0006968021,0.00016363688,0.00033465293,0.00080780406,0.00022812358,0.00070875173],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98907083,0.002107386,0.0032150613,0.0022409908,0.0020690844,0.001296674],"domain_scores_gemma":[0.99271226,0.002236461,0.0009410694,0.002399447,0.0005353343,0.0011754486],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0023539683,0.00084496586,0.0023715307,0.00054411584,0.00046927604,0.0001359923,0.0016316785,0.0004552592,0.00050461426],"category_scores_gemma":[0.0017207187,0.000673639,0.00012298799,0.0015748636,0.0009322367,0.00060356356,0.002805171,0.00096982194,0.0000316737],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.31646904,0.087678656,0.11679991,0.00020318826,0.0006453996,0.004170267,0.0012592457,0.000018356863,0.00035363247,0.000024301069,0.0011235507,0.47125444],"study_design_scores_gemma":[0.38240552,0.05172385,0.55640674,0.00017161295,0.00025726942,0.00014225279,0.00066004146,0.004890279,0.00005787874,0.000004049057,0.002759588,0.00052091613],"about_ca_topic_score_codex":0.0012639253,"about_ca_topic_score_gemma":0.0004833176,"teacher_disagreement_score":0.47073352,"about_ca_system_score_codex":0.021952817,"about_ca_system_score_gemma":0.014441988,"threshold_uncertainty_score":0.9995715},"labels":[],"label_agreement":null},{"id":"W4296532110","doi":"10.1016/s2152-2650(22)00749-2","title":"Poster: AML-397 Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients With Hematologic Malignancies","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; Alberta Hospital Edmonton; Princess Margaret Cancer Centre","funders":"","keywords":"Hematologic Neoplasms; Medicine; Oncology; Interleukin-3 receptor; Internal medicine; Intensive care medicine; Leukemia; Cancer","score_opus":0.021351125916885073,"score_gpt":0.29769149897282654,"score_spread":0.27634037305594145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532110","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616575,0.00049805234,0.000018666857,0.0001809256,0.00020004205,0.0015022437,0.00039174844,0.00027010232,0.0007724741],"genre_scores_gemma":[0.9959283,0.00014303451,0.00048389798,0.0007864113,0.00004473146,0.00019921653,0.001824835,0.00009340505,0.00049618346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99224085,0.0011761223,0.0025125886,0.0012833365,0.0017245044,0.001062576],"domain_scores_gemma":[0.995029,0.0015031463,0.0007621349,0.0015069555,0.00074531743,0.00045345092],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017679993,0.0006075544,0.0026347593,0.001240255,0.00022793624,0.00003420621,0.0007950099,0.0003971256,0.0017221787],"category_scores_gemma":[0.0012779309,0.00046066075,0.00080783444,0.0068076365,0.00079941587,0.00014362806,0.00057550863,0.00075222604,0.000029845169],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.026429143,0.0027095275,0.89064103,0.00012760809,0.0040125065,0.0009425722,0.0005887684,0.0003861233,0.00035344038,0.00012445956,0.0011509178,0.0725339],"study_design_scores_gemma":[0.04312558,0.00331804,0.94059074,0.00013382865,0.00069390173,0.00006906619,0.00028908983,0.008463546,0.00051858055,0.000035072746,0.0022808316,0.00048174764],"about_ca_topic_score_codex":0.001929126,"about_ca_topic_score_gemma":0.00026791106,"teacher_disagreement_score":0.07205214,"about_ca_system_score_codex":0.019816704,"about_ca_system_score_gemma":0.012451732,"threshold_uncertainty_score":0.9997845},"labels":[],"label_agreement":null},{"id":"W4296532114","doi":"10.1016/s2152-2650(22)00866-7","title":"Poster: CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Atrial fibrillation; Internal medicine; Persistence (discontinuity); Stroke (engine); Oncology; Lymphoma; Cardiology; Leukemia","score_opus":0.048856901715748684,"score_gpt":0.3180669262570643,"score_spread":0.2692100245413156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532114","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9847443,0.0002545457,0.000006640346,0.00007275999,0.00035866958,0.013417716,0.00062689144,0.00021946114,0.00029899413],"genre_scores_gemma":[0.9890599,0.0002847882,0.00068603916,0.00018105091,0.0007859817,0.0012824581,0.00088533654,0.00034273058,0.00649168],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98879606,0.001149788,0.0026584733,0.003146657,0.002076345,0.002172664],"domain_scores_gemma":[0.99133164,0.0035677578,0.0011593807,0.0020010672,0.00053339574,0.0014067666],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013139934,0.0015404378,0.0028873547,0.0009999295,0.0013471394,0.00022717023,0.0006577958,0.0003933947,0.00040170786],"category_scores_gemma":[0.0006183348,0.0011309248,0.00070183835,0.0017534274,0.0005296767,0.0003854408,0.0011888484,0.0002517026,0.00021244115],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.13441929,0.0011709719,0.5047441,0.00018363059,0.0018714394,0.0006595541,0.0016489382,0.0051908116,0.000017000326,0.000004857307,0.00013261326,0.34995675],"study_design_scores_gemma":[0.27760583,0.08744665,0.60401857,0.00031463496,0.001637217,0.00015880381,0.00031058353,0.024227912,0.00009398301,0.0000063386665,0.0030585267,0.0011209137],"about_ca_topic_score_codex":0.012111588,"about_ca_topic_score_gemma":0.0057370244,"teacher_disagreement_score":0.49882454,"about_ca_system_score_codex":0.57181054,"about_ca_system_score_gemma":0.07298599,"threshold_uncertainty_score":0.999953},"labels":[],"label_agreement":null},{"id":"W4296532123","doi":"10.1016/s2152-2650(22)01095-3","title":"Poster: MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"","keywords":"Carfilzomib; Dexamethasone; Multiple myeloma; Psychology; Medicine; Internal medicine; Bortezomib","score_opus":0.04094230007902169,"score_gpt":0.3441232329738066,"score_spread":0.30318093289478487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532123","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962655,0.0010662619,0.000025972364,0.00039811246,0.00015020861,0.0011607215,0.00036990317,0.000077062265,0.00048627492],"genre_scores_gemma":[0.99630195,0.00013192924,0.0019265622,0.0002507376,0.000056233726,0.0001474085,0.00044342777,0.00008078587,0.0006609852],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99195987,0.0022180665,0.0024885526,0.0012011844,0.0012502973,0.00088203343],"domain_scores_gemma":[0.9925643,0.004174593,0.0007926699,0.0014276676,0.0003462572,0.00069451873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034452002,0.0005187737,0.0025375308,0.0013109988,0.00019273408,0.000022137638,0.000497855,0.00038645588,0.00037906182],"category_scores_gemma":[0.0043502045,0.00048253225,0.00083170435,0.0029807864,0.0007692325,0.000118838914,0.00080748287,0.0006498717,0.000020124085],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06670621,0.0015282911,0.8183306,0.000147647,0.0025267703,0.0016411447,0.0005955393,0.00014259748,0.0070674033,0.00002689885,0.00036053368,0.10092639],"study_design_scores_gemma":[0.0394988,0.002704774,0.9413657,0.000083503015,0.0010393524,0.00016255816,0.0005052926,0.009481134,0.0042239157,0.000038767826,0.0005414187,0.0003547446],"about_ca_topic_score_codex":0.0017856981,"about_ca_topic_score_gemma":0.0005177116,"teacher_disagreement_score":0.12303517,"about_ca_system_score_codex":0.0017906772,"about_ca_system_score_gemma":0.0022512781,"threshold_uncertainty_score":0.99976265},"labels":[],"label_agreement":null},{"id":"W4296532403","doi":"10.1016/s2152-2650(22)01303-9","title":"AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Venetoclax; Medicine; Azacitidine; Cohort; Internal medicine; Neutropenia; Myeloid leukemia; Myeloid; Myelodysplastic syndromes; Oncology; Hypomethylating agent; Tolerability; Leukemia; Gastroenterology; Chemotherapy; Adverse effect; Chronic lymphocytic leukemia; Bone marrow","score_opus":0.02956475525237945,"score_gpt":0.32890525914134455,"score_spread":0.2993405038889651,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532403","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99154514,0.00019244186,0.000015465768,0.00070300093,0.00045069816,0.005101601,0.0007724203,0.0003020862,0.0009171493],"genre_scores_gemma":[0.99311066,0.00008536974,0.0019729037,0.0012414424,0.00047371798,0.00087562006,0.0011765452,0.0003204418,0.0007433086],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98591405,0.0014065682,0.0047840565,0.0026463317,0.003174841,0.002074135],"domain_scores_gemma":[0.9899096,0.003242266,0.0017438853,0.0028119995,0.0008027822,0.0014894678],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0038002967,0.001241051,0.0031444426,0.0010142009,0.0011108845,0.00009099455,0.0016752728,0.00057379634,0.00027030305],"category_scores_gemma":[0.0051860632,0.0011481509,0.000640196,0.0035194047,0.0014067586,0.0004986323,0.0025006242,0.002477221,0.0000767876],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07002507,0.014506269,0.57617676,0.0004660564,0.0024733248,0.0076762782,0.006382441,0.0050187823,0.0009160416,0.00007522316,0.019283049,0.2970007],"study_design_scores_gemma":[0.17951836,0.036222048,0.76579356,0.00053735654,0.00068414083,0.00013540828,0.0013437114,0.009039472,0.0005439062,0.00007048151,0.0050065196,0.0011050184],"about_ca_topic_score_codex":0.0025335895,"about_ca_topic_score_gemma":0.0004719463,"teacher_disagreement_score":0.2958957,"about_ca_system_score_codex":0.015910089,"about_ca_system_score_gemma":0.012170118,"threshold_uncertainty_score":0.9998241},"labels":[],"label_agreement":null},{"id":"W4296532460","doi":"10.1016/s2152-2650(22)00702-9","title":"Oral Abstract: HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; University of British Columbia; Ottawa Hospital","funders":"","keywords":"Classical Hodgkin lymphoma; Refractory (planetary science); Open label; Medicine; Internal medicine; Oncology; Phases of clinical research; Multicenter study; Lymphoma; Gastroenterology; Adverse effect; Clinical trial; Hodgkin lymphoma; Biology; Randomized controlled trial","score_opus":0.06725159472618122,"score_gpt":0.39759381578532066,"score_spread":0.33034222105913946,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532460","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99336284,0.00010993165,0.000003374425,0.0001267948,0.00034645494,0.005336198,0.00021257391,0.00016169417,0.0003401487],"genre_scores_gemma":[0.99667966,0.000060708302,0.0005952604,0.0005020262,0.00015763147,0.00031941666,0.00081679615,0.00022400952,0.0006444675],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98964435,0.001380152,0.0033115873,0.0021999408,0.0021339222,0.0013300437],"domain_scores_gemma":[0.9928548,0.0021775584,0.0010029939,0.002237594,0.00051957817,0.0012075113],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026596284,0.0008550453,0.0023989885,0.0005152883,0.00047276283,0.00014173321,0.0015923127,0.00048515265,0.0007559243],"category_scores_gemma":[0.0018072808,0.0006844852,0.00012496788,0.0014990852,0.0009853657,0.00065908517,0.0022555406,0.0010980163,0.000036396996],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.26083785,0.090965256,0.0825462,0.00019607056,0.00058357365,0.004388959,0.0009116902,0.00003631425,0.0003290574,0.000027456777,0.0013532601,0.5578243],"study_design_scores_gemma":[0.36306372,0.03615956,0.5902332,0.00015117902,0.00023663559,0.00010038482,0.00070478045,0.0055097956,0.00004788774,0.0000051741777,0.0032684985,0.00051913445],"about_ca_topic_score_codex":0.001780724,"about_ca_topic_score_gemma":0.00069767557,"teacher_disagreement_score":0.5573052,"about_ca_system_score_codex":0.021216832,"about_ca_system_score_gemma":0.015119169,"threshold_uncertainty_score":0.99956065},"labels":[],"label_agreement":null},{"id":"W4296532704","doi":"10.1016/s2152-2650(22)01552-x","title":"IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Lenalidomide; Rituximab; Medicine; Internal medicine; Follicular lymphoma; Phases of clinical research; Gastroenterology; Lymphoma; Oncology; Clinical trial; Multiple myeloma","score_opus":0.051951077989837335,"score_gpt":0.3526723269500253,"score_spread":0.300721248960188,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852535,0.005256513,0.00010657576,0.0006466633,0.0012996938,0.0061368975,0.0006489302,0.00027431312,0.00037690377],"genre_scores_gemma":[0.9908484,0.0009548774,0.0018238267,0.00090608426,0.00075156335,0.002993488,0.0003672025,0.00030711986,0.0010474302],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98861325,0.0011567074,0.0037063377,0.0028987597,0.0018977767,0.0017271461],"domain_scores_gemma":[0.9888414,0.0057409965,0.0016338492,0.0018375991,0.0004914051,0.0014547135],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026956133,0.0016002613,0.004540067,0.00070640683,0.001267562,0.00020200359,0.00082289113,0.0006761407,0.00025580174],"category_scores_gemma":[0.0017532767,0.0014006296,0.0011350805,0.0009424334,0.0010801445,0.00050423533,0.0013292085,0.00043759454,0.0000652862],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38616696,0.050523005,0.0069350167,0.00074307993,0.0047583827,0.008613889,0.0022370564,0.000040045292,0.00035949168,0.00046940328,0.005162466,0.5339912],"study_design_scores_gemma":[0.7921175,0.030551976,0.12654933,0.00040367234,0.004512838,0.002601694,0.005626377,0.0035095073,0.00082584366,0.00013218536,0.03160765,0.001561439],"about_ca_topic_score_codex":0.0014089132,"about_ca_topic_score_gemma":0.00029457608,"teacher_disagreement_score":0.53242975,"about_ca_system_score_codex":0.007237346,"about_ca_system_score_gemma":0.0055290097,"threshold_uncertainty_score":0.9996745},"labels":[],"label_agreement":null},{"id":"W4296532744","doi":"10.1016/s2152-2650(22)00871-0","title":"Poster: CLL-492 Real-World Adherence to First-Line Ibrutinib and Acalabrutinib Single-Agent Among Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Ibrutinib; Chronic lymphocytic leukemia; Medicine; Lymphoma; Oncology; Leukemia; Internal medicine","score_opus":0.04370418158202723,"score_gpt":0.3126730898348428,"score_spread":0.2689689082528156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296532744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9855405,0.0008287304,0.00008316714,0.0003299992,0.0015036298,0.005038628,0.0002770611,0.00089096715,0.0055073076],"genre_scores_gemma":[0.98384875,0.000526837,0.0009261541,0.0033715994,0.0012977248,0.0011898471,0.0006646651,0.0005984663,0.0075759823],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9828892,0.0011056196,0.004283457,0.0043033324,0.0036476927,0.0037707496],"domain_scores_gemma":[0.98677266,0.0032635934,0.0013822656,0.0038983289,0.00094322994,0.0037399062],"candidate_categories":["metaepi_narrow","sts","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0026774565,0.0020453464,0.0033974452,0.0012282741,0.0016362034,0.0004183553,0.0021630304,0.000850721,0.0011771935],"category_scores_gemma":[0.0018643936,0.0018847431,0.0009555912,0.003578589,0.0020990388,0.000528391,0.0040129516,0.0010989254,0.0007868794],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.029114965,0.0022159086,0.20217197,0.0020356956,0.0020419348,0.006514146,0.001398896,0.0051257424,0.00032321239,0.0003970325,0.010306682,0.73835385],"study_design_scores_gemma":[0.11847344,0.018136665,0.80201435,0.0014723674,0.001005595,0.0013444298,0.00018999535,0.026031334,0.00094789854,0.000118438584,0.027622867,0.0026426099],"about_ca_topic_score_codex":0.011107202,"about_ca_topic_score_gemma":0.0035614546,"teacher_disagreement_score":0.7357112,"about_ca_system_score_codex":0.37748033,"about_ca_system_score_gemma":0.097504996,"threshold_uncertainty_score":0.9999911},"labels":[],"label_agreement":null},{"id":"W4296533011","doi":"10.1016/s2152-2650(22)01578-6","title":"TCL-323 Outcome of Relapsed and Refractory Peripheral T-Cell Lymphoma (PTCL) With Intention for Curative Therapy Incorporating High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant (HDC/SCT)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Leukemia & Lymphoma Society of Canada; University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; Internal medicine; Brentuximab vedotin; Oncology; Chemotherapy; Anaplastic large-cell lymphoma; Gemcitabine; Progression-free survival; Lymphoma; Hematopoietic stem cell transplantation; Regimen; Refractory (planetary science); Peripheral T-cell lymphoma; Salvage therapy; Chemotherapy regimen; Gastroenterology; Romidepsin; Transplantation; Immunology; T cell; CD30","score_opus":0.029522456149170376,"score_gpt":0.29152269695165867,"score_spread":0.2620002408024883,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296533011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994471,0.002124645,0.00015275361,0.00059599575,0.00026544233,0.001837708,0.00012457739,0.00009888979,0.00032899602],"genre_scores_gemma":[0.994485,0.0010490672,0.0018009827,0.0010642904,0.00010806198,0.0005521279,0.00015817065,0.00011790626,0.00066435616],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9960158,0.00033067874,0.0015837767,0.0010171476,0.0005632394,0.00048936723],"domain_scores_gemma":[0.99690884,0.000991222,0.00093810237,0.00059339893,0.00019454739,0.00037386306],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007823703,0.0005983357,0.0014649122,0.00014798381,0.0003940656,0.000054574768,0.00020461589,0.00027106045,0.00006301147],"category_scores_gemma":[0.000026478703,0.00045783882,0.0003808645,0.0002810195,0.00049231754,0.00019341703,0.00009799017,0.00021060047,0.0000035158664],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019790318,0.0062378244,0.3886693,0.00079905847,0.0007897358,0.0005109946,0.0042397743,0.000016109901,0.006564464,0.00084858056,0.0003877783,0.5711461],"study_design_scores_gemma":[0.095504105,0.01507437,0.86626315,0.00034528787,0.0005312837,0.0004737133,0.0028731583,0.0010734735,0.013154247,0.00040397907,0.0034857409,0.00081752083],"about_ca_topic_score_codex":0.00021168037,"about_ca_topic_score_gemma":0.000019305544,"teacher_disagreement_score":0.57032853,"about_ca_system_score_codex":0.0010615392,"about_ca_system_score_gemma":0.00074036996,"threshold_uncertainty_score":0.99978733},"labels":[],"label_agreement":null},{"id":"W4296533650","doi":"10.1016/s2152-2650(22)01554-3","title":"IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Refractory (planetary science); Internal medicine; Dosing; Gastroenterology; Follicular lymphoma; Clinical endpoint; Surgery; Lymphoma; Clinical trial","score_opus":0.02636925942745788,"score_gpt":0.32061302432645694,"score_spread":0.29424376489899906,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296533650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880267,0.0010418175,0.000014962082,0.0001881401,0.0002928332,0.008633067,0.001600468,0.00013826309,0.000063767184],"genre_scores_gemma":[0.99223644,0.00080756657,0.0006455135,0.00049049506,0.000298393,0.0027543886,0.0022876011,0.0001616451,0.00031798793],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9940055,0.00082883646,0.001876261,0.0018559066,0.0008319331,0.0006015776],"domain_scores_gemma":[0.9950831,0.0014770954,0.0011186292,0.0012780947,0.00051577704,0.0005273178],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063517195,0.0008917533,0.0019952424,0.00022621831,0.0007633313,0.000068215144,0.0002676647,0.00035166898,0.000077662495],"category_scores_gemma":[0.00016795468,0.00065475225,0.00051393453,0.0003546846,0.00028753266,0.00026948247,0.00014166873,0.00015254409,0.000006336467],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10112676,0.047591597,0.12110365,0.000021138412,0.0029723127,0.00019875918,0.0054028,0.000036427762,0.00020962804,0.000006118686,0.0003660567,0.7209647],"study_design_scores_gemma":[0.22718781,0.119417764,0.64186054,0.00011892742,0.0007925599,0.000014995935,0.0008032712,0.0027954804,0.001535605,0.00003680181,0.004964659,0.000471543],"about_ca_topic_score_codex":0.0018166439,"about_ca_topic_score_gemma":0.000085795175,"teacher_disagreement_score":0.7204932,"about_ca_system_score_codex":0.002885222,"about_ca_system_score_gemma":0.0009619862,"threshold_uncertainty_score":0.9995904},"labels":[],"label_agreement":null},{"id":"W4296533666","doi":"10.1016/s2152-2650(22)01457-4","title":"MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Internal medicine; Phases of clinical research; Clinical trial","score_opus":0.01947532067221452,"score_gpt":0.2836838542439213,"score_spread":0.26420853357170676,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296533666","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99616593,0.00010166206,0.000021851574,0.0003251657,0.000315814,0.0025602537,0.00025626307,0.000099237324,0.00015382981],"genre_scores_gemma":[0.9958949,0.00014759185,0.001314621,0.0006244223,0.000109127,0.0009594143,0.0006909357,0.00012665759,0.00013233152],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99385226,0.0009994752,0.002201896,0.0010931109,0.0011513832,0.00070184824],"domain_scores_gemma":[0.9959693,0.0014808065,0.0012142354,0.0007187998,0.00027706276,0.0003397919],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009494406,0.0006499367,0.0021412182,0.0006250033,0.00020511173,0.0000457835,0.00033661255,0.00029532457,0.00031388042],"category_scores_gemma":[0.00028830286,0.00047310296,0.00021940387,0.0012400756,0.0003553139,0.0002229066,0.00021325104,0.00078039785,0.000023471819],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.033256304,0.0053057764,0.8514604,0.00011483348,0.0003378533,0.00015847108,0.0012867902,0.00019513782,0.000019058467,0.000113526,0.00037565804,0.1073762],"study_design_scores_gemma":[0.056193314,0.016779622,0.9230623,0.00067211007,0.00022256424,0.00001587364,0.00051281706,0.0004737716,0.0009465838,0.000110247965,0.00052202697,0.00048877386],"about_ca_topic_score_codex":0.0015500414,"about_ca_topic_score_gemma":0.0013657309,"teacher_disagreement_score":0.10688743,"about_ca_system_score_codex":0.0022357253,"about_ca_system_score_gemma":0.0012391694,"threshold_uncertainty_score":0.9997721},"labels":[],"label_agreement":null},{"id":"W4296533948","doi":"10.1016/s2152-2650(22)01262-9","title":"AML-295 AGILE: A Global, Randomized, Double-Blind, Phase 3 Study of Ivosidenib + Azacitidine Versus Placebo + Azacitidine in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Azacitidine; Myeloid leukemia; Isocitrate dehydrogenase; IDH1; Internal medicine; Placebo; Adverse effect; Gastroenterology; Mutation; Biology; Enzyme; Pathology","score_opus":0.03753250305841633,"score_gpt":0.358132601442889,"score_spread":0.3206000983844727,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296533948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98527443,0.0001293318,0.0001372372,0.0002763136,0.00053640996,0.012229274,0.00036751878,0.00031721115,0.00073226285],"genre_scores_gemma":[0.9922422,0.00009935143,0.0014982062,0.0004945241,0.00041006296,0.002847204,0.0019575555,0.0002687444,0.00018214008],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9857772,0.0024888013,0.0038236768,0.0025131376,0.0036710866,0.0017261225],"domain_scores_gemma":[0.9901904,0.0031927917,0.0016913202,0.0023566103,0.0012073402,0.0013615775],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0040226937,0.0013295268,0.0041570775,0.00089810777,0.00056867494,0.00014905269,0.0013523612,0.000548439,0.0004627203],"category_scores_gemma":[0.0012896719,0.0010857253,0.00059304124,0.003632457,0.001400428,0.00091282796,0.0008265645,0.0017224633,0.000060220173],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.8824024,0.008442568,0.0534897,0.00011635324,0.0023135555,0.004812453,0.0010734305,0.0015637572,0.0000615092,0.00013014066,0.0006677763,0.04492632],"study_design_scores_gemma":[0.80801874,0.03897883,0.14176226,0.00020582417,0.0018916283,0.00020169622,0.0034776833,0.0040209084,0.00021161418,0.000047934067,0.00018742129,0.0009954801],"about_ca_topic_score_codex":0.003444092,"about_ca_topic_score_gemma":0.0012461146,"teacher_disagreement_score":0.088272564,"about_ca_system_score_codex":0.011139984,"about_ca_system_score_gemma":0.007708708,"threshold_uncertainty_score":0.9999456},"labels":[],"label_agreement":null},{"id":"W4296613255","doi":"10.1016/s2152-2650(22)01064-3","title":"Poster: IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Refractory (planetary science); Follicular lymphoma; Medicine; Oncology; Internal medicine; Follicular phase; Lymphoma; Biology","score_opus":0.025252225964605732,"score_gpt":0.3178122279718731,"score_spread":0.29256000200726734,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296613255","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875559,0.0010441488,0.000007717478,0.0002207134,0.00029880813,0.008869531,0.001800279,0.00013530633,0.00006756246],"genre_scores_gemma":[0.992617,0.00071821106,0.00042080905,0.00058629503,0.00028071925,0.0024395147,0.0024885645,0.0001641773,0.0002846795],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9939692,0.0008489749,0.0019017024,0.0018543852,0.0008212204,0.0006045383],"domain_scores_gemma":[0.9951299,0.001414596,0.0011299403,0.0012892323,0.00050990836,0.00052646274],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006048766,0.00090389146,0.0019911388,0.0002317335,0.00073467655,0.00007375134,0.00027230644,0.00035247544,0.00007126139],"category_scores_gemma":[0.00014767706,0.00066366704,0.00051802216,0.0003346352,0.00027444537,0.000283296,0.00015411142,0.00015086672,0.000006468477],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11188491,0.044865333,0.14796335,0.000022049077,0.0029333173,0.00021613775,0.0057657864,0.0000214017,0.00023384042,0.0000040198365,0.00028853808,0.6858013],"study_design_scores_gemma":[0.22148325,0.12871934,0.64049697,0.0001265628,0.0007852083,0.000019354937,0.0006792935,0.0018023466,0.0017019375,0.000027401913,0.0036898076,0.00046851815],"about_ca_topic_score_codex":0.0017666557,"about_ca_topic_score_gemma":0.00008656241,"teacher_disagreement_score":0.6853328,"about_ca_system_score_codex":0.002789571,"about_ca_system_score_gemma":0.0009046647,"threshold_uncertainty_score":0.99958146},"labels":[],"label_agreement":null},{"id":"W4296613368","doi":"10.1016/s2152-2650(22)01062-x","title":"Poster: IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Lenalidomide; Rituximab; Medicine; Follicular lymphoma; Internal medicine; Lymphoma; Refractory (planetary science); Oncology; Placebo; Pathology; Multiple myeloma; Biology","score_opus":0.049127865764089895,"score_gpt":0.3488319352136375,"score_spread":0.2997040694495476,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296613368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9850038,0.0051947245,0.000055756605,0.0007438562,0.0013068876,0.006301783,0.0007320253,0.00026687558,0.0003942758],"genre_scores_gemma":[0.99187124,0.0008495996,0.0012019261,0.001066592,0.0007040128,0.0026606116,0.00040331885,0.00030951668,0.0009331954],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9886226,0.0011778675,0.00373175,0.0028849903,0.001862329,0.0017204374],"domain_scores_gemma":[0.98912746,0.0054544085,0.0016431161,0.0018481257,0.0004857439,0.001441159],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00254561,0.0016123552,0.0045010406,0.0007158203,0.0012178936,0.00021541116,0.00082935666,0.00067374244,0.00023403093],"category_scores_gemma":[0.001525581,0.0014094856,0.0011364055,0.0008841825,0.0010233276,0.0005259748,0.0014151378,0.00042920184,0.00006535004],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4255727,0.049195565,0.0091397865,0.0007729792,0.0048153824,0.009327207,0.0024586022,0.000024793391,0.00040649233,0.00031430137,0.0041701337,0.49380207],"study_design_scores_gemma":[0.7766777,0.03391991,0.14776196,0.00042588645,0.0044434466,0.0032004856,0.0047458042,0.0023173832,0.0009211205,0.00009977326,0.023938695,0.0015477994],"about_ca_topic_score_codex":0.0013744687,"about_ca_topic_score_gemma":0.00029360363,"teacher_disagreement_score":0.49225426,"about_ca_system_score_codex":0.006958313,"about_ca_system_score_gemma":0.00515052,"threshold_uncertainty_score":0.9996624},"labels":[],"label_agreement":null},{"id":"W4296613459","doi":"10.1016/s2152-2650(22)00982-x","title":"Poster: MPN-375 BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis-JAK Inhibitor-Naïve or With Suboptimal Response to Ruxolitinib-Preliminary Data From the MANIFEST Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Myelofibrosis; Myeloproliferative neoplasm; Internal medicine; Oncology; Bone marrow","score_opus":0.03944203951438547,"score_gpt":0.31124101279108096,"score_spread":0.2717989732766955,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296613459","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98532975,0.000092709444,0.0000033999256,0.0031010585,0.0003790416,0.008124683,0.0024538857,0.00020982722,0.00030564534],"genre_scores_gemma":[0.9884316,0.0000131059605,0.0014036418,0.0036150087,0.00062080065,0.0023033977,0.0027811823,0.00028058572,0.0005507245],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9887131,0.0023564294,0.0022510504,0.0028789025,0.0023992693,0.0014012365],"domain_scores_gemma":[0.9881185,0.0056981323,0.0007783375,0.0038374038,0.0005128935,0.0010546957],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021968053,0.0012713319,0.0021219691,0.00032477762,0.00088634586,0.0002414572,0.0014941621,0.00026675285,0.0005030886],"category_scores_gemma":[0.0010005271,0.00074181875,0.00021023939,0.0013671936,0.0006031556,0.00046195474,0.0021835985,0.0011108689,0.0001769103],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29528677,0.007580502,0.67962396,0.000034516546,0.000660954,0.003601906,0.0012896232,0.000027843582,0.000014436337,0.000019493247,0.004060095,0.0077999225],"study_design_scores_gemma":[0.052841354,0.094455466,0.84351355,0.00070206734,0.0008059695,0.00023763615,0.003327853,0.0000899073,0.00011768324,0.000008367907,0.0029992643,0.00090089266],"about_ca_topic_score_codex":0.00092398195,"about_ca_topic_score_gemma":0.0011827868,"teacher_disagreement_score":0.24244541,"about_ca_system_score_codex":0.0018685589,"about_ca_system_score_gemma":0.0033554551,"threshold_uncertainty_score":0.9995033},"labels":[],"label_agreement":null},{"id":"W4296613467","doi":"10.1016/s2152-2650(22)00950-8","title":"Poster: MPN-478 MOMENTUM: Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic and Anemic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Danazol; Ruxolitinib; Medicine; Internal medicine; Randomized controlled trial; Gastroenterology; Bone marrow; Endometriosis","score_opus":0.022196037003589065,"score_gpt":0.31451704398633307,"score_spread":0.292321006982744,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296613467","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9902462,0.00038813,0.0000012127788,0.0001414602,0.00027089473,0.008433399,0.00009377913,0.00010787273,0.00031710253],"genre_scores_gemma":[0.99548084,0.0001991298,0.00012668931,0.0002054108,0.000090524256,0.0033630957,0.00030628862,0.00010448926,0.00012356242],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.992862,0.001415184,0.0026412953,0.0012668271,0.0011070811,0.0007076019],"domain_scores_gemma":[0.9946725,0.0027039442,0.000969519,0.00086007826,0.00025987346,0.00053410133],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012246793,0.0007432366,0.0030986888,0.00044454535,0.00026824384,0.000053107768,0.0002729555,0.00020147044,0.00015064499],"category_scores_gemma":[0.0007669171,0.0005651964,0.00038555005,0.0008663375,0.00041795612,0.0001753301,0.00038214016,0.0003840501,0.000013513389],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.250626,0.018944189,0.6645393,0.00023568046,0.0016338925,0.00052297977,0.0021211335,0.000018673174,0.000107876935,0.000028715946,0.00022627017,0.060995344],"study_design_scores_gemma":[0.5018189,0.024135938,0.46997842,0.0003331838,0.001250754,0.00005124014,0.0009058953,0.00052368507,0.0005101009,0.000010074341,0.00008974203,0.00039207964],"about_ca_topic_score_codex":0.00040230204,"about_ca_topic_score_gemma":0.00009946969,"teacher_disagreement_score":0.2511929,"about_ca_system_score_codex":0.001510782,"about_ca_system_score_gemma":0.0006962846,"threshold_uncertainty_score":0.9996799},"labels":[],"label_agreement":null},{"id":"W4296614337","doi":"10.1016/s2152-2650(22)00973-9","title":"Poster: MPN-379 Matching-Adjusted Indirect Comparison (MAIC) of Pelabresib (CPI-0610) in Combination With Ruxolitinib vs. JAK Inhibitor Monotherapy in Patients With Intermediate or High-Risk Myelofibrosis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Matching (statistics); Internal medicine; Pathology","score_opus":0.01883409622815097,"score_gpt":0.28202109503869616,"score_spread":0.2631869988105452,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296614337","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9959401,0.000105129504,0.00001235348,0.000386293,0.000325898,0.002669772,0.0002990002,0.000098498116,0.00016297813],"genre_scores_gemma":[0.9962528,0.00013370768,0.00086486613,0.0007592222,0.000104597755,0.0008560975,0.0007726271,0.00013050988,0.00012557991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937593,0.0010310636,0.0022493901,0.0011067876,0.0011423719,0.0007111306],"domain_scores_gemma":[0.9959701,0.001424274,0.001236987,0.00073570415,0.00028884056,0.0003441333],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009069108,0.0006673786,0.0021513752,0.0006415625,0.00020169599,0.000050529852,0.0003458895,0.00029931954,0.00028616737],"category_scores_gemma":[0.00025279282,0.00048633892,0.00022511613,0.0011621767,0.0003412625,0.00023798671,0.00023516062,0.0007677595,0.000024020812],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037628952,0.005115843,0.8559647,0.000119778124,0.00034325063,0.00017436956,0.0014480896,0.00010602313,0.00002220873,0.00007154959,0.00030100322,0.09870423],"study_design_scores_gemma":[0.056611195,0.019279018,0.92033386,0.0007229852,0.00022895419,0.000021378659,0.0004479893,0.0002768786,0.0010935906,0.000082538856,0.00040237838,0.0004992212],"about_ca_topic_score_codex":0.0014892991,"about_ca_topic_score_gemma":0.0013330587,"teacher_disagreement_score":0.098205,"about_ca_system_score_codex":0.0021714875,"about_ca_system_score_gemma":0.0011661547,"threshold_uncertainty_score":0.99975884},"labels":[],"label_agreement":null},{"id":"W4296962943","doi":"10.1016/s2152-2650(22)00747-9","title":"Poster: AML-484 First Results of a Phase II Study (STIMULUS-AML1) Investigating Sabatolimab + Azacitidine + Venetoclax in Patients With Newly Diagnosed Acute Myeloid Leukemia (ND AML)","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of British Columbia; McGill University; University of Toronto; Jewish General Hospital","funders":"","keywords":"Venetoclax; Azacitidine; Myeloid leukemia; Medicine; Internal medicine; Myeloid; Oncology; Leukemia; Biology; Genetics","score_opus":0.028363067495474653,"score_gpt":0.3261240952854576,"score_spread":0.2977610277899829,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296962943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99109304,0.00020130113,0.000009766797,0.00082790985,0.0004623846,0.0052654315,0.0008881237,0.00029606884,0.0009559564],"genre_scores_gemma":[0.9935665,0.00007769921,0.001307539,0.0014990694,0.00044759107,0.0007790947,0.0013041199,0.0003260444,0.0006923356],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98588324,0.001443184,0.0048362054,0.002649169,0.0031128945,0.0020752912],"domain_scores_gemma":[0.9900024,0.0030986792,0.0017620019,0.00282975,0.00082428165,0.0014828894],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0035763346,0.0012622322,0.003139515,0.001031307,0.0010706233,0.000099438206,0.0016913468,0.00057654356,0.00024579908],"category_scores_gemma":[0.004451892,0.0011659599,0.0006470929,0.0032609277,0.0013321895,0.0005263551,0.0026867085,0.0024078998,0.00007755631],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07210596,0.012597424,0.6285304,0.00043922526,0.0022474655,0.007469544,0.006467382,0.0020780496,0.0010474725,0.000042982043,0.013628347,0.2533458],"study_design_scores_gemma":[0.17414528,0.039987512,0.77358484,0.0005660009,0.00067601824,0.000173586,0.0011238673,0.004272332,0.00066169316,0.000051470564,0.003668647,0.0010887426],"about_ca_topic_score_codex":0.0024283938,"about_ca_topic_score_gemma":0.00046606554,"teacher_disagreement_score":0.25225705,"about_ca_system_score_codex":0.015193188,"about_ca_system_score_gemma":0.01123247,"threshold_uncertainty_score":0.9998936},"labels":[],"label_agreement":null},{"id":"W4296964454","doi":"10.1016/s2152-2650(22)00874-6","title":"Poster: CLL-517 Hypertension as an Adverse Event of Ibrutinib: Does Age Matter?","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Cascades (Canada)","funders":"","keywords":"Ibrutinib; Adverse effect; Medicine; Event (particle physics); Internal medicine; Oncology; Chronic lymphocytic leukemia; Leukemia; Physics","score_opus":0.034980729570881185,"score_gpt":0.3508717584928351,"score_spread":0.3158910289219539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296964454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9900698,0.00023002656,0.000008008046,0.00089527684,0.0012366065,0.0010807221,0.000080443235,0.00020407853,0.006195046],"genre_scores_gemma":[0.9875732,0.00011952126,0.00041081858,0.0049355854,0.0006476066,0.00012368597,0.000281785,0.00015886828,0.0057489467],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99221855,0.00092728756,0.002442416,0.0014126692,0.0019062862,0.0010928061],"domain_scores_gemma":[0.9945263,0.0011593868,0.0006332047,0.0023145366,0.0003177652,0.0010487925],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0023762067,0.0005416132,0.0015512428,0.00032581418,0.00037988534,0.00003395438,0.00097123545,0.0004197568,0.0038605274],"category_scores_gemma":[0.001066981,0.0004316566,0.00091711496,0.0006529595,0.0008680367,0.00023476826,0.0014713848,0.0007597344,0.0010355113],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.03553277,0.009257679,0.08976138,0.0018498729,0.0019433664,0.046227023,0.0032153723,0.00028364992,0.028594796,0.0017496798,0.057861578,0.7237228],"study_design_scores_gemma":[0.058236036,0.0068069245,0.8549702,0.00042825664,0.0005940838,0.0071327672,0.0019193055,0.0052584526,0.00607912,0.0012175328,0.056231186,0.0011261232],"about_ca_topic_score_codex":0.0013768112,"about_ca_topic_score_gemma":0.000032418815,"teacher_disagreement_score":0.76520884,"about_ca_system_score_codex":0.0155687155,"about_ca_system_score_gemma":0.014832552,"threshold_uncertainty_score":0.9998135},"labels":[],"label_agreement":null},{"id":"W4296964702","doi":"10.1016/s2152-2650(22)00886-2","title":"Poster: CML-046 Dose Modification Dynamics of Ponatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia From the PACE and OPTIC Trials","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myeloid leukemia; Ponatinib; Medicine; Pace; Oncology; Internal medicine; Nilotinib; Physics","score_opus":0.03591066286180756,"score_gpt":0.3327238929423084,"score_spread":0.29681323008050087,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296964702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9913371,0.002650906,0.00004160848,0.0010431518,0.00047135877,0.0031876967,0.0008307838,0.00010954675,0.0003278452],"genre_scores_gemma":[0.9949704,0.00036753147,0.0005587378,0.00044219225,0.00045152864,0.0004189549,0.002346455,0.00014642833,0.00029779342],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9917557,0.0014971066,0.003091669,0.0014465428,0.0013452193,0.00086374296],"domain_scores_gemma":[0.99164945,0.004073179,0.0016807537,0.001905862,0.0002569887,0.00043376873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028923166,0.0007453743,0.0022219983,0.0002466985,0.00036660407,0.0000650894,0.0007355632,0.00041981498,0.00043755633],"category_scores_gemma":[0.00166846,0.0005488377,0.0004692517,0.0008591934,0.00076195906,0.0002551321,0.0006421273,0.0009378688,0.000037558795],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.01571271,0.0023539215,0.23618363,0.0002435137,0.0012675282,0.0003026925,0.0008767376,0.0006567408,0.0004126737,0.0006464875,0.0012045136,0.7401388],"study_design_scores_gemma":[0.077041805,0.0057766098,0.8974603,0.00037010259,0.00076807005,0.000069080954,0.0002428446,0.015959864,0.00016831806,0.00018798311,0.0014189146,0.0005361048],"about_ca_topic_score_codex":0.0016702884,"about_ca_topic_score_gemma":0.000468451,"teacher_disagreement_score":0.73960274,"about_ca_system_score_codex":0.027161205,"about_ca_system_score_gemma":0.009171084,"threshold_uncertainty_score":0.9996963},"labels":[],"label_agreement":null},{"id":"W4296965070","doi":"10.1016/s2152-2650(22)00954-5","title":"Poster: MPN-145 Retrospective Analysis of Anemia Benefit of Pacritinib From the PERSIST-2 Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Anemia; Medicine; Internal medicine","score_opus":0.034934633993297694,"score_gpt":0.327188234025527,"score_spread":0.2922536000322293,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965070","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9919247,0.00071617786,0.0000045876973,0.0015247859,0.00048221127,0.0012177302,0.0014500989,0.00004276941,0.0026369395],"genre_scores_gemma":[0.9963346,0.00021715609,0.0002273376,0.0014432571,0.00045728963,0.00033070703,0.0006108023,0.000042143965,0.0003366991],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952776,0.0005187318,0.0018599896,0.0008774863,0.0010654392,0.0004007561],"domain_scores_gemma":[0.99409056,0.0031884888,0.0008486804,0.0012115497,0.000401782,0.00025896193],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001083277,0.00037882308,0.0020404384,0.00021319889,0.0003045668,0.000023066785,0.0004481461,0.00022458528,0.0022538693],"category_scores_gemma":[0.0011253873,0.00027500483,0.0017789354,0.0013008822,0.00047699994,0.000063854364,0.00037233683,0.00040418646,0.000018664465],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02708091,0.0019124966,0.89746284,0.000025994008,0.0069739944,0.00016470408,0.0009129932,0.00004089855,0.00022965489,0.001215967,0.0029239021,0.061055616],"study_design_scores_gemma":[0.033825308,0.0041663987,0.95126957,0.00005438717,0.006254466,0.000016847182,0.0007253456,0.00024269622,0.00097203726,0.0002966177,0.0019471316,0.00022918911],"about_ca_topic_score_codex":0.00097406417,"about_ca_topic_score_gemma":0.00016871038,"teacher_disagreement_score":0.060826425,"about_ca_system_score_codex":0.0011613664,"about_ca_system_score_gemma":0.00086234324,"threshold_uncertainty_score":0.9999702},"labels":[],"label_agreement":null},{"id":"W4296965222","doi":"10.1016/s2152-2650(22)00742-x","title":"Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"IDH2; Myeloid leukemia; Refractory (planetary science); Mutant; Medicine; Internal medicine; Stage (stratigraphy); Oncology; IDH1; Cancer research; Biology; Gene; Genetics","score_opus":0.04324224856268057,"score_gpt":0.35374002342380345,"score_spread":0.3104977748611229,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965222","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9812191,0.0003582704,0.000017312927,0.00097093167,0.00067079184,0.013170806,0.0018029418,0.00022340976,0.0015664274],"genre_scores_gemma":[0.9754426,0.00062513375,0.00035769635,0.0026132152,0.00044537202,0.0027556294,0.006430949,0.00043500355,0.010894392],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98052204,0.005818543,0.0044652224,0.0029833252,0.0038594787,0.0023513956],"domain_scores_gemma":[0.9881359,0.0056257606,0.0018015805,0.0025863647,0.0008077195,0.0010426939],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0063060885,0.0016454149,0.004613753,0.0007880299,0.0009045667,0.0004559252,0.0028868963,0.00096457626,0.002593648],"category_scores_gemma":[0.0020676884,0.0010078019,0.00065608905,0.0024242196,0.0016568963,0.0009023592,0.0015760948,0.003490383,0.00012713987],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.94643617,0.00609255,0.008981361,0.000165138,0.0019271991,0.011132706,0.0014488234,0.00005071887,0.0006358195,0.00009456903,0.008649164,0.014385787],"study_design_scores_gemma":[0.91902107,0.022617862,0.02931518,0.0004510779,0.0010844098,0.00035321832,0.0015281838,0.0007669987,0.00037732194,0.0000318362,0.022989435,0.0014634246],"about_ca_topic_score_codex":0.0025927976,"about_ca_topic_score_gemma":0.0012416416,"teacher_disagreement_score":0.027415112,"about_ca_system_score_codex":0.013107108,"about_ca_system_score_gemma":0.013800366,"threshold_uncertainty_score":0.9996293},"labels":[],"label_agreement":null},{"id":"W4296965454","doi":"10.1016/s2152-2650(22)00951-x","title":"Poster: MPN-483 Thrombocytopenic Myelofibrosis (MF) Patients Previously Treated With a JAK Inhibitor in a Phase 3 Randomized Study of Momelotinib (MMB) versus Danazol (DAN) [MOMENTUM]","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Danazol; Ruxolitinib; Medicine; Internal medicine; Gastroenterology; Bone marrow; Endometriosis","score_opus":0.03254762962863671,"score_gpt":0.3342227044601921,"score_spread":0.30167507483155537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965454","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9873743,0.00029658613,0.0000018444007,0.00021475927,0.0004556081,0.0107075,0.00013368276,0.00012697378,0.00068872015],"genre_scores_gemma":[0.99344045,0.00017339172,0.0001427336,0.00036600308,0.00014249505,0.004912663,0.00046931766,0.00013808275,0.00021489331],"study_design_codex":"observational","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9907916,0.001968787,0.0032416538,0.0015838693,0.0015006855,0.00091337267],"domain_scores_gemma":[0.9938435,0.0027120516,0.0012161441,0.0012378049,0.00039440277,0.00059611903],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016183004,0.0008841965,0.004074021,0.00047000527,0.0003322141,0.00006194412,0.00046827126,0.00024506042,0.00042839564],"category_scores_gemma":[0.0009321975,0.0006703958,0.0007328037,0.0012465463,0.00044064815,0.00022761758,0.0005506201,0.0005420305,0.000040000887],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42968395,0.03565824,0.4652577,0.00013406452,0.0025036072,0.0008246549,0.0022034578,0.000030734882,0.0001458152,0.000053037482,0.0005167216,0.06298801],"study_design_scores_gemma":[0.53687507,0.033036236,0.42537367,0.00025031215,0.00134411,0.00003279222,0.00093437405,0.00019551202,0.0010398306,0.000008280673,0.00044635477,0.0004634561],"about_ca_topic_score_codex":0.00076617236,"about_ca_topic_score_gemma":0.0002515273,"teacher_disagreement_score":0.1071911,"about_ca_system_score_codex":0.0026513997,"about_ca_system_score_gemma":0.0014911728,"threshold_uncertainty_score":0.9995747},"labels":[],"label_agreement":null},{"id":"W4296965640","doi":"10.1016/s2152-2650(22)01601-9","title":"MM-188 Depth of Response of Isatuximab plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Updated Analysis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saint John Regional Hospital; Dalhousie University; University of New Brunswick","funders":"","keywords":"Medicine; Internal medicine; Carfilzomib; Clinical endpoint; Multiple myeloma; Dexamethasone; Oncology; Nuclear medicine; Gastroenterology; Surgery; Randomized controlled trial; Lenalidomide","score_opus":0.04308698812435666,"score_gpt":0.34772240567931995,"score_spread":0.30463541755496326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296965640","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9964775,0.0010529527,0.000049100046,0.00032984104,0.0001438684,0.0010978675,0.000312562,0.00007720428,0.0004591484],"genre_scores_gemma":[0.99517393,0.00014558388,0.0030911195,0.00020006415,0.0000579487,0.00016287604,0.00038751445,0.000077442965,0.00070352637],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99209934,0.002156624,0.0024337685,0.001182929,0.0012589077,0.0008684526],"domain_scores_gemma":[0.99242896,0.004382256,0.00077328744,0.0013973056,0.00033095296,0.00068723474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036658908,0.00050142885,0.002525553,0.0012864544,0.00019533403,0.000019602803,0.00048361922,0.00038011334,0.00041743365],"category_scores_gemma":[0.0051110126,0.0004673914,0.000819737,0.0032265722,0.00080895936,0.000109554945,0.00073575607,0.0006574007,0.000019323475],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.062495414,0.0016673872,0.80434203,0.0001506163,0.0027009335,0.0015983239,0.0005549884,0.00029935507,0.0068557677,0.0000475344,0.00048454653,0.1188031],"study_design_scores_gemma":[0.03845872,0.0022547957,0.93516356,0.00007442767,0.0010147309,0.00011975177,0.00058628793,0.017597534,0.0036273326,0.000052293202,0.00070900336,0.00034155592],"about_ca_topic_score_codex":0.0018500054,"about_ca_topic_score_gemma":0.00051850866,"teacher_disagreement_score":0.13082154,"about_ca_system_score_codex":0.0018337689,"about_ca_system_score_gemma":0.002408908,"threshold_uncertainty_score":0.9997778},"labels":[],"label_agreement":null},{"id":"W4296969016","doi":"10.1016/s2152-2650(22)01000-x","title":"Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Sunnybrook Health Science Centre; Health Sciences Centre; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Prednisone; Rituximab; Cyclophosphamide; Vincristine; Medicine; Doxorubicin; CHOP; Internal medicine; Oncology; Chemotherapy; Lymphoma","score_opus":0.015765062508904634,"score_gpt":0.2811204971392092,"score_spread":0.2653554346303046,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4296969016","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9745974,0.012538669,0.0000057002912,0.0007857241,0.0009821432,0.0077611604,0.0025206008,0.00040310447,0.0004055321],"genre_scores_gemma":[0.99065065,0.0027868554,0.00032304073,0.0020663517,0.0004159121,0.0007996718,0.0022479035,0.00033806084,0.00037153854],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9864542,0.001565182,0.0039677117,0.0036494883,0.0021674202,0.0021959895],"domain_scores_gemma":[0.9893718,0.0041375556,0.001687552,0.002963991,0.00048203656,0.0013570687],"candidate_categories":["metaepi_narrow","sts"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019310097,0.0019968566,0.0036936167,0.0004098772,0.0015859181,0.00037705502,0.0010761416,0.00068330276,0.00013882125],"category_scores_gemma":[0.00093101076,0.0014749988,0.00055543653,0.0015585461,0.00090898393,0.00053623173,0.001584148,0.0010017755,0.000061209044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.19513601,0.1068613,0.55659443,0.00007429537,0.001818307,0.0022464907,0.0045650476,0.000008320749,0.00007907325,0.000038414873,0.0018564749,0.13072185],"study_design_scores_gemma":[0.43779802,0.014068488,0.5413945,0.0002170453,0.00089746667,0.000064095046,0.0010237325,0.00034528307,0.00016889833,0.000029802304,0.0031249702,0.0008677265],"about_ca_topic_score_codex":0.014147044,"about_ca_topic_score_gemma":0.0012537831,"teacher_disagreement_score":0.24266203,"about_ca_system_score_codex":0.0045634997,"about_ca_system_score_gemma":0.0022152902,"threshold_uncertainty_score":0.9997139},"labels":[],"label_agreement":null},{"id":"W4307154696","doi":"10.1016/j.clml.2022.10.005","title":"Real-world Outcomes With Cumulative Bortezomib Dose and Efficacy in the Treatment of Transplant-ineligible Multiple Myeloma With Cyclophosphamide, Bortezomib, and Dexamethasone","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Baker Hughes (Canada); Alberta Cancer Foundation","funders":"","keywords":"Bortezomib; Discontinuation; Medicine; Cumulative dose; Multiple myeloma; Dexamethasone; Internal medicine; Cyclophosphamide; Cumulative incidence; Gastroenterology; Oncology; Surgery; Cohort; Chemotherapy","score_opus":0.04323960663855163,"score_gpt":0.3505000595739032,"score_spread":0.30726045293535154,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4307154696","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99514085,0.0006820857,0.0000110214305,0.0005555893,0.00006118391,0.0024255414,0.00017858928,0.00007408286,0.0008710264],"genre_scores_gemma":[0.99520594,0.0015786784,0.0015825673,0.00026212327,0.000064295964,0.0005014157,0.00019088839,0.000082868435,0.00053119974],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99529815,0.00082108617,0.0011632615,0.0009662955,0.0009523707,0.00079884275],"domain_scores_gemma":[0.99283975,0.0052486802,0.00037121848,0.00091232825,0.00011334407,0.000514661],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010025045,0.0006335143,0.0016007657,0.0003480361,0.00043824696,0.000047753743,0.00027494656,0.0001435579,0.000048102116],"category_scores_gemma":[0.00023321046,0.00036237584,0.00023604133,0.0009077091,0.00083118,0.0001432724,0.00010024755,0.00047409383,0.000005073734],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014401881,0.0030557043,0.8003471,0.000078210185,0.00076306035,0.0019593656,0.001984899,0.000046514906,0.000075034855,0.0000932856,0.000035412922,0.17715952],"study_design_scores_gemma":[0.049131583,0.009416515,0.93716824,0.0001500379,0.0004652034,0.00034494797,0.0008228827,0.000935603,0.0002940011,0.000052101266,0.000859942,0.00035892637],"about_ca_topic_score_codex":0.0052784653,"about_ca_topic_score_gemma":0.0020277237,"teacher_disagreement_score":0.1768006,"about_ca_system_score_codex":0.00080182025,"about_ca_system_score_gemma":0.00086287386,"threshold_uncertainty_score":0.9998828},"labels":[],"label_agreement":null},{"id":"W4308319341","doi":"10.1016/j.clml.2022.11.002","title":"Azacitidine Monotherapy in Patients With Treatment-Naïve Higher-risk Myelodysplastic Syndrome: A Systematic Literature Review and Meta-analysis","year":2022,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Internal medicine; Azacitidine; Observational study; Meta-analysis; Myelodysplastic syndromes; Adverse effect; Randomized controlled trial; Incidence (geometry); Retrospective cohort study","score_opus":0.06970053631404995,"score_gpt":0.36682568422570905,"score_spread":0.2971251479116591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4308319341","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0007454776,0.9862768,0.000010766615,0.00014650413,0.00011723629,0.011120383,0.00122077,0.00016212402,0.0001999126],"genre_scores_gemma":[0.00022712727,0.9860214,0.00043166216,0.0008987766,0.00011705532,0.0050001824,0.002780676,0.00038668734,0.0041364417],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98385453,0.004796707,0.005377125,0.0029669004,0.0016960889,0.0013086346],"domain_scores_gemma":[0.9863166,0.006126973,0.0028046106,0.0033280686,0.00035603475,0.0010677134],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0028036712,0.002338841,0.027680187,0.0018232134,0.0002827571,0.0002036019,0.0009722318,0.0012995582,0.0019751731],"category_scores_gemma":[0.0013744482,0.0013698323,0.006733675,0.006794027,0.0004974413,0.00025973274,0.00043168612,0.0021345823,0.0001656477],"study_design_candidate":"meta_analysis","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00052950665,0.000924549,0.0008395748,0.4085045,0.3235137,0.0041787457,0.000052452575,0.000002277751,4.87742e-9,0.00002954711,0.0006194098,0.26080576],"study_design_scores_gemma":[0.006452827,0.0031543884,0.013374746,0.044428162,0.77061415,0.0007755281,0.000006520093,0.000028738692,2.1820382e-8,0.0000100754705,0.16000092,0.0011539331],"about_ca_topic_score_codex":0.000090189395,"about_ca_topic_score_gemma":0.000026132682,"teacher_disagreement_score":0.44710043,"about_ca_system_score_codex":0.007413663,"about_ca_system_score_gemma":0.0032754783,"threshold_uncertainty_score":0.99999696},"labels":[],"label_agreement":null},{"id":"W4310019125","doi":"10.1016/j.clml.2022.11.007","title":"Post Salvage Therapy Autologous Transplant for Relapsed Myeloma, Ongoing Relevance within Modern Treatment Paradigms?","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Refractory (planetary science); Overall survival; Cohort; Multiple myeloma; Salvage therapy; Oncology; Internal medicine; Progression-free survival; Surgery; Chemotherapy","score_opus":0.05518662296403471,"score_gpt":0.3486581173803121,"score_spread":0.2934714944162774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4310019125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888701,0.0023232743,0.00037366312,0.0018182963,0.00080633856,0.0034357554,0.00078068185,0.0004776658,0.0011142605],"genre_scores_gemma":[0.985921,0.0010727007,0.0037603485,0.0021416498,0.00047946675,0.0018845516,0.0010585891,0.00020139542,0.0034803015],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99362004,0.00062644115,0.0017397841,0.0016076724,0.0010174972,0.0013885492],"domain_scores_gemma":[0.99439055,0.0025628107,0.0004880464,0.0013949139,0.0002070865,0.0009565928],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011483425,0.00078001345,0.0015935851,0.0002580289,0.00103601,0.00007679612,0.00056132453,0.00037749344,0.00024908248],"category_scores_gemma":[0.0006668406,0.00063087355,0.001158571,0.00040459906,0.00040088163,0.00017958449,0.00013716696,0.00055827526,0.00013205194],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023888601,0.0024244443,0.027462067,0.00010037358,0.0014747094,0.0039806785,0.0012747142,0.00019577843,0.003821022,0.0006304883,0.0009484466,0.9337987],"study_design_scores_gemma":[0.058972962,0.020955354,0.834141,0.00018181629,0.00046864178,0.0020516797,0.0002607315,0.027965628,0.003792045,0.0013155096,0.048828162,0.0010664571],"about_ca_topic_score_codex":0.00036976486,"about_ca_topic_score_gemma":0.000113360205,"teacher_disagreement_score":0.9327322,"about_ca_system_score_codex":0.00331177,"about_ca_system_score_gemma":0.002822324,"threshold_uncertainty_score":0.99961424},"labels":[],"label_agreement":null},{"id":"W4311909246","doi":"10.1016/s2152-2650(22)01761-x","title":"Editorial Board","year":2022,"lang":"en","type":"paratext","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Diverse Scientific and Economic Studies","field":"Economics, Econometrics and Finance","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Calgary Laboratory Services","funders":"","keywords":"Editorial board; Computer science; Library science","score_opus":0.049710729255917595,"score_gpt":0.27933036404606587,"score_spread":0.22961963479014827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4311909246","genre_codex":"other","genre_gemma":"other","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"other","genre_consensus":"other","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0008315688,0.0027399198,0.000012823346,0.000098535245,0.45167136,0.00024479814,0.0032747316,0.000060742423,0.5410655],"genre_scores_gemma":[0.0006690577,0.0032120754,0.00012666684,0.00083289435,0.1361622,0.0001419862,0.00054005586,0.00012468855,0.85819036],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99335563,0.000104346786,0.003074965,0.0022771847,0.00019469135,0.0009931647],"domain_scores_gemma":[0.9956896,0.0005569155,0.0018280986,0.0014498545,0.000083854946,0.0003916788],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0024717045,0.0007008097,0.0024462088,0.0003814342,0.000600125,0.0003200393,0.0016470838,0.001113767,0.25159204],"category_scores_gemma":[0.0006942194,0.0008530132,0.0013584101,0.00039308614,0.00061965326,0.00025916132,0.0014185911,0.0008794825,0.59986234],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009402263,0.000101961836,0.0003084075,0.000042132917,0.00039428787,0.000012973591,0.000074151714,0.00003268344,1.0620908e-7,0.0050672977,0.9801241,0.013747868],"study_design_scores_gemma":[0.0016797037,0.0001507058,0.0036862053,0.000025863621,0.000039727758,0.0000024685098,0.00011829549,0.00007620569,8.265897e-7,0.0016325958,0.99161917,0.0009682274],"about_ca_topic_score_codex":0.00050952646,"about_ca_topic_score_gemma":0.000009962621,"teacher_disagreement_score":0.3482703,"about_ca_system_score_codex":0.0024233528,"about_ca_system_score_gemma":0.00075131457,"threshold_uncertainty_score":0.9993921},"labels":[],"label_agreement":null},{"id":"W4312118687","doi":"10.1016/j.clml.2022.12.013","title":"A Comprehensive Multidisciplinary Diagnostic Algorithm for the Early and Efficient Detection of Amyloidosis","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Ottawa Hospital; University of Ottawa; Université de Montréal; Hôpital Maisonneuve-Rosemont; University Health Network; University of Toronto; University of Calgary; Centre Hospitalier de l’Université de Montréal; Alberta Cancer Foundation","funders":"","keywords":"Amyloidosis; Medicine; AL amyloidosis; Algorithm; Disease; Amyloid fibril; Amyloid (mycology); Multidisciplinary approach; Intensive care medicine; Pathology; Computer science; Immunoglobulin light chain; Amyloid β; Immunology","score_opus":0.019756159606318675,"score_gpt":0.3001207432873258,"score_spread":0.28036458368100714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312118687","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9911398,0.0034782798,0.0033304105,0.00021536223,0.00056617474,0.0010025995,0.000222778,0.000027190492,0.000017400032],"genre_scores_gemma":[0.9962536,0.00069765537,0.0012828576,0.0003122156,0.00023489924,0.000989192,0.000071479364,0.000049940187,0.000108151326],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9977829,0.0002685891,0.0006801494,0.00066833117,0.00024981477,0.0003502074],"domain_scores_gemma":[0.99612087,0.0026781475,0.0003457982,0.0005824267,0.00013636106,0.00013637615],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00040752706,0.00027987832,0.00042459817,0.000055993583,0.0005409943,0.00002364193,0.00034868915,0.00017605735,0.000012343773],"category_scores_gemma":[0.0005772922,0.0002267255,0.00040829982,0.00017269785,0.00042096886,0.0000046891955,0.00073405635,0.00013319099,0.000005426063],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00044041275,0.00048572212,0.03125999,0.000035480585,0.0004914794,0.000014683873,0.00015086718,0.0006761918,0.017245887,0.000026486854,0.00035624273,0.94881654],"study_design_scores_gemma":[0.003394374,0.0020251407,0.95998,0.000015199968,0.0002487797,0.000041262272,0.00037761914,0.006663215,0.018580362,0.00004667711,0.008338881,0.00028848049],"about_ca_topic_score_codex":0.000116649324,"about_ca_topic_score_gemma":0.000012145817,"teacher_disagreement_score":0.94852805,"about_ca_system_score_codex":0.00018013951,"about_ca_system_score_gemma":0.00019495405,"threshold_uncertainty_score":0.9245598},"labels":[],"label_agreement":null},{"id":"W4312204841","doi":"10.1016/j.clml.2022.12.012","title":"Monoclonal Gammopathy of Undetermined Significance in Patients With Transthyretin Amyloidosis (ATTR): Analysis Using the iStopMM Criteria","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; Calgary Laboratory Services; University of Calgary; Libin Cardiovascular Institute of Alberta","funders":"","keywords":"Monoclonal gammopathy of undetermined significance; Transthyretin; Amyloidosis; Monoclonal gammopathy; Medicine; Pathology; Monoclonal; Monoclonal antibody; Immunology; Antibody","score_opus":0.019556628939664988,"score_gpt":0.29909965232171304,"score_spread":0.27954302338204806,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4312204841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99823225,0.00027992495,0.00031732774,0.00015524212,0.00016684168,0.00050857343,0.00023807955,0.000017538687,0.000084224615],"genre_scores_gemma":[0.99743724,0.000056687615,0.0011743878,0.0006295559,0.00008934988,0.00018433337,0.00028158422,0.000054390828,0.00009245145],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99632376,0.00070511457,0.0011348063,0.00088225974,0.0004812041,0.0004728565],"domain_scores_gemma":[0.9979573,0.0002973635,0.0005448631,0.0009337796,0.00012251467,0.00014421136],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006814712,0.00038502953,0.00078868755,0.00017093956,0.00022913939,0.000029639827,0.00068996777,0.00019118193,0.00014716377],"category_scores_gemma":[0.00016032463,0.00030487304,0.0005891744,0.0008693376,0.00045315037,0.000012786425,0.00027440445,0.00018903932,0.000002925016],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015833715,0.0006846413,0.97386277,0.000016876847,0.00077161577,0.000024277253,0.00013178057,0.0010351557,0.004058405,0.000016968293,0.00018855328,0.01762559],"study_design_scores_gemma":[0.003675578,0.0010056455,0.9875969,0.000015318317,0.0006275704,0.0000045956344,0.00015338737,0.00072751974,0.004951814,0.000018209414,0.0008506138,0.000372824],"about_ca_topic_score_codex":0.00026230467,"about_ca_topic_score_gemma":0.00012686443,"teacher_disagreement_score":0.017252767,"about_ca_system_score_codex":0.00046375164,"about_ca_system_score_gemma":0.0005381999,"threshold_uncertainty_score":0.99994034},"labels":[],"label_agreement":null},{"id":"W4313201618","doi":"10.1016/j.clml.2022.12.011","title":"SOHO State of the Art Updates and Next Questions | Optimal Timing of Blinatumomab for the Treatment of B-Acute Lymphoblastic Leukemia","year":2022,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"SickKids Foundation; Hospital for Sick Children; University of Toronto","funders":"","keywords":"Blinatumomab; Medicine; Hematopoietic stem cell transplantation; CD19; Minimal residual disease; Chemotherapy; Lymphoblastic Leukemia; Oncology; Leukemia; Internal medicine; Transplantation; Immunology; Antibody","score_opus":0.10113126277775292,"score_gpt":0.40438592425702263,"score_spread":0.3032546614792697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313201618","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.025915645,0.9667391,0.00008573849,0.00016331293,0.0007264296,0.0048767724,0.0010238065,0.00004835969,0.00042083857],"genre_scores_gemma":[0.0012175854,0.99185735,0.0006729458,0.00006170161,0.00028509696,0.00066042773,0.00023895975,0.00016446286,0.0048414627],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9941471,0.00063385826,0.0028914507,0.00085973064,0.00083753484,0.00063028216],"domain_scores_gemma":[0.9865071,0.009485436,0.001654427,0.0017819034,0.00030367862,0.00026741254],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014081242,0.00071532436,0.0038421063,0.00026535874,0.00026433598,0.000036818426,0.0008473906,0.0004220765,0.00060806534],"category_scores_gemma":[0.0008155979,0.00041055086,0.0024727036,0.00080603256,0.0016870234,0.000075448945,0.0004498371,0.00044563727,0.000011076022],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009823121,0.00043789455,0.00004893799,0.0039284364,0.0028085755,0.000035852987,0.00016692792,0.000024465608,0.000074987045,0.00007913315,0.0008009368,0.99061155],"study_design_scores_gemma":[0.004830873,0.0038312362,0.003505075,0.0038781858,0.0076842434,0.00037579445,0.00006324329,0.00209604,0.00022082427,0.00007277156,0.9730756,0.000366101],"about_ca_topic_score_codex":0.000121180885,"about_ca_topic_score_gemma":0.0000105909785,"teacher_disagreement_score":0.99024546,"about_ca_system_score_codex":0.0027413687,"about_ca_system_score_gemma":0.007795475,"threshold_uncertainty_score":0.99983466},"labels":[],"label_agreement":null},{"id":"W4313334167","doi":"10.1016/j.clml.2022.12.015","title":"CAR T-Cells for the Treatment of Refractory or Relapsed Large B-Cell Lymphoma: A Single-Center Retrospective Canadian Study","year":2022,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Centre hospitalier de l'Université Laval; Université Laval","funders":"","keywords":"Medicine; Cytokine release syndrome; Internal medicine; Refractory (planetary science); Chimeric antigen receptor; Lymphoma; Retrospective cohort study; Cohort; Population; Oncology; Clinical trial; Gastroenterology; Immunotherapy; Cancer","score_opus":0.057318149621745584,"score_gpt":0.3451042323808731,"score_spread":0.28778608275912754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4313334167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886291,0.00057768653,0.000010285618,0.0004435907,0.0012631097,0.0053072646,0.0006453031,0.00007775393,0.0030458916],"genre_scores_gemma":[0.9695012,0.00027632347,0.000107912056,0.00081697234,0.00065473316,0.0010734188,0.00010825036,0.00015497737,0.0273062],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99473274,0.0007043006,0.0013693793,0.0010685574,0.0010055576,0.0011194426],"domain_scores_gemma":[0.99428976,0.002490194,0.00040706154,0.0016919238,0.00037769938,0.00074336794],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018170776,0.00048209642,0.0012867709,0.00028802713,0.00072840735,0.000045001638,0.00062495336,0.0002662376,0.0024535113],"category_scores_gemma":[0.00042794517,0.00033539266,0.00091844815,0.0007114791,0.0003409292,0.00006671237,0.000189511,0.00031533212,0.000056242545],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047699645,0.09029494,0.19101757,0.00018411955,0.0038776165,0.0032181714,0.0089595625,0.00001703848,0.017384565,0.000109872206,0.034221962,0.60301495],"study_design_scores_gemma":[0.083782054,0.04187241,0.2637752,0.00003405307,0.0006253144,0.00012954992,0.004502999,0.0005262883,0.0023595658,0.00003074917,0.6019007,0.00046112912],"about_ca_topic_score_codex":0.013987041,"about_ca_topic_score_gemma":0.021778911,"teacher_disagreement_score":0.6025538,"about_ca_system_score_codex":0.014687064,"about_ca_system_score_gemma":0.005274857,"threshold_uncertainty_score":0.9999098},"labels":[],"label_agreement":null},{"id":"W4319073050","doi":"10.1016/j.clml.2023.01.016","title":"First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"London Health Sciences Centre; McMaster University; Juravinski Cancer Centre; University of Saskatchewan; Université de Montréal; Memorial University of Newfoundland; CancerCare Manitoba; Centre hospitalier universitaire de Québec; University of Manitoba; Western University; Hôpital Maisonneuve-Rosemont","funders":"Hamilton Health Sciences Foundation; Dalhousie University; Hamilton Health Sciences; Sierra Oncology; GlaxoSmithKline","keywords":"Medicine; Multiple myeloma; Guideline; Oncology; Internal medicine; Family medicine; Intensive care medicine; Pathology","score_opus":0.24478193990965672,"score_gpt":0.4566497579962298,"score_spread":0.2118678180865731,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4319073050","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0086768605,0.9512155,0.000026924808,0.008365247,0.0018806157,0.011592459,0.016417941,0.00048018087,0.0013442363],"genre_scores_gemma":[0.013315197,0.95872724,0.001949448,0.00033966446,0.0024206329,0.0020296995,0.018915255,0.0004637306,0.0018391245],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9831254,0.0028915298,0.006691647,0.002576828,0.0019942569,0.0027203213],"domain_scores_gemma":[0.9610498,0.029730055,0.0013377853,0.0035739176,0.0013529384,0.0029555333],"candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0038582955,0.0017651119,0.006401496,0.0012964648,0.0015583382,0.00022982754,0.0015207678,0.0021682803,0.0006261348],"category_scores_gemma":[0.0076944176,0.0011799751,0.0029070403,0.0027543982,0.0021074316,0.00010777519,0.0003689656,0.001623808,0.002114804],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00087710103,0.0013022207,0.005538519,0.0018752565,0.003976131,0.004899592,0.00020742233,0.0000050122526,0.0000017266498,0.00010967707,0.041173678,0.9400337],"study_design_scores_gemma":[0.01436002,0.002150838,0.056480348,0.0116669675,0.0028682395,0.00026076107,0.0001536692,0.00072543515,0.000009815627,0.00017645113,0.91024846,0.0008990224],"about_ca_topic_score_codex":0.3218518,"about_ca_topic_score_gemma":0.58076227,"teacher_disagreement_score":0.93913466,"about_ca_system_score_codex":0.0078736385,"about_ca_system_score_gemma":0.019463884,"threshold_uncertainty_score":0.9997415},"labels":[],"label_agreement":null},{"id":"W4323353350","doi":"10.1016/j.clml.2023.03.002","title":"Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Loxo Oncology; Pharmacyclics; Kite Pharma; Genentech; National Cancer Institute; Gilead Sciences; Servier; Alexion Pharmaceuticals; Apellis Pharmaceuticals; BeiGene; Pfizer; Incyte; Innovent Biologics; Adaptive Biotechnologies; Sierra Oncology; CTI Biopharma; bluebird bio; TG Therapeutics; Regeneron Pharmaceuticals; Sanofi; Amgen; AstraZeneca; Cidara Therapeutics; MorphoSys; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Vaccination; Seroconversion; Lymphoma; Immunology; Multiple myeloma; Antibody; Cancer; Chimeric antigen receptor; Immune system; Immunotherapy; Virology; Internal medicine","score_opus":0.03695353903935361,"score_gpt":0.3572703254441805,"score_spread":0.3203167864048269,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4323353350","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99179417,0.00006727169,0.000035622776,0.004348734,0.00027556284,0.002760021,0.00006434229,0.0003269323,0.0003273295],"genre_scores_gemma":[0.98907304,0.00021652867,0.00044518532,0.007066525,0.00024790727,0.00018505119,0.00022104535,0.00017180786,0.0023729275],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99411064,0.00093412976,0.0012780533,0.0013875973,0.0012165816,0.0010729772],"domain_scores_gemma":[0.9924431,0.0041198106,0.00023305528,0.0012078487,0.000520679,0.0014755474],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0036738166,0.00055433,0.0010814833,0.0010083125,0.00023722324,0.00010826028,0.00045403966,0.00055972865,0.0005093696],"category_scores_gemma":[0.0059813163,0.00046753572,0.00025166615,0.0021635685,0.00025901027,0.00022969455,0.00033040525,0.0003281375,0.00047448624],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060418032,0.0003920061,0.431937,0.000048039863,0.00010475183,0.0003768191,0.00065035897,0.00002348711,0.0042706984,0.000007019893,0.0017802997,0.49999148],"study_design_scores_gemma":[0.04294798,0.006424471,0.9246277,0.00011952626,0.000028239565,0.000041225863,0.00021965367,0.0010642234,0.00081991515,0.000050254966,0.02315609,0.0005006971],"about_ca_topic_score_codex":0.000434583,"about_ca_topic_score_gemma":0.00020941647,"teacher_disagreement_score":0.49949077,"about_ca_system_score_codex":0.002633385,"about_ca_system_score_gemma":0.0028715823,"threshold_uncertainty_score":0.9997776},"labels":[],"label_agreement":null},{"id":"W4327719861","doi":"10.1016/j.clml.2023.03.005","title":"Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Johnson and Johnson","keywords":"Medicine; Quality of life (healthcare); Checklist; Health related quality of life; Disease; Physical therapy; Internal medicine","score_opus":0.18961982451733672,"score_gpt":0.4915562219223763,"score_spread":0.3019363974050396,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4327719861","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.13883767,0.85121953,3.8866042e-7,0.00015828772,0.00009080231,0.008744018,0.0008777665,0.00006142461,0.000010122425],"genre_scores_gemma":[0.030287197,0.9677854,0.00011221296,0.00009055389,0.000071738206,0.0006203897,0.00075086625,0.00015223546,0.00012936346],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9788632,0.008338377,0.009581162,0.00117183,0.0013027313,0.00074272713],"domain_scores_gemma":[0.97769785,0.0127803795,0.0053382833,0.002070589,0.00060692633,0.0015059792],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009143701,0.0010082993,0.012823683,0.0008597129,0.00006675674,0.000019634997,0.00050832843,0.0008807974,0.000027548878],"category_scores_gemma":[0.0407509,0.0006073262,0.0028677604,0.0022809969,0.0006195996,0.00008679869,0.00026849736,0.0008618168,0.000030548577],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01195806,0.0012615356,0.004962021,0.5118785,0.0013833715,0.00028945875,0.00006325673,2.992424e-7,0.0000012246934,0.0000099717545,0.0001901582,0.46800217],"study_design_scores_gemma":[0.0073062195,0.0034002522,0.36571816,0.62226206,0.00048904656,0.000035372625,0.0000074355216,0.000046249268,6.2220806e-7,0.0000168701,0.00044219248,0.00027553047],"about_ca_topic_score_codex":0.00023637222,"about_ca_topic_score_gemma":0.000017133414,"teacher_disagreement_score":0.46772662,"about_ca_system_score_codex":0.0012302827,"about_ca_system_score_gemma":0.010142616,"threshold_uncertainty_score":0.9996378},"labels":[],"label_agreement":null},{"id":"W4353050819","doi":"10.1016/j.clml.2023.03.009","title":"Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Cancer Foundation; Institute of Cancer Research","funders":"Cilag; EUSA Pharma; Janssen Pharmaceuticals; Genentech; Celgene; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Context (archaeology); Immune system; Multiple myeloma; Vaccination; Medicine; Session (web analytics); Immunology; Biology; Computer science","score_opus":0.12128700098053999,"score_gpt":0.4174896918128727,"score_spread":0.29620269083233275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4353050819","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.022969466,0.96378535,0.00008982113,0.0016058355,0.0028167379,0.004877838,0.0018678328,0.0005095938,0.001477497],"genre_scores_gemma":[0.0071421764,0.97838783,0.0013579999,0.00023232629,0.0020060667,0.0009388242,0.006075255,0.00020013502,0.0036594088],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9910606,0.00076856837,0.003918073,0.0020339263,0.0011501955,0.0010686188],"domain_scores_gemma":[0.9869392,0.008863563,0.0012994091,0.0017788016,0.00044855246,0.0006704564],"candidate_categories":["metaresearch","metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.002716403,0.0010673876,0.0033833869,0.0003746988,0.0004966385,0.00022183084,0.0009566059,0.0015624091,0.00018998227],"category_scores_gemma":[0.009666223,0.0007601678,0.002057027,0.001309619,0.00078329915,0.00036692232,0.0010434432,0.0017061367,0.0006358414],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00029150752,0.00038637547,0.009170085,0.0008542753,0.0021599499,0.0037996625,0.00017085303,9.67678e-7,8.2544017e-7,0.00007544328,0.007146655,0.9759434],"study_design_scores_gemma":[0.005716957,0.00011661531,0.43265495,0.008735182,0.0009923952,0.0015916873,0.00026284106,0.0006285964,0.0000011903433,0.00015414915,0.5485382,0.00060726935],"about_ca_topic_score_codex":0.0007877584,"about_ca_topic_score_gemma":0.0005342882,"teacher_disagreement_score":0.97533613,"about_ca_system_score_codex":0.0028429595,"about_ca_system_score_gemma":0.004758349,"threshold_uncertainty_score":0.99973375},"labels":[],"label_agreement":null},{"id":"W4360798156","doi":"10.1016/j.clml.2023.03.006","title":"A Phase II, Open-Label Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus; Princess Margaret Cancer Centre; Queen's University; McGill University; Université Laval; University of Saskatchewan; Université de Montréal; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Daratumumab; Medicine; Multiple myeloma; Refractory (planetary science); Dosing; Phases of clinical research; Clinical trial; Surgery; Anesthesia; Internal medicine; Bortezomib","score_opus":0.0861937956303593,"score_gpt":0.4005179872177594,"score_spread":0.3143241915874001,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360798156","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99605674,0.00004341617,0.0000010524753,0.00004088382,0.000108695305,0.0033207815,0.000097756354,0.00009170201,0.00023898388],"genre_scores_gemma":[0.9983792,0.0000764243,0.00040268633,0.00007361744,0.00004338079,0.00014747251,0.00055029086,0.00007961211,0.00024737246],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951842,0.00071567745,0.0017382973,0.0010162996,0.00070113037,0.0006444054],"domain_scores_gemma":[0.99619347,0.00090222125,0.0006023762,0.0011300722,0.0005390207,0.0006328689],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001364148,0.0004431921,0.0014774811,0.0005177895,0.00022145374,0.000045541954,0.0004916488,0.00033079527,0.000042513297],"category_scores_gemma":[0.0017024939,0.0003387437,0.00007616064,0.0014887581,0.00039202318,0.0005127756,0.00078385964,0.00039216,0.000020940442],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.043434463,0.038870975,0.49518707,0.000100746765,0.00034741155,0.00060309615,0.00066902593,0.0000033750853,0.0019922499,0.0000053383965,0.0001670324,0.41861922],"study_design_scores_gemma":[0.21503976,0.04591823,0.73438764,0.0002915095,0.00009951882,0.0000050482895,0.0003307211,0.002910679,0.00067514315,0.00001672723,0.00009638022,0.00022864004],"about_ca_topic_score_codex":0.000907859,"about_ca_topic_score_gemma":0.00044386444,"teacher_disagreement_score":0.41839057,"about_ca_system_score_codex":0.0003688744,"about_ca_system_score_gemma":0.0009162947,"threshold_uncertainty_score":0.9999065},"labels":[],"label_agreement":null},{"id":"W4360874186","doi":"10.1016/j.clml.2023.03.010","title":"Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"AbbVie","keywords":"Venetoclax; Discontinuation; Medicine; Internal medicine; Adverse effect; Regimen; Chronic lymphocytic leukemia; Pediatrics; Leukemia","score_opus":0.053800879809759505,"score_gpt":0.3791683002437791,"score_spread":0.3253674204340196,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4360874186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184537,0.000027174156,0.00006448732,0.0002887143,0.0009012001,0.004980586,0.0010325448,0.00041211376,0.0004478036],"genre_scores_gemma":[0.98790455,0.00023746477,0.000632688,0.00019231912,0.001160456,0.0011143364,0.0050771916,0.00018764703,0.0034933276],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99248624,0.00036015187,0.0025285063,0.0020389084,0.0013067343,0.0012794894],"domain_scores_gemma":[0.9940969,0.0027619288,0.00065670547,0.0014797625,0.0004610094,0.0005437368],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011814123,0.00074680895,0.0013844272,0.0007144473,0.00018177721,0.00015458683,0.000658184,0.00036959187,0.000060348513],"category_scores_gemma":[0.0016087462,0.0005864407,0.0004670976,0.0010265134,0.0002663139,0.00034105036,0.0003843347,0.00031020882,0.00035429763],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.018036684,0.0031491383,0.67572236,0.00009524562,0.0012094014,0.0011615228,0.0017032305,0.0006184429,0.000023177608,0.000017997112,0.0019067375,0.29635605],"study_design_scores_gemma":[0.2167574,0.003127161,0.6609022,0.00052749884,0.00017431422,0.00000950837,0.0002823218,0.114876784,0.00005265697,0.000012944263,0.0028679362,0.00040928394],"about_ca_topic_score_codex":0.014725101,"about_ca_topic_score_gemma":0.012217318,"teacher_disagreement_score":0.29594675,"about_ca_system_score_codex":0.25805068,"about_ca_system_score_gemma":0.031216769,"threshold_uncertainty_score":0.9996587},"labels":[],"label_agreement":null},{"id":"W4377826847","doi":"10.1016/j.clml.2023.05.008","title":"Recommendations for Management of Secondary Antibody Deficiency in Multiple Myeloma","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"CSL Behring","keywords":"Hypogammaglobulinemia; Medicine; Intensive care medicine; Immunodeficiency; Primary immunodeficiency; Disease; Antibody; Immunology; Pediatrics; Internal medicine; Immune system","score_opus":0.19724998876862215,"score_gpt":0.46812037936177925,"score_spread":0.2708703905931571,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4377826847","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.003192463,0.9806221,0.00014920076,0.00021645312,0.0011117341,0.008930524,0.0014991707,0.00028027,0.0039980817],"genre_scores_gemma":[0.0007464446,0.982544,0.0062822984,0.00007814054,0.0003003439,0.0015090365,0.0051657185,0.00025479958,0.0031191856],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9919742,0.00047333204,0.004067482,0.0015701579,0.0006941343,0.001220717],"domain_scores_gemma":[0.9925576,0.0039930083,0.0010495816,0.0015343464,0.0002514151,0.00061408896],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019015872,0.0008931955,0.0044087167,0.00095127255,0.00018859124,0.0000464842,0.0007678388,0.0009696437,0.00016769607],"category_scores_gemma":[0.0011473281,0.00075093005,0.0021961452,0.0015853386,0.00040524013,0.00013687239,0.00054770336,0.00068814115,0.00063304347],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00033031777,0.0008304743,0.0010025514,0.036726825,0.001141284,0.00069046987,0.00002079127,3.361545e-7,7.191757e-7,0.0003453465,0.0029023064,0.95600855],"study_design_scores_gemma":[0.01060294,0.0009206325,0.11693723,0.032718796,0.0017501282,0.000112874295,0.000102503735,0.00022492281,0.0000041645744,0.00024870824,0.83568317,0.00069393124],"about_ca_topic_score_codex":0.00010202865,"about_ca_topic_score_gemma":0.000058096422,"teacher_disagreement_score":0.95531464,"about_ca_system_score_codex":0.0016759138,"about_ca_system_score_gemma":0.0029349376,"threshold_uncertainty_score":0.9994942},"labels":[],"label_agreement":null},{"id":"W4378675662","doi":"10.1016/j.clml.2023.05.013","title":"External Validation of the FLIPI Risk Score Measured at Diagnosis and POD24 Among Individuals With Follicular Lymphoma at the Time of Subsequent Relapse","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"Janssen Canada; Janssen Pharmaceuticals; Canadian Institutes of Health Research","keywords":"Medicine; Follicular lymphoma; Internal medicine; Oncology; Follicular phase; Lymphoma","score_opus":0.029738740034475547,"score_gpt":0.2829057458374034,"score_spread":0.25316700580292784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4378675662","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99582595,0.0012907885,0.0000025136665,0.0007021986,0.00024711865,0.0014131127,0.00019190852,0.00008865728,0.00023777838],"genre_scores_gemma":[0.9967163,0.001333873,0.000120628654,0.0002991078,0.00016857035,0.00032323127,0.00009339136,0.00007463511,0.0008702314],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523693,0.0006869347,0.0014464705,0.000799704,0.0013107003,0.00051926565],"domain_scores_gemma":[0.9947771,0.0020170587,0.001190618,0.0014044391,0.00027193132,0.00033889632],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018233763,0.00047201148,0.0010923508,0.00012931325,0.00040276087,0.000040267623,0.00041940657,0.00037957652,0.00014143044],"category_scores_gemma":[0.0011436485,0.00025039958,0.0006638174,0.0007932143,0.0012683048,0.00012824762,0.00062961056,0.00013524097,0.00015835397],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00059715693,0.00041396578,0.93752366,0.00007656942,0.00079220656,0.00011836,0.00035596592,0.00004523896,0.00039179542,0.000047417332,0.002652769,0.056984875],"study_design_scores_gemma":[0.008920367,0.0007740443,0.94219154,0.00084243575,0.0014981992,0.00015906691,0.00006193535,0.00017808733,0.04375709,0.00016140776,0.0012020065,0.0002538427],"about_ca_topic_score_codex":0.0004963045,"about_ca_topic_score_gemma":0.00010594597,"teacher_disagreement_score":0.05673103,"about_ca_system_score_codex":0.0013480914,"about_ca_system_score_gemma":0.00063623255,"threshold_uncertainty_score":0.9999948},"labels":[],"label_agreement":null},{"id":"W4379379925","doi":"10.1016/j.clml.2023.06.001","title":"Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre; Dalhousie University; Vancouver General Hospital; CancerCare Manitoba; Université de Montréal; Queen Elizabeth II Health Sciences Centre; Ontario Institute for Cancer Research","funders":"Karyopharm Therapeutics","keywords":"Medicine; Multiple myeloma; Monoclonal antibody; CD38; Oncology; Antibody; Virology; Internal medicine; Cancer research; Immunology","score_opus":0.03189090537878026,"score_gpt":0.3160870044201881,"score_spread":0.28419609904140786,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4379379925","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99506134,0.00011290351,0.000028265726,0.00056347577,0.00011489092,0.0027379263,0.0001869195,0.0006457876,0.00054852176],"genre_scores_gemma":[0.9928654,0.00013328172,0.0024452189,0.00047619623,0.00022495055,0.00027070538,0.002170024,0.00020004813,0.0012142075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99304193,0.0004807996,0.001581595,0.0016396984,0.0014703977,0.0017855869],"domain_scores_gemma":[0.99487525,0.0016011957,0.00045012034,0.0013719281,0.0006069279,0.001094572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00092658435,0.00089852634,0.0018535368,0.0007500914,0.00028013714,0.000098194345,0.00043831853,0.0005152999,0.00010231802],"category_scores_gemma":[0.0013699392,0.00061718596,0.00040866787,0.0020795478,0.00074430765,0.00027567608,0.00017633005,0.00057473604,0.0005977307],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013397425,0.0015861151,0.90901536,0.00017293188,0.00058334565,0.0035012357,0.00006450459,0.000121425735,0.00007306,0.000010304373,0.0018511772,0.069623135],"study_design_scores_gemma":[0.05978403,0.0044983327,0.9250703,0.0007848711,0.00023973158,0.00005155162,0.00005385312,0.0068575316,0.00068473734,0.000010512703,0.0013079942,0.0006565754],"about_ca_topic_score_codex":0.0004179299,"about_ca_topic_score_gemma":0.0002488627,"teacher_disagreement_score":0.06896656,"about_ca_system_score_codex":0.0011023898,"about_ca_system_score_gemma":0.0020185197,"threshold_uncertainty_score":0.99962795},"labels":[],"label_agreement":null},{"id":"W4380148718","doi":"10.1016/j.clml.2023.06.004","title":"Cross-Study Comparisons of JAK2 Inhibitors in Myelofibrosis: Risks and Recommendations","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Sierra Oncology; CTI Biopharma; Gilead Sciences","keywords":"Medicine; Myelofibrosis; Clinical trial; Spurious relationship; Janus kinase; Ruxolitinib; Oncology; Intensive care medicine; Internal medicine","score_opus":0.10245799520236465,"score_gpt":0.42278286234884843,"score_spread":0.3203248671464838,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4380148718","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.995123,0.00024028748,0.000005168916,0.0013423461,0.0004110196,0.0013922615,0.000076686665,0.00013974095,0.001269442],"genre_scores_gemma":[0.997304,0.00061237253,0.0006338726,0.00026167184,0.00019656013,0.00044854454,0.00013742763,0.000045977937,0.00035953167],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99631435,0.0003198694,0.0017580112,0.0007714608,0.0003734725,0.00046283627],"domain_scores_gemma":[0.9969136,0.0016390764,0.0003384483,0.00057684263,0.0001754474,0.00035658467],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011687997,0.0003422004,0.0011587883,0.00034173467,0.0001722455,0.000052770447,0.0001483408,0.00028257273,0.00013358152],"category_scores_gemma":[0.0009182636,0.00029414322,0.00025426783,0.00094946864,0.00038387836,0.00013401435,0.00023851327,0.00028239744,0.00019119028],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00031542376,0.0013149362,0.8290703,0.00004619083,0.00017987732,0.000112524634,0.0003201613,0.000012557837,0.00005182825,0.00015530152,0.004676425,0.16374443],"study_design_scores_gemma":[0.008396063,0.001543365,0.98178416,0.0003058928,0.00015826084,0.000023166434,0.0008109304,0.0006400057,0.0005777908,0.00010236649,0.0054216343,0.00023637542],"about_ca_topic_score_codex":0.0005144142,"about_ca_topic_score_gemma":0.00027755668,"teacher_disagreement_score":0.16350806,"about_ca_system_score_codex":0.0003737434,"about_ca_system_score_gemma":0.0004945867,"threshold_uncertainty_score":0.99995106},"labels":[],"label_agreement":null},{"id":"W4383875518","doi":"10.1016/j.clml.2023.07.003","title":"Real-World Experience With CPX-351 Treatment for Acute Myeloid Leukemia in England: An Analysis From the National Cancer Registration and Analysis Service","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Chinese Academy of Sciences; Jazz Pharmaceuticals; CMC Microsystems","keywords":"Medicine; Cytarabine; Cancer; Population; Pediatrics; Transplantation; Myeloid leukemia; Cancer registry; Cohort; Retrospective cohort study; Chemotherapy regimen; Internal medicine; Survival analysis","score_opus":0.06922871382395486,"score_gpt":0.411631391700547,"score_spread":0.3424026778765922,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4383875518","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941381,0.00009351343,0.0002270006,0.0031450575,0.000090334004,0.0011507084,0.00057695416,0.00019613285,0.00038217995],"genre_scores_gemma":[0.9873056,0.0018485418,0.0017886326,0.0018451962,0.0008866112,0.0011993548,0.0030487648,0.00007378012,0.0020035387],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99476826,0.00042018664,0.0013555547,0.0015690792,0.0010855984,0.0008013456],"domain_scores_gemma":[0.9943084,0.0029914652,0.0004402331,0.0010622792,0.0006522281,0.000545402],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015752899,0.0005326885,0.0014793251,0.0009221207,0.00035892063,0.00017429962,0.0005202928,0.00037068094,0.000119675664],"category_scores_gemma":[0.00043785886,0.000357133,0.00050999486,0.0077074277,0.00043421952,0.00036671927,0.00014725392,0.00033936783,0.000028694327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005454593,0.00017492539,0.87605655,0.000032286214,0.011119088,0.00025825456,0.0037141629,0.0031245365,0.0007387296,0.00020372015,0.0007562693,0.0983669],"study_design_scores_gemma":[0.0069159907,0.00049435295,0.8193557,0.000048153823,0.005342004,0.000010054413,0.0005116241,0.1627755,0.00025154845,0.00013126823,0.003824245,0.0003395121],"about_ca_topic_score_codex":0.0359854,"about_ca_topic_score_gemma":0.110094205,"teacher_disagreement_score":0.15965097,"about_ca_system_score_codex":0.007961642,"about_ca_system_score_gemma":0.0047563473,"threshold_uncertainty_score":0.99988806},"labels":[],"label_agreement":null},{"id":"W4384565542","doi":"10.1016/j.clml.2023.07.004","title":"Effect of the Presence of t(11;14) for Patients With AL Amyloidosis Treated With Bortezomib-Containing Regimens: Experience From the Amyloidosis Program of Calgary","year":2023,"lang":"en","type":"letter","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Institute of Cancer Research; Foothills Medical Centre; University of Calgary","funders":"","keywords":"Bortezomib; AL amyloidosis; Amyloidosis; Immunoglobulin light chain; Amyloid (mycology); Medicine; Internal medicine; Melphalan; Oncology; Gastroenterology; Pathology; Immunology; Multiple myeloma; Antibody","score_opus":0.01389741909341276,"score_gpt":0.29465546753332394,"score_spread":0.2807580484399112,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4384565542","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908069,0.00036729677,0.00002274402,0.0036397546,0.0003265176,0.0039976053,0.0007322532,0.000062711115,0.000044217744],"genre_scores_gemma":[0.98074186,0.00029555932,0.0007849598,0.012366481,0.00052237214,0.003049414,0.00167039,0.00026886642,0.00030012763],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942304,0.00086365343,0.0017177978,0.001498507,0.00090441224,0.00078525126],"domain_scores_gemma":[0.99026906,0.0043618195,0.0022915788,0.0023895917,0.00055086974,0.00013707648],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00060737564,0.00096579525,0.0018381359,0.0000790587,0.00018984602,0.000039404433,0.0016970608,0.0012607645,0.0000095371015],"category_scores_gemma":[0.001681524,0.00051243923,0.0010402886,0.00050728413,0.0019430729,0.00002035778,0.00055332464,0.00047271352,0.0000028177678],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004183227,0.00042963517,0.8813247,0.00025109242,0.0017673641,0.000021079293,0.00015031846,0.000009758725,0.00052944245,0.00000261095,0.0565363,0.05479447],"study_design_scores_gemma":[0.009708747,0.013777895,0.88692874,0.0013515783,0.0017050161,0.0000057990296,0.00008416289,0.000059864346,0.060096733,0.0000069757994,0.025483824,0.0007906862],"about_ca_topic_score_codex":0.0013782453,"about_ca_topic_score_gemma":0.00016261873,"teacher_disagreement_score":0.05956729,"about_ca_system_score_codex":0.00021819554,"about_ca_system_score_gemma":0.000718103,"threshold_uncertainty_score":0.99973273},"labels":[],"label_agreement":null},{"id":"W4385432225","doi":"10.1016/j.clml.2023.07.012","title":"Very late relapse in Hodgkin lymphoma: Characterizing an understudied population","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; Public Health Ontario; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Internal medicine; Lymphoma; Population; Oncology; Univariate analysis; Proportional hazards model; Hodgkin lymphoma; Multivariate analysis","score_opus":0.14835162407570415,"score_gpt":0.41677099581923704,"score_spread":0.2684193717435329,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385432225","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.21270066,0.78015155,0.0000012089502,0.00019846695,0.0023651656,0.002940267,0.0001262047,0.0007417083,0.0007747737],"genre_scores_gemma":[0.01282103,0.9793992,0.00022018484,0.0006464842,0.0015076306,0.0007042543,0.0032515042,0.00042856607,0.0010211186],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98993784,0.0010639853,0.0044763875,0.002359789,0.0008545017,0.0013075134],"domain_scores_gemma":[0.99332,0.0021804997,0.0015181707,0.0019680366,0.00012991289,0.00088337396],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0019034523,0.0015091572,0.006697508,0.0008679142,0.00025752818,0.00015938094,0.00059025735,0.0021508555,0.000058484864],"category_scores_gemma":[0.0010919803,0.0012555837,0.0022110534,0.0015628558,0.00026493703,0.00038063573,0.0004620758,0.00053799956,0.0019766984],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00024863475,0.0012169927,0.0072277924,0.004751354,0.0009685494,0.0034185029,0.00006413144,8.4575976e-7,5.38749e-7,0.00021495142,0.00063431705,0.9812534],"study_design_scores_gemma":[0.00719891,0.0007061766,0.6777496,0.020873437,0.0025830856,0.00028895566,0.0000337872,0.000075628705,8.8778694e-7,0.00016321114,0.28931746,0.0010088647],"about_ca_topic_score_codex":0.00079627475,"about_ca_topic_score_gemma":0.00021933755,"teacher_disagreement_score":0.9802445,"about_ca_system_score_codex":0.009226388,"about_ca_system_score_gemma":0.0031201048,"threshold_uncertainty_score":0.99976575},"labels":[],"label_agreement":null},{"id":"W4385797799","doi":"10.1016/j.clml.2023.07.014","title":"The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Bortezomib; Multiple myeloma; Medicine; Autologous stem-cell transplantation; Transplantation; Stem cell; Cohort; Internal medicine; CD34; Confounding; Oncology; Overall survival; Surgery; Biology","score_opus":0.14981611638150955,"score_gpt":0.441903336462083,"score_spread":0.2920872200805735,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4385797799","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.17749746,0.79518104,0.000054698852,0.00024078222,0.0032671313,0.017888198,0.0029500204,0.0005804085,0.0023402635],"genre_scores_gemma":[0.050730873,0.9428297,0.00015681681,0.000027207607,0.000392044,0.0013653666,0.00082479144,0.00026743667,0.0034057267],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9921139,0.000996556,0.00336008,0.0012718154,0.0008669341,0.0013906965],"domain_scores_gemma":[0.97406054,0.022701126,0.0010012514,0.0013763185,0.00024027623,0.00062047254],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0022276298,0.0010993788,0.0056041563,0.0006157937,0.00035849086,0.00006456711,0.0007458583,0.0015725303,0.000030738844],"category_scores_gemma":[0.0041488716,0.0006296251,0.004486712,0.001094651,0.0004898243,0.00006404783,0.00014180398,0.0009662747,0.00026141392],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.003064892,0.0010121042,0.023902303,0.0051404317,0.002001177,0.00054886343,0.000045423396,0.0000071174013,0.0000018487173,0.000030431296,0.001437507,0.9628079],"study_design_scores_gemma":[0.01691085,0.006542316,0.90357435,0.008994675,0.0015201794,0.00012913793,0.000042046773,0.0014863285,0.000021073518,0.00011428512,0.0598226,0.00084213977],"about_ca_topic_score_codex":0.0011768364,"about_ca_topic_score_gemma":0.000678292,"teacher_disagreement_score":0.96196574,"about_ca_system_score_codex":0.0030082143,"about_ca_system_score_gemma":0.005601541,"threshold_uncertainty_score":0.9997236},"labels":[],"label_agreement":null},{"id":"W4386269939","doi":"10.1016/s2152-2650(23)00451-2","title":"POSTER: AML-391 WHO and ICC 2022 Cytogenetic Abnormalities Defining Acute Myelogenous Leukemia (AML) Myelodysplasia-Related in First-Line Decitabine in Unfit AML Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Calgary","funders":"","keywords":"Decitabine; Medicine; Leukemia; Internal medicine; Oncology; Biology; Genetics; DNA methylation","score_opus":0.023337901544357626,"score_gpt":0.31111381978212793,"score_spread":0.2877759182377703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905884,0.0014312043,0.000010139586,0.0014840887,0.00080631394,0.002144039,0.00028751796,0.0005292157,0.0027190475],"genre_scores_gemma":[0.9853138,0.006854867,0.00040989887,0.0016036433,0.0003850254,0.00035690822,0.0013754471,0.00036804916,0.0033324028],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98723626,0.0009222482,0.0045455825,0.0025342205,0.0017260108,0.0030356983],"domain_scores_gemma":[0.9919917,0.0035255412,0.00073827244,0.001851001,0.0005141221,0.0013793409],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0034803113,0.0013629518,0.002997732,0.002038366,0.00047121893,0.0001927548,0.0011720733,0.0017867051,0.00030250725],"category_scores_gemma":[0.0034349605,0.0013390151,0.00062306714,0.0042810547,0.001315788,0.00055492524,0.0017599628,0.0022047854,0.0013002554],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00495372,0.00048415601,0.74208945,0.00046635323,0.0006771738,0.007033863,0.0020198144,0.0003083729,0.0005079509,0.00031172257,0.0036417642,0.23750567],"study_design_scores_gemma":[0.02648493,0.0022666154,0.9572133,0.0011383565,0.000308445,0.0006923428,0.0004401897,0.0059150415,0.00055260217,0.0008200657,0.0029360398,0.0012321073],"about_ca_topic_score_codex":0.0014363676,"about_ca_topic_score_gemma":0.0011811784,"teacher_disagreement_score":0.23627357,"about_ca_system_score_codex":0.0075149722,"about_ca_system_score_gemma":0.0041001653,"threshold_uncertainty_score":0.99991214},"labels":[],"label_agreement":null},{"id":"W4386269941","doi":"10.1016/s2152-2650(23)00421-4","title":"POSTER: AML-197 Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Hematopoietic cell; Haematopoiesis; Transplantation; Hematopoietic stem cell transplantation; Tandem exon duplication; Tyrosine kinase; Leukemia; Oncology; Immunology; Gene duplication; Internal medicine; Stem cell; Biology; Genetics; Gene; Receptor","score_opus":0.025514020932101332,"score_gpt":0.3305546129086902,"score_spread":0.3050405919765889,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269941","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99494076,0.00007690517,0.0000782985,0.0019500689,0.00018629032,0.001891253,0.0007776997,0.000033685705,0.0000650457],"genre_scores_gemma":[0.99120015,0.004603973,0.00019899005,0.0012188443,0.00016469246,0.00026455647,0.0021394545,0.00006130581,0.00014802894],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99471563,0.0007388076,0.001531001,0.0012589341,0.0009431653,0.00081245304],"domain_scores_gemma":[0.9944119,0.0038292427,0.0002731055,0.0004982454,0.00057377294,0.0004137456],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018844723,0.00047714374,0.0010223805,0.000667763,0.00020445502,0.00012987664,0.00036750644,0.00036251917,0.000008524732],"category_scores_gemma":[0.00041109926,0.0003359404,0.00022776837,0.00072525296,0.00044617118,0.00020044806,0.00012770614,0.00060890726,0.0000033505257],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0041226437,0.00043833433,0.97340035,0.00011887938,0.0011071045,0.00079860474,0.0007018131,0.000013299364,0.00008192809,0.000017421988,0.00012692806,0.01907267],"study_design_scores_gemma":[0.027469141,0.0018055106,0.96637946,0.0003262353,0.0010825436,0.00010393821,0.00027720674,0.0019651286,0.00017419703,0.000020036698,0.00007927447,0.00031734613],"about_ca_topic_score_codex":0.04447401,"about_ca_topic_score_gemma":0.3068573,"teacher_disagreement_score":0.26238325,"about_ca_system_score_codex":0.0021977741,"about_ca_system_score_gemma":0.0018255699,"threshold_uncertainty_score":0.9999093},"labels":[],"label_agreement":null},{"id":"W4386269946","doi":"10.1016/s2152-2650(23)00508-6","title":"POSTER: AML-288 The Result of Post Chemotherapy Bone Marrow Recovery in Patients With Acute Leukemia and Lymphoid Malignancies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Medicine; Bone marrow; Chemotherapy; Lymphoid leukemia; Leukemia; Oncology; Internal medicine","score_opus":0.013848836595507478,"score_gpt":0.2789037413703244,"score_spread":0.26505490477481697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269946","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950912,0.00016734019,0.000002211932,0.0017724085,0.00038123384,0.00078795134,0.000106642954,0.00012167937,0.0015693378],"genre_scores_gemma":[0.9935673,0.0011039281,0.0000978959,0.003061625,0.0002013949,0.000076412136,0.00011808777,0.000076373006,0.001697008],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970891,0.00016270675,0.001105856,0.0006418891,0.00047459357,0.0005258383],"domain_scores_gemma":[0.9977375,0.0005780999,0.00036743612,0.0008010892,0.00029279137,0.00022308208],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00065958936,0.00034649723,0.00086599163,0.00021476892,0.00015073657,0.000045121138,0.00023683254,0.00028851943,0.000056490913],"category_scores_gemma":[0.00023974899,0.00023108635,0.00024359104,0.0009347537,0.0006027155,0.0001955527,0.00015469787,0.00025923093,0.00007696686],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009759779,0.00024393901,0.7431019,0.00011005341,0.00040144363,0.0002441815,0.00028212852,0.000009259449,0.002273364,0.000097848315,0.006239204,0.2372369],"study_design_scores_gemma":[0.012315651,0.0019584254,0.9788113,0.00034311495,0.00018240382,0.00017121377,0.00009474243,0.000023645167,0.001563662,0.00011260685,0.0041535306,0.00026965275],"about_ca_topic_score_codex":0.00036502065,"about_ca_topic_score_gemma":0.00013528318,"teacher_disagreement_score":0.23696724,"about_ca_system_score_codex":0.000830028,"about_ca_system_score_gemma":0.0013211088,"threshold_uncertainty_score":0.94234276},"labels":[],"label_agreement":null},{"id":"W4386269948","doi":"10.1016/s2152-2650(23)00547-5","title":"POSTER: CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Myeloid leukemia; Tyrosine kinase; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Cancer research; Cancer; Receptor","score_opus":0.06094914429382921,"score_gpt":0.36048216634178104,"score_spread":0.29953302204795185,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269948","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9903159,0.0021067602,0.000021410971,0.0007638835,0.0014322017,0.002923041,0.00035227824,0.0007857843,0.0012987033],"genre_scores_gemma":[0.9910634,0.0013254437,0.00048154342,0.00090747146,0.0015699863,0.00035130596,0.0009561398,0.0004502082,0.0028944775],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98654175,0.0009889193,0.0057473104,0.002552365,0.0015699099,0.002599755],"domain_scores_gemma":[0.9920211,0.0024484976,0.001559385,0.0025936184,0.00029746688,0.0010799201],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0030537741,0.0016503637,0.0043666367,0.0018876555,0.0002302879,0.00010435691,0.0012029299,0.001791983,0.00095827953],"category_scores_gemma":[0.0013742971,0.0014501292,0.0010789519,0.0045916773,0.0011407993,0.0005323614,0.00090842193,0.0018831325,0.0013354528],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.037514918,0.0074402927,0.23070817,0.0051423586,0.0026325462,0.018325066,0.0038951503,0.004929256,0.05028737,0.00029925062,0.034819357,0.6040063],"study_design_scores_gemma":[0.10946542,0.009002327,0.8026009,0.006097211,0.0007907951,0.000512127,0.00038579566,0.020224333,0.032043938,0.00018562337,0.016670316,0.002021225],"about_ca_topic_score_codex":0.003433982,"about_ca_topic_score_gemma":0.008166461,"teacher_disagreement_score":0.60198504,"about_ca_system_score_codex":0.038880095,"about_ca_system_score_gemma":0.019971848,"threshold_uncertainty_score":0.999955},"labels":[],"label_agreement":null},{"id":"W4386269952","doi":"10.1016/s2152-2650(23)00631-6","title":"POSTER: MPN-133 Reduction in Red Blood Cell Transfusion Burden: A Novel Longitudinal Time-Dependent Analysis in Patients With Transfusion-Dependent Myelofibrosis Treated With Momelotinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Red blood cell; Reduction (mathematics); Blood transfusion; Internal medicine; Bone marrow","score_opus":0.015510990277060228,"score_gpt":0.2628728778025586,"score_spread":0.24736188752549834,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269952","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950871,0.00006792739,0.000038837916,0.00064965,0.00012523988,0.00295052,0.00014045596,0.0002660146,0.00067425735],"genre_scores_gemma":[0.99598813,0.0005946557,0.00040297088,0.00008694083,0.00017175497,0.0006209031,0.0010198357,0.00014349312,0.00097131514],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99299705,0.00037822605,0.0020617396,0.002074059,0.0014522081,0.0010367325],"domain_scores_gemma":[0.9970744,0.0004987202,0.0004359445,0.0009903206,0.00039379857,0.0006068143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089179614,0.0009076161,0.0021507656,0.0014429134,0.00021510603,0.00009050962,0.00028947016,0.0006177711,0.00032574745],"category_scores_gemma":[0.00009741574,0.00067512546,0.00056609826,0.0041346946,0.00024426603,0.00028697183,0.000090204856,0.0005420024,0.00017005844],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.012475789,0.005065728,0.9485361,0.00010714037,0.0014978495,0.0008941738,0.0005531671,0.0009934937,0.0019538393,0.0000038299468,0.00005160434,0.027867278],"study_design_scores_gemma":[0.045538727,0.0060068844,0.93726987,0.00058963976,0.0030281446,0.00007942248,0.00017928093,0.0010222673,0.0055539096,0.00000556396,0.000034067914,0.00069219613],"about_ca_topic_score_codex":0.0016638555,"about_ca_topic_score_gemma":0.001215275,"teacher_disagreement_score":0.03306294,"about_ca_system_score_codex":0.0012953737,"about_ca_system_score_gemma":0.0007355175,"threshold_uncertainty_score":0.99957},"labels":[],"label_agreement":null},{"id":"W4386269963","doi":"10.1016/s2152-2650(23)00386-5","title":"POSTER: ALL-553 Unexplained Increase in Incidence of T-Acute Lymphoblastic Leukemia/Lymphoma in Armenia","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lymphoblastic Leukemia; Incidence (geometry); Lymphoblastic lymphoma; Medicine; Lymphoma; Oncology; Internal medicine; Cancer research; Leukemia; Immunology; T cell; Mathematics","score_opus":0.0311938561939125,"score_gpt":0.34368962286590526,"score_spread":0.31249576667199275,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269963","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909492,0.00021454056,0.000052330917,0.0009149834,0.00069374964,0.0017042486,0.00014675871,0.0004818835,0.0048423205],"genre_scores_gemma":[0.993111,0.0010328372,0.00082379405,0.0019374025,0.00048210393,0.00031556463,0.00041823136,0.00026631457,0.0016127108],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98698527,0.0010390407,0.0048613483,0.00228545,0.002211648,0.0026172432],"domain_scores_gemma":[0.9891156,0.005644396,0.0008909492,0.0023402318,0.00051175506,0.0014970662],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0042850934,0.001143963,0.0030810242,0.0022155724,0.00013825583,0.00008840129,0.0015769314,0.0014280145,0.000234409],"category_scores_gemma":[0.0062719667,0.0011028325,0.00083897094,0.0053706877,0.0014648852,0.0005706536,0.0014978361,0.00080354785,0.0016929326],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030717278,0.002772931,0.502973,0.0016756512,0.0018589813,0.057550307,0.0020686167,0.0004792289,0.028433794,0.0013603423,0.018331412,0.35177842],"study_design_scores_gemma":[0.033282813,0.0016461683,0.934014,0.0015063125,0.0003484877,0.0012435408,0.0002643452,0.022334756,0.0018234141,0.0008785316,0.0016783621,0.0009792293],"about_ca_topic_score_codex":0.0031840089,"about_ca_topic_score_gemma":0.00043458433,"teacher_disagreement_score":0.431041,"about_ca_system_score_codex":0.015275848,"about_ca_system_score_gemma":0.015282301,"threshold_uncertainty_score":0.99986833},"labels":[],"label_agreement":null},{"id":"W4386269965","doi":"10.1016/s2152-2650(23)00530-x","title":"POSTER: CLL-587 Real-World Treatment Outcomes in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated With First-Line Single-Agent Ibrutinib vs Chemoimmunotherapy","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"St. Paul's Hospital","funders":"","keywords":"Chemoimmunotherapy; Ibrutinib; Chronic lymphocytic leukemia; Medicine; Oncology; Venetoclax; Internal medicine; Leukemia; Cancer research","score_opus":0.04926282876990089,"score_gpt":0.32450287670601624,"score_spread":0.27524004793611534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269965","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98894763,0.0003472872,0.000015417141,0.0005945801,0.00053273403,0.0055726864,0.00018772099,0.0015459602,0.0022560062],"genre_scores_gemma":[0.9641554,0.0030431782,0.00040190486,0.0012865883,0.00072323706,0.0010262533,0.0013046229,0.0008578004,0.027201064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98470014,0.0007061444,0.004080624,0.0037667307,0.0026430425,0.0041032904],"domain_scores_gemma":[0.9874877,0.004221163,0.001316453,0.004353207,0.0007670007,0.0018544983],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013733322,0.0027047046,0.005294682,0.001783725,0.0006343849,0.00037527317,0.0015607894,0.0013437688,0.00049650006],"category_scores_gemma":[0.00078885944,0.0018161932,0.0011929099,0.0049124933,0.0017016334,0.00052638975,0.00065554434,0.00057947775,0.0014605906],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10218772,0.0031919684,0.5702285,0.0014849422,0.004383304,0.012023058,0.00076904637,0.0026280624,0.0000864557,0.00006364287,0.0023943996,0.3005589],"study_design_scores_gemma":[0.22293359,0.018877657,0.72843486,0.002610442,0.000766623,0.00042483147,0.0000747737,0.013972002,0.0010624763,0.000017556178,0.009034892,0.0017902671],"about_ca_topic_score_codex":0.015983338,"about_ca_topic_score_gemma":0.018333804,"teacher_disagreement_score":0.33968028,"about_ca_system_score_codex":0.4624632,"about_ca_system_score_gemma":0.12278291,"threshold_uncertainty_score":0.9999527},"labels":[],"label_agreement":null},{"id":"W4386269975","doi":"10.1016/s2152-2650(23)00551-7","title":"POSTER: CML-415 Comparative Study Between Brand and Generic Imatinib Mesylate Using Molecular Genetic Analysis on CML Libyan Patients","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Imatinib mesylate; Medicine; Imatinib; Pharmacology; Internal medicine","score_opus":0.07137290501369091,"score_gpt":0.37564205739467377,"score_spread":0.30426915238098284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269975","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99661237,0.00024004099,0.00004509344,0.00008582832,0.00024402681,0.0018217375,0.000104741805,0.00027448716,0.00057164725],"genre_scores_gemma":[0.9974366,0.00007456368,0.0008380356,0.0004478675,0.0002941187,0.00006686111,0.0004534571,0.00011715897,0.00027136857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9937807,0.00073101954,0.0019455624,0.0016037594,0.00103045,0.0009085248],"domain_scores_gemma":[0.9959453,0.0010459849,0.00060940586,0.0013309229,0.0002691558,0.0007992488],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007031645,0.0007698552,0.0023392292,0.0007041319,0.00029627752,0.00011990942,0.00036139687,0.00040434022,0.00007906773],"category_scores_gemma":[0.00037865344,0.0006755224,0.0006662542,0.002330476,0.00035846006,0.00014186105,0.00044164291,0.00038364276,0.00037706963],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0006078582,0.0007082711,0.90995765,0.00005649859,0.004796044,0.0007404162,0.00080276857,0.00031900994,0.00017768083,0.000004323589,0.0002048097,0.08162469],"study_design_scores_gemma":[0.016366774,0.0027069885,0.96577626,0.0001226702,0.0053861267,0.00002134938,0.00017759846,0.008223342,0.0004126812,0.000047781657,0.00019220462,0.0005662339],"about_ca_topic_score_codex":0.00027356215,"about_ca_topic_score_gemma":0.000029118324,"teacher_disagreement_score":0.08105845,"about_ca_system_score_codex":0.0020088446,"about_ca_system_score_gemma":0.00085129926,"threshold_uncertainty_score":0.9995696},"labels":[],"label_agreement":null},{"id":"W4386269976","doi":"10.1016/s2152-2650(23)00382-8","title":"POSTER: ALL-471 Veno-Occlusive Disease Risk and Other Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin and Proceeding to Hematopoietic Stem Cell Transplantation","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada); McGill University Health Centre","funders":"","keywords":"Medicine; Hematopoietic stem cell transplantation; Lymphoblastic Leukemia; Hepatic veno-occlusive disease; Transplantation; Oncology; Hematopoietic cell; Internal medicine; Stem cell; Haematopoiesis; Leukemia; Biology; Genetics","score_opus":0.01592887886064565,"score_gpt":0.29145391585914443,"score_spread":0.2755250369984988,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386269976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9958893,0.00009372813,0.00014300778,0.00029319036,0.00019952038,0.002426824,0.00030584162,0.000245604,0.0004030054],"genre_scores_gemma":[0.9968425,0.00027505323,0.00042680142,0.0010338422,0.00012894794,0.00018463704,0.00013315241,0.000210425,0.00076461333],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99428743,0.00030161015,0.0014611813,0.0016072026,0.0011153903,0.0012271716],"domain_scores_gemma":[0.9952308,0.0020164195,0.00044966495,0.0006734089,0.00025741395,0.0013723037],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008964077,0.0007733367,0.0013548832,0.0006862517,0.00023660903,0.00014733306,0.00038237596,0.0004134347,0.000021803682],"category_scores_gemma":[0.00038945765,0.00063681084,0.00019096734,0.001041877,0.00039459678,0.00034104605,0.000391762,0.0005014984,0.00021625236],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0073213484,0.0003876132,0.9589567,0.0010074672,0.00027071364,0.0007276355,0.00326015,0.0000688302,0.00031317686,0.000017876726,0.0003653657,0.027303101],"study_design_scores_gemma":[0.02488896,0.0017039953,0.9667576,0.0010505432,0.0008832742,0.00006728911,0.00040406524,0.0028898132,0.00043846475,0.000088588284,0.0001232988,0.0007041413],"about_ca_topic_score_codex":0.00017895285,"about_ca_topic_score_gemma":0.000033751498,"teacher_disagreement_score":0.02659896,"about_ca_system_score_codex":0.0034631898,"about_ca_system_score_gemma":0.002361313,"threshold_uncertainty_score":0.99960834},"labels":[],"label_agreement":null},{"id":"W4386270458","doi":"10.1016/s2152-2650(23)00489-5","title":"POSTER: AML-475 Activity, Tolerability, and Resistance Profile of the Menin Inhibitor Ziftomenib in Adults With Relapsed/Refractory NPM1-Mutated AML","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Peptidase Inhibition and Analysis","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Tolerability; Refractory (planetary science); NPM1; Medicine; Internal medicine; Cancer research; Oncology; Chemistry; Biology; Adverse effect; Biochemistry","score_opus":0.01889096528625123,"score_gpt":0.29692070971046886,"score_spread":0.27802974442421763,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270458","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99384123,0.00007056199,0.0000023558116,0.0024959876,0.00009375123,0.000698446,0.000108756874,0.0001430156,0.0025459235],"genre_scores_gemma":[0.9957368,0.00008100869,0.0001560984,0.00051571766,0.0001617003,0.00007245389,0.00006538489,0.00005048634,0.0031603978],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963329,0.00045400206,0.0012267245,0.00083585497,0.0006635614,0.00048700202],"domain_scores_gemma":[0.9973114,0.00077713816,0.00049709,0.0008710291,0.0002315576,0.0003117422],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010373073,0.00034408006,0.0010125581,0.00025163993,0.0001261997,0.000031090334,0.00023259036,0.00035836888,0.000094787945],"category_scores_gemma":[0.0008745688,0.00023710552,0.00030873818,0.0015775023,0.00082240853,0.00019696717,0.00027618435,0.0005004855,0.00006510808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025913639,0.0031064178,0.7079946,0.0023479252,0.0006856988,0.0014904944,0.0025834558,0.000013356643,0.051070776,0.00028729645,0.023467325,0.18103902],"study_design_scores_gemma":[0.008556366,0.00063671754,0.9749115,0.0032147851,0.00010183669,0.00003567974,0.0002453797,0.00036310006,0.010699747,0.00017488176,0.0007697401,0.0002902722],"about_ca_topic_score_codex":0.00014403509,"about_ca_topic_score_gemma":0.00069325825,"teacher_disagreement_score":0.2669169,"about_ca_system_score_codex":0.00053559523,"about_ca_system_score_gemma":0.0008545725,"threshold_uncertainty_score":0.96688825},"labels":[],"label_agreement":null},{"id":"W4386270668","doi":"10.1016/s2152-2650(23)00826-1","title":"POSTER: MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)- Directed Therapies: Pooled Analysis From MagnetisMM Studies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Safety profile; Internal medicine; Adverse effect; Biology","score_opus":0.02350944719620967,"score_gpt":0.31043864061616494,"score_spread":0.28692919341995526,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99445474,0.0030488768,0.000007650706,0.00022218528,0.00011181689,0.0015637476,0.00029000366,0.00018959929,0.00011138457],"genre_scores_gemma":[0.9932554,0.004099981,0.0009516068,0.00011782451,0.00008167425,0.000056510875,0.0011281668,0.00007213674,0.00023670238],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954052,0.000536386,0.001480319,0.0011283346,0.0007988259,0.00065093994],"domain_scores_gemma":[0.9947768,0.003072633,0.00048945437,0.0008028805,0.00040633217,0.000451914],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006390612,0.00053352595,0.0017183962,0.00067838986,0.0001963314,0.00005231131,0.00020864885,0.00038369946,0.00005807963],"category_scores_gemma":[0.0013528205,0.0003986337,0.00024458545,0.00154992,0.0005943908,0.00026028376,0.00026598756,0.0003378327,0.000037815742],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014504762,0.0007083429,0.68348664,0.00011299608,0.0028414037,0.0001868739,0.0007657928,0.000003160685,0.0004069715,0.0000018901897,0.00009183591,0.2968893],"study_design_scores_gemma":[0.045602597,0.0019291932,0.94846046,0.0003406929,0.0011332261,0.0000033608626,0.00034712773,0.001273229,0.00032642303,0.000026146912,0.00019995085,0.00035757976],"about_ca_topic_score_codex":0.0005534695,"about_ca_topic_score_gemma":0.00041230154,"teacher_disagreement_score":0.29653174,"about_ca_system_score_codex":0.0004185355,"about_ca_system_score_gemma":0.00036740073,"threshold_uncertainty_score":0.9998466},"labels":[],"label_agreement":null},{"id":"W4386270690","doi":"10.1016/s2152-2650(23)00568-2","title":"POSTER: CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Myeloid leukemia; Medicine; Internal medicine; Oncology; Cancer research; Nilotinib; Imatinib","score_opus":0.020010388771337477,"score_gpt":0.3236364272275156,"score_spread":0.30362603845617814,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879241,0.0006267079,0.000013761428,0.00054846605,0.00021021455,0.0061796857,0.0039657387,0.00023855067,0.0002927897],"genre_scores_gemma":[0.9947868,0.00016390676,0.00033419288,0.00023993345,0.00025283662,0.0005597089,0.0024441592,0.00027547314,0.0009429626],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9899321,0.0014641976,0.0033032652,0.0020242282,0.0018555127,0.0014206734],"domain_scores_gemma":[0.9883065,0.005393543,0.0017912745,0.0030952897,0.0007380957,0.00067526055],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0011639994,0.0014487026,0.0034824563,0.0005935728,0.00022385585,0.000058888054,0.0009832478,0.0008018366,0.0004063383],"category_scores_gemma":[0.0016411357,0.0009169623,0.0009929449,0.0019638166,0.0015240287,0.00032583342,0.00038276406,0.0005750298,0.00013531065],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.82211506,0.0076799206,0.072956786,0.00016050387,0.007444563,0.0029525075,0.0014856478,0.0001546861,0.005449614,0.000023847913,0.0006008047,0.07897604],"study_design_scores_gemma":[0.3664872,0.06795168,0.5446205,0.001125654,0.0019804097,0.000023227201,0.0001817004,0.0011476065,0.015697418,0.000020236132,0.0001849897,0.00057936757],"about_ca_topic_score_codex":0.00224574,"about_ca_topic_score_gemma":0.00021299698,"teacher_disagreement_score":0.4716637,"about_ca_system_score_codex":0.021426003,"about_ca_system_score_gemma":0.01469309,"threshold_uncertainty_score":0.99982625},"labels":[],"label_agreement":null},{"id":"W4386270699","doi":"10.1016/s2152-2650(23)01449-0","title":"MM-388 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): A KarMMa-3 Analysis in High-Risk Subgroups","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Celgene; Bristol-Myers Squibb","keywords":"Refractory (planetary science); Medicine; Internal medicine; Multiple myeloma; Oncology; Lenalidomide; Materials science; Metallurgy","score_opus":0.027328453517233554,"score_gpt":0.3056269084531221,"score_spread":0.27829845493588856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270699","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99567837,0.00026269702,0.000023654822,0.00031857035,0.0004289757,0.002187773,0.0004057687,0.00035427063,0.0003399185],"genre_scores_gemma":[0.99518245,0.00077491865,0.0012634576,0.00019167794,0.00018999408,0.00023879828,0.0013167732,0.00018721954,0.00065468496],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9902851,0.0011729097,0.00253472,0.0022334557,0.0019028425,0.0018709825],"domain_scores_gemma":[0.9914634,0.004049616,0.0007809286,0.0018324149,0.0004462291,0.0014273904],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024346204,0.00097341335,0.0026565103,0.001987782,0.00030845683,0.00012642935,0.00051268924,0.0008773095,0.00013592016],"category_scores_gemma":[0.004804746,0.000819314,0.0006285254,0.0049888515,0.0006893787,0.00043740348,0.00043538652,0.0011124717,0.00026957982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055893112,0.0010504378,0.8021967,0.00008187265,0.0018566973,0.002193887,0.00028791634,0.000055152817,0.00013360397,0.00001828254,0.0005512289,0.13568111],"study_design_scores_gemma":[0.12196802,0.0057332213,0.86572856,0.00023648563,0.0009337266,0.000007205397,0.00022175361,0.0030893344,0.00032934712,0.000057506844,0.0009927565,0.00070205407],"about_ca_topic_score_codex":0.0017724517,"about_ca_topic_score_gemma":0.0051811575,"teacher_disagreement_score":0.13497904,"about_ca_system_score_codex":0.0033658072,"about_ca_system_score_gemma":0.001524824,"threshold_uncertainty_score":0.99942577},"labels":[],"label_agreement":null},{"id":"W4386270713","doi":"10.1016/s2152-2650(23)00549-9","title":"POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Internal medicine; Number needed to treat; Intensive care medicine; Relative risk","score_opus":0.02197721660446914,"score_gpt":0.33858092278543794,"score_spread":0.3166037061809688,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270713","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9909437,0.00041799815,0.000022456219,0.00097216544,0.0003255199,0.004602184,0.00030874886,0.00036728382,0.002039985],"genre_scores_gemma":[0.99141943,0.00080980506,0.0012074301,0.0010499605,0.00038398424,0.0006069717,0.00077047024,0.00038209878,0.0033698175],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98940426,0.0011686776,0.0029016717,0.0027405147,0.0018238743,0.00196101],"domain_scores_gemma":[0.9916066,0.0029785002,0.0010770665,0.0022217021,0.0005074715,0.0016086733],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026813871,0.0015480458,0.0029328696,0.0009645364,0.00036421936,0.00014795174,0.0006355364,0.0009684061,0.00047171183],"category_scores_gemma":[0.0010015679,0.0012522236,0.00038911353,0.0018712489,0.0013051669,0.00061250327,0.0007250102,0.0012150559,0.0003128155],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.07854736,0.0035107306,0.4091039,0.0013925998,0.0016250587,0.0032846732,0.0017806339,0.00016288747,0.0041735177,0.00011404305,0.006830732,0.48947385],"study_design_scores_gemma":[0.11794064,0.017772524,0.8485267,0.0017938104,0.00084880774,0.0003756471,0.00048951444,0.0012099919,0.00078963913,0.000018767698,0.009038144,0.0011958076],"about_ca_topic_score_codex":0.00089899346,"about_ca_topic_score_gemma":0.0006157548,"teacher_disagreement_score":0.48827803,"about_ca_system_score_codex":0.020064985,"about_ca_system_score_gemma":0.011184758,"threshold_uncertainty_score":0.9997268},"labels":[],"label_agreement":null},{"id":"W4386270746","doi":"10.1016/s2152-2650(23)00683-3","title":"POSTER: HL-393 5-year Overall Survival Rate of Patients With Classical Hodgkin Lymphoma in Armenia","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Classical Hodgkin lymphoma; Hodgkin lymphoma; Lymphoma; Oncology; Internal medicine; Medicine; Demography; Sociology","score_opus":0.02585206691894636,"score_gpt":0.30184431209628065,"score_spread":0.2759922451773343,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99385256,0.00007140743,0.0000026870516,0.00091078784,0.0006519604,0.0009787438,0.0001338384,0.00022362177,0.0031743862],"genre_scores_gemma":[0.9968363,0.00020741965,0.0002707634,0.00087422406,0.0003099954,0.00011835663,0.0004708403,0.00011709771,0.0007950146],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9946996,0.00046626333,0.0018427235,0.0011605567,0.00083642657,0.00099445],"domain_scores_gemma":[0.9959408,0.0015500388,0.00049396633,0.0010794101,0.00030307582,0.0006327022],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010096858,0.0006265014,0.001728408,0.00036857242,0.000096917116,0.00005077598,0.0003659545,0.00054124516,0.0001463336],"category_scores_gemma":[0.0006353398,0.00047715,0.0005433043,0.0010157286,0.0004993154,0.00019735662,0.0003037313,0.0001993366,0.00073537836],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.004789536,0.0022482225,0.85845035,0.00009229776,0.0003412363,0.0008634745,0.000097970275,0.0000071113695,0.000041599276,0.00056262314,0.0031218878,0.12938365],"study_design_scores_gemma":[0.039620444,0.0026120732,0.9505392,0.00039851663,0.00024075739,0.000018481218,0.000052950494,0.00016198219,0.00047620345,0.00026300387,0.0051435255,0.0004728884],"about_ca_topic_score_codex":0.00027270912,"about_ca_topic_score_gemma":0.00010027584,"teacher_disagreement_score":0.12891077,"about_ca_system_score_codex":0.0015050776,"about_ca_system_score_gemma":0.0015089364,"threshold_uncertainty_score":0.999768},"labels":[],"label_agreement":null},{"id":"W4386270762","doi":"10.1016/s2152-2650(23)00862-5","title":"POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Refractory (planetary science); Medicine; Multiple myeloma; Phase (matter); Phases of clinical research; Internal medicine; Nuclear medicine; Materials science; Chemistry; Clinical trial; Metallurgy; Organic chemistry","score_opus":0.06028986609263801,"score_gpt":0.36688599263435107,"score_spread":0.30659612654171303,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270762","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939722,0.00011529611,0.0000023907432,0.0001869236,0.00037883047,0.003173013,0.000262873,0.00037257685,0.0015359184],"genre_scores_gemma":[0.99425316,0.0001101877,0.000110895664,0.00022540346,0.00026595147,0.00019730152,0.00067712984,0.00017990492,0.0039800843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99141675,0.0008700582,0.0029672256,0.0016330375,0.0018700112,0.0012429414],"domain_scores_gemma":[0.9937188,0.0020993554,0.00067178864,0.0020053766,0.00073951745,0.0007651409],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020896576,0.0007006908,0.0018371036,0.0007845503,0.00017111625,0.000055880766,0.0006666148,0.00063188886,0.00022635647],"category_scores_gemma":[0.0025290353,0.0005884509,0.00039931154,0.0023527883,0.0005445988,0.00027134878,0.0004170498,0.0009340907,0.00027298287],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.055336956,0.01531882,0.6434467,0.00016508246,0.00055943185,0.0020927608,0.0017091974,0.00004957427,0.0043510757,0.0000022253303,0.0021449695,0.27482322],"study_design_scores_gemma":[0.13267557,0.019314565,0.8409334,0.00046070182,0.00017666274,0.000025460587,0.00045903822,0.00089930225,0.0017976767,0.0000073137858,0.0027685803,0.00048173513],"about_ca_topic_score_codex":0.00087164296,"about_ca_topic_score_gemma":0.00058454653,"teacher_disagreement_score":0.2743415,"about_ca_system_score_codex":0.0016100022,"about_ca_system_score_gemma":0.0018292561,"threshold_uncertainty_score":0.9996567},"labels":[],"label_agreement":null},{"id":"W4386270767","doi":"10.1016/s2152-2650(23)01361-7","title":"IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"Jewish General Hospital; Royal Adelaide Hospital; McGill University; American Society of Hematology","keywords":"Refractory (planetary science); Follicular lymphoma; Medicine; Safety profile; Follicular phase; Internal medicine; Phases of clinical research; Oncology; Surgery; Lymphoma; Clinical trial; Adverse effect; Materials science","score_opus":0.018487413939307234,"score_gpt":0.29245203938368375,"score_spread":0.2739646254443765,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270767","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908148,0.00033169423,0.0000075547305,0.000499785,0.00023684122,0.0058515053,0.00058044435,0.00064540963,0.0010319619],"genre_scores_gemma":[0.9921527,0.000525347,0.0010145609,0.000482101,0.00019790318,0.0006629747,0.0027550538,0.00025334695,0.001956002],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9915299,0.00068773434,0.0026387027,0.002445793,0.0013134464,0.0013844608],"domain_scores_gemma":[0.9942872,0.001546604,0.00095297664,0.0020794098,0.00039641355,0.00073742616],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010665212,0.0011950032,0.0023668753,0.0004528,0.00063994585,0.00016887444,0.0005835717,0.00062435656,0.00019276237],"category_scores_gemma":[0.00040114232,0.00083709724,0.00043872625,0.0021002742,0.00048038652,0.0005076835,0.00022671859,0.00038357798,0.00029947885],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.114545226,0.03328529,0.40639406,0.000043715158,0.0035748417,0.0036200972,0.002750906,0.00013478044,0.00006593117,0.000015938527,0.0036067849,0.43196243],"study_design_scores_gemma":[0.23395382,0.020715227,0.7373135,0.0007152851,0.0005405998,0.000017218192,0.00086038123,0.0011513827,0.00023531707,0.000023111565,0.003710807,0.0007633255],"about_ca_topic_score_codex":0.0021614542,"about_ca_topic_score_gemma":0.0004207447,"teacher_disagreement_score":0.4311991,"about_ca_system_score_codex":0.0025884928,"about_ca_system_score_gemma":0.0020990106,"threshold_uncertainty_score":0.999408},"labels":[],"label_agreement":null},{"id":"W4386270785","doi":"10.1016/s2152-2650(23)00684-5","title":"POSTER: HL-456 A Retrospective Analysis of Impact of EBV Status on Outcomes in Hodgkin Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Hodgkin lymphoma; Lymphoma; Medicine; Internal medicine; Oncology","score_opus":0.03763797479878597,"score_gpt":0.3871336197560925,"score_spread":0.34949564495730656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270785","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952041,0.00015703206,0.00000143932,0.00024298255,0.00026079296,0.0006992788,0.0005099479,0.00013610747,0.0027883132],"genre_scores_gemma":[0.9981809,0.00053052075,0.00010610984,0.00029691771,0.00008683671,0.00008251051,0.00030655906,0.000068562746,0.00034108275],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943579,0.00032949256,0.0023978858,0.0010463201,0.00094517437,0.00092325854],"domain_scores_gemma":[0.994609,0.0022605192,0.0008496134,0.0014162103,0.00031909632,0.0005455879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009746397,0.00059834897,0.0033377549,0.0016258102,0.000061005638,0.000024921876,0.00031616475,0.0004991465,0.0002177852],"category_scores_gemma":[0.0017828051,0.00044453054,0.002734039,0.0040446133,0.00040477578,0.000117773,0.00021240159,0.00015484828,0.00018025587],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016191793,0.0020950974,0.8548443,0.00004334092,0.0057104193,0.0005845663,0.00029933738,0.00008966628,0.00012556277,0.00023608029,0.00060233363,0.13375017],"study_design_scores_gemma":[0.013617418,0.004168988,0.97728163,0.00024359126,0.002156577,0.000014829183,0.000109540386,0.00091631775,0.0008677317,0.0001867521,0.00008897025,0.00034765436],"about_ca_topic_score_codex":0.0032248392,"about_ca_topic_score_gemma":0.000303329,"teacher_disagreement_score":0.13340251,"about_ca_system_score_codex":0.0045413543,"about_ca_system_score_gemma":0.0017879574,"threshold_uncertainty_score":0.9998006},"labels":[],"label_agreement":null},{"id":"W4386270891","doi":"10.1016/s2152-2650(23)00857-1","title":"POSTER: MM-163 Long-Term Follow-Up From MajesTEC-1 of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients With Relapsed/ Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Antibody; Medicine; Refractory (planetary science); Bispecific antibody; Antigen; Cancer research; Virology; Immunology; Materials science; Monoclonal antibody","score_opus":0.03199682874755631,"score_gpt":0.3220475571111516,"score_spread":0.2900507283635953,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270891","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946215,0.0003719043,0.000021649012,0.00016692898,0.0008751867,0.0022904933,0.00047411243,0.00031559085,0.0008626472],"genre_scores_gemma":[0.9912631,0.00057754974,0.0006182293,0.00015504251,0.00033673184,0.00010422099,0.0053580864,0.00020167558,0.0013853532],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9924378,0.00053523557,0.0023397307,0.0016578044,0.001692932,0.0013365435],"domain_scores_gemma":[0.99420685,0.0016767017,0.00084263267,0.00184211,0.00058225193,0.0008494516],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008115043,0.00081811915,0.0017711811,0.0008147031,0.00021993366,0.00010568639,0.00064559764,0.0008289699,0.00021908252],"category_scores_gemma":[0.0011314482,0.0006704538,0.0005963391,0.0015516847,0.00060498115,0.0004957821,0.0004106535,0.00073095656,0.0008870357],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016964773,0.0017222771,0.8553568,0.00023195297,0.00036478788,0.001521417,0.00021827675,0.0000027490291,0.0033135985,0.00000536988,0.00078220194,0.119515814],"study_design_scores_gemma":[0.050092112,0.0026345262,0.94161123,0.0009838691,0.00016281173,0.00001715214,0.000089044064,0.00034861622,0.002809874,0.000034480938,0.0006153207,0.00060095027],"about_ca_topic_score_codex":0.0006756799,"about_ca_topic_score_gemma":0.00045834953,"teacher_disagreement_score":0.118914865,"about_ca_system_score_codex":0.0011921509,"about_ca_system_score_gemma":0.0013212119,"threshold_uncertainty_score":0.99989086},"labels":[],"label_agreement":null},{"id":"W4386270903","doi":"10.1016/s2152-2650(23)00730-9","title":"POSTER: ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; CHOP; Rituximab; Lymphoma; Internal medicine; Phases of clinical research; Oncology; Clinical trial","score_opus":0.02425523765960327,"score_gpt":0.3135336478314217,"score_spread":0.28927841017181843,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270903","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9901943,0.000370152,0.0000055213345,0.00032094054,0.0024549458,0.00382813,0.00050999003,0.00044470094,0.0018712836],"genre_scores_gemma":[0.994887,0.00080734695,0.00021932606,0.00064242433,0.00077098556,0.00047243084,0.0013016984,0.00026111907,0.0006376667],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9901584,0.0004956817,0.0035777767,0.0020440887,0.0017910134,0.0019330473],"domain_scores_gemma":[0.99089116,0.0038103568,0.0012521686,0.0022649416,0.00050697505,0.0012743983],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0010713766,0.0012779292,0.0032664745,0.00071056857,0.00027348413,0.00010864539,0.00076208304,0.0010542079,0.00012249293],"category_scores_gemma":[0.0012926152,0.0010449587,0.0011682819,0.0018583548,0.0005654812,0.00035463832,0.00047641463,0.00039420614,0.00071210216],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4447537,0.104807526,0.15048596,0.00024041162,0.0009897979,0.013034489,0.0005449582,0.000004743871,0.00004299347,0.000118972544,0.0041119955,0.28086445],"study_design_scores_gemma":[0.5429736,0.014656792,0.43795216,0.00035629576,0.00063121034,0.00005493128,0.00015209054,0.00016690927,0.00020550145,0.000023800747,0.0022024643,0.00062425964],"about_ca_topic_score_codex":0.0006332692,"about_ca_topic_score_gemma":0.00020403588,"teacher_disagreement_score":0.2874662,"about_ca_system_score_codex":0.0026301183,"about_ca_system_score_gemma":0.0022831531,"threshold_uncertainty_score":0.99999726},"labels":[],"label_agreement":null},{"id":"W4386270917","doi":"10.1016/s2152-2650(23)00762-0","title":"POSTER: IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"Universitat de Barcelona; Rigshospitalet; Universitair Medisch Centrum Groningen; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; Gentofte Hospital; Rijksuniversiteit Groningen; Odense Universitetshospital; Helsingin Yliopisto","keywords":"Refractory (planetary science); Follicular lymphoma; Medicine; Safety profile; Follicular phase; Oncology; Internal medicine; Lymphoma; Intensive care medicine; Adverse effect; Biology","score_opus":0.017855556000897835,"score_gpt":0.2902768768952964,"score_spread":0.2724213208943986,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270917","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99043846,0.00033727082,0.0000038762023,0.0005822758,0.00024239768,0.0060399636,0.00066145207,0.0006230727,0.0010712299],"genre_scores_gemma":[0.99255115,0.00046908535,0.0006536592,0.0005776126,0.00018660811,0.00059487193,0.0029900947,0.00025635934,0.0017205382],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9915091,0.0007063215,0.0026700408,0.0024398721,0.0012921613,0.0013825035],"domain_scores_gemma":[0.994333,0.0014818272,0.0009659626,0.0020914087,0.0003928112,0.0007349746],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010120359,0.0012092378,0.0023604096,0.00046090892,0.00061821553,0.0001814294,0.0005912327,0.00062300294,0.00017600987],"category_scores_gemma":[0.00035046937,0.00084772176,0.0004432627,0.0019493297,0.00045734277,0.0005315023,0.0002464527,0.0003768667,0.00029518583],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12364606,0.030649543,0.45939118,0.000044346947,0.0034370702,0.0037333036,0.0028817963,0.00007577956,0.00007261426,0.000010122145,0.0027184803,0.3733397],"study_design_scores_gemma":[0.2317172,0.023472706,0.7381056,0.0007626185,0.0005471715,0.000022678849,0.0007380754,0.0007567848,0.00027120698,0.00001761467,0.0028188673,0.00076948653],"about_ca_topic_score_codex":0.0021030174,"about_ca_topic_score_gemma":0.00041805074,"teacher_disagreement_score":0.37257022,"about_ca_system_score_codex":0.002503256,"about_ca_system_score_gemma":0.0019636685,"threshold_uncertainty_score":0.99939734},"labels":[],"label_agreement":null},{"id":"W4386270935","doi":"10.1016/s2152-2650(23)00654-7","title":"POSTER: MPN-574 Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Polycythemia vera; Ruxolitinib; Observational study; Medicine; Internal medicine; Clinical trial; Pediatrics; Myelofibrosis","score_opus":0.05766674354178424,"score_gpt":0.3603647340024213,"score_spread":0.30269799046063706,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270935","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99413705,0.000037663754,0.0000012824145,0.00045559707,0.00040098384,0.004454539,0.00041325638,0.000059319093,0.00004032297],"genre_scores_gemma":[0.9970818,0.00010001028,0.00026134428,0.0005441336,0.00044239726,0.0006819386,0.000751495,0.0000818261,0.000055029064],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99081355,0.0013629254,0.003994501,0.0017455424,0.0013678173,0.0007156741],"domain_scores_gemma":[0.98399323,0.011468838,0.0024137278,0.0011204152,0.0005699974,0.00043381075],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002313779,0.0007512311,0.0030464293,0.00034093362,0.00016868165,0.00010666877,0.0003620606,0.0005152239,0.00006377022],"category_scores_gemma":[0.005289295,0.0004621702,0.0005453455,0.0014997096,0.0005922317,0.0003716683,0.00035628327,0.00096984755,0.000022718126],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.106062695,0.0098027,0.8690649,0.000022237418,0.0038582932,0.0002209466,0.0005089789,0.0000025676613,1.2415626e-7,0.0000062955346,0.000039696533,0.010410544],"study_design_scores_gemma":[0.11181824,0.009838784,0.8746936,0.00030497866,0.002600316,0.000001814257,0.00016914132,0.00009480429,0.0000018616131,0.000024348714,0.00003132065,0.00042083932],"about_ca_topic_score_codex":0.0009886221,"about_ca_topic_score_gemma":0.0019763976,"teacher_disagreement_score":0.010105913,"about_ca_system_score_codex":0.0006827894,"about_ca_system_score_gemma":0.0010483176,"threshold_uncertainty_score":0.999783},"labels":[],"label_agreement":null},{"id":"W4386270936","doi":"10.1016/s2152-2650(23)00651-1","title":"POSTER: MPN-540 Disease Progression and Leukemic Transformation in Patients With Lower-Risk Myelofibrosis: An Analysis From the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Essential thrombocythemia; Medicine; Observational study; Internal medicine; Disease; Oncology; Polycythemia vera; Bone marrow","score_opus":0.03200216297594318,"score_gpt":0.33100134329576514,"score_spread":0.298999180319822,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270936","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9956709,0.0002033207,0.000023040695,0.0007334827,0.00012884685,0.0027007272,0.00035639925,0.00014884955,0.00003439533],"genre_scores_gemma":[0.9960547,0.00040039638,0.00022912938,0.00039178628,0.00019252207,0.0005687528,0.0020770517,0.00006080722,0.00002484208],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9955316,0.0005950638,0.0011973574,0.0011983808,0.0009593865,0.00051821],"domain_scores_gemma":[0.996892,0.001064382,0.0004211361,0.00078028097,0.0002552157,0.0005870184],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008028338,0.0005607449,0.0010928775,0.000267338,0.00045816146,0.00020044453,0.00021574092,0.00024781286,0.000058464273],"category_scores_gemma":[0.00031031822,0.00035556784,0.00023385283,0.0013888789,0.00038867362,0.0005676531,0.00015935242,0.00030916327,0.000024266585],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044726324,0.0013107053,0.87481546,0.000032477958,0.0009133327,0.000056451714,0.0010560657,0.00004126643,0.000015786998,0.000028325641,0.000084241736,0.11717327],"study_design_scores_gemma":[0.013612059,0.0028250918,0.9740083,0.00029342974,0.0028590248,0.0000024890296,0.0005485192,0.005237586,0.000050519746,0.00009709338,0.00007524893,0.0003906133],"about_ca_topic_score_codex":0.0004519514,"about_ca_topic_score_gemma":0.0005156274,"teacher_disagreement_score":0.11678266,"about_ca_system_score_codex":0.00050704344,"about_ca_system_score_gemma":0.0006314978,"threshold_uncertainty_score":0.9998896},"labels":[],"label_agreement":null},{"id":"W4386270957","doi":"10.1016/s2152-2650(23)01220-x","title":"MPN-133 Reduction in Red Blood Cell Transfusion Burden: A Novel Longitudinal Time-Dependent Analysis in Patients With Transfusion-Dependent Myelofibrosis Treated With Momelotinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Blood transfusion; Reduction (mathematics); Red blood cell; Red Blood Cell Transfusion; Internal medicine; Bone marrow","score_opus":0.015933669431979786,"score_gpt":0.2642112244048966,"score_spread":0.2482775549729168,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270957","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9952948,0.00006575033,0.00006932075,0.00055468734,0.00012089419,0.0028518077,0.00012064747,0.0002732281,0.00064886914],"genre_scores_gemma":[0.99566036,0.00066581886,0.0006123199,0.00007101701,0.00018093784,0.00069583027,0.0009242268,0.00014067438,0.0010488366],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9930296,0.00036495322,0.0020264543,0.0020717715,0.0014728574,0.001034376],"domain_scores_gemma":[0.99709433,0.0005153215,0.00042602312,0.0009766265,0.00038149706,0.0006061698],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009375705,0.0008925595,0.002151022,0.0014299544,0.00021967321,0.000083451734,0.00028339436,0.00061764073,0.00035728898],"category_scores_gemma":[0.0001101741,0.00066367397,0.00055971375,0.0044886344,0.0002549114,0.0002720406,0.000081904356,0.0005519002,0.00017129924],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.011024755,0.005311952,0.9464134,0.00010448958,0.0015182286,0.00084118947,0.0004942149,0.0018823007,0.0017867418,0.000006006815,0.00006423348,0.030552493],"study_design_scores_gemma":[0.04513752,0.0051752417,0.93847615,0.0005496812,0.00302359,0.000060511353,0.00020425438,0.0017763114,0.0048620407,0.0000072420785,0.000043330998,0.000684158],"about_ca_topic_score_codex":0.0017282473,"about_ca_topic_score_gemma":0.00124037,"teacher_disagreement_score":0.034112763,"about_ca_system_score_codex":0.0013296927,"about_ca_system_score_gemma":0.0007793456,"threshold_uncertainty_score":0.99958146},"labels":[],"label_agreement":null},{"id":"W4386270961","doi":"10.1016/s2152-2650(23)01076-5","title":"AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital","funders":"","keywords":"Refractory (planetary science); Hematopoietic stem cell transplantation; Medicine; Regimen; Conditioning regimen; Internal medicine; Stem cell; Transplantation; Randomized controlled trial; Oncology; Biology","score_opus":0.03855014632654694,"score_gpt":0.3425980365523169,"score_spread":0.30404789022576995,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270961","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97907066,0.00017201234,0.00025103436,0.0002153943,0.00022921768,0.01953396,0.00014170243,0.00029943333,0.00008657043],"genre_scores_gemma":[0.9926618,0.00063176133,0.0012289996,0.00012242547,0.0001969292,0.0029683462,0.00065843354,0.00036118642,0.001170151],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888932,0.002855561,0.0032529493,0.0018715163,0.0017683731,0.0013583916],"domain_scores_gemma":[0.9845503,0.010055346,0.0021366258,0.0018610716,0.0008510096,0.00054566556],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027943419,0.0012500345,0.004162444,0.00083440216,0.00048150244,0.00011032473,0.00076663063,0.0007475034,0.000093100374],"category_scores_gemma":[0.0005158813,0.00062156044,0.00058381946,0.0024487243,0.0011707824,0.0005228251,0.000092338196,0.00075309566,0.000012813788],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9248416,0.00734055,0.003617469,0.00041815327,0.0026681419,0.0011132985,0.009380874,0.00007789365,0.0016631086,0.0000037853802,0.000112674155,0.048762497],"study_design_scores_gemma":[0.870733,0.07358052,0.03750074,0.00085962005,0.0026401533,0.000058197184,0.009285657,0.001815378,0.0024125099,0.000013802287,0.00027209503,0.0008283197],"about_ca_topic_score_codex":0.0010160061,"about_ca_topic_score_gemma":0.0011497715,"teacher_disagreement_score":0.06623997,"about_ca_system_score_codex":0.0032433805,"about_ca_system_score_gemma":0.0059458786,"threshold_uncertainty_score":0.99968946},"labels":[],"label_agreement":null},{"id":"W4386270971","doi":"10.1016/s2152-2650(23)00760-7","title":"POSTER: IBCL-098 TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"University of Texas MD Anderson Cancer Center; School of Medicine, Stanford University; Centre hospitalier régional universitaire de Lille; Washington University School of Medicine in St. Louis; University College London Hospitals NHS Foundation Trust; Universität zu Köln; Massachusetts General Hospital; Hokkaido University; Bristol-Myers Squibb; Centro de Investigación Biomédica en Red de Cáncer; Medizinische Universität Wien; Karolinska Institutet; Memorial Sloan-Kettering Cancer Center; Universität Wien; University College London","keywords":"Follicular lymphoma; Follicular phase; Oncology; Medicine; Internal medicine; Biology; Lymphoma","score_opus":0.02781592921887291,"score_gpt":0.3251656614464571,"score_spread":0.2973497322275842,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270971","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9935011,0.00032524482,0.000001948575,0.00062175986,0.00052556995,0.00314838,0.00039582828,0.0003036355,0.0011765083],"genre_scores_gemma":[0.99655175,0.0002680057,0.00018359414,0.00057648495,0.00026656358,0.0003096838,0.00094070984,0.0001660919,0.00073709234],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918836,0.00049703434,0.003176037,0.0017779968,0.0014652802,0.0012000675],"domain_scores_gemma":[0.9952952,0.0008946759,0.0007486769,0.0018726854,0.00039999562,0.0007887457],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013606576,0.00091981876,0.002321865,0.0005955857,0.00026215607,0.000058198795,0.00056860293,0.0005828682,0.0000653275],"category_scores_gemma":[0.00056578754,0.0007170573,0.0007908995,0.0018444234,0.00042417267,0.00027743072,0.0003108993,0.0002289291,0.00024225401],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.017728157,0.029418007,0.5917895,0.0001247983,0.0009722182,0.0024642672,0.0010389724,0.000015730297,0.000080680824,0.000023360784,0.0024526163,0.35389167],"study_design_scores_gemma":[0.17205125,0.021892928,0.7998889,0.00048116638,0.0007210537,0.000028099412,0.00028321764,0.00017896881,0.0009179838,0.00002339466,0.002955379,0.00057765306],"about_ca_topic_score_codex":0.00065605936,"about_ca_topic_score_gemma":0.00020828843,"teacher_disagreement_score":0.353314,"about_ca_system_score_codex":0.001508419,"about_ca_system_score_gemma":0.001352222,"threshold_uncertainty_score":0.99952805},"labels":[],"label_agreement":null},{"id":"W4386270977","doi":"10.1016/s2152-2650(23)01133-3","title":"CML-311 Matching-Adjusted Indirect Comparisons (MAICs) of Asciminib vs Other Tyrosine Kinase Inhibitors (TKIs) in Third- or Later-Line Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Myeloid leukemia; Tyrosine kinase; Medicine; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Dasatinib; Cancer research; Imatinib; Cancer; Receptor","score_opus":0.06451954575063161,"score_gpt":0.3641190200027269,"score_spread":0.29959947425209527,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270977","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9905644,0.0021608586,0.000037204212,0.00064676773,0.0014144521,0.0028187602,0.0003056977,0.0008093206,0.0012425078],"genre_scores_gemma":[0.9904305,0.0015603947,0.0007200515,0.00076028326,0.0016859061,0.0003903062,0.00086716877,0.0004451164,0.0031403166],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9866138,0.00096061727,0.005690998,0.0025450329,0.0015876716,0.0026018524],"domain_scores_gemma":[0.9919746,0.0025541259,0.0015368595,0.0025681094,0.00028667075,0.0010796695],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0032257508,0.0016250042,0.0043794885,0.0018643894,0.00023427789,0.000095961404,0.0011869741,0.0018012311,0.0010549967],"category_scores_gemma":[0.0015806853,0.0014290657,0.0010703934,0.004949335,0.0011988336,0.0005052074,0.00083936844,0.0019269497,0.0013601182],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.032442883,0.007539482,0.17966631,0.0050083096,0.0025818797,0.017086323,0.0034286424,0.008890742,0.04608088,0.0004608136,0.044703674,0.65211004],"study_design_scores_gemma":[0.11493352,0.008241293,0.7756122,0.006125849,0.000818982,0.00041936222,0.00046266077,0.036853842,0.03047577,0.00025968786,0.023682624,0.00211423],"about_ca_topic_score_codex":0.0035014488,"about_ca_topic_score_gemma":0.00818678,"teacher_disagreement_score":0.6499958,"about_ca_system_score_codex":0.040935624,"about_ca_system_score_gemma":0.021631878,"threshold_uncertainty_score":0.9998582},"labels":[],"label_agreement":null},{"id":"W4386270978","doi":"10.1016/s2152-2650(23)00864-9","title":"POSTER: MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"TEC; Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Materials science; Geology; Metallurgy","score_opus":0.022460602139336257,"score_gpt":0.28669273690375563,"score_spread":0.26423213476441937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99295175,0.00027964954,0.0000030014771,0.0008657625,0.00026884684,0.00397028,0.0005629083,0.0004945914,0.00060323806],"genre_scores_gemma":[0.99594235,0.00017877146,0.00048553816,0.00037563953,0.00042267068,0.00025664188,0.0014389537,0.00022494429,0.000674484],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99140424,0.00082312996,0.002163959,0.0022442173,0.0018160325,0.0015483972],"domain_scores_gemma":[0.9866208,0.009347589,0.0006834288,0.0018739621,0.00053262163,0.00094161654],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018008199,0.0009898738,0.0016184733,0.00035214855,0.000713039,0.00021137294,0.0006760509,0.0005446322,0.000049191494],"category_scores_gemma":[0.0075291777,0.00061477744,0.00026327226,0.0014721256,0.00087692245,0.00037100454,0.0006176921,0.001120548,0.0002945891],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038198933,0.0020897372,0.8071797,0.000057296482,0.00069300213,0.0049537797,0.0012935513,0.000041536117,0.000033380868,0.0000016043417,0.0012185617,0.14423893],"study_design_scores_gemma":[0.07196919,0.007858971,0.9115982,0.0006617952,0.00026738466,0.0000480194,0.0011160261,0.0020607389,0.000063789936,0.000015449375,0.0036732124,0.00066719565],"about_ca_topic_score_codex":0.0030375111,"about_ca_topic_score_gemma":0.0039801844,"teacher_disagreement_score":0.14357173,"about_ca_system_score_codex":0.0012226513,"about_ca_system_score_gemma":0.00089429534,"threshold_uncertainty_score":0.99963033},"labels":[],"label_agreement":null},{"id":"W4386270996","doi":"10.1016/s2152-2650(23)00655-9","title":"POSTER: MPN-346 INDEPENDENCE: Enrolling Phase III Trial to Study the Efficacy and Safety of Luspatercept versus Placebo in Patients With Myelofibrosis on JAK2 Inhibitor (JAK2i) Therapy Requiring Red Blood Cell Transfusions (RBCTs)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Myelofibrosis; Placebo; Medicine; Internal medicine; Phases of clinical research; Clinical trial; Bone marrow; Pathology; Alternative medicine","score_opus":0.042019637120578365,"score_gpt":0.3397200616766584,"score_spread":0.29770042455608003,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386270996","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99018985,0.00005036057,0.0000040428117,0.0004875992,0.0005323818,0.008277566,0.000051787523,0.00009887993,0.00030753363],"genre_scores_gemma":[0.9980538,0.00038021282,0.00011776706,0.00027561677,0.00030114094,0.0006618802,0.000063528205,0.0000826395,0.00006343331],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99487877,0.000624642,0.001700728,0.0011351341,0.0010372003,0.00062350987],"domain_scores_gemma":[0.99494076,0.0032075453,0.00035427467,0.00084232277,0.00020933838,0.00044574315],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013668583,0.0005728257,0.0013133842,0.00031881942,0.00034258756,0.00005953462,0.00028803025,0.00033957485,0.00007605044],"category_scores_gemma":[0.00040776847,0.00036639406,0.00025102505,0.0009233163,0.0002113136,0.00011917771,0.00016391164,0.0004584073,0.000035046436],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.597486,0.010026901,0.14793003,0.000028948985,0.0007127746,0.00018261066,0.00368512,0.0000572269,0.0005162112,0.000007862419,0.00006380879,0.2393025],"study_design_scores_gemma":[0.40096635,0.030966083,0.5636506,0.00029415765,0.00032617783,0.000002075646,0.0004161213,0.00003357706,0.0030240992,0.0000027641781,0.0000757794,0.00024218834],"about_ca_topic_score_codex":0.000099747165,"about_ca_topic_score_gemma":0.00006864007,"teacher_disagreement_score":0.4157206,"about_ca_system_score_codex":0.00033593233,"about_ca_system_score_gemma":0.00046852077,"threshold_uncertainty_score":0.9998788},"labels":[],"label_agreement":null},{"id":"W4386271023","doi":"10.1016/s2152-2650(23)00732-2","title":"POSTER: ABCL-187 Phase 2 Response-Adapted Study of Ibrutinib With Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Ibrutinib; Temozolomide; Rituximab; Medicine; Etoposide; Dexamethasone; Lymphoma; Doxorubicin; Pharmacology; Oncology; Internal medicine; Chemotherapy; Leukemia","score_opus":0.04750053828667632,"score_gpt":0.3651694180102589,"score_spread":0.31766887972358254,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271023","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98940873,0.0005730341,0.000030835516,0.0016144032,0.0007664908,0.0051489184,0.0004985145,0.0007891994,0.0011698896],"genre_scores_gemma":[0.9929958,0.00019042955,0.0018139402,0.001400258,0.0005366752,0.0010561995,0.00055834634,0.00029147015,0.0011568624],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99038076,0.0009921533,0.0034659994,0.0022220372,0.0013324773,0.0016065435],"domain_scores_gemma":[0.98673064,0.007739214,0.0012183985,0.0023379761,0.00083954586,0.0011342029],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002716173,0.001217942,0.0033482122,0.0007924184,0.00048894953,0.000117061834,0.0007490162,0.0008712104,0.0002024649],"category_scores_gemma":[0.002112949,0.00096987723,0.0010805655,0.0017946109,0.0007569629,0.00036184952,0.00044281592,0.0003458039,0.00038540942],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.112574086,0.027408525,0.14128032,0.00039221862,0.0035921955,0.0046301493,0.0013494523,0.000012235349,0.0027023787,0.00019651883,0.014600549,0.69126135],"study_design_scores_gemma":[0.1609208,0.032262467,0.7820662,0.0004992869,0.001694567,0.0006609548,0.0013155859,0.0006115953,0.008798148,0.00008898767,0.010231149,0.00085020455],"about_ca_topic_score_codex":0.00049093226,"about_ca_topic_score_gemma":0.00020318705,"teacher_disagreement_score":0.69041115,"about_ca_system_score_codex":0.0015362506,"about_ca_system_score_gemma":0.004522646,"threshold_uncertainty_score":0.99927515},"labels":[],"label_agreement":null},{"id":"W4386271025","doi":"10.1016/s2152-2650(23)00863-7","title":"POSTER: MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Alberta Health Services; University of Calgary; McGill University; Institute of Cancer Research; McGill University Health Centre","funders":"","keywords":"Dexamethasone; Medicine; Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Phase (matter); Materials science; Chemistry; Composite material","score_opus":0.08768596957785604,"score_gpt":0.38017107697080915,"score_spread":0.2924851073929531,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271025","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98769337,0.00070730405,0.0000068507634,0.0027919696,0.0019936443,0.004097102,0.0010218094,0.00030474467,0.0013832102],"genre_scores_gemma":[0.9920034,0.00061750214,0.00038472711,0.0009920239,0.0014969094,0.00030612742,0.0011967379,0.00018275398,0.002819827],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98800516,0.0024226317,0.003895477,0.0018873351,0.002142604,0.0016468178],"domain_scores_gemma":[0.9761642,0.017761514,0.0012162507,0.003518293,0.00040225353,0.00093746587],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.004450195,0.0009257845,0.0022070408,0.00038515803,0.0004905802,0.00010015597,0.0015575635,0.0010948326,0.00015827818],"category_scores_gemma":[0.02131494,0.0005642071,0.0013087073,0.0019846412,0.0013162823,0.00026449445,0.0010676142,0.0014961162,0.00086235924],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.33021864,0.007844941,0.025867954,0.00009599286,0.0009699994,0.001971543,0.001291354,0.000039281407,0.004261592,0.000029461924,0.012686728,0.6147225],"study_design_scores_gemma":[0.42807335,0.0023834396,0.5524653,0.0005652939,0.00027235554,0.000042009247,0.00028570657,0.0042238208,0.002237172,0.0001657596,0.008869586,0.0004162219],"about_ca_topic_score_codex":0.0049220426,"about_ca_topic_score_gemma":0.0014517793,"teacher_disagreement_score":0.6143063,"about_ca_system_score_codex":0.0023128306,"about_ca_system_score_gemma":0.004484211,"threshold_uncertainty_score":0.9999156},"labels":[],"label_agreement":null},{"id":"W4386271028","doi":"10.1016/s2152-2650(23)01446-5","title":"MM-372 A Phase III, Two-Stage, Randomized Study of Mezigdomide, Bortezomib, and Dexamethasone (MeziVd) Versus Pomalidomide, Bortezomib, and Dexamethasone (PVd) in Relapsed/Refractory Multiple Myeloma (RRMM): SUCCESSOR-1","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Pomalidomide; Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Internal medicine; Refractory (planetary science); Oncology; Materials science","score_opus":0.07187944943131912,"score_gpt":0.405540219406015,"score_spread":0.33366076997469585,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271028","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9879542,0.0024257845,0.000039411043,0.00029274463,0.00073657616,0.0069310493,0.00019232472,0.00043235757,0.000995543],"genre_scores_gemma":[0.99186987,0.0028840855,0.0018773641,0.0002045179,0.00041334215,0.0009533378,0.00029484066,0.00026292625,0.0012397182],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.985494,0.0030613863,0.0047557238,0.0027313586,0.0018765766,0.0020809236],"domain_scores_gemma":[0.97186977,0.022097785,0.0014313147,0.0020836482,0.0005517325,0.001965727],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0081800185,0.0014205768,0.0059431177,0.0015598139,0.0004127841,0.00017022593,0.00071589055,0.0009538191,0.00021656975],"category_scores_gemma":[0.018323045,0.0012233075,0.0009046718,0.0023595658,0.0021742745,0.0005423089,0.0010118228,0.0013168921,0.00010600923],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.49929574,0.0055524097,0.20031954,0.00033244642,0.0026545604,0.005116345,0.0011752613,0.000030245157,0.0021886835,0.00010104363,0.0004736973,0.28276002],"study_design_scores_gemma":[0.5799948,0.0042377827,0.40035823,0.00034677758,0.0008683267,0.00008974438,0.0014892289,0.010424832,0.0008363249,0.00010161571,0.00051978877,0.0007325352],"about_ca_topic_score_codex":0.0048318366,"about_ca_topic_score_gemma":0.002169132,"teacher_disagreement_score":0.28202748,"about_ca_system_score_codex":0.0010673346,"about_ca_system_score_gemma":0.0016962303,"threshold_uncertainty_score":0.99985445},"labels":[],"label_agreement":null},{"id":"W4386271084","doi":"10.1016/s2152-2650(23)01409-x","title":"MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"Universidad de Navarra; Janssen Research and Development; Memorial Sloan-Kettering Cancer Center","keywords":"Daratumumab; Multiple myeloma; Medicine; Oncology; Internal medicine; Lenalidomide","score_opus":0.03261970465901573,"score_gpt":0.3211507475403363,"score_spread":0.2885310428813206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271084","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895535,0.00015804794,0.000008766242,0.0005837497,0.0006314872,0.002376755,0.00042883042,0.00076988613,0.00548899],"genre_scores_gemma":[0.98831356,0.00020327441,0.00073712284,0.00047998645,0.00039659065,0.00022326605,0.005146464,0.00022968961,0.004270048],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99066603,0.0007160197,0.0026630107,0.0020988819,0.0018322411,0.0020238017],"domain_scores_gemma":[0.99325716,0.001942032,0.00062587217,0.0021281736,0.0005906779,0.0014560912],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0016235386,0.0009597037,0.001866729,0.0009270037,0.0003789156,0.00012067908,0.000699763,0.00095971354,0.00017784465],"category_scores_gemma":[0.0043116305,0.0007564749,0.00056917075,0.002854919,0.00073712587,0.0005143378,0.0004530823,0.0011437357,0.0031714987],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.038246647,0.0023012215,0.5652796,0.00009582041,0.00058800896,0.003481397,0.00015115287,0.00002005983,0.00012030137,0.00003328648,0.015043503,0.37463897],"study_design_scores_gemma":[0.092448354,0.0036758508,0.8797369,0.00041763895,0.00014689323,0.00003945113,0.00008347397,0.0017386036,0.00036752882,0.000044643966,0.020604419,0.00069622765],"about_ca_topic_score_codex":0.00042679653,"about_ca_topic_score_gemma":0.00029743777,"teacher_disagreement_score":0.37394276,"about_ca_system_score_codex":0.0022655304,"about_ca_system_score_gemma":0.0022839925,"threshold_uncertainty_score":0.99948865},"labels":[],"label_agreement":null},{"id":"W4386271092","doi":"10.1016/s2152-2650(23)00628-6","title":"POSTER: MPN-093 Impact of Transfusion Burden on Health-Related Quality of Life and Functioning in Patients With Myelofibrosis: Post Hoc Analysis of SIMPLIFY-1 and -2","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Post-hoc analysis; Medicine; Quality of life (healthcare); Health related quality of life; Quality-adjusted life year; Intensive care medicine; Internal medicine; Risk analysis (engineering); Disease; Cost effectiveness","score_opus":0.032754464477425915,"score_gpt":0.3414316607324285,"score_spread":0.30867719625500256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271092","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9980476,0.00031691528,0.000002375693,0.00042463903,0.00004419665,0.00082209526,0.00023788033,0.000032216536,0.00007208513],"genre_scores_gemma":[0.99866503,0.0006892206,0.00006876758,0.00014576454,0.000021272766,0.000030959425,0.00033355603,0.000029102974,0.000016350572],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99608856,0.00039414957,0.0021057166,0.0005934223,0.00050018856,0.00031797847],"domain_scores_gemma":[0.9965817,0.0014743252,0.000831595,0.00042637915,0.00032339143,0.0003626355],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009650214,0.00031053345,0.0020491823,0.00060225144,0.00007144017,0.000010693792,0.00007246714,0.00025295315,0.000044278026],"category_scores_gemma":[0.00057345594,0.00022033212,0.00039839858,0.0012388672,0.00029218584,0.000085671134,0.00006005309,0.00016127042,0.0000031438808],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010356386,0.0005588361,0.85644835,0.0002100138,0.0017918844,0.0000062534546,0.0006734978,0.00015061455,0.00014816738,0.00003404152,0.000028412727,0.12959354],"study_design_scores_gemma":[0.012954626,0.012511797,0.97246426,0.00057153875,0.0005738564,0.0000018399176,0.00018997442,0.00043693843,0.000106194224,0.000020327854,0.000004021836,0.0001646036],"about_ca_topic_score_codex":0.0028933703,"about_ca_topic_score_gemma":0.00035703176,"teacher_disagreement_score":0.12942892,"about_ca_system_score_codex":0.00031824366,"about_ca_system_score_gemma":0.00063181604,"threshold_uncertainty_score":0.8984883},"labels":[],"label_agreement":null},{"id":"W4386271138","doi":"10.1016/s2152-2650(23)00894-7","title":"POSTER: CT-343 Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) for Lymphoma Patients: Single-Institution Experience","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Hematopoietic cell; Lymphoma; Medicine; Hematopoietic stem cell transplantation; Transplantation; Oncology; Haematopoiesis; Internal medicine; Stem cell; Biology","score_opus":0.048916569568724914,"score_gpt":0.35338594125318123,"score_spread":0.3044693716844563,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271138","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438083,0.00016847289,0.00042724027,0.00022367526,0.0009835067,0.0018442037,0.00013200345,0.00034410588,0.001495973],"genre_scores_gemma":[0.9960683,0.0003454317,0.00068066467,0.0006443866,0.00024121438,0.00031196175,0.0005940936,0.000112997725,0.00100097],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99417716,0.00020723777,0.0022354578,0.0011293463,0.0011850977,0.001065692],"domain_scores_gemma":[0.99525875,0.0019507929,0.0005400871,0.001121446,0.00056474487,0.0005641813],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009439898,0.0005432787,0.0013504316,0.00037034735,0.00022574465,0.00005259761,0.0005788755,0.0004105281,0.00008253686],"category_scores_gemma":[0.0014346855,0.00047945027,0.00084543775,0.00085403235,0.00082667376,0.00030610996,0.00018451594,0.0001503277,0.00047385896],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0072856746,0.0042212238,0.40363207,0.005254236,0.0007328295,0.0016463592,0.0036293215,0.00013856361,0.009293492,0.001041558,0.0045070606,0.5586176],"study_design_scores_gemma":[0.047865808,0.0017172678,0.9067883,0.00044489122,0.00036830353,0.00027705208,0.00031756583,0.0016977042,0.036672488,0.00025100188,0.002993709,0.00060590054],"about_ca_topic_score_codex":0.00018407,"about_ca_topic_score_gemma":0.000019783218,"teacher_disagreement_score":0.5580117,"about_ca_system_score_codex":0.008961383,"about_ca_system_score_gemma":0.006664474,"threshold_uncertainty_score":0.9997657},"labels":[],"label_agreement":null},{"id":"W4386271141","doi":"10.1016/s2152-2650(23)01447-7","title":"MM-374 Efficacy and Safety of Elranatamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) and Prior B-Cell Maturation Antigen (BCMA)-Directed Therapies: Pooled Analysis From MagnetisMM Studies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Multiple myeloma; Medicine; Refractory (planetary science); Oncology; Internal medicine; Cancer research; Materials science","score_opus":0.02495679098042566,"score_gpt":0.3137765315023438,"score_spread":0.28881974052191817,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9946059,0.0030036552,0.000013482627,0.0001937194,0.00010994996,0.0015202636,0.0002443417,0.0002048846,0.00010381717],"genre_scores_gemma":[0.9923335,0.0044693905,0.0016080919,0.00010261305,0.00008789858,0.0000612623,0.0010156576,0.00007083121,0.00025079696],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99540836,0.00052318134,0.001471932,0.0011304151,0.00081264856,0.00065348187],"domain_scores_gemma":[0.9946632,0.0031909866,0.00048695147,0.00079588196,0.0004089537,0.000454073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006843034,0.0005267489,0.0017259116,0.000688314,0.00020390429,0.000048483183,0.00020594007,0.00039642633,0.000066104796],"category_scores_gemma":[0.001547957,0.00039581064,0.00024221915,0.0016959478,0.0006259212,0.0002472635,0.00024044003,0.00035018136,0.000039665403],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01318626,0.000726824,0.661899,0.00011292104,0.0029512218,0.00017686693,0.00069839414,0.0000061974415,0.00035830724,0.0000029800929,0.00013269801,0.31974834],"study_design_scores_gemma":[0.045983985,0.0016916252,0.94708616,0.0003169998,0.0011223721,0.0000027102571,0.0004204479,0.0024535225,0.0002768558,0.000035599864,0.0002563503,0.00035335627],"about_ca_topic_score_codex":0.0005700039,"about_ca_topic_score_gemma":0.00042425597,"teacher_disagreement_score":0.319395,"about_ca_system_score_codex":0.00043332708,"about_ca_system_score_gemma":0.00040898015,"threshold_uncertainty_score":0.9998494},"labels":[],"label_agreement":null},{"id":"W4386271142","doi":"10.1016/s2152-2650(23)00834-0","title":"POSTER: MM-464 LocoMMotion: A Prospective, Observational, Multinational Study of Real-Life Current Standards of Care in Patients With Relapsed/Refractory Multiple Myeloma – Final Analysis at 2-Year Follow-Up","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Refractory (planetary science); Observational study; Medicine; Multinational corporation; Multiple myeloma; Internal medicine; Materials science; Political science; Metallurgy","score_opus":0.0589811832027855,"score_gpt":0.3656391311726682,"score_spread":0.3066579479698827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271142","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955944,0.00014050792,0.000011379322,0.00005913872,0.0002268678,0.0026086834,0.0010022824,0.00009681909,0.00025995093],"genre_scores_gemma":[0.9965139,0.00010445272,0.0002386721,0.00002458025,0.0001037298,0.00026311187,0.0024421285,0.00006749751,0.0002419254],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99291456,0.00053165155,0.002028247,0.0010762275,0.0028120177,0.0006372806],"domain_scores_gemma":[0.99368817,0.001338159,0.00081928476,0.0009814717,0.0026519778,0.0005209681],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010051631,0.00048931263,0.0016435881,0.0009161027,0.00019680115,0.000023667484,0.00035700388,0.00027555946,0.00016240921],"category_scores_gemma":[0.0027732519,0.000403906,0.00057231257,0.0027711526,0.00036492595,0.00024320766,0.0003809805,0.00038352798,0.00004152915],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.023745414,0.0039921133,0.93267304,0.00027394205,0.0017377669,0.000095578,0.00094567065,0.00014575427,0.000013090295,0.000026189931,0.00030305295,0.036048368],"study_design_scores_gemma":[0.06433529,0.006835633,0.9256072,0.00031188794,0.00066120946,0.0000015694268,0.0006263089,0.0010353837,0.000056280205,0.0000110340325,0.00021251189,0.00030567014],"about_ca_topic_score_codex":0.0004198352,"about_ca_topic_score_gemma":0.0017941231,"teacher_disagreement_score":0.040589876,"about_ca_system_score_codex":0.0029520153,"about_ca_system_score_gemma":0.0023653773,"threshold_uncertainty_score":0.9998413},"labels":[],"label_agreement":null},{"id":"W4386271158","doi":"10.1016/s2152-2650(23)01066-2","title":"AML-469 Ivosidenib + Azacitidine vs Placebo + Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Azacitidine; Myeloid leukemia; Medicine; Placebo; Term (time); Oncology; Internal medicine; Alternative medicine; Biology; Pathology","score_opus":0.025455862086935576,"score_gpt":0.316729295405215,"score_spread":0.29127343331827943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271158","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9877217,0.00013892405,0.000017003365,0.0027726062,0.00052298396,0.0064566187,0.0010406692,0.00076669303,0.0005628453],"genre_scores_gemma":[0.98812616,0.0009835839,0.0003445042,0.0018221455,0.0010599319,0.00032884107,0.0055246023,0.00033364765,0.0014766131],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872213,0.0015674515,0.0037121999,0.0030539732,0.0022425912,0.0022024722],"domain_scores_gemma":[0.9843426,0.009567159,0.0008697107,0.0031392397,0.0007045645,0.0013767212],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0037664296,0.0013746142,0.002705521,0.00063921895,0.0006777719,0.00029674466,0.0015042132,0.001057529,0.00023337439],"category_scores_gemma":[0.0046585496,0.0009780008,0.0004158401,0.0033400233,0.001454633,0.00056635245,0.0015599414,0.0022936214,0.00095903024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08319464,0.0014742804,0.7681533,0.00005964429,0.0015888986,0.0066714366,0.0010810026,0.000107938475,0.00016054646,0.000017892855,0.023096614,0.11439378],"study_design_scores_gemma":[0.14311996,0.0039673154,0.84744966,0.0006148323,0.0007356017,0.000058042056,0.00045109142,0.0009568954,0.00018110492,0.000029782108,0.0015182702,0.0009174322],"about_ca_topic_score_codex":0.0017368406,"about_ca_topic_score_gemma":0.0013320782,"teacher_disagreement_score":0.11347634,"about_ca_system_score_codex":0.004491337,"about_ca_system_score_gemma":0.003653384,"threshold_uncertainty_score":0.99990046},"labels":[],"label_agreement":null},{"id":"W4386271162","doi":"10.1016/s2152-2650(23)00507-4","title":"POSTER: AML-280 A Prospective Study to Evaluate the Prognostic Implications of Methylation and Expression of Wilms Tumor -1 (WT-1) Gene in Acute Myeloid Leukemia","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Renal and related cancers","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Myeloid leukemia; Wilms' tumor; Methylation; Oncology; Internal medicine; Cancer research; Medicine; Gene; Biology; Genetics","score_opus":0.019591264701750155,"score_gpt":0.3284242595440699,"score_spread":0.30883299484231974,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271162","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9976707,0.00032939954,0.000044888835,0.00022017192,0.00013204504,0.0013868163,0.00004054423,0.00002177222,0.00015363659],"genre_scores_gemma":[0.99883395,0.00034933616,0.00013909939,0.00013565188,0.00009503222,0.00023070002,0.00005690358,0.000029613979,0.0001297122],"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","domain_scores_codex":[0.9976426,0.00031432282,0.00089962024,0.0006122769,0.00024797817,0.00028320172],"domain_scores_gemma":[0.99860203,0.00022654349,0.0002709591,0.00055591937,0.00021538227,0.00012916143],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00095571065,0.0002234391,0.00042757526,0.00011018593,0.00009277227,0.000016088003,0.00032938053,0.00017699467,0.000003345168],"category_scores_gemma":[0.0005105368,0.00015029355,0.00015302796,0.0006201347,0.00023987574,0.000010959964,0.00035698566,0.00014526893,0.000010517218],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009619065,0.0001919178,0.22526342,0.000035533212,0.00024410487,0.000014946317,0.0007298818,0.00041130686,0.7290298,0.000023147524,0.00035002094,0.042744048],"study_design_scores_gemma":[0.0016458386,0.001191245,0.83570874,0.000076194636,0.00011494463,0.000016370514,0.00024330923,0.00012969185,0.16036874,0.0002783574,0.00007100249,0.00015554587],"about_ca_topic_score_codex":0.00008326943,"about_ca_topic_score_gemma":0.00004263323,"teacher_disagreement_score":0.6104453,"about_ca_system_score_codex":0.00018164644,"about_ca_system_score_gemma":0.0006044738,"threshold_uncertainty_score":0.61287934},"labels":[],"label_agreement":null},{"id":"W4386271167","doi":"10.1016/s2152-2650(23)01445-3","title":"MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Hôpital du Sacré-Cœur de Montréal; Thames Valley Children's Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"","keywords":"Pomalidomide; Daratumumab; Lenalidomide; Multiple myeloma; Dexamethasone; Medicine; Oncology; Refractory (planetary science); Internal medicine; Materials science","score_opus":0.05760666670056215,"score_gpt":0.3624146327548958,"score_spread":0.3048079660543337,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9955311,0.00015758911,0.000005998613,0.00020956549,0.00025864775,0.0031890448,0.00037094322,0.00012142277,0.00015573138],"genre_scores_gemma":[0.99630034,0.00016085042,0.0003255473,0.00018217358,0.00014220263,0.000472412,0.00039917865,0.0001123991,0.0019048912],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99218166,0.0013751587,0.0021185533,0.0015849776,0.0015766377,0.0011630299],"domain_scores_gemma":[0.99313736,0.0031989187,0.0006599502,0.001849815,0.00037764345,0.0007763094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015185239,0.0008508543,0.0025770455,0.0009158517,0.00037074042,0.000068996094,0.0004560677,0.0004251486,0.00024021641],"category_scores_gemma":[0.0022758378,0.000498886,0.00078637054,0.002855821,0.00071538327,0.00027220353,0.0005403978,0.0004989827,0.000047671183],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.071971856,0.008604333,0.7906348,0.000054464574,0.004410414,0.0013518217,0.0005704846,0.00003201402,0.00007573533,0.0000046696127,0.00014668466,0.12214272],"study_design_scores_gemma":[0.12666033,0.014041745,0.8529,0.00019857583,0.0024091238,0.000011109714,0.00025841882,0.0022904938,0.00014157477,0.000010898594,0.00064579246,0.0004319297],"about_ca_topic_score_codex":0.001534857,"about_ca_topic_score_gemma":0.004061507,"teacher_disagreement_score":0.121710785,"about_ca_system_score_codex":0.001622732,"about_ca_system_score_gemma":0.0013956764,"threshold_uncertainty_score":0.99974626},"labels":[],"label_agreement":null},{"id":"W4386271173","doi":"10.1016/s2152-2650(23)01206-5","title":"MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; London Health Sciences Centre","funders":"","keywords":"Decitabine; Myelodysplastic syndromes; Interim analysis; Medicine; Interim; Oncology; Internal medicine; Randomized controlled trial; Chemistry","score_opus":0.0443610251947838,"score_gpt":0.3911708461793387,"score_spread":0.34680982098455493,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271173","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99149,0.00012367078,0.0009380843,0.00044421817,0.0007177606,0.005229549,0.00040992745,0.00031568602,0.00033108718],"genre_scores_gemma":[0.9959342,0.00091078115,0.0008701561,0.0003067523,0.000265558,0.00022993927,0.00069151114,0.00019414318,0.0005969705],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9854168,0.003262356,0.0053847414,0.0023741396,0.0018828346,0.0016790802],"domain_scores_gemma":[0.97820556,0.01597274,0.001117081,0.0021554118,0.00094615517,0.0016030543],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009990019,0.0011469725,0.0065918234,0.002665946,0.00027756902,0.00012244882,0.0010752459,0.00059879775,0.00044033004],"category_scores_gemma":[0.031522498,0.000958107,0.0015319826,0.0077135293,0.0011655542,0.00037872433,0.0016214772,0.0012233834,0.00038391148],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5122122,0.0100227045,0.2105806,0.00038967232,0.0072467197,0.0023827292,0.001347724,0.00085701374,0.00026046738,0.00005893886,0.0015673983,0.2530738],"study_design_scores_gemma":[0.31859267,0.004093157,0.65873563,0.0004008438,0.00259931,0.000028373339,0.0005467247,0.013891718,0.000059280443,0.000025640436,0.00041353487,0.0006131025],"about_ca_topic_score_codex":0.0007774517,"about_ca_topic_score_gemma":0.00028900985,"teacher_disagreement_score":0.44815505,"about_ca_system_score_codex":0.0024803204,"about_ca_system_score_gemma":0.0021303075,"threshold_uncertainty_score":0.99928695},"labels":[],"label_agreement":null},{"id":"W4386271177","doi":"10.1016/s2152-2650(23)01250-8","title":"MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Double blind; Biomarker; Placebo; Systemic mastocytosis; Medicine; Internal medicine; Pathology; Chemistry; Disease; Alternative medicine","score_opus":0.06755286897072173,"score_gpt":0.32497164658791605,"score_spread":0.25741877761719434,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271177","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884265,0.0007449124,0.000015653772,0.0021356218,0.0014371189,0.0028503486,0.000036412068,0.0001304378,0.004222969],"genre_scores_gemma":[0.9905172,0.0002220422,0.00003266818,0.00017999095,0.0004361626,0.0013660762,0.00039836866,0.000041740164,0.0068057426],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99536246,0.0010556558,0.0018827388,0.0008157897,0.00020242183,0.0006809502],"domain_scores_gemma":[0.99680054,0.001784547,0.0004607396,0.0007719645,0.000115732495,0.0000664721],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030451666,0.0003915633,0.0010292303,0.00044703332,0.00027218455,0.000078811776,0.0006156502,0.00072071963,0.00033104088],"category_scores_gemma":[0.00037204567,0.0002716449,0.00033699395,0.0010210942,0.0005934322,0.00012512745,0.000114852905,0.0005976358,0.0009530774],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9232728,0.0009947782,0.0022842973,0.000116537165,0.0007171921,0.00040424007,0.0014786553,0.00040376105,0.0069501596,0.0043148263,0.019647148,0.039415624],"study_design_scores_gemma":[0.8487777,0.001234163,0.10873532,0.00045453347,0.0002395329,0.00059027673,0.0022681253,0.00023383238,0.00020338579,0.0001946625,0.0363454,0.000723051],"about_ca_topic_score_codex":0.00039097178,"about_ca_topic_score_gemma":0.00046389733,"teacher_disagreement_score":0.10645103,"about_ca_system_score_codex":0.00044237674,"about_ca_system_score_gemma":0.0009837185,"threshold_uncertainty_score":0.9999736},"labels":[],"label_agreement":null},{"id":"W4386271181","doi":"10.1016/s2152-2650(23)01403-9","title":"MM-074 How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Autologous stem-cell transplantation; Transplantation; Stem cell; Oncology; Business; Medicine; Internal medicine; Biology; Cell biology","score_opus":0.03288966119194654,"score_gpt":0.3410242301994113,"score_spread":0.3081345690074648,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99693596,0.0008719023,0.000004758479,0.00047526107,0.00012500696,0.0013574874,0.00006450662,0.00010850244,0.000056614354],"genre_scores_gemma":[0.99844927,0.0006785274,0.000027281065,0.00014282438,0.00007664079,0.0002591733,0.000045594352,0.000047681857,0.00027302792],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966423,0.0005074182,0.00079309224,0.0008316211,0.0004626092,0.0007629693],"domain_scores_gemma":[0.99805784,0.00097407325,0.00013949076,0.00040324932,0.00004707314,0.0003782977],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005607279,0.00047431493,0.0011142206,0.00039494305,0.0000999359,0.0001556178,0.0001563102,0.00032057607,0.000016275908],"category_scores_gemma":[0.000092684844,0.0003400973,0.00017131258,0.00047351845,0.00028450318,0.00019963365,0.00008845504,0.00036883214,0.000013820746],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016222117,0.0003788898,0.7661805,0.00014963152,0.00008498752,0.0025826688,0.0023843637,0.00000366798,0.00014525009,0.0000060134576,0.00000792885,0.22645389],"study_design_scores_gemma":[0.013491915,0.0015491326,0.9818747,0.00015938641,0.00009417743,0.000048815797,0.0016595153,0.0005753124,0.00007638552,0.00014397547,0.000029536352,0.00029714097],"about_ca_topic_score_codex":0.00074446783,"about_ca_topic_score_gemma":0.0023500165,"teacher_disagreement_score":0.22615674,"about_ca_system_score_codex":0.00037734254,"about_ca_system_score_gemma":0.00056520524,"threshold_uncertainty_score":0.9999051},"labels":[],"label_agreement":null},{"id":"W4386271204","doi":"10.1016/s2152-2650(23)00836-4","title":"POSTER: MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Daratumumab; Lenalidomide; Dexamethasone; Bortezomib; Multiple myeloma; Medicine; Oncology; Internal medicine","score_opus":0.04014677747190292,"score_gpt":0.3526198703852113,"score_spread":0.3124730929133084,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386271204","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99041164,0.002015442,0.000008004207,0.00093667983,0.00024729033,0.005715408,0.00025136548,0.00018402578,0.00023012073],"genre_scores_gemma":[0.99068135,0.006591231,0.00035010983,0.00033724462,0.000103997525,0.00068560266,0.0010210812,0.000107339525,0.0001220224],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99272984,0.0010750187,0.0023133727,0.0012524521,0.0016486405,0.0009806725],"domain_scores_gemma":[0.99385065,0.0028977327,0.0006338417,0.0013411626,0.0005361366,0.00074046577],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026230016,0.0006638556,0.0022940412,0.0005346954,0.00018703243,0.0000547742,0.00051209505,0.00033155363,0.000044569235],"category_scores_gemma":[0.0043530934,0.0004916859,0.00030499065,0.0016284655,0.00040903332,0.00031821575,0.0003145223,0.00049075566,0.000058299913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014260626,0.0035437858,0.78752905,0.0010620597,0.0003851214,0.0016348681,0.0002926089,0.0000011435949,0.00006496698,0.00001165804,0.001092746,0.19012135],"study_design_scores_gemma":[0.096716814,0.0070916815,0.88958025,0.004373348,0.00035223004,0.000047475693,0.00016997752,0.00045355665,0.00034239626,0.000032836608,0.00042147364,0.00041797708],"about_ca_topic_score_codex":0.0006022219,"about_ca_topic_score_gemma":0.0007577896,"teacher_disagreement_score":0.18970338,"about_ca_system_score_codex":0.00051217474,"about_ca_system_score_gemma":0.0008603271,"threshold_uncertainty_score":0.9997535},"labels":[],"label_agreement":null},{"id":"W4386277230","doi":"10.1016/s2152-2650(23)00617-1","title":"POSTER: MDS-641 Randomized Phase 1-2 Study to Assess Safety and Efficacy of Low-Dose (LD) Oral Decitabine/Cedazuridine (ASTX727) in Lower-Risk Myelodysplastic Syndromes (LR-MDS) Patients: Interim Safety Analysis","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta Hospital; London Health Sciences Centre","funders":"","keywords":"Decitabine; Interim analysis; Medicine; Myelodysplastic syndromes; Interim; Safety profile; Randomized controlled trial; Oncology; Internal medicine; Adverse effect; Chemistry","score_opus":0.042164357307559144,"score_gpt":0.3869995978362735,"score_spread":0.3448352405287144,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277230","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9915755,0.00012723415,0.0005129821,0.0005240389,0.00073156203,0.005400014,0.00047458534,0.00030813928,0.00034595196],"genre_scores_gemma":[0.99626327,0.0008047254,0.000575512,0.00037389924,0.00025109155,0.0002072346,0.0007698056,0.00019837008,0.0005561139],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9853201,0.0033255974,0.005438871,0.0023782144,0.0018555581,0.0016816857],"domain_scores_gemma":[0.9791251,0.014997918,0.001135018,0.0021770871,0.00097169343,0.0015931902],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.009329658,0.0011675406,0.006537791,0.0026889723,0.0002711398,0.00013323851,0.0010904107,0.00060056907,0.00040026274],"category_scores_gemma":[0.026489086,0.0009745982,0.0015374919,0.0070860707,0.0011035431,0.0004004983,0.0017500707,0.0011973098,0.00037997824],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5166797,0.0090247085,0.24283391,0.00037709734,0.0067087268,0.0024086824,0.0014214435,0.00043349495,0.00027825846,0.000034824785,0.0011597961,0.21863933],"study_design_scores_gemma":[0.3163647,0.0047786497,0.666358,0.0004322679,0.0026036117,0.000038030867,0.00047786484,0.007915898,0.00006997768,0.000019343488,0.0003187038,0.0006229428],"about_ca_topic_score_codex":0.00074953126,"about_ca_topic_score_gemma":0.00028578032,"teacher_disagreement_score":0.42352408,"about_ca_system_score_codex":0.0024059725,"about_ca_system_score_gemma":0.0019944906,"threshold_uncertainty_score":0.99927044},"labels":[],"label_agreement":null},{"id":"W4386277247","doi":"10.1016/s2152-2650(23)00485-8","title":"POSTER: AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Refractory (planetary science); Hematopoietic stem cell transplantation; Medicine; Regimen; Hematopoietic cell; Transplantation; Randomized controlled trial; Internal medicine; Oncology; Stem cell; Haematopoiesis; Biology","score_opus":0.03691495735154922,"score_gpt":0.33996844779076624,"score_spread":0.30305349043921703,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277247","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97882146,0.00017654609,0.0001648741,0.00024854773,0.00023319483,0.019813644,0.0001606519,0.00029156785,0.000089511406],"genre_scores_gemma":[0.99342436,0.00056339224,0.0008801104,0.00014544737,0.00018575232,0.002636955,0.0007171289,0.00036299365,0.001083839],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9888853,0.0028877456,0.003275034,0.0018650598,0.0017345054,0.001352352],"domain_scores_gemma":[0.98506916,0.009512252,0.002142215,0.0018673782,0.0008657837,0.00054323376],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026410692,0.001258505,0.0041236123,0.00084417505,0.00046581778,0.00011762747,0.00077089644,0.0007413716,0.00008564304],"category_scores_gemma":[0.00045236314,0.00062748534,0.0005855237,0.0022833454,0.001107645,0.0005440083,0.000099918674,0.0007346324,0.000012868587],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.9252646,0.0070313215,0.0045550577,0.0004237,0.002630231,0.0011790863,0.010151589,0.000041500723,0.001981429,0.0000025715744,0.000091598864,0.04664734],"study_design_scores_gemma":[0.8582616,0.08089828,0.044366308,0.0008978414,0.0026062464,0.00007328508,0.008056244,0.0010028817,0.0027900164,0.000010691533,0.00021308518,0.0008235433],"about_ca_topic_score_codex":0.0009746868,"about_ca_topic_score_gemma":0.0011162768,"teacher_disagreement_score":0.073866956,"about_ca_system_score_codex":0.0031297444,"about_ca_system_score_gemma":0.005530655,"threshold_uncertainty_score":0.99961764},"labels":[],"label_agreement":null},{"id":"W4386277272","doi":"10.1016/s2152-2650(23)00909-6","title":"POSTER: CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Randomized controlled trial; Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Materials science","score_opus":0.032151055754009526,"score_gpt":0.3358029235009634,"score_spread":0.3036518677469539,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277272","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97832817,0.0004548769,0.000015930575,0.0005623353,0.0014814833,0.016994257,0.00021670318,0.0005307838,0.0014154715],"genre_scores_gemma":[0.9925664,0.00061455497,0.00042654388,0.00041118558,0.00052575994,0.0017209018,0.0010598534,0.00024878315,0.0024259817],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.98659235,0.0024404754,0.0044469093,0.0021708412,0.0023650106,0.0019843988],"domain_scores_gemma":[0.9821796,0.012132915,0.0013995764,0.0017328011,0.0007005057,0.0018545999],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.005164002,0.001299883,0.006725107,0.0010465127,0.00044077873,0.00019137812,0.00053757237,0.00069513643,0.00023055584],"category_scores_gemma":[0.013764187,0.00094726763,0.0014364629,0.0013828846,0.0012489684,0.00046432833,0.00041359017,0.0010108547,0.00030919848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.88143855,0.0027161026,0.015892584,0.000091682836,0.0025012852,0.0029656047,0.00024233191,0.000002662456,0.0002823134,0.000021792344,0.0016555309,0.09218955],"study_design_scores_gemma":[0.82440794,0.015239035,0.15434211,0.00038451032,0.00096595084,0.000026885997,0.00012745461,0.0015928567,0.0004460868,0.00004223953,0.0016509633,0.00077394396],"about_ca_topic_score_codex":0.0002250728,"about_ca_topic_score_gemma":0.00018803753,"teacher_disagreement_score":0.13844953,"about_ca_system_score_codex":0.0023048199,"about_ca_system_score_gemma":0.002964078,"threshold_uncertainty_score":0.99997526},"labels":[],"label_agreement":null},{"id":"W4386277421","doi":"10.1016/s2152-2650(23)01364-2","title":"IBCL-489 Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Refractory (planetary science); Lymphoma; Medicine; Oncology; Internal medicine; Cancer research; Biology","score_opus":0.012945079043927426,"score_gpt":0.28596927122502575,"score_spread":0.2730241921810983,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277421","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99286,0.0002936855,0.000002681028,0.0003739253,0.00043717818,0.0027587868,0.00006839501,0.00031892568,0.0028864238],"genre_scores_gemma":[0.99345195,0.0008023998,0.00039982967,0.0014403093,0.0001975114,0.0005686029,0.00043125133,0.0001671059,0.002541058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943861,0.00036646932,0.0015429107,0.0017560886,0.0008697866,0.0010786706],"domain_scores_gemma":[0.99553025,0.0016890435,0.00048643915,0.0012051217,0.00028510878,0.0008040135],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006501539,0.0009112782,0.0017803956,0.0004281414,0.0002423989,0.00009424183,0.00025097484,0.0007703861,0.00019056513],"category_scores_gemma":[0.00032420896,0.0006271913,0.00035134182,0.0014756765,0.00042612964,0.0002480474,0.0002529142,0.00026128508,0.0010517213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009349749,0.0035789579,0.58121973,0.00013286997,0.00049228844,0.0023816042,0.00043968274,0.0000051982634,0.00002471392,0.000010519336,0.0073841223,0.39498055],"study_design_scores_gemma":[0.07510286,0.010457078,0.9047421,0.00070147193,0.0004751666,0.000051431947,0.0001325662,0.0007263298,0.0011840805,0.000034917735,0.005746006,0.00064597087],"about_ca_topic_score_codex":0.0005058854,"about_ca_topic_score_gemma":0.00007752265,"teacher_disagreement_score":0.39433458,"about_ca_system_score_codex":0.0038843842,"about_ca_system_score_gemma":0.001552797,"threshold_uncertainty_score":0.9999395},"labels":[],"label_agreement":null},{"id":"W4386277475","doi":"10.1016/s2152-2650(23)01256-9","title":"MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Subgroup analysis; Medicine; Anemia; Internal medicine; Oncology; Bone marrow; Meta-analysis","score_opus":0.024545140548926824,"score_gpt":0.32648908092638934,"score_spread":0.3019439403774625,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277475","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99678767,0.00006123173,0.000011502663,0.0006633078,0.00014711864,0.0014127145,0.00020437843,0.0001706181,0.00054148195],"genre_scores_gemma":[0.99604577,0.0003643369,0.001139943,0.0010411426,0.00011886271,0.00025548544,0.00066032313,0.00009904979,0.0002751174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99345887,0.0004288797,0.002714302,0.001507508,0.0009959866,0.0008944678],"domain_scores_gemma":[0.9926721,0.0041855373,0.00079018617,0.0011158857,0.0004559192,0.0007803834],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013608757,0.0007182563,0.0034527578,0.00083209184,0.00013842221,0.000055483717,0.00026916288,0.00060719776,0.00012028144],"category_scores_gemma":[0.0011049173,0.00047717386,0.00070125685,0.0029317378,0.00088676915,0.00018993298,0.00023253619,0.00046070688,0.00007793722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0044398303,0.0014891413,0.91719437,0.00012087735,0.0027091668,0.0002450815,0.00012808846,0.000031041745,0.0000021049436,0.00025693656,0.00040734076,0.07297605],"study_design_scores_gemma":[0.020289669,0.005223186,0.9694616,0.00031676423,0.0031548298,0.000009351063,0.00012127497,0.00037860835,0.00005416256,0.00004339636,0.00044556052,0.00050155225],"about_ca_topic_score_codex":0.000240032,"about_ca_topic_score_gemma":0.0003451431,"teacher_disagreement_score":0.0724745,"about_ca_system_score_codex":0.00040476874,"about_ca_system_score_gemma":0.00072692806,"threshold_uncertainty_score":0.999768},"labels":[],"label_agreement":null},{"id":"W4386277530","doi":"10.1016/s2152-2650(23)00614-6","title":"POSTER: MDS-634 Efficacy and Safety of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subpopulation from Phase 2 and ASCERTAIN Phase 3 Studies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta Hospital; Queen Elizabeth II Health Sciences Centre; Ottawa Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Decitabine; Phase (matter); Medicine; Internal medicine; Pharmacology; Chemistry; Biology; Genetics; Organic chemistry","score_opus":0.10738174308216894,"score_gpt":0.4665188563372431,"score_spread":0.35913711325507414,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277530","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9931051,0.002553534,0.0000032765415,0.0028839866,0.00034797867,0.0007516464,0.00014275646,0.00006230661,0.0001493867],"genre_scores_gemma":[0.9951355,0.002924053,0.00008926846,0.0007832295,0.0003937082,0.000045753983,0.0004726071,0.000027444734,0.0001284591],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99755573,0.00034054322,0.0010124401,0.00051405444,0.00024949564,0.00032771367],"domain_scores_gemma":[0.9964085,0.002749699,0.00022846853,0.00033612564,0.00010704164,0.00017012656],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009575226,0.00027365406,0.0008979749,0.00015265329,0.00010435312,0.000017306,0.00012418041,0.000186857,0.00007328143],"category_scores_gemma":[0.00079153525,0.00019229288,0.0001251715,0.00055058673,0.00043201336,0.00009841257,0.00012950331,0.00018516011,0.000018708548],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016156644,0.0015574791,0.12984404,0.00010435592,0.0006235567,0.0005645356,0.0018763378,0.0000051729744,0.0029400452,0.00010248316,0.007149487,0.83907586],"study_design_scores_gemma":[0.06384502,0.0025283755,0.9234818,0.00015469373,0.00054052006,0.000044655695,0.00039812227,0.00081239996,0.000496215,0.0003685737,0.007144842,0.00018476314],"about_ca_topic_score_codex":0.0004491031,"about_ca_topic_score_gemma":0.00022518796,"teacher_disagreement_score":0.8388911,"about_ca_system_score_codex":0.0002316166,"about_ca_system_score_gemma":0.0002529641,"threshold_uncertainty_score":0.7841476},"labels":[],"label_agreement":null},{"id":"W4386277702","doi":"10.1016/s2152-2650(23)00861-3","title":"POSTER: MM-371 Pomalidomide, Daratumumab, and Dexamethasone After Lenalidomide Treatment in Patients With Relapsed or Refractory Multiple Myeloma (RRMM): Final Overall Survival (OS) Analysis of the Phase II MM-014 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Institute of Cancer Research; McGill University Health Centre; University of Calgary","funders":"","keywords":"Pomalidomide; Lenalidomide; Daratumumab; Dexamethasone; Multiple myeloma; Medicine; Oncology; Refractory (planetary science); Internal medicine; Materials science","score_opus":0.05485545763940222,"score_gpt":0.35894997089294606,"score_spread":0.30409451325354386,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277702","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99530196,0.00016199495,0.0000035157389,0.00024693267,0.00026599286,0.0033069397,0.00042788853,0.000119915145,0.00016484696],"genre_scores_gemma":[0.9965195,0.0001460039,0.00022059138,0.00022137891,0.00013600527,0.00042645438,0.00044604158,0.00011560885,0.0017684283],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920986,0.0014128746,0.002160495,0.0015968415,0.0015599803,0.0011711753],"domain_scores_gemma":[0.9932211,0.0030608734,0.0006747399,0.0018729887,0.00039113357,0.00077916926],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014479834,0.00086920464,0.002581896,0.0009339036,0.0003622675,0.00007531608,0.00046621016,0.00042827326,0.00022089148],"category_scores_gemma":[0.001971266,0.00051121204,0.0007951843,0.002658635,0.0006829584,0.00028874353,0.00058693846,0.00049325824,0.00004832617],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.07964312,0.008225664,0.7935904,0.00005664036,0.004339946,0.0014476588,0.00063678896,0.000018058132,0.00008577036,0.0000030570104,0.00011871837,0.111834146],"study_design_scores_gemma":[0.12678827,0.016056083,0.8518221,0.00021498544,0.0024167285,0.000014810701,0.00022774127,0.0013429333,0.00016568147,0.000008448912,0.0005012068,0.0004410187],"about_ca_topic_score_codex":0.0014816023,"about_ca_topic_score_gemma":0.0039317408,"teacher_disagreement_score":0.11139313,"about_ca_system_score_codex":0.0015842635,"about_ca_system_score_gemma":0.0013162341,"threshold_uncertainty_score":0.9997339},"labels":[],"label_agreement":null},{"id":"W4386277771","doi":"10.1016/s2152-2650(23)01412-x","title":"MM-164 First Results From the RedirecTT-1 Study With Teclistamab (Tec) + Talquetamab (Tal) Simultaneously Targeting BCMA and GPRC5D in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Alberta Health Services; McGill University; McGill University Health Centre","funders":"lékařská fakulta Univerzity Karlovy; University of California, San Francisco; Erasmus Universitair Medisch Centrum Rotterdam; Université de Toulouse; Centre Hospitalier Universitaire de Toulouse; Ankara Universitesi; Univerzita Karlova v Praze; Department of Medicine, University of California, San Francisco; Sanofi","keywords":"Multiple myeloma; TEC; Medicine; Oncology; Internal medicine; Refractory (planetary science); Biology; Geology","score_opus":0.023300873658625102,"score_gpt":0.2885946003179734,"score_spread":0.2652937266593483,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277771","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9932947,0.0002740207,0.000005257755,0.0007454705,0.00026156552,0.003844068,0.0004887628,0.0005099948,0.00057611964],"genre_scores_gemma":[0.9957728,0.00019864131,0.00073642284,0.00031098526,0.00044872044,0.0002850364,0.0013052548,0.00022084867,0.00072131393],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99144155,0.0007990589,0.002126757,0.0022419896,0.0018440244,0.0015466426],"domain_scores_gemma":[0.98610955,0.009903481,0.00066997064,0.0018566157,0.0005171232,0.00094324903],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019019414,0.00097336434,0.0016125714,0.00034330992,0.00073687226,0.00019629598,0.00066545064,0.00054296764,0.00005303282],"category_scores_gemma":[0.00881024,0.0006029911,0.0002583598,0.0015809141,0.0009247057,0.00035189715,0.0005688756,0.0011461112,0.0002973119],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03421566,0.0021750415,0.79645747,0.00005534198,0.0006975746,0.0047033424,0.0011680394,0.00007634975,0.000029280107,0.0000025021002,0.0015652763,0.15885416],"study_design_scores_gemma":[0.071395285,0.0067832046,0.9104522,0.00061541086,0.0002611756,0.000036259575,0.0012934059,0.0035783383,0.000053538362,0.000020260262,0.004854313,0.0006566431],"about_ca_topic_score_codex":0.0031773816,"about_ca_topic_score_gemma":0.004121331,"teacher_disagreement_score":0.1581975,"about_ca_system_score_codex":0.001252091,"about_ca_system_score_gemma":0.0009475153,"threshold_uncertainty_score":0.99964213},"labels":[],"label_agreement":null},{"id":"W4386277871","doi":"10.1016/s2152-2650(23)01273-9","title":"HL-353 Long-Term Outcomes of Bulky Classic Hodgkin Lymphoma Managed With a Positron Emission Tomography (PET)-Adapted Approach Demonstrate Excellent Outcomes in PET-Negative Cases","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Positron emission tomography; Hodgkin lymphoma; Lymphoma; Nuclear medicine; Term (time); Medicine; Pet imaging; Positron emission; PET-CT; Physics; Internal medicine","score_opus":0.04336737510032816,"score_gpt":0.3250377707127791,"score_spread":0.28167039561245094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277871","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9945296,0.00035204695,0.000023848172,0.00071370316,0.00029585307,0.0020010753,0.00010240967,0.00042987926,0.0015515857],"genre_scores_gemma":[0.99499786,0.00060179987,0.001649484,0.00045629844,0.00011169827,0.0004340422,0.00033300195,0.00015439471,0.0012614469],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99282813,0.00045126057,0.002491248,0.0017214046,0.0012492439,0.0012587244],"domain_scores_gemma":[0.9934188,0.0030948524,0.00092989247,0.0014674243,0.000258635,0.0008303722],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009680815,0.0011302482,0.0029790518,0.00097528554,0.0002490713,0.0000962836,0.0005713482,0.00040367193,0.00006513856],"category_scores_gemma":[0.0006649004,0.0007922534,0.0012238509,0.0019685703,0.000847241,0.0002747846,0.0003714049,0.0003229432,0.00010572042],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024324534,0.003582664,0.86280936,0.0002929,0.0014703852,0.011947713,0.0001841221,0.000015719002,0.00017657851,0.000108100845,0.00046096387,0.11651902],"study_design_scores_gemma":[0.024918329,0.0022124413,0.96564275,0.00086855027,0.0009336194,0.000981559,0.0005063845,0.0006918727,0.0022986098,0.000113691,0.000050588314,0.00078162475],"about_ca_topic_score_codex":0.00091697264,"about_ca_topic_score_gemma":0.00030007187,"teacher_disagreement_score":0.11573739,"about_ca_system_score_codex":0.0015301136,"about_ca_system_score_gemma":0.0012852569,"threshold_uncertainty_score":0.9994528},"labels":[],"label_agreement":null},{"id":"W4386277882","doi":"10.1016/s2152-2650(23)01205-3","title":"MDS-634 Efficacy and Safety of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subpopulation from Phase 2 and ASCERTAIN Phase 3 Studies","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Juravinski Cancer Centre; Sunnybrook Health Science Centre; Hôpital Maisonneuve-Rosemont; University of Alberta Hospital; Queen Elizabeth II Health Sciences Centre; Princess Margaret Cancer Centre; Ottawa Hospital; University of Ottawa","funders":"University of Colorado School of Medicine, Anschutz Medical Campus; School of Medicine, Vanderbilt University; Yale Cancer Center; Yale University; Vanderbilt-Ingram Cancer Center; Vanderbilt University; London Health Sciences Centre; University of Texas MD Anderson Cancer Center; Roswell Park Cancer Institute","keywords":"Decitabine; Phase (matter); Medicine; Internal medicine; Oncology; Chemistry; Biology; Genetics; Organic chemistry","score_opus":0.11731023287305228,"score_gpt":0.4757566492205611,"score_spread":0.35844641634750884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936467,0.0025541575,0.0000061579294,0.002429213,0.0003357727,0.000706461,0.00011839213,0.00006269267,0.00014044698],"genre_scores_gemma":[0.9947622,0.0034237748,0.00013989974,0.0006278627,0.00041957296,0.000050573915,0.00041388345,0.000026098027,0.00013616538],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99762666,0.0003238444,0.0009795309,0.0005024572,0.00024753425,0.00031995864],"domain_scores_gemma":[0.9962867,0.0029021015,0.00021938566,0.00032447782,0.00010100586,0.00016635204],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0010099063,0.00026284307,0.00088432746,0.0001459921,0.00010558929,0.000015300517,0.000118993215,0.00018322746,0.00007968161],"category_scores_gemma":[0.00093558204,0.00018438934,0.000120645775,0.0005894015,0.0004547756,0.00009063024,0.000114966366,0.00018540178,0.000018205626],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.013223302,0.0015437838,0.09587752,0.000095915806,0.0005944455,0.00049296353,0.0015893634,0.000009535948,0.0025150885,0.00016994208,0.009222061,0.8746661],"study_design_scores_gemma":[0.064453475,0.0021371173,0.91945094,0.00014288767,0.0005376712,0.000032658838,0.000471874,0.0015435454,0.0004266258,0.00053533015,0.010086164,0.00018171486],"about_ca_topic_score_codex":0.0004625052,"about_ca_topic_score_gemma":0.00022517705,"teacher_disagreement_score":0.87448436,"about_ca_system_score_codex":0.00023261471,"about_ca_system_score_gemma":0.0002659995,"threshold_uncertainty_score":0.7519179},"labels":[],"label_agreement":null},{"id":"W4386277907","doi":"10.1016/s2152-2650(23)00548-7","title":"POSTER: CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Post-hoc analysis; Medicine; Post hoc; Oncology; Internal medicine; Pharmacology; Imatinib","score_opus":0.03539221462855332,"score_gpt":0.3543851135315048,"score_spread":0.3189928989029515,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277907","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9962466,0.00025907755,0.000015137679,0.0002977539,0.0002648929,0.0021037154,0.00067909993,0.00004981498,0.00008394918],"genre_scores_gemma":[0.99860656,0.00019390877,0.00036680192,0.0001519337,0.000069684844,0.00005784359,0.00042423359,0.00005853219,0.00007049853],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99172324,0.0018106948,0.0034418115,0.00066660397,0.0018411039,0.0005165464],"domain_scores_gemma":[0.98607206,0.008800153,0.0021935713,0.0016036232,0.0011397818,0.00019083162],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0026014347,0.00032375703,0.0015533171,0.0004449544,0.00012334593,0.000025204228,0.0006272032,0.00026699185,0.00013844299],"category_scores_gemma":[0.010138348,0.0002087051,0.0007187223,0.003469293,0.0007302655,0.00012749,0.00052537344,0.00025434126,0.000009428083],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.5158153,0.009510191,0.13708438,0.00091407,0.020812547,0.00030220012,0.0345005,0.05107827,0.015523659,0.00023228097,0.003649122,0.21057744],"study_design_scores_gemma":[0.15197335,0.011551793,0.7340516,0.00050053484,0.0049898336,0.000007782811,0.015088762,0.07395168,0.007337049,0.000076812954,0.00010652854,0.00036427533],"about_ca_topic_score_codex":0.004097028,"about_ca_topic_score_gemma":0.00018303342,"teacher_disagreement_score":0.5969672,"about_ca_system_score_codex":0.00249756,"about_ca_system_score_gemma":0.00727987,"threshold_uncertainty_score":0.99834794},"labels":[],"label_agreement":null},{"id":"W4386277964","doi":"10.1016/s2152-2650(23)01136-9","title":"CML-319 Molecular Response of ≤10% BCR::ABL1IS Is Predictive of Positive Outcomes in Patients With Treatment-Resistant Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Treated With Ponatinib From the Phase 2 OPTIC Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Myeloid leukemia; Medicine; Oncology; Internal medicine; Immunology; Dasatinib; Cancer research; Imatinib","score_opus":0.02052534718663807,"score_gpt":0.32626226008500225,"score_spread":0.3057369128983642,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386277964","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886163,0.0006338688,0.000022903023,0.0004675794,0.00020390868,0.0059967865,0.0035401708,0.00024209413,0.00027641896],"genre_scores_gemma":[0.9947267,0.0001866899,0.00048317108,0.00020031768,0.00026563735,0.0006176258,0.0022436474,0.00027050887,0.001005685],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.9900255,0.0014266461,0.0032506243,0.0020110144,0.0018747686,0.0014114563],"domain_scores_gemma":[0.98812956,0.005646832,0.0017668756,0.0030683933,0.0007171884,0.00067117356],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0012129508,0.0014237936,0.0034799147,0.00057843793,0.00022719505,0.000054051787,0.00096807844,0.000799076,0.0004416485],"category_scores_gemma":[0.0018725516,0.00089911895,0.0009828153,0.0020860266,0.0015991656,0.00030804132,0.00035220833,0.000580884,0.00013488671],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.82338053,0.008267814,0.060779426,0.0001612073,0.007838845,0.0028815062,0.0013875943,0.0002762939,0.0052142353,0.00003702029,0.00078234036,0.088993214],"study_design_scores_gemma":[0.37905258,0.062885754,0.5373708,0.0010889944,0.0020190885,0.000018256833,0.00020862141,0.0019319506,0.014570408,0.00002652766,0.00024295069,0.0005840807],"about_ca_topic_score_codex":0.0022802516,"about_ca_topic_score_gemma":0.00020652774,"teacher_disagreement_score":0.47659135,"about_ca_system_score_codex":0.02237023,"about_ca_system_score_gemma":0.015786162,"threshold_uncertainty_score":0.9998512},"labels":[],"label_agreement":null},{"id":"W4386278009","doi":"10.1016/s2152-2650(23)00652-3","title":"POSTER: MPN-551 Clinical Outcomes With Momelotinib vs Ruxolitinib in Patients With Myelofibrosis and Anemia: Subgroup Analysis of SIMPLIFY-1","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Anemia; Subgroup analysis; Internal medicine; Meta-analysis; Bone marrow","score_opus":0.023892048971928592,"score_gpt":0.323527816953411,"score_spread":0.2996357679814824,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386278009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99652207,0.00006407385,0.0000062852337,0.0007892799,0.00015366828,0.0014825371,0.00024145469,0.00016780807,0.0005728423],"genre_scores_gemma":[0.9962317,0.00032641133,0.0007217425,0.0012712302,0.00011440843,0.00023042764,0.00074181304,0.00010241114,0.0002598952],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99335784,0.00044812157,0.0027738854,0.0015239107,0.0009907999,0.00090547395],"domain_scores_gemma":[0.9927961,0.0039953045,0.00081077777,0.0011394459,0.00047315034,0.0007851776],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012938947,0.0007382443,0.0034555313,0.0008475661,0.0001370637,0.00006143111,0.00027822438,0.00061235245,0.00011127337],"category_scores_gemma":[0.0009582262,0.00049151975,0.000712736,0.0027059347,0.0008420545,0.00020333096,0.00025789178,0.00045682245,0.000079172976],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005216755,0.0014671516,0.92306554,0.00012726933,0.0027081785,0.00027256866,0.00014968423,0.000016654833,0.0000025297181,0.00015613866,0.00032765433,0.06648986],"study_design_scores_gemma":[0.020768384,0.006138282,0.96829605,0.00034584533,0.0031654693,0.000012865391,0.00010635774,0.00021235233,0.00006578016,0.000032527663,0.00034173785,0.0005143646],"about_ca_topic_score_codex":0.00023669467,"about_ca_topic_score_gemma":0.00034423487,"teacher_disagreement_score":0.065975495,"about_ca_system_score_codex":0.00040203644,"about_ca_system_score_gemma":0.00068912015,"threshold_uncertainty_score":0.99975365},"labels":[],"label_agreement":null},{"id":"W4386278342","doi":"10.1016/s2152-2650(23)00511-6","title":"POSTER: AML-453 Synchronous Diagnosis of Acute Myeloid Leukemia (AML) and Colorectal Adenocarcinoma (CRC)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pediatric Oncology Group","funders":"","keywords":"Myeloid leukemia; Medicine; Internal medicine; Colorectal cancer; Oncology; Cancer research; Adenocarcinoma; Myeloid; Cancer","score_opus":0.02953358290996531,"score_gpt":0.328162638471348,"score_spread":0.2986290555613827,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386278342","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98958683,0.0015229129,0.000019572226,0.0016921089,0.0008358279,0.0018198895,0.0003078332,0.0007585725,0.0034564699],"genre_scores_gemma":[0.9886348,0.004785102,0.0007339974,0.0015342229,0.0012218214,0.00041279694,0.00038890445,0.00029912454,0.0019891884],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908243,0.00062364945,0.002892754,0.0021100359,0.0015223364,0.0020269214],"domain_scores_gemma":[0.9914312,0.003642778,0.0007448704,0.0018513182,0.00064624596,0.0016835816],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0022483815,0.00103535,0.0027022187,0.0008863929,0.0003993935,0.0001302766,0.001084338,0.0014402615,0.00039957388],"category_scores_gemma":[0.0022116727,0.00095564214,0.001038613,0.0022342687,0.002265749,0.0004222751,0.0015951366,0.001268432,0.0015477142],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0035908404,0.00032128624,0.5879309,0.00056855526,0.0018921797,0.004643687,0.00058019,0.0000067304295,0.0054135513,0.00029099366,0.033067375,0.3616937],"study_design_scores_gemma":[0.01046659,0.0034508158,0.96292794,0.00046749462,0.0010143648,0.0012980647,0.00025831314,0.0015123015,0.011354287,0.0002729552,0.0060963617,0.0008805419],"about_ca_topic_score_codex":0.0005730178,"about_ca_topic_score_gemma":0.000050408446,"teacher_disagreement_score":0.37499702,"about_ca_system_score_codex":0.0043934686,"about_ca_system_score_gemma":0.005940169,"threshold_uncertainty_score":0.99985605},"labels":[],"label_agreement":null},{"id":"W4386281911","doi":"10.1016/s2152-2650(23)00354-3","title":"Oral Abstract: IBCL-098 TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Follicular lymphoma; Follicular phase; Medicine; Phase (matter); Internal medicine; Gastroenterology; Lymphoma; Chemistry; Organic chemistry","score_opus":0.03522214240249506,"score_gpt":0.3376478688833309,"score_spread":0.3024257264808359,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386281911","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99400014,0.000252964,0.0000021187216,0.00047007634,0.00051842385,0.0028596807,0.00038621624,0.00030385767,0.0012065376],"genre_scores_gemma":[0.99671173,0.00023827063,0.00028827298,0.00040623968,0.00025471198,0.00029481685,0.0009497655,0.00016317601,0.0006930023],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919133,0.00031993413,0.0032736394,0.0017440745,0.001517994,0.0012310272],"domain_scores_gemma":[0.99536496,0.0008770775,0.0008025369,0.0017376622,0.0004034132,0.0008143605],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015573541,0.00092883245,0.0023471254,0.00055843254,0.0002658871,0.00006144051,0.000559862,0.0006210894,0.000103411476],"category_scores_gemma":[0.0006019558,0.0007273432,0.00078450114,0.0017372328,0.00045372566,0.00030736497,0.0002515834,0.0002656699,0.000273251],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015027455,0.032438286,0.49352443,0.00012547876,0.0009028101,0.0027338122,0.00078964804,0.000032590728,0.00007910216,0.000027241444,0.0030984594,0.4512207],"study_design_scores_gemma":[0.16582768,0.015306243,0.8122141,0.00042731478,0.00067249424,0.000020333588,0.0003209072,0.00019152666,0.0007551388,0.000030829513,0.0036409814,0.00059246557],"about_ca_topic_score_codex":0.000941556,"about_ca_topic_score_gemma":0.0003090417,"teacher_disagreement_score":0.45062822,"about_ca_system_score_codex":0.0015010233,"about_ca_system_score_gemma":0.0014614074,"threshold_uncertainty_score":0.99951774},"labels":[],"label_agreement":null},{"id":"W4386281969","doi":"10.1016/s2152-2650(23)01441-6","title":"MM-360 Mezigdomide (MEZI) Plus Dexamethasone (DEX) in Relapsed/refractory Multiple Myeloma (RRMM): Results From the Dose-Expansion Phase of the CC-92480-MM-001 Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Institute of Cancer Research; University of Calgary","funders":"","keywords":"Dexamethasone; Multiple myeloma; Medicine; Phase (matter); Oncology; Nuclear medicine; Internal medicine; Physics","score_opus":0.09324318455389913,"score_gpt":0.3844113765912489,"score_spread":0.2911681920373498,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386281969","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98838335,0.0007011617,0.0000122236215,0.002409818,0.0019822896,0.0039654598,0.00088972226,0.00031323475,0.00134273],"genre_scores_gemma":[0.9915801,0.00069941714,0.0005855711,0.00082345883,0.0016171818,0.000343344,0.00108193,0.00017947514,0.0030895174],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9880624,0.0023742893,0.0038519334,0.0018823332,0.0021825037,0.0016465435],"domain_scores_gemma":[0.9749905,0.018970147,0.0012012701,0.003509293,0.00038964255,0.00093915546],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0047482513,0.0009090533,0.0022053162,0.00037492425,0.0005062608,0.00009192666,0.0015466702,0.0010993707,0.00017310467],"category_scores_gemma":[0.025375815,0.0005526282,0.0013049814,0.0021446187,0.0013973309,0.00024901668,0.0009864819,0.0015369438,0.00087932247],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.29739887,0.008072751,0.019565878,0.00009082137,0.0009530351,0.0017995673,0.0011316843,0.000071539136,0.003785063,0.000046436355,0.016360572,0.65072376],"study_design_scores_gemma":[0.44054124,0.0020606834,0.5337717,0.0005366284,0.0002715668,0.000032018543,0.00033359908,0.0076453686,0.0019896384,0.00022958209,0.01217124,0.00041677774],"about_ca_topic_score_codex":0.005190808,"about_ca_topic_score_gemma":0.0014918792,"teacher_disagreement_score":0.650307,"about_ca_system_score_codex":0.0023911349,"about_ca_system_score_gemma":0.004848642,"threshold_uncertainty_score":0.9998986},"labels":[],"label_agreement":null},{"id":"W4386281987","doi":"10.1016/s2152-2650(23)01333-2","title":"ABCL-517 Phase III Trial of Subcutaneous Epcoritamab + R-CHOP Versus R-CHOP Alone in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): EPCORE DLBCL-2","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Diffuse large B-cell lymphoma; Medicine; CHOP; Internal medicine; Lymphoma; Oncology; Rituximab; Phases of clinical research; Clinical trial","score_opus":0.025283672554976166,"score_gpt":0.31651602205791074,"score_spread":0.2912323495029346,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386281987","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9906751,0.00036110624,0.000009867949,0.0003055025,0.0024035564,0.0036807328,0.00043915343,0.00045818524,0.0016668035],"genre_scores_gemma":[0.9946771,0.0009090672,0.00033334768,0.00051808887,0.00080805126,0.00052897655,0.0011720231,0.00025638056,0.00079690904],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.990208,0.0004776885,0.0035265984,0.0020371212,0.0018175651,0.0019330191],"domain_scores_gemma":[0.990765,0.003988288,0.0012324128,0.002243903,0.00049038423,0.0012800397],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011247718,0.0012571777,0.0032725371,0.00069647684,0.00027728727,0.000100706086,0.0007547841,0.0010566018,0.00013397839],"category_scores_gemma":[0.0014443197,0.001028582,0.0011604287,0.0020025144,0.0005232521,0.0003347192,0.00044153866,0.00039827373,0.00072790135],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.42440054,0.11329945,0.13403091,0.00023845474,0.0010084582,0.012554404,0.0004815987,0.000008764747,0.000038083268,0.00018301909,0.0053494605,0.30840686],"study_design_scores_gemma":[0.5652073,0.013179039,0.41648012,0.0003423161,0.0006446033,0.00004260059,0.00018096826,0.00030063328,0.00018133284,0.000034964338,0.0027669722,0.00063910795],"about_ca_topic_score_codex":0.0008033162,"about_ca_topic_score_gemma":0.00025172599,"teacher_disagreement_score":0.30776775,"about_ca_system_score_codex":0.0032623755,"about_ca_system_score_gemma":0.0025938067,"threshold_uncertainty_score":0.99921644},"labels":[],"label_agreement":null},{"id":"W4386282071","doi":"10.1016/s2152-2650(23)00779-6","title":"POSTER: MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Mantle cell lymphoma; Refractory (planetary science); Mantle (geology); Medicine; Cancer research; Lymphoma; Oncology; Internal medicine; Geochemistry; Geology; Materials science; Metallurgy","score_opus":0.03224054143366972,"score_gpt":0.3083022262537733,"score_spread":0.27606168482010357,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282071","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99501735,0.0002717613,0.0000010484308,0.0010258199,0.00053527387,0.0017942269,0.00023021358,0.0005129117,0.0006114013],"genre_scores_gemma":[0.99390215,0.00045374988,0.00037682324,0.0019000877,0.00019880857,0.0002758201,0.0007589979,0.00021285842,0.0019207158],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99337655,0.0009235775,0.0019404752,0.0015808955,0.00097255176,0.0012059689],"domain_scores_gemma":[0.9938414,0.003012829,0.00060753967,0.0014928099,0.00033916303,0.0007062766],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0010507902,0.0009088404,0.0017866115,0.00058982475,0.00025425115,0.00012205209,0.00047477885,0.00075754593,0.00021221885],"category_scores_gemma":[0.0005729412,0.00063634146,0.00040237248,0.0016400425,0.00043894275,0.00033002338,0.00020529045,0.00027327836,0.0012030044],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08764255,0.005179227,0.7237093,0.00011429888,0.0004997394,0.0027074916,0.0003521199,0.000007034019,0.00062874734,0.000024618479,0.0043234103,0.17481147],"study_design_scores_gemma":[0.07271788,0.009121159,0.90866935,0.00061548897,0.00022090197,0.000046003643,0.00011077923,0.0000937337,0.0026901297,0.000043069682,0.004969111,0.00070236984],"about_ca_topic_score_codex":0.00064824295,"about_ca_topic_score_gemma":0.000066083776,"teacher_disagreement_score":0.18496007,"about_ca_system_score_codex":0.0028409695,"about_ca_system_score_gemma":0.002170402,"threshold_uncertainty_score":0.9996088},"labels":[],"label_agreement":null},{"id":"W4386282091","doi":"10.1016/s2152-2650(23)00860-1","title":"POSTER: MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Bispecific antibody; Multiple myeloma; Antibody; Oncology; Internal medicine; Immunology; Monoclonal antibody","score_opus":0.03282828537900095,"score_gpt":0.33006032396092655,"score_spread":0.2972320385819256,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99075794,0.00039607772,0.000069472204,0.0007178351,0.00078197545,0.0059668464,0.00071630167,0.00034160647,0.00025195454],"genre_scores_gemma":[0.9909208,0.00046137386,0.00079905044,0.00031317899,0.00057904504,0.00042846389,0.005082165,0.00016590212,0.00125003],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939264,0.0005648201,0.0015464155,0.001643284,0.0012760392,0.0010430386],"domain_scores_gemma":[0.9934824,0.0032215852,0.0005662115,0.0014339751,0.0005746428,0.0007211768],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00096922944,0.0007469411,0.0011160929,0.00027823646,0.0007289384,0.0002918627,0.00048445663,0.00049644534,0.000089816785],"category_scores_gemma":[0.0013622487,0.0005105411,0.00039958348,0.0007828577,0.0004615885,0.00047325538,0.00026538095,0.0004731344,0.00028873864],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02269827,0.002602237,0.7110248,0.00009569942,0.0006029751,0.00051087845,0.00054089795,6.81197e-7,0.0011804239,0.000012360586,0.003768411,0.25696233],"study_design_scores_gemma":[0.05019143,0.010093541,0.9317835,0.00019074896,0.00039130397,0.000023278446,0.00074901077,0.001018099,0.000424512,0.000085297586,0.004528919,0.000520345],"about_ca_topic_score_codex":0.00042308384,"about_ca_topic_score_gemma":0.0005897651,"teacher_disagreement_score":0.25644198,"about_ca_system_score_codex":0.000460732,"about_ca_system_score_gemma":0.001108751,"threshold_uncertainty_score":0.99973464},"labels":[],"label_agreement":null},{"id":"W4386282097","doi":"10.1016/s2152-2650(23)00681-x","title":"POSTER: HL-353 Long-Term Outcomes of Bulky Classic Hodgkin Lymphoma Managed With a Positron Emission Tomography (PET)-Adapted Approach Demonstrate Excellent Outcomes in PET-Negative Cases","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Positron emission tomography; Term (time); Medicine; Lymphoma; Nuclear medicine; Positron emission; Hodgkin lymphoma; Medical physics; Radiology; Internal medicine; Physics","score_opus":0.04161993237991492,"score_gpt":0.3221626072723113,"score_spread":0.28054267489239637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282097","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99420017,0.00036290922,0.000013534364,0.0008456092,0.00030759993,0.0021058584,0.000121730794,0.00042314676,0.00161946],"genre_scores_gemma":[0.99559855,0.00054085493,0.0010831194,0.00055979646,0.00010789279,0.00039366275,0.00037772805,0.0001602497,0.00117817],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9926971,0.00047309452,0.0025580225,0.0017471423,0.0012472133,0.0012774239],"domain_scores_gemma":[0.9934606,0.0029692287,0.0009568397,0.001502078,0.00027181083,0.00083943637],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009316329,0.0011628402,0.0030017453,0.0010044443,0.00024660397,0.00010639395,0.0005890136,0.00041105732,0.00006096689],"category_scores_gemma":[0.00058132573,0.00081670436,0.0012428768,0.0018498877,0.00081344496,0.0002951303,0.0004108512,0.00032349737,0.00010723883],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002855492,0.0035055007,0.8709402,0.00030625958,0.0014878802,0.012701609,0.0002141768,0.000008884771,0.00020275642,0.00006883829,0.0003722231,0.10733618],"study_design_scores_gemma":[0.025296388,0.00262135,0.96448344,0.0009387489,0.0009559764,0.0012805654,0.00044635328,0.00040225877,0.0026455407,0.000085828724,0.00004046065,0.000803109],"about_ca_topic_score_codex":0.0008928646,"about_ca_topic_score_gemma":0.00029989556,"teacher_disagreement_score":0.106533065,"about_ca_system_score_codex":0.0015022234,"about_ca_system_score_gemma":0.0012177735,"threshold_uncertainty_score":0.9994284},"labels":[],"label_agreement":null},{"id":"W4386282116","doi":"10.1016/s2152-2650(23)01461-1","title":"MM-508 Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Observational study; Multiple myeloma; Refractory (planetary science); Medicine; Internal medicine; Oncology; Physics; Astrobiology","score_opus":0.1904529076169951,"score_gpt":0.4317338980922159,"score_spread":0.2412809904752208,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282116","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9898298,0.00009084447,0.000052206222,0.0015372828,0.00093309715,0.0047275717,0.000455947,0.0009515815,0.0014216932],"genre_scores_gemma":[0.96448004,0.00048575952,0.0036706624,0.0010388535,0.0014239919,0.0014222657,0.0026096087,0.00024413886,0.024624683],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920517,0.0005935734,0.0024282862,0.0018079258,0.0014660978,0.001652419],"domain_scores_gemma":[0.98941886,0.006455243,0.0005634321,0.0016742466,0.0006338372,0.0012543792],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0025120475,0.00078989106,0.0017333948,0.00064941857,0.00063027994,0.00012291566,0.0006905618,0.00052088685,0.00048517482],"category_scores_gemma":[0.0065200017,0.0006204975,0.00083755783,0.0018449551,0.00040080654,0.00034597042,0.00048230798,0.00061723,0.0023505213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016592665,0.0024511537,0.6203492,0.00018438094,0.0011145178,0.0026721149,0.00015441971,0.000006828414,0.00030783282,0.00021279673,0.036938705,0.31901535],"study_design_scores_gemma":[0.03709439,0.003625223,0.9026406,0.00020145587,0.0003625898,0.00006403958,0.00029978054,0.0052298596,0.00020118665,0.00022821914,0.04947998,0.0005726864],"about_ca_topic_score_codex":0.00071232923,"about_ca_topic_score_gemma":0.0016149196,"teacher_disagreement_score":0.31844264,"about_ca_system_score_codex":0.0017645056,"about_ca_system_score_gemma":0.003206423,"threshold_uncertainty_score":0.9996246},"labels":[],"label_agreement":null},{"id":"W4386282130","doi":"10.1016/s2152-2650(23)01510-0","title":"CT-356 Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens in Patients With Triple-Class–Exposed (TCE) Relapsed and Refractory Multiple Myeloma (RRMM): KarMMa-3, a Phase III Randomized Controlled Trial (RCT)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Randomized controlled trial; Medicine; Refractory (planetary science); Internal medicine; Multiple myeloma; Oncology; Materials science","score_opus":0.033422919757554743,"score_gpt":0.33872499839986336,"score_spread":0.3053020786423086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282130","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9787888,0.0004483084,0.000027873375,0.00048183728,0.0014656341,0.016684635,0.00018632488,0.00054730335,0.0013692684],"genre_scores_gemma":[0.9919861,0.0006907526,0.00064168026,0.00034155138,0.0005588734,0.0019439231,0.00096046634,0.00024475466,0.0026318745],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866553,0.0023907952,0.0043977876,0.0021663308,0.0024045536,0.0019852112],"domain_scores_gemma":[0.98150474,0.012850675,0.0013810011,0.0017142125,0.0006814973,0.0018678885],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0054921424,0.0012804057,0.006785988,0.001030023,0.0004525356,0.00017748613,0.0005275499,0.00069375505,0.00025148308],"category_scores_gemma":[0.016139481,0.0009323487,0.001430947,0.0014795049,0.0013195567,0.00044111192,0.00038023092,0.0010320221,0.0003122542],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.87713534,0.002785897,0.012235999,0.000087801534,0.002502746,0.0027622487,0.000212383,0.000004632082,0.00024783798,0.000033999884,0.0020795907,0.09991152],"study_design_scores_gemma":[0.8444864,0.01361289,0.13415217,0.00036580215,0.0009767639,0.000020821613,0.00014780206,0.0028049909,0.00039169475,0.000057035413,0.002202072,0.0007815335],"about_ca_topic_score_codex":0.00022952766,"about_ca_topic_score_gemma":0.00018880707,"teacher_disagreement_score":0.12191618,"about_ca_system_score_codex":0.0023716022,"about_ca_system_score_gemma":0.0031663638,"threshold_uncertainty_score":0.99999475},"labels":[],"label_agreement":null},{"id":"W4386282140","doi":"10.1016/s2152-2650(23)00802-9","title":"POSTER: MM-074 How can Different Therapeutic Strategies and Financial Resources Impact Outcomes After Autologous Stem Cell Transplantation in Myeloma? Study in France and Algeria","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Transplantation; Autologous stem-cell transplantation; Stem cell; Medicine; Business; Internal medicine; Oncology; Biology; Cell biology","score_opus":0.03137610605555136,"score_gpt":0.3378752403231444,"score_spread":0.30649913426759307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99674326,0.0008845035,0.0000026987218,0.00056427956,0.00013056447,0.0014290251,0.000077135555,0.000107621476,0.000060902807],"genre_scores_gemma":[0.9985336,0.00060317124,0.000018471676,0.00017718601,0.000073839044,0.00023378697,0.000052802054,0.00004977479,0.00025734626],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965656,0.00052881247,0.00082087825,0.000845865,0.00046451614,0.0007743559],"domain_scores_gemma":[0.99806225,0.0009419675,0.00014578586,0.0004164822,0.00005016319,0.0003833435],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053869036,0.0004898159,0.0011292312,0.00040783238,0.00009927956,0.00017013012,0.00016260077,0.00032514895,0.000015344353],"category_scores_gemma":[0.00008206194,0.00035160987,0.00017672566,0.00044789934,0.0002742627,0.00021393376,0.00009878017,0.00036639886,0.000014238586],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.001948551,0.00038029125,0.7800603,0.0001581237,0.00008909216,0.0028060637,0.0027053321,0.0000020764417,0.00016882425,0.0000038973058,0.0000066510165,0.21167079],"study_design_scores_gemma":[0.013892485,0.0018493928,0.98162806,0.0001752317,0.00009851363,0.00006591133,0.0014311856,0.0003302294,0.000091618975,0.00010697853,0.000023430537,0.00030696203],"about_ca_topic_score_codex":0.0007223046,"about_ca_topic_score_gemma":0.0022905562,"teacher_disagreement_score":0.21136382,"about_ca_system_score_codex":0.00037383134,"about_ca_system_score_gemma":0.00053712196,"threshold_uncertainty_score":0.9998936},"labels":[],"label_agreement":null},{"id":"W4386282152","doi":"10.1016/s2152-2650(23)01190-4","title":"MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Spleen; Pediatrics; Internal medicine; Bone marrow","score_opus":0.029721782192800052,"score_gpt":0.3497908632459027,"score_spread":0.32006908105310267,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282152","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936874,0.00032912422,0.0000047761296,0.002349385,0.000349537,0.0025421528,0.00031024544,0.00010475568,0.00032263808],"genre_scores_gemma":[0.9960935,0.0009213928,0.00026404776,0.0009704349,0.00033986423,0.00060836785,0.0003201716,0.000082217215,0.00039999431],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99588513,0.00015098095,0.0016189193,0.0009551045,0.0004968422,0.00089303503],"domain_scores_gemma":[0.9941364,0.004116068,0.00037214812,0.00080410566,0.00021240259,0.00035891013],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010493277,0.00047525147,0.0012703395,0.00013889806,0.00026122766,0.00006696036,0.00031037157,0.00039853744,0.00005375977],"category_scores_gemma":[0.001518841,0.00033547851,0.0004825078,0.0007262695,0.0005166825,0.00012176531,0.00031203812,0.00025994104,0.000095175645],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014552741,0.0006234795,0.69612914,0.00015913411,0.00021293825,0.000051391504,0.00037132864,0.000008285677,0.00006758578,0.0008172942,0.0019247624,0.2981794],"study_design_scores_gemma":[0.017389774,0.0019654324,0.9721932,0.00035954808,0.00021117108,0.000022634382,0.00014560271,0.00033219322,0.0017952012,0.00055021193,0.004721911,0.0003131414],"about_ca_topic_score_codex":0.00016887953,"about_ca_topic_score_gemma":0.00018965399,"teacher_disagreement_score":0.29786626,"about_ca_system_score_codex":0.0004787521,"about_ca_system_score_gemma":0.0004151893,"threshold_uncertainty_score":0.9999097},"labels":[],"label_agreement":null},{"id":"W4386282157","doi":"10.1016/s2152-2650(23)00805-4","title":"POSTER: MM-161 Talquetamab + Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Updated TRIMM-2 Results","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary; Princess Margaret Cancer Centre","funders":"","keywords":"Daratumumab; Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Lenalidomide; Oncology; Materials science; Metallurgy","score_opus":0.03119223362108285,"score_gpt":0.3182786297286981,"score_spread":0.2870863961076152,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282157","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98905385,0.00016521869,0.0000046575487,0.0006966472,0.00065207103,0.00249294,0.00050833105,0.000744097,0.005682175],"genre_scores_gemma":[0.98834074,0.00018393806,0.0004558477,0.00059408747,0.00037606386,0.00020182268,0.0056893225,0.00023649709,0.0039216797],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99054366,0.0007495902,0.0027308506,0.0021210709,0.0018171379,0.0020377096],"domain_scores_gemma":[0.9932374,0.0018722083,0.0006475559,0.002167265,0.00061476347,0.001460837],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015428548,0.0009878905,0.0018879385,0.0009485693,0.0003720449,0.00013329413,0.0007202338,0.00096737704,0.0001637726],"category_scores_gemma":[0.0036821251,0.00077909866,0.0005818126,0.0026365109,0.0007044904,0.00054831355,0.0005033632,0.0011283772,0.0030877795],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.042358205,0.0021714012,0.6104069,0.00009803716,0.00057968963,0.0036446408,0.00017142044,0.000010035418,0.00013502318,0.000019427398,0.011075379,0.32932985],"study_design_scores_gemma":[0.093630284,0.0043910416,0.88399106,0.00046095264,0.00015447101,0.000054485245,0.00007322592,0.00093518855,0.00044708286,0.000033249053,0.015111032,0.0007178937],"about_ca_topic_score_codex":0.00042331303,"about_ca_topic_score_gemma":0.00029907192,"teacher_disagreement_score":0.32861197,"about_ca_system_score_codex":0.0022140683,"about_ca_system_score_gemma":0.0021469397,"threshold_uncertainty_score":0.999466},"labels":[],"label_agreement":null},{"id":"W4386282163","doi":"10.1016/s2152-2650(23)01365-4","title":"IBCL-492 A Cost-Effectiveness Analysis of Mosunetuzumab for Treatment of Thirdor Higher-Line Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States (US)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital","funders":"","keywords":"Follicular lymphoma; Refractory (planetary science); Follicular phase; Oncology; Line (geometry); Lymphoma; Medicine; First line treatment; Internal medicine; Cancer research; Medical physics; Mathematics; Biology; Chemotherapy","score_opus":0.09003371517577248,"score_gpt":0.3918500559816391,"score_spread":0.3018163408058666,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282163","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941267,0.0007061651,0.00004005719,0.00058755995,0.00032769688,0.0034374224,0.0004883139,0.00014571677,0.0001404092],"genre_scores_gemma":[0.9907525,0.0028465353,0.0003066237,0.0005484191,0.0001732477,0.0018812984,0.0029413288,0.00008912634,0.00046087426],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.994112,0.0009333598,0.0023422083,0.0010503731,0.00078491523,0.0007771296],"domain_scores_gemma":[0.98629993,0.010490186,0.00087021006,0.001555412,0.00047123933,0.00031301036],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018131454,0.00067353115,0.002891729,0.001102741,0.00014662849,0.000032946606,0.00044017803,0.00056805596,0.00008046937],"category_scores_gemma":[0.00092684844,0.00040405235,0.0017745892,0.0051966524,0.0004579877,0.00010543931,0.00010009338,0.00008166221,0.000035451838],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.02619018,0.0149593,0.39467174,0.0007063404,0.016063202,0.0021378133,0.0016882851,0.0032682864,0.00050359586,0.0010195697,0.0018172114,0.5369745],"study_design_scores_gemma":[0.036026616,0.007844825,0.90731645,0.00033296674,0.0062500527,0.000028258888,0.0003726575,0.011920223,0.0021063362,0.00017621618,0.027263336,0.0003620583],"about_ca_topic_score_codex":0.0032184413,"about_ca_topic_score_gemma":0.00039399587,"teacher_disagreement_score":0.53661245,"about_ca_system_score_codex":0.002855299,"about_ca_system_score_gemma":0.001271881,"threshold_uncertainty_score":0.99984115},"labels":[],"label_agreement":null},{"id":"W4386282202","doi":"10.1016/s2152-2650(23)00380-4","title":"POSTER: ALL-422 Therapy of Childhood Acute Lymphoblastic Leukemia (ALL) in Resource-Poor Geospaces","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lymphoblastic Leukemia; Medicine; Intensive care medicine; Pediatrics; Leukemia; Internal medicine","score_opus":0.04605208535438257,"score_gpt":0.3526680073636234,"score_spread":0.3066159220092408,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282202","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98636144,0.00074886566,0.000025918924,0.0032649597,0.00063136965,0.0017870327,0.00013805921,0.00069349754,0.006348879],"genre_scores_gemma":[0.9839708,0.0040881033,0.000564348,0.0065040686,0.0009693943,0.00021914589,0.0005142634,0.00034568395,0.002824143],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9890067,0.0008073558,0.0034796353,0.0020615063,0.0022261008,0.0024187062],"domain_scores_gemma":[0.9906895,0.004488373,0.0008419014,0.0022327567,0.00041641964,0.0013310614],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030539427,0.0011011433,0.002714261,0.0012751357,0.00017951238,0.00010942611,0.0015648231,0.0014230028,0.00035328153],"category_scores_gemma":[0.002880897,0.0009515574,0.0011420241,0.0029181046,0.0013540227,0.00035627838,0.0010176466,0.0010213284,0.0017754034],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.013266777,0.0022004081,0.075876355,0.0005347942,0.0047138715,0.010543802,0.0024908038,0.00027582096,0.016095279,0.0006461231,0.1193027,0.75405324],"study_design_scores_gemma":[0.028445665,0.0026834009,0.91276187,0.000715223,0.00032947652,0.0008392355,0.0003657851,0.0054411716,0.0036109309,0.00051759806,0.04334548,0.00094416115],"about_ca_topic_score_codex":0.000456022,"about_ca_topic_score_gemma":0.000062286716,"teacher_disagreement_score":0.8368855,"about_ca_system_score_codex":0.006431046,"about_ca_system_score_gemma":0.00857619,"threshold_uncertainty_score":0.99987334},"labels":[],"label_agreement":null},{"id":"W4386282232","doi":"10.1016/s2152-2650(23)00615-8","title":"POSTER: MDS-460 Efficacy of Pacritinib for Spleen, Symptoms, and Anemia Benefit in Myelofibrosis Patients Across the Cytopenic Spectrum","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Myelofibrosis; Ruxolitinib; Medicine; Anemia; Internal medicine; Bone marrow","score_opus":0.028470738352065237,"score_gpt":0.34542074319377575,"score_spread":0.3169500048417105,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282232","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99305606,0.00033827036,0.0000025636925,0.002763797,0.00036210808,0.0026592964,0.00036914254,0.00010377888,0.00034498356],"genre_scores_gemma":[0.9961427,0.00081097655,0.00016690198,0.0011945256,0.00032129633,0.00053866435,0.00036539033,0.00008542197,0.0003741133],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99579453,0.00016065541,0.0016664083,0.00097299373,0.0004992042,0.00090621697],"domain_scores_gemma":[0.9942929,0.0039059634,0.00038592968,0.0008268098,0.00022315838,0.00036523506],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000999104,0.00049265,0.0012886,0.0001452446,0.00025672163,0.00007461831,0.00032134017,0.000404511,0.000050309343],"category_scores_gemma":[0.0012941085,0.00034834983,0.00049308775,0.00068032375,0.00049273024,0.00013170899,0.00034725663,0.00026004275,0.00009686838],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017033399,0.0006030581,0.72902894,0.00016262208,0.00021393195,0.00005717607,0.00042032226,0.000004267803,0.00007680301,0.00046424582,0.0014542444,0.26581106],"study_design_scores_gemma":[0.01790345,0.0023695263,0.9724441,0.0003960034,0.00021998367,0.000031465075,0.00012711166,0.00018151996,0.0021198427,0.00039258617,0.0034897819,0.00032462995],"about_ca_topic_score_codex":0.00016702626,"about_ca_topic_score_gemma":0.00019090979,"teacher_disagreement_score":0.26548645,"about_ca_system_score_codex":0.000475325,"about_ca_system_score_gemma":0.00039576722,"threshold_uncertainty_score":0.9998968},"labels":[],"label_agreement":null},{"id":"W4386282236","doi":"10.1016/s2152-2650(23)00531-1","title":"POSTER: CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; Medicine; Rituximab; Oncology; Internal medicine; Leukemia; Chemotherapy; Lymphoma; Cyclophosphamide","score_opus":0.02448581812995936,"score_gpt":0.3018563122573838,"score_spread":0.2773704941274244,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282236","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99488926,0.0009923493,0.0000033599647,0.0001290781,0.00027139604,0.0029539543,0.00028494126,0.00025450072,0.00022115553],"genre_scores_gemma":[0.9946315,0.0010087726,0.00017345582,0.00068767165,0.00019901777,0.00044392524,0.00071943377,0.00022175997,0.0019144132],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925494,0.0003227541,0.0022506784,0.0018783102,0.00094476464,0.0020540818],"domain_scores_gemma":[0.9957748,0.0015848161,0.0003864488,0.0009701878,0.0003622703,0.0009214765],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013879329,0.000714743,0.0024843747,0.0004942681,0.0003188729,0.00045353262,0.00048787822,0.0008348173,0.00010169957],"category_scores_gemma":[0.0011918333,0.0008212072,0.00026716792,0.0012784118,0.001379228,0.00041110927,0.00052739115,0.0006450869,0.00004313626],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.001354249,0.00022649372,0.7303583,0.0010680453,0.00023500151,0.0049028983,0.00018695972,0.000014308839,0.00003621379,0.0000062993545,0.0014039698,0.26020727],"study_design_scores_gemma":[0.117220305,0.0024169148,0.87047696,0.0014792513,0.00019606779,0.0010789441,0.00011122737,0.0056698225,0.00006639186,0.00006734152,0.00043826154,0.00077851274],"about_ca_topic_score_codex":0.23966944,"about_ca_topic_score_gemma":0.5109057,"teacher_disagreement_score":0.27123624,"about_ca_system_score_codex":0.08946448,"about_ca_system_score_gemma":0.049571108,"threshold_uncertainty_score":0.99942386},"labels":[],"label_agreement":null},{"id":"W4386282271","doi":"10.1016/s2152-2650(23)00661-4","title":"POSTER: MPN-524 Reductions in Indolent Systemic Mastocytosis Biomarker Burden With Avapritinib in the Registrational, Double-Blind, Placebo-Controlled PIONEER Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Systemic mastocytosis; Double blind; Medicine; Placebo; Biomarker; Internal medicine; Pathology; Biology; Alternative medicine; Disease","score_opus":0.06310151596938657,"score_gpt":0.3214162376218272,"score_spread":0.2583147216524406,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282271","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9878194,0.0007537819,0.000008395883,0.0025071837,0.0014574389,0.0029577161,0.00004415191,0.00012806001,0.0043239105],"genre_scores_gemma":[0.9912565,0.00019837393,0.0000214395,0.00022485288,0.00041120063,0.001196116,0.00045279422,0.000043618973,0.006195139],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9952452,0.0010933202,0.0019339953,0.00083114457,0.00020464965,0.00069167704],"domain_scores_gemma":[0.9968297,0.0017089365,0.0004770061,0.00079277955,0.0001227365,0.00006886538],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0028622032,0.00040603252,0.0010456906,0.00046159566,0.00026761467,0.00008724863,0.00063062366,0.00072727306,0.00030167174],"category_scores_gemma":[0.000323016,0.00028236257,0.0003461124,0.0009521092,0.0005670461,0.00013519567,0.0001291367,0.00059081207,0.00093598466],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.93542093,0.0009279642,0.0029718645,0.00011650312,0.0006924411,0.00042130038,0.0015864474,0.00019498855,0.0073639737,0.002379717,0.0141197005,0.033804145],"study_design_scores_gemma":[0.8327363,0.0014927911,0.13445906,0.0004976896,0.00024983857,0.0007914695,0.001923978,0.00013047582,0.0002455528,0.00014192588,0.0265882,0.00074270956],"about_ca_topic_score_codex":0.00038137805,"about_ca_topic_score_gemma":0.0004584716,"teacher_disagreement_score":0.1314872,"about_ca_system_score_codex":0.00043781823,"about_ca_system_score_gemma":0.00092870236,"threshold_uncertainty_score":0.99996287},"labels":[],"label_agreement":null},{"id":"W4386282282","doi":"10.1016/s2152-2650(23)01349-6","title":"IBCL-098 TRANSCEND FL: Phase II Study Results of Lisocabtagene Maraleucel (Liso-Cel) in Patients With R/R Follicular Lymphoma (FL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Princess Margaret Cancer Centre","funders":"","keywords":"Follicular lymphoma; Follicular phase; Medicine; Internal medicine; Lymphoma","score_opus":0.029069847383775885,"score_gpt":0.3288922633345039,"score_spread":0.299822415950728,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282282","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9938868,0.00031569667,0.0000040806685,0.0005178326,0.0005100753,0.0030007926,0.00033496114,0.00031112303,0.0011185906],"genre_scores_gemma":[0.99648285,0.00029924655,0.00029693387,0.0004630385,0.00028142892,0.00034449206,0.00083620584,0.00016112202,0.0008346813],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919697,0.00047647773,0.0031189795,0.0017626958,0.0014823024,0.0011898667],"domain_scores_gemma":[0.99531335,0.00092667696,0.0007301653,0.0018441483,0.00040132532,0.000784318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014392853,0.00089676835,0.0023120584,0.0005812228,0.00026757744,0.000052346702,0.000554538,0.0005784618,0.000070816706],"category_scores_gemma":[0.0006573737,0.00069884706,0.0007792616,0.0019952953,0.00044445085,0.0002594116,0.00028060644,0.00022993238,0.00024246295],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015455311,0.03161439,0.5407746,0.00012078114,0.000978317,0.0023006913,0.0009511988,0.000029019198,0.00007062531,0.00003843249,0.0032725676,0.4043941],"study_design_scores_gemma":[0.17346969,0.01896493,0.80041075,0.00044193014,0.00070585025,0.000020329342,0.000331909,0.00028300245,0.0007866208,0.000031703592,0.0039880113,0.00056529045],"about_ca_topic_score_codex":0.000661426,"about_ca_topic_score_gemma":0.00020518206,"teacher_disagreement_score":0.4038288,"about_ca_system_score_codex":0.0015450967,"about_ca_system_score_gemma":0.0014432858,"threshold_uncertainty_score":0.9995463},"labels":[],"label_agreement":null},{"id":"W4386282286","doi":"10.1016/s2152-2650(23)00763-2","title":"POSTER: IBCL-489 Mosunetuzumab Retreatment Is Effective and Well-Tolerated in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; McGill University; Spinal Cord Injury BC; University of British Columbia","funders":"Universitat de Barcelona; Rigshospitalet; Universitair Medisch Centrum Groningen; Universiteit Leiden; Leids Universitair Medisch Centrum; University of California, Los Angeles; Memorial Sloan-Kettering Cancer Center; Karolinska Institutet; Gentofte Hospital; Rijksuniversiteit Groningen; Odense Universitetshospital; Helsingin Yliopisto","keywords":"Refractory (planetary science); Medicine; Lymphoma; Oncology; Internal medicine; Hodgkin lymphoma; Cancer research; Biology","score_opus":0.012633692421430935,"score_gpt":0.2837801952237903,"score_spread":0.27114650280235936,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282286","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924871,0.0003023068,0.0000012884234,0.0004460184,0.0004521868,0.00289575,0.00008212805,0.00031134943,0.0030218961],"genre_scores_gemma":[0.9937308,0.0007087184,0.0002452807,0.0017455453,0.00018785012,0.0005091343,0.0004882871,0.00017189808,0.002212479],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99430436,0.00038453253,0.0015849383,0.0017717478,0.00086566363,0.001088775],"domain_scores_gemma":[0.99554676,0.0016272323,0.0005024456,0.001230383,0.0002854873,0.00080766634],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006218383,0.0009345462,0.0017952736,0.00044008048,0.0002380537,0.00010359767,0.00025954616,0.00077453715,0.0001741869],"category_scores_gemma":[0.00028364785,0.00064443704,0.00035999043,0.0013725223,0.0004075479,0.00026478583,0.00028021386,0.0002601133,0.0010334982],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010885706,0.0034642373,0.62620455,0.00013819801,0.0004998097,0.002569306,0.0004879558,0.000002940417,0.000028712348,0.000006603869,0.005573812,0.35013816],"study_design_scores_gemma":[0.07547749,0.01221622,0.9040898,0.0007612445,0.00048927165,0.000069772235,0.00011413229,0.0004580971,0.0013833063,0.000025950805,0.0042543993,0.000660307],"about_ca_topic_score_codex":0.00050686294,"about_ca_topic_score_gemma":0.00007977115,"teacher_disagreement_score":0.34947783,"about_ca_system_score_codex":0.0037760113,"about_ca_system_score_gemma":0.0014595333,"threshold_uncertainty_score":0.9997443},"labels":[],"label_agreement":null},{"id":"W4386282297","doi":"10.1016/s2152-2650(23)01378-2","title":"MCL-467 Glofitamab Monotherapy Induces High Complete Response Rates in Patients With Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Mantle cell lymphoma; Refractory (planetary science); Internal medicine; Lymphoma; Medicine; Cancer research; Mantle (geology); Oncology; Biology; Geology; Geochemistry","score_opus":0.033724029113427985,"score_gpt":0.3111347993158181,"score_spread":0.27741077020239013,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9953359,0.00026283448,0.0000019057667,0.0008653219,0.00052055955,0.0017125438,0.00019471669,0.00052908325,0.0005771313],"genre_scores_gemma":[0.9938492,0.00050917617,0.0005945879,0.0015523591,0.00020804578,0.00030769105,0.0006765338,0.00020773365,0.002094681],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934664,0.00089176215,0.0018952703,0.0015678691,0.0009803402,0.0011983948],"domain_scores_gemma":[0.9937554,0.0031561048,0.0005907969,0.001468283,0.0003259354,0.0007034545],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0011066621,0.000887874,0.0017751172,0.00057599996,0.00025952817,0.00011138614,0.0004630827,0.00075483444,0.00023312206],"category_scores_gemma":[0.0006506467,0.0006206613,0.00039445705,0.0017698234,0.0004590622,0.00031022567,0.00018507581,0.0002751643,0.0012309109],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08156968,0.0056339954,0.7000755,0.00011453317,0.00051533245,0.002630109,0.00031748952,0.0000138363885,0.00058047863,0.00004201308,0.005885558,0.20262146],"study_design_scores_gemma":[0.07218253,0.007787916,0.90916353,0.00056685874,0.00021348633,0.000033824148,0.00013463158,0.00016650555,0.0022971157,0.00005811682,0.00670669,0.0006887651],"about_ca_topic_score_codex":0.00066390476,"about_ca_topic_score_gemma":0.0000652225,"teacher_disagreement_score":0.20908804,"about_ca_system_score_codex":0.002894449,"about_ca_system_score_gemma":0.0023260394,"threshold_uncertainty_score":0.9996245},"labels":[],"label_agreement":null},{"id":"W4386282299","doi":"10.1016/s2152-2650(23)00880-7","title":"POSTER: CT-107 Cost-Effectiveness of the Chimeric Antigen Receptor (CAR) T-Cell Treatments, Lisocabtagene Maraleucel (liso-cel) Versus Axicabtagene Ciloleucel (axicel), as Second-Line (2L) Treatment of Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital du Sacré-Cœur de Montréal","funders":"","keywords":"Chimeric antigen receptor; Lymphoma; Medicine; B-cell lymphoma; Cancer research; Virology; Immunology; Internal medicine; Immunotherapy; Cancer","score_opus":0.058699882457818923,"score_gpt":0.36835500546202554,"score_spread":0.3096551230042066,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282299","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792904,0.0029762045,0.000007947857,0.00023830004,0.0021666444,0.0046840757,0.00092326594,0.00029232033,0.0094208205],"genre_scores_gemma":[0.96003723,0.0068892376,0.00013972336,0.00027480657,0.00067892676,0.0005247976,0.0009999374,0.00033538326,0.030119946],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.9899285,0.0019178388,0.0026989426,0.0019422101,0.0016721445,0.0018404057],"domain_scores_gemma":[0.99035156,0.0037238945,0.0011841807,0.0031600164,0.0005866534,0.0009937093],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0022404462,0.0012716224,0.0030159024,0.0005548119,0.0003926021,0.000067007735,0.0012285112,0.00075348007,0.0027876752],"category_scores_gemma":[0.0004971044,0.00097427587,0.0024349913,0.0024737578,0.0010336037,0.00021021336,0.0007090423,0.0003965131,0.0012760385],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028561132,0.014252577,0.05100325,0.0011224145,0.0028328577,0.0008045891,0.0005084975,0.00002450465,0.5288144,0.0000511884,0.002257483,0.36976716],"study_design_scores_gemma":[0.066338725,0.00818862,0.40565202,0.00030599342,0.000721387,0.00008331766,0.00027214587,0.00025149458,0.47671577,0.00003237253,0.040776003,0.0006621578],"about_ca_topic_score_codex":0.00078070496,"about_ca_topic_score_gemma":0.000075885735,"teacher_disagreement_score":0.36910498,"about_ca_system_score_codex":0.0034250326,"about_ca_system_score_gemma":0.0034963097,"threshold_uncertainty_score":0.9995016},"labels":[],"label_agreement":null},{"id":"W4386282307","doi":"10.1016/s2152-2650(23)01052-2","title":"AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Calgary","funders":"","keywords":"Medicine; Cancer research","score_opus":0.060132127131103094,"score_gpt":0.4006586392529771,"score_spread":0.340526512121874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282307","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9742331,0.000081330596,0.00010388999,0.0010744312,0.0012391341,0.0013861655,0.0003415451,0.0005977668,0.020942632],"genre_scores_gemma":[0.9895855,0.0002512021,0.0024769004,0.00044885243,0.0011079822,0.00021004002,0.0007373597,0.00015159835,0.0050305305],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99290246,0.0002732591,0.0025524595,0.0013804329,0.0017007879,0.001190626],"domain_scores_gemma":[0.9929029,0.0035915594,0.0006367048,0.001205851,0.00090563786,0.0007573923],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0013250492,0.00058444624,0.0012617753,0.0005905185,0.00022218328,0.0001435952,0.0009276972,0.00068211684,0.0001531094],"category_scores_gemma":[0.010509335,0.00057437224,0.00070034515,0.0013407633,0.0012081988,0.00019362038,0.00065181765,0.0007576474,0.0007886176],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.025151502,0.007945866,0.05683823,0.0017011876,0.00151047,0.010856554,0.0014542458,0.00063684495,0.01910513,0.0005858666,0.04090685,0.83330727],"study_design_scores_gemma":[0.08840292,0.007946915,0.63932884,0.0027493013,0.0006447161,0.0076152203,0.0020695527,0.15877016,0.02253329,0.0004943224,0.067255944,0.0021887978],"about_ca_topic_score_codex":0.00019309769,"about_ca_topic_score_gemma":0.00011865571,"teacher_disagreement_score":0.83111846,"about_ca_system_score_codex":0.001188338,"about_ca_system_score_gemma":0.0040211813,"threshold_uncertainty_score":0.9999894},"labels":[],"label_agreement":null},{"id":"W4386282331","doi":"10.1016/s2152-2650(23)01457-x","title":"MM-493 Progression-Free Survival of Daratumumab vs Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Newly Diagnosed Multiple Myeloma Patients: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lenalidomide; Daratumumab; Bortezomib; Dexamethasone; Multiple myeloma; Medicine; Oncology; Internal medicine; Progression-free survival; Overall survival","score_opus":0.041909718688102546,"score_gpt":0.3558880232178257,"score_spread":0.31397830452972314,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282331","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9907518,0.002012803,0.000014119696,0.0008053872,0.00024087782,0.005550214,0.00021672869,0.00018844104,0.00021963175],"genre_scores_gemma":[0.9895882,0.007569188,0.0005311815,0.00027935865,0.00010914686,0.000767542,0.0009212835,0.000104972016,0.00012913843],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927809,0.0010459129,0.002277042,0.0012454668,0.0016743001,0.0009763267],"domain_scores_gemma":[0.993752,0.0030380294,0.00062182674,0.0013262661,0.00052119297,0.00074070983],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027797234,0.0006508339,0.002294925,0.0005243967,0.0001909147,0.000050135804,0.0005033623,0.0003295672,0.000048081452],"category_scores_gemma":[0.005089349,0.0004819394,0.00030007894,0.0017508856,0.0004285944,0.00030133856,0.00028881224,0.00049874326,0.000057988582],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01249652,0.0036699965,0.7731265,0.0010476185,0.0003819532,0.0015270001,0.00025869973,0.0000020183,0.000057205492,0.000018319506,0.0013886584,0.20602551],"study_design_scores_gemma":[0.09639259,0.0061297817,0.89066267,0.00415884,0.00034583514,0.000036077556,0.00019487488,0.0007827331,0.00029423766,0.000043526557,0.0005476222,0.00041123197],"about_ca_topic_score_codex":0.00061996584,"about_ca_topic_score_gemma":0.0007720758,"teacher_disagreement_score":0.20561427,"about_ca_system_score_codex":0.00052098226,"about_ca_system_score_gemma":0.0009116121,"threshold_uncertainty_score":0.99976325},"labels":[],"label_agreement":null},{"id":"W4386282346","doi":"10.1016/s2152-2650(23)00629-8","title":"POSTER: MPN-111 SVR (Spleen Volume Reduction) Predicts OS (Overall Survival) in MF (Myelofibrosis) Patients on PAC (Pacritinib) but Not BAT (Best Available Therapy): PERSIST-2 Landmark OS Analysis","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Myelofibrosis; Medicine; Spleen; Internal medicine; Bone marrow","score_opus":0.049535927681756665,"score_gpt":0.31279730629499675,"score_spread":0.26326137861324006,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98605376,0.00021453312,0.000002743185,0.0021131402,0.0012082934,0.0020032069,0.0005774841,0.00035205783,0.0074747675],"genre_scores_gemma":[0.9805405,0.0023860808,0.0001448004,0.0016951549,0.00091379875,0.00067704916,0.0020852203,0.00015737681,0.011399985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9920336,0.00084902113,0.002231602,0.0020748454,0.0014724744,0.0013384788],"domain_scores_gemma":[0.9948581,0.0015542671,0.0005443165,0.001558918,0.00056773465,0.0009166585],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0014284746,0.00096050184,0.0023258133,0.0008795968,0.00039941448,0.00018284118,0.00047792657,0.00076918496,0.0017115447],"category_scores_gemma":[0.0011460085,0.00081837655,0.0013494637,0.0021047662,0.00036631533,0.00035377365,0.00025961644,0.0005944679,0.004535677],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0047962647,0.0025054659,0.8717947,0.00009597115,0.0022783906,0.00045955522,0.00033558725,0.000059715632,0.00013617701,0.000058537724,0.022272898,0.09520673],"study_design_scores_gemma":[0.01570947,0.0043278113,0.95742416,0.00038791832,0.0010893294,0.000028537137,0.00019523856,0.0010785826,0.0009865077,0.000031004005,0.018010002,0.00073143904],"about_ca_topic_score_codex":0.0012649848,"about_ca_topic_score_gemma":0.0002763611,"teacher_disagreement_score":0.09447529,"about_ca_system_score_codex":0.0018158283,"about_ca_system_score_gemma":0.00090367877,"threshold_uncertainty_score":0.9994267},"labels":[],"label_agreement":null},{"id":"W4386282368","doi":"10.1016/s2152-2650(23)00484-6","title":"POSTER: AML-469 Ivosidenib + Azacitidine vs Placebo + Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Daiichi Sankyo Europe; College of Medicine, Catholic University of Korea; Universitätsklinikum Heidelberg; Catholic University of Korea; Fakultní nemocnice Hradec Králové; Johns Hopkins University; Duke Cancer Institute; University of Miami; Augusta University; University of Pennsylvania; Chang Gung Medical Foundation; Deutsches Krebsforschungszentrum; Seoul St. Mary's Hospital, Catholic University of Korea","keywords":"Azacitidine; Myeloid leukemia; Medicine; Placebo; Oncology; Term (time); Internal medicine; Biology; Pathology; Alternative medicine; Physics","score_opus":0.024503963590829358,"score_gpt":0.3143090550814487,"score_spread":0.28980509149061934,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282368","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869208,0.00014574645,0.000010882425,0.0032030544,0.00053660583,0.0066529573,0.0011937842,0.00074520713,0.00059098116],"genre_scores_gemma":[0.987729,0.00087205664,0.00023390022,0.0021689958,0.0009904054,0.0002958251,0.0060033426,0.0003386661,0.0013677959],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98714846,0.0016089149,0.0037685363,0.003057281,0.0022116993,0.0022051071],"domain_scores_gemma":[0.9847947,0.009053541,0.0008877285,0.003163842,0.0007265321,0.0013736953],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0035554452,0.0013986517,0.0027112926,0.00065503764,0.00065828394,0.0003197158,0.0015231828,0.0010572601,0.00021436169],"category_scores_gemma":[0.004003695,0.0009964781,0.00042337453,0.0031060139,0.0013788809,0.0005972824,0.0016850939,0.0022361018,0.00094352255],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088175535,0.0013676594,0.78173375,0.000059522346,0.0015074073,0.006726903,0.0011522945,0.00004924319,0.00019311055,0.000010901191,0.017046127,0.10197752],"study_design_scores_gemma":[0.14314519,0.004629173,0.8475153,0.00066222256,0.00074741564,0.00007694344,0.00039389753,0.00047993276,0.00022840916,0.000022695718,0.001166993,0.00093184074],"about_ca_topic_score_codex":0.0016716917,"about_ca_topic_score_gemma":0.0013016211,"teacher_disagreement_score":0.101045676,"about_ca_system_score_codex":0.004350088,"about_ca_system_score_gemma":0.0034170512,"threshold_uncertainty_score":0.9998764},"labels":[],"label_agreement":null},{"id":"W4386282375","doi":"10.1016/s2152-2650(23)01134-5","title":"CML-313 Post Hoc Analysis of Patient Responses by T315I Mutation Status From the 3-Year Update of the OPTIC Trial: A Dose-Optimization Study of 3 Starting Doses of Ponatinib","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Ponatinib; Medicine; Post hoc; Post-hoc analysis; Mutation; Oncology; Internal medicine; Genetics; Biology; Gene","score_opus":0.03633673717965375,"score_gpt":0.35773757400516276,"score_spread":0.321400836825509,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386282375","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965333,0.00025570046,0.000026086322,0.00024410355,0.00025251566,0.0019845483,0.0005777217,0.00004892764,0.00007712927],"genre_scores_gemma":[0.9984863,0.00022070858,0.00053773995,0.00012133064,0.00007154469,0.000061955216,0.00037245132,0.000055296903,0.0000727216],"study_design_codex":"randomized_trial","study_design_gemma":"observational","domain_scores_codex":[0.99192,0.001746698,0.003344908,0.0006458276,0.0018421242,0.0005004308],"domain_scores_gemma":[0.9857601,0.009267496,0.002137821,0.0015567475,0.0010935508,0.00018430676],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.0027212342,0.00030769708,0.0015199009,0.00042382197,0.00012280035,0.000022275324,0.0006038327,0.00025917625,0.00014845518],"category_scores_gemma":[0.011947218,0.00019767624,0.0006978766,0.0036852425,0.00075475255,0.00011646951,0.00047267173,0.0002512557,0.000008972368],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.4732482,0.009963822,0.10865129,0.0008967747,0.021490116,0.00027611273,0.031986706,0.09905496,0.0142863495,0.0003694069,0.0047873394,0.23498893],"study_design_scores_gemma":[0.1557224,0.010139421,0.6706206,0.00047042413,0.005077669,0.000005703808,0.018038513,0.13268371,0.0066405325,0.00010341288,0.00013941662,0.0003581816],"about_ca_topic_score_codex":0.004186009,"about_ca_topic_score_gemma":0.00017528313,"teacher_disagreement_score":0.56196934,"about_ca_system_score_codex":0.002557817,"about_ca_system_score_gemma":0.0078101447,"threshold_uncertainty_score":0.99781466},"labels":[],"label_agreement":null},{"id":"W4386301304","doi":"10.1016/s2152-2650(23)00685-7","title":"POSTER: HL-603 Hodgkin Lymphoma in Tripoli University Hospital Libya","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Hodgkin lymphoma; Medicine; Lymphoma; Ancient history; General surgery; Pediatrics; History; Internal medicine","score_opus":0.028993087539450898,"score_gpt":0.3081496081471979,"score_spread":0.279156520607747,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386301304","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9810335,0.00025479446,0.00000270926,0.0033022822,0.0011867074,0.00090991514,0.000080540136,0.0006206571,0.012608874],"genre_scores_gemma":[0.9917969,0.0012131049,0.00021378695,0.001264268,0.00058964203,0.000036906964,0.00023927515,0.00009584949,0.0045502833],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952343,0.00035096586,0.0012883054,0.0013102193,0.00066159584,0.0011545977],"domain_scores_gemma":[0.996278,0.0012146967,0.0003226575,0.001165019,0.00015725265,0.00086240063],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008480497,0.0006075129,0.0013700292,0.0005631077,0.00020830808,0.00006930158,0.0005095584,0.0007280109,0.00019372506],"category_scores_gemma":[0.0006809075,0.0005682619,0.000875546,0.0017325922,0.00045212943,0.00028083028,0.00045703637,0.00021449346,0.0032499698],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0009325988,0.0014616679,0.49103126,0.00005595243,0.00026748434,0.008074039,0.00023408995,0.0000031288055,0.000026166732,0.0008087182,0.015983107,0.4811218],"study_design_scores_gemma":[0.020464424,0.0014657198,0.91587067,0.00027304134,0.00023685014,0.0001603305,0.0002853917,0.0002841311,0.00033833866,0.00025942829,0.059815176,0.00054647186],"about_ca_topic_score_codex":0.0007935609,"about_ca_topic_score_gemma":0.000105477855,"teacher_disagreement_score":0.48057532,"about_ca_system_score_codex":0.0034707151,"about_ca_system_score_gemma":0.0020124544,"threshold_uncertainty_score":0.9996769},"labels":[],"label_agreement":null},{"id":"W4386331411","doi":"10.1016/s2152-2650(23)01443-x","title":"MM-364 Elranatamab, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, for Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Extended Follow-Up and Biweekly Administration From the MagnetisMM-3 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Antibody; Antigen; Bispecific antibody; CD3; Immunology; Cancer research; Monoclonal antibody; CD8","score_opus":0.034242861841062316,"score_gpt":0.33296083776315466,"score_spread":0.29871797592209237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386331411","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99106705,0.00039063167,0.0001243737,0.0006188416,0.0007710246,0.0058100796,0.0006269722,0.0003520636,0.00023898548],"genre_scores_gemma":[0.990724,0.000516738,0.0012131172,0.00026062073,0.00061821594,0.0004792313,0.004677144,0.00016301466,0.0013479106],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939626,0.00054770935,0.001517371,0.0016394221,0.0012927752,0.0010401532],"domain_scores_gemma":[0.9933517,0.003391741,0.0005551723,0.0014191042,0.0005602139,0.00072206726],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010190564,0.000734168,0.0011104079,0.00027089097,0.00075521995,0.00027248738,0.0004766774,0.00049548625,0.000097268916],"category_scores_gemma":[0.0015771368,0.0005011043,0.00039480656,0.0008355056,0.0004845855,0.00045018722,0.00024372741,0.00048097532,0.00029163327],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020807007,0.00279065,0.67840743,0.00009582618,0.00062483613,0.00048893807,0.0005004374,0.0000012320156,0.0011057811,0.000020004549,0.0050235623,0.2901343],"study_design_scores_gemma":[0.049660522,0.008760346,0.93139046,0.0001759676,0.00038460878,0.000017598983,0.0008650362,0.0017481864,0.0003646195,0.00011328282,0.0060070944,0.00051225873],"about_ca_topic_score_codex":0.00043489164,"about_ca_topic_score_gemma":0.00059884303,"teacher_disagreement_score":0.28962207,"about_ca_system_score_codex":0.00046859874,"about_ca_system_score_gemma":0.0011782119,"threshold_uncertainty_score":0.99974406},"labels":[],"label_agreement":null},{"id":"W4386331412","doi":"10.1016/s2152-2650(23)01119-9","title":"CLL-617 Long Term Outcomes and Secondary Malignancies in 673 Patients Treated With Oral Fludarabine and Intravenous Rituximab (FR) for Chronic Lymphocytic Leukemia (CLL) in British Columbia (BC), CanadaElys","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"St. Paul's Hospital; Vancouver General Hospital; BC Cancer Agency","funders":"","keywords":"Fludarabine; Chronic lymphocytic leukemia; Medicine; Rituximab; Oncology; Internal medicine; Immunology; Leukemia; Antibody; Chemotherapy; Cyclophosphamide","score_opus":0.025503224660656458,"score_gpt":0.30430110853862136,"score_spread":0.2787978838779649,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386331412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9950628,0.0009846614,0.0000057331094,0.0001095448,0.00026424188,0.0028554485,0.00024723777,0.00026036223,0.00020992503],"genre_scores_gemma":[0.9943855,0.0011382666,0.00025676715,0.000576373,0.00020967716,0.00049477955,0.00065223547,0.00021825702,0.0020681582],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925934,0.00031139015,0.0022134709,0.0018734159,0.0009524945,0.002055823],"domain_scores_gemma":[0.995744,0.0016508397,0.00037725325,0.000954576,0.00035069184,0.0009226533],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014595042,0.0007009571,0.0024845314,0.0004837306,0.0003265738,0.00042499075,0.0004785799,0.00083602587,0.00010981102],"category_scores_gemma":[0.0013696253,0.00080824306,0.0002625079,0.0013641801,0.0014539167,0.0003907753,0.000486646,0.00065630325,0.000042784315],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0011789581,0.00023146931,0.70644933,0.0010652794,0.00023484102,0.00468056,0.00016728319,0.00002534878,0.000032261356,0.000009736036,0.0017816552,0.2841433],"study_design_scores_gemma":[0.116513856,0.002069129,0.8677542,0.0013895521,0.00019053397,0.0008439902,0.00012495313,0.0096425535,0.000056252018,0.000088240144,0.00056045136,0.00076625415],"about_ca_topic_score_codex":0.25507253,"about_ca_topic_score_gemma":0.5310735,"teacher_disagreement_score":0.28337705,"about_ca_system_score_codex":0.094397016,"about_ca_system_score_gemma":0.05384675,"threshold_uncertainty_score":0.99943686},"labels":[],"label_agreement":null},{"id":"W4386331958","doi":"10.1016/s2152-2650(23)00453-6","title":"POSTER: AML-396 Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Initial Results of a Novel, Ongoing BPDCN International Registry Program","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Children's Hospital of Eastern Ontario; University of Calgary","funders":"","keywords":"Medicine; Oncology","score_opus":0.056434896633028454,"score_gpt":0.3946708101579323,"score_spread":0.33823591352490384,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386331958","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97367275,0.00008709679,0.0000616514,0.0012822496,0.0012668485,0.0014645184,0.00040492226,0.00058068894,0.021179298],"genre_scores_gemma":[0.9908946,0.00022309103,0.001551438,0.00055850187,0.0010321004,0.00018863821,0.0008317215,0.00015656793,0.0045633437],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.992788,0.00028954778,0.0026199452,0.0014040347,0.0016896911,0.0012087895],"domain_scores_gemma":[0.9929649,0.0034377773,0.0006572161,0.0012350618,0.0009399679,0.00076507777],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0012615471,0.0006061628,0.0012823319,0.0006104683,0.00021966499,0.00015935181,0.0009516158,0.00068936526,0.00014105381],"category_scores_gemma":[0.008827862,0.00059457455,0.0007136208,0.0012524902,0.0011479188,0.00020949065,0.0007225318,0.00075156474,0.00078118365],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.031149544,0.008097912,0.08056026,0.0018503054,0.0016142178,0.012384143,0.0017682875,0.0002889256,0.024886351,0.0003657348,0.03226051,0.8047738],"study_design_scores_gemma":[0.087105736,0.009205491,0.7448976,0.0028920043,0.00064617774,0.0097307535,0.0017091607,0.067717694,0.026836758,0.00034770404,0.046741787,0.0021691136],"about_ca_topic_score_codex":0.00019180855,"about_ca_topic_score_gemma":0.000121537414,"teacher_disagreement_score":0.8026047,"about_ca_system_score_codex":0.0011721579,"about_ca_system_score_gemma":0.0037459647,"threshold_uncertainty_score":0.99999684},"labels":[],"label_agreement":null},{"id":"W4386332154","doi":"10.1016/s2152-2650(23)01011-x","title":"AML-197 Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Myeloid leukemia; Medicine; Fms-Like Tyrosine Kinase 3; Tandem exon duplication; Tyrosine kinase; Leukemia; Haematopoiesis; Transplantation; Myeloid; Gene duplication; Hematopoietic stem cell transplantation; Oncology; Immunology; Cancer research; Internal medicine; Biology; Stem cell; Genetics; Gene; Mutation; Receptor","score_opus":0.02434578935180782,"score_gpt":0.3220667128557471,"score_spread":0.2977209235039393,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386332154","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99619025,0.00010036037,0.000060998012,0.00089276454,0.0002243801,0.0017412388,0.0007027233,0.00003420657,0.000053080545],"genre_scores_gemma":[0.99148446,0.0045426474,0.00023443317,0.0007905553,0.00014184558,0.00028657887,0.0023358413,0.000054540968,0.00012911328],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9953742,0.00051669014,0.0014585175,0.0012060925,0.00075910374,0.00068537035],"domain_scores_gemma":[0.9955089,0.0030196512,0.00030003817,0.0004663072,0.00036427862,0.00034081665],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011809985,0.00048582215,0.0010002472,0.0004782278,0.00017872806,0.00009189959,0.00026435702,0.00031971905,0.00000914261],"category_scores_gemma":[0.0002752638,0.00034250205,0.00022392924,0.00056076306,0.00033502598,0.00016537693,0.00008120025,0.00041267258,0.0000028951229],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026827184,0.00057633827,0.97345805,0.00010253346,0.0014056497,0.0006818797,0.00063172675,0.000027720826,0.000032322674,0.000017191802,0.00007661883,0.020307226],"study_design_scores_gemma":[0.036229435,0.0015468815,0.95720226,0.00037146168,0.0017064412,0.00008296704,0.00021596889,0.0021316595,0.00011756948,0.000021172727,0.00007171537,0.00030249954],"about_ca_topic_score_codex":0.049989935,"about_ca_topic_score_gemma":0.37563407,"teacher_disagreement_score":0.32564414,"about_ca_system_score_codex":0.0030566265,"about_ca_system_score_gemma":0.0017602143,"threshold_uncertainty_score":0.9999027},"labels":[],"label_agreement":null},{"id":"W4386525650","doi":"10.1016/j.clml.2023.08.020","title":"Evaluating Response Trends of Chlormethine/Mechlorethamine Gel in Patients With Stage I-IIA Mycosis Fungoides: Analysis of Individual Patient Data From a Randomized Controlled Phase II Study to Facilitate Optimal Treatment Experiences","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"European Academy of Dermatology and Venereology; Recordati Rare Diseases; ReCor Medical; Helsinn; Mallinckrodt Pharmaceuticals; Regeneron Pharmaceuticals; Helsinn Therapeutics; Sanofi","keywords":"Medicine; Mycosis fungoides; Post-hoc analysis; Internal medicine; Progressive disease; Randomized controlled trial; Stage (stratigraphy); Disease; Surgery; Lymphoma","score_opus":0.1717103885479401,"score_gpt":0.45512165747651456,"score_spread":0.2834112689285745,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386525650","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9916159,0.00015563141,0.000044437696,0.00010185884,0.00008245214,0.0056505846,0.0022428264,0.00007502673,0.000031280728],"genre_scores_gemma":[0.9944568,0.0000407309,0.0010527575,0.00008170496,0.000028264792,0.001387182,0.0024752365,0.000055566856,0.00042173572],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9866803,0.004024479,0.00413099,0.0016598352,0.0027417615,0.0007625899],"domain_scores_gemma":[0.9824609,0.013056776,0.0011315942,0.002074413,0.0007730573,0.0005032628],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0099260975,0.0006655044,0.006191646,0.002443569,0.00016857467,0.000049019363,0.0008320726,0.00021295557,0.00048727784],"category_scores_gemma":[0.018638365,0.00044526713,0.00089442986,0.0049596634,0.00070122484,0.00019145328,0.00097270287,0.00022225508,0.0000149770285],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.6885915,0.0087281745,0.104633115,0.000017837667,0.010336941,0.00016951066,0.055933025,0.0013234589,0.00022256456,4.7437376e-7,0.00003565602,0.13000776],"study_design_scores_gemma":[0.4502727,0.039592624,0.42514488,0.00009841676,0.0036264234,0.0000011755385,0.020726731,0.06002963,0.00020974904,0.0000019850038,0.000010822349,0.0002848299],"about_ca_topic_score_codex":0.0015804057,"about_ca_topic_score_gemma":0.00043396858,"teacher_disagreement_score":0.32051176,"about_ca_system_score_codex":0.00088440836,"about_ca_system_score_gemma":0.0017338706,"threshold_uncertainty_score":0.9997999},"labels":[],"label_agreement":null},{"id":"W4386697187","doi":"10.1016/j.clml.2023.09.003","title":"Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Janssen Pharmaceuticals; Janssen Scientific Affairs; Regeneron Pharmaceuticals; Celgene; Array BioPharma; Alnylam Pharmaceuticals; National Comprehensive Cancer Network; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Hazard ratio; Medicine; Lenalidomide; Daratumumab; Internal medicine; Multiple myeloma; Oncology; Progression-free survival; Population; Proportional hazards model; Confidence interval; Chemotherapy","score_opus":0.04650279661337501,"score_gpt":0.3550013715950573,"score_spread":0.30849857498168226,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4386697187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99248034,0.0013187458,0.000013594519,0.00041825324,0.00020939103,0.0050476626,0.00016751286,0.00014978406,0.00019472823],"genre_scores_gemma":[0.9942983,0.0032066605,0.0007611868,0.00009994588,0.00007418916,0.00060518784,0.0008008574,0.00009355098,0.00006015471],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9940795,0.0007215474,0.001606645,0.0010941427,0.0016576017,0.0008406036],"domain_scores_gemma":[0.9941743,0.0030633828,0.0005182357,0.0011448442,0.00046782562,0.0006314272],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018977713,0.0005837235,0.0018980701,0.00041538567,0.00016755848,0.000040306335,0.0003949497,0.0002500666,0.000028727742],"category_scores_gemma":[0.0029839375,0.0003986854,0.00019007218,0.0015986427,0.0004093767,0.00025863477,0.00020068603,0.00042805288,0.000031722],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037617467,0.0032973462,0.8019742,0.0007443742,0.0005207388,0.0014612051,0.00019194237,0.0000034309537,0.00002141338,0.000014078666,0.0004735424,0.15368031],"study_design_scores_gemma":[0.1669475,0.00805724,0.820308,0.0030012024,0.00039355847,0.000016993308,0.0001746323,0.0004256027,0.00013789414,0.000012495901,0.00018355055,0.00034127844],"about_ca_topic_score_codex":0.00048482508,"about_ca_topic_score_gemma":0.0011273886,"teacher_disagreement_score":0.15333903,"about_ca_system_score_codex":0.00045905414,"about_ca_system_score_gemma":0.0009132182,"threshold_uncertainty_score":0.9998465},"labels":[],"label_agreement":null},{"id":"W4387003560","doi":"10.1016/s2152-2650(23)01803-7","title":"P-185 Discovery of novel proteasome activators that enhance antigen presentation and trigger anti-myeloma T-cell immunity","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Proteasome; Multiple myeloma; Antigen presentation; Immunity; Antigen; Presentation (obstetrics); Cell; Immunology; Medicine; Cancer research; Cell biology; Chemistry; Biology; T cell; Immune system; Biochemistry","score_opus":0.03707939929249852,"score_gpt":0.3197582601650209,"score_spread":0.28267886087252236,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003560","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99667764,0.0003920721,0.000405269,0.00010720271,0.00032641177,0.00072937633,0.000107495216,0.00006590091,0.0011886597],"genre_scores_gemma":[0.99549395,0.0012776137,0.00043117933,0.00014597888,0.0003337795,0.000087107845,0.0002839305,0.00006102181,0.0018854521],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.997386,0.00027759105,0.0007628296,0.0007577069,0.00032629087,0.0004895962],"domain_scores_gemma":[0.998228,0.0002479486,0.00046486137,0.0007543854,0.00011783456,0.00018696811],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009021219,0.00034350943,0.00054377445,0.000100225865,0.00017609137,0.00007104808,0.0004295929,0.00049916323,0.000013020806],"category_scores_gemma":[0.0005307076,0.00032155428,0.00028922225,0.00035038427,0.00046551743,0.00005045663,0.00047567248,0.00020347786,0.000029200239],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00040833405,0.0002515646,0.035089646,0.0001530701,0.00009696759,0.000011698442,0.00009549419,0.000009338398,0.91580576,0.000091997805,0.0008453158,0.04714081],"study_design_scores_gemma":[0.0012883117,0.00025414256,0.44072556,0.000051998402,0.000018644552,0.000010017209,0.00007297759,0.00009559905,0.553941,0.0000775525,0.0032169593,0.0002471987],"about_ca_topic_score_codex":0.00006092646,"about_ca_topic_score_gemma":0.000006299634,"teacher_disagreement_score":0.40563592,"about_ca_system_score_codex":0.000055106284,"about_ca_system_score_gemma":0.00052136974,"threshold_uncertainty_score":0.99992365},"labels":[],"label_agreement":null},{"id":"W4387003616","doi":"10.1016/s2152-2650(23)01901-8","title":"P-283 Systematic literature review of prognostic factors for relapsed/refractory multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Multiple myeloma; Refractory (planetary science); Internal medicine; Medicine; Oncology; Biology","score_opus":0.056644533830111865,"score_gpt":0.3672240830086483,"score_spread":0.3105795491785364,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003616","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93724906,0.050103787,0.00006961709,0.00058653025,0.00094459864,0.009212158,0.0005135044,0.0006061664,0.0007145526],"genre_scores_gemma":[0.9550336,0.03583748,0.0011752832,0.00073121535,0.00049323804,0.0012190675,0.0020037664,0.00018614563,0.0033201803],"study_design_codex":"systematic_review","study_design_gemma":"observational","domain_scores_codex":[0.9933759,0.00058457983,0.00273539,0.0010777991,0.0011303569,0.0010959483],"domain_scores_gemma":[0.9866694,0.009116989,0.00084343227,0.0015197269,0.0009204376,0.00092998246],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0020769306,0.00067093037,0.0026492747,0.0004220127,0.00020927656,0.000057718167,0.00053480215,0.00063525647,0.00008185038],"category_scores_gemma":[0.033250332,0.0004813521,0.001487682,0.001527837,0.0003565863,0.00023466418,0.00022776327,0.000451817,0.00045146],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022300652,0.0014398841,0.20706497,0.6427859,0.002127748,0.0016786583,0.0003929241,0.0000017750191,0.00077360135,0.00026219804,0.026269069,0.11497322],"study_design_scores_gemma":[0.008602387,0.001987361,0.7949315,0.1877872,0.0008247754,0.00013395464,0.00011293279,0.0011757225,0.00053014903,0.00009939948,0.0033653146,0.000449359],"about_ca_topic_score_codex":0.000016233149,"about_ca_topic_score_gemma":0.0000075427906,"teacher_disagreement_score":0.5878665,"about_ca_system_score_codex":0.0006891901,"about_ca_system_score_gemma":0.0012809597,"threshold_uncertainty_score":0.9997638},"labels":[],"label_agreement":null},{"id":"W4387003657","doi":"10.1016/s2152-2650(23)01797-4","title":"P-179 Altered lipid metabolism in IMiD/CELMoD resistant multiple myeloma confers novel and targetable vulnerabilities","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Multiple myeloma; Metabolism; Lipid metabolism; Chemistry; Cancer research; Biology; Biochemistry; Medicine; Internal medicine","score_opus":0.06091220127442547,"score_gpt":0.34551812921428204,"score_spread":0.28460592793985656,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9924578,0.000856645,0.000040024366,0.0012922062,0.00078365125,0.0014664344,0.00024811973,0.00043016486,0.0024249747],"genre_scores_gemma":[0.9910737,0.000990933,0.00248012,0.0005904105,0.00087861076,0.0003266827,0.0004003972,0.00014114512,0.003117949],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933775,0.00045380733,0.0019129623,0.001574801,0.0009814501,0.0016994812],"domain_scores_gemma":[0.99426013,0.0026922785,0.00028725227,0.0012331149,0.00029659667,0.0012306318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002053584,0.00071229186,0.0018391509,0.0006283537,0.0003266335,0.00014805044,0.00040994308,0.00059343106,0.00020193576],"category_scores_gemma":[0.0046965056,0.00061011914,0.0005006075,0.0010927307,0.0009175547,0.00035214267,0.0004969533,0.0006648684,0.0004511938],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0145260785,0.0021263347,0.48915312,0.00091376493,0.0014311766,0.0026037171,0.0010658308,0.00008544266,0.031025525,0.0027141436,0.007922901,0.44643196],"study_design_scores_gemma":[0.02208123,0.00058709056,0.93825763,0.00025282003,0.00013503004,0.00009639598,0.00045928865,0.012688379,0.0019446241,0.00040427299,0.022549234,0.0005439938],"about_ca_topic_score_codex":0.0014307223,"about_ca_topic_score_gemma":0.00049045513,"teacher_disagreement_score":0.44910452,"about_ca_system_score_codex":0.0008738875,"about_ca_system_score_gemma":0.0016098457,"threshold_uncertainty_score":0.99963504},"labels":[],"label_agreement":null},{"id":"W4387003693","doi":"10.1016/s2152-2650(23)01900-6","title":"P-282 Ranking importance of prognostic factors for relapsed/refractory multiple myeloma (RRMM): international physician panel consensus following a systematic review of the literature","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Multiple myeloma; Medicine; Ranking (information retrieval); Oncology; Family medicine; Internal medicine; Computer science; Information retrieval","score_opus":0.10684521102053852,"score_gpt":0.39988145775982925,"score_spread":0.29303624673929074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003693","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.011909872,0.9721272,0.000007971509,0.000083662926,0.0015881793,0.0127730025,0.0012289687,0.0001344321,0.0001467156],"genre_scores_gemma":[0.01492522,0.9795723,0.00040744324,0.0002761882,0.0005073021,0.0014645812,0.0017750786,0.00029155845,0.00078033353],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9894715,0.001129889,0.0056411917,0.0012694345,0.0016256871,0.0008623119],"domain_scores_gemma":[0.9779867,0.014388996,0.004332592,0.0020386968,0.0008331383,0.00041987246],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022789014,0.0011254553,0.008002356,0.00035776748,0.00019378726,0.00005713636,0.0013301218,0.00096383085,0.000014885548],"category_scores_gemma":[0.03628364,0.00067867263,0.006561903,0.001317519,0.0004439028,0.00011078242,0.00044482455,0.0008962637,0.000040295603],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00020625489,0.00039881194,0.0048370874,0.81646365,0.0052210665,0.00034182446,0.00008890979,1.2407699e-7,0.0000055645296,0.000035461802,0.00051072385,0.17189054],"study_design_scores_gemma":[0.0046841507,0.0004434299,0.020075265,0.9526088,0.008859766,0.00011897762,0.0000612037,0.00007044833,0.000013710239,0.000059515816,0.012446825,0.00055788533],"about_ca_topic_score_codex":0.000021709398,"about_ca_topic_score_gemma":0.000013350809,"teacher_disagreement_score":0.17133266,"about_ca_system_score_codex":0.0013174078,"about_ca_system_score_gemma":0.003496606,"threshold_uncertainty_score":0.99956644},"labels":[],"label_agreement":null},{"id":"W4387003704","doi":"10.1016/s2152-2650(23)01968-7","title":"P-350 Single cell analysis identifies new insights into the development of venetoclax resistant in multiple myeloma patients","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Venetoclax; Multiple myeloma; Medicine; Immunology; Leukemia; Chronic lymphocytic leukemia","score_opus":0.054993687948832415,"score_gpt":0.33175393006872256,"score_spread":0.27676024211989014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003704","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9970694,0.00041591545,0.000038040154,0.00017943152,0.00025223612,0.0009485112,0.00001259096,0.00012360215,0.00096026936],"genre_scores_gemma":[0.9942264,0.00012717456,0.0016503824,0.00011998948,0.0001529809,0.000097929034,0.0004484104,0.000062446066,0.0031143127],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99430555,0.00040276046,0.0022719603,0.0009480587,0.0012403205,0.0008313776],"domain_scores_gemma":[0.99569285,0.0016901405,0.00048669832,0.0011672466,0.00032965865,0.0006333975],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009667265,0.0004506109,0.0012249824,0.0008901508,0.00029850626,0.00006175217,0.00059247564,0.00035358217,0.000082336446],"category_scores_gemma":[0.001592363,0.00032119048,0.0006417065,0.0034365007,0.00039727223,0.00015912084,0.00049426325,0.00031322066,0.0004924726],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00256937,0.0009267189,0.562149,0.00020867329,0.001383792,0.00032030826,0.0051492215,0.000084960186,0.004767571,0.000019785344,0.001205185,0.42121542],"study_design_scores_gemma":[0.0081692515,0.00048020823,0.97000146,0.00016864631,0.00034816688,0.0000010856717,0.00049481756,0.0022545925,0.012862605,0.00023294665,0.0046912297,0.00029499814],"about_ca_topic_score_codex":0.0019743724,"about_ca_topic_score_gemma":0.006048848,"teacher_disagreement_score":0.4209204,"about_ca_system_score_codex":0.0020290376,"about_ca_system_score_gemma":0.0028741914,"threshold_uncertainty_score":0.999924},"labels":[],"label_agreement":null},{"id":"W4387003729","doi":"10.1016/s2152-2650(23)01802-5","title":"P-184 Lenalidomide: rash or no rash, that is the question","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Hospital Foundation","funders":"","keywords":"Rash; Lenalidomide; Dermatology; Medicine; Internal medicine; Multiple myeloma","score_opus":0.08374022546651005,"score_gpt":0.4219831253059677,"score_spread":0.33824289983945766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003729","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97607046,0.00023890243,0.000022332728,0.015384624,0.0014024018,0.0011676339,0.000037386886,0.000779237,0.0048970208],"genre_scores_gemma":[0.9341734,0.0029843478,0.0003637453,0.009528898,0.0020720856,0.00020696488,0.000078145364,0.00014994295,0.050442494],"study_design_codex":"not_applicable","study_design_gemma":"observational","domain_scores_codex":[0.9948548,0.0006603208,0.0011262537,0.0009951668,0.0012322037,0.0011312439],"domain_scores_gemma":[0.9932464,0.0040274914,0.0002986195,0.0014348979,0.00033904667,0.00065358495],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016677309,0.0004390839,0.00088981335,0.00020210823,0.00032866833,0.00012019975,0.000731071,0.00009797302,0.0010832293],"category_scores_gemma":[0.008626565,0.0002652014,0.0005539258,0.0010949547,0.00086058024,0.00028653388,0.00051447377,0.0006937623,0.014069448],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031342318,0.00021918384,0.06307704,0.0002529611,0.0002560421,0.011147773,0.00007396768,0.0000075303064,0.0013126256,0.0004488501,0.48120302,0.43886676],"study_design_scores_gemma":[0.005861604,0.0007105601,0.69545174,0.00028124236,0.00012786745,0.0015246369,0.00015157445,0.0009773306,0.00501884,0.0010854219,0.28845382,0.0003553302],"about_ca_topic_score_codex":0.00010355556,"about_ca_topic_score_gemma":0.000041949213,"teacher_disagreement_score":0.6323747,"about_ca_system_score_codex":0.0005553967,"about_ca_system_score_gemma":0.0014200602,"threshold_uncertainty_score":0.99998003},"labels":[],"label_agreement":null},{"id":"W4387003741","doi":"10.1016/s2152-2650(23)01902-x","title":"P-284 Carfilzomib, lenalidomide, and dexamethasone combination chemotherapy in the real-world 364 Asian multiple myeloma patients on behalf of the Korean multiple myeloma working party (KMM2201 study)","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Lenalidomide; Carfilzomib; Multiple myeloma; Dexamethasone; Medicine; Oncology; Internal medicine; Chemotherapy","score_opus":0.06025833011488428,"score_gpt":0.3517906386139641,"score_spread":0.2915323084990798,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003741","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9908691,0.000069936264,0.0000032760763,0.0015674153,0.0004556781,0.0045588,0.000071949326,0.00016843074,0.0022354366],"genre_scores_gemma":[0.99716663,0.0002794758,0.00018989446,0.00064004236,0.00028663917,0.0004676433,0.00023142663,0.00013530307,0.0006029318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919328,0.0017782826,0.0020078097,0.0013150378,0.001776998,0.001189056],"domain_scores_gemma":[0.9918111,0.0048988177,0.0007421378,0.0017382503,0.00032647586,0.00048322522],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030507392,0.0007429232,0.0014827416,0.0005827895,0.0005098193,0.00011829839,0.0008945177,0.00041268268,0.000041866657],"category_scores_gemma":[0.0036169442,0.00046930872,0.0005667738,0.0023630618,0.00078302185,0.0001945361,0.00042309097,0.0008335112,0.00009137095],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0028972118,0.002236497,0.68058753,0.000057886828,0.00026815923,0.00016137323,0.0011457383,0.0000067687442,0.00012430166,0.00007810041,0.0006380998,0.3117983],"study_design_scores_gemma":[0.0392221,0.0019278947,0.95202655,0.00046156204,0.00016346974,0.000013039363,0.0010661118,0.002383509,0.0011419079,0.00020413719,0.0009845922,0.00040512826],"about_ca_topic_score_codex":0.001988479,"about_ca_topic_score_gemma":0.0041861283,"teacher_disagreement_score":0.31139317,"about_ca_system_score_codex":0.0009549922,"about_ca_system_score_gemma":0.0005770409,"threshold_uncertainty_score":0.9997759},"labels":[],"label_agreement":null},{"id":"W4387003746","doi":"10.1016/s2152-2650(23)01822-0","title":"P-204 Targeting TENT5C-associated regulation of antibody synthesis against multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Multiple myeloma; Antibody; Cancer research; Medicine; Immunology","score_opus":0.04588058022428575,"score_gpt":0.35794465009087356,"score_spread":0.3120640698665878,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003746","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99440384,0.00018550773,0.000047399873,0.00047416345,0.0004328805,0.0010010124,0.00014888289,0.00059971365,0.0027066146],"genre_scores_gemma":[0.9945935,0.00054560165,0.001054547,0.00019070265,0.00042256684,0.0001066833,0.0014507684,0.00013065644,0.0015049839],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99396306,0.00057358085,0.002039677,0.001026537,0.0012199727,0.0011771722],"domain_scores_gemma":[0.99306995,0.0039139804,0.00071280095,0.000973687,0.00057601597,0.00075357425],"candidate_categories":["metaresearch","metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0021196692,0.0005154765,0.001449269,0.0004823556,0.0003094302,0.000050092498,0.0003970389,0.000646229,0.0001911452],"category_scores_gemma":[0.017068285,0.0004505737,0.0008531516,0.0015676594,0.00048458413,0.00022627387,0.00031317936,0.00035256537,0.0010134717],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012477987,0.00068373955,0.5064601,0.00019678542,0.0008273451,0.000560217,0.00010182874,0.000046327485,0.03945436,0.0000494889,0.004502617,0.44586942],"study_design_scores_gemma":[0.0067713982,0.0004326976,0.95223075,0.00059051585,0.00020713039,0.000018407209,0.00015504402,0.024611104,0.012819453,0.000112296104,0.0016788099,0.00037238724],"about_ca_topic_score_codex":0.0001858035,"about_ca_topic_score_gemma":0.0000244732,"teacher_disagreement_score":0.44577068,"about_ca_system_score_codex":0.0010092611,"about_ca_system_score_gemma":0.0010373511,"threshold_uncertainty_score":0.9997946},"labels":[],"label_agreement":null},{"id":"W4387003753","doi":"10.1016/s2152-2650(23)01908-0","title":"P-290 Updated long-term follow-up results of a phase 1b/2 study (FUMANBA-1) in patients with relapsed/refractory multiple myeloma (RRMM) treated with equecabtagene autoleucel","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Saskatchewan Cancer Agency; Memorial University of Newfoundland; University of Ottawa; McGill University; Princess Margaret Cancer Centre; Vancouver General Hospital; Micropharma (Canada); Nova Scotia Health Authority; Alberta Health Services; BC Cancer Agency; McMaster University; London Health Sciences Centre; Western University","funders":"","keywords":"Refractory (planetary science); Medicine; Term (time); Multiple myeloma; Phase (matter); Oncology; Internal medicine; Materials science; Physics; Metallurgy","score_opus":0.04524721464682365,"score_gpt":0.35010331379787735,"score_spread":0.3048560991510537,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003753","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934437,0.00007400265,0.000011228508,0.00008858895,0.00023844714,0.0045250338,0.00047667418,0.0005479808,0.00059428695],"genre_scores_gemma":[0.99225765,0.00007151442,0.00028283277,0.00010151388,0.00015295928,0.00034810728,0.0038649335,0.00024585062,0.0026746446],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9905058,0.0008430862,0.002886906,0.002088142,0.0019940687,0.0016820092],"domain_scores_gemma":[0.99330914,0.0013695444,0.0009807313,0.002261638,0.0008452699,0.0012336699],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013961963,0.0010694914,0.0024025263,0.0010266205,0.00025701945,0.000075187825,0.0006655844,0.0006280326,0.00011201247],"category_scores_gemma":[0.001594294,0.000773123,0.00045273305,0.0027400744,0.00072114955,0.00041482586,0.00037135938,0.00077180023,0.00038689197],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.088204235,0.014704966,0.72751063,0.00012135259,0.001253481,0.0054072374,0.00036760897,0.000010647556,0.0002329515,0.0000019747438,0.0007781858,0.1614067],"study_design_scores_gemma":[0.25926402,0.019231997,0.71801186,0.0005728315,0.00041856978,0.000025211571,0.00015360334,0.00081363105,0.00076318206,0.0000034723362,0.00018187714,0.00055973075],"about_ca_topic_score_codex":0.0008519493,"about_ca_topic_score_gemma":0.0011572272,"teacher_disagreement_score":0.17105977,"about_ca_system_score_codex":0.0015832694,"about_ca_system_score_gemma":0.0019878258,"threshold_uncertainty_score":0.99947196},"labels":[],"label_agreement":null},{"id":"W4387003780","doi":"10.1016/s2152-2650(23)01884-0","title":"P-266 Pre-clinical characterization of SAR442257, a CD38xCD28xCD3 trispecific T-cell engager in relapsed/refractory multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Multiple myeloma; Refractory (planetary science); Cancer research; Medicine; Internal medicine; Materials science","score_opus":0.06391069332254784,"score_gpt":0.36361574012151027,"score_spread":0.2997050467989624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003780","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99306166,0.00024171708,0.000044907858,0.00034816115,0.0011143076,0.0020191183,0.00018550962,0.0004127595,0.0025718533],"genre_scores_gemma":[0.98777944,0.0018673058,0.00060111657,0.0003375825,0.0009538843,0.00022283584,0.0012345151,0.00018602457,0.006817317],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9900057,0.0015817807,0.004030774,0.0016724572,0.0012974131,0.0014118839],"domain_scores_gemma":[0.9906513,0.005122084,0.00093475386,0.0017548789,0.000410251,0.0011267008],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003946286,0.00072068215,0.0021886106,0.00084681594,0.00020303998,0.00005937327,0.00064056495,0.001211772,0.00051078096],"category_scores_gemma":[0.006331859,0.0006483749,0.0011042049,0.0019164495,0.0007681027,0.00028913934,0.00042526895,0.0013078958,0.0020366972],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0058463197,0.0025186385,0.5541511,0.00026559478,0.00027185894,0.0014471076,0.0002773884,0.0000056181702,0.019702017,0.000027095015,0.0023499238,0.41313735],"study_design_scores_gemma":[0.026487827,0.0020109774,0.94708025,0.0004041589,0.00013520037,0.00004307815,0.00010208582,0.0046204645,0.0040124767,0.0000635879,0.014531239,0.0005086493],"about_ca_topic_score_codex":0.00018129937,"about_ca_topic_score_gemma":0.000060996925,"teacher_disagreement_score":0.41262868,"about_ca_system_score_codex":0.00096376624,"about_ca_system_score_gemma":0.0020282099,"threshold_uncertainty_score":0.9995968},"labels":[],"label_agreement":null},{"id":"W4387003819","doi":"10.1016/s2152-2650(23)01939-0","title":"P-321 Real-world outcomes in myeloma patients with t(11;14): a matched comparison using the Canadian myeloma research group national clinical database","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Saskatchewan Cancer Agency; Memorial University of Newfoundland; McGill University; Princess Margaret Cancer Centre; Vancouver General Hospital; Micropharma (Canada); Nova Scotia Health Authority; Saint John Regional Hospital; Alberta Health Services; BC Cancer Agency; Canadiana.org; Western University; University of British Columbia; McMaster University; London Health Sciences Centre","funders":"","keywords":"Multiple myeloma; Medicine; Database; National database; Internal medicine; Oncology; Computer science","score_opus":0.19534024444972697,"score_gpt":0.47128722238003096,"score_spread":0.275946977930304,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003819","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9890481,0.000058501122,0.0000101307805,0.0031090912,0.0006346208,0.0028472077,0.00037916042,0.00023892058,0.0036742715],"genre_scores_gemma":[0.9923793,0.00010124011,0.0019034847,0.0010104682,0.00070304325,0.00030755895,0.0017843711,0.00018787735,0.0016226354],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9856909,0.0024303228,0.0031326658,0.0019213074,0.0041217306,0.0027030704],"domain_scores_gemma":[0.98709,0.0065498482,0.00051431975,0.0019659996,0.0015220935,0.0023577556],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.009815804,0.00079340546,0.002065813,0.0017814306,0.001199486,0.00029452436,0.0011784432,0.00071777427,0.00023784679],"category_scores_gemma":[0.006573708,0.00054502505,0.00059873227,0.004269814,0.0016429097,0.00043361456,0.00075865525,0.0019685873,0.001050578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0021701844,0.0012484012,0.92864627,0.0000789744,0.0004913715,0.0014275333,0.00015060481,0.000021022324,0.000015094899,0.00073116797,0.008395382,0.05662401],"study_design_scores_gemma":[0.016647615,0.0008941911,0.9653737,0.00041908075,0.00012359006,0.000028619255,0.00027142762,0.008289782,0.000021570486,0.00027728634,0.0071080825,0.00054508244],"about_ca_topic_score_codex":0.117068626,"about_ca_topic_score_gemma":0.5669636,"teacher_disagreement_score":0.449895,"about_ca_system_score_codex":0.0063161203,"about_ca_system_score_gemma":0.009878502,"threshold_uncertainty_score":0.99972725},"labels":[],"label_agreement":null},{"id":"W4387003971","doi":"10.1016/s2152-2650(23)01733-0","title":"P-115 Progression-free survival of daratumumab vs. bortezomib triplet combination with lenalidomide and dexamethasone in transplant ineligible newly diagnosed multiple myeloma patients: a chart review study","year":2023,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Lenalidomide; Daratumumab; Bortezomib; Dexamethasone; Medicine; Multiple myeloma; Oncology; Internal medicine","score_opus":0.081715692748588,"score_gpt":0.40215142749487637,"score_spread":0.3204357347462884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003971","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.1905687,0.7915834,0.000007900098,0.00016886836,0.00036477981,0.016215151,0.0007534403,0.00020723042,0.00013053996],"genre_scores_gemma":[0.030879017,0.96274024,0.00042669944,0.000121357836,0.00018689851,0.0025868916,0.002601131,0.00029480807,0.00016296357],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98702806,0.0024501604,0.004941972,0.0021054503,0.0022313292,0.0012430528],"domain_scores_gemma":[0.9878596,0.0063883434,0.0018874585,0.0022063467,0.00064832385,0.0010099424],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003895683,0.0014608755,0.008705326,0.00090212026,0.00019393908,0.000078056015,0.0009280711,0.0008874708,0.0000403331],"category_scores_gemma":[0.007697619,0.0010106483,0.0010201108,0.002287124,0.0005474934,0.00026945525,0.0005025396,0.0011524518,0.00007981807],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005067479,0.0046861414,0.15647942,0.03630191,0.0014474645,0.002378472,0.00009901244,1.875392e-7,2.403437e-7,0.000011407414,0.0009842647,0.792544],"study_design_scores_gemma":[0.088226,0.007647293,0.71315795,0.14768247,0.00377521,0.00012898426,0.00007401127,0.00009312541,0.000003610547,0.000021763472,0.038143642,0.0010459261],"about_ca_topic_score_codex":0.00059015176,"about_ca_topic_score_gemma":0.00089111226,"teacher_disagreement_score":0.79149806,"about_ca_system_score_codex":0.0012277542,"about_ca_system_score_gemma":0.0030521767,"threshold_uncertainty_score":0.9998141},"labels":[],"label_agreement":null},{"id":"W4387003976","doi":"10.1016/s2152-2650(23)01646-4","title":"P-028 Canadian-made single domain antibody (sdAb) BCMA CAR-T cells for multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Single-domain antibody; Multiple myeloma; Antibody; Domain (mathematical analysis); Medicine; Immunology; Mathematics","score_opus":0.05718393129945083,"score_gpt":0.3656824003563769,"score_spread":0.3084984690569261,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387003976","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982141,0.00025490214,0.00015825669,0.002510129,0.0022740131,0.0025975797,0.00038863724,0.00065796165,0.009017484],"genre_scores_gemma":[0.9473288,0.00033943742,0.0026089158,0.0028469835,0.003065002,0.0003144137,0.0011270102,0.00039040498,0.041979015],"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","domain_scores_codex":[0.99255145,0.0003999592,0.0018356332,0.001650656,0.0010680135,0.002494286],"domain_scores_gemma":[0.99041945,0.004590516,0.00029900688,0.001820821,0.0005165489,0.0023536787],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0026640112,0.00072605576,0.0016030294,0.00074594445,0.0005161622,0.00017087442,0.0008628934,0.00110853,0.0015041347],"category_scores_gemma":[0.0027769164,0.00070414855,0.0012202687,0.0016088522,0.00077199127,0.00018855206,0.00029773705,0.00067325955,0.0033351958],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020656923,0.00034625488,0.022674708,0.0002675686,0.00047453117,0.0016679271,0.00034396283,0.000019565818,0.45059925,0.00022086609,0.071964085,0.44935557],"study_design_scores_gemma":[0.010434924,0.001499564,0.4660397,0.00023970036,0.0001474814,0.00015443777,0.00031892039,0.0030273427,0.027752124,0.000641632,0.4889501,0.00079408183],"about_ca_topic_score_codex":0.0083052665,"about_ca_topic_score_gemma":0.008634136,"teacher_disagreement_score":0.4485615,"about_ca_system_score_codex":0.0033943292,"about_ca_system_score_gemma":0.0050632246,"threshold_uncertainty_score":0.999541},"labels":[],"label_agreement":null},{"id":"W4387004108","doi":"10.1016/s2152-2650(23)01644-0","title":"P-026 Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; Terry Fox Research Institute; University of Calgary","funders":"","keywords":"Chimeric antigen receptor; Cart; Multiple myeloma; Refractory (planetary science); Medicine; Antigen; Receptor; Cancer research; Virology; Immunotherapy; Immunology; Internal medicine; Biology; Immune system","score_opus":0.04908132357785517,"score_gpt":0.34190956089097674,"score_spread":0.2928282373131216,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387004108","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99322397,0.0018934039,0.00008689436,0.0007309932,0.00037599067,0.0031236438,0.00015344941,0.00012212202,0.0002895159],"genre_scores_gemma":[0.9789863,0.01575219,0.0011441788,0.0001176509,0.00051634584,0.000118219126,0.00015310099,0.00013154675,0.0030804272],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958384,0.00023069016,0.0016398759,0.0010183685,0.00059049716,0.0006821476],"domain_scores_gemma":[0.9912067,0.0062792897,0.00053715875,0.0012210048,0.00035736896,0.0003984536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015621743,0.0004624093,0.0015375824,0.00022220491,0.00022035411,0.00002739835,0.00030820994,0.00041579007,0.00010817182],"category_scores_gemma":[0.0016623785,0.0003247563,0.0005314986,0.0007635352,0.0011363474,0.00008653552,0.00016914961,0.00024050356,0.000030296185],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009604884,0.0012883141,0.0283079,0.00027984724,0.0005393098,0.000020361998,0.00061548065,0.0000115835865,0.34071088,0.000019964578,0.0007044983,0.617897],"study_design_scores_gemma":[0.028085236,0.0056090527,0.84720683,0.00019704971,0.00025665434,0.000035469246,0.00023494563,0.0035276841,0.053324234,0.000009301094,0.061230037,0.00028348257],"about_ca_topic_score_codex":0.00016128435,"about_ca_topic_score_gemma":0.000016370168,"teacher_disagreement_score":0.818899,"about_ca_system_score_codex":0.0004034707,"about_ca_system_score_gemma":0.0010802919,"threshold_uncertainty_score":0.9999204},"labels":[],"label_agreement":null},{"id":"W4387004140","doi":"10.1016/s2152-2650(23)01640-3","title":"P-022 Development of trogocytosis resistant CAR-NK for multiple myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"National Research Council Canada; University of Ottawa; Ottawa Hospital","funders":"University of Texas MD Anderson Cancer Center; Université de Liège; University of Arkansas for Medical Sciences","keywords":"Multiple myeloma; Biology; Immunology","score_opus":0.08841249716564327,"score_gpt":0.37913653795428,"score_spread":0.29072404078863673,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387004140","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9947048,0.0002892552,0.0002738061,0.00042665825,0.00044526547,0.0019750742,0.00022124282,0.0003963914,0.0012675063],"genre_scores_gemma":[0.9768526,0.0001945243,0.017712427,0.00022822038,0.00043257384,0.00068684085,0.0007230003,0.00013789372,0.0030319518],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99404573,0.00021624196,0.0022409973,0.0011245122,0.0010665864,0.0013059119],"domain_scores_gemma":[0.99414015,0.002774334,0.00045062153,0.0011333071,0.0005338606,0.00096773787],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017036122,0.00053988275,0.0014937222,0.00043986263,0.0003906311,0.000041792613,0.0004871622,0.0004912053,0.00012368627],"category_scores_gemma":[0.0039191456,0.00045976893,0.0008990723,0.0009794513,0.00043057266,0.00012755839,0.0003455776,0.00025899586,0.0005820033],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008801049,0.000713553,0.091038145,0.00070267566,0.0011746711,0.0004381625,0.00037989064,0.0000056120475,0.012121829,0.00020248536,0.007905005,0.87651694],"study_design_scores_gemma":[0.015831165,0.0012543354,0.9059233,0.00033216868,0.00019510962,0.000030523366,0.00024145425,0.002306968,0.025890734,0.000161543,0.047418326,0.00041434835],"about_ca_topic_score_codex":0.00009765379,"about_ca_topic_score_gemma":0.0001245704,"teacher_disagreement_score":0.87610257,"about_ca_system_score_codex":0.0013122397,"about_ca_system_score_gemma":0.0032224776,"threshold_uncertainty_score":0.9997854},"labels":[],"label_agreement":null},{"id":"W4387124851","doi":"10.1016/j.clml.2023.09.007","title":"Indirect Treatment Comparisons of Mosunetuzumab With Third- and Later-Line Treatments for Relapsed/Refractory Follicular Lymphoma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"F. Hoffmann-La Roche","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Oncology; Internal medicine; Follicular phase; Rituximab; Lymphoma; Cancer research","score_opus":0.05146645465287799,"score_gpt":0.3362929252474394,"score_spread":0.28482647059456145,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4387124851","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939867,0.0014160066,0.000029908393,0.0005515954,0.00030148236,0.0020555598,0.00025538902,0.00035313368,0.0010502255],"genre_scores_gemma":[0.9908988,0.002261342,0.002364877,0.00028320967,0.0002717144,0.0007517386,0.00067433936,0.0001280612,0.0023659477],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9958731,0.00016875865,0.0014511102,0.0011669517,0.0005276871,0.0008124139],"domain_scores_gemma":[0.99591786,0.0016210807,0.0005680844,0.0010217904,0.00021961163,0.00065159536],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00043626383,0.0007473281,0.002074536,0.00029103627,0.00025555197,0.000047930134,0.00019381435,0.00050881057,0.000028513083],"category_scores_gemma":[0.00020584514,0.00050924515,0.0007145626,0.00060484785,0.00047826022,0.00014299333,0.0001167214,0.000079895304,0.00011932351],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005263088,0.004217955,0.33467087,0.00016869386,0.0044980557,0.00096657424,0.00033321595,0.000029249273,0.00029402447,0.00023297816,0.00492012,0.6444052],"study_design_scores_gemma":[0.045303024,0.013080963,0.90657043,0.00036966347,0.0025047078,0.00021352421,0.00014019526,0.0012712498,0.0067133773,0.00012679228,0.02324789,0.0004581692],"about_ca_topic_score_codex":0.00029037677,"about_ca_topic_score_gemma":0.00007793828,"teacher_disagreement_score":0.643947,"about_ca_system_score_codex":0.001891739,"about_ca_system_score_gemma":0.0013613497,"threshold_uncertainty_score":0.9997359},"labels":[],"label_agreement":null},{"id":"W4388666218","doi":"10.1016/j.clml.2023.11.001","title":"Teclistamab Improves Patient-Reported Symptoms and Health-Related Quality of Life in Relapsed or Refractory Multiple Myeloma: Results From the Phase II MajesTEC-1 Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Quality of life (healthcare); Post-hoc analysis; Physical therapy; Internal medicine; Refractory (planetary science); Health related quality of life; Clinical trial; Multiple myeloma; Minimal clinically important difference; Disease; Randomized controlled trial","score_opus":0.1184171867158281,"score_gpt":0.41028812813908366,"score_spread":0.29187094142325554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4388666218","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99246264,0.00073171454,0.0000012825354,0.0017200983,0.0004075347,0.0036875436,0.0005292386,0.00032309812,0.00013686091],"genre_scores_gemma":[0.99726623,0.00029269533,0.00015883624,0.00048176813,0.00016183176,0.00022558276,0.0007946275,0.00009570244,0.0005227097],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98862696,0.0016835083,0.005794048,0.0015705206,0.001273219,0.001051722],"domain_scores_gemma":[0.9872255,0.007525782,0.0018716065,0.0019996248,0.00032502192,0.0010525025],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0049098376,0.00060931826,0.0022066897,0.00032323,0.00043957596,0.000050103212,0.00044142824,0.0005394671,0.0000467615],"category_scores_gemma":[0.022266679,0.00039744386,0.00038405703,0.001500555,0.0007288795,0.00016692112,0.00066069624,0.0008105974,0.00006286306],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.035599835,0.0059652384,0.384251,0.00009519726,0.001046945,0.0012519951,0.0023172863,0.0000027194358,0.00078491593,0.000007978719,0.0014599757,0.56721693],"study_design_scores_gemma":[0.10316209,0.010593485,0.8812061,0.00032626995,0.00012236067,0.000022961576,0.0021105383,0.0014640776,0.000093343035,0.00007063673,0.00050425535,0.0003238698],"about_ca_topic_score_codex":0.015323601,"about_ca_topic_score_gemma":0.0024349438,"teacher_disagreement_score":0.56689304,"about_ca_system_score_codex":0.000909878,"about_ca_system_score_gemma":0.0030666357,"threshold_uncertainty_score":0.99984777},"labels":[],"label_agreement":null},{"id":"W4389044694","doi":"10.1016/j.clml.2023.11.008","title":"Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Multiple myeloma; Medicine; Internal medicine; Progression-free survival; Fluorescence in situ hybridization; Oncology; Autologous stem-cell transplantation; Gastroenterology; Overall survival; Surgery; Biology","score_opus":0.06304123243416956,"score_gpt":0.39384388262424075,"score_spread":0.33080265019007116,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389044694","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.997107,0.0010784351,0.000005385509,0.000084873376,0.00013303399,0.0011378529,0.00006296201,0.0001153243,0.0002750847],"genre_scores_gemma":[0.997473,0.0013631687,0.00054106384,0.000038961647,0.0001092581,0.00008296668,0.0002144129,0.00006193091,0.000115231174],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9964701,0.00027116644,0.0012413533,0.00062963116,0.00074422295,0.00064355705],"domain_scores_gemma":[0.99674696,0.0014421743,0.00030899915,0.00062149024,0.00011958639,0.0007607875],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010164719,0.00034088676,0.0010812761,0.00043661956,0.00008148983,0.000016755694,0.0002053935,0.00025204738,0.000036511337],"category_scores_gemma":[0.0015565963,0.00024959113,0.00070858776,0.0008221623,0.00039333678,0.00017810632,0.00018546179,0.000219667,0.000019635667],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0038579872,0.00037637964,0.60358155,0.00014865745,0.00028877263,0.00044968593,0.00011111325,0.000006563131,0.0024488675,0.0000020943876,0.00016170474,0.38856664],"study_design_scores_gemma":[0.014263704,0.0019029832,0.9761865,0.0008568393,0.00007755468,0.000010110149,0.000037910406,0.005360574,0.0009884737,0.00006379622,0.00006709192,0.00018446104],"about_ca_topic_score_codex":0.0001797484,"about_ca_topic_score_gemma":0.0000086235805,"teacher_disagreement_score":0.3883822,"about_ca_system_score_codex":0.0005301854,"about_ca_system_score_gemma":0.0013807911,"threshold_uncertainty_score":0.99999565},"labels":[],"label_agreement":null},{"id":"W4389623269","doi":"10.1016/j.clml.2023.12.005","title":"Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II Trial","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McGill University; Jewish General Hospital; Roche (Canada)","funders":"Genentech; F. Hoffmann-La Roche; Roche; Roche Canada","keywords":"Medicine; Internal medicine; Cytokine release syndrome; Follicular lymphoma; Neutropenia; Lymphoma; Adverse effect; Febrile neutropenia; Gastroenterology; Tumor lysis syndrome; Refractory (planetary science); Rituximab; Cyclophosphamide; Oncology; Surgery; Cancer; Chemotherapy; Immunotherapy","score_opus":0.03510957312794868,"score_gpt":0.3631146871045697,"score_spread":0.328005113976621,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389623269","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98448855,0.00008218259,0.00003901993,0.00016882575,0.0018329397,0.0045666187,0.00015251042,0.00039251833,0.00827685],"genre_scores_gemma":[0.98246044,0.00045677417,0.001212586,0.00066805887,0.0014178987,0.0006541195,0.0010492281,0.00023348388,0.011847402],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98931116,0.0008861443,0.0037113128,0.0023902368,0.0020970635,0.001604059],"domain_scores_gemma":[0.99340314,0.0021799873,0.0006885421,0.0022943253,0.0002948527,0.0011391819],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0028113595,0.00083861797,0.0021185721,0.0004963415,0.00033979793,0.00009451952,0.0009986726,0.00097482884,0.0020968071],"category_scores_gemma":[0.00085345504,0.0007138659,0.00084036635,0.001819541,0.0010627088,0.00035239558,0.0010109014,0.0009432687,0.0012900822],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.25048184,0.011451481,0.056365345,0.00007815563,0.0003407872,0.0016216271,0.00052201084,0.0000050275294,0.00015419292,0.000013778127,0.005902842,0.6730629],"study_design_scores_gemma":[0.34041846,0.015811885,0.61633474,0.0002780947,0.00013969053,0.0000060348325,0.00029018737,0.0012050952,0.00016622979,0.000036005258,0.02472477,0.0005888374],"about_ca_topic_score_codex":0.00029140533,"about_ca_topic_score_gemma":0.000037641963,"teacher_disagreement_score":0.6724741,"about_ca_system_score_codex":0.0025414014,"about_ca_system_score_gemma":0.0021227014,"threshold_uncertainty_score":0.99953127},"labels":[],"label_agreement":null},{"id":"W4389988294","doi":"10.1016/j.clml.2023.12.010","title":"Recent Advances in the Biology and CD123-Directed Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cutaneous lymphoproliferative disorders research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University; Juravinski Hospital; Juravinski Cancer Centre","funders":"","keywords":"Interleukin-3 receptor; Plasmacytoid dendritic cell; Medicine; Myeloid; Disease; Chemotherapy; Internal medicine; Oncology; Immunology; Dendritic cell; Immune system","score_opus":0.0421832653020348,"score_gpt":0.38365950606495086,"score_spread":0.34147624076291605,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4389988294","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98718107,0.0077948403,0.000005512678,0.0010703021,0.0002294535,0.0009061468,0.00003541447,0.00012366616,0.0026536253],"genre_scores_gemma":[0.9396525,0.05906785,0.00012754853,0.00026937126,0.00014721799,0.00013906791,0.00009795322,0.000038658018,0.00045985647],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99677587,0.0005904399,0.0009843041,0.00066111976,0.00035362807,0.0006346623],"domain_scores_gemma":[0.9944275,0.0044720466,0.00016027353,0.00051851704,0.00019683335,0.00022485002],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005802249,0.00031102533,0.00088299613,0.00028292567,0.00010932082,0.000021825135,0.00022985126,0.00027368788,0.000078668425],"category_scores_gemma":[0.0018387703,0.00021019,0.00018847572,0.0010069315,0.0007618437,0.0000611715,0.000095083924,0.0001745501,0.0001670204],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014278645,0.0007628792,0.1796286,0.00013843071,0.000082191276,0.0008093242,0.000665147,0.000020003494,0.0014451707,0.0001753358,0.00043264087,0.8144124],"study_design_scores_gemma":[0.012146413,0.0046496536,0.90395194,0.00015455003,0.00013623758,0.00092053344,0.0010653533,0.0064576953,0.002277262,0.0011594123,0.066746205,0.00033476565],"about_ca_topic_score_codex":0.00006295527,"about_ca_topic_score_gemma":0.00025466512,"teacher_disagreement_score":0.8140776,"about_ca_system_score_codex":0.00056672486,"about_ca_system_score_gemma":0.0010200349,"threshold_uncertainty_score":0.85713},"labels":[],"label_agreement":null},{"id":"W4390029779","doi":"10.1016/j.clml.2023.12.009","title":"Utilization of Autologous Hematopoietic Cell Transplantation Over Time in Multiple Myeloma: A Population-Based Study","year":2023,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"National Institute of Allergy and Infectious Diseases; Office of Naval Research; Legend Biotech; Pharmacyclics; Takeda Oncology; Health Resources and Services Administration; Centers for Disease Control and Prevention; National Institutes of Health; MorphoSys; Seagen; Astellas Pharma; Adaptive Biotechnologies; Kiadis Pharma; bluebird bio; TG Therapeutics; Medac; Jazz Pharmaceuticals; Swedish Orphan Biovitrum; Omeros Corporation; Vertex Pharmaceuticals; StemCyte; BeiGene; National Center for Advancing Translational Sciences; HistoGenetics; Comprehensive Cancer Center, University of California, Davis; Mallinckrodt Pharmaceuticals; Astellas Pharma US; University of Southern California; Atara Biotherapeutics; CareDx; Actinium Pharmaceuticals; National Cancer Institute; Gilead Sciences; Sanofi; GlaxoSmithKline; Incyte; Pfizer; National Center for Chronic Disease Prevention and Health Promotion; National Heart, Lung, and Blood Institute; Novartis Pharmaceuticals Corporation; CSL Behring; Bristol-Myers Squibb; AstraZeneca; Amgen","keywords":"Medicine; Hazard ratio; Population; Proportional hazards model; Hematopoietic cell; Transplantation; Medicaid; Confidence interval; Oncology; Internal medicine; Haematopoiesis; Stem cell; Health care","score_opus":0.057046776532737556,"score_gpt":0.36223962794040304,"score_spread":0.3051928514076655,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390029779","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99720025,0.00006224121,0.00007724702,0.00009649151,0.00014087989,0.0017854217,0.000064036445,0.00025061905,0.00032282944],"genre_scores_gemma":[0.9977121,0.00004345302,0.00039900528,0.000089233145,0.000074071904,0.00014741029,0.0010367417,0.00006477047,0.0004332624],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99596053,0.00046436235,0.0014908029,0.0007252774,0.00077844475,0.00058059045],"domain_scores_gemma":[0.99690956,0.0016754186,0.00030393084,0.0006314118,0.00015705098,0.0003226143],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00089254556,0.00033598606,0.0009358625,0.00055560295,0.00010849352,0.000022662967,0.00020468836,0.00033292768,0.00020113235],"category_scores_gemma":[0.00086298044,0.00030330676,0.00030316503,0.0012699354,0.00011755424,0.00012758591,0.000054257725,0.00021055603,0.00046860913],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0022212018,0.0016673383,0.9132595,0.0003078336,0.00008409874,0.000943062,0.0002583203,0.00024431595,0.0005424176,0.000010295903,0.0001405675,0.080321066],"study_design_scores_gemma":[0.017635254,0.0011296596,0.93868893,0.00018046636,0.00014196744,0.000017043712,0.00009540695,0.040569678,0.0012193469,0.000071005656,0.000028991279,0.00022227215],"about_ca_topic_score_codex":0.00063695794,"about_ca_topic_score_gemma":0.00023486889,"teacher_disagreement_score":0.08009879,"about_ca_system_score_codex":0.0005743956,"about_ca_system_score_gemma":0.0007635927,"threshold_uncertainty_score":0.9999419},"labels":[],"label_agreement":null},{"id":"W4390817926","doi":"10.1016/j.clml.2024.01.005","title":"A Review of the Therapeutic Role of Bosutinib in Chronic Myeloid Leukemia","year":2024,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Pfizer","keywords":"Bosutinib; Medicine; Dasatinib; Myeloid leukemia; Adverse effect; Oncology; Nilotinib; Population; Internal medicine; Tolerability; Imatinib","score_opus":0.05436446885694737,"score_gpt":0.3869147897249001,"score_spread":0.3325503208679528,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390817926","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009255345,0.98849624,8.579813e-7,0.00012661485,0.0010979568,0.004717027,0.00019422518,0.00013047302,0.0043110955],"genre_scores_gemma":[0.0012543997,0.99431664,0.00010512378,0.00080531545,0.00089310127,0.00050465675,0.00023525275,0.00036775973,0.0015177489],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9867833,0.0013593326,0.0074948496,0.0019079045,0.001272765,0.0011818176],"domain_scores_gemma":[0.99039024,0.0018964498,0.0029362265,0.0040441416,0.00029078146,0.00044218323],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0026303707,0.0016599534,0.009714701,0.00050653104,0.000077598874,0.000027782286,0.0018793396,0.0019053855,0.00041055479],"category_scores_gemma":[0.0014603053,0.0010303453,0.005929258,0.0028148203,0.0012277025,0.000108976536,0.0010513285,0.0021085048,0.0006193375],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00006513031,0.0001761074,0.00010253234,0.20966235,0.001282842,0.00011064679,0.000033068613,4.963408e-7,0.000008133424,0.0002624733,0.0026299586,0.7856663],"study_design_scores_gemma":[0.0022287916,0.0004380995,0.003505859,0.36407888,0.008012272,0.0004648617,0.000011717908,0.000051985015,0.000025297097,0.00019230956,0.6204749,0.000515075],"about_ca_topic_score_codex":0.00030914956,"about_ca_topic_score_gemma":0.000059758255,"teacher_disagreement_score":0.7851512,"about_ca_system_score_codex":0.027431497,"about_ca_system_score_gemma":0.055208478,"threshold_uncertainty_score":0.9996148},"labels":[],"label_agreement":null},{"id":"W4390990818","doi":"10.1016/j.clml.2024.01.007","title":"Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"Kite Pharma; Genentech; Daiichi Sankyo Europe; Gilead Sciences; Servier; Astellas Pharma; bluebird bio; H. Lundbeck A/S; Syndax Pharmaceuticals; Argenx; Arog Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Loxo Oncology; Astex Pharmaceuticals; Jazz Pharmaceuticals; Pfizer; Incyte; F. Hoffmann-La Roche; Ablynx; AbbVie; Sanofi; GlaxoSmithKline; Amgen; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Venetoclax; Medicine; Internal medicine; Neutropenia; Nausea; Gastroenterology; Febrile neutropenia; Salvage therapy; Mucositis; Oncology; Chemotherapy regimen; Refractory (planetary science); Leukemia; Chemotherapy; Biology; Chronic lymphocytic leukemia","score_opus":0.051772418474466675,"score_gpt":0.4032015996761817,"score_spread":0.351429181201715,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4390990818","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98439014,0.0040515605,0.000036025012,0.0012712391,0.0014343857,0.0016740153,0.00004190455,0.00039944248,0.006701274],"genre_scores_gemma":[0.99003756,0.0012732504,0.00074165146,0.0013053598,0.002410294,0.0002058431,0.000098001176,0.00016665593,0.0037613914],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9942288,0.00058469054,0.0019159093,0.0014720677,0.00077721506,0.001021329],"domain_scores_gemma":[0.9944993,0.003243285,0.00016902763,0.0010112065,0.00013699515,0.0009401773],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0030982166,0.00052898,0.0013448122,0.0005666715,0.00011660775,0.00016370697,0.00039487408,0.0009530612,0.00036980995],"category_scores_gemma":[0.0032923808,0.00046352795,0.00049805787,0.0010373374,0.0008733701,0.00021576948,0.00036381796,0.001525174,0.0009427743],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.05794533,0.0010604394,0.0014722813,0.0003463265,0.00029598264,0.0064444784,0.00027078265,0.0000018510175,0.0012772897,0.0009236105,0.02488695,0.90507466],"study_design_scores_gemma":[0.39130026,0.010519356,0.13632359,0.0014205576,0.0004173073,0.0010392372,0.00020081515,0.015966244,0.00064943,0.001130153,0.4400254,0.0010076712],"about_ca_topic_score_codex":0.00020841353,"about_ca_topic_score_gemma":0.000027497716,"teacher_disagreement_score":0.904067,"about_ca_system_score_codex":0.0041717044,"about_ca_system_score_gemma":0.007814138,"threshold_uncertainty_score":0.99983513},"labels":[],"label_agreement":null},{"id":"W4391066568","doi":"10.1016/j.clml.2024.01.004","title":"Serologic Response to Vaccine for COVID-19 in Patients with Hematologic Malignancy: A Prospective Cohort Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Western University; McGill University; London Health Sciences Centre; University of Toronto","funders":"Roche Diagnostics","keywords":"Medicine; Vaccination; Serology; Internal medicine; Malignancy; Antibody titer; Cancer; Immunology; Prospective cohort study; Titer; Population; Immune system; Antibody","score_opus":0.039585519353697904,"score_gpt":0.39134749863278806,"score_spread":0.35176197927909014,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391066568","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9880108,0.0002151786,0.00018919607,0.0013401444,0.00027278386,0.009293331,0.000039232644,0.00039979204,0.00023950146],"genre_scores_gemma":[0.9608125,0.0000022893305,0.0004217393,0.036116943,0.00016739435,0.0022191992,0.00001531811,0.000087316,0.00015730417],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9947516,0.00059021596,0.0012668993,0.0017094511,0.00079789176,0.00088395353],"domain_scores_gemma":[0.9946925,0.003473278,0.00013086261,0.00096433493,0.0003619943,0.00037704044],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00391859,0.00047950374,0.0013344794,0.00052654935,0.00014483136,0.000097025964,0.00043903984,0.00040616843,0.000029155766],"category_scores_gemma":[0.0077406326,0.0003375298,0.0002825942,0.0014725162,0.00016500607,0.00013095715,0.00027747254,0.00044071433,0.00028206312],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06089212,0.0015807223,0.92342126,0.00024145198,0.00031470982,0.0018877414,0.00040455384,0.000002260722,0.00008608314,0.00012985751,0.0015096917,0.009529528],"study_design_scores_gemma":[0.017586948,0.014061687,0.95443565,0.00022341117,0.00018239582,0.00006539188,0.00018182726,0.00021884829,0.00022171823,0.0006099955,0.011828037,0.00038406384],"about_ca_topic_score_codex":0.00014344964,"about_ca_topic_score_gemma":0.00018549954,"teacher_disagreement_score":0.043305174,"about_ca_system_score_codex":0.0034806777,"about_ca_system_score_gemma":0.00458554,"threshold_uncertainty_score":0.9999077},"labels":[],"label_agreement":null},{"id":"W4391812167","doi":"10.1016/j.clml.2024.02.006","title":"Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa; McMaster University","funders":"","keywords":"Medicine; Multiple myeloma; Cohort; Population; Health care; Oncology; Internal medicine; Environmental health","score_opus":0.04032604097197609,"score_gpt":0.3367106443747134,"score_spread":0.2963846034027373,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4391812167","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921109,0.0005003498,0.00009792021,0.000496427,0.00025507552,0.005734732,0.00017988558,0.00044885167,0.00017585818],"genre_scores_gemma":[0.99514246,0.000067210196,0.00018319637,0.00020772892,0.0003808295,0.00070708833,0.0025517438,0.00015918036,0.0006005381],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943018,0.0006573487,0.0013572064,0.0016438547,0.0011984123,0.00084135495],"domain_scores_gemma":[0.9960223,0.0013153922,0.00026005154,0.001041446,0.00031964178,0.0010411874],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00053420506,0.0006957724,0.0012101731,0.00037575644,0.00037903804,0.00021866194,0.0001952523,0.0003970048,0.00007084877],"category_scores_gemma":[0.00054087676,0.0005035833,0.00030366643,0.00064530026,0.00025813078,0.00023560178,0.00010765425,0.00031091552,0.00007023323],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015478305,0.00096299633,0.6474535,0.00014221745,0.0005727006,0.0005151661,0.00020477771,0.000010914348,0.0000030907179,0.0000046197856,0.00011239986,0.3484698],"study_design_scores_gemma":[0.02517659,0.006107931,0.9380313,0.00045071324,0.000514976,0.00001987376,0.00021923316,0.027375821,0.000036623223,0.000007839915,0.0016339055,0.00042519454],"about_ca_topic_score_codex":0.0037336282,"about_ca_topic_score_gemma":0.0008853411,"teacher_disagreement_score":0.34804457,"about_ca_system_score_codex":0.002627233,"about_ca_system_score_gemma":0.0010892919,"threshold_uncertainty_score":0.99974155},"labels":[],"label_agreement":null},{"id":"W4397049853","doi":"10.1016/j.clml.2024.05.014","title":"Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"Bristol-Myers Squibb","keywords":"Pomalidomide; Medicine; Nivolumab; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine; Lenalidomide; Materials science; Immunotherapy; Cancer","score_opus":0.06850739743317062,"score_gpt":0.38812460186264236,"score_spread":0.3196172044294717,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4397049853","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98969877,0.00375495,0.00003115508,0.0010609785,0.00035518128,0.0036504504,0.00095734093,0.00017195762,0.00031921908],"genre_scores_gemma":[0.9948529,0.0013884107,0.00075626705,0.0000901802,0.0003470876,0.0003473398,0.0007034793,0.000089669855,0.0014246713],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9956782,0.00044140883,0.0015474205,0.0012213319,0.0005513371,0.00056030357],"domain_scores_gemma":[0.9907767,0.007149264,0.00033775604,0.0010003276,0.000246719,0.00048922526],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011228813,0.00049987825,0.0011668521,0.00016445293,0.00030683514,0.00012578489,0.00019021111,0.00032756515,0.00002063505],"category_scores_gemma":[0.0024483937,0.000330417,0.00035419024,0.00029643034,0.0005753094,0.00020550136,0.00014163746,0.00017818881,0.000030227895],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.029605925,0.005488791,0.029239805,0.00016088509,0.0021781828,0.00081007346,0.00239511,7.989228e-7,0.0019268331,0.00016072995,0.002518328,0.9255145],"study_design_scores_gemma":[0.12383962,0.015438027,0.8346671,0.00035822924,0.00091521686,0.000073144736,0.00077175564,0.009498199,0.0015737558,0.0003600509,0.012186826,0.00031807474],"about_ca_topic_score_codex":0.0014410448,"about_ca_topic_score_gemma":0.00023728948,"teacher_disagreement_score":0.92519647,"about_ca_system_score_codex":0.0009654802,"about_ca_system_score_gemma":0.0008022673,"threshold_uncertainty_score":0.99991477},"labels":[],"label_agreement":null},{"id":"W4400231709","doi":"10.1016/j.clml.2024.06.012","title":"Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Swedish Orphan Biovitrum; CTI Biopharma","keywords":"Medicine; Myelofibrosis; Cytopenia; Consistency (knowledge bases); Internal medicine; Bone marrow","score_opus":0.013909071689812024,"score_gpt":0.28155096078063574,"score_spread":0.2676418890908237,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400231709","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9965064,0.00052546355,0.000005622894,0.00024605947,0.000082691266,0.0010715247,0.000080931015,0.0000532333,0.0014280784],"genre_scores_gemma":[0.9979912,0.00026464436,0.0011563378,0.00005289647,0.00006873418,0.00012338787,0.000117234216,0.000051790837,0.00017375],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99732214,0.0001548948,0.001103042,0.0007020908,0.00042227653,0.000295539],"domain_scores_gemma":[0.9982256,0.00053232536,0.00024605295,0.00043774056,0.0003357324,0.00022249497],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003043686,0.00034002986,0.0011626454,0.00021243471,0.000047522753,0.00002839876,0.00008166211,0.00023114354,0.000048164708],"category_scores_gemma":[0.00014301,0.0002236713,0.00014482895,0.0005273124,0.0006164345,0.00015157482,0.000052265194,0.00016549249,0.000008224309],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0034293488,0.00070059916,0.8562763,0.00040611625,0.0004331081,0.00012433167,0.00018077358,0.0000017236792,0.0001629795,0.00066367234,0.00015402595,0.13746704],"study_design_scores_gemma":[0.009679407,0.0049163285,0.97554374,0.0030287595,0.0005168572,0.00008453106,0.00012109502,0.00006530327,0.0055016573,0.000044229262,0.00027175882,0.00022630607],"about_ca_topic_score_codex":0.00021046435,"about_ca_topic_score_gemma":0.00004148334,"teacher_disagreement_score":0.13724074,"about_ca_system_score_codex":0.00032093932,"about_ca_system_score_gemma":0.0006828151,"threshold_uncertainty_score":0.91210514},"labels":[],"label_agreement":null},{"id":"W4400643471","doi":"10.1016/j.clml.2024.07.007","title":"Pomalidomide Use and Kidney Outcomes in Patients With Relapsed/Refractory Multiple Myeloma and Chronic Kidney Disease: A Real-World, Population-Based Cohort Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University Health Network; University of Toronto; St. Michael's Hospital; Seven Oaks General Hospital; University of Manitoba; Ottawa Hospital; McMaster University; St. Boniface Hospital","funders":"Ontario Ministry of Health and Long-Term Care; Government of Ontario; Amgen","keywords":"Pomalidomide; Medicine; Internal medicine; Kidney disease; Cohort; Renal function; Multiple myeloma; Population; Oncology; Lenalidomide; Environmental health","score_opus":0.023755765837815017,"score_gpt":0.32616980036152243,"score_spread":0.3024140345237074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4400643471","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9942223,0.00031638265,0.000008784987,0.0005197609,0.00030455535,0.0038861972,0.0003653293,0.00028413054,0.000092555965],"genre_scores_gemma":[0.9956552,0.00015890377,0.0004680393,0.0007123951,0.00018553488,0.0003899313,0.0012248254,0.00015438219,0.0010508205],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9943966,0.0005442463,0.0013956694,0.0016704636,0.0010994066,0.0008935991],"domain_scores_gemma":[0.99333876,0.0024191812,0.00021557735,0.0010825485,0.00020381853,0.002740095],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00079414254,0.00071443233,0.0013907126,0.000656834,0.00022692133,0.00028655078,0.00019844729,0.00026532647,0.00010489705],"category_scores_gemma":[0.0043902206,0.0005305845,0.0002479761,0.0006861728,0.00039456272,0.0005615963,0.00020948942,0.00053512206,0.00005100926],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0056516505,0.0019041761,0.9464383,0.00035544994,0.0007887862,0.0016095478,0.000049213177,0.0000050065205,0.000006656083,0.000028896968,0.000561141,0.042601183],"study_design_scores_gemma":[0.034436066,0.0020240308,0.9557923,0.00097572635,0.0005328954,0.000006974128,0.000014557777,0.0044681886,0.000005616137,0.000021456994,0.0012010472,0.0005211183],"about_ca_topic_score_codex":0.003351737,"about_ca_topic_score_gemma":0.0013261539,"teacher_disagreement_score":0.042080063,"about_ca_system_score_codex":0.002425383,"about_ca_system_score_gemma":0.0032792462,"threshold_uncertainty_score":0.99971455},"labels":[],"label_agreement":null},{"id":"W4401433011","doi":"10.1016/j.clml.2024.07.014","title":"Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Vancouver General Hospital; Surrey Place Centre; Princess Margaret Cancer Centre; McGill University Health Centre; University of Calgary","funders":"EMD Serono; Pharmacyclics; Genentech; Incyte; bluebird bio; Celgene; Teva Pharmaceutical Industries; Gilead Sciences; BeiGene; Sanofi; Amgen; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb; GlaxoSmithKline","keywords":"Pomalidomide; Lenalidomide; Medicine; Daratumumab; Internal medicine; Dexamethasone; Multiple myeloma; Cohort; Clinical endpoint; Adverse effect; Oncology; Refractory (planetary science); Discontinuation; Surgery; Clinical trial","score_opus":0.0919602946311303,"score_gpt":0.3804131323060837,"score_spread":0.2884528376749534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401433011","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98603565,0.003461683,0.00010975771,0.0010012054,0.002365324,0.0013947122,0.0003406185,0.00063079165,0.004660274],"genre_scores_gemma":[0.9837461,0.0008782845,0.0038092101,0.0006535429,0.0019521574,0.00022153133,0.00072946533,0.0002439723,0.0077657164],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99072117,0.0010947256,0.0025748212,0.0023280154,0.0015639726,0.0017173113],"domain_scores_gemma":[0.98726064,0.009025374,0.00029710575,0.0017288345,0.000250022,0.001438049],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.002001753,0.0010022075,0.0022104252,0.00060465594,0.00024960688,0.00026777972,0.00068614684,0.0011825596,0.0016865218],"category_scores_gemma":[0.0067702946,0.0007823812,0.0010185059,0.0010957472,0.0007056861,0.00042366883,0.00045424106,0.0016213806,0.0026259313],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.026724543,0.0019510258,0.18438572,0.0003502895,0.0013236639,0.030176822,0.00032228814,0.0000118177095,0.0026309167,0.00034895973,0.008572973,0.743201],"study_design_scores_gemma":[0.031683017,0.001992642,0.90499765,0.0012468009,0.00026824995,0.0002411241,0.00011904799,0.009522045,0.0007608713,0.00058719993,0.047789782,0.00079155405],"about_ca_topic_score_codex":0.0028836858,"about_ca_topic_score_gemma":0.0013240159,"teacher_disagreement_score":0.7424094,"about_ca_system_score_codex":0.0032168273,"about_ca_system_score_gemma":0.003912265,"threshold_uncertainty_score":0.9994627},"labels":[],"label_agreement":null},{"id":"W4401525609","doi":"10.1016/j.clml.2024.08.003","title":"Talquetamab Versus Real-World Physician's Choice Treatment: Comparative Effectiveness in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Global Risk Institute in Financial Services","keywords":"Medicine; Internal medicine; Refractory (planetary science); Multiple myeloma; Overall survival; Surgery; Gastroenterology","score_opus":0.05868525513036327,"score_gpt":0.36450511369899596,"score_spread":0.3058198585686327,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401525609","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9844219,0.00055729324,0.000015373938,0.00009863053,0.0011889458,0.003452897,0.00020395244,0.0004716748,0.009589344],"genre_scores_gemma":[0.9952196,0.000180256,0.00031532807,0.00012368536,0.0006298066,0.00066276686,0.0010303663,0.00019103102,0.0016471628],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99290663,0.001111592,0.0014494035,0.0019764467,0.001162044,0.0013938595],"domain_scores_gemma":[0.9891576,0.007918239,0.00031531378,0.0012855056,0.0003489042,0.00097440445],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00063124235,0.0010848928,0.0022450672,0.00071322493,0.00025916306,0.00017072698,0.00039647418,0.0004925983,0.00009855047],"category_scores_gemma":[0.0007103024,0.00080481207,0.00073636585,0.0017139182,0.00069360976,0.0006161081,0.00016514264,0.0007612024,0.0007796866],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04701209,0.0043296586,0.5360645,0.00030882598,0.0022015243,0.0017243,0.0002836688,0.000022369177,0.00026053577,0.00017301926,0.0005214654,0.40709803],"study_design_scores_gemma":[0.08631408,0.0093626855,0.888059,0.0011439438,0.00044429462,0.000007295813,0.00007095633,0.0025582984,0.0014494887,0.000030395773,0.009876674,0.0006828383],"about_ca_topic_score_codex":0.0012130341,"about_ca_topic_score_gemma":0.0016436036,"teacher_disagreement_score":0.4064152,"about_ca_system_score_codex":0.0072374986,"about_ca_system_score_gemma":0.0022841492,"threshold_uncertainty_score":0.99999833},"labels":[],"label_agreement":null},{"id":"W4401875014","doi":"10.1016/s2152-2650(24)00611-6","title":"Tolerability of Asciminib vs Investigator-Selected (IS) Tyrosine Kinase Inhibitors (TKIs) in the Phase 3 ASC4FIRST Study in Newly Diagnosed Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Adverse effect; Receptor","score_opus":0.026442817578052422,"score_gpt":0.33461210375836103,"score_spread":0.3081692861803086,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875014","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9884293,0.0028583072,0.00000687051,0.0006311247,0.00064268126,0.0068257935,0.00017339265,0.00024123437,0.00019128267],"genre_scores_gemma":[0.99626696,0.00033808654,0.00014204704,0.0007680355,0.00070314104,0.0009495121,0.0005265676,0.0002302247,0.00007543545],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9871134,0.0015675775,0.004841913,0.002767381,0.0019010439,0.001808682],"domain_scores_gemma":[0.9921524,0.0031870157,0.00076661137,0.0025888404,0.0003962959,0.0009088616],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.003195867,0.0014214956,0.0029629841,0.0011008842,0.00016347744,0.00015864382,0.0011228479,0.00092446216,0.00027328258],"category_scores_gemma":[0.003296661,0.0010659782,0.0005572643,0.005788758,0.0013658938,0.00068396854,0.0003724757,0.0020410563,0.0001337415],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0075344024,0.0136358235,0.7056814,0.0011329569,0.00049370114,0.0050855097,0.003941359,0.00025949834,0.00096437475,0.000039817347,0.002489507,0.25874168],"study_design_scores_gemma":[0.13642532,0.015725598,0.83350575,0.0029042417,0.0004565898,0.000053155836,0.00034281373,0.0058861743,0.0016125898,0.00007945733,0.0021211095,0.0008871836],"about_ca_topic_score_codex":0.004670236,"about_ca_topic_score_gemma":0.007903834,"teacher_disagreement_score":0.2578545,"about_ca_system_score_codex":0.0474402,"about_ca_system_score_gemma":0.034153443,"threshold_uncertainty_score":0.9998535},"labels":[],"label_agreement":null},{"id":"W4401875032","doi":"10.1016/s2152-2650(24)00613-x","title":"ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Cancer research; Receptor; Cancer","score_opus":0.019348148863125917,"score_gpt":0.29995262759059965,"score_spread":0.28060447872747374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875032","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964113,0.0020463734,0.000007674222,0.00043812997,0.0011294953,0.004955962,0.0004148445,0.0006283294,0.00073805],"genre_scores_gemma":[0.9942188,0.00031899888,0.00076470897,0.00088728004,0.000985265,0.00048056312,0.0013503578,0.00038430127,0.00060972705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98717993,0.0007567183,0.0048551937,0.003165648,0.002274631,0.0017678927],"domain_scores_gemma":[0.9915509,0.0024171951,0.0010821737,0.0024931703,0.0007182858,0.0017382792],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001474793,0.001589312,0.003107226,0.001042126,0.00023732691,0.00017053886,0.0008442916,0.0010881346,0.00013639561],"category_scores_gemma":[0.003325618,0.0013446934,0.00065193314,0.004043289,0.0011812162,0.0007257767,0.0005332032,0.0015761259,0.0002656636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030219391,0.01654534,0.4471882,0.0019341462,0.0025126075,0.009877523,0.0038120446,0.00018635699,0.0016530973,0.000039077662,0.029092057,0.45694014],"study_design_scores_gemma":[0.14580198,0.02112852,0.81901056,0.003488943,0.0010828318,0.00010933244,0.0001672658,0.0018253353,0.0020267195,0.00003422776,0.004187194,0.001137122],"about_ca_topic_score_codex":0.0023725862,"about_ca_topic_score_gemma":0.0007695158,"teacher_disagreement_score":0.45580304,"about_ca_system_score_codex":0.02267708,"about_ca_system_score_gemma":0.02635173,"threshold_uncertainty_score":0.99968547},"labels":[],"label_agreement":null},{"id":"W4401875426","doi":"10.1016/s2152-2650(24)01697-5","title":"MM-520 Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Internal medicine; Oncology; Refractory (planetary science)","score_opus":0.047108712013716955,"score_gpt":0.33103404425382993,"score_spread":0.28392533224011296,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875426","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9881013,0.0021866695,0.000032075277,0.0011202303,0.0013979968,0.004463019,0.0011990753,0.0004016748,0.0010979439],"genre_scores_gemma":[0.99043554,0.00088736304,0.0018614166,0.00088927697,0.0016813362,0.00042248482,0.0014261025,0.00027283,0.0021236702],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98926836,0.0012541028,0.0031141134,0.0027197201,0.0019130643,0.0017306526],"domain_scores_gemma":[0.9813689,0.0138865765,0.00058870047,0.002287719,0.000385673,0.0014824063],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024143558,0.001212867,0.0023618694,0.00041417227,0.00042785448,0.00037115024,0.0008169337,0.0010899771,0.00020214134],"category_scores_gemma":[0.009956139,0.0007263069,0.00064693054,0.0012553129,0.0012670122,0.0005890659,0.0005866654,0.0017173991,0.0004016781],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38423082,0.0029405246,0.1422918,0.00013530512,0.001606265,0.0039544576,0.00070026855,0.0000074926975,0.00004439372,0.000034515197,0.008309819,0.45574433],"study_design_scores_gemma":[0.32423002,0.0041254247,0.64956343,0.0008728502,0.00047977705,0.00005051685,0.00017716021,0.0027283435,0.00011336301,0.00007296554,0.016959857,0.00062632485],"about_ca_topic_score_codex":0.0038957985,"about_ca_topic_score_gemma":0.002619043,"teacher_disagreement_score":0.5072716,"about_ca_system_score_codex":0.0027725757,"about_ca_system_score_gemma":0.004629256,"threshold_uncertainty_score":0.9995188},"labels":[],"label_agreement":null},{"id":"W4401875816","doi":"10.1016/s2152-2650(24)01421-6","title":"MPN-274 Avapritinib in Patients With Advanced Systemic Mastocytosis (AdvSM): Efficacy and Safety Analysis From the Phase 2 PATHFINDER Study With 3-Year Follow-up","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Mast cells and histamine","field":"Immunology and Microbiology","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; St. Michael's Hospital","funders":"","keywords":"Medicine; Systemic mastocytosis; Pathfinder; Internal medicine; Dermatology; Oncology; Library science; Bone marrow","score_opus":0.011288517237793465,"score_gpt":0.26665818859785806,"score_spread":0.2553696713600646,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875816","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99527496,0.0021345068,0.00010764837,0.00008392377,0.0004837505,0.0012040643,0.00033074518,0.00011602666,0.00026435545],"genre_scores_gemma":[0.998189,0.00011641671,0.00008957168,0.00015395842,0.00007279026,0.00008485421,0.00054541434,0.00005774515,0.00069026],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9963377,0.0006562609,0.0011448653,0.0011605826,0.00016726487,0.00053332426],"domain_scores_gemma":[0.99700737,0.0016861858,0.00024362707,0.000844925,0.00011980718,0.000098082135],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006891821,0.00046248882,0.0011220073,0.00018726721,0.0002617524,0.00008879932,0.00040532614,0.00035017938,0.0003971235],"category_scores_gemma":[0.00014554716,0.00027911214,0.00021876437,0.0008747127,0.0004875098,0.00013732095,0.00018459772,0.00050404895,0.00016599275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020843985,0.0017435362,0.61554295,0.000057370293,0.0043855617,0.00017492952,0.0015823076,0.00005404694,0.00031040818,0.0001296499,0.00046275725,0.3547125],"study_design_scores_gemma":[0.041793123,0.0030066052,0.94550127,0.00029810183,0.0015912406,0.00001084288,0.00097164133,0.000054839405,0.000038807706,0.000009450184,0.0062985346,0.00042555356],"about_ca_topic_score_codex":0.0003736402,"about_ca_topic_score_gemma":0.00068569893,"teacher_disagreement_score":0.35428694,"about_ca_system_score_codex":0.00030359734,"about_ca_system_score_gemma":0.00033600282,"threshold_uncertainty_score":0.9999661},"labels":[],"label_agreement":null},{"id":"W4401875841","doi":"10.1016/s2152-2650(24)01330-2","title":"CML-628 Impact on Healthcare Resource Utilization and Cost of Care of Concomitant Prescribing of Acid-Reducing Agents With Tyrosine Kinase Inhibitors: A US Payer Perspective","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Potassium and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Perspective (graphical); Concomitant; Health care; Tyrosine kinase; Tyrosine-kinase inhibitor; Intensive care medicine; Internal medicine; Cancer","score_opus":0.037519333426989904,"score_gpt":0.3589868836663657,"score_spread":0.3214675502393758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9804236,0.016490221,0.00002937444,0.0004186699,0.00017557193,0.0007507,0.00013441553,0.000056658475,0.0015207294],"genre_scores_gemma":[0.9988629,0.0005900369,0.00010059806,0.00013578947,0.00011883382,0.000011904206,0.00007367372,0.000056490746,0.000049777645],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99746156,0.0002020305,0.0010277741,0.0005669476,0.00043075506,0.00031095548],"domain_scores_gemma":[0.99810445,0.0003706807,0.0003779099,0.0004239168,0.00042614323,0.00029691448],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00036173098,0.00029737904,0.0008905324,0.00022219676,0.00006228108,0.000015863408,0.00010028497,0.0003796085,0.000021761563],"category_scores_gemma":[0.0005703678,0.00020339462,0.00028845985,0.00050926034,0.00054084114,0.000090253176,0.00007124914,0.00032020506,0.000002408074],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021479458,0.0013195332,0.21186014,0.0067351423,0.0021940528,0.0007527787,0.022492042,0.0005855608,0.019738968,0.001603258,0.00414193,0.7070972],"study_design_scores_gemma":[0.008777629,0.007203558,0.92466736,0.011905527,0.00076191325,0.00011980854,0.009963901,0.004678628,0.030735834,0.000065559296,0.0007579265,0.00036235267],"about_ca_topic_score_codex":0.0012016078,"about_ca_topic_score_gemma":0.000029499988,"teacher_disagreement_score":0.71280724,"about_ca_system_score_codex":0.00088622817,"about_ca_system_score_gemma":0.0014261395,"threshold_uncertainty_score":0.8294192},"labels":[],"label_agreement":null},{"id":"W4401875886","doi":"10.1016/s2152-2650(24)01345-4","title":"MDS-157 Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Red blood cell; Blood transfusion; Clinical trial; Red Blood Cell Transfusion; Internal medicine; Oncology; Bone marrow","score_opus":0.03013156918352923,"score_gpt":0.3401590380652639,"score_spread":0.31002746888173466,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875886","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98878026,0.0020009384,0.0004943117,0.001004182,0.0019041032,0.0036736275,0.0002477163,0.00023627923,0.001658606],"genre_scores_gemma":[0.97409934,0.022151789,0.0007882914,0.0002700334,0.0009609559,0.00018640305,0.00013415824,0.00022816674,0.0011808367],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9863854,0.0021670018,0.0040828376,0.0026817573,0.0030388928,0.001644115],"domain_scores_gemma":[0.9859564,0.009950152,0.0006449174,0.0019352966,0.0004522518,0.0010610372],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009870557,0.0011455241,0.0028225062,0.0006626359,0.0003665648,0.0002327339,0.0012331012,0.001599746,0.00044652293],"category_scores_gemma":[0.0021639518,0.000792261,0.0010765864,0.0015335078,0.0013434798,0.00056479,0.00037766722,0.00344136,0.00011003205],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.39271355,0.014051476,0.056239124,0.0022719984,0.00267266,0.022996249,0.001747854,0.00017899851,0.017752662,0.0006119851,0.0026639914,0.48609945],"study_design_scores_gemma":[0.46210966,0.046100944,0.45015743,0.0034925658,0.0052330904,0.0032305294,0.001012638,0.013813488,0.0059077186,0.0009966088,0.0055445246,0.0024008192],"about_ca_topic_score_codex":0.0021567326,"about_ca_topic_score_gemma":0.001042848,"teacher_disagreement_score":0.48369864,"about_ca_system_score_codex":0.00086133275,"about_ca_system_score_gemma":0.0044202255,"threshold_uncertainty_score":0.9996964},"labels":[],"label_agreement":null},{"id":"W4401875916","doi":"10.1016/s2152-2650(24)01666-5","title":"MM-336 Long-Term Follow-Up From the Phase 1/2 MajesTEC-1 Trial of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Internal medicine; Oncology; Term (time); Nuclear medicine","score_opus":0.038792346269578074,"score_gpt":0.34768720031977113,"score_spread":0.30889485405019307,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401875916","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922091,0.0013538918,0.000048737606,0.0003310694,0.0015495302,0.0032218292,0.00049058336,0.0002170445,0.0005782281],"genre_scores_gemma":[0.9959531,0.00026772934,0.00035419542,0.00027916828,0.00086847664,0.0002606337,0.0009428202,0.00016638504,0.0009075167],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9930501,0.0006384892,0.00220912,0.0014516271,0.0015918949,0.001058742],"domain_scores_gemma":[0.991971,0.0047189854,0.00043284392,0.0018056207,0.00033114266,0.0007404111],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011004137,0.0007382979,0.0015817311,0.0003173935,0.00018324832,0.0001397813,0.0007121529,0.0006646117,0.000327313],"category_scores_gemma":[0.0027118311,0.00046607325,0.00078723003,0.0009109021,0.00085224234,0.0003668419,0.00030994322,0.0009782412,0.0003471051],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.12599504,0.0027896087,0.42012748,0.00011893091,0.0007254521,0.0012077302,0.00016238251,6.917883e-7,0.00010318104,0.000018892588,0.00081395736,0.44793665],"study_design_scores_gemma":[0.26726723,0.005768121,0.72245204,0.0011486028,0.00035472304,0.000014358066,0.00004347713,0.00031934734,0.00032761693,0.00005502197,0.0019019799,0.00034750596],"about_ca_topic_score_codex":0.00064616726,"about_ca_topic_score_gemma":0.00047786746,"teacher_disagreement_score":0.44758916,"about_ca_system_score_codex":0.0013689701,"about_ca_system_score_gemma":0.0024630865,"threshold_uncertainty_score":0.9997791},"labels":[],"label_agreement":null},{"id":"W4401876009","doi":"10.1016/s2152-2650(24)01390-9","title":"MPN-086 Time-Dependent Transfusion Status as an Independent Predictor of Overall Survival: A Post Hoc Analysis of 3 Phase 3 Trials","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Radiomics and Machine Learning in Medical Imaging","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Post-hoc analysis; Oncology; Internal medicine; Post hoc; Phase (matter)","score_opus":0.034297783247627604,"score_gpt":0.39510527755382924,"score_spread":0.3608074943062016,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876009","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927912,0.0013494767,0.0016266499,0.00061389455,0.0010984726,0.0007119821,0.00037148938,0.00022249331,0.0012143737],"genre_scores_gemma":[0.99473876,0.0016810456,0.0008155171,0.00051847246,0.00064756395,0.000020479589,0.0006564689,0.00010120109,0.00082050834],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99216616,0.0012474052,0.0034017959,0.001063551,0.0015010033,0.0006200942],"domain_scores_gemma":[0.993974,0.0030314913,0.00066559226,0.00096401025,0.00037193077,0.0009929788],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0073444205,0.0004507265,0.0030281188,0.00081492594,0.00007611254,0.000077220495,0.00040495026,0.0005316686,0.0016990723],"category_scores_gemma":[0.005102159,0.00035610513,0.0017540896,0.0010000243,0.000444829,0.00021823436,0.00012926548,0.0007019632,0.000068525],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009721479,0.0021994202,0.013014108,0.00052343454,0.0075897505,0.0008541138,0.0010428008,0.00030735406,0.044991773,0.0007263067,0.00075366313,0.9182758],"study_design_scores_gemma":[0.039141055,0.013212853,0.6145734,0.0014503822,0.021460872,0.00017673503,0.00039182854,0.29126745,0.0030903255,0.0008825405,0.01335541,0.0009971132],"about_ca_topic_score_codex":0.0011447115,"about_ca_topic_score_gemma":0.000036651098,"teacher_disagreement_score":0.9172787,"about_ca_system_score_codex":0.00053690147,"about_ca_system_score_gemma":0.0023539555,"threshold_uncertainty_score":0.9998891},"labels":[],"label_agreement":null},{"id":"W4401876038","doi":"10.1016/s2152-2650(24)01493-9","title":"ABCL-183 Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Roche (Canada)","funders":"","keywords":"Medicine; CHOP; Oncology; Internal medicine; Cancer research; Lymphoma","score_opus":0.0330960549158833,"score_gpt":0.3426735272200144,"score_spread":0.3095774723041311,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876038","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99245024,0.0048986897,0.000033265173,0.00016244123,0.0012969506,0.0005402325,0.00005479371,0.000008585378,0.0005548238],"genre_scores_gemma":[0.99694437,0.0018611824,0.00013845746,0.00021131369,0.00066854974,0.00003751327,0.000022715272,0.00004266768,0.000073203686],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9966092,0.00034864168,0.0016503879,0.00069357513,0.0003002892,0.0003978723],"domain_scores_gemma":[0.99658215,0.0019975218,0.00025032877,0.0009839083,0.00007795907,0.00010814554],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014219744,0.00030725476,0.0006010812,0.0000747079,0.000052288455,0.00005787636,0.00087908097,0.00035418558,0.000017808256],"category_scores_gemma":[0.00061089045,0.00020160546,0.00040765243,0.00032950737,0.0003087652,0.0000063316347,0.00039208127,0.00034703355,0.000010084444],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.002001846,0.0016647717,0.8002333,0.0001146192,0.00028889824,0.00013457543,0.0006464223,0.00051307393,0.0065217107,0.00063271745,0.0008248924,0.18642315],"study_design_scores_gemma":[0.0034283362,0.0015999211,0.9869675,0.000058549093,0.00011771178,0.0000062098043,0.00046050665,0.000433077,0.0013614659,0.00038052653,0.004945083,0.00024112622],"about_ca_topic_score_codex":0.00086828903,"about_ca_topic_score_gemma":0.002796953,"teacher_disagreement_score":0.18673417,"about_ca_system_score_codex":0.00017506865,"about_ca_system_score_gemma":0.0007337306,"threshold_uncertainty_score":0.8221232},"labels":[],"label_agreement":null},{"id":"W4401876091","doi":"10.1016/s2152-2650(24)01267-9","title":"CLL-186 Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Interim; Interim analysis; Leukemia; Oncology; Internal medicine; Clinical trial","score_opus":0.036451679534786716,"score_gpt":0.3677568805810247,"score_spread":0.33130520104623795,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876091","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.991654,0.0009364279,0.000057845657,0.00011734919,0.0009668429,0.0033641844,0.00046872016,0.0004366785,0.0019979933],"genre_scores_gemma":[0.9961128,0.00019828981,0.0003449633,0.0002639389,0.0009991751,0.00015573826,0.0007903236,0.00027375962,0.0008609794],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98728895,0.00092737895,0.0048881248,0.002804931,0.0024446405,0.0016459782],"domain_scores_gemma":[0.9903984,0.004448613,0.00069040863,0.0028720107,0.00056707585,0.0010235129],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028261272,0.0010850364,0.0027526594,0.0007377392,0.00015402597,0.00016721814,0.0011565053,0.001016481,0.00035166758],"category_scores_gemma":[0.0029862374,0.000865197,0.0006177586,0.0023311952,0.0010460105,0.00046725,0.00083411665,0.0013426418,0.0005431206],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.12105972,0.0068124053,0.031113021,0.001384696,0.003501656,0.007470269,0.003806085,0.00087043125,0.00045708552,0.00015774582,0.0071250442,0.81624186],"study_design_scores_gemma":[0.30919966,0.01605204,0.60081196,0.004177903,0.0007422542,0.00011049121,0.000438911,0.06013375,0.00054204115,0.00008178751,0.006708572,0.0010006515],"about_ca_topic_score_codex":0.007980486,"about_ca_topic_score_gemma":0.0009057936,"teacher_disagreement_score":0.81524116,"about_ca_system_score_codex":0.18187475,"about_ca_system_score_gemma":0.09575624,"threshold_uncertainty_score":0.9993799},"labels":[],"label_agreement":null},{"id":"W4401876095","doi":"10.1016/s2152-2650(24)01222-9","title":"AML-609 Gilteritinib-Based Combinations Improve Survival and Enhances Allogenic Transplant Eligibility in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Canadian Single Center Experience","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Single Center; Internal medicine; Transplantation; Oncology","score_opus":0.032060372399925124,"score_gpt":0.34348354237782996,"score_spread":0.31142316997790487,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876095","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98852617,0.0011639721,0.0001426491,0.002191661,0.0019641228,0.0013760544,0.0005506729,0.0003515397,0.0037331844],"genre_scores_gemma":[0.99422616,0.00093833,0.0007861431,0.0016395922,0.00053655705,0.00028633958,0.00045884182,0.0001628999,0.00096514943],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99201703,0.0006807048,0.0022380964,0.00225838,0.0009854629,0.0018203371],"domain_scores_gemma":[0.9941774,0.002123818,0.00021579332,0.0013655953,0.00030957005,0.001807836],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021210625,0.0008407757,0.0015003403,0.00074844353,0.00034393606,0.00032609134,0.0007855547,0.0010682165,0.00028160587],"category_scores_gemma":[0.0009795912,0.0007929314,0.0005305148,0.0011024085,0.001618815,0.00045985164,0.00020568029,0.0015749423,0.00023503663],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0057867174,0.0025675062,0.113810875,0.0016921465,0.0013628536,0.015650788,0.0037059796,0.000027213222,0.17926729,0.002072942,0.0052951807,0.66876054],"study_design_scores_gemma":[0.024466502,0.0041142493,0.86765486,0.0021548101,0.00056746614,0.0008605406,0.0008888228,0.018904401,0.019366918,0.0007008985,0.058046028,0.0022745314],"about_ca_topic_score_codex":0.017525148,"about_ca_topic_score_gemma":0.022854393,"teacher_disagreement_score":0.75384396,"about_ca_system_score_codex":0.010083807,"about_ca_system_score_gemma":0.012329081,"threshold_uncertainty_score":0.9994522},"labels":[],"label_agreement":null},{"id":"W4401876257","doi":"10.1016/s2152-2650(24)01494-0","title":"ABCL-185 Mosunetuzumab with Polatuzumab Vedotin: Subgroup Analyses in Patients (pts) With Primary Refractory or Early Relapsed Large B-Cell Lymphoma (LBCL)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada); McGill University; Jewish General Hospital","funders":"","keywords":"Medicine; Oncology; Refractory (planetary science); Internal medicine; Lymphoma","score_opus":0.028299857927520617,"score_gpt":0.31862729576335885,"score_spread":0.29032743783583825,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876257","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9869937,0.0036237496,0.000027694046,0.00026214847,0.0006060858,0.0015319015,0.000117370524,0.0005414795,0.0062959176],"genre_scores_gemma":[0.99156046,0.0006554485,0.0013049323,0.001493102,0.00050130195,0.00027607096,0.00064141926,0.00030672102,0.0032605554],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9919706,0.00042319056,0.0022218055,0.00228908,0.0015606907,0.0015346304],"domain_scores_gemma":[0.99471855,0.0016108509,0.0005327185,0.0017669472,0.00035491877,0.0010160386],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00063989824,0.0012234712,0.0022534165,0.0006385192,0.00025819245,0.0002864333,0.0005450731,0.00088057684,0.00021020552],"category_scores_gemma":[0.00026917324,0.00078134605,0.0006810519,0.0018542765,0.00045891886,0.00066000276,0.00027829834,0.000554144,0.0006867273],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021752667,0.015105699,0.63666,0.00074475334,0.0016255961,0.01202871,0.0006867229,0.000010337283,0.00009018508,0.0002190503,0.004366768,0.3067095],"study_design_scores_gemma":[0.06645372,0.01105108,0.90077734,0.001803195,0.0011523842,0.00021442806,0.00015477824,0.00037448647,0.00032789534,0.000037637765,0.016680304,0.0009727705],"about_ca_topic_score_codex":0.0010105035,"about_ca_topic_score_gemma":0.0004031476,"teacher_disagreement_score":0.30573675,"about_ca_system_score_codex":0.0089911055,"about_ca_system_score_gemma":0.0063730674,"threshold_uncertainty_score":0.99946374},"labels":[],"label_agreement":null},{"id":"W4401876264","doi":"10.1016/s2152-2650(24)01436-8","title":"MPN-470 Efficacy of Pacritinib in Patients With Myelofibrosis Who Have Both Thrombocytopenia and Anemia","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Anemia; Internal medicine; Oncology; Bone marrow","score_opus":0.019116769765462005,"score_gpt":0.3116485406359668,"score_spread":0.2925317708705048,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876264","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9936696,0.0009707049,0.0000111342415,0.0004905417,0.00018022566,0.0013828988,0.00009051498,0.0000958245,0.0031085],"genre_scores_gemma":[0.9968838,0.00054130395,0.0010744289,0.0005174752,0.00020800349,0.00014080817,0.0001276385,0.00008946329,0.00041705123],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9962604,0.00019306791,0.0013336074,0.001073923,0.00058517855,0.00055379246],"domain_scores_gemma":[0.9969616,0.0016008377,0.00019307598,0.00062283326,0.00017910586,0.00044258195],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00047549134,0.0005134444,0.0015295466,0.00022222617,0.00008781761,0.00009214425,0.00016142784,0.00038124956,0.00017459832],"category_scores_gemma":[0.000427269,0.00036971422,0.00026697974,0.00042505728,0.0005512859,0.00021318813,0.0001507334,0.00033995227,0.00006158446],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015258798,0.0007767235,0.7086819,0.00029779755,0.00022175566,0.00027589474,0.0002592032,0.000001640004,0.000030213321,0.00058810716,0.0014327166,0.28590816],"study_design_scores_gemma":[0.013481006,0.003223553,0.9760342,0.00225563,0.00034943005,0.000039679384,0.00006953766,0.00020738058,0.001007388,0.000096918266,0.0028652304,0.00037004266],"about_ca_topic_score_codex":0.00011398808,"about_ca_topic_score_gemma":0.00005058406,"teacher_disagreement_score":0.28553814,"about_ca_system_score_codex":0.0005700209,"about_ca_system_score_gemma":0.0008238249,"threshold_uncertainty_score":0.9998755},"labels":[],"label_agreement":null},{"id":"W4401876389","doi":"10.1016/s2152-2650(24)01687-2","title":"MM-488 Iberdomide, Bortezomib, and Dexamethasone (IberVd) in Transplant-Ineligible Newly Diagnosed Multiple Myeloma (NDMM): Results From the CC-220-MM-001 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University","funders":"","keywords":"Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Internal medicine; Oncology","score_opus":0.051436834759031554,"score_gpt":0.34713429406455604,"score_spread":0.2956974593055245,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876389","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98262477,0.0054137143,0.000055827462,0.0034536303,0.0014887967,0.0032556062,0.0013404165,0.00043874513,0.0019284725],"genre_scores_gemma":[0.9859865,0.004639914,0.0016791354,0.0011952682,0.00251541,0.00044359165,0.0016029769,0.00019432808,0.0017428998],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9905125,0.0011266005,0.0030394983,0.0023460551,0.001307862,0.0016675193],"domain_scores_gemma":[0.9753534,0.021015912,0.00033026902,0.0017656024,0.00019112458,0.0013436978],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030066231,0.0010000239,0.0020102048,0.000388518,0.0003432938,0.0004002748,0.00075673667,0.0010073257,0.00016936802],"category_scores_gemma":[0.006581052,0.0006978812,0.0008154366,0.0011290812,0.0009028708,0.00042326466,0.00033020505,0.0013386435,0.0007053178],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15216272,0.0035832482,0.042371847,0.00016915907,0.0012207344,0.013017447,0.0009397108,0.0000066565012,0.0003088489,0.00011385489,0.014563219,0.77154255],"study_design_scores_gemma":[0.36067364,0.0014108343,0.6027284,0.0010507726,0.0004886258,0.00022589993,0.00014693274,0.007690426,0.00046722568,0.0005223298,0.023960494,0.0006344115],"about_ca_topic_score_codex":0.009167991,"about_ca_topic_score_gemma":0.003308463,"teacher_disagreement_score":0.7709082,"about_ca_system_score_codex":0.0010632949,"about_ca_system_score_gemma":0.002154143,"threshold_uncertainty_score":0.99954724},"labels":[],"label_agreement":null},{"id":"W4401876465","doi":"10.1016/s2152-2650(24)01517-9","title":"ABCL-340 Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chimeric antigen receptor; Refractory (planetary science); Phases of clinical research; Oncology; Lymphoma; Internal medicine; Cancer research; Immunotherapy; Clinical trial; Cancer","score_opus":0.029723763590510346,"score_gpt":0.34594281705386265,"score_spread":0.31621905346335233,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876465","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9778013,0.017909959,0.000024941746,0.00011172041,0.00040744108,0.0031132286,0.0003697743,0.00018845162,0.00007314404],"genre_scores_gemma":[0.99109846,0.0036557904,0.0005914492,0.00045688218,0.0003359686,0.00023766767,0.00041468575,0.00027793527,0.0029311697],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99211454,0.0012626081,0.002055795,0.0022319683,0.0011661389,0.0011689462],"domain_scores_gemma":[0.9961065,0.0014548466,0.00036791922,0.0011167454,0.00019101736,0.00076294877],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0018781764,0.00097310415,0.0023025624,0.00069174246,0.00016602867,0.00022784031,0.00039121386,0.00045579948,0.0011164728],"category_scores_gemma":[0.00033939097,0.0007244711,0.00036839096,0.0017022049,0.00039951774,0.00038664028,0.00020298526,0.00072947773,0.00006289966],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.060634654,0.021187665,0.28180707,0.00009070414,0.00079581636,0.0010654288,0.0014661201,5.0519526e-7,0.026342621,0.0000011253273,0.0008909985,0.6057173],"study_design_scores_gemma":[0.19248965,0.010094285,0.7842683,0.00021362893,0.00022500864,0.000024597888,0.00072922587,0.0033650526,0.0017220401,0.000009056189,0.0060797296,0.00077940064],"about_ca_topic_score_codex":0.0016823171,"about_ca_topic_score_gemma":0.00025339815,"teacher_disagreement_score":0.6049379,"about_ca_system_score_codex":0.0009801816,"about_ca_system_score_gemma":0.0016796611,"threshold_uncertainty_score":0.9997966},"labels":[],"label_agreement":null},{"id":"W4401876575","doi":"10.1016/s2152-2650(24)00986-8","title":"Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","score_opus":0.03394083343133087,"score_gpt":0.3328008750787567,"score_spread":0.29886004164742586,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876575","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9888236,0.0028282765,0.000076691664,0.00037912448,0.00054393726,0.0065737115,0.00017716094,0.00032597294,0.00027152596],"genre_scores_gemma":[0.99589133,0.00035639037,0.0015892612,0.0003747016,0.000205771,0.0005298817,0.00064447057,0.00020901927,0.00019919808],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98947865,0.0021100168,0.0031545325,0.0023300264,0.0016122271,0.0013145335],"domain_scores_gemma":[0.9819982,0.014193653,0.00073788833,0.0016184094,0.00033041308,0.0011214239],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0030503268,0.0012014891,0.0038196023,0.00046351823,0.00043565786,0.0004065997,0.0004159775,0.0005690195,0.000110007146],"category_scores_gemma":[0.0059059495,0.0007491076,0.0005345138,0.0008625312,0.0014139483,0.0005284685,0.0006156,0.0014410956,0.000059222308],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.110139824,0.0032262246,0.6473425,0.00006760318,0.0026889383,0.0020194196,0.00097147067,0.0000015523142,0.000023120352,0.000013320103,0.00021628111,0.23328973],"study_design_scores_gemma":[0.32991853,0.0028945198,0.66004163,0.0005343046,0.0011639021,0.00006477379,0.0004277605,0.004010949,0.000052876032,0.000043433116,0.0003226384,0.000524705],"about_ca_topic_score_codex":0.0037248828,"about_ca_topic_score_gemma":0.00092613604,"teacher_disagreement_score":0.23276502,"about_ca_system_score_codex":0.00093169033,"about_ca_system_score_gemma":0.00095827854,"threshold_uncertainty_score":0.999496},"labels":[],"label_agreement":null},{"id":"W4401876784","doi":"10.1016/s2152-2650(24)00886-3","title":"Efficacy and Safety of Ibrutinib Plus Venetoclax in Patients With Mantle Cell Lymphoma (MCL) and TP53 Mutations in the SYMPATICO Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre","funders":"","keywords":"Ibrutinib; Mantle cell lymphoma; Venetoclax; Medicine; Lymphoma; Oncology; Cancer research; Internal medicine; Leukemia; Chronic lymphocytic leukemia","score_opus":0.02119839309452989,"score_gpt":0.3245038845152921,"score_spread":0.30330549142076224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876784","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944972,0.0012609016,0.000009908722,0.00015172317,0.00013082776,0.0025801645,0.000027780776,0.000051895568,0.0012896045],"genre_scores_gemma":[0.9990294,0.00016143493,0.00016189356,0.00017372821,0.0000876112,0.0001045293,0.000057145407,0.00006581807,0.00015843046],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99567145,0.000522334,0.0014391205,0.00089577615,0.000871067,0.00060023135],"domain_scores_gemma":[0.9950957,0.0035773567,0.00016742942,0.0008037617,0.00012179137,0.00023401118],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016784074,0.0003743837,0.0009307763,0.00033470718,0.00009953256,0.000089979956,0.00033023788,0.00027418934,0.000029967598],"category_scores_gemma":[0.00064878917,0.0002532683,0.00010764539,0.0010038167,0.000743243,0.00015772632,0.00026725527,0.00035337528,0.0000338874],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.011226146,0.0036764243,0.3857888,0.001323225,0.00038565422,0.002064994,0.009259555,0.0002175933,0.000026596716,0.0004697983,0.00032420878,0.585237],"study_design_scores_gemma":[0.07872399,0.00229342,0.90584856,0.0006831707,0.0002043978,0.000090737456,0.00090905,0.010299641,0.00003312637,0.000098104574,0.00056879135,0.0002470118],"about_ca_topic_score_codex":0.00072564086,"about_ca_topic_score_gemma":0.00016781136,"teacher_disagreement_score":0.58498996,"about_ca_system_score_codex":0.00874829,"about_ca_system_score_gemma":0.010148646,"threshold_uncertainty_score":0.99999195},"labels":[],"label_agreement":null},{"id":"W4401876795","doi":"10.1016/s2152-2650(24)00983-2","title":"Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients With Relapsed/Refractory Multiple Myeloma (RRMM): Results From the CC-92480-MM-002 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Queen Elizabeth II Health Sciences Centre; Dalhousie University; Université de Montréal; Hôpital Maisonneuve-Rosemont; University of Alberta","funders":"","keywords":"Carfilzomib; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Lenalidomide; Oncology; Internal medicine","score_opus":0.04655856962218402,"score_gpt":0.33104658670500936,"score_spread":0.28448801708282534,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876795","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889141,0.0020711448,0.000030103554,0.0010403186,0.0012841607,0.0042016055,0.0010663528,0.00037113173,0.0010211165],"genre_scores_gemma":[0.99113625,0.0008159341,0.0017888101,0.00081753824,0.001528224,0.00038786596,0.0012928841,0.00024668858,0.0019858165],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9900705,0.0011465172,0.0028913005,0.0025292572,0.0017675862,0.0015948064],"domain_scores_gemma":[0.98218596,0.013447168,0.0005310816,0.0021323443,0.00035242856,0.0013510444],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022770658,0.0011098023,0.002175515,0.00038203484,0.0003904868,0.00034297013,0.0007387791,0.0009960701,0.00017851923],"category_scores_gemma":[0.009345072,0.00065517204,0.0005880336,0.0011699068,0.0011833103,0.00054548326,0.0005362136,0.0015779196,0.00036369334],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.3810925,0.002685713,0.13657303,0.000116484414,0.0014235348,0.0035593242,0.0006151418,0.0000057668467,0.000038224687,0.00003201125,0.006995948,0.46686232],"study_design_scores_gemma":[0.32405818,0.0038844782,0.65197927,0.0008060382,0.00042954244,0.00004543613,0.00015787157,0.0022998767,0.000093335606,0.000067358604,0.015618609,0.000560041],"about_ca_topic_score_codex":0.003515396,"about_ca_topic_score_gemma":0.002519679,"teacher_disagreement_score":0.5154062,"about_ca_system_score_codex":0.002576218,"about_ca_system_score_gemma":0.0043726317,"threshold_uncertainty_score":0.99959},"labels":[],"label_agreement":null},{"id":"W4401876847","doi":"10.1016/s2152-2650(24)00857-7","title":"Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Follicular phase; Oncology; Internal medicine; Lymphoma","score_opus":0.018964239231852156,"score_gpt":0.31255429481854125,"score_spread":0.2935900555866891,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876847","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9927053,0.0025663052,0.000010393218,0.00048751617,0.00054650364,0.003085372,0.00020644927,0.00027927372,0.00011292573],"genre_scores_gemma":[0.9945572,0.00040593854,0.0009905259,0.0010649539,0.00025155634,0.00089669524,0.000086904365,0.000169977,0.0015762185],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99464077,0.0005125156,0.0015732972,0.001706318,0.00078234577,0.0007847328],"domain_scores_gemma":[0.9963765,0.0014621657,0.00022702148,0.0010734492,0.00018980846,0.00067106256],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006931168,0.00081042416,0.0015788124,0.0003555029,0.00022671997,0.00024342172,0.00026290183,0.00043428392,0.00021101533],"category_scores_gemma":[0.0004154611,0.0005450689,0.0003870024,0.00068579544,0.00028108462,0.00036637223,0.00017286476,0.00022794717,0.00012366273],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.08036345,0.006634571,0.43071043,0.000035831,0.0012920361,0.0031432193,0.0025714166,5.254432e-7,0.0000821351,0.000010955057,0.00062469876,0.47453073],"study_design_scores_gemma":[0.099884726,0.026616663,0.86221254,0.0010223684,0.0005510411,0.000028469958,0.00075011404,0.00011268293,0.00022041688,0.000049069426,0.007949651,0.00060223666],"about_ca_topic_score_codex":0.0007221695,"about_ca_topic_score_gemma":0.00042565976,"teacher_disagreement_score":0.47392848,"about_ca_system_score_codex":0.0016154634,"about_ca_system_score_gemma":0.0017405935,"threshold_uncertainty_score":0.99970007},"labels":[],"label_agreement":null},{"id":"W4401876864","doi":"10.1016/s2152-2650(24)01317-x","title":"CML-425 Dose-Optimization Study of 3 Starting Doses of Ponatinib: Long-Term Results From the OPTIC Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ponatinib; Term (time); Oncology; Internal medicine; Dasatinib; Myeloid leukemia; Imatinib","score_opus":0.07699754545939498,"score_gpt":0.39549925531204505,"score_spread":0.3185017098526501,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876864","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9930805,0.0009931563,0.00013121853,0.000413261,0.001222044,0.0024962188,0.00012777906,0.0001861612,0.0013496652],"genre_scores_gemma":[0.99599546,0.00020638498,0.0011097295,0.00014920147,0.0015844256,0.000075523,0.00019764925,0.000104638726,0.0005770029],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9920705,0.00081844133,0.0036837154,0.0011563797,0.001630356,0.00064060424],"domain_scores_gemma":[0.98510426,0.011603706,0.00073884573,0.0017404748,0.00048141158,0.00033131367],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0035174452,0.00043834752,0.0013490767,0.00021173849,0.0001462706,0.00010615487,0.0007640186,0.00045083987,0.00019965776],"category_scores_gemma":[0.009301702,0.00030204706,0.00057906023,0.0010479558,0.0007133149,0.00020887957,0.00050068024,0.00056156865,0.000078470744],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.23822992,0.0057921363,0.01341468,0.0011117168,0.003724287,0.0032964023,0.0079497695,0.005129608,0.0010439614,0.00040107506,0.0057803723,0.71412605],"study_design_scores_gemma":[0.442436,0.009617305,0.39446643,0.0024756028,0.001581243,0.00011660942,0.0018245237,0.14479557,0.0014483256,0.00020446385,0.00039836642,0.0006355745],"about_ca_topic_score_codex":0.0016731381,"about_ca_topic_score_gemma":0.00009250921,"teacher_disagreement_score":0.7134905,"about_ca_system_score_codex":0.0055766725,"about_ca_system_score_gemma":0.013955304,"threshold_uncertainty_score":0.99994314},"labels":[],"label_agreement":null},{"id":"W4401876867","doi":"10.1016/s2152-2650(24)00909-1","title":"Valemetostat for Patients With R/R Peripheral T-Cell Lymphomas (PTCLs): A Phase 2 VALENTINE-PTCL01 Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"T-cell and Retrovirus Studies","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Medicine; Peripheral; Internal medicine; Oncology; Pathology","score_opus":0.01994996629773042,"score_gpt":0.30534003424420186,"score_spread":0.2853900679464714,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401876867","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9813143,0.0057010013,0.0003806745,0.00021355669,0.007132684,0.0017875336,0.00051160634,0.0004791892,0.0024794443],"genre_scores_gemma":[0.9825571,0.00031872635,0.0004951723,0.0003745315,0.00087928004,0.00034468775,0.00067490997,0.00013601445,0.014219589],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9956043,0.00035024277,0.0014626604,0.0013002263,0.00017041076,0.0011121773],"domain_scores_gemma":[0.99713415,0.0015188293,0.00030132232,0.0006406711,0.00025278312,0.00015224137],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00069282664,0.000677704,0.0011590116,0.00017527245,0.0005540145,0.00012631084,0.0005245013,0.00072913384,0.00055747636],"category_scores_gemma":[0.00033580334,0.00048179989,0.0008842034,0.0003556684,0.00088818464,0.00021587904,0.00024155871,0.00036966612,0.0008630106],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.10566225,0.004666968,0.0066512334,0.0004452602,0.0022629045,0.00012800138,0.0005894673,0.0000029072894,0.0066915494,0.0013883008,0.06050799,0.81100315],"study_design_scores_gemma":[0.26664138,0.015130889,0.025655119,0.0002522652,0.0010568688,0.000049344366,0.00022860807,0.00008453203,0.0052786143,0.0006461459,0.68357676,0.0013994868],"about_ca_topic_score_codex":0.0000492275,"about_ca_topic_score_gemma":0.000016556967,"teacher_disagreement_score":0.8096037,"about_ca_system_score_codex":0.00050923065,"about_ca_system_score_gemma":0.0009536081,"threshold_uncertainty_score":0.99991494},"labels":[],"label_agreement":null},{"id":"W4401877094","doi":"10.1016/s2152-2650(24)00789-4","title":"Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin (COO) in the POLARIX Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia; Roche (Canada)","funders":"","keywords":"Medicine; CHOP; Oncology; Internal medicine; Cancer research; Lymphoma","score_opus":0.03292318217930183,"score_gpt":0.3422123431779536,"score_spread":0.3092891609986518,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877094","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929542,0.0045187483,0.000031021125,0.00013774261,0.0012295989,0.0005043762,0.00004723403,0.000007511169,0.0005695772],"genre_scores_gemma":[0.99733293,0.00156629,0.00012649996,0.00019637999,0.000629166,0.000034277484,0.000019563202,0.00003804098,0.000056827157],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99685013,0.0003319167,0.0015411061,0.00063804886,0.00027595847,0.0003628356],"domain_scores_gemma":[0.9967839,0.0019073158,0.00022733562,0.0009149306,0.00007008812,0.00009639707],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0013582938,0.00027903283,0.0005528211,0.00006838194,0.000047214773,0.000051144678,0.0008109903,0.0003220109,0.000015707305],"category_scores_gemma":[0.0006038805,0.00018115249,0.00037764816,0.00030724696,0.00032378797,0.000005569626,0.0003608623,0.00031759552,0.000008642032],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0018841989,0.0015430779,0.80343604,0.000105538435,0.00026216332,0.00012185959,0.00062638597,0.00048569683,0.0061957124,0.00067133637,0.00078649033,0.18388149],"study_design_scores_gemma":[0.0030984548,0.0015347552,0.9879321,0.000052037423,0.00010475448,0.0000054489865,0.00043763456,0.00040137963,0.0012652015,0.00033770993,0.0046167104,0.0002138363],"about_ca_topic_score_codex":0.00062773575,"about_ca_topic_score_gemma":0.0022176392,"teacher_disagreement_score":0.18449603,"about_ca_system_score_codex":0.00013087183,"about_ca_system_score_gemma":0.0006433154,"threshold_uncertainty_score":0.7387184},"labels":[],"label_agreement":null},{"id":"W4401877238","doi":"10.1016/s2152-2650(24)01664-1","title":"MM-328 Efficacy and Safety of Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) With High-Risk (HR) Features: a Subgroup Analysis From the Phase 1/2 MajesTEC-1 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Calgary","funders":"","keywords":"Medicine; Subgroup analysis; Internal medicine; Oncology; Multiple myeloma; Confidence interval","score_opus":0.01636859731662604,"score_gpt":0.3111379459528655,"score_spread":0.29476934863623944,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877238","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9941262,0.0013160821,0.00006926872,0.00017454544,0.00014625565,0.003118975,0.0007761386,0.00016265314,0.00010985232],"genre_scores_gemma":[0.99722975,0.00030204226,0.0008483137,0.00011931774,0.00020999061,0.00016197895,0.0008114869,0.00012565055,0.00019145511],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933157,0.0009641958,0.0016932047,0.0017013504,0.0014732507,0.0008522739],"domain_scores_gemma":[0.9905562,0.0061770794,0.00048687513,0.00176946,0.00032141779,0.0006889879],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0012307051,0.00076806644,0.0019136159,0.0005409928,0.00027730296,0.00015205808,0.0004974505,0.00042243514,0.00010178685],"category_scores_gemma":[0.0015714429,0.00043381864,0.00040696986,0.0022812614,0.0008812223,0.00028224217,0.00028043232,0.0010745286,0.00003979857],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0351788,0.004708793,0.693038,0.000066522196,0.0051886123,0.0010693789,0.0006730351,0.000016545198,0.000019393447,0.000013874574,0.00014477823,0.25988227],"study_design_scores_gemma":[0.08725791,0.009952937,0.8963099,0.00057950075,0.0037017106,0.000013456032,0.0005087683,0.0006607558,0.000055260145,0.000022631595,0.0005142543,0.00042293576],"about_ca_topic_score_codex":0.005104135,"about_ca_topic_score_gemma":0.0038662897,"teacher_disagreement_score":0.25945935,"about_ca_system_score_codex":0.0009057547,"about_ca_system_score_gemma":0.0011184966,"threshold_uncertainty_score":0.99981135},"labels":[],"label_agreement":null},{"id":"W4401877385","doi":"10.1016/s2152-2650(24)01700-2","title":"MM-542 Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Dexamethasone; Bortezomib; Internal medicine; Oncology; Refractory (planetary science); Multiple myeloma","score_opus":0.034740617643537634,"score_gpt":0.33254429824586,"score_spread":0.2978036806023224,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877385","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883651,0.0029885906,0.00008195206,0.0003933984,0.000580172,0.0067671817,0.00019814605,0.00034261832,0.00028283702],"genre_scores_gemma":[0.99570405,0.00037939774,0.0016248812,0.00037974672,0.00021806348,0.00055927376,0.0007047198,0.00022250078,0.00020733787],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.988971,0.0022028913,0.0032999103,0.0024384283,0.0017009272,0.0013868328],"domain_scores_gemma":[0.98164207,0.014341344,0.000789098,0.0017067454,0.0003509653,0.0011697778],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0031217127,0.0012675165,0.0039906455,0.0004886826,0.00046108235,0.0004265966,0.0004723344,0.00060428184,0.00011551367],"category_scores_gemma":[0.006124524,0.00079610193,0.00056671666,0.0009057606,0.0014441746,0.0005545033,0.00064523047,0.0015127904,0.00006350062],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.11313674,0.0034246875,0.64315534,0.000072456416,0.0028408105,0.0021325669,0.0010070902,0.0000017099778,0.000025267625,0.000013645463,0.0002315602,0.23395815],"study_design_scores_gemma":[0.33328763,0.0030341565,0.656314,0.000548305,0.001239349,0.000070289774,0.00045141557,0.0040521338,0.00006129912,0.000045296445,0.00034159442,0.00055452844],"about_ca_topic_score_codex":0.0038128344,"about_ca_topic_score_gemma":0.00096065615,"teacher_disagreement_score":0.23340362,"about_ca_system_score_codex":0.0010184282,"about_ca_system_score_gemma":0.0010386225,"threshold_uncertainty_score":0.999449},"labels":[],"label_agreement":null},{"id":"W4401877474","doi":"10.1016/s2152-2650(24)00811-5","title":"Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase 2 Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Chimeric antigen receptor; Oncology; Refractory (planetary science); Internal medicine; Lymphoma; Phases of clinical research; Immunotherapy; Clinical trial; Cancer","score_opus":0.030020297283375175,"score_gpt":0.3461436852849306,"score_spread":0.3161233880015554,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877474","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9786215,0.017266657,0.000022876891,0.000096243035,0.00038318732,0.0030224994,0.00033922205,0.00017609993,0.00007172616],"genre_scores_gemma":[0.9920046,0.003339086,0.00056227244,0.00043783922,0.00031578902,0.00022339569,0.0003873222,0.00025890087,0.0024708465],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9925216,0.0012183638,0.0019397578,0.0021207295,0.0010993968,0.0011001943],"domain_scores_gemma":[0.9963248,0.0013894399,0.00033958713,0.0010500003,0.0001800658,0.0007161077],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0017930348,0.00091287534,0.0021846658,0.0006550331,0.00015456996,0.00021079788,0.00035983516,0.000425396,0.0010681399],"category_scores_gemma":[0.00033583157,0.0006759042,0.00034200898,0.0016285017,0.0004157016,0.00036380612,0.00019020455,0.000684725,0.000057056186],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06014099,0.02056964,0.277336,0.00008542255,0.0007446889,0.0010058335,0.0014347399,4.4673024e-7,0.026054827,0.0000010850406,0.0008549444,0.6117714],"study_design_scores_gemma":[0.18614067,0.0098855365,0.7913134,0.00019953628,0.0002056887,0.000022277765,0.0006479199,0.0032190462,0.0016922712,0.000007551991,0.0059506777,0.00071540236],"about_ca_topic_score_codex":0.0013099244,"about_ca_topic_score_gemma":0.000194033,"teacher_disagreement_score":0.61105597,"about_ca_system_score_codex":0.0007802566,"about_ca_system_score_gemma":0.001529623,"threshold_uncertainty_score":0.999845},"labels":[],"label_agreement":null},{"id":"W4401877498","doi":"10.1016/s2152-2650(24)00991-1","title":"DREAMM-7 Update: Subgroup Analyses From a Phase 3 Trial of Belantamab Mafodotin (Belamaf) + Bortezomib and Dexamethasone (BVd) vs Daratumumab, Bortezomib, and Dexamethasone (DVd) in Relapsed/Refractory Multiple Myeloma (RRMM)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Daratumumab; Dexamethasone; Bortezomib; Oncology; Internal medicine; Multiple myeloma","score_opus":0.07079501631935992,"score_gpt":0.40671953953289164,"score_spread":0.3359245232135317,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401877498","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98072284,0.013687532,0.00019789096,0.00048000584,0.0007931683,0.0024619282,0.0008357722,0.00029951314,0.00052135973],"genre_scores_gemma":[0.9859717,0.004829235,0.0058057667,0.00029830332,0.0008880737,0.00024314043,0.0011798955,0.0002286433,0.0005552339],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98965555,0.0013139651,0.0034521963,0.0026389358,0.0014109777,0.001528361],"domain_scores_gemma":[0.9879098,0.007869787,0.0006761809,0.0016432377,0.00027937657,0.0016216394],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0026102504,0.0012055619,0.0033739277,0.0010440461,0.00023719882,0.00025997218,0.0005485807,0.0012888698,0.00041344474],"category_scores_gemma":[0.004585422,0.0010343924,0.0008181513,0.0014408472,0.0015330584,0.0005423299,0.0006089098,0.0014766958,0.00014220529],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.15030953,0.004139854,0.10596964,0.0004953791,0.0024979764,0.0060471306,0.00049496925,0.00000235901,0.009714229,0.00012797769,0.0020024416,0.71819854],"study_design_scores_gemma":[0.2508529,0.006600271,0.7138761,0.0012323834,0.001376198,0.00033709873,0.00029716885,0.011834532,0.0061937496,0.00040595527,0.0060198857,0.0009737567],"about_ca_topic_score_codex":0.0040731835,"about_ca_topic_score_gemma":0.0010381963,"teacher_disagreement_score":0.7172248,"about_ca_system_score_codex":0.0010852448,"about_ca_system_score_gemma":0.0020172822,"threshold_uncertainty_score":0.99921066},"labels":[],"label_agreement":null},{"id":"W4401878183","doi":"10.1016/s2152-2650(24)00662-1","title":"Efficacy and Safety Is Maintained in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan for Up to 3 Years","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network","funders":"","keywords":"Paroxysmal nocturnal hemoglobinuria; Medicine; Nocturnal; Internal medicine","score_opus":0.014580681075656613,"score_gpt":0.2952509919852363,"score_spread":0.28067031090957967,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878183","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99551034,0.0004868591,0.00012988248,0.00040068323,0.0015591943,0.0012798966,0.0003489264,0.00013083598,0.00015337445],"genre_scores_gemma":[0.9974183,0.000025212441,0.00030417656,0.0007786957,0.00015840108,0.00010667611,0.00025078972,0.000052136802,0.00090562005],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9971658,0.00026522556,0.001017915,0.00084053824,0.00009581383,0.00061470567],"domain_scores_gemma":[0.99769914,0.0014955049,0.00013390784,0.00040784833,0.000115037066,0.000148572],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005473137,0.0003220568,0.0006120885,0.00016224591,0.0001311415,0.00007945421,0.00032121138,0.0002916826,0.00036999752],"category_scores_gemma":[0.00062078435,0.00027470873,0.00016460277,0.0002582452,0.00019595255,0.000112088775,0.00020057076,0.0002171144,0.00030249546],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.014518126,0.00029339918,0.39004546,0.0003574488,0.00068837637,0.00009534421,0.001411495,0.000014958657,0.00047330128,0.0009231463,0.04691679,0.5442621],"study_design_scores_gemma":[0.011445947,0.00075186347,0.9532015,0.0006677526,0.000098431075,0.000032946573,0.00012759055,0.000054617456,0.00011353019,0.00010425512,0.033036236,0.00036533308],"about_ca_topic_score_codex":0.000065499604,"about_ca_topic_score_gemma":0.000082480095,"teacher_disagreement_score":0.563156,"about_ca_system_score_codex":0.00052431354,"about_ca_system_score_gemma":0.00044730108,"threshold_uncertainty_score":0.9999705},"labels":[],"label_agreement":null},{"id":"W4401878208","doi":"10.1016/s2152-2650(24)00694-3","title":"Transfusion Intensity Over Time in Patients From the Phase 3 SIMPLIFY-1 and MOMENTUM Trials of Momelotinib","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Intensity (physics); Phase (matter); Oncology; Internal medicine; Quantum mechanics","score_opus":0.04017904735557419,"score_gpt":0.36146646303458746,"score_spread":0.32128741567901326,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878208","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9948804,0.0014764384,0.000015448633,0.0007456486,0.0007359422,0.0013410919,0.000366245,0.00011003493,0.00032876522],"genre_scores_gemma":[0.997206,0.0007169427,0.00013035926,0.00065619696,0.00043356683,0.00003691956,0.00038294878,0.000064775,0.00037234498],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99513537,0.0005116936,0.0024431497,0.0008902891,0.00057756493,0.0004419547],"domain_scores_gemma":[0.99398583,0.0044981698,0.00032281893,0.00076553744,0.00012299122,0.00030464318],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0022799491,0.00041716947,0.0018076517,0.00014756549,0.000069870046,0.00004873043,0.00023333577,0.00043117086,0.00064406614],"category_scores_gemma":[0.002454117,0.00027233016,0.0005677791,0.00043984145,0.0004105816,0.00015473957,0.0001849338,0.00041701132,0.00016117236],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.006377344,0.0014766178,0.16812836,0.00015157601,0.00077589304,0.00025513856,0.00063453405,0.0000018187321,0.0027739587,0.00006090331,0.009942664,0.8094212],"study_design_scores_gemma":[0.032137223,0.0012763422,0.9541881,0.0008699048,0.00059956935,0.000016132284,0.000039720886,0.0028746743,0.0013779331,0.0005132169,0.0058627627,0.00024439706],"about_ca_topic_score_codex":0.00070592633,"about_ca_topic_score_gemma":0.000028440689,"teacher_disagreement_score":0.8091768,"about_ca_system_score_codex":0.0015789841,"about_ca_system_score_gemma":0.0011431873,"threshold_uncertainty_score":0.9999729},"labels":[],"label_agreement":null},{"id":"W4401878210","doi":"10.1016/s2152-2650(24)00689-x","title":"The Impact of New or Worsening Anemia on Clinical Outcomes in 2233 Patients With Myelofibrosis Treated With Ruxolitinib: Results From the Expanded-Access JUMP Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Anemia; Internal medicine; Oncology; Intensive care medicine; Bone marrow","score_opus":0.0710747234573941,"score_gpt":0.40867704013906925,"score_spread":0.3376023166816752,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99481285,0.00014845864,0.0000035097537,0.0007678593,0.00028558733,0.0029931373,0.00027428512,0.00014245015,0.00057184504],"genre_scores_gemma":[0.9974236,0.00023499377,0.00017630126,0.0003636139,0.000456257,0.00027512744,0.00020294831,0.00011245966,0.0007546841],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99327826,0.0008467232,0.0027458214,0.0014091935,0.0009838744,0.0007361296],"domain_scores_gemma":[0.97969645,0.017325887,0.00064159016,0.0015035536,0.0002771892,0.00055532466],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013822871,0.000783637,0.0018420751,0.00014272142,0.00026967272,0.0003017262,0.0005989066,0.00035003593,0.00008788623],"category_scores_gemma":[0.002336352,0.00029290965,0.00065887393,0.0009694852,0.0005531593,0.00022148054,0.00020743675,0.00070472865,0.00006294914],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.028642097,0.0021782233,0.7642855,0.000012109443,0.00150007,0.0004513841,0.00051127473,0.00002955708,6.7688865e-7,0.000017870861,0.0022865804,0.20008467],"study_design_scores_gemma":[0.028251046,0.017594932,0.95075727,0.0013155502,0.0006545936,0.000013525957,0.00040781428,0.00015308255,0.00005828145,0.000038683185,0.00039691897,0.00035833567],"about_ca_topic_score_codex":0.004907187,"about_ca_topic_score_gemma":0.0016433349,"teacher_disagreement_score":0.19972634,"about_ca_system_score_codex":0.0008871921,"about_ca_system_score_gemma":0.0026816623,"threshold_uncertainty_score":0.9999523},"labels":[],"label_agreement":null},{"id":"W4401878297","doi":"10.1016/s2152-2650(24)00620-7","title":"Dose-Optimization Study of 3 Starting Doses of Ponatinib: Long-Term Results From the OPTIC Trial","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ponatinib; Term (time); Oncology; Internal medicine; Dasatinib","score_opus":0.0779670394684194,"score_gpt":0.395783041813826,"score_spread":0.31781600234540663,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878297","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99367917,0.0008798289,0.000119860466,0.0003725379,0.001105878,0.0023108898,0.000110441644,0.00016725136,0.0012541686],"genre_scores_gemma":[0.9963891,0.00017545701,0.001039611,0.00012989693,0.0014465797,0.0000660747,0.00017246343,0.00009307837,0.00048774978],"study_design_codex":"design_other","study_design_gemma":"randomized_trial","domain_scores_codex":[0.9927307,0.00073841267,0.0034177594,0.0010465123,0.0014958483,0.0005707642],"domain_scores_gemma":[0.9860238,0.010981123,0.0006675673,0.0015963836,0.00043528815,0.0002958288],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0032611121,0.00038996153,0.0012271119,0.0001882583,0.00012838068,0.00009291821,0.0006844897,0.0004000699,0.00017812838],"category_scores_gemma":[0.008571846,0.00026570875,0.00052774453,0.00096113764,0.00065369764,0.00018718302,0.00044411496,0.00050077506,0.000067855886],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.23444702,0.0052283495,0.012770555,0.00094966026,0.0033593427,0.0029514257,0.0073480806,0.004637677,0.00090179825,0.00035452028,0.0047347117,0.72231686],"study_design_scores_gemma":[0.43607214,0.009321929,0.40751624,0.0022169477,0.00140505,0.00010315466,0.0016529451,0.13937284,0.001294786,0.00017845718,0.0003173848,0.00054812466],"about_ca_topic_score_codex":0.001539441,"about_ca_topic_score_gemma":0.000081233884,"teacher_disagreement_score":0.72176874,"about_ca_system_score_codex":0.0050474075,"about_ca_system_score_gemma":0.013054314,"threshold_uncertainty_score":0.9999795},"labels":[],"label_agreement":null},{"id":"W4401878485","doi":"10.1016/s2152-2650(24)00565-2","title":"Final Analysis of the RESONATE-2 Study: Up to 10 Years of Follow-Up of First-Line Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Ibrutinib; Medicine; Chronic lymphocytic leukemia; Internal medicine; Oncology; Lymphoma; Leukemia","score_opus":0.04363337908781482,"score_gpt":0.33270961913500186,"score_spread":0.289076240047187,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878485","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.993752,0.0012137789,0.000024611712,0.00006662329,0.00077762426,0.0034502868,0.00023936972,0.00012050949,0.00035521184],"genre_scores_gemma":[0.9956227,0.0002629867,0.00017987125,0.00010599922,0.0002180158,0.00025045933,0.00014557327,0.00019303638,0.0030213655],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9894514,0.00067224354,0.0040998952,0.0019711393,0.0024008416,0.0014044787],"domain_scores_gemma":[0.9911499,0.0031844636,0.0009034103,0.0032313778,0.00081685185,0.00071400026],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019340485,0.0009824989,0.003700685,0.0017155723,0.000127162,0.000063109,0.0014204379,0.0006848006,0.0003237538],"category_scores_gemma":[0.0018610937,0.00071519695,0.0017997179,0.0074379737,0.0011590642,0.00017701037,0.00082564796,0.0003036842,0.000108607666],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.034028098,0.0025346274,0.29280233,0.002047177,0.013487639,0.0011850689,0.00424616,0.014106234,0.00016109983,0.00016546677,0.0008028462,0.63443327],"study_design_scores_gemma":[0.09683895,0.009382097,0.8276249,0.0017776178,0.0049947402,0.00004439614,0.00026284563,0.05494986,0.0015152176,0.000030046933,0.001961013,0.00061827793],"about_ca_topic_score_codex":0.0113315545,"about_ca_topic_score_gemma":0.0058158017,"teacher_disagreement_score":0.633815,"about_ca_system_score_codex":0.18878855,"about_ca_system_score_gemma":0.09878354,"threshold_uncertainty_score":0.9995299},"labels":[],"label_agreement":null},{"id":"W4401878520","doi":"10.1016/s2152-2650(24)00390-2","title":"ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Oncology; Cancer research; Receptor","score_opus":0.019348148863125917,"score_gpt":0.29995262759059965,"score_spread":0.28060447872747374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98964113,0.0020463734,0.000007674222,0.00043812997,0.0011294953,0.004955962,0.0004148445,0.0006283294,0.00073805],"genre_scores_gemma":[0.9942188,0.00031899888,0.00076470897,0.00088728004,0.000985265,0.00048056312,0.0013503578,0.00038430127,0.00060972705],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98717993,0.0007567183,0.0048551937,0.003165648,0.002274631,0.0017678927],"domain_scores_gemma":[0.9915509,0.0024171951,0.0010821737,0.0024931703,0.0007182858,0.0017382792],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.001474793,0.001589312,0.003107226,0.001042126,0.00023732691,0.00017053886,0.0008442916,0.0010881346,0.00013639561],"category_scores_gemma":[0.003325618,0.0013446934,0.00065193314,0.004043289,0.0011812162,0.0007257767,0.0005332032,0.0015761259,0.0002656636],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030219391,0.01654534,0.4471882,0.0019341462,0.0025126075,0.009877523,0.0038120446,0.00018635699,0.0016530973,0.000039077662,0.029092057,0.45694014],"study_design_scores_gemma":[0.14580198,0.02112852,0.81901056,0.003488943,0.0010828318,0.00010933244,0.0001672658,0.0018253353,0.0020267195,0.00003422776,0.004187194,0.001137122],"about_ca_topic_score_codex":0.0023725862,"about_ca_topic_score_gemma":0.0007695158,"teacher_disagreement_score":0.45580304,"about_ca_system_score_codex":0.02267708,"about_ca_system_score_gemma":0.02635173,"threshold_uncertainty_score":0.99968547},"labels":[],"label_agreement":null},{"id":"W4401878537","doi":"10.1016/s2152-2650(24)00372-0","title":"What Is Dark Zone Lymphoma and Is It Clinically Relevant?","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Lymphoma; Oncology; Internal medicine","score_opus":0.037758515209233665,"score_gpt":0.3579115738942809,"score_spread":0.32015305868504723,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878537","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93530583,0.020538291,0.000045307446,0.030791963,0.0037039693,0.00096097053,0.0001001361,0.00052544236,0.008028071],"genre_scores_gemma":[0.9014242,0.044080347,0.001775038,0.037666444,0.0016902462,0.00015386977,0.0001072313,0.00018710693,0.012915503],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99249107,0.00025853454,0.002861573,0.0023184544,0.0009958586,0.0010745152],"domain_scores_gemma":[0.99315816,0.0031872622,0.00033394608,0.0016842305,0.0002711333,0.0013652695],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0015751617,0.0008927022,0.0018416352,0.00025456655,0.00027794053,0.0007892746,0.0004131472,0.001080485,0.0009132071],"category_scores_gemma":[0.0006499059,0.0007120416,0.0012251186,0.0006642697,0.0009056615,0.0007800526,0.00046863346,0.0003519418,0.0036691483],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0007891329,0.0008557205,0.035151627,0.0002793038,0.0009756272,0.0030570545,0.0006499283,1.5558355e-7,0.000046560894,0.00064316293,0.14782389,0.80972785],"study_design_scores_gemma":[0.0091981655,0.0022999225,0.60818636,0.0023359768,0.0011426723,0.0013118061,0.0004238662,0.0010782141,0.00055493833,0.0012846709,0.37144062,0.00074278034],"about_ca_topic_score_codex":0.00013848692,"about_ca_topic_score_gemma":0.00001704362,"teacher_disagreement_score":0.80898505,"about_ca_system_score_codex":0.0014464336,"about_ca_system_score_gemma":0.0025298207,"threshold_uncertainty_score":0.9998978},"labels":[],"label_agreement":null},{"id":"W4401878546","doi":"10.1016/s2152-2650(24)00530-5","title":"Gilteritinib-Based Combinations Improve Survival and Enhance Allogenic Transplant Eligibility in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML): Canadian Single-Center Experience","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Refractory (planetary science); Myeloid leukemia; Internal medicine; Oncology; Single Center","score_opus":0.0323790115743905,"score_gpt":0.3485089521187956,"score_spread":0.31612994054440513,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878546","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9886862,0.0010388495,0.00023348814,0.0023795785,0.0018028874,0.0015294795,0.0004947969,0.00035225897,0.0034824703],"genre_scores_gemma":[0.9939892,0.00075280765,0.00090777304,0.0018912792,0.00047167964,0.0003338728,0.00038513506,0.00017064573,0.0010975851],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99213916,0.00064663304,0.0022055493,0.0022862013,0.0009427061,0.0017797374],"domain_scores_gemma":[0.9941286,0.0020916774,0.00019920332,0.0014412191,0.00031430364,0.0018249991],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00212777,0.0008154208,0.0014380809,0.00071917794,0.0003073622,0.00025396104,0.00074614317,0.0010849365,0.00025063902],"category_scores_gemma":[0.0010597066,0.0007892653,0.00050158275,0.0011235786,0.0014880757,0.00041180267,0.00020281792,0.0016599268,0.0002508499],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.005353299,0.0022766218,0.11906452,0.0014794902,0.0010705357,0.0162641,0.002653712,0.000020680101,0.11132009,0.0016373368,0.0046471404,0.73421246],"study_design_scores_gemma":[0.022584459,0.0036862183,0.8829927,0.0021852318,0.00050362595,0.00091000245,0.0005092803,0.019515416,0.014475389,0.00054160244,0.04994237,0.0021536897],"about_ca_topic_score_codex":0.011936676,"about_ca_topic_score_gemma":0.020400861,"teacher_disagreement_score":0.7639282,"about_ca_system_score_codex":0.0118207205,"about_ca_system_score_gemma":0.013295303,"threshold_uncertainty_score":0.9994558},"labels":[],"label_agreement":null},{"id":"W4401878556","doi":"10.1016/s2152-2650(24)00388-4","title":"Overall Survival (OS), Clinical Benefit, and Durable Red Blood Cell (RBC) Transfusion Independence (TI) With Imetelstat in the IMerge Phase 3 Trial of RBC-Transfusion Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Blood transfusion; Clinical trial; Red blood cell; Oncology; Bone marrow","score_opus":0.030145264743437827,"score_gpt":0.3402547526484732,"score_spread":0.3101094879050354,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878556","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9894118,0.0018631449,0.00048335936,0.00095996296,0.0017710226,0.0034788577,0.0002204597,0.00021713441,0.0015943076],"genre_scores_gemma":[0.9753356,0.02115369,0.0007607888,0.0002473694,0.00088536885,0.0001714966,0.000118498334,0.000207764,0.001119428],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9872543,0.002035157,0.0038355943,0.002506286,0.0028464918,0.0015221665],"domain_scores_gemma":[0.9866901,0.009514366,0.0005929699,0.0018070778,0.0004177639,0.0009777303],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.009515097,0.0010566666,0.0026392657,0.00061845355,0.00033593414,0.00021363488,0.0011352831,0.0014817026,0.00040539517],"category_scores_gemma":[0.0020143308,0.0007242862,0.0009993293,0.0014394278,0.0012658188,0.0005240133,0.00034245255,0.0032223738,0.000097574455],"study_design_candidate":"randomized_trial","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.38559294,0.013197384,0.056189913,0.0020951133,0.0024322977,0.021521218,0.0015956816,0.00015628106,0.016325204,0.000571826,0.002302889,0.49801925],"study_design_scores_gemma":[0.4474162,0.0443872,0.47017583,0.0031830478,0.0047900123,0.0029769465,0.0009131796,0.012851496,0.0053253677,0.0009362901,0.004900493,0.0021439474],"about_ca_topic_score_codex":0.0018969751,"about_ca_topic_score_gemma":0.0009392465,"teacher_disagreement_score":0.4958753,"about_ca_system_score_codex":0.0007795071,"about_ca_system_score_gemma":0.0041453117,"threshold_uncertainty_score":0.99981457},"labels":[],"label_agreement":null},{"id":"W4401878573","doi":"10.1016/s2152-2650(24)00353-7","title":"Transplant in Adult ALL: Who and When","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Intensive care medicine; Family medicine","score_opus":0.029164410784156235,"score_gpt":0.3274227186459994,"score_spread":0.2982583078618432,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878573","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9851391,0.0036649166,0.00004023863,0.0026129992,0.0006011454,0.00062109303,0.00004145155,0.00033199083,0.006947092],"genre_scores_gemma":[0.98952824,0.0028653855,0.00097414217,0.0026744758,0.0005544493,0.00007579919,0.00010403799,0.00009969331,0.0031237663],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99644035,0.00015133842,0.001218311,0.0010856562,0.0004306029,0.0006737451],"domain_scores_gemma":[0.9977785,0.0008953844,0.00007920753,0.000635456,0.00006351881,0.0005479657],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006082676,0.00043899956,0.00095572893,0.00022570787,0.00005089122,0.0000844929,0.0001975132,0.0005307006,0.00025424434],"category_scores_gemma":[0.00031472533,0.0003648134,0.00032637804,0.00028923125,0.0003282271,0.00019159497,0.000096275246,0.00050120865,0.0004850672],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00083555194,0.00024226304,0.07516202,0.00057064154,0.00049082,0.0075437496,0.00112309,0.0000017969057,0.00026854774,0.002377148,0.010080247,0.9013041],"study_design_scores_gemma":[0.009859034,0.0006621181,0.9222207,0.002150804,0.00043944106,0.0013919085,0.000065301574,0.0067440504,0.00032376853,0.0012912657,0.054388653,0.00046294692],"about_ca_topic_score_codex":0.0004524291,"about_ca_topic_score_gemma":0.00018960216,"teacher_disagreement_score":0.9008412,"about_ca_system_score_codex":0.0024021645,"about_ca_system_score_gemma":0.0018105175,"threshold_uncertainty_score":0.9998804},"labels":[],"label_agreement":null},{"id":"W4401878668","doi":"10.1016/s2152-2650(24)00573-1","title":"Interim Results From ASSURE: A Phase 3b Safety Study of Acalabrutinib in Patients With Chronic Lymphocytic Leukemia","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Interim; Chronic lymphocytic leukemia; Interim analysis; Oncology; Internal medicine; Leukemia; Clinical trial; Law","score_opus":0.03560786394838119,"score_gpt":0.3675414112304161,"score_spread":0.33193354728203495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401878668","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9921288,0.00097086054,0.00006246266,0.00010469262,0.0009981154,0.003104564,0.00034506657,0.00039743676,0.0018880356],"genre_scores_gemma":[0.996526,0.00019213767,0.0002936402,0.00022730495,0.00088744774,0.00013766851,0.00070482184,0.00024529672,0.00078569993],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9882941,0.0008270668,0.004534534,0.0025895217,0.002261256,0.0014935205],"domain_scores_gemma":[0.9911529,0.004142889,0.00061494444,0.002649888,0.00051264704,0.00092676346],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025749642,0.0009844577,0.0025612446,0.0006893843,0.00013552833,0.0001483872,0.001041008,0.00090581586,0.00032716364],"category_scores_gemma":[0.0027365205,0.00077925035,0.00056121394,0.0021859775,0.00094926084,0.0004276085,0.00074426696,0.0012004995,0.0004839248],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.10452981,0.005742875,0.032209765,0.0011111002,0.0029554116,0.007248282,0.003165863,0.0008609398,0.00029081816,0.00011590399,0.005456451,0.8363128],"study_design_scores_gemma":[0.2839254,0.014189695,0.6284736,0.003101673,0.00067227543,0.000090005226,0.00035117535,0.062085953,0.00041344613,0.00006815856,0.005793698,0.0008349506],"about_ca_topic_score_codex":0.007700028,"about_ca_topic_score_gemma":0.0009651208,"teacher_disagreement_score":0.8354778,"about_ca_system_score_codex":0.18008341,"about_ca_system_score_gemma":0.09383873,"threshold_uncertainty_score":0.9994658},"labels":[],"label_agreement":null},{"id":"W4401879520","doi":"10.1016/s2152-2650(24)00445-2","title":"Real-World Outcomes and Age-Related Analysis of Adult Acute Lymphoblastic Leukemia (ALL) Patients Treated With a Pediatric-Inspired Regimen","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Regimen; Pediatrics; Oncology; Internal medicine; Leukemia","score_opus":0.018081602950186834,"score_gpt":0.32022027631901906,"score_spread":0.3021386733688322,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401879520","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99190104,0.00020557035,0.000058658512,0.00034980188,0.0003123855,0.0012358442,0.00025371852,0.0006626613,0.0050203432],"genre_scores_gemma":[0.98985165,0.0013590532,0.0010164762,0.00047621003,0.0002332919,0.00012310059,0.00085342425,0.00024239156,0.0058443956],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99117935,0.00043469813,0.003113346,0.0021041976,0.0018207893,0.0013476489],"domain_scores_gemma":[0.9918415,0.0035866601,0.0007140287,0.0016419677,0.0008975055,0.0013183606],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00084487034,0.0010656052,0.0033684608,0.0023127159,0.00018011629,0.00018005731,0.0006289477,0.0008844128,0.00017255469],"category_scores_gemma":[0.0012941303,0.00077663566,0.0011691839,0.0062815165,0.0012417802,0.00037866985,0.00045687216,0.00066554087,0.00017844973],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0042661526,0.00059808476,0.91537327,0.00060674566,0.023724623,0.005121812,0.0004470673,0.00006481625,0.00025283315,0.0013017613,0.003286716,0.04495613],"study_design_scores_gemma":[0.014948909,0.0016719047,0.93531924,0.00042396667,0.024035182,0.00009786908,0.000043236527,0.022121593,0.00012663739,0.00012621093,0.00032550012,0.00075975555],"about_ca_topic_score_codex":0.0019494342,"about_ca_topic_score_gemma":0.00027902814,"teacher_disagreement_score":0.044196375,"about_ca_system_score_codex":0.0068211425,"about_ca_system_score_gemma":0.005327886,"threshold_uncertainty_score":0.99946845},"labels":[],"label_agreement":null},{"id":"W4401896783","doi":"10.1016/s2152-2650(24)00633-5","title":"Impact on Healthcare Resource Utilization and Cost of Care of Concomitant Prescribing of Acid-Reducing Agents With Tyrosine Kinase Inhibitors: A US Payer Perspective","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Potassium and Related Disorders","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"","keywords":"Medicine; Concomitant; Perspective (graphical); Health care; Tyrosine kinase; Intensive care medicine; Internal medicine; Receptor","score_opus":0.03779756422248617,"score_gpt":0.3603052363912616,"score_spread":0.32250767216877546,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401896783","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.982765,0.014414363,0.000027532426,0.0003588691,0.00015532285,0.00068605377,0.00011916486,0.000050578674,0.0014230785],"genre_scores_gemma":[0.9990105,0.00051282655,0.0000934838,0.00011145018,0.00010455254,0.000010422395,0.00006440513,0.000050375944,0.00004198201],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9976816,0.00018011365,0.0009438225,0.00051980175,0.0003942823,0.00028038322],"domain_scores_gemma":[0.99826384,0.00033515104,0.00034227603,0.00038794905,0.00040226532,0.00026855132],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00031585962,0.0002687093,0.00081812683,0.00020433709,0.000054875858,0.000013721457,0.000088881745,0.0003439451,0.000019250949],"category_scores_gemma":[0.0005179507,0.00018236208,0.00026068656,0.00046974223,0.0005010491,0.00008068121,0.000063072795,0.00028750388,0.0000020195505],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01832524,0.0011793374,0.2542745,0.0053868685,0.0018121818,0.00059123535,0.01829184,0.00041118782,0.015450698,0.0013399816,0.0029214614,0.6800155],"study_design_scores_gemma":[0.006918047,0.0060562887,0.9464625,0.009084267,0.0005728032,0.000087761335,0.0069491,0.0032014183,0.019853454,0.000045303022,0.00050187483,0.00026714423],"about_ca_topic_score_codex":0.0010619217,"about_ca_topic_score_gemma":0.000025246702,"teacher_disagreement_score":0.6921881,"about_ca_system_score_codex":0.0007955273,"about_ca_system_score_gemma":0.0013223883,"threshold_uncertainty_score":0.743651},"labels":[],"label_agreement":null},{"id":"W4401896808","doi":"10.1016/s2152-2650(24)01551-9","title":"ABCL-711 Brentuximab Vedotin (BV) in Combination With Lenalidomide (Len) and Rituximab (R) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL): Results From the Phase 3 ECHELON-3 Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Queen Elizabeth II Health Sciences Centre; Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Brentuximab vedotin; Lenalidomide; Diffuse large B-cell lymphoma; Rituximab; Internal medicine; Oncology; Refractory (planetary science); Lymphoma; Multiple myeloma; Hodgkin lymphoma","score_opus":0.016213739826199818,"score_gpt":0.29246344216781545,"score_spread":0.2762497023416156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401896808","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9934598,0.0015970736,0.00001148918,0.00088324153,0.00040211913,0.0026472688,0.00036315984,0.00018553832,0.00045026012],"genre_scores_gemma":[0.9969905,0.0003673268,0.00022769018,0.00072462036,0.00020678487,0.00029762334,0.0008221611,0.0001382197,0.00022506337],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9934667,0.0007367327,0.0020318215,0.0018306295,0.0010567355,0.0008773777],"domain_scores_gemma":[0.99432206,0.0032963676,0.0004535089,0.0012856706,0.00019794005,0.0004444313],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015348194,0.0008222203,0.0014979559,0.00032479604,0.00020498059,0.000236207,0.00038216345,0.00044519195,0.000022984466],"category_scores_gemma":[0.0005360754,0.00051049545,0.00023895658,0.00088698854,0.00033785202,0.00046147243,0.00025542954,0.0005055107,0.00013420683],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.019349078,0.15115258,0.58230644,0.00007668541,0.00043471562,0.0024185188,0.0016794818,0.00000120844,0.0000059984345,0.000068894864,0.0008855425,0.24162084],"study_design_scores_gemma":[0.3750206,0.0049316813,0.6152381,0.00082354015,0.00041857787,0.00001881395,0.00046868832,0.0005633719,0.0000594862,0.00006750923,0.0020002432,0.00038943713],"about_ca_topic_score_codex":0.0020878213,"about_ca_topic_score_gemma":0.0015399732,"teacher_disagreement_score":0.35567153,"about_ca_system_score_codex":0.0027712865,"about_ca_system_score_gemma":0.0014634678,"threshold_uncertainty_score":0.99973464},"labels":[],"label_agreement":null},{"id":"W4401897141","doi":"10.1016/s2152-2650(24)01563-5","title":"IBCL-335 Mosunetuzumab Monotherapy Continues to Demonstrate Durable Responses in Patients With Relapsed and/or Refractory Follicular Lymphoma After ≥2 Prior Therapies: 3-Year Follow-Up From a Pivotal Phase II Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; Jewish General Hospital; Spinal Cord Injury BC; University of British Columbia","funders":"","keywords":"Medicine; Follicular lymphoma; Refractory (planetary science); Internal medicine; Follicular phase; Oncology; Phases of clinical research; Lymphoma; Clinical trial","score_opus":0.018944815220853627,"score_gpt":0.31241898043882904,"score_spread":0.2934741652179754,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401897141","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.992245,0.0027387089,0.000011297064,0.00051689707,0.00059195946,0.0032338032,0.00024009775,0.00029963997,0.00012260703],"genre_scores_gemma":[0.99418634,0.0004570774,0.0010220063,0.0011386209,0.00027500882,0.0009530374,0.0000976299,0.00018550477,0.001684777],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9942496,0.0005566684,0.0016863036,0.0018180604,0.00084190903,0.0008475026],"domain_scores_gemma":[0.99610853,0.0015607807,0.0002515519,0.0011530505,0.00020612201,0.0007199582],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00074529357,0.0008752966,0.0016887725,0.00038046553,0.0002469542,0.00026373155,0.00028887356,0.00047201742,0.00022282037],"category_scores_gemma":[0.00044905962,0.00059314264,0.00042148487,0.00073181605,0.000305433,0.0003945509,0.00018932568,0.00024992652,0.00013497456],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.081550755,0.007308134,0.4315049,0.000040487295,0.0014164515,0.003381314,0.0027321607,6.1401425e-7,0.00009312108,0.000012222174,0.0007222298,0.4712376],"study_design_scores_gemma":[0.10357957,0.026513247,0.8575848,0.0010844284,0.000593338,0.00003145787,0.0007952142,0.000121683624,0.00023691884,0.00005299284,0.008755263,0.0006511296],"about_ca_topic_score_codex":0.00077308837,"about_ca_topic_score_gemma":0.00045294358,"teacher_disagreement_score":0.47058648,"about_ca_system_score_codex":0.0017324913,"about_ca_system_score_gemma":0.0018494651,"threshold_uncertainty_score":0.99965197},"labels":[],"label_agreement":null},{"id":"W4401897346","doi":"10.1016/s2152-2650(24)00705-5","title":"Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Oncology; Bone marrow","score_opus":0.04308279592004458,"score_gpt":0.35312180724785097,"score_spread":0.31003901132780637,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4401897346","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9918587,0.0022128362,0.000005621032,0.0008970036,0.00036375804,0.0041709687,0.00004063226,0.00006610809,0.0003843608],"genre_scores_gemma":[0.9967338,0.0010018843,0.00018416054,0.000535204,0.00020079107,0.0010105219,0.00011148806,0.00006782988,0.00015433325],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99481803,0.0008777751,0.0018099828,0.0009922639,0.0010043042,0.0004976307],"domain_scores_gemma":[0.9945956,0.003816499,0.0003503278,0.0007826879,0.000272922,0.00018199529],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018035199,0.0004978457,0.0011479246,0.00038160657,0.000093457755,0.000097637174,0.00027105495,0.0002908756,0.00007749974],"category_scores_gemma":[0.0006842679,0.00032051047,0.00029053545,0.0009663153,0.0002774719,0.00042654955,0.00010916876,0.00045128068,0.00005255936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015155568,0.00915976,0.52629256,0.00030096242,0.00022487168,0.0011478954,0.0021335816,0.000011904665,0.000051470146,0.00024386868,0.00075807865,0.44451946],"study_design_scores_gemma":[0.025474025,0.029417679,0.93911386,0.0034535215,0.00018955786,0.000052357333,0.0006615672,0.00041824862,0.0004374192,0.00018745958,0.00029188322,0.0003024299],"about_ca_topic_score_codex":0.0003261023,"about_ca_topic_score_gemma":0.0001359271,"teacher_disagreement_score":0.44421703,"about_ca_system_score_codex":0.0012552636,"about_ca_system_score_gemma":0.0012413402,"threshold_uncertainty_score":0.9999247},"labels":[],"label_agreement":null},{"id":"W4403467786","doi":"10.1016/j.clml.2024.10.001","title":"Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor–Naive or –Experienced Myelofibrosis Treated With Momelotinib","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; University of Toronto","funders":"GlaxoSmithKline","keywords":"Medicine; Myelofibrosis; Ruxolitinib; Internal medicine; Oncology; Bone marrow","score_opus":0.02601167438967047,"score_gpt":0.32898140265542736,"score_spread":0.3029697282657569,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403467786","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99659294,0.00009002223,0.00007868477,0.00029098542,0.00022413183,0.0017902282,0.00005603463,0.0001385449,0.00073843624],"genre_scores_gemma":[0.99656683,0.00016562568,0.002120512,0.0002122159,0.00013385172,0.00036312532,0.00016972153,0.000077563076,0.00019054723],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99593484,0.00014713303,0.0013328879,0.0011886886,0.0008566315,0.0005397999],"domain_scores_gemma":[0.9976469,0.0006457063,0.00023090742,0.0005660513,0.0005050837,0.00040534747],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003819292,0.0005811265,0.0015115071,0.0002979634,0.00010808707,0.00006291645,0.0001564105,0.00032919866,0.0002217112],"category_scores_gemma":[0.00012365209,0.0003346709,0.0002766626,0.001066223,0.0005300481,0.00024683698,0.00007924717,0.00037220342,0.000023005674],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010225465,0.0019098521,0.91231996,0.00020221507,0.00046586743,0.00068002206,0.00041098872,0.000011006011,0.0001350095,0.00010284379,0.00020374333,0.07333304],"study_design_scores_gemma":[0.0133582065,0.01272618,0.9652447,0.00238831,0.00040472246,0.000063559644,0.00023138484,0.0007404911,0.004137201,0.000008903306,0.0003064077,0.0003899033],"about_ca_topic_score_codex":0.0004238504,"about_ca_topic_score_gemma":0.00026777503,"teacher_disagreement_score":0.072943136,"about_ca_system_score_codex":0.0012764618,"about_ca_system_score_gemma":0.0016614472,"threshold_uncertainty_score":0.99991053},"labels":[],"label_agreement":null},{"id":"W4403667780","doi":"10.1016/j.clml.2024.10.012","title":"First Line Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Recommendations From a Canadian Consensus Guideline Consortium","year":2024,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Ottawa; University of Manitoba; Juravinski Cancer Centre; McMaster University; Saskatchewan Science Centre; London Health Sciences Centre; Université de Montréal; Western University; GLS Industries (Canada); Hôpital Maisonneuve-Rosemont; Ottawa Hospital; Saskatchewan Cancer Agency; Windsor Regional Hospital; CancerCare Manitoba; Centre hospitalier universitaire de Québec; Memorial University of Newfoundland","funders":"Hamilton Health Sciences; Celgene; Leukemia and Lymphoma Society; Sanofi; Amgen; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Guideline; Multiple myeloma; Family medicine; Intensive care medicine; Internal medicine; Oncology; Pathology","score_opus":0.10348786416042127,"score_gpt":0.40949220947574555,"score_spread":0.3060043453153243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403667780","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0051029003,0.9680882,0.000029692554,0.0019735165,0.0016396234,0.0048374105,0.016814895,0.0003048188,0.0012089524],"genre_scores_gemma":[0.0074551874,0.96604943,0.0038621894,0.00029713064,0.001521846,0.00089484465,0.017598616,0.000345097,0.0019756365],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98874986,0.0006906391,0.0059038154,0.00220023,0.00082574284,0.0016296874],"domain_scores_gemma":[0.98691696,0.006309625,0.0010456459,0.0022021427,0.00051920244,0.0030064047],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.00071629474,0.0017450971,0.006823131,0.0010747226,0.00033897324,0.00012269018,0.00064422016,0.0017503119,0.0009921388],"category_scores_gemma":[0.0018025493,0.0012918152,0.003431792,0.0010877337,0.00070604344,0.000074826996,0.00014206312,0.00073921756,0.0019897516],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005402428,0.0011243797,0.0015864212,0.003252901,0.0050637354,0.007952751,0.00010142289,0.0000028629715,0.0000013252512,0.00003248039,0.02288116,0.95746034],"study_design_scores_gemma":[0.01215169,0.0020141832,0.007506548,0.016373541,0.00956165,0.00045444627,0.000040626397,0.0010311884,0.00001702348,0.000080390644,0.94982797,0.0009407289],"about_ca_topic_score_codex":0.14327218,"about_ca_topic_score_gemma":0.14709015,"teacher_disagreement_score":0.9565196,"about_ca_system_score_codex":0.0057021896,"about_ca_system_score_gemma":0.017803488,"threshold_uncertainty_score":0.9999211},"labels":[],"label_agreement":null},{"id":"W4403848280","doi":"10.1016/j.clml.2024.10.008","title":"Incidence, Risk Factors and Early Prediction of Doxorubicin-Induced Cardiotoxicity by Global Longitudinal Strain and Cardiac Biomarkers in Indian Patients With Lymphoma: A Prospective Observational Study","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Centre Technologique des Résidus Industriels; Postgraduate Institute of Medical Education and Research, Chandigarh","keywords":"Medicine; Cardiotoxicity; Incidence (geometry); Observational study; Internal medicine; Doxorubicin; Lymphoma; Oncology; Prospective cohort study; Strain (injury); Cardiology; Chemotherapy","score_opus":0.029662997542162315,"score_gpt":0.30092626341777157,"score_spread":0.2712632658756092,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4403848280","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9960274,0.0003607871,0.000026070029,0.0000366292,0.0002817279,0.0021175437,0.00094973063,0.00009806706,0.000102027174],"genre_scores_gemma":[0.99938065,0.00008091548,0.000101953774,0.000028384022,0.00015078908,0.00007078056,0.00013848957,0.000039284998,0.000008784043],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9965051,0.00034494305,0.0010012571,0.001004047,0.0007703113,0.00037437648],"domain_scores_gemma":[0.99836034,0.000482745,0.00027281657,0.00034899978,0.00020774582,0.0003273793],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010422665,0.00042338824,0.0010458251,0.00018564357,0.00012758392,0.00008264934,0.00010579549,0.00042868976,0.000003893052],"category_scores_gemma":[0.00042956506,0.00034797002,0.0002340099,0.00086381315,0.0004148362,0.00041087365,0.00008279538,0.00028210436,0.0000013198086],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00092648657,0.00043760994,0.92475194,0.00009733133,0.0012598641,0.000053779364,0.00095823983,0.0000012712268,0.0018468772,0.000034180655,0.000046605328,0.0695858],"study_design_scores_gemma":[0.007413036,0.0025551284,0.9859285,0.00035799254,0.00043262262,0.000018369583,0.00067823095,0.00008000666,0.0020881162,0.00015101169,0.000016454333,0.00028052615],"about_ca_topic_score_codex":0.0017966809,"about_ca_topic_score_gemma":0.00011865286,"teacher_disagreement_score":0.06930527,"about_ca_system_score_codex":0.0015034436,"about_ca_system_score_gemma":0.00092352246,"threshold_uncertainty_score":0.99989724},"labels":[],"label_agreement":null},{"id":"W4404554442","doi":"10.1016/j.clml.2024.11.008","title":"De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CNS Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta; University of Calgary","funders":"","keywords":"Medicine; ThioTEPA; Busulfan; Primary central nervous system lymphoma; Induction therapy; Transplantation; Autologous stem-cell transplantation; Central nervous system; Stem cell; Lymphoma; Rituximab; Oncology; Hematopoietic stem cell transplantation; Internal medicine; Chemotherapy; Cyclophosphamide","score_opus":0.027301440449814803,"score_gpt":0.291623580930419,"score_spread":0.2643221404806042,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404554442","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889904,0.004448769,0.0012459931,0.0007228296,0.0013079642,0.0017011553,0.00013676552,0.0008175644,0.00062854384],"genre_scores_gemma":[0.9943484,0.001524205,0.0013715781,0.00092405535,0.00066077174,0.00036043205,0.00043268336,0.00013502239,0.00024282251],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9962533,0.00026337404,0.0012031625,0.0010793948,0.000397705,0.00080303155],"domain_scores_gemma":[0.99730057,0.0012690534,0.00022164748,0.0005050674,0.00014258648,0.0005610992],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00067838165,0.0005532058,0.0009842211,0.00022290624,0.00024469613,0.0002036486,0.00015977235,0.00078580657,0.000018220233],"category_scores_gemma":[0.000033446297,0.00045676195,0.0006203476,0.00036845412,0.00023092589,0.00017090041,0.000025719879,0.00017228637,0.000043432323],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0023624846,0.00044786665,0.009386132,0.0013968193,0.00035470803,0.0010779559,0.00027292772,0.000044708893,0.0012222703,0.00040176752,0.00083807885,0.9821943],"study_design_scores_gemma":[0.006555121,0.001485789,0.96732235,0.00083936105,0.0007678743,0.0011430192,0.00011938984,0.011620144,0.005334423,0.000051867,0.0043295464,0.00043112753],"about_ca_topic_score_codex":0.00016587455,"about_ca_topic_score_gemma":0.000008436672,"teacher_disagreement_score":0.9817631,"about_ca_system_score_codex":0.0030016894,"about_ca_system_score_gemma":0.0023053563,"threshold_uncertainty_score":0.9997884},"labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"observational","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"},{"model":"gpt","categories":[],"domain":null,"study_design":"design_other","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"low"}],"label_agreement":"split"},{"id":"W4404633978","doi":"10.1016/j.clml.2024.11.009","title":"Let's Agree to Disagree: Reflections From the Smoldering Multiple Myeloma Session at the International Myeloma Society Study Summit","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"","keywords":"Medicine; Summit; Multiple myeloma; Session (web analytics); Oncology; Internal medicine; Cartography; Advertising","score_opus":0.09523749738024062,"score_gpt":0.4045810270794931,"score_spread":0.3093435296992525,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4404633978","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97702956,0.00092970213,0.00033742876,0.013208266,0.0026559278,0.0024123762,0.00027382918,0.00047745963,0.0026754204],"genre_scores_gemma":[0.981672,0.00022814146,0.0010561093,0.0030104308,0.0029733926,0.0005034954,0.0002974113,0.0001452943,0.010113712],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9935374,0.00052331656,0.001431405,0.001687927,0.001790876,0.0010290489],"domain_scores_gemma":[0.9914074,0.0054083453,0.00019945158,0.0018680488,0.00029330634,0.00082348124],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["insufficient_payload"],"category_scores_codex":[0.0016232532,0.0006844963,0.00081420527,0.00012726794,0.0012656703,0.00053721224,0.0012370528,0.00039525193,0.0011509303],"category_scores_gemma":[0.0021652915,0.00039057177,0.0011611222,0.00097095186,0.0005504752,0.00030172337,0.0016634776,0.00093397737,0.0020214224],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0014174036,0.0007604286,0.28238222,0.000033794928,0.002177118,0.00097062474,0.0016544166,0.000031953485,0.0021799328,0.00003726469,0.06975727,0.63859755],"study_design_scores_gemma":[0.004460732,0.00071517396,0.85486346,0.0003468584,0.00036912644,0.000094864896,0.0018437825,0.0056905705,0.0010053808,0.000105013976,0.13012011,0.00038491713],"about_ca_topic_score_codex":0.0015429859,"about_ca_topic_score_gemma":0.0041086776,"teacher_disagreement_score":0.6382126,"about_ca_system_score_codex":0.0030245294,"about_ca_system_score_gemma":0.0011102688,"threshold_uncertainty_score":0.9998546},"labels":[],"label_agreement":null},{"id":"W4405105877","doi":"10.1016/j.clml.2024.12.006","title":"Associations Between Patient Characteristics and Progression to Multiple Myeloma Among Patients With Monoclonal Gammopathy of Undetermined Significance: A Systematic Review","year":2024,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"York University","funders":"National Cancer Institute","keywords":"Medicine; Monoclonal gammopathy of undetermined significance; Multiple myeloma; Monoclonal gammopathy; Oncology; Internal medicine; Monoclonal; Monoclonal antibody; Immunology; Antibody","score_opus":0.052160912604549046,"score_gpt":0.3816797154227979,"score_spread":0.32951880281824886,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4405105877","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.06424026,0.91500103,0.000017930115,0.000054481025,0.00025995678,0.016706415,0.003485127,0.00015795897,0.00007684121],"genre_scores_gemma":[0.026987849,0.96380776,0.0012935129,0.00013759409,0.0003121401,0.0022929043,0.0046234364,0.00027382775,0.00027095556],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9905029,0.0009683872,0.0046563316,0.0014570984,0.0015697592,0.00084553263],"domain_scores_gemma":[0.9920915,0.0021893897,0.0024262196,0.0012789337,0.0007163001,0.001297658],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011087315,0.0011371981,0.008409742,0.00043188623,0.00016266514,0.000101541475,0.00043053337,0.0007578029,0.000018042037],"category_scores_gemma":[0.0049942564,0.00071104884,0.001146602,0.0009738328,0.0003839219,0.00012899406,0.00046770228,0.0007004428,0.00016890888],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00012202247,0.00034355032,0.031462397,0.36783966,0.001453394,0.00023041903,0.000034154888,9.781257e-9,1.362581e-7,0.0000024443837,0.00030255716,0.59820926],"study_design_scores_gemma":[0.0018145243,0.0021553785,0.41923454,0.5587955,0.012561878,0.000027995899,0.0000057503235,0.000022382701,0.0000019147692,0.000003847913,0.004797974,0.00057828426],"about_ca_topic_score_codex":0.000037977457,"about_ca_topic_score_gemma":0.000009662012,"teacher_disagreement_score":0.597631,"about_ca_system_score_codex":0.0017828856,"about_ca_system_score_gemma":0.002272857,"threshold_uncertainty_score":0.9995341},"labels":[],"label_agreement":null},{"id":"W4406771622","doi":"10.1016/j.clml.2025.01.010","title":"Minimal Residual Disease Testing Infrastructure in Multiple Myeloma: Guidance for Clinical Trial and Routine Practice Use in Canada","year":2025,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of British Columbia; University of Manitoba; William Osler Health System; Saskatchewan Science Centre; London Health Sciences Centre; University of Alberta; University of Saskatchewan; University of Ottawa; Kingston Health Sciences Centre; McGill University; McGill University Health Centre; Hôpital Maisonneuve-Rosemont; CancerCare Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; Princess Margaret Cancer Centre; Jewish General Hospital; Western University; University of Toronto; Queen's University; McMaster University","funders":"Janssen Research and Development; Johnson and Johnson; Hamilton Health Sciences","keywords":"Medicine; Multiple myeloma; Minimal residual disease; Residual; Clinical trial; Clinical Practice; Disease; Oncology; Internal medicine; Intensive care medicine; Family medicine; Bone marrow; Algorithm","score_opus":0.1723257882737399,"score_gpt":0.4460666182586723,"score_spread":0.2737408299849324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4406771622","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.12040743,0.86534613,0.000010617928,0.00036712998,0.0014329812,0.0107613,0.0013728825,0.00009270599,0.00020878563],"genre_scores_gemma":[0.010876432,0.970508,0.011867022,0.0008555251,0.002138095,0.0016151015,0.0012756239,0.00020860632,0.00065558625],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.98581594,0.0025125348,0.0064057102,0.0026079833,0.0010341048,0.0016236951],"domain_scores_gemma":[0.9276499,0.066687614,0.0016944105,0.001628369,0.0005610853,0.0017786087],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0038358264,0.0012970028,0.0059653986,0.00054027356,0.00020293774,0.00016102905,0.0006916364,0.0012906635,0.00001840758],"category_scores_gemma":[0.21111107,0.001084789,0.00096626894,0.0012751552,0.00051219907,0.00038428014,0.00074083725,0.0018564084,0.000012341977],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04283283,0.00057064305,0.14145985,0.0076173404,0.0004098174,0.0047567347,0.000007360498,0.000001978941,4.212327e-8,0.000015070204,0.0038590692,0.79846925],"study_design_scores_gemma":[0.08497954,0.0009552906,0.608646,0.016706176,0.0013121299,0.00012978847,0.00003147496,0.000642432,1.482807e-7,0.00002066006,0.28591058,0.0006657879],"about_ca_topic_score_codex":0.13908432,"about_ca_topic_score_gemma":0.20421498,"teacher_disagreement_score":0.79780346,"about_ca_system_score_codex":0.006002825,"about_ca_system_score_gemma":0.06526137,"threshold_uncertainty_score":0.9999782},"labels":[],"label_agreement":null},{"id":"W4407064943","doi":"10.1016/j.clml.2025.01.024","title":"A Real-World Evaluation of Frontline Treatment for Acute Myeloid Leukemia With Azacitidine Plus Venetoclax","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Venetoclax; Medicine; Azacitidine; Myeloid leukemia; Oncology; Myeloid; Internal medicine; Leukemia; Genetics","score_opus":0.06526847665426186,"score_gpt":0.4154694203873827,"score_spread":0.35020094373312083,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407064943","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9741268,0.0005652668,0.0013771083,0.0013930766,0.0005123526,0.0056991014,0.00023431594,0.00026390678,0.015828036],"genre_scores_gemma":[0.96316344,0.001174144,0.012602376,0.00083138,0.0009854943,0.0017174128,0.0009475825,0.00018109406,0.018397087],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9927837,0.0005395904,0.0023840289,0.0015658499,0.0015135612,0.00121326],"domain_scores_gemma":[0.9926163,0.0020246292,0.000718337,0.0019370898,0.0020641608,0.00063951436],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0033635749,0.00081472186,0.0024500256,0.00076400867,0.00026417553,0.00005966014,0.00061198074,0.0006564389,0.00020188128],"category_scores_gemma":[0.0012583401,0.000632802,0.00089240633,0.0015141409,0.00086131156,0.00021690517,0.00023602138,0.00044166678,0.00007676942],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.030314162,0.00062254537,0.014222325,0.00047984428,0.0057867435,0.00025790703,0.00024155896,0.0010538615,0.00503766,0.0030584356,0.018124735,0.9208002],"study_design_scores_gemma":[0.08901642,0.007682618,0.6846281,0.0013189918,0.00935934,0.00014712726,0.00022553613,0.1482617,0.022521859,0.0018666547,0.033988025,0.0009835919],"about_ca_topic_score_codex":0.0014829824,"about_ca_topic_score_gemma":0.00074966706,"teacher_disagreement_score":0.9198166,"about_ca_system_score_codex":0.03845377,"about_ca_system_score_gemma":0.04135444,"threshold_uncertainty_score":0.99961233},"labels":[],"label_agreement":null},{"id":"W4407987841","doi":"10.1016/j.clml.2025.01.022","title":"Real-World Safety and Tolerability of Rapid, 30-Minutes, Intravenous Isatuximab in Patients With Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"CancerCare Manitoba","funders":"","keywords":"Medicine; Tolerability; Multiple myeloma; Adverse effect; Oncology; Internal medicine","score_opus":0.018595504712545678,"score_gpt":0.3097689885473519,"score_spread":0.29117348383480623,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407987841","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99048483,0.0003146132,0.000039441748,0.0003377246,0.00017256576,0.0017793576,0.00011352219,0.00008946177,0.0066685053],"genre_scores_gemma":[0.9958919,0.0003964372,0.0021296137,0.00028818683,0.00008268045,0.000064695596,0.00021035205,0.000050397804,0.0008857196],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9949758,0.00042905723,0.0019533627,0.0011207238,0.00067819585,0.0008428375],"domain_scores_gemma":[0.99545974,0.0020291544,0.00035293718,0.0011764666,0.0004149181,0.00056677987],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010401077,0.0005071916,0.00177906,0.00044466066,0.00014629491,0.000034497283,0.00030310018,0.0003702141,0.00015260572],"category_scores_gemma":[0.0017838592,0.00039840836,0.000253138,0.00095495576,0.000924986,0.00015872827,0.00029960545,0.00047293192,0.00003333526],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009047791,0.0013455781,0.5616549,0.00020280131,0.00023518899,0.00010100363,0.000054986518,0.0000019152487,0.000020038458,0.00013480039,0.00015874878,0.42704225],"study_design_scores_gemma":[0.036604803,0.001991185,0.9568657,0.00059984956,0.00014742422,0.0000069442967,0.00004328682,0.0007220739,0.00036208486,0.00016393408,0.0021922712,0.0003004263],"about_ca_topic_score_codex":0.0014833879,"about_ca_topic_score_gemma":0.0009125109,"teacher_disagreement_score":0.4267418,"about_ca_system_score_codex":0.001439239,"about_ca_system_score_gemma":0.0017496403,"threshold_uncertainty_score":0.99984676},"labels":[],"label_agreement":null},{"id":"W4407992657","doi":"10.1016/j.clml.2025.02.011","title":"Treatment Patterns and Outcomes of Multiple Myeloma Patients Undergoing Second-Line Therapy: A Canadian Myeloma Research Group (CMRG) Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Jewish General Hospital; Memorial University of Newfoundland; Saint John Regional Hospital; Université de Montréal; University of Saskatchewan; Dalhousie University; Juravinski Cancer Centre; University of British Columbia; McGill University; Princess Margaret Cancer Centre; Vancouver General Hospital; University of Calgary; Queen Elizabeth II Health Sciences Centre; University of Alberta; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Regional Cancer Foundation; Ottawa Hospital","funders":"Janssen Canada; Johnson and Johnson","keywords":"Medicine; Multiple myeloma; Internal medicine; Oncology","score_opus":0.06408015381037947,"score_gpt":0.38643911078947374,"score_spread":0.3223589569790943,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4407992657","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9929991,0.0006622597,0.000050068065,0.00092084566,0.00026392489,0.0019938485,0.0004970637,0.00009981121,0.0025130857],"genre_scores_gemma":[0.99367434,0.0011624034,0.00060228753,0.0005656259,0.00013915788,0.00025496475,0.00074767356,0.000084308944,0.0027692176],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9928088,0.0009266536,0.0019388578,0.0015541812,0.0011290162,0.0016424548],"domain_scores_gemma":[0.99152744,0.004057975,0.00033715568,0.0016245185,0.00079600094,0.0016569128],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013066,0.00074835616,0.0022464755,0.0020767862,0.00057668786,0.00012584303,0.00050144264,0.00064851186,0.0003925736],"category_scores_gemma":[0.0021197265,0.000580931,0.001053202,0.0021444608,0.0007278094,0.00021141558,0.00032427625,0.00049818686,0.000072734794],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012220456,0.0009325647,0.6392568,0.00010332552,0.0046658255,0.00024810364,0.00014865735,0.0000017480676,0.00005082508,0.00011881954,0.00016253564,0.35308874],"study_design_scores_gemma":[0.022708368,0.003283414,0.96736825,0.00019360546,0.0007548347,0.00001174709,0.0002505068,0.0014676623,0.0006001987,0.00017440565,0.002795665,0.00039133587],"about_ca_topic_score_codex":0.062265653,"about_ca_topic_score_gemma":0.23362878,"teacher_disagreement_score":0.3526974,"about_ca_system_score_codex":0.0033478916,"about_ca_system_score_gemma":0.0035449069,"threshold_uncertainty_score":0.9996642},"labels":[],"label_agreement":null},{"id":"W4408985065","doi":"10.1016/j.clml.2025.03.014","title":"Outcomes of Patients With Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma From the Pooled LocoMMotion and MoMMent Studies","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hotel Dieu Hospital","funders":"Legend Biotech; Johnson and Johnson","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine","score_opus":0.03591341014526184,"score_gpt":0.3351751832576492,"score_spread":0.2992617731123874,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4408985065","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922399,0.0026086955,0.000033084183,0.002421618,0.00031195022,0.002029722,0.00018077009,0.00006411726,0.000110170295],"genre_scores_gemma":[0.9967914,0.0005796901,0.0005154764,0.0011446186,0.00007388844,0.00021415917,0.00032134543,0.000043493954,0.00031588762],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9958559,0.0005965682,0.0014121097,0.0008297593,0.00074355816,0.0005620905],"domain_scores_gemma":[0.9929666,0.004834912,0.00037017668,0.0010331125,0.00032929666,0.0004659127],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00062657904,0.0004800607,0.0012867677,0.00021188185,0.00016844587,0.000034559467,0.0003088486,0.00024938173,0.000031047035],"category_scores_gemma":[0.0041851536,0.00028961536,0.00028952418,0.00044130848,0.0007970576,0.00017386397,0.00032970062,0.00040072657,0.000015931213],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.007590243,0.0012441449,0.7642829,0.00010731363,0.0010951677,0.00015171723,0.00019740923,0.000003667568,0.000033648317,0.000035408815,0.00045818827,0.22480018],"study_design_scores_gemma":[0.03682359,0.0007862451,0.9587267,0.00070654036,0.00045305898,9.0555284e-7,0.00040370494,0.00066716236,0.00015427207,0.00026978867,0.00077216944,0.00023586111],"about_ca_topic_score_codex":0.00034993608,"about_ca_topic_score_gemma":0.00022113005,"teacher_disagreement_score":0.22456431,"about_ca_system_score_codex":0.00091044005,"about_ca_system_score_gemma":0.0008613139,"threshold_uncertainty_score":0.9999556},"labels":[],"label_agreement":null},{"id":"W4409016409","doi":"10.1016/j.clml.2025.03.012","title":"Treatment Patterns and Clinical Outcomes of Patients With Systemic Light Chain Amyloidosis in the United States: Evidence From Real-World Clinical Practice","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Group for Research in Decision Analysis","funders":"Genentech","keywords":"Medicine; Clinical Practice; Immunoglobulin light chain; Systemic therapy; Amyloidosis; AL amyloidosis; Intensive care medicine; Dermatology; Internal medicine; Family medicine; Immunology; Cancer","score_opus":0.026267736577355757,"score_gpt":0.35539523188921135,"score_spread":0.3291274953118556,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409016409","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.994841,0.0006594871,0.00008065494,0.0022951197,0.00046904283,0.0012568914,0.0002096045,0.000037162255,0.00015104373],"genre_scores_gemma":[0.97596717,0.01883664,0.00067456067,0.003273113,0.00019383727,0.0002170196,0.0005469185,0.000053093187,0.00023765441],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918922,0.0026378941,0.0030437198,0.0014177782,0.0004694427,0.00053896895],"domain_scores_gemma":[0.9858377,0.010737032,0.001178114,0.0016538941,0.0003374486,0.00025580262],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0019601728,0.0006316677,0.0014981877,0.00020041854,0.00012855206,0.00007778535,0.00076703983,0.0006124988,0.00001110461],"category_scores_gemma":[0.004136604,0.0003967633,0.000591956,0.0005626257,0.00054583227,0.000038824393,0.0003674805,0.00031700684,0.000015299578],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017493326,0.0018339059,0.9435701,0.00003847892,0.001441013,0.000056545065,0.00013731238,0.000011018093,0.000007793478,0.000038724866,0.0007047709,0.050411057],"study_design_scores_gemma":[0.0081322845,0.0023001584,0.9809044,0.00047140176,0.0009294682,0.0000038573094,0.0005085747,0.00007962298,0.00016342234,0.00002299714,0.00610503,0.00037875772],"about_ca_topic_score_codex":0.0056512766,"about_ca_topic_score_gemma":0.0026416662,"teacher_disagreement_score":0.0500323,"about_ca_system_score_codex":0.00041961626,"about_ca_system_score_gemma":0.0007361897,"threshold_uncertainty_score":0.9998484},"labels":[],"label_agreement":null},{"id":"W4409195656","doi":"10.1016/j.clml.2025.03.013","title":"Ranking the Importance of Prognostic Factors for Relapsed/Refractory Multiple Myeloma: International Physician Panel Consensus Following a Systematic Literature Review","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"EVERSANA (Canada)","funders":"Regeneron Pharmaceuticals","keywords":"Medicine; Multiple myeloma; Oncology; Internal medicine; Ranking (information retrieval); Intensive care medicine; Family medicine; Machine learning","score_opus":0.04914085767088743,"score_gpt":0.36332775307073184,"score_spread":0.3141868953998444,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409195656","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.93892103,0.04994071,0.00015749363,0.0015978676,0.0013452941,0.0065135937,0.00015957153,0.00013839628,0.0012260249],"genre_scores_gemma":[0.9922391,0.002766448,0.0008073196,0.002005039,0.00024850023,0.00064003124,0.00035599162,0.00005846796,0.000879075],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952239,0.00046927278,0.002142175,0.0007745322,0.0007740703,0.0006160611],"domain_scores_gemma":[0.9878342,0.009420556,0.00081264914,0.0010717179,0.0006045379,0.0002562989],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015751759,0.0004901281,0.0017556599,0.00018720965,0.00025969322,0.0000720699,0.00060161366,0.00032191997,0.000012623358],"category_scores_gemma":[0.019615347,0.00030834976,0.0014204425,0.0006753455,0.0003079831,0.00012409844,0.0001845966,0.00043108506,0.000017581275],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0026943514,0.0015335779,0.7644492,0.10704339,0.0066304,0.0010360545,0.00047925417,0.0000037635045,0.0009242398,0.0010425069,0.0065558534,0.10760744],"study_design_scores_gemma":[0.01168346,0.0004937485,0.8515609,0.12947693,0.0016653716,0.00006208044,0.00026992825,0.0019314444,0.00033314351,0.0003000732,0.0018743462,0.0003485699],"about_ca_topic_score_codex":0.00001447305,"about_ca_topic_score_gemma":0.000016954167,"teacher_disagreement_score":0.10725887,"about_ca_system_score_codex":0.00076571055,"about_ca_system_score_gemma":0.0011427087,"threshold_uncertainty_score":0.9999369},"labels":[],"label_agreement":null},{"id":"W4409534748","doi":"10.1016/j.clml.2025.04.009","title":"Role of a Multidisciplinary Program (Amyloidosis Program of Calgary) on Recognition and Intervention for AL and ATTR Amyloidosis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Amyloidosis: Diagnosis, Treatment, Outcomes","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"University of Calgary; Libin Cardiovascular Institute of Alberta; Foothills Medical Centre","funders":"","keywords":"Medicine; AL amyloidosis; Amyloidosis; Multidisciplinary approach; Intervention (counseling); Dermatology; Pathology; Immunology; Nursing; Immunoglobulin light chain; Antibody","score_opus":0.02435612943670549,"score_gpt":0.34900307939169556,"score_spread":0.32464694995499005,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409534748","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99564993,0.0015099075,0.00012786934,0.00021322588,0.00014087067,0.0019086433,0.000105724896,0.000056204186,0.00028762172],"genre_scores_gemma":[0.98827624,0.0011974598,0.008332296,0.00019014534,0.00006661874,0.0013483481,0.00041404788,0.00004005907,0.00013480306],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9974961,0.00018192363,0.0010461075,0.00079492526,0.00015236731,0.0003285566],"domain_scores_gemma":[0.99837846,0.00037584567,0.0004531024,0.00043879208,0.0002061757,0.0001476511],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00046380155,0.00033502464,0.0006386498,0.00013281348,0.00010197464,0.0000286864,0.0001920914,0.00044403473,0.000006595338],"category_scores_gemma":[0.00056803145,0.0003108008,0.00047308262,0.00018558309,0.00049207284,0.000014447989,0.00029742406,0.00009543669,0.0000027555088],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012824921,0.0017983317,0.098603904,0.000220091,0.00040949014,0.0000014552212,0.000030133751,7.32779e-7,0.011111224,0.000054775235,0.00034314775,0.8861442],"study_design_scores_gemma":[0.0062449183,0.0066532767,0.8847028,0.0004569544,0.00036920758,0.000006295806,0.00014223262,0.00071017415,0.09556589,0.0007456897,0.0040796646,0.00032288826],"about_ca_topic_score_codex":0.00012841962,"about_ca_topic_score_gemma":0.000065565204,"teacher_disagreement_score":0.88582134,"about_ca_system_score_codex":0.00009545891,"about_ca_system_score_gemma":0.0001633505,"threshold_uncertainty_score":0.99993443},"labels":[],"label_agreement":null},{"id":"W4409816148","doi":"10.1016/j.clml.2025.04.016","title":"SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia","year":2025,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Dalhousie University","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Leukemia; Oncology; Internal medicine","score_opus":0.029672944055525157,"score_gpt":0.35295621070716343,"score_spread":0.32328326665163826,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4409816148","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.012589556,0.97473645,0.00019594432,0.00063974207,0.001520672,0.005095578,0.0013536236,0.0002536644,0.0036147714],"genre_scores_gemma":[0.002323097,0.9887488,0.00055167894,0.000851324,0.00034123383,0.00041846125,0.0004290809,0.00020769112,0.006128637],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.98905617,0.001274237,0.004913525,0.0019743238,0.0013115803,0.0014701502],"domain_scores_gemma":[0.98783916,0.007165359,0.0012594152,0.0023911009,0.00052568706,0.0008192948],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0015528369,0.0014725664,0.0062022335,0.0008763532,0.00023433319,0.00012539438,0.0015577197,0.0016675332,0.00007965944],"category_scores_gemma":[0.0034724402,0.0010012186,0.001929962,0.002329206,0.0020885323,0.00024754409,0.0009462125,0.0017193535,0.00026991102],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0005625483,0.00025467522,0.00044056436,0.018287025,0.0012512465,0.00084695773,0.00011321896,0.0000069544685,0.000008228237,0.00045049906,0.0050762864,0.9727018],"study_design_scores_gemma":[0.01689716,0.001138305,0.05422204,0.17995882,0.012834202,0.00384903,0.000054002205,0.002839631,0.000039621867,0.0008071982,0.7251209,0.002239097],"about_ca_topic_score_codex":0.00031706406,"about_ca_topic_score_gemma":0.00015382747,"teacher_disagreement_score":0.9704627,"about_ca_system_score_codex":0.008256377,"about_ca_system_score_gemma":0.035545286,"threshold_uncertainty_score":0.99980235},"labels":[],"label_agreement":null},{"id":"W4410049939","doi":"10.1016/j.clml.2025.04.020","title":"Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cytokine Signaling Pathways and Interactions","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Jewish General Hospital","funders":"Takeda Pharmaceuticals U.S.A.; Takeda Development Center Americas","keywords":"Medicine; Internal medicine; Rituximab; Chills; Phases of clinical research; Pharmacodynamics; Gastroenterology; Lymphoma; Refractory (planetary science); Adverse effect; Oncology; Dosing; Pharmacology; Immunology; Toxicity; Pharmacokinetics","score_opus":0.02805496074734917,"score_gpt":0.35500675746282656,"score_spread":0.3269517967154774,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410049939","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9939055,0.00014183769,0.00011322946,0.00032379144,0.0005526291,0.001295183,0.000017191982,0.00008171644,0.0035689166],"genre_scores_gemma":[0.99820507,0.000049123693,0.00029578985,0.00047832963,0.00010204399,0.00013077006,0.00006376425,0.000054204196,0.00062090973],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.99564135,0.0003283384,0.0021720051,0.0008548169,0.0005115857,0.0004918845],"domain_scores_gemma":[0.99714255,0.0009641256,0.0004917009,0.0008692125,0.0003320914,0.0002003417],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011370287,0.00041186222,0.0013846584,0.00084191473,0.00013150997,0.0000285748,0.0003023951,0.0003625647,0.000084560124],"category_scores_gemma":[0.0008589771,0.00036510767,0.00024505105,0.0014395553,0.00026226506,0.00020564882,0.00016683704,0.00047709674,0.00003138194],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0130276745,0.09714504,0.13787332,0.00022174061,0.0003063051,0.000955854,0.0016178014,0.000056151166,0.0053864922,0.00046381223,0.0015921171,0.7413537],"study_design_scores_gemma":[0.14416498,0.020125948,0.8230048,0.0012178316,0.00019969723,0.000042100226,0.001442845,0.0033612049,0.0029127027,0.0001690468,0.0030158823,0.00034300808],"about_ca_topic_score_codex":0.0012436315,"about_ca_topic_score_gemma":0.0009649692,"teacher_disagreement_score":0.74101067,"about_ca_system_score_codex":0.001477402,"about_ca_system_score_gemma":0.0018370897,"threshold_uncertainty_score":0.9998801},"labels":[],"label_agreement":null},{"id":"W4410197384","doi":"10.1016/j.clml.2025.05.006","title":"Clinical Outcomes for Multiple Myeloma Patients With Prior Exposure to a Combination of a Proteasome Inhibitor and an Immunomodulatory Agent in Alberta, Canada","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Alberta Cancer Foundation","funders":"Janssen Canada; Johnson and Johnson","keywords":"Medicine; Multiple myeloma; Confidence interval; Attrition; Health care; Internal medicine; Emergency medicine","score_opus":0.019803092311802772,"score_gpt":0.3308765082936681,"score_spread":0.31107341598186533,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410197384","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99378234,0.00006822948,0.000037589125,0.00057775766,0.00033268888,0.0049915835,0.00009437277,0.000029756266,0.000085705666],"genre_scores_gemma":[0.99526995,0.000013008941,0.002430726,0.00076415436,0.000075302174,0.00059773086,0.0001975415,0.000049521874,0.0006020346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957503,0.0003245229,0.0017865106,0.0009229364,0.0006041163,0.0006115985],"domain_scores_gemma":[0.9954793,0.0021896583,0.00032727534,0.00079852546,0.0005221899,0.00068309094],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00083519256,0.00040220915,0.0013137133,0.00026320288,0.00012781253,0.000031232103,0.00025545724,0.00032631902,0.000009522691],"category_scores_gemma":[0.0040165656,0.0003119584,0.00023297833,0.00039010413,0.00025613522,0.0001668026,0.00018151026,0.00025998274,0.00000450922],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0051445384,0.0015000948,0.69885105,0.00016720209,0.00028318228,0.000034410707,0.00006257741,0.0000025730442,0.000021079626,0.000053970267,0.00020337167,0.29367596],"study_design_scores_gemma":[0.03798883,0.004471367,0.9546806,0.0004504721,0.00011315495,0.000002836293,0.00006393548,0.00052633986,0.00019360104,0.00005602711,0.0011841013,0.00026872457],"about_ca_topic_score_codex":0.07526652,"about_ca_topic_score_gemma":0.20461984,"teacher_disagreement_score":0.29340723,"about_ca_system_score_codex":0.0011908244,"about_ca_system_score_gemma":0.00406297,"threshold_uncertainty_score":0.99993324},"labels":[],"label_agreement":null},{"id":"W4410431776","doi":"10.1016/j.clml.2025.05.011","title":"Feasibility of Bruton’s Tyrosine Kinase Inhibitor Discontinuation in Chronic Lymphocytic Leukemia: The Patient Perspective","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"Foundation for the National Institutes of Health","keywords":"Medicine; Discontinuation; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Perspective (graphical); Tyrosine-kinase inhibitor; Ibrutinib; Tyrosine kinase; Internal medicine; Oncology; Cancer research; Leukemia; Receptor; Cancer","score_opus":0.034815132707061984,"score_gpt":0.3708855288940279,"score_spread":0.33607039618696594,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4410431776","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9849244,0.0037744152,0.0000865829,0.0010702016,0.00078405795,0.0026192437,0.00003459937,0.00013654382,0.0065699928],"genre_scores_gemma":[0.9962052,0.00041441742,0.00018774219,0.0008221695,0.0005142728,0.0002183342,0.00005021326,0.000070296046,0.0015173545],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9926327,0.0008208887,0.0027832575,0.0014875868,0.0011831339,0.0010924451],"domain_scores_gemma":[0.9933573,0.0025556802,0.0005999768,0.0022245157,0.00088299153,0.00037955877],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024527689,0.00061324914,0.0015852429,0.00045467788,0.00021553713,0.00006896054,0.00074250525,0.0007257418,0.00012508723],"category_scores_gemma":[0.0061103585,0.00045441068,0.0007841121,0.0019609206,0.0018390296,0.00025676456,0.000709211,0.00079748704,0.000111843605],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.02035974,0.0026525029,0.07095782,0.0022523375,0.0014952446,0.0018672504,0.0042944034,0.0029550528,0.012662939,0.02740461,0.017010823,0.8360873],"study_design_scores_gemma":[0.06215155,0.0021567426,0.8483347,0.0022387477,0.00044323146,0.00016471464,0.0018283486,0.060366407,0.016028937,0.002690688,0.0029057711,0.00069013954],"about_ca_topic_score_codex":0.006767858,"about_ca_topic_score_gemma":0.0010475133,"teacher_disagreement_score":0.8353971,"about_ca_system_score_codex":0.39275604,"about_ca_system_score_gemma":0.14194305,"threshold_uncertainty_score":0.99984616},"labels":[],"label_agreement":null},{"id":"W4411399412","doi":"10.1016/j.clml.2025.06.009","title":"Incidence and Burden of Lower-Risk Myelodysplastic Syndrome: A Nationwide Population Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Micropalaeontological Society; Bristol-Myers Squibb; Bamfield Marine Sciences Centre","keywords":"Medicine; Myelodysplastic syndromes; Incidence (geometry); Internal medicine; Cohort; Anemia; Retrospective cohort study; International Prognostic Scoring System; Population; Pediatrics; Bone marrow","score_opus":0.017983247766018104,"score_gpt":0.34668904013915436,"score_spread":0.32870579237313624,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411399412","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99563974,0.0003541066,0.00026594204,0.00060149,0.00047015972,0.001440418,0.000020777257,0.00013617381,0.001071192],"genre_scores_gemma":[0.9961999,0.00024778518,0.0011038933,0.00024750418,0.00019430455,0.00007626028,0.000036096477,0.000046905403,0.0018473585],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9954975,0.00054943084,0.0016299834,0.0009645399,0.0008396949,0.0005188245],"domain_scores_gemma":[0.99466544,0.0029650955,0.00048814062,0.0010007132,0.0005096598,0.00037093327],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0021796648,0.00037489977,0.0012022336,0.000540794,0.00022170704,0.000054298333,0.0004099655,0.00043900285,0.00007417244],"category_scores_gemma":[0.008862119,0.000339658,0.00025115802,0.0011943873,0.0005040301,0.00022797116,0.0005151185,0.0006020991,0.00007929097],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00175234,0.00043393686,0.72796345,0.00023635829,0.00045996328,0.0007217031,0.00018713706,0.000056558205,0.00028712203,0.00041529973,0.00089449005,0.26659164],"study_design_scores_gemma":[0.0066733826,0.0019764926,0.9823706,0.0004650888,0.0005025243,0.0002680271,0.00033540395,0.0058301073,0.00005904744,0.00076873926,0.0004981236,0.00025245233],"about_ca_topic_score_codex":0.0015436701,"about_ca_topic_score_gemma":0.00010930034,"teacher_disagreement_score":0.2663392,"about_ca_system_score_codex":0.0011614733,"about_ca_system_score_gemma":0.0019144547,"threshold_uncertainty_score":0.9999055},"labels":[],"label_agreement":null},{"id":"W4411605405","doi":"10.1016/j.clml.2025.06.010","title":"Identifying Risk Factors and Outcome for CNS Involvement in AML","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Outcome (game theory); Oncology; Intensive care medicine; Internal medicine","score_opus":0.08031903326607367,"score_gpt":0.40762752288969695,"score_spread":0.32730848962362324,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4411605405","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99346304,0.0005276987,0.0011996252,0.0010473263,0.0006493467,0.0015904707,0.000052088097,0.00013506017,0.0013353672],"genre_scores_gemma":[0.99107134,0.000624753,0.0031490878,0.001613994,0.00025967267,0.00018293266,0.00008395903,0.00006301276,0.002951268],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99550724,0.0002705461,0.0018501467,0.0010574344,0.00043992896,0.00087470555],"domain_scores_gemma":[0.9953003,0.0029153377,0.0002788477,0.0008466474,0.00019832622,0.0004605757],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0024119632,0.0004306733,0.0012419496,0.00053053116,0.00022690032,0.00009754246,0.00039397748,0.00056311744,0.000050696006],"category_scores_gemma":[0.004788584,0.00035973653,0.00046197802,0.0006822981,0.0004603083,0.00017739036,0.00049821544,0.0006858156,0.000050714076],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00061835913,0.00016102081,0.83530724,0.00031096122,0.00020762502,0.00007532799,0.00017401864,0.00000252226,0.00022786102,0.000930303,0.0032655254,0.15871921],"study_design_scores_gemma":[0.0101009775,0.00035440194,0.9710909,0.0002857057,0.00021879574,0.000010332256,0.0005648133,0.0021744203,0.00075913506,0.0021357974,0.0120046055,0.00030009932],"about_ca_topic_score_codex":0.0009187899,"about_ca_topic_score_gemma":0.00027211418,"teacher_disagreement_score":0.15841912,"about_ca_system_score_codex":0.0028479036,"about_ca_system_score_gemma":0.0017204979,"threshold_uncertainty_score":0.99988544},"labels":[],"label_agreement":null},{"id":"W4412435012","doi":"10.1016/j.clml.2025.07.003","title":"Real-World Practice in the Management of Transplant-Eligible Newly Diagnosed Multiple Myeloma: A US-Based Cross-Sectional National Survey","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Multiple myeloma; Cross-sectional study; Family medicine; Internal medicine; Oncology; Pathology","score_opus":0.06866963713237662,"score_gpt":0.423243187999214,"score_spread":0.3545735508668374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412435012","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.96682495,0.00021758256,0.00012330474,0.00081588357,0.00031164297,0.0015367195,0.00022585128,0.000080292746,0.029863756],"genre_scores_gemma":[0.9926663,0.00056561164,0.0021922947,0.0016810575,0.00015194778,0.00036002684,0.00079392083,0.000037895185,0.0015509594],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9939271,0.0011019635,0.0017984258,0.00091307756,0.0015505959,0.00070884434],"domain_scores_gemma":[0.98532754,0.012521395,0.00036256644,0.0007971393,0.0007190429,0.0002722941],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0046543134,0.0004060537,0.0007857613,0.0005213825,0.00023507515,0.00010286318,0.0006051619,0.00031483165,0.000094895615],"category_scores_gemma":[0.0028741716,0.00031116788,0.00046717515,0.0016724734,0.0005117113,0.00022423537,0.00011227668,0.00048070555,0.000104957544],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010180529,0.002173243,0.9532412,0.0002964045,0.00076048943,0.001145561,0.000047002675,0.00016902508,0.000033854434,0.0010351177,0.001698332,0.029219184],"study_design_scores_gemma":[0.023766037,0.00029391673,0.9668975,0.0003724136,0.00015022137,0.000030107787,0.000040156505,0.0031483122,0.00022734095,0.00021956164,0.0046267016,0.00022773776],"about_ca_topic_score_codex":0.004222122,"about_ca_topic_score_gemma":0.0017711164,"teacher_disagreement_score":0.028991446,"about_ca_system_score_codex":0.0012310462,"about_ca_system_score_gemma":0.0030135876,"threshold_uncertainty_score":0.999934},"labels":[],"label_agreement":null},{"id":"W4412435047","doi":"10.1016/j.clml.2025.07.004","title":"Cognitive Performance in Patients With Multiple Myeloma Treated With an Autologous Stem Cell Transplant: Results of the Brilliant Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Cancer-related cognitive impairment studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"Comprehensive Cancer Center at Wake Forest Baptist Medical Center","keywords":"Medicine; Multiple myeloma; Montreal Cognitive Assessment; Internal medicine; Transplantation; Hematopoietic stem cell transplantation; Chemotherapy; Melphalan; Surgery; Cognitive impairment; Disease","score_opus":0.016470215689490884,"score_gpt":0.27973206882628504,"score_spread":0.2632618531367942,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4412435047","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99362063,0.00009678961,0.000008486435,0.000088969784,0.00015152404,0.0032245407,0.00020894699,0.000104035906,0.0024960542],"genre_scores_gemma":[0.9987379,0.00007799545,0.000033462624,0.00028793523,0.00003954563,0.00013222144,0.00007819467,0.00004893456,0.00056384166],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9960575,0.00044047547,0.001400561,0.0009335998,0.0006069248,0.00056092045],"domain_scores_gemma":[0.9970693,0.0010117213,0.0005033959,0.0006713054,0.00056860154,0.0001756729],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005174016,0.0004927627,0.0011666239,0.00020496985,0.00021493903,0.000017500233,0.0002848277,0.00025848765,0.000005535532],"category_scores_gemma":[0.00014038413,0.00029759048,0.0001621114,0.0011108549,0.0007703369,0.00015723931,0.00010683542,0.00044735693,0.000010945021],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.04549899,0.0025702845,0.8156145,0.00013383782,0.0004609361,0.00009975827,0.0009559907,0.000023698078,0.0000060761795,0.0000012439278,0.000031546453,0.13460311],"study_design_scores_gemma":[0.063221164,0.012453339,0.91778684,0.0024148189,0.00087573135,0.000010288334,0.0013461822,0.00041682724,0.0010861838,0.0000012888839,0.00006722103,0.00032009967],"about_ca_topic_score_codex":0.0002596285,"about_ca_topic_score_gemma":0.0006427803,"teacher_disagreement_score":0.134283,"about_ca_system_score_codex":0.0006690021,"about_ca_system_score_gemma":0.0009939483,"threshold_uncertainty_score":0.9999476},"labels":[],"label_agreement":null},{"id":"W4413291323","doi":"10.1016/j.clml.2025.08.015","title":"A Systematic Review of MicroRNAs in Nasal NK/T-Cell Lymphoma: Diagnostic, Prognostic, and Therapeutic Perspectives","year":2025,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Global Health Research","funders":"","keywords":"Medicine; Lymphoma; Oncology; microRNA; Cancer research; Immunology; Internal medicine","score_opus":0.02092987163806847,"score_gpt":0.31803467248306033,"score_spread":0.29710480084499186,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413291323","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0003251675,0.991685,0.000011870776,0.000040693634,0.0026208456,0.003655505,0.000034576355,0.000086306325,0.0015400619],"genre_scores_gemma":[0.00069952453,0.9920977,0.00002461893,0.00046481646,0.00007235283,0.00063560886,0.00024038687,0.00007621677,0.00568879],"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","domain_scores_codex":[0.9907348,0.0031185506,0.004281343,0.0011503476,0.00011807068,0.0005968839],"domain_scores_gemma":[0.9838198,0.012782524,0.00199986,0.0010265845,0.00030074074,0.00007052196],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0017264468,0.00091888255,0.0062074135,0.00048292836,0.00013362194,0.000038951177,0.000692566,0.0014520515,0.00025657134],"category_scores_gemma":[0.008191824,0.00072263606,0.0014488865,0.0006489786,0.0006369442,0.0001021434,0.00033446346,0.00068427954,0.00060647744],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000063690546,0.0006002327,0.000024672157,0.6557813,0.00072703866,0.000028655799,0.00009353204,1.5652228e-8,0.000014641402,0.00018851415,0.0018421948,0.34063545],"study_design_scores_gemma":[0.002444132,0.0003666754,0.0009640495,0.7789388,0.004679715,0.00035523844,0.00025653234,0.0000011015411,0.000040980878,0.000022856126,0.21126403,0.0006659094],"about_ca_topic_score_codex":0.00006569397,"about_ca_topic_score_gemma":0.000006950882,"teacher_disagreement_score":0.33996955,"about_ca_system_score_codex":0.0009102572,"about_ca_system_score_gemma":0.0021545033,"threshold_uncertainty_score":0.99984425},"labels":[],"label_agreement":null},{"id":"W4413774125","doi":"10.1016/s2152-2650(25)00753-0","title":"POSTER: CML-754 Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Oncology; Internal medicine; Dasatinib; Imatinib","score_opus":0.01578916958822854,"score_gpt":0.2878932926959074,"score_spread":0.27210412310767884,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774125","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.987176,0.0016438849,0.00004938317,0.0027549432,0.0011735081,0.0051863207,0.00016068674,0.0008574488,0.0009978318],"genre_scores_gemma":[0.9860473,0.00037999905,0.0014077128,0.005994605,0.00050602335,0.001220052,0.0012335883,0.00033246327,0.0028782121],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98476654,0.000779183,0.006013511,0.003974578,0.0018102068,0.0026559595],"domain_scores_gemma":[0.98866934,0.0019569357,0.002217061,0.0038863618,0.0011530406,0.0021172538],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0013570298,0.0022402613,0.0050341855,0.0020467849,0.00052210054,0.00031450385,0.0010967456,0.0018500772,0.0003296938],"category_scores_gemma":[0.0058448245,0.0018863259,0.0017022165,0.009153638,0.0015709361,0.0007114709,0.0007442796,0.0017900569,0.00026081654],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0052549965,0.0020691117,0.83990705,0.0005703797,0.0067431564,0.0035060481,0.0006299248,0.00009242733,0.0032234262,0.00004127752,0.007838319,0.13012388],"study_design_scores_gemma":[0.052822534,0.00384813,0.91240776,0.001521638,0.0058643534,0.00016462356,0.00017437091,0.0041752853,0.0117652295,0.00008265562,0.0054966896,0.0016767397],"about_ca_topic_score_codex":0.0045407885,"about_ca_topic_score_gemma":0.0033353264,"teacher_disagreement_score":0.12844715,"about_ca_system_score_codex":0.027275495,"about_ca_system_score_gemma":0.033830903,"threshold_uncertainty_score":0.99944574},"labels":[],"label_agreement":null},{"id":"W4413774258","doi":"10.1016/s2152-2650(25)00791-8","title":"POSTER: MDS-249 Outcomes With Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Erythropoietin; Internal medicine; Erythropoiesis; Oncology; International Prognostic Scoring System; Anemia; Bone marrow","score_opus":0.027181587150734567,"score_gpt":0.3327986468750761,"score_spread":0.30561705972434156,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774258","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99005866,0.00036836337,0.00018287476,0.0016083028,0.00038672722,0.005253451,0.000864922,0.00036618073,0.00091054133],"genre_scores_gemma":[0.97578764,0.00059544813,0.0024947962,0.000922809,0.0001454756,0.0005159985,0.0003968824,0.00039563762,0.018745318],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98867387,0.0009496744,0.0027498533,0.0030904948,0.002005406,0.0025307108],"domain_scores_gemma":[0.99068743,0.003692905,0.001170824,0.0024405762,0.00075643475,0.0012518533],"candidate_categories":["metaepi_narrow"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.00077355135,0.0022326286,0.0044925613,0.00083091675,0.0007878372,0.0003026275,0.00081801636,0.0009551403,0.0004741183],"category_scores_gemma":[0.0008101933,0.0013062544,0.00065886934,0.0018632208,0.0017100397,0.00060722674,0.00048242242,0.0010090262,0.00022103556],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.021511491,0.0027493325,0.7854733,0.0002796468,0.003654602,0.002671983,0.00056140224,0.000117858064,0.000009597889,0.0000109287475,0.0017497438,0.18121013],"study_design_scores_gemma":[0.07122095,0.036915362,0.880445,0.0028438007,0.0018703743,0.0001779742,0.0005695198,0.0013173169,0.00026459745,0.000015815669,0.0029966093,0.0013626692],"about_ca_topic_score_codex":0.0017420647,"about_ca_topic_score_gemma":0.0011438061,"teacher_disagreement_score":0.17984746,"about_ca_system_score_codex":0.013514744,"about_ca_system_score_gemma":0.0075075803,"threshold_uncertainty_score":0.9990413},"labels":[],"label_agreement":null},{"id":"W4413774279","doi":"10.1016/s2152-2650(25)02350-x","title":"ABCL-1144: Differences in Demographic Characteristics Between Male and Female Survivors of Non-Hodgkin Lymphoma Admitted With Colorectal Cancer in the United States","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple and Secondary Primary Cancers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Brampton Civic Hospital; Red Deer Regional Hospital","funders":"","keywords":"Medicine; Colorectal cancer; Oncology; Hodgkin lymphoma; Internal medicine; Lymphoma; Cancer","score_opus":0.02479363711321702,"score_gpt":0.3133066837383166,"score_spread":0.2885130466250996,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774279","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9974953,0.00036213855,0.000024212242,0.0005557191,0.00020135613,0.00074197014,0.00016359173,0.000028769651,0.00042694155],"genre_scores_gemma":[0.9962664,0.0017188493,0.00012622893,0.0012445593,0.00010138092,0.00010551465,0.00023756185,0.000028505225,0.0001709883],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9968427,0.00040065803,0.0013065564,0.0006097935,0.00034337552,0.0004969577],"domain_scores_gemma":[0.99683267,0.0020828487,0.00034370486,0.00041754724,0.00014267994,0.00018052166],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009107373,0.00036877306,0.001272871,0.0005361126,0.00008736549,0.000037501155,0.00036334444,0.00034802093,0.00007366312],"category_scores_gemma":[0.0002532489,0.00025542188,0.00014572071,0.0016300336,0.0007438405,0.00010013119,0.00010721894,0.00033419742,0.0000021587803],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016868976,0.00017098038,0.84097826,0.00021696933,0.00017559927,0.00013678882,0.00063291116,0.0000035606317,0.00009795641,0.000022010801,0.00007618781,0.15580189],"study_design_scores_gemma":[0.0073357653,0.0007430524,0.9865478,0.0007151654,0.0001828387,0.000020982621,0.0009279055,0.0024231083,0.00019281253,0.00004483391,0.00059803925,0.0002676556],"about_ca_topic_score_codex":0.0071195606,"about_ca_topic_score_gemma":0.005108763,"teacher_disagreement_score":0.15553424,"about_ca_system_score_codex":0.00046183894,"about_ca_system_score_gemma":0.0016956932,"threshold_uncertainty_score":0.9999898},"labels":[],"label_agreement":null},{"id":"W4413774493","doi":"10.1016/s2152-2650(25)02385-7","title":"ABCL-1487: Large B-Cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) Clinically Identify Subgroups With Greatest Benefit From CD19 CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; CD19; Lymphoma; Oncology; Internal medicine; Immunology; Antigen","score_opus":0.02548499021004296,"score_gpt":0.3236153303053004,"score_spread":0.2981303400952574,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774493","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9792811,0.0040947385,0.00022775748,0.001111524,0.000925673,0.0028426305,0.0003319269,0.00045970854,0.010724896],"genre_scores_gemma":[0.93748593,0.0070042037,0.002664729,0.005052947,0.0011878713,0.00039942464,0.0009208133,0.0003812105,0.044902865],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9882563,0.0008265137,0.0035647391,0.0031787727,0.0018620446,0.002311671],"domain_scores_gemma":[0.9903213,0.0031899977,0.0008929107,0.0036940218,0.0004972577,0.001404523],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0026828551,0.0014708221,0.0027577942,0.00048949267,0.0005362576,0.000318604,0.0017473452,0.0015449597,0.002489491],"category_scores_gemma":[0.0003808309,0.0012303126,0.0015043712,0.0011886897,0.001287185,0.00030002109,0.0008797054,0.0010581422,0.0016513724],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01847873,0.008791785,0.4733893,0.00030291243,0.0014025941,0.0016070281,0.0004230345,0.000008424993,0.08758232,0.00015673082,0.005344894,0.40251222],"study_design_scores_gemma":[0.05626212,0.0029266821,0.811587,0.0005534137,0.00050631986,0.000099733734,0.00027984663,0.0003142815,0.045402177,0.00058287935,0.08036857,0.0011169767],"about_ca_topic_score_codex":0.0015090642,"about_ca_topic_score_gemma":0.00019989155,"teacher_disagreement_score":0.40139526,"about_ca_system_score_codex":0.0038187208,"about_ca_system_score_gemma":0.004077554,"threshold_uncertainty_score":0.99980414},"labels":[],"label_agreement":null},{"id":"W4413774531","doi":"10.1016/s2152-2650(25)01319-9","title":"POSTER: MM-1049 DREAMM-7 Study of BelantamabMafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Multiple myeloma; Refractory (planetary science); Oncology; Internal medicine","score_opus":0.03154759248529704,"score_gpt":0.3419932738643108,"score_spread":0.31044568137901374,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774531","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98956823,0.0021049783,0.000009349326,0.00026880353,0.00065464806,0.005921235,0.00018282705,0.00017788207,0.0011120411],"genre_scores_gemma":[0.9960469,0.0009279602,0.00040044394,0.00054420874,0.00013869027,0.00043116193,0.0006596011,0.00018224727,0.00066880346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98736066,0.0021330703,0.0044506546,0.0023988092,0.0017486144,0.0019081966],"domain_scores_gemma":[0.990207,0.0048161224,0.0010009005,0.002444514,0.0005728665,0.00095855247],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0027561784,0.0012435417,0.0034488568,0.0013039848,0.00024487195,0.00008924453,0.0010927165,0.00111878,0.00013352779],"category_scores_gemma":[0.0045856778,0.0011096273,0.00072492,0.0023117736,0.00071570213,0.0003211243,0.0005879972,0.001591507,0.00010727387],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.021331651,0.02486284,0.66873854,0.00011274596,0.00073076715,0.0006781802,0.00047611207,0.000007651508,0.0007693848,0.000010316706,0.0009427719,0.28133902],"study_design_scores_gemma":[0.13626346,0.008354738,0.84940886,0.00073799316,0.00019729369,0.000016706686,0.00036066998,0.00033035144,0.0024490268,0.00002696406,0.0011729737,0.0006809732],"about_ca_topic_score_codex":0.0039015908,"about_ca_topic_score_gemma":0.0016844305,"teacher_disagreement_score":0.28065807,"about_ca_system_score_codex":0.0034278007,"about_ca_system_score_gemma":0.0020929214,"threshold_uncertainty_score":0.9991354},"labels":[],"label_agreement":null},{"id":"W4413774548","doi":"10.1016/s2152-2650(25)00721-9","title":"POSTER: CML-124 Tracking the Rising Burden of Major Cardiovascular Disease-Related Mortality Among Chronic Myeloid Leukemia Patients: Epidemiological Trends and Disparities in United States Adults Aged 25 and Above (2010–2020)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Medicine; Myeloid leukemia; Epidemiology; Disease; Disease burden; Gerontology; Environmental health; Intensive care medicine; Internal medicine","score_opus":0.019942205254524992,"score_gpt":0.2947420931033744,"score_spread":0.2747998878488494,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413774548","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9832837,0.013523315,0.000016993887,0.0008221139,0.00045560888,0.0012954734,0.00019767326,0.00015732189,0.0002477934],"genre_scores_gemma":[0.99204403,0.005728515,0.000081416605,0.00042787855,0.00021481201,0.0001231957,0.0009064561,0.00007745913,0.00039620846],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9921392,0.0014956644,0.002936774,0.0016360244,0.00074318744,0.0010491351],"domain_scores_gemma":[0.9936611,0.0031499376,0.0006860547,0.0016064416,0.0002866478,0.0006097873],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025315518,0.0008660222,0.002428106,0.00047069945,0.00032581665,0.00009182319,0.00046318347,0.0008155675,0.00005649901],"category_scores_gemma":[0.0032570371,0.0006303165,0.0008146358,0.0013414528,0.002205408,0.00031893462,0.00057998655,0.001020594,0.0000064569663],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0011968544,0.0002102036,0.7869885,0.0006372031,0.0021505803,0.00036199647,0.0004162666,0.00041827426,0.000018336983,0.0000825601,0.00032667935,0.20719254],"study_design_scores_gemma":[0.019029753,0.00055803446,0.96258557,0.0024247786,0.0020507379,0.00003641186,0.00026058033,0.011524465,0.00004083738,0.00056514086,0.0004127085,0.00051096664],"about_ca_topic_score_codex":0.009476051,"about_ca_topic_score_gemma":0.00039570994,"teacher_disagreement_score":0.20668156,"about_ca_system_score_codex":0.004519782,"about_ca_system_score_gemma":0.0015122521,"threshold_uncertainty_score":0.99961483},"labels":[],"label_agreement":null},{"id":"W4413779902","doi":"10.1016/s2152-2650(25)01224-8","title":"POSTER: MM-119 Trends and Disparities in Ischemic Heart Disease and Multiple Myeloma-Related Mortality in United States Adults Aged 25 and Above: A 22-Year Population-Based Analysis (1999–2020)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chemotherapy-induced cardiotoxicity and mitigation","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Medicine; Multiple myeloma; Demography; Disease; Gerontology; Internal medicine","score_opus":0.011902397454653352,"score_gpt":0.3024099772014989,"score_spread":0.2905075797468456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413779902","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9966489,0.0008613139,0.000009021792,0.0016082827,0.000069615904,0.0004728864,0.00013916996,0.00008721646,0.00010357982],"genre_scores_gemma":[0.995629,0.00044862885,0.00011126182,0.0018879621,0.00004584076,0.00003575169,0.0016735301,0.000028632738,0.00013935714],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9970243,0.0003351324,0.001159389,0.00083339686,0.0002726158,0.0003751546],"domain_scores_gemma":[0.99790734,0.0009936616,0.00018257584,0.00046283385,0.00007879234,0.0003748218],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00068336667,0.0003525811,0.0010363818,0.0007841419,0.00010691307,0.0000720806,0.0000845418,0.0004083244,0.00002079018],"category_scores_gemma":[0.0006627525,0.00035031573,0.00023444899,0.0019429078,0.0003301915,0.00016731225,0.000078617115,0.00036010935,0.000001219946],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0016946727,0.00017256419,0.9735673,0.00025980026,0.0003699618,0.00008072832,0.00016888216,0.000080898644,0.000780595,0.000024381681,0.000118770724,0.022681443],"study_design_scores_gemma":[0.012070126,0.00010835557,0.9642192,0.0005973865,0.0006748324,0.0000073223077,0.00013573858,0.021113109,0.00045801123,0.00022325396,0.00008636368,0.00030627026],"about_ca_topic_score_codex":0.0037702445,"about_ca_topic_score_gemma":0.0014280776,"teacher_disagreement_score":0.022375172,"about_ca_system_score_codex":0.00039485248,"about_ca_system_score_gemma":0.00028234939,"threshold_uncertainty_score":0.99989486},"labels":[],"label_agreement":null},{"id":"W4413780336","doi":"10.1016/s2152-2650(25)00858-4","title":"POSTER: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Azacitidine; Medicine; Venetoclax; Myelodysplastic syndromes; Placebo; Internal medicine; Oncology; Leukemia; Alternative medicine; Pathology; Chronic lymphocytic leukemia; Bone marrow; Genetics","score_opus":0.01747856256461705,"score_gpt":0.3145682214075111,"score_spread":0.29708965884289407,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413780336","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438566,0.00021670692,0.000023930099,0.00010158068,0.00017634555,0.0042126887,0.00019327122,0.000050402155,0.0006394061],"genre_scores_gemma":[0.99832904,0.00021926886,0.00023705928,0.000101035344,0.00005066002,0.00030700082,0.00021270463,0.000076871795,0.00046637456],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99395305,0.0011230257,0.001958041,0.0011609767,0.0011086316,0.0006962972],"domain_scores_gemma":[0.9915542,0.005156089,0.0010221761,0.0014149694,0.00050235976,0.00035020814],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0010787806,0.0007429737,0.0037702236,0.0009841318,0.00014064551,0.00003807177,0.00050513697,0.00030328007,0.000050713017],"category_scores_gemma":[0.00074284844,0.000405046,0.00041583963,0.0028375976,0.0019433758,0.00018936308,0.00034798402,0.00053566654,0.0000036345953],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.46440297,0.002146148,0.49357265,0.00016122882,0.010315264,0.00019833016,0.00032659626,0.00014345559,0.00001946471,0.00001674912,0.000032610995,0.028664539],"study_design_scores_gemma":[0.3908394,0.012726048,0.5865844,0.00047773749,0.008179186,0.000008728424,0.000183957,0.0006450151,0.00009727237,0.0000046090577,0.000025099565,0.00022858469],"about_ca_topic_score_codex":0.00083513214,"about_ca_topic_score_gemma":0.0006262614,"teacher_disagreement_score":0.09301173,"about_ca_system_score_codex":0.002926362,"about_ca_system_score_gemma":0.0029270553,"threshold_uncertainty_score":0.99984014},"labels":[],"label_agreement":null},{"id":"W4413781006","doi":"10.1016/s2152-2650(25)02676-x","title":"MM-1049: DREAMM-7 Study of Belantamab Mafodotin + Bortezomib + Dexamethasone vs Daratumumab + Bortezomib + Dexamethasone in Relapsed/Refractory Multiple Myeloma: Efficacy in Patients by Subsequent Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Daratumumab; Medicine; Bortezomib; Dexamethasone; Internal medicine; Oncology; Multiple myeloma; Refractory (planetary science)","score_opus":0.032112283500004626,"score_gpt":0.3444139536119541,"score_spread":0.3123016701119495,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413781006","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896647,0.0021236434,0.000016882273,0.00024164851,0.0006511168,0.005872199,0.00017101086,0.00018639624,0.0010724453],"genre_scores_gemma":[0.9956485,0.0010478954,0.00064959185,0.00045283602,0.00014620184,0.00049515284,0.0006223327,0.00018593777,0.0007515627],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9872224,0.002114792,0.0044581974,0.0024454033,0.0018073855,0.0019518345],"domain_scores_gemma":[0.99009156,0.0048992615,0.0010034619,0.002476332,0.00055557786,0.00097378535],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0028958712,0.0012552231,0.0035071028,0.0013058772,0.00025258044,0.0000855127,0.001107462,0.0011488751,0.00015468516],"category_scores_gemma":[0.0050954744,0.0011241039,0.00073161855,0.0024823176,0.00074394536,0.0003080089,0.0005627778,0.0016599549,0.000114054514],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01999973,0.026461357,0.65385056,0.00011433788,0.00074784004,0.0006807007,0.00040882846,0.000013140288,0.0006859356,0.000016350865,0.0011515566,0.29586968],"study_design_scores_gemma":[0.14196256,0.007288923,0.84450346,0.00070113695,0.00020067174,0.000014306545,0.0004311558,0.00057368114,0.0021379287,0.000036773898,0.0014631922,0.00068624644],"about_ca_topic_score_codex":0.0039633536,"about_ca_topic_score_gemma":0.0016575878,"teacher_disagreement_score":0.29518342,"about_ca_system_score_codex":0.0036971495,"about_ca_system_score_gemma":0.002266757,"threshold_uncertainty_score":0.9991209},"labels":[],"label_agreement":null},{"id":"W4413782928","doi":"10.1016/s2152-2650(25)01341-2","title":"POSTER: MM-1193 Daratumumab-Bortezomib-Lenalidomide-Dexamethasone vs Contemporary Treatment Alternatives in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Results of a Systematic Literature Review and Network Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; BC Cancer Agency; Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Medicine; Daratumumab; Multiple myeloma; Meta-analysis; Bortezomib; Dexamethasone; Oncology; Internal medicine","score_opus":0.06223099620461319,"score_gpt":0.3533510164860563,"score_spread":0.2911200202814431,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413782928","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.777352,0.21097018,0.00007574604,0.0012996923,0.00012879254,0.007805399,0.0012519973,0.00010698791,0.0010092439],"genre_scores_gemma":[0.96974444,0.02474806,0.0012328865,0.0012128666,0.00006976951,0.0008304926,0.001316433,0.00006160979,0.00078346033],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9912125,0.0017880184,0.0037084457,0.0015415784,0.0009115975,0.0008378932],"domain_scores_gemma":[0.99056035,0.005384195,0.0011787497,0.0015921044,0.0006552258,0.0006293566],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018375404,0.0009560757,0.007356987,0.0007331714,0.00015643261,0.00010507645,0.00042984812,0.0003742359,0.000026142223],"category_scores_gemma":[0.0018486364,0.00058615184,0.0017640841,0.0026496886,0.00042316277,0.00031237342,0.00013757328,0.0003954221,0.000011790498],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.03077061,0.0029990843,0.7657105,0.0334127,0.15423854,0.002911233,0.00055514666,0.000058346355,0.000009935952,0.00004358424,0.0011061557,0.008184199],"study_design_scores_gemma":[0.053302366,0.0023071324,0.83166194,0.0214877,0.08977027,0.000033642853,0.000035513614,0.00053607294,0.00014282746,0.000027749511,0.00022206256,0.00047270194],"about_ca_topic_score_codex":0.00080995524,"about_ca_topic_score_gemma":0.0006157334,"teacher_disagreement_score":0.19239245,"about_ca_system_score_codex":0.00065423764,"about_ca_system_score_gemma":0.0009628986,"threshold_uncertainty_score":0.999659},"labels":[],"label_agreement":null},{"id":"W4413782934","doi":"10.1016/s2152-2650(25)02033-6","title":"MDS-736: Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Internal medicine; Oncology; Bone marrow","score_opus":0.029276367505173533,"score_gpt":0.33116804191809496,"score_spread":0.3018916744129214,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413782934","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99279934,0.0005810998,0.000099293655,0.00093257317,0.0004525248,0.0036992389,0.00016388409,0.00007868612,0.0011933488],"genre_scores_gemma":[0.9963163,0.0017317057,0.00007265798,0.0003217118,0.00006328741,0.00015237546,0.00007526351,0.00007883653,0.0011878556],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9908394,0.0022441319,0.0030707496,0.0015150917,0.0014229896,0.0009076238],"domain_scores_gemma":[0.98916596,0.0066423994,0.0008397825,0.0025638372,0.00042199917,0.00036601478],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0034510903,0.00072369585,0.0025798415,0.0009367372,0.00042769933,0.000045753597,0.0012896715,0.0007247957,0.0002780784],"category_scores_gemma":[0.0033981064,0.00045576124,0.0008603477,0.0041713757,0.0016066338,0.0001318267,0.0017058298,0.0012768097,0.000023641936],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.048435554,0.0066979653,0.5447035,0.00072505884,0.009746689,0.0011345788,0.0042058877,0.0021294574,0.00278246,0.000079433725,0.00080511364,0.37855428],"study_design_scores_gemma":[0.023346681,0.002785269,0.9553492,0.00047579492,0.005587959,0.000093157425,0.0016389667,0.009649641,0.000396697,0.000091837166,0.00021708674,0.0003677279],"about_ca_topic_score_codex":0.0019840433,"about_ca_topic_score_gemma":0.0018138253,"teacher_disagreement_score":0.41064566,"about_ca_system_score_codex":0.0019517953,"about_ca_system_score_gemma":0.0021088314,"threshold_uncertainty_score":0.9997894},"labels":[],"label_agreement":null},{"id":"W4413783181","doi":"10.1016/s2152-2650(25)01940-8","title":"CML-575: ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Medicine; Myeloid leukemia; Internal medicine; breakpoint cluster region; Oncology; Cancer research; Receptor","score_opus":0.012512351634301826,"score_gpt":0.3084303981712043,"score_spread":0.2959180465369025,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783181","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9896854,0.00060399715,0.00001066009,0.00004390787,0.00030949063,0.00652561,0.00019859223,0.00020133403,0.002420998],"genre_scores_gemma":[0.99650466,0.00017800009,0.00026067795,0.0001864992,0.0002451485,0.0005142615,0.0005092905,0.00017088388,0.0014305598],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99060637,0.0008488425,0.0036902742,0.002104065,0.0013152978,0.0014351567],"domain_scores_gemma":[0.99300057,0.0015107404,0.0016572837,0.001996742,0.0012440832,0.0005905743],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00093060575,0.0012217002,0.0036364184,0.0009956986,0.00017850516,0.000036932768,0.0006401129,0.0009096972,0.0001664429],"category_scores_gemma":[0.0012852754,0.0010234835,0.00053098274,0.0032842103,0.00079799467,0.00042617237,0.00044759273,0.0009999974,0.00006520779],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.04658964,0.029710017,0.55797935,0.0009957223,0.004113557,0.000574109,0.0021723344,0.00010172101,0.0013956156,0.000037593716,0.0020978902,0.35423243],"study_design_scores_gemma":[0.17617334,0.02603834,0.78254575,0.0021465037,0.0017085465,0.000023901146,0.0004431457,0.00060263765,0.008860115,0.000042745407,0.0007307586,0.00068420003],"about_ca_topic_score_codex":0.0030325463,"about_ca_topic_score_gemma":0.0012109625,"teacher_disagreement_score":0.35354823,"about_ca_system_score_codex":0.023720214,"about_ca_system_score_gemma":0.014356404,"threshold_uncertainty_score":0.99922156},"labels":[],"label_agreement":null},{"id":"W4413783186","doi":"10.1016/s2152-2650(25)01835-x","title":"CLL-122: A Late Surge in Major Cardiovascular Disease-Related Mortality Among Chronic Lymphocytic Leukemia Patients: Epidemiological Trends and Disparities in United States Adults Aged 25 and Above (1999–2020)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Continental (Canada)","funders":"","keywords":"Medicine; Chronic lymphocytic leukemia; Epidemiology; Disease; Gerontology; Leukemia; Immunology; Internal medicine","score_opus":0.019716517864858698,"score_gpt":0.3137408335321797,"score_spread":0.294024315667321,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783186","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98493785,0.01193281,0.000011482073,0.0003251641,0.00039510883,0.0015885349,0.00015986626,0.00025523113,0.00039397893],"genre_scores_gemma":[0.9849074,0.011609519,0.00006199956,0.0007776421,0.00015689478,0.00032030654,0.0011764606,0.000105558494,0.0008842298],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9888685,0.0021235053,0.0035702395,0.002470066,0.0010655136,0.0019022094],"domain_scores_gemma":[0.9918595,0.0043526785,0.0004297153,0.0017928856,0.00027934182,0.0012858781],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0045032776,0.001051476,0.003205026,0.0011775703,0.00024226856,0.00012900068,0.0005480943,0.0012698917,0.00007297232],"category_scores_gemma":[0.0062408377,0.0009143413,0.00091423484,0.0029814073,0.0026012128,0.00039324522,0.000934629,0.0012443062,0.00002552933],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0037066676,0.00044576736,0.8930979,0.0015058469,0.0015327894,0.0035865132,0.00024757176,0.0015948119,0.000004219873,0.00026509812,0.0009540732,0.09305878],"study_design_scores_gemma":[0.07230931,0.00036695282,0.7628505,0.0020776659,0.0006001876,0.000041892006,0.00008614556,0.15956624,0.0000081389735,0.00083866157,0.00062102184,0.0006332638],"about_ca_topic_score_codex":0.03162451,"about_ca_topic_score_gemma":0.0023439447,"teacher_disagreement_score":0.15797143,"about_ca_system_score_codex":0.0742908,"about_ca_system_score_gemma":0.017396048,"threshold_uncertainty_score":0.9993307},"labels":[],"label_agreement":null},{"id":"W4413783187","doi":"10.1016/s2152-2650(25)01538-1","title":"ALL-562: Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Medicine; Lymphoblastic Leukemia; Oncology; Internal medicine; Pediatrics; Leukemia","score_opus":0.02242904538383347,"score_gpt":0.3368691806410551,"score_spread":0.31444013525722164,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783187","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9852603,0.00013705358,0.00009750677,0.00048818247,0.0005052343,0.002319205,0.00010235232,0.00021995377,0.0108702015],"genre_scores_gemma":[0.9722633,0.00014536556,0.0006658632,0.0020290236,0.00012255633,0.00015049473,0.0003556755,0.00014790264,0.02411985],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927637,0.0006452333,0.0022487321,0.0016747884,0.0012826533,0.0013849238],"domain_scores_gemma":[0.99382335,0.0030560552,0.00051147334,0.0015173701,0.000456074,0.0006356993],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011400672,0.0008866989,0.0020468722,0.0005516521,0.00017659119,0.00014192626,0.0007655647,0.0008487226,0.0005587312],"category_scores_gemma":[0.0011641727,0.0007249262,0.0005008046,0.0012602078,0.00068103825,0.00034408807,0.0003826429,0.0009993411,0.0002185456],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.016173393,0.0021750086,0.7315467,0.00024425433,0.0015218307,0.00029708364,0.00047041842,0.00008001621,0.0038700243,0.00010156493,0.007634167,0.23588552],"study_design_scores_gemma":[0.041704487,0.0020775092,0.946709,0.0006128044,0.00043616834,0.000009108023,0.000101992,0.0018259941,0.002597349,0.00018039696,0.0030655512,0.00067966984],"about_ca_topic_score_codex":0.00049978687,"about_ca_topic_score_gemma":0.00015484182,"teacher_disagreement_score":0.23520584,"about_ca_system_score_codex":0.0078433845,"about_ca_system_score_gemma":0.004850331,"threshold_uncertainty_score":0.9995202},"labels":[],"label_agreement":null},{"id":"W4413783339","doi":"10.1016/s2152-2650(25)02742-9","title":"MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Pomalidomide; Medicine; Dexamethasone; Internal medicine; Oncology; Subgroup analysis; Bortezomib; Multiple myeloma; Refractory (planetary science); Lenalidomide; Confidence interval","score_opus":0.016639519967585864,"score_gpt":0.2954803109364394,"score_spread":0.2788407909688535,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783339","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9944503,0.0014147576,0.000059004156,0.000081378086,0.00013556758,0.0034051747,0.00021233456,0.00009479502,0.00014674566],"genre_scores_gemma":[0.995603,0.00066807005,0.0024948646,0.00015573506,0.000077275596,0.00031579178,0.00025287713,0.00011050201,0.0003218486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9903714,0.0019400113,0.0030624494,0.002010322,0.0012351864,0.0013806302],"domain_scores_gemma":[0.9907943,0.005501446,0.00093760435,0.0015299615,0.00041132234,0.0008253789],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0025031331,0.0010133344,0.003797684,0.0020780494,0.00024404266,0.000103872495,0.00047674493,0.0007137938,0.00005338032],"category_scores_gemma":[0.0032811053,0.0008546402,0.0003886916,0.0027787453,0.0010133977,0.00028794006,0.00064554403,0.0009603726,0.000010523132],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.037870962,0.0033762932,0.89529216,0.000276613,0.0032470564,0.0009823664,0.0010038269,0.0001791019,0.000047816,0.000027256696,0.000026242193,0.05767031],"study_design_scores_gemma":[0.12540549,0.005207187,0.86120063,0.0004783576,0.002364562,0.000026914751,0.0015013398,0.002896156,0.00023146006,0.00006288235,0.000022050353,0.00060299685],"about_ca_topic_score_codex":0.022632437,"about_ca_topic_score_gemma":0.015988251,"teacher_disagreement_score":0.08753453,"about_ca_system_score_codex":0.0021360046,"about_ca_system_score_gemma":0.0015251713,"threshold_uncertainty_score":0.9993904},"labels":[],"label_agreement":null},{"id":"W4413783982","doi":"10.1016/s2152-2650(25)00381-7","title":"ORAL ABSTRACT: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Refractory (planetary science); Lymphoma; Internal medicine; Gastroenterology; Oncology; Cancer research; Metallurgy","score_opus":0.030105559221708125,"score_gpt":0.3463035311878021,"score_spread":0.316197971966094,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783982","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9917109,0.0005127219,0.0000074945115,0.0009689329,0.0005726693,0.0035499453,0.00008293511,0.00012730376,0.0024671233],"genre_scores_gemma":[0.99458784,0.0002513753,0.0002985027,0.0024910565,0.0002015834,0.00059743226,0.00028617002,0.00009861315,0.0011874287],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9927053,0.00068345125,0.0026097703,0.0016180265,0.0012122266,0.0011712246],"domain_scores_gemma":[0.99537724,0.0017535379,0.0004954242,0.0017186744,0.00021609776,0.00043900197],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0017882824,0.00095157535,0.0019536933,0.00054844964,0.00025312032,0.00014295045,0.0007932531,0.00043848838,0.00028786302],"category_scores_gemma":[0.00047537065,0.00059633143,0.00048762074,0.0015746364,0.0004972969,0.0003557287,0.00014177067,0.00055384013,0.00015195597],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.015494357,0.03159684,0.5432981,0.00009485558,0.00037262944,0.005149505,0.00043954683,0.000004648884,0.000011128017,0.000046093264,0.001962279,0.40152997],"study_design_scores_gemma":[0.13806498,0.0068769413,0.84188396,0.00060771336,0.0006060167,0.000059884063,0.00081161404,0.00007369917,0.0000744669,0.000030777577,0.010372225,0.00053774717],"about_ca_topic_score_codex":0.0010780008,"about_ca_topic_score_gemma":0.0015348808,"teacher_disagreement_score":0.4009922,"about_ca_system_score_codex":0.003076177,"about_ca_system_score_gemma":0.0027993002,"threshold_uncertainty_score":0.9996488},"labels":[],"label_agreement":null},{"id":"W4413783988","doi":"10.1016/s2152-2650(25)00369-6","title":"ORAL ABSTRACT: MDS-1497 Primary Analysis of the Randomized, Phase 3 VERONA Study of Venetoclax With Azacitidine Versus Placebo With Azacitidine in Patients With Treatment-Naïve, Intermediate and Higher-Risk Myelodysplastic Syndromes","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital de l'Enfant-Jésus","funders":"","keywords":"Azacitidine; Medicine; Venetoclax; Myelodysplastic syndromes; Placebo; Internal medicine; Oncology; Leukemia; Alternative medicine; Bone marrow; Pathology","score_opus":0.021537512807600735,"score_gpt":0.3250841045744558,"score_spread":0.30354659176685506,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413783988","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99485356,0.00016982296,0.000021838108,0.00007928319,0.00017251835,0.0038077093,0.00018698353,0.000050337356,0.00065797585],"genre_scores_gemma":[0.9983517,0.00019328507,0.00033343362,0.00007375212,0.000048765425,0.00028839815,0.00021441691,0.00007463176,0.00042164486],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99430007,0.00074588065,0.0019913283,0.001128294,0.0011301049,0.0007043192],"domain_scores_gemma":[0.991858,0.004932193,0.001066164,0.001307631,0.000478796,0.00035722952],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011961933,0.00073768804,0.003734955,0.0009108184,0.00014053457,0.000039165774,0.0004895841,0.00031683684,0.00007446038],"category_scores_gemma":[0.0007721822,0.00040463437,0.00040803995,0.002642607,0.0020006741,0.00020450707,0.00028328097,0.00059482374,0.0000041246067],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.469139,0.002617015,0.47388074,0.00017416847,0.010244013,0.00024255902,0.00027386102,0.000300476,0.000020703581,0.000020767533,0.000044668195,0.043042045],"study_design_scores_gemma":[0.38338158,0.009268655,0.598246,0.00042098502,0.00738494,0.000006491269,0.00019879654,0.000744535,0.00008158674,0.00000578611,0.000030403115,0.00023023147],"about_ca_topic_score_codex":0.0011406484,"about_ca_topic_score_gemma":0.0008643296,"teacher_disagreement_score":0.12436528,"about_ca_system_score_codex":0.002859857,"about_ca_system_score_gemma":0.0030774446,"threshold_uncertainty_score":0.99984056},"labels":[],"label_agreement":null},{"id":"W4413788424","doi":"10.1016/s2152-2650(25)01742-2","title":"AML-881: Mortality Rates and Risk Factors Among Neutropenic Active Acute Myeloid Leukemia Patients With Invasive Pulmonary Aspergillosis: A Retrospective Analysis From the United States","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Red Deer Regional Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Retrospective cohort study; Neutropenia; Internal medicine; Aspergillosis; Oncology; Intensive care medicine; Immunology; Chemotherapy","score_opus":0.015368487299132287,"score_gpt":0.29540303645043414,"score_spread":0.2800345491513019,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413788424","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99588615,0.00015908846,0.000039947714,0.0002295464,0.0003205446,0.0012824963,0.001019547,0.00018619646,0.0008764787],"genre_scores_gemma":[0.993543,0.0027384309,0.000048404807,0.001127294,0.00017560706,0.0001886339,0.0017927137,0.000068244546,0.0003176466],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99523443,0.0007649952,0.0012257172,0.0014899992,0.00061898463,0.0006658483],"domain_scores_gemma":[0.9942991,0.002354911,0.00078923063,0.0013280824,0.0007500653,0.0004786073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00041538267,0.00073157455,0.0016512588,0.00040824417,0.00079952215,0.0001845228,0.00046826914,0.0004448349,0.00014172264],"category_scores_gemma":[0.0006591085,0.00046747306,0.0007064103,0.0032699227,0.0013925396,0.00042588328,0.0003832522,0.0009823483,0.0000206764],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0017664367,0.00027610667,0.9723062,0.000018159857,0.016121801,0.00008361962,0.00033770755,0.00013659462,0.00003573314,0.000057639274,0.0005318983,0.008328127],"study_design_scores_gemma":[0.0044186264,0.0006648387,0.9744593,0.00020218785,0.016579848,0.000003978622,0.0008975121,0.0007535588,0.0007579799,0.00036179114,0.0004034468,0.0004969428],"about_ca_topic_score_codex":0.02645138,"about_ca_topic_score_gemma":0.004844431,"teacher_disagreement_score":0.02160695,"about_ca_system_score_codex":0.0026334298,"about_ca_system_score_gemma":0.0014027304,"threshold_uncertainty_score":0.9997777},"labels":[],"label_agreement":null},{"id":"W4413788439","doi":"10.1016/s2152-2650(25)02630-8","title":"MM-691: Phase 3 AQUILA Study of Daratumumab Monotherapy Versus Active Monitoring in Patients With High-Risk Smoldering Multiple Myeloma (SMM)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Medicine; Daratumumab; Multiple myeloma; Oncology; Internal medicine; Bortezomib","score_opus":0.03567797545871287,"score_gpt":0.36619478685123347,"score_spread":0.3305168113925206,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413788439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9954293,0.00015841996,0.000043372605,0.000041229836,0.00079125864,0.0028586504,0.00008018153,0.00012613232,0.00047146372],"genre_scores_gemma":[0.9980184,0.00012819955,0.0009891208,0.000033010972,0.00020581766,0.0002740272,0.00009315024,0.00009550568,0.00016276444],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99462676,0.0005178319,0.0016190283,0.0012685336,0.0010197839,0.0009480665],"domain_scores_gemma":[0.99527526,0.0018886165,0.0005448252,0.0013543738,0.00043325956,0.0005036627],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005598867,0.00065175944,0.0015800835,0.00058046106,0.0002601397,0.000054644115,0.00047950866,0.0003870875,0.00003869069],"category_scores_gemma":[0.0013629145,0.00053694536,0.00029359089,0.0011346019,0.00033386174,0.00029602513,0.00026688178,0.0006817828,0.00003176298],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.047016848,0.005810477,0.5494621,0.00004775044,0.0010616728,0.0002309636,0.00030272568,0.00003003942,0.000090461865,0.0000064346423,0.000024123065,0.39591646],"study_design_scores_gemma":[0.17989084,0.009994275,0.80439025,0.00042083632,0.0002835387,0.0000017762364,0.0006875706,0.0005095584,0.0033560588,0.000019114015,0.000117871525,0.00032827625],"about_ca_topic_score_codex":0.0020330593,"about_ca_topic_score_gemma":0.00035193612,"teacher_disagreement_score":0.3955882,"about_ca_system_score_codex":0.0018728712,"about_ca_system_score_gemma":0.0010004039,"threshold_uncertainty_score":0.99970824},"labels":[],"label_agreement":null},{"id":"W4413789824","doi":"10.1016/s2152-2650(25)02141-x","title":"MPN-785: Results From VERIFY, an International, Randomized, Phase 3, Double-Blind, Placebo-Controlled Study of Rusfertide (First-in-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Polycythemia vera; Hepcidin; Double blind; Placebo; Internal medicine; Gastroenterology; Anemia; Pathology; Alternative medicine","score_opus":0.06723351044361701,"score_gpt":0.40402092516422355,"score_spread":0.3367874147206065,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413789824","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9833893,0.00051869545,0.000084194086,0.0010816255,0.0009137867,0.011499164,0.00039561858,0.000060553437,0.0020570303],"genre_scores_gemma":[0.9919823,0.0008679323,0.0011511393,0.00022489758,0.00035143897,0.004109714,0.0005930538,0.00005836975,0.00066118373],"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","domain_scores_codex":[0.99285054,0.0005945175,0.0041469187,0.001295137,0.00061016233,0.0005027081],"domain_scores_gemma":[0.9872778,0.009602971,0.0010578666,0.0012464806,0.00047213054,0.00034271742],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015985797,0.0006857066,0.004408838,0.00047440847,0.00012007673,0.000049561677,0.00041905805,0.00043803582,0.00009955152],"category_scores_gemma":[0.0022113703,0.00050732447,0.001192165,0.0003770996,0.0003406451,0.00017107534,0.00010328285,0.00014420012,0.000015993875],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.897613,0.02264292,0.021624172,0.000046676792,0.005143255,0.00015212875,0.00094725465,0.000083585364,0.000273197,0.0005330813,0.00028761962,0.050653096],"study_design_scores_gemma":[0.91706127,0.009078598,0.049474128,0.00042774924,0.0025713118,0.0000061560163,0.00045982425,0.005530715,0.013069062,0.00022380413,0.001778435,0.00031894678],"about_ca_topic_score_codex":0.0023719051,"about_ca_topic_score_gemma":0.00092509715,"teacher_disagreement_score":0.050334148,"about_ca_system_score_codex":0.0015125539,"about_ca_system_score_gemma":0.0012837203,"threshold_uncertainty_score":0.99973786},"labels":[],"label_agreement":null},{"id":"W4413789968","doi":"10.1016/s2152-2650(25)01954-8","title":"CML-754: Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Myeloid leukemia; Tyrosine kinase; Internal medicine; Tyrosine-kinase inhibitor; Oncology; Cancer; Receptor","score_opus":0.016278072813078547,"score_gpt":0.28991046760751565,"score_spread":0.27363239479443713,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413789968","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9875882,0.0017052866,0.000088082255,0.0023817094,0.0011682657,0.0050650425,0.00013956506,0.00089293875,0.0009708672],"genre_scores_gemma":[0.98568183,0.00044864285,0.002137763,0.005180149,0.0005432283,0.0013849863,0.0011314128,0.00033221475,0.0031597733],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9847086,0.0007622276,0.0059912456,0.0040098596,0.0018467483,0.0026813378],"domain_scores_gemma":[0.9885674,0.00204877,0.002206414,0.0038940415,0.0011354645,0.0021478692],"candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0014343224,0.002232721,0.005097834,0.0020437483,0.0005409079,0.00029586724,0.0010920679,0.001875769,0.00036685116],"category_scores_gemma":[0.006772424,0.0018818349,0.0017111814,0.009932047,0.0016691359,0.000683737,0.0006931488,0.0018483107,0.00026729098],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.004753338,0.002212864,0.82094014,0.00058019516,0.007123999,0.0034258,0.0005823869,0.00017182673,0.0030264952,0.00006702722,0.010628622,0.14648731],"study_design_scores_gemma":[0.05259997,0.0033396026,0.9093338,0.0014414405,0.0059496863,0.00012889788,0.00019827415,0.0072083157,0.010529905,0.00011066166,0.007473646,0.001685752],"about_ca_topic_score_codex":0.0046440065,"about_ca_topic_score_gemma":0.0033163363,"teacher_disagreement_score":0.14480157,"about_ca_system_score_codex":0.028683757,"about_ca_system_score_gemma":0.036818054,"threshold_uncertainty_score":0.99942},"labels":[],"label_agreement":null},{"id":"W4413791120","doi":"10.1016/s2152-2650(25)00902-4","title":"POSTER: MPN-780 Safety and Efficacy of Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis (MF) and Other Advanced Myeloid Neoplasms: A Phase 1 Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Myelofibrosis; Bromodomain; Refractory (planetary science); Myeloid; Phases of clinical research; Internal medicine; Cancer research; Oncology; Clinical trial; Epigenetics; Bone marrow; Gene","score_opus":0.020424472641104884,"score_gpt":0.3417641464352782,"score_spread":0.32133967379417333,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791120","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99591345,0.0005161412,0.000011851543,0.00010422071,0.000106186344,0.0027969792,0.00013274155,0.00006182899,0.00035659835],"genre_scores_gemma":[0.9976605,0.00023309713,0.0010949402,0.0002833783,0.00006292332,0.00009030928,0.000058935693,0.000072921845,0.0004430047],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99526435,0.0005363227,0.0016440066,0.0012462673,0.00062749645,0.0006815314],"domain_scores_gemma":[0.9957482,0.002258765,0.00039444515,0.000763517,0.00019230375,0.00064273115],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008026042,0.00059697416,0.0015601651,0.00042911456,0.00018553137,0.000060642764,0.00019038575,0.0003782527,0.000040364448],"category_scores_gemma":[0.0011886322,0.00043190332,0.00012563409,0.000582911,0.00085220387,0.00027299524,0.0004251101,0.00043025962,0.0000058238784],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.06604556,0.0032817489,0.5016228,0.00020404201,0.00030407077,0.0003262535,0.00033452344,2.516786e-7,0.00028562755,0.0000076072256,0.000028021565,0.42755952],"study_design_scores_gemma":[0.12960778,0.014463123,0.8528604,0.0010969214,0.00027497945,0.000051372685,0.00031162615,0.00010001336,0.0002499142,0.00002421902,0.00062412454,0.00033551556],"about_ca_topic_score_codex":0.00019884539,"about_ca_topic_score_gemma":0.0001856223,"teacher_disagreement_score":0.427224,"about_ca_system_score_codex":0.0005547718,"about_ca_system_score_gemma":0.0009479985,"threshold_uncertainty_score":0.99981326},"labels":[],"label_agreement":null},{"id":"W4413791289","doi":"10.1016/s2152-2650(25)02310-9","title":"ABCL-818: Utility of Khorana, ThroLy, and “Roma” Scores in Predicting VTE in DLBCL and Follicular Lymphoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Follicular lymphoma; Internal medicine; Oncology; Lymphoma","score_opus":0.021686881864033926,"score_gpt":0.3286328388341788,"score_spread":0.3069459569701449,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791289","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9889594,0.006143082,0.000012634049,0.0009530717,0.0002436709,0.0008976794,0.000029412635,0.00006906297,0.0026919947],"genre_scores_gemma":[0.99656916,0.0018165499,0.0005501747,0.0006799429,0.0000898117,0.00010076494,0.000025526786,0.000033408363,0.00013468137],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9957137,0.0003030062,0.0018993634,0.0010924088,0.00038309177,0.0006084412],"domain_scores_gemma":[0.9971291,0.0013550549,0.00030825584,0.0007647357,0.000111214045,0.0003316583],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0013256295,0.00046352076,0.001592046,0.0003753779,0.00009814553,0.000045591194,0.00020270461,0.00054081675,0.000022692666],"category_scores_gemma":[0.0011845877,0.00040098847,0.0002878079,0.00072118937,0.0005461211,0.00017470522,0.00034775113,0.00017824858,0.000007870991],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00064098905,0.0008999857,0.6527495,0.00022783517,0.00015385858,0.00037387878,0.00014243259,8.3537e-7,0.0000786377,0.00035210277,0.00021438082,0.3441656],"study_design_scores_gemma":[0.022372024,0.00046171996,0.9687621,0.0014713015,0.00025758648,0.00008275432,0.00022109336,0.0033363954,0.0010063403,0.0010599853,0.0007035942,0.00026513],"about_ca_topic_score_codex":0.0027689862,"about_ca_topic_score_gemma":0.0008588605,"teacher_disagreement_score":0.34390044,"about_ca_system_score_codex":0.00082266517,"about_ca_system_score_gemma":0.0012056436,"threshold_uncertainty_score":0.9998442},"labels":[],"label_agreement":null},{"id":"W4413791306","doi":"10.1016/s2152-2650(25)02276-1","title":"ABCL-544: Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Oxaliplatin; Diffuse large B-cell lymphoma; Internal medicine; Refractory (planetary science); Oncology; Lymphoma; Phases of clinical research; Clinical trial; Chemotherapy; Cancer","score_opus":0.013681318148002447,"score_gpt":0.28937860924308473,"score_spread":0.2756972910950823,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791306","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9922937,0.0007546087,0.000012863763,0.00042733017,0.001355673,0.0027005353,0.00029561942,0.000094929535,0.002064726],"genre_scores_gemma":[0.9958038,0.0002713562,0.00036629965,0.0009725871,0.00021644217,0.00017916133,0.0002152636,0.00008965322,0.0018854454],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9942944,0.00044711083,0.002171993,0.0012282551,0.00095087197,0.0009073533],"domain_scores_gemma":[0.99561405,0.001251396,0.00077298586,0.0015899201,0.00031063196,0.00046104132],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000838965,0.0007490615,0.0018510965,0.00029331702,0.0002448239,0.00006842352,0.00049657957,0.0006688777,0.00007316289],"category_scores_gemma":[0.00094170065,0.0005031394,0.0006320683,0.0009028498,0.00053056015,0.00023149462,0.0004786925,0.00031481404,0.00003927124],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.1351837,0.039682068,0.6458906,0.00028170733,0.0007095347,0.00021670939,0.00036029052,0.0000018148863,0.000051140094,0.00068888365,0.0043974807,0.17253606],"study_design_scores_gemma":[0.45406103,0.0026768495,0.53592557,0.00040882264,0.000461817,0.0000047260924,0.000103521656,0.000100156154,0.00021944755,0.00007944584,0.0056774993,0.00028113986],"about_ca_topic_score_codex":0.0003415719,"about_ca_topic_score_gemma":0.00018900602,"teacher_disagreement_score":0.31887734,"about_ca_system_score_codex":0.0026453596,"about_ca_system_score_gemma":0.0027655666,"threshold_uncertainty_score":0.99974203},"labels":[],"label_agreement":null},{"id":"W4413791504","doi":"10.1016/s2152-2650(25)01391-6","title":"POSTER: CT-230 Lisocabtagene Maraleucel (liso-cel) in Patients With Relapsed or Refractory (R/R) Marginal Zone Lymphoma (MZL) in the Phase 2 TRANSCEND FL Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Hôpital Maisonneuve-Rosemont","funders":"","keywords":"Medicine; Refractory (planetary science); Oncology; Internal medicine; Phases of clinical research; Lymphoma; Gastroenterology; Clinical trial","score_opus":0.023934277908603474,"score_gpt":0.3349150465922123,"score_spread":0.3109807686836088,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791504","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9910637,0.000656145,0.000007787188,0.0012762705,0.0005739846,0.0038592196,0.00008207503,0.00012342651,0.0023573602],"genre_scores_gemma":[0.9934573,0.0002791147,0.00019578477,0.0035584432,0.00020697569,0.00062263705,0.00027532424,0.00009786383,0.0013065346],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925575,0.0010424089,0.0024967042,0.0016253414,0.0011528572,0.0011251374],"domain_scores_gemma":[0.9953033,0.0017856397,0.0004532485,0.0018239291,0.000217638,0.00041630073],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015510914,0.0009290694,0.0019051447,0.0005725132,0.00024568167,0.00013481741,0.0007965534,0.00040483772,0.00018416732],"category_scores_gemma":[0.00044094535,0.00057731516,0.00048164657,0.0016379686,0.00045917885,0.00031719054,0.00016993827,0.00047566826,0.00013212682],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.018224189,0.028876202,0.59931475,0.00009362042,0.00039534114,0.0047175176,0.0005871532,0.0000021044705,0.000011056194,0.000038916154,0.0015653027,0.34617385],"study_design_scores_gemma":[0.1441083,0.009652493,0.83488256,0.0006815822,0.0006432929,0.00008190035,0.00073158636,0.000059496586,0.00008772449,0.000023262264,0.008530157,0.00051768136],"about_ca_topic_score_codex":0.0007431479,"about_ca_topic_score_gemma":0.001047902,"teacher_disagreement_score":0.3456562,"about_ca_system_score_codex":0.0030967551,"about_ca_system_score_gemma":0.0025917424,"threshold_uncertainty_score":0.9996678},"labels":[],"label_agreement":null},{"id":"W4413791590","doi":"10.1016/s2152-2650(25)02640-0","title":"MM-771: Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Patients With Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of Transplant-ineligible (TIE) Patients in the Phase 3 CEPHEUS Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Institute of Cancer Research; University of Alberta; University of Calgary","funders":"","keywords":"Lenalidomide; Daratumumab; Medicine; Bortezomib; Multiple myeloma; Dexamethasone; Oncology; Internal medicine; Subgroup analysis; Confidence interval","score_opus":0.02306697003661301,"score_gpt":0.3389365604046721,"score_spread":0.3158695903680591,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791590","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99454534,0.00031845222,0.000094452575,0.00012970816,0.0001416207,0.0040263645,0.00034266402,0.000054191492,0.00034721766],"genre_scores_gemma":[0.997306,0.00023208548,0.0004164904,0.00050282327,0.00004755393,0.00035081737,0.0010057144,0.000058913258,0.00007964072],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9925272,0.0011701793,0.0024778193,0.0014158005,0.00134217,0.0010668372],"domain_scores_gemma":[0.9931501,0.004033851,0.0005110685,0.0013903565,0.00043266604,0.00048193557],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0016484438,0.0007409437,0.0025100166,0.0014419106,0.0002023218,0.000091210226,0.00064994855,0.0003618447,0.000043784723],"category_scores_gemma":[0.0017998741,0.00050587463,0.00048253266,0.0038422698,0.000560849,0.00028592718,0.000189592,0.0006344015,0.00001079718],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.027912974,0.010513813,0.8167167,0.00012039352,0.0022064464,0.000663475,0.0011935044,0.000050774295,0.0000096443455,0.000013084613,0.00013950071,0.14045973],"study_design_scores_gemma":[0.15762566,0.003764964,0.8317453,0.00035039007,0.0018525089,0.0000029205814,0.00062736176,0.003454031,0.00006753813,0.000017668131,0.0001313732,0.0003602234],"about_ca_topic_score_codex":0.0054184184,"about_ca_topic_score_gemma":0.0076310937,"teacher_disagreement_score":0.1400995,"about_ca_system_score_codex":0.0010431554,"about_ca_system_score_gemma":0.0010614478,"threshold_uncertainty_score":0.9997393},"labels":[],"label_agreement":null},{"id":"W4413791664","doi":"10.1016/s2152-2650(25)01097-3","title":"POSTER: ABCL-1487 Large B-Cell Lymphoma Microenvironment Archetype Profiles (LymphoMAPs) Clinically Identify Subgroups With Greatest Benefit From CD19 CAR T-Cell Therapy","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia; Spinal Cord Injury BC","funders":"","keywords":"Medicine; CD19; Lymphoma; CAR T-cell therapy; Internal medicine; Oncology; Immunology; Immunotherapy; Chimeric antigen receptor; Cancer; Antigen","score_opus":0.024492328462297062,"score_gpt":0.3206075723707601,"score_spread":0.29611524390846305,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791664","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9783328,0.0040743873,0.00012089519,0.0011485838,0.0009355935,0.002955039,0.00038479682,0.00044306862,0.011604834],"genre_scores_gemma":[0.9491367,0.005968685,0.0016524275,0.0059551257,0.0011010066,0.00035067156,0.0010047137,0.0003801301,0.034450553],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98823506,0.0008528237,0.003609632,0.0031679107,0.0018323412,0.0023022324],"domain_scores_gemma":[0.9904331,0.003050992,0.00090769154,0.003704028,0.00051168504,0.0013925271],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0025402883,0.0014874763,0.0027515234,0.0004993659,0.00052298163,0.00034019112,0.0017473849,0.001533175,0.002202207],"category_scores_gemma":[0.00034460032,0.0012433694,0.0015067159,0.0011052657,0.0013886543,0.0003165658,0.00094079616,0.0010372999,0.0016011781],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020759579,0.008275289,0.50669026,0.0003042705,0.0013664063,0.0016891871,0.00048025305,0.0000045030915,0.09251461,0.00010115022,0.0040896516,0.36372486],"study_design_scores_gemma":[0.05617129,0.0033774155,0.82428724,0.0005827644,0.00050337834,0.00012885376,0.00023579443,0.00017518544,0.04966481,0.00038691354,0.06338356,0.0011028246],"about_ca_topic_score_codex":0.0011565035,"about_ca_topic_score_gemma":0.00015913758,"teacher_disagreement_score":0.36262202,"about_ca_system_score_codex":0.0030336848,"about_ca_system_score_gemma":0.0035200464,"threshold_uncertainty_score":0.99978745},"labels":[],"label_agreement":null},{"id":"W4413791744","doi":"10.1016/s2152-2650(25)02669-2","title":"MM-1034: Characterization of Ophthalmic Examination Findings and Impact on Reading and Driving in Patients With Relapsed/Refractory Multiple Myeloma Treated With Belantamab Mafodotin","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Refractory (planetary science); Multiple myeloma; Reading (process); Characterization (materials science); Ophthalmology; Internal medicine; Optics; Metallurgy; Linguistics","score_opus":0.014288166023179479,"score_gpt":0.2982431722143342,"score_spread":0.2839550061911547,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791744","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99817914,0.00003232494,0.00002190016,0.000047512207,0.000041338437,0.0011485809,0.000043283133,0.000054993634,0.00043090043],"genre_scores_gemma":[0.99861866,0.00010130402,0.00024708096,0.000055689092,0.00003302791,0.00004947301,0.0005104327,0.000053251824,0.00033109583],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9971744,0.00027507744,0.00082337315,0.00076659943,0.00047100356,0.0004895817],"domain_scores_gemma":[0.99769205,0.001052844,0.00031000047,0.00042509774,0.00021147798,0.00030852447],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005250559,0.0004207734,0.00087911787,0.0005878878,0.00013193605,0.000049928938,0.00011301559,0.00031181597,0.000019677875],"category_scores_gemma":[0.0006844445,0.00029396339,0.0000867967,0.00060396345,0.000305986,0.00029448557,0.000092044764,0.0003081096,0.0000061256565],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.005771991,0.0006941614,0.79905456,0.000112184745,0.00022331136,0.00013076742,0.00009882064,0.000001587309,0.0023423433,0.000015892507,0.0000067959418,0.19154757],"study_design_scores_gemma":[0.023396395,0.0042595337,0.9665361,0.0017927362,0.00013574703,0.000033286626,0.000040037,0.0012146538,0.002324119,0.0000063009234,0.000016710408,0.00024435722],"about_ca_topic_score_codex":0.00016967177,"about_ca_topic_score_gemma":0.000030841227,"teacher_disagreement_score":0.19130322,"about_ca_system_score_codex":0.0009082552,"about_ca_system_score_gemma":0.00039525205,"threshold_uncertainty_score":0.99995124},"labels":[],"label_agreement":null},{"id":"W4413791759","doi":"10.1016/s2152-2650(25)01744-6","title":"AML-886: Demographics, Management, and Outcomes of Active Acute Myeloid Leukemia Patients Admitted for Acute Pulmonary Embolism: A Propensity Score-Matched Study From the United States","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Red Deer Regional Hospital","funders":"","keywords":"Medicine; Pulmonary embolism; Propensity score matching; Demographics; Myeloid leukemia; Internal medicine; Intensive care medicine; Oncology; Demography","score_opus":0.032062653653082224,"score_gpt":0.32782600224960656,"score_spread":0.2957633485965243,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413791759","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9895791,0.0001740626,0.00007021681,0.0010766174,0.00043146373,0.0074937814,0.00080575043,0.00012634491,0.00024265914],"genre_scores_gemma":[0.99051917,0.0018430882,0.00078479835,0.0033808209,0.00009304216,0.0012574233,0.0015061457,0.00007210812,0.0005433857],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9952637,0.00047982598,0.0017161333,0.0012937951,0.00060372014,0.00064285507],"domain_scores_gemma":[0.99428266,0.0027845278,0.00068635365,0.0011455467,0.00074364385,0.00035726945],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005846546,0.00074855087,0.0020966353,0.00033420953,0.00044048484,0.00008848217,0.00048969913,0.0003661368,0.000018604293],"category_scores_gemma":[0.0004707598,0.0004861903,0.0005672243,0.0009943085,0.00065233296,0.00018494594,0.0006178203,0.0003664513,0.000010623024],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0049677966,0.0022812157,0.84160984,0.000077985715,0.013501607,0.00017838998,0.00042352662,0.0000030459,0.00001920615,0.0003335865,0.0010646373,0.13553916],"study_design_scores_gemma":[0.017446736,0.0016132427,0.9686526,0.0003340375,0.0075527867,0.0000066816183,0.0008609254,0.00063309487,0.00040391824,0.0007854272,0.0013114309,0.00039913907],"about_ca_topic_score_codex":0.00092623616,"about_ca_topic_score_gemma":0.00015670496,"teacher_disagreement_score":0.13514002,"about_ca_system_score_codex":0.00069818454,"about_ca_system_score_gemma":0.000656922,"threshold_uncertainty_score":0.99975896},"labels":[],"label_agreement":null},{"id":"W4413792288","doi":"10.1016/s2152-2650(25)02748-x","title":"CT-041: Third-Line (3L) CAR T-Cell Therapy in the Golden Years: A Single-Center Experience on Outcomes for Elderly Patients in Large B-Cell Lymphoma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Single Center; Center (category theory); Aggressive lymphoma; Oncology; Lymphoma; Internal medicine; Rituximab","score_opus":0.04795534734860198,"score_gpt":0.36277100446945076,"score_spread":0.3148156571208488,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413792288","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98795164,0.00031714395,0.00001991615,0.00084029825,0.0006964103,0.0031184237,0.00005874478,0.000085841035,0.00691158],"genre_scores_gemma":[0.9829394,0.00036915392,0.00017330066,0.00859892,0.00024368298,0.00061562797,0.00010612519,0.00009369815,0.0068600667],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99434686,0.00061325857,0.0017128787,0.0011824069,0.0009413611,0.0012032571],"domain_scores_gemma":[0.99487287,0.0029102215,0.00026672185,0.0014794708,0.00021562407,0.00025509598],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0018294319,0.0005603865,0.0012168665,0.00044700917,0.00012431355,0.00012173914,0.0010652757,0.00042330584,0.00015768496],"category_scores_gemma":[0.0008826446,0.00041584863,0.00070625136,0.0009542835,0.00032597984,0.00015306869,0.00021505346,0.00051339203,0.00012053826],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00420144,0.01092942,0.5007,0.00009975842,0.00007875549,0.00029759115,0.0016639108,0.0000025461413,0.0012574624,0.00009537541,0.0032496415,0.4774241],"study_design_scores_gemma":[0.067149654,0.0035101562,0.8486403,0.000300679,0.000030492307,0.0000107837905,0.00071420014,0.00028820313,0.0025432867,0.00016612725,0.07623959,0.00040648613],"about_ca_topic_score_codex":0.0002603273,"about_ca_topic_score_gemma":0.00021120565,"teacher_disagreement_score":0.4770176,"about_ca_system_score_codex":0.0017105241,"about_ca_system_score_gemma":0.0010121816,"threshold_uncertainty_score":0.99982935},"labels":[],"label_agreement":null},{"id":"W4413810049","doi":"10.1016/s2152-2650(25)01688-x","title":"AML-542: GO-First: Real-World Data of Frontline Gemtuzumab Ozogamicin in Intermediate- and Favorable-Risk Patients With AML in a Multicenter Retrospective Chart Review","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Pfizer (Canada)","funders":"","keywords":"Gemtuzumab ozogamicin; Medicine; Chart; Real world evidence; Intensive care medicine; Pediatrics; Internal medicine","score_opus":0.02913672146435998,"score_gpt":0.35397922078914945,"score_spread":0.3248424993247895,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810049","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99134964,0.0022943392,0.00003940536,0.0012850715,0.00024251975,0.002680505,0.00042185158,0.00006923037,0.0016174504],"genre_scores_gemma":[0.96789914,0.027092373,0.0014220048,0.0015622725,0.00015640447,0.000100741425,0.00065857597,0.00009140044,0.0010170888],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9931443,0.00066899305,0.0026927404,0.0017812516,0.00078148337,0.0009312362],"domain_scores_gemma":[0.994204,0.0015678019,0.00082646735,0.0025195247,0.00047701434,0.00040520448],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002961833,0.00060475414,0.0026029674,0.0008090782,0.0000825587,0.000034950015,0.0010216864,0.00033852423,0.000080526486],"category_scores_gemma":[0.0052541825,0.00048693118,0.00022047598,0.0019476118,0.0011133044,0.00038499854,0.0014327917,0.0013249406,0.000059139955],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0045454986,0.00074675237,0.8723869,0.0013470119,0.00025896795,0.00021706262,0.000113165705,0.000002046255,0.0000067927604,0.00006657577,0.0076131904,0.112696044],"study_design_scores_gemma":[0.024653679,0.0009641076,0.9551941,0.011027526,0.00036107883,0.000006411087,0.00008516581,0.004044992,0.00003324207,0.00008194964,0.0031718079,0.00037589663],"about_ca_topic_score_codex":0.004798522,"about_ca_topic_score_gemma":0.016274784,"teacher_disagreement_score":0.11232015,"about_ca_system_score_codex":0.004583383,"about_ca_system_score_gemma":0.0021340088,"threshold_uncertainty_score":0.99975824},"labels":[],"label_agreement":null},{"id":"W4413810210","doi":"10.1016/s2152-2650(25)01007-9","title":"POSTER: ABCL-544 Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Gemcitabine; Diffuse large B-cell lymphoma; Oxaliplatin; Refractory (planetary science); Internal medicine; Phases of clinical research; Lymphoma; Oncology; Chemotherapy; Cancer; Colorectal cancer; Metallurgy; Materials science","score_opus":0.013464250707773583,"score_gpt":0.2872150006567484,"score_spread":0.2737507499489748,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810210","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99184436,0.000754643,0.000006955885,0.00044212257,0.0013820565,0.002787884,0.0003393515,0.000092824936,0.0023498018],"genre_scores_gemma":[0.99613416,0.00023903004,0.00023482769,0.0011832621,0.00020821884,0.00015988167,0.00024007977,0.00009138047,0.001509156],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99426806,0.0004609432,0.0021968957,0.0012293804,0.0009376487,0.0009070902],"domain_scores_gemma":[0.99563414,0.0012077972,0.00078204565,0.0015984336,0.00031732797,0.00046025205],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007975235,0.0007586966,0.0018440556,0.0002987256,0.00023940814,0.00007324589,0.0004988029,0.00066529535,0.00006660858],"category_scores_gemma":[0.00083762314,0.00050999253,0.00063529843,0.00084279425,0.0005672228,0.0002442653,0.0005117117,0.00030933303,0.00003886467],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13843095,0.0350338,0.6722871,0.00027065264,0.00067268213,0.00022655395,0.00039469101,9.618095e-7,0.0000547642,0.0004327408,0.0032913273,0.14890376],"study_design_scores_gemma":[0.44681805,0.0030547145,0.5438901,0.00043281453,0.00046338857,0.0000063124244,0.00009008109,0.00005807105,0.00025002877,0.00005616631,0.004597499,0.00028276132],"about_ca_topic_score_codex":0.00027931627,"about_ca_topic_score_gemma":0.00015556382,"teacher_disagreement_score":0.3083871,"about_ca_system_score_codex":0.0021334,"about_ca_system_score_gemma":0.0024354996,"threshold_uncertainty_score":0.9997352},"labels":[],"label_agreement":null},{"id":"W4413810249","doi":"10.1016/s2152-2650(25)01335-7","title":"POSTER: MM-1157 Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Class (philosophy); Refractory (planetary science); Multiple myeloma; Oncology; Internal medicine; Artificial intelligence; Composite material","score_opus":0.029116074895706334,"score_gpt":0.35439127306206136,"score_spread":0.32527519816635503,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810249","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99266595,0.0006518014,0.0000058194387,0.00017964125,0.0003122098,0.005813948,0.000050673847,0.00007634895,0.00024361923],"genre_scores_gemma":[0.99846864,0.0001210685,0.00031747884,0.00011689405,0.0000911803,0.00041063063,0.00014222352,0.00006671648,0.00026517478],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938171,0.00085679215,0.002340413,0.0013470597,0.0008267473,0.00081189367],"domain_scores_gemma":[0.9961539,0.0015197513,0.00053771917,0.0009451471,0.00030458806,0.0005388825],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011233463,0.000602158,0.0018571309,0.0008137044,0.00012139299,0.00006837029,0.00028810205,0.00046679593,0.000023737288],"category_scores_gemma":[0.0020335738,0.00048103192,0.00017680075,0.00092159293,0.0007233721,0.00027549276,0.00032713247,0.0005598669,0.000006401962],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.14972822,0.011582101,0.5805512,0.00017658113,0.00032833955,0.00057249103,0.00043858064,4.7590592e-7,0.00017713915,0.000006569385,0.00006505098,0.25637323],"study_design_scores_gemma":[0.35426885,0.012584185,0.63061965,0.000547321,0.0001538362,0.000007751304,0.0004307142,0.00064812845,0.00034221832,0.000014902564,0.00013803848,0.00024442544],"about_ca_topic_score_codex":0.0006433622,"about_ca_topic_score_gemma":0.0009961546,"teacher_disagreement_score":0.25612882,"about_ca_system_score_codex":0.00074974867,"about_ca_system_score_gemma":0.0012709216,"threshold_uncertainty_score":0.99976414},"labels":[],"label_agreement":null},{"id":"W4413810439","doi":"10.1016/s2152-2650(25)02692-8","title":"MM-1157: Trial in Progress: Quintessential—A Phase 2 Study of Arlocabtagene Autoleucel in Triple- and Quad-Class Exposed Patients With Relapsed and Refractory Multiple Myeloma","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Occupational Cancer Research Centre; University of Calgary","funders":"","keywords":"Medicine; Multiple myeloma; Refractory (planetary science); Class (philosophy); Oncology; Lenalidomide; Internal medicine; Artificial intelligence","score_opus":0.030155378113087584,"score_gpt":0.3578107111767318,"score_spread":0.3276553330636442,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810439","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99289024,0.000645256,0.000010373964,0.00015116221,0.00030635102,0.005641951,0.00004258799,0.0000771936,0.00023487843],"genre_scores_gemma":[0.99826086,0.00013463268,0.0004827432,0.00009568002,0.00009582213,0.0004587542,0.00012519662,0.000064684624,0.00028162682],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9938888,0.0008309844,0.0023021451,0.0013393839,0.00083282194,0.000805871],"domain_scores_gemma":[0.99613094,0.0015837764,0.0005255521,0.000929515,0.0002939659,0.00053621817],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0011827418,0.0005891582,0.0018535447,0.00080134807,0.00012325191,0.00006278297,0.0002810979,0.00046506905,0.000025393096],"category_scores_gemma":[0.0023634199,0.00047086418,0.00017254152,0.0009872965,0.00075577555,0.00026005643,0.0002991736,0.00056968216,0.0000061935657],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.13907579,0.01233656,0.5694959,0.00017375301,0.0003290663,0.0005335047,0.0003856397,8.542357e-7,0.00015579007,0.000010774332,0.00008250377,0.27741984],"study_design_scores_gemma":[0.35725245,0.010904841,0.6288286,0.00051038107,0.00014960085,0.0000057433535,0.00048800028,0.0011306504,0.0002893862,0.000019853407,0.00018147881,0.00023903538],"about_ca_topic_score_codex":0.0006666122,"about_ca_topic_score_gemma":0.001020119,"teacher_disagreement_score":0.2771808,"about_ca_system_score_codex":0.0007650258,"about_ca_system_score_gemma":0.0013641319,"threshold_uncertainty_score":0.9997743},"labels":[],"label_agreement":null},{"id":"W4413810836","doi":"10.1016/s2152-2650(25)00817-1","title":"POSTER: MDS-736 Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Myelodysplastic syndromes; Oncology; Internal medicine; Bone marrow","score_opus":0.028124573699951284,"score_gpt":0.32819388254861914,"score_spread":0.30006930884866784,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810836","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99250275,0.0005844059,0.00005520203,0.0010884511,0.0004594507,0.0038173546,0.00019007488,0.000077505836,0.0012248233],"genre_scores_gemma":[0.99658275,0.00151929,0.000049373844,0.00039021752,0.000059950205,0.00013713054,0.00008524723,0.000080848746,0.0010952058],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9907797,0.0022861909,0.0031041272,0.0015182919,0.0014012565,0.0009104135],"domain_scores_gemma":[0.98950225,0.0062722554,0.00084957504,0.0025738433,0.00043440124,0.00036767576],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.003243377,0.000735988,0.0025708163,0.0009503604,0.00041364605,0.000049926057,0.0012986733,0.00072237576,0.0002528861],"category_scores_gemma":[0.0028924565,0.00046432207,0.00086353894,0.0038378788,0.0015091518,0.00013989255,0.0018302738,0.0012435914,0.000023969003],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.051903754,0.005994121,0.59958446,0.0006897815,0.0088967895,0.0011459916,0.0043540318,0.0010630634,0.0028864054,0.000046322606,0.0005870787,0.32284817],"study_design_scores_gemma":[0.023829056,0.0032771677,0.9585841,0.0005122051,0.005562139,0.0001240004,0.0014262175,0.005618957,0.00045356216,0.0000687035,0.00016852077,0.00037541543],"about_ca_topic_score_codex":0.0018904683,"about_ca_topic_score_gemma":0.0017512244,"teacher_disagreement_score":0.35899958,"about_ca_system_score_codex":0.0018893532,"about_ca_system_score_gemma":0.0019670266,"threshold_uncertainty_score":0.99978083},"labels":[],"label_agreement":null},{"id":"W4413810923","doi":"10.1016/s2152-2650(25)00588-9","title":"POSTER: AML-881 Mortality Rates and Risk Factors Among Neutropenic Active Acute Myeloid Leukemia Patients With Invasive Pulmonary Aspergillosis: A Retrospective Analysis From the United States","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Neutropenia and Cancer Infections","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Red Deer Regional Hospital","funders":"","keywords":"Medicine; Myeloid leukemia; Aspergillosis; Internal medicine; Oncology; Neutropenia; Retrospective cohort study; Leukemia; Intensive care medicine; Immunology; Chemotherapy","score_opus":0.014801613290662713,"score_gpt":0.29326191036480037,"score_spread":0.27846029707413766,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4413810923","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99561816,0.00016601084,0.000024496037,0.00027171223,0.00032831178,0.0013358904,0.0011688299,0.00018165211,0.0009049036],"genre_scores_gemma":[0.99356383,0.002388823,0.000032615117,0.0013501324,0.00016578089,0.0001692082,0.0019653111,0.00006999279,0.0002942786],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9951883,0.00078670506,0.0012505173,0.0014924722,0.00061277597,0.00066920783],"domain_scores_gemma":[0.99437416,0.002236533,0.00080206746,0.0013399558,0.0007685817,0.0004786923],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00039616186,0.0007434649,0.0016520795,0.00041664956,0.000768558,0.00019848884,0.00047534195,0.00044454462,0.00012785707],"category_scores_gemma":[0.0005680158,0.00047608,0.0007101957,0.0030120749,0.0013064814,0.00044880176,0.0004172086,0.00095734757,0.00002090595],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0020714633,0.00027239905,0.9730777,0.000019151674,0.015648097,0.00009249657,0.00038590524,0.000063196254,0.000046324254,0.000035493515,0.0004192477,0.007868486],"study_design_scores_gemma":[0.0045697573,0.0007955664,0.9749739,0.00021982165,0.016260268,0.0000054674742,0.00077823416,0.00036523218,0.00095621013,0.00026492655,0.00030556385,0.00050502236],"about_ca_topic_score_codex":0.024655037,"about_ca_topic_score_gemma":0.0046529775,"teacher_disagreement_score":0.020002058,"about_ca_system_score_codex":0.002537822,"about_ca_system_score_gemma":0.0013147652,"threshold_uncertainty_score":0.9997691},"labels":[],"label_agreement":null},{"id":"W4414194885","doi":"10.1016/j.clml.2026.04.016","title":"Use of CD38 Antibodies in High-Risk Newly Diagnosed Multiple Myeloma: A Meta-Analysis","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Columbia College","funders":"Alexion Pharmaceuticals; Celgene; Sanofi","keywords":"Daratumumab; Multiple myeloma; Monoclonal antibody; Clinical trial; Antibody; Randomized controlled trial; Immunopathology; Cancer","score_opus":0.09720225098659022,"score_gpt":0.3758695564124113,"score_spread":0.2786673054258211,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414194885","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99438304,0.0020260024,0.00031786194,0.00070310896,0.00021194185,0.0012960144,0.00035563685,0.0001359748,0.0005704001],"genre_scores_gemma":[0.9874272,0.0012904364,0.007513815,0.00060002826,0.000100665864,0.00021814,0.00030308941,0.00005683536,0.0024898425],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99289405,0.0010695053,0.0027075391,0.0013894673,0.0009212227,0.0010181986],"domain_scores_gemma":[0.9880085,0.008303432,0.000666083,0.0019145822,0.0005034466,0.0006039732],"candidate_categories":["metaresearch","metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0014870173,0.00067977904,0.0043569864,0.0013887412,0.00017287733,0.00008709308,0.0004989298,0.00060607865,0.00034844145],"category_scores_gemma":[0.010074805,0.00052078534,0.0035759106,0.0030066113,0.0007347048,0.00031073263,0.00042368908,0.00056767755,0.00013551241],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0024970144,0.0012998605,0.7741462,0.000120201716,0.08435127,0.0010752595,0.00006890541,0.00016442905,0.00011493803,0.0002257918,0.0012387119,0.13469742],"study_design_scores_gemma":[0.011838006,0.00044450568,0.9125097,0.000065718996,0.067115836,0.00000832691,0.00006048386,0.004583342,0.0012767856,0.0002753483,0.0014878738,0.00033407204],"about_ca_topic_score_codex":0.011114146,"about_ca_topic_score_gemma":0.003515911,"teacher_disagreement_score":0.13836351,"about_ca_system_score_codex":0.00076356006,"about_ca_system_score_gemma":0.0014133235,"threshold_uncertainty_score":0.9997244},"labels":[],"label_agreement":null},{"id":"W4414303437","doi":"10.1016/s2152-2650(25)03661-4","title":"Clinical Utility of Quantitative, Mass Spectrometry-Based EasyM for MRD Monitoring in Multiple Myeloma: Integration with Established MRD Detection Techniques in a Pan-Canadian Real-World Cohort Study","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Cohort study; Cohort; Prognostic model; MEDLINE","score_opus":0.05968875976820813,"score_gpt":0.3989852415055754,"score_spread":0.33929648173736726,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414303437","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9861304,0.00006523879,0.0053248885,0.00015127158,0.00031487085,0.006187594,0.00005818795,0.00013850752,0.0016290124],"genre_scores_gemma":[0.9659869,0.000081137056,0.032236744,0.000058809663,0.00013341615,0.0011559204,0.00011219886,0.000060484163,0.0001743917],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9933982,0.0009846184,0.0026712795,0.0013604554,0.0006705053,0.00091497635],"domain_scores_gemma":[0.9929586,0.0043442203,0.00047497326,0.0010400529,0.00063878414,0.0005433491],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004704035,0.0005157881,0.0018178594,0.0019577206,0.0001604091,0.00006896017,0.00036706115,0.0005064992,0.00002195492],"category_scores_gemma":[0.0068633794,0.00043944592,0.0004069124,0.0027165588,0.00047315544,0.00026915243,0.00007388552,0.00077813986,0.000007839567],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.008561113,0.0015684224,0.74560404,0.00012673321,0.00025159967,0.00018942852,0.000041164207,0.000002921661,0.0006256102,0.000037563204,0.000028115504,0.24296331],"study_design_scores_gemma":[0.016332394,0.0037993542,0.95726573,0.0008070852,0.00018868227,0.000002747337,0.0004644633,0.010985623,0.009565698,0.00017959277,0.000101992184,0.0003066565],"about_ca_topic_score_codex":0.074034974,"about_ca_topic_score_gemma":0.32069334,"teacher_disagreement_score":0.24665835,"about_ca_system_score_codex":0.0030902755,"about_ca_system_score_gemma":0.0038897754,"threshold_uncertainty_score":0.99980575},"labels":[],"label_agreement":null},{"id":"W4414889730","doi":"10.1016/j.clml.2025.09.007","title":"Changes in Frailty Categorization Over One Year among Real-World Patients With Multiple Myeloma: A Prospective Cohort Study (MFRAIL)","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Frailty in Older Adults","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital; Western University; McMaster University; Population Health Research Institute","funders":"Johnson and Johnson; Hamilton Health Sciences","keywords":"Prospective cohort study; Categorization; Categorical variable; Cohort study; Frailty syndrome; Cohort","score_opus":0.01932500318865773,"score_gpt":0.3084291798198389,"score_spread":0.2891041766311812,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4414889730","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98505753,0.00002218545,0.000071233284,0.0003039613,0.0005489882,0.0054706135,0.00003727591,0.00029620147,0.008192007],"genre_scores_gemma":[0.9922893,0.000040532243,0.0005525268,0.00050721416,0.00032521843,0.00063373626,0.0002710755,0.00010475265,0.0052756188],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99510694,0.00033534717,0.0013724407,0.0014807108,0.0009623714,0.0007422093],"domain_scores_gemma":[0.9965699,0.00085890014,0.00043372717,0.0012399293,0.0005492825,0.00034829002],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008156398,0.0005700639,0.0014051019,0.00055873056,0.00016112014,0.000071318595,0.00037039115,0.00043800016,0.00014311163],"category_scores_gemma":[0.0017348037,0.00050520845,0.00017278413,0.0018631004,0.0004899119,0.0002734119,0.00028849702,0.00061517255,0.00009637886],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0019776423,0.0028292786,0.9515354,0.000094808805,0.0004712739,0.000094736126,0.00041696496,0.000007983048,0.0000148826175,0.00020044565,0.0009953809,0.041361187],"study_design_scores_gemma":[0.024206739,0.0015630128,0.9713822,0.00059912604,0.00037584917,0.0000012497046,0.00021137802,0.00037480553,0.00014741062,0.00018689051,0.00046482222,0.0004864867],"about_ca_topic_score_codex":0.0032984233,"about_ca_topic_score_gemma":0.033678364,"teacher_disagreement_score":0.0408747,"about_ca_system_score_codex":0.002763778,"about_ca_system_score_gemma":0.0010043029,"threshold_uncertainty_score":0.99973994},"labels":[],"label_agreement":null},{"id":"W4415534197","doi":"10.1016/j.clml.2025.10.016","title":"What is the Prognostic Relevance of Responses Less Than a CR to Initial AML Treatment?","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University Health Network; University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Spliceosome; Disease; Relevance (law); Clinical significance; MEDLINE; Progressive disease","score_opus":0.062104025553241196,"score_gpt":0.4075722733192606,"score_spread":0.3454682477660194,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415534197","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.97256863,0.001760997,0.00009864417,0.019067341,0.0010320373,0.0020630658,0.000055764154,0.00014212707,0.0032114063],"genre_scores_gemma":[0.97135276,0.0023021307,0.0009612734,0.009074651,0.00062512694,0.00034968354,0.000030619103,0.00007525378,0.015228496],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9948322,0.00077761296,0.0016211092,0.0011020022,0.0007820365,0.0008850004],"domain_scores_gemma":[0.98709553,0.009542006,0.00028953174,0.0019971805,0.0005711669,0.0005045856],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0015304347,0.00050547946,0.0012819185,0.00034840213,0.00026118086,0.00014851603,0.0008713891,0.0006696377,0.00009703454],"category_scores_gemma":[0.00830144,0.00033945436,0.0006715555,0.00137355,0.0010893634,0.00027387464,0.0005125389,0.00062036567,0.00034309627],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":false,"study_design_scores_codex":[0.010458404,0.0005604771,0.05999106,0.00017722958,0.0006405074,0.0006219489,0.00070963963,0.0000034493444,0.0009578356,0.0009889405,0.012273402,0.9126171],"study_design_scores_gemma":[0.006922441,0.002684936,0.9108701,0.0013762895,0.00044796334,0.00015956379,0.0011615657,0.0004230203,0.0126314815,0.0009011607,0.06208498,0.00033652224],"about_ca_topic_score_codex":0.00027026745,"about_ca_topic_score_gemma":0.00009319064,"teacher_disagreement_score":0.91228056,"about_ca_system_score_codex":0.0018406895,"about_ca_system_score_gemma":0.006602532,"threshold_uncertainty_score":0.99990577},"labels":[],"label_agreement":null},{"id":"W4415833999","doi":"10.1016/j.clml.2025.10.027","title":"Proposed Modifications to Prognostic Classification of AML Patients Treated With Intensive Chemotherapy Based on Recent Real-World Data","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Alberta","funders":"","keywords":"Chemotherapy; Prognostic model; Overall survival; Risk assessment; MEDLINE","score_opus":0.08273501749831795,"score_gpt":0.3906585236187967,"score_spread":0.30792350612047875,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415833999","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9767342,0.000014629138,0.00066661957,0.01016871,0.00012653504,0.003881746,0.00018233221,0.00020486431,0.008020328],"genre_scores_gemma":[0.9870289,0.00016514289,0.003940142,0.0047541074,0.00011501866,0.00019901709,0.0018753192,0.00008663315,0.0018357099],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9953757,0.00037436266,0.0014615242,0.001391331,0.0008226614,0.00057440763],"domain_scores_gemma":[0.991642,0.0015632269,0.000497613,0.0032039445,0.0026094888,0.0004837541],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008708709,0.00042505737,0.0010217597,0.00069047604,0.00014242315,0.000043797998,0.00092486985,0.0002542321,0.0000672055],"category_scores_gemma":[0.0049872007,0.00032600667,0.00014681068,0.0027433143,0.000681673,0.0001163737,0.00021519662,0.00043664846,0.000117565614],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.01025013,0.0015841412,0.4270824,0.00013424916,0.00029354703,0.000027255372,0.000049629896,0.000026613001,0.0010236348,0.0005007645,0.019860242,0.5391674],"study_design_scores_gemma":[0.009166062,0.0023644061,0.9548058,0.0007218695,0.00025343645,0.0000020778814,0.00007643584,0.020395981,0.0026848384,0.00002950342,0.009223559,0.00027601008],"about_ca_topic_score_codex":0.00032784409,"about_ca_topic_score_gemma":0.00014300144,"teacher_disagreement_score":0.5388914,"about_ca_system_score_codex":0.0026711843,"about_ca_system_score_gemma":0.005029707,"threshold_uncertainty_score":0.9999192},"labels":[],"label_agreement":null},{"id":"W4415897690","doi":"10.1016/j.clml.2025.10.019","title":"Real-World Outcomes in Myeloma Patients With t (11;14): A Matched Comparison Using the Canadian Myeloma Research Group National Clinical Database","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Memorial University of Newfoundland; Jewish General Hospital; Saint John Regional Hospital; Juravinski Cancer Centre; McGill University; Vancouver General Hospital; Princess Margaret Cancer Centre; University of Calgary; University of Saskatchewan; University of Alberta; Queen Elizabeth II Health Sciences Centre; Dalhousie University; Saskatchewan Cancer Agency; CancerCare Manitoba; Ottawa Hospital; Ottawa Regional Cancer Foundation","funders":"AbbVie","keywords":"Multiple myeloma; National database; MEDLINE; Outcomes research; Benchmark (surveying)","score_opus":0.13771947700868384,"score_gpt":0.46515680384845237,"score_spread":0.32743732683976856,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4415897690","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.98335916,0.000112764705,0.000034300912,0.0034981656,0.0006622091,0.0029577715,0.0002418096,0.00012120191,0.009012621],"genre_scores_gemma":[0.9910212,0.000068431946,0.0036127667,0.001657309,0.00041615506,0.0002651459,0.00082727545,0.000112503134,0.0020191765],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.98742867,0.0023802735,0.003140488,0.0018123805,0.003055525,0.0021826557],"domain_scores_gemma":[0.98812866,0.0060317214,0.00045824994,0.0019510478,0.0017077057,0.0017226202],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0076879244,0.00075423793,0.0020617102,0.0016447528,0.0011401746,0.0002915095,0.0011757792,0.00071658153,0.00018597928],"category_scores_gemma":[0.006221239,0.00051557814,0.0005583323,0.0030939472,0.0017123608,0.0003766617,0.00068461546,0.0019929083,0.00024463923],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.0028492433,0.001820551,0.92174584,0.00009591008,0.00062796206,0.0005915657,0.000082122024,0.000010811463,0.000013899282,0.0020610238,0.0057940925,0.06430696],"study_design_scores_gemma":[0.01865108,0.0006907564,0.96588045,0.00064935745,0.0001724895,0.000015672298,0.00018164306,0.004759135,0.000032702166,0.0004127907,0.008097379,0.00045657065],"about_ca_topic_score_codex":0.13523707,"about_ca_topic_score_gemma":0.60101926,"teacher_disagreement_score":0.46578217,"about_ca_system_score_codex":0.008144209,"about_ca_system_score_gemma":0.014360493,"threshold_uncertainty_score":0.9997296},"labels":[],"label_agreement":null},{"id":"W4416020872","doi":"10.1016/j.clml.2025.10.014","title":"“Upfront Use of Blinatumomab in Adolescents and Adults With Philadelphia Chromosome: Negative B-cell Acute Lymphoblastic Leukemia: A Systematic Review and Proportional Meta-Analysis”","year":2025,"lang":"en","type":"review","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Acute Lymphoblastic Leukemia research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Western University","funders":"","keywords":"Blinatumomab; Clinical trial; Meta-analysis; Chemotherapy; Minimal residual disease; Lymphoblastic Leukemia; Acute lymphocytic leukemia; Clinical endpoint","score_opus":0.05662401907304467,"score_gpt":0.3581698320988692,"score_spread":0.30154581302582456,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416020872","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0009750808,0.98604685,0.000096251504,0.00018862751,0.00008965576,0.011770287,0.00065386854,0.00009739695,0.000081983926],"genre_scores_gemma":[0.01067451,0.9838006,0.0009714927,0.000776629,0.000100964,0.001932035,0.0005085746,0.0002032422,0.0010319868],"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","domain_scores_codex":[0.98389655,0.0021959003,0.0075901924,0.0030161368,0.0020386034,0.0012626129],"domain_scores_gemma":[0.986054,0.0052955765,0.003968771,0.0024303002,0.001159673,0.0010916854],"candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0023938485,0.0020965557,0.024930103,0.0018330225,0.00015257047,0.0001326989,0.0008981754,0.0016945635,0.00007310046],"category_scores_gemma":[0.0051391907,0.0013564656,0.0039591417,0.0044850595,0.0016814279,0.00040843172,0.0010304782,0.0015083079,0.00004062679],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":true,"about_ca_system_consensus":true,"study_design_scores_codex":[0.00082916557,0.00064989895,0.00012723342,0.8947116,0.08833232,0.0017457114,0.000042637723,0.0000033608521,3.634575e-7,0.000043112683,0.0004622792,0.013052276],"study_design_scores_gemma":[0.007215923,0.00092783204,0.002233208,0.3867615,0.5995191,0.0012360588,0.000023897408,0.00050118857,0.0000017604468,0.000017431288,0.00062687555,0.0009353021],"about_ca_topic_score_codex":0.00023832494,"about_ca_topic_score_gemma":0.000089947454,"teacher_disagreement_score":0.5111867,"about_ca_system_score_codex":0.0064195124,"about_ca_system_score_gemma":0.021542832,"threshold_uncertainty_score":0.9996014},"labels":[],"label_agreement":null},{"id":"W4416853882","doi":"10.1016/j.clml.2025.10.026","title":"Salvage Autologous Stem Cell Transplantation Outcomes and The Use of Maintenance in Relapsed Multiple Myeloma: Real world evidence from the Canadian Myeloma Research Group Database","year":2025,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"Hôpital Maisonneuve-Rosemont; Memorial University of Newfoundland; Université de Montréal; University of Saskatchewan; Queen Elizabeth II Health Sciences Centre; Dalhousie University; McGill University; University of British Columbia; University of Alberta; CancerCare Manitoba; Saskatchewan Cancer Agency; Ottawa Hospital; Saint John Regional Hospital; BC Cancer Agency; Vancouver General Hospital; Princess Margaret Cancer Centre; Juravinski Cancer Centre; Jewish General Hospital; Alberta Cancer Foundation; Canadian Centre for Applied Research in Cancer Control","funders":"","keywords":"Real world evidence; Multiple myeloma; Real world data; Stem cell; Autologous stem-cell transplantation; Transplantation","score_opus":0.12446060375010545,"score_gpt":0.38362339408857327,"score_spread":0.2591627903384678,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4416853882","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9883349,0.001213644,0.000058016412,0.006210091,0.0002972697,0.0025202779,0.0004185185,0.00006309624,0.0008842169],"genre_scores_gemma":[0.9922846,0.0024204198,0.00141699,0.0010256767,0.00009877155,0.0002780496,0.00023324505,0.000050121853,0.002192138],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.9918983,0.0029076915,0.0017457291,0.0011546878,0.0010793175,0.0012142783],"domain_scores_gemma":[0.96878797,0.02817779,0.0002993237,0.0017293086,0.00038464763,0.0006209676],"candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0048304354,0.0004679318,0.0012401587,0.00055417046,0.00062706135,0.0001648592,0.00082321436,0.0003997833,0.00003513828],"category_scores_gemma":[0.0045026285,0.00027771838,0.00034399328,0.0014558347,0.0024078924,0.00031611073,0.00031194455,0.0011860083,0.000050181552],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00821734,0.00020854668,0.81029606,0.00018646101,0.000246127,0.0013514583,0.00060616544,0.000008025408,0.00027728188,0.0009826109,0.00224031,0.17537959],"study_design_scores_gemma":[0.017653914,0.00022962004,0.97319555,0.0014141989,0.00020194254,0.000022871262,0.00028667084,0.0047302824,0.00040661756,0.00024157266,0.0013922108,0.0002245716],"about_ca_topic_score_codex":0.45276958,"about_ca_topic_score_gemma":0.7162903,"teacher_disagreement_score":0.26352072,"about_ca_system_score_codex":0.0018667663,"about_ca_system_score_gemma":0.0035213141,"threshold_uncertainty_score":0.9999675},"labels":[],"label_agreement":null}]}